PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MARK, DB; SHAW, LK; DELONG, ER; CALIFF, RM; PRYOR, DB				MARK, DB; SHAW, LK; DELONG, ER; CALIFF, RM; PRYOR, DB			ABSENCE OF SEX BIAS IN THE REFERRAL OF PATIENTS FOR CARDIAC-CATHETERIZATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; ACUTE MYOCARDIAL-INFARCTION; GOOD CLINICAL JUDGMENT; GENDER DIFFERENCES; BYPASS-SURGERY; MANAGEMENT; LIKELIHOOD; WOMEN	Background. It has been suggested that women with clinical evidence of coronary artery disease are less often referred for cardiac catheterization than are men. To determine whether there is sex-related bias in referral for cardiac catheterization, we prospectively studied a cohort of 410 symptomatic outpatients (280 men and 130 women) who were being evaluated with exercise testing for possible coronary artery disease. Methods. Before the patients underwent exercise testing, 15 cardiologists from an academic medical center were asked to predict the probability that the patients they saw in the cardiology clinic would have angiographic evidence of any obstructive coronary disease (stenosis of 75 percent or more); the probability of severe coronary disease (three-vessel or left main coronary artery disease); the probability of left main coronary artery disease; and the probability of survival one, three, and five years after the evaluation. Similar predictions were generated by previously validated statistical models with use of data collected before exercise testing from the history, physical examination, and 12-lead electrocardiography with the patient at rest. Results. Overall, women were referred for cardiac catheterization significantly less often than men (18 percent vs. 27 percent, P = 0.03). As compared with men, women had a significantly lower pretest probability of coronary disease (as estimated by their physicians) and a lower rate of positive exercise-test results. After accounting for differences in these two factors, sex was not an independent predictor of referral for catheterization. Comparing physicians' estimates of outcome with those generated by the statistical models revealed no evidence that the physicians were underestimating the risk of coronary disease in women. Furthermore, physicians' predictions did not underestimate the probability of any obstructive coronary disease in men and women who subsequently underwent catheterization. Conclusions. Academic cardiologists made appropriately lower pretest predictions of categories of disease in women with possible coronary artery disease than in men, and these assessments, along with women's lower rate of positive exercise tests, rather than bias based on sex, accounted for the lower rate of catheterization among women.	DUKE UNIV,MED CTR,DEPT COMMUNITY & FAMILY MED,DIV BIOMETRY,DURHAM,NC 27710	Duke University	MARK, DB (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOL,BOX 3485,DURHAM,NC 27710, USA.			Mark, Daniel/0000-0001-6340-8087	AHRQ HHS [HS-05635, HS-06503] Funding Source: Medline; NHLBI NIH HHS [HL-36587] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036587] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; JOHNSON SH, 1991, AM J CARDIOL, V67, P919, DOI 10.1016/0002-9149(91)90161-D; KANNEL WB, 1972, AM J CARDIOL, V29, P154, DOI 10.1016/0002-9149(72)90624-8; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; LASKEY WK, 1992, ANN INTERN MED, V116, P869, DOI 10.7326/0003-4819-116-10-869; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MARK DB, 1986, TXB SURGERY BIOL BAS, V2, P2135; MARK DB, 1993, CARDIOVASCULAR HLTH, P81; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; PRYOR DB, 1991, AM J MED, V90, P553; PRYOR DB, 1983, AM J MED, V75, P771, DOI 10.1016/0002-9343(83)90406-0; PRYOR DB, 1991, STAT MED, V10, P617, DOI 10.1002/sim.4780100412; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; PRYOR DB, 1989, CIRCULATION S2, V80, P409; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530	20	150	149	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 21	1994	330	16					1101	1106		10.1056/NEJM199404213301601	http://dx.doi.org/10.1056/NEJM199404213301601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF699	8133852				2022-12-01	WOS:A1994NF69900001
J	HARRIS, RS; LONGERICH, S; ROSENBERG, SM				HARRIS, RS; LONGERICH, S; ROSENBERG, SM			RECOMBINATION IN ADAPTIVE MUTATION	SCIENCE			English	Article							ESCHERICHIA-COLI; MUTANTS; RECD; REARRANGEMENTS; BREAKS; LAMBDA; MODEL; GENE	The genetic requirements for adaptive mutation in Escherichia coli parallel those for homologous recombination in the RecBCD pathway. Recombination-deficient recA and recB null mutant strains are deficient in adaptive reversion. A hyper-recombinagenic recD strain is hypermutable, and its hypermutation depends on functional recA and recB genes. Genes of subsidiary recombination systems are not required. These results indicate that the molecular mechanism by which adaptive mutation occurs includes recombination. No such association is seen for spontaneous mutation in growing cells.	UNIV ALBERTA,FAC MED,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV ALBERTA,DEPT GENET,EDMONTON T6G 2E9,ALBERTA,CANADA	University of Alberta; University of Alberta				Rosenberg, Susan M./0000-0003-1444-473X				AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; CAIRNS J, 1993, SCIENCE, V260, P1221, DOI 10.1126/science.8493560; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CLARK AJ, 1988, RECOMBINATION GENETI, P115; DEMEREC M, 1962, P NATL ACAD SCI USA, V48, P1696, DOI 10.1073/pnas.48.10.1696; DEVORET R, 1991, BIOCHIMIE, V73; ESPOSITO MS, 1993, CURR GENET, V23, P430, DOI 10.1007/BF00312630; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; FRANCOIS V, 1987, GENE, V56, P99, DOI 10.1016/0378-1119(87)90162-4; HASTINGS PJ, 1992, ENCY IMMUNOLOGY, P602; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LENSKI RE, 1993, SCIENCE, V259, P188, DOI 10.1126/science.7678468; LENSKI RE, 1993, SCIENCE, V260, P1222, DOI 10.1126/science.260.5112.1222; LOUARN JM, 1991, J BACTERIOL, V173, P5097, DOI 10.1128/jb.173.16.5097-5104.1991; Luria SE, 1943, GENETICS, V28, P491; MAGNI GE, 1962, GENETICS, V47, P1097; MAHAN MJ, 1989, GENETICS, V121, P433; MCGILL C, COMMUNICATION; PASZEWSKI A, 1964, NATURE, V204, P809, DOI 10.1038/204809a0; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; ROSENBERG SM, 1991, BIOCHIMIE, V73, P385, DOI 10.1016/0300-9084(91)90105-A; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; THALER DS, 1989, GENOME, V31, P53, DOI 10.1139/g89-013; THALER DS, 1988, ANNU REV GENET, V22, P169, DOI 10.1146/annurev.ge.22.120188.001125; THALER DS, 1990, BACTERIAL CHROMOSOME, P445; THALER DS, IN PRESS TRENDS ECOL; Von Borstel R C, 1978, Methods Cell Biol, V20, P1, DOI 10.1016/S0091-679X(08)62005-1	30	227	232	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					258	260		10.1126/science.8146657	http://dx.doi.org/10.1126/science.8146657			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146657				2022-12-01	WOS:A1994NE41000036
J	ALBERINI, CM; GHIRARDI, M; METZ, R; KANDEL, ER				ALBERINI, CM; GHIRARDI, M; METZ, R; KANDEL, ER			C/EBP IS AN IMMEDIATE-EARLY GENE REQUIRED FOR THE CONSOLIDATION OF LONG-TERM FACILITATION IN APLYSIA	CELL			English	Article							ENHANCER-BINDING-PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; SPONTANEOUS TRANSMITTER RELEASE; SENSORY NEURONS; C-FOS; HETEROSYNAPTIC FACILITATION; BEHAVIORAL SENSITIZATION; STRUCTURAL-CHANGES; GILL-WITHDRAWAL; TRANSCRIPTIONAL REGULATION	The consolidation of long-term memory requires protein and mRNA synthesis. A similar requirement has been demonstrated for learning-related synaptic plasticity in the gill-withdrawal reflex of Aplysia. The monosynaptic component of this reflex can be reconstituted in vitro, where it undergoes both short- and long-term increases in synaptic strength in response to serotonin (5-HT), a neurotransmitter released during behavioral sensitization, a simple form of learning. As with sensitization, the long-term synaptic modification is characterized by a brief consolidation period during which gene expression is required. We f ind that during this phase, the transcription factor Aplysia CCAAT enhancer-binding protein (ApC/EBP) is induced rapidly by 5-HT and by cAMP, even in the presence of protein synthesis inhibitors. Blocking the function of ApC/EBP blocks long-term facilitation selectively without affecting the short-term process. These data indicate that cAMP-inducible immediate-early genes have an essential role in the consolidation of stable long-term synaptic plasticity in Aplysia.	BRISTOL MYERS SQUIBB,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb	ALBERINI, CM (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032, USA.		ghirardi, mirella/AEQ-0420-2022					AGRANOFF BW, 1972, CHEM MOOD MOTIVATION; ASHBURNER M, 1990, CELL, V61, P1, DOI 10.1016/0092-8674(90)90205-S; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAILEY CH, 1992, NEURON, V9, P749, DOI 10.1016/0896-6273(92)90037-E; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; BAILEY CH, 1989, J NEUROSCI, V9, P1774; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BARONDES SH, 1975, SHORT TERM MEMORY, P379; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BERGOLD PJ, 1990, P NATL ACAD SCI USA, V87, P3788, DOI 10.1073/pnas.87.10.3788; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; BYRNE JH, 1987, PHYSIOL REV, V67, P329, DOI 10.1152/physrev.1987.67.2.329; CAO Z, 1991, GENE DEV, V5, P1539; CAREW TJ, 1986, ANNU REV NEUROSCI, V9, P435, DOI 10.1146/annurev.ne.09.030186.002251; CASTELLUCCI V, 1976, SCIENCE, V194, P1176, DOI 10.1126/science.11560; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK GA, 1984, P NATL ACAD SCI-BIOL, V81, P2577, DOI 10.1073/pnas.81.8.2577; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; CROW T, 1990, P NATL ACAD SCI USA, V87, P4490, DOI 10.1073/pnas.87.12.4490; DALE N, 1993, P NATL ACAD SCI USA, V90, P7163, DOI 10.1073/pnas.90.15.7163; DALE N, 1990, J PHYSIOL-LONDON, V421, P203, DOI 10.1113/jphysiol.1990.sp017941; DALE N, 1988, SCIENCE, V239, P282, DOI 10.1126/science.2892269; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DRAGUNOW M, 1989, NEUROSCI BIOBEHAV R, V13, P301, DOI 10.1016/S0149-7634(89)80066-1; DUNCAN CP, 1949, J COMP PHYSIOL PSYCH, V42, P32, DOI 10.1037/h0058173; FLEXNER J, 1983, SCIENCE, V141, P57; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; Hawkins RD, 1987, HDB PHYSL 1, VV, P25; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOCHNER B, 1992, P NATL ACAD SCI USA, V89, P11476, DOI 10.1073/pnas.89.23.11476; HU YH, 1993, NEURON, V10, P921, DOI 10.1016/0896-6273(93)90207-8; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KENNEDY TE, 1992, NEURON, V9, P1013, DOI 10.1016/0896-6273(92)90062-I; KLEIN M, 1980, P NATL ACAD SCI-BIOL, V77, P6912, DOI 10.1073/pnas.77.11.6912; KUHL D, 1992, J CELL BIOL, V119, P1069, DOI 10.1083/jcb.119.5.1069; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LIU JS, 1991, J BIOL CHEM, V266, P19095; LO DC, 1993, P NATL ACAD SCI USA, V90, P7230, DOI 10.1073/pnas.90.15.7230; MCGAUGH JL, 1989, ANNU REV NEUROSCI, V12, P255, DOI 10.1146/annurev.ne.12.030189.001351; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MULLER GE, 1990, Z PSYCHOL, V1, P1; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NATSUKA S, 1992, BLOOD, V79, P460; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; RAYPORT SG, 1986, J NEUROSCI, V6, P759; Russell WR, 1971, TRAUMATIC AMNESIAS; RUSSELL WR, 1946, BRAIN, V69, P183; SCHACHER S, 1988, SCIENCE, V240, P167; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SCHOLZ KP, 1988, SCIENCE, V240, P1664, DOI 10.1126/science.2837826; SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; THOMAS MS, 1987, J MOL BIOL, V196, P333, DOI 10.1016/0022-2836(87)90694-2; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; Zubin J, 1941, P SOC EXP BIOL MED, V48, P596	82	460	471	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1099	1114		10.1016/0092-8674(94)90386-7	http://dx.doi.org/10.1016/0092-8674(94)90386-7			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137425				2022-12-01	WOS:A1994ND24600015
J	GRAZIANO, V; GERCHMAN, SE; SCHNEIDER, DK; RAMAKRISHNAN, V				GRAZIANO, V; GERCHMAN, SE; SCHNEIDER, DK; RAMAKRISHNAN, V			HISTONE H1 IS LOCATED IN THE INTERIOR OF THE CHROMATIN 30-NM FILAMENT	NATURE			English	Article							HIGHER-ORDER STRUCTURE; GLOBULAR DOMAIN; RNA GENES; TRANSCRIPTION; ACCESSIBILITY; ORGANIZATION; ANTIBODIES; FRAGMENTS; EXCHANGE; FIBER	THE linker histone H1 binds to the nucleosome and is essential for the organization of nucleosomes into the 30-nm filament of chromatin(1). It has been implicated in the repression of transcription(2,5), and phosphorylation of H1 may be involved in cell-cycle-dependent chromatin condensation and decondensation(6). A long-standing issue concerns the location of H1 in the chromatin filament(7). The original solenoidal model(8) proposes that H1 is inside the 30-nm filament, but other models, also helical, suggest a variable(9) or more accessible(10) location for H1. Investigations to determine the location of the linker histone based on its accessibility to antibodies(11-15) or immobilized proteases(16) under various ionic conditions have yielded conflicting results. Here we use neutron scattering in a direct structural determination to show that H1 is located in the interior of the filament.	BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	United States Department of Energy (DOE); Brookhaven National Laboratory				Ramakrishnan, V/0000-0002-4699-2194				BANCHEV TB, 1990, MOL CELL BIOCHEM, V95, P167; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CATTINI PA, 1988, J HISTOCHEM CYTOCHEM, V36, P425, DOI 10.1177/36.4.2450120; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DIMITROV SI, 1987, EMBO J, V6, P2387, DOI 10.1002/j.1460-2075.1987.tb02516.x; FELSENFELD G, 1986, CELL, V44, P375, DOI 10.1016/0092-8674(86)90456-3; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; GERCHMAN SE, 1987, P NATL ACAD SCI USA, V87, P7802; GRAZIANO V, 1990, J MOL BIOL, V214, P897, DOI 10.1016/0022-2836(90)90344-L; GRAZIANO V, 1988, J MOL BIOL, V203, P997, DOI 10.1016/0022-2836(88)90124-6; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; IBEL K, 1975, J MOL BIOL, V93, P255, DOI 10.1016/0022-2836(75)90131-X; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; LASTERS I, 1985, EUR J BIOCHEM, V151, P283, DOI 10.1111/j.1432-1033.1985.tb09098.x; LEUBA SH, 1993, J MOL BIOL, V229, P917, DOI 10.1006/jmbi.1993.1096; MCGHEE JD, 1983, CELL, V33, P831, DOI 10.1016/0092-8674(83)90025-9; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; RUSSANOVA VR, 1987, EUR J BIOCHEM, V167, P321, DOI 10.1111/j.1432-1033.1987.tb13339.x; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SERDYUK IN, 1975, BROOKHAVEN S BIOL, V27, P49; SHANNON MF, 1987, J BIOL CHEM, V262, P9664; STUDIER FW, 1990, METHOD ENZYMOL, V185, P61; SUAU P, 1979, EUR J BIOCHEM, V97, P593, DOI 10.1111/j.1432-1033.1979.tb13148.x; THIBODEAU A, 1988, J BIOL CHEM, V263, P16236; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1983, EUR J BIOCHEM, V134, P109, DOI 10.1111/j.1432-1033.1983.tb07538.x; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42	29	100	100	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					351	354		10.1038/368351a0	http://dx.doi.org/10.1038/368351a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127372				2022-12-01	WOS:A1994NB98500051
J	WAISBREN, SJ; GEIBEL, JP; MODLIN, IM; BORON, WF				WAISBREN, SJ; GEIBEL, JP; MODLIN, IM; BORON, WF			UNUSUAL PERMEABILITY PROPERTIES OF GASTRIC GLAND-CELLS	NATURE			English	Article							NH3; PERMEATION; MEMBRANES	PHYSIOLOGISTS have long pondered the riddle of why the stomach is itself not digested by the very juice it secretes. One explanation is that a mucus-bicarbonate barrier, coating the stomach lumen as well as superficial portions of gastric glands, prevents autodigestion(1). However, this leaves unanswered the question of what protects cells deeper in the glands, which seem to lack a mucus barrier(2). These are the parietal and chief cells, which secrete acid and pepsin. Using perfused single gastric glands from rabbit, we recently found that intracellular pH is uniquely resistant to extreme degrees of luminal acidification(2), suggesting that the apical (luminal) barrier might also exclude ammonia and carbon dioxide, to which cell membranes are generally highly permeable(3,4). We now show that this is indeed the case. There are three reports of membranes with very low permeabilities to NH3 (refs 5-7), and none of membranes impermeable to CO2.	YALE UNIV,SCH MED,DEPT SURG,GASTROINTESTINAL SURG PATHOBIOL RES UNIT,NEW HAVEN,CT 06510	Yale University	WAISBREN, SJ (corresponding author), YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510, USA.		Boron, Walter/ABI-1564-2020	Boron, Walter/0000-0003-4741-7287				BORON WF, 1976, NATURE, V259, P240, DOI 10.1038/259240a0; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P83, DOI 10.1007/BF00378645; BURG MB, 1982, KIDNEY INT, V22, P417, DOI 10.1038/ki.1982.194; GARVIN J L, 1988, American Journal of Physiology, V255, pF57; GEIBEL J, 1993, GASTROENTEROLOGY, V104, pA86; GOLCHINI K, 1988, AM J PHYSIOL, V255, pF135, DOI 10.1152/ajprenal.1988.255.1.F135; GUTKNECHT J, 1977, J GEN PHYSIOL, V69, P779; HELANDER HF, 1972, GASTROENTEROLOGY, V63, P951; Jacobs MH, 1922, J GEN PHYSIOL, V5, P181, DOI 10.1085/jgp.5.2.181; Jacobs MH, 1920, AM J PHYSIOL, V51, P321, DOI 10.1152/ajplegacy.1920.51.2.321; KIKERI D, 1989, NATURE, V339, P478, DOI 10.1038/339478a0; LAPENNAS GN, 1977, J EXP BIOL, V67, P175; PRIVER NA, 1993, BIOCHEMISTRY-US, V32, P2459, DOI 10.1021/bi00061a002; SCHOFIELD GC, 1979, J ANAT, V128, P669; SILEN W, 1985, AM J MED, V79, P45, DOI 10.1016/0002-9343(85)90572-8; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TOWNSLEY MC, 1989, AM J PHYSIOL, V257, pG350, DOI 10.1152/ajpgi.1989.257.3.G350; WAISBREN SJ, IN PRESS AM J PHYSL	20	132	136	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					332	335		10.1038/368332a0	http://dx.doi.org/10.1038/368332a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127367				2022-12-01	WOS:A1994NB98500045
J	MOYLE, WR; CAMPBELL, RK; MYERS, RV; BERNARD, MP; HAN, Y; WANG, XY				MOYLE, WR; CAMPBELL, RK; MYERS, RV; BERNARD, MP; HAN, Y; WANG, XY			COEVOLUTION OF LIGAND-RECEPTOR PAIRS	NATURE			English	Article							FOLLICLE-STIMULATING-HORMONE; HUMAN CHORIONIC-GONADOTROPIN; GLYCOPROTEIN HORMONES; EXTRACELLULAR DOMAIN; HIGH-AFFINITY; BETA-SUBUNIT; CHORIOGONADOTROPIN; CHIMERAS; EXPRESSION; SEQUENCE	SPECIFIC receptors for lutropin(1,2) (luteinizing hormone; LH) and follitropin(3,4) (follicle-stimulating hormone; FSH) mediate the actions of human chorionic gonadotropin (hCG) and FSH5 on the gonads. Here we report that short independent sequences of the beta-subunit enable hCG to distinguish between the receptors for FSH and LH. Residues between the 11th and 12th cysteines restrict FSH receptor binding; residues between the 10th and 11th cysteines and, to a much lesser extent, residues carboxy-terminal to the 12th cysteine also affect LH receptor binding. CF101-109, an hCG analogue containing hFSH beta residues between the 11th and 12th cysteines, had high affinity for both LH and FSH receptors. Modifications to CF101-109 that reduce binding to either LH or FSH receptors yield gonadotropin analogues having differing ratios of LH:FSH activity. Ligand-binding specificity of the LH receptor is determined by residues encoded by parts of exons 2-4 and 7-9 which prevent hFSH binding but have little effect on hCG binding. FSH receptor specificity is controlled primarily by residues encoded by exons 5 and 6 that prevent hCG binding but have little effect on hFSH binding. These determinants can be interchanged to create receptor analogues that bind hCG and hFSH. Our observations support a model in which distinct negative determinants restrict ligand-receptor interaction. This explains coevolution of binding specificity in families of homologous ligands and their receptors. Natural or designed manipulation of these determinants leads to the 'evolution' of new, specific protein-protein interactions.			MOYLE, WR (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON RUTGERS MED SCH,DEPT OBSTET & GYNECOL,PISCATAWAY,NJ 08854, USA.		Campbell, Robert/G-4112-2012					BERNARD MP, 1990, MOL CELL ENDOCRINOL, V71, pR19, DOI 10.1016/0303-7207(90)90034-6; BEWLEY TA, 1975, ADV ENZYMOL RAMB, V42, P73; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; BROOKER J, 1992, ADV CYCLIC NUCLEOTID, V10, P1; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; FIDDES JC, 1984, RECENT PROG HORM RES, V40, P43; HECKERT LL, 1992, MOL ENDOCRINOL, V6, P70, DOI 10.1210/me.6.1.70; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LEE J, 1992, J BIOL CHEM, V267, P16283; Licht P, 1976, Recent Prog Horm Res, V33, P169; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1991, J BIOL CHEM, V266, P10807; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY BD, 1991, ENDOCR REV, V12, P27, DOI 10.1210/edrv-12-1-27; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NOCE T, 1989, J MOL ENDOCRINOL, V3, P129, DOI 10.1677/jme.0.0030129; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Segaloff D L, 1990, Recent Prog Horm Res, V46, P261; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; VANOSTADE X, 1993, NATURE, V361, P206; VILCEK J, 1991, J BIOL CHEM, V266, P7313; XIE YB, 1990, J BIOL CHEM, V265, P21411	24	312	328	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					251	255		10.1038/368251a0	http://dx.doi.org/10.1038/368251a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145825				2022-12-01	WOS:A1994NA87000058
J	BIOU, V; YAREMCHUK, A; TUKALO, M; CUSACK, S				BIOU, V; YAREMCHUK, A; TUKALO, M; CUSACK, S			THE 2.9 ANGSTROM CRYSTAL-STRUCTURE OF THERMUS-THERMOPHILUS SERYL-TRANSFER-RNA SYNTHETASE COMPLEXED WITH TRNA(SER)	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; TRANSFER RNA(SER); RESOLUTION; REFINEMENT; SEQUENCE; ERRORS; LOOP; MAPS	The crystal structure of Thermus thermophilus seryl-transfer RNA synthetase, a class 2 aminoacyl-tRNA synthetase, complexed with a single tRNA(Ser) molecule was solved at 2.9 Angstrom resolution. The structure revealed how insertion of conserved base G20b from the D loop into the core of the tRNA determines the orientation of the long variable arm, which is a characteristic feature of most serine specific tRNAs. On tRNA binding, the antiparallel coiled-coil domain of one subunit of the synthetase makes contacts with the variable arm and T Psi C loop of the tRNA and directs the acceptor stem of the tRNA into the active site of the other subunit. Specificity depends principally on recognition of the shape of tRNA(Ser) through backbone contacts and secondarily on sequence specific interactions.	EUROPEAN MOLEC BIOL LAB,F-38042 GRENOBLE,FRANCE	European Molecular Biology Laboratory (EMBL)				Tukalo, Michael/0000-0002-0982-2372; Cusack, Stephen/0000-0002-9324-0796				BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BRENNAN T, 1976, NUCLEIC ACIDS RES, V3, P3235, DOI 10.1093/nar/3.11.3235; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; CAVERELLI J, 1993, NATURE, V362, P181; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DOCKBREGEON AC, 1989, J MOL BIOL, V206, P707, DOI 10.1016/0022-2836(89)90578-0; DOCKBREGEON AC, 1987, COLD SPRING HARB SYM, V52, P113, DOI 10.1101/SQB.1987.052.01.016; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FOURME R, 1992, REV SCI INSTRUM, V63, P982, DOI 10.1063/1.1143716; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LESLIE AGW, 1981, JOINT CCP4 ESF EACBM; MCCLAIN WH, 1993, J MOL BIOL, V234, P257, DOI 10.1006/jmbi.1993.1582; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; NASSAR N, 1992, THESISU GRENOBLE; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1992, P NATL ACAD SCI USA, V89, P5680, DOI 10.1073/pnas.89.12.5680; PETRUSHENKO Z, UNPUB; PRICE S, 1993, FEBS LETT, V324, P167, DOI 10.1016/0014-5793(93)81386-E; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAKS ME, 1991, PROG NUCLEIC ACID RE, V41, P23; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; SUNDHARA.G, 1968, P NATL ACAD SCI USA, V61, P693, DOI 10.1073/pnas.61.2.693; THUNE T, 1993, THESIS TU MUNICH; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589; YAREMCHUK AD, 1992, FEBS LETT, V310, P157, DOI 10.1016/0014-5793(92)81319-H; YAREMCHUK AD, 1992, J MOL BIOL, V224, P519, DOI 10.1016/0022-2836(92)91014-G; YAREMCHUK AD, UNPUB	39	420	431	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1404	1410		10.1126/science.8128220	http://dx.doi.org/10.1126/science.8128220			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128220				2022-12-01	WOS:A1994MZ92700021
J	KONDO, M; TAKESHITA, T; HIGUCHI, M; NAKAMURA, M; SUDO, T; NISHIKAWA, SI; SUGAMURA, K				KONDO, M; TAKESHITA, T; HIGUCHI, M; NAKAMURA, M; SUDO, T; NISHIKAWA, SI; SUGAMURA, K			FUNCTIONAL PARTICIPATION OF THE IL-2 RECEPTOR-GAMMA CHAIN IN IL-7 RECEPTOR COMPLEXES	SCIENCE			English	Article							INTERLEUKIN-2; GENERATION; DEFICIENT; MOLECULE; CLONING; MICE; P64	The gamma chain of the interleukin-2 (IL-2) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency (XSCID), which is ascribed to a profound T cell defect. Studies with monoclonal antibodies specific for the IL-2 receptor gamma chain showed that the gamma chain participates in the functional high-affinity receptor complexes for IL-7 that are involved in the differentiation of T and B cells. Participation of the gamma subunit in more than one receptor may enable the elucidation of the mechanisms of XSCID development and lymphocyte differentiation.	TOHOKU UNIV,SCH MED,DEPT MICROBIOL,SENDAI,MIYAGI 980,JAPAN; TORAY INDUSTRIES LTD,BASIC RES LABS,KAMAKURA,KANAGAWA 248,JAPAN; KYOTO UNIV,FAC MED,DEPT MOLEC GENET,KYOTO,KYOTO 606,JAPAN	Tohoku University; Toray Industries, Inc.; Kyoto University			Takeshita, Toshikazu/AAL-1382-2021					ARMITAGE RJ, 1992, BLOOD, V79, P1738; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; CARDING SR, 1991, IMMUNOL TODAY, V12, P239, DOI 10.1016/0167-5699(91)90037-T; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KONDO M, UNPUB; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUMAKI S, 1993, BIOCHEM BIOPH RES CO, V193, P356, DOI 10.1006/bbrc.1993.1631; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.iy.10.040192.001455; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PARK LS, 1990, J EXP MED, V171, P1073, DOI 10.1084/jem.171.4.1073; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; Takeshita T. Y., UNPUB; TANAKA Y, 1990, INT J CANCER, V46, P675, DOI 10.1002/ijc.2910460421; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G	24	361	372	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1453	1454		10.1126/science.8128231	http://dx.doi.org/10.1126/science.8128231			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128231				2022-12-01	WOS:A1994MZ92700037
J	SHI, L; NISHIOKA, WK; THNG, J; BRADBURY, EM; LITCHFIELD, DW; GREENBERG, AH				SHI, L; NISHIOKA, WK; THNG, J; BRADBURY, EM; LITCHFIELD, DW; GREENBERG, AH			PREMATURE P34(CDC2) ACTIVATION REQUIRED FOR APOPTOSIS	SCIENCE			English	Article							PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; NUCLEAR LAMINA; CDC2 KINASE; IDENTIFICATION; MITOSIS; P34CDC2; SITES; CELLS	Activation of the serine-threonine kinase p34cdc2 at an inappropriate time during the cell cycle leads to cell death that resembles apoptosis. Premature activation of p34cdc2 was shown to be required for apoptosis induced by a lymphocyte granule protease. The kinase was rapidly activated and tyrosine dephosphorylated at the initiation of apoptosis. DNA fragmentation and nuclear collapse could be prevented by blocking p34cdc2 activity with excess peptide substrate, or by inactivating p34cdc2 in a temperature-sensitive mutant. Premature p34cdc2 activation may be a general mechanism by which cells induced to undergo apoptosis initiate the disruption of the nucleus.	UNIV MANITOBA,MANITOBA INST CELL BIOL,100 OLIVIA ST,WINNIPEG R3E 0V9,MANITOBA,CANADA; LA JOLLA INST ALLERGY & IMMUNOL,LA JOLLA,CA 92037; UNIV CALIF DAVIS,DEPT BIOL CHEM,DAVIS,CA 95616	University of Manitoba; La Jolla Institute for Immunology; University of California System; University of California Davis			Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620				BISONETTE RP, 1992, NATURE, V359, P552; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LANGAN TA, 1989, MOL CELL BIOL, V9, P233; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; NISHIOKA WK, IN PRESS J EXP MED; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PASTERNACK MS, 1986, NATURE, V322, P740, DOI 10.1038/322740a0; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Shi L., UNPUB; SHI L, 1993, J EXP MED, V176, P1521; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHIVER JW, 1992, CELL, V71, P615; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; UCKER DS, 1992, MOL CELL BIOL, V12, P3030; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZYCHLINSHY A, 1985, J CELL SCI, V74, P169	25	616	639	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1143	1145		10.1126/science.8108732	http://dx.doi.org/10.1126/science.8108732			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108732				2022-12-01	WOS:A1994MX75900034
J	MILLAUER, B; SHAWVER, LK; PLATE, KH; RISAU, W; ULLRICH, A				MILLAUER, B; SHAWVER, LK; PLATE, KH; RISAU, W; ULLRICH, A			GLIOBLASTOMA GROWTH INHIBITED IN-VIVO BY A DOMINANT-NEGATIVE FLK-1 MUTANT	NATURE			English	Article							RETROVIRAL VECTORS; ANGIOGENESIS; RECEPTOR; EXPRESSION	ANGIOGENESIS, the sprouting of capillaries from pre-existing blood vessels, is a fundamental process in the formation of the vascular system during embryonic development. In adulthood, angiogenesis takes place during corpus luteum formation and in pathological conditions such as wound healing, diabetic retinopathy, and tumorigenesis. Vascularization is essential for solid tumour growth and is thought to be regulated by tumour cell-produced factors, which have a chemotactic and mitogenic effect on endothelial cells1-4. Vascular endothelial growth factor (VEGF), a homodimeric glycoprotein of relative molecular mass 45,000, is the only mitogen, however, that specifically acts on endothelial cells, and it may be a major regulator of tumour angiogeness in vivo5,6. Its expression has been shown to be upregulated by hypoxia, and its cell-surface receptor, Flk-1, is exclusively expressed in endothelial cells7,8. Here we investigate the biological relevance of the VEGF/Flk-1 receptor/ligand system for angiogenesis using a retrovirus encoding a dominant-negative mutant of the Flk-1/VEGF receptor to infect endothelial target cells in vivo, and find that tumour growth is prevented in nude mice. Our results emphasize the central role of the Flk-1 /VEGF system in angiogenesis in general and in the development of solid tumours in particular.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY; SUGEN INC,REDWOOD CITY,CA 94063; MAX PLANCK INST PHYSIOL & CLIN RES,WG KERCKHOFF INST,DEPT MOLEC CELL BIOL,D-61231 BAD NAUHEIM,GERMANY	Max Planck Society; Max Planck Society								AMAYA E, 1991, CELL, V66, P287; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEWART CL, 1987, EMBO J, V6, P383, DOI 10.1002/j.1460-2075.1987.tb04766.x; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331	19	1120	1208	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					576	579		10.1038/367576a0	http://dx.doi.org/10.1038/367576a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	8107827				2022-12-01	WOS:A1994MV86300064
J	KUNDRA, V; ESCOBEDO, JA; KAZLAUSKAS, A; KIM, HK; RHEE, SG; WILLIAMS, LT; ZETTER, BR				KUNDRA, V; ESCOBEDO, JA; KAZLAUSKAS, A; KIM, HK; RHEE, SG; WILLIAMS, LT; ZETTER, BR			REGULATION OF CHEMOTAXIS BY THE PLATELET-DERIVED GROWTH-FACTOR RECEPTOR-BETA	NATURE			English	Article							PHOSPHOLIPASE-C-GAMMA; PDGF RECEPTOR; SIGNALING COMPLEX; ASSOCIATION; BINDING; SITES; GAP; PHOSPHORYLATION; KINASE	CHEMOTAXIS is an important component of wound healing, development, immunity and metastasis, yet the signalling pathways that mediate chemotaxis are poorly understood. Platelet-derived growth factor (PDGF) acts both as a mitogen and a chemoattractant1. Upon stimulation, the tyrosine kinase PDGF receptor-beta (PDGFR-beta) autophosphorylates2 and forms a complex that includes SH2(Src homology 2)-domain-containing proteins such as the phosphatidylinositol-specific phospholipase C-gamma (ref. 3), Ras-GTPase-activating protein (GAP)4, and phosphatidylinositol-3-OH kinase5. Specific tyrosine-to-phenylalanine substitutions in the PDGFR-beta can prevent binding of one SH2-domain-containing protein without affecting binding of other receptor-associated proteins6,7. Here we use phospholipase C-gamma (ref. 8) and PDGFR-beta mutants9-11 to map specific tyrosines involved in both positive and negative regulation of chemotaxis towards the PDGF-BB homodimer. Our results indicate that a delicate balance of migration-promoting (phospholipase C-gamma and phosphatidylinositol-3-OH kinase) and migration-suppressing (GAP) activities are recruited by the PDGFR-beta to drive chemotaxis towards PDGF-BB.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,300 LONGWOOD AVE,BOSTON,MA 02115; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143; NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; University of California System; University of California San Francisco; National Jewish Health; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; COUGHLIN SR, 1989, SCIENCE, V243, P1191; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KIM K, 1991, CELL, V6, P435; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; TURKER MS, 1988, CELL BIOL TOXICOL, V4, P211, DOI 10.1007/BF00119247; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	19	417	421	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					474	476		10.1038/367474a0	http://dx.doi.org/10.1038/367474a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107807				2022-12-01	WOS:A1994MU67900058
J	LEE, IM; MANSON, JE; HENNEKENS, CH; PAFFENBARGER, RS				LEE, IM; MANSON, JE; HENNEKENS, CH; PAFFENBARGER, RS			BODY-WEIGHT AND MORTALITY - A 27-YEAR FOLLOW-UP OF MIDDLE-AGED MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; RELATIVE WEIGHT; MASS INDEX; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; PHYSICAL-ACTIVITY; COLLEGE ALUMNI; RISK-FACTORS; SMOKING; POPULATION	Objective.-To investigate the nature of the relation between body weight and all-cause mortality. Design.-Prospective cohort study, following up men from 1962 or 1966 (1962/1966) through 1988. Setting/Participants.-Harvard University alumni with a mean age of 46.6 years in 1962/1966 and without self-reported, physician-diagnosed coronary heart disease, stroke, or cancer, who completed questionnaires on weight, height, cigarette smoking habit, and physical activity (n=19297). We calculated body mass index (weight in kilograms divided by the square of height in meters) using self-reported measures. Main Outcome Measure.-All-cause mortality (4370 deaths). Results.-In multivariate analysis adjusting for age, cigarette smoking habit, and physical activity, we found a J-shaped relation between body mass index and mortality. Relative risks of dying for men with a body mass index of less than 22.5, 22.5 to less than 23.5, 23.5 to less than 24.5, 24.5 to less than 26.0, and 26.0 or greater were 1.00 (referent), 0.99 (95% confidence interval, 0.89 to 1.20), 0.95 (0.87 to 1.05), 1.01 (0.91 to 1.10), and 1.18 (1.08 to 1.28), respectively (P for linear trend=.0008). Among current smokers, the relation between body mass index and mortality was U-shaped, with lowest risk of death at a body mass index of 23.5 to less than 24.5. During early follow-up (1962/1966 through 1974), we also observed a U-shaped curve, this time with lowest mortality risk at a body mass index of 24.5 to less than 26.0. To minimize confounding by cigarette smoking and bias from antecedent disease and early mortality, we conducted analysis only among never smokers and omitted the first 5 years of follow-up (51 0 deaths). The corresponding relative risks from this analysis, adjusted for age and physical activity, were 1.00, 1.23 (95% confidence interval, 0.90 to 1.67), 1.06 (0.80 to 1.42), 1.27 (0.96 to 1.68), and 1.67 (1.29 to 2.17), respectively (P for linear trend=.0001). Conclusions.-In these prospective data, body weight and mortality were directly related. After accounting for confounding by cigarette smoking and bias resulting from illness-related weight loss or inappropriate control for the biologic effects of obesity, we found no evidence of excess mortality among lean men. Indeed, lowest mortality was observed among men weighing, on average, 20% below the US average for men of comparable age and height.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02115 USA; STANFORD UNIV, MED CTR, SCH MED, DIV EPIDEMIOL, STANFORD, CA 94305 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Stanford University	LEE, IM (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Lee, I-Min/ABD-5409-2021		NATIONAL CANCER INSTITUTE [R01CA044854] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034174] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44854] Funding Source: Medline; NHLBI NIH HHS [HL 34174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; BORHANI NO, 1963, J CHRON DIS, V16, P1251, DOI 10.1016/0021-9681(63)90067-5; BOTTIGER LE, 1980, ATHEROSCLEROSIS, V36, P389, DOI 10.1016/0021-9150(80)90219-1; CAMPBELL AJ, 1990, AGE AGEING, V19, P131, DOI 10.1093/ageing/19.2.131; CHAPMAN JM, 1964, J CHRON DIS, V17, P933, DOI 10.1016/0021-9681(64)90163-8; COMSTOCK GW, 1966, AM J EPIDEMIOL, V83, P548, DOI 10.1093/oxfordjournals.aje.a120606; COX DR, 1972, J R STAT SOC B, V34, P187; DYER AR, 1975, J CHRON DIS, V28, P109, DOI 10.1016/0021-9681(75)90067-3; FITZGERALD AP, 1992, INT J OBESITY, V16, P119; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; GARFINKEL L, 1988, CANCER, V62, P1844, DOI 10.1002/1097-0142(19881015)62:1+<1844::AID-CNCR2820621328>3.0.CO;2-O; GARN SM, 1983, AM J CLIN NUTR, V38, P313, DOI 10.1093/ajcn/38.2.313; GARRISON RJ, 1983, JAMA-J AM MED ASSOC, V249, P2199, DOI 10.1001/jama.249.16.2199; GORDON T, 1988, INT J EPIDEMIOL, V17, P77, DOI 10.1093/ije/17.1.77; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KEYS A, 1989, ANN MED, V21, P163, DOI 10.3109/07853898909149927; KEYS A, 1971, ARCH INTERN MED, V128, P201, DOI 10.1001/archinte.1971.00310200037002; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KOZAREVIC D, 1976, AM J EPIDEMIOL, V104, P133, DOI 10.1093/oxfordjournals.aje.a112283; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; LEE IM, 1992, AM J EPIDEMIOL, V135, P915, DOI 10.1093/oxfordjournals.aje.a116387; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LINDSTED K, 1991, INT J OBESITY, V15, P397; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; Lissner L., 1989, Obesity in Europe 88. Proceedings of the 1st European Congress on Obesity, 5-6 June, 1988, Stockholm, Sweden., P55; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; NOPPA H, 1980, AM J EPIDEMIOL, V111, P682, DOI 10.1093/oxfordjournals.aje.a112946; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PALTA M, 1982, AM J EPIDEMIOL, V115, P223, DOI 10.1093/oxfordjournals.aje.a113294; PAUL O, 1963, CIRCULATION, V28, P20, DOI 10.1161/01.CIR.28.1.20; PYORALA K, 1979, J CHRON DIS, V32, P729, DOI 10.1016/0021-9681(79)90052-3; RABKIN SW, 1977, AM J CARDIOL, V39, P452, DOI 10.1016/S0002-9149(77)80104-5; RHOADS GG, 1983, LANCET, V1, P492; RISSANEN A, 1989, J CLIN EPIDEMIOL, V42, P781, DOI 10.1016/0895-4356(89)90076-0; ROSENMAN RH, 1976, AM J CARDIOL, V37, P903, DOI 10.1016/0002-9149(76)90117-X; SCHROLL M, 1981, DAN MED BULL, V28, P106; SIDNEY S, 1987, AM J PUBLIC HEALTH, V77, P317, DOI 10.2105/AJPH.77.3.317; STEVENS J, 1992, AM J EPIDEMIOL, V135, P1137, DOI 10.1093/oxfordjournals.aje.a116214; STEVENS J, 1992, ARCH INTERN MED, V152, P1257, DOI 10.1001/archinte.152.6.1257; STEWART AW, 1987, AM J EPIDEMIOL, V125, P122, DOI 10.1093/oxfordjournals.aje.a114494; STUNKARD AJ, 1981, AM J CLIN NUTR, V34, P1593, DOI 10.1093/ajcn/34.8.1593; TIBBLIN G, 1975, AM J CARDIOL, V35, P514, DOI 10.1016/0002-9149(75)90834-6; TUOMILEHTO J, 1987, BRIT MED J, V295, P623, DOI 10.1136/bmj.295.6599.623; VANDENBROUCKE JP, 1984, JAMA-J AM MED ASSOC, V252, P2859, DOI 10.1001/jama.252.20.2859; WAALER HT, 1984, ACTA MED SCAND, P1; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WESTLUND K, 1972, SCAND J CLIN LAB INV, V30, P1; WILCOSKY T, 1990, J CLIN EPIDEMIOL, V43, P743, DOI 10.1016/0895-4356(90)90232-E; WILLETT WC, 1991, AM J CLIN NUTR, V53, P1102, DOI 10.1093/ajcn/53.5.1102; WILLIAMSON DF, 1991, NEW ENGL J MED, V324, P739, DOI 10.1056/NEJM199103143241106; [No title captured]; 1990, NUTRITION YOUR HLTH; 1959, B METROPOLITAN LIFE, V40, P1; 1966, VITAL HLTH STAT, V11; 1980, BUILD STUDY 1979	59	334	335	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2823	2828		10.1001/jama.270.23.2823	http://dx.doi.org/10.1001/jama.270.23.2823			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK941	8133621				2022-12-01	WOS:A1993MK94100031
J	SAUVE, JS; LAUPACIS, A; OSTBYE, T; FEAGAN, B; SACKETT, DL				SAUVE, JS; LAUPACIS, A; OSTBYE, T; FEAGAN, B; SACKETT, DL			DOES THIS PATIENT HAVE A CLINICALLY IMPORTANT CAROTID BRUIT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATURAL-HISTORY; HIGH-GRADE; STROKE; RISK; POPULATION; STENOSIS; SURGERY; TRIALS; NECK		MCMASTER UNIV, DEPT MED, HAMILTON L8S 4L8, ONTARIO, CANADA; MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON L8S 4L8, ONTARIO, CANADA; UNIV OTTAWA, DEPT MED, OTTAWA K1N 6N5, ONTARIO, CANADA; UNIV OTTAWA, DEPT EPIDEMIOL & COMMUNITY MED, OTTAWA K1N 6N5, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT EPIDEMIOL & BIOSTAT, LONDON N6A 3K7, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT FAMILY MED, LONDON N6A 3K7, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT MED, LONDON N6A 3K7, ONTARIO, CANADA	McMaster University; McMaster University; University of Ottawa; University of Ottawa; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)			Feagan, Brian G/M-4283-2015					BARNES RW, 1981, SURGERY, V90, P1075; CHAMBERS BR, 1985, NEUROLOGY, V35, P742, DOI 10.1212/WNL.35.5.742; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EVANS WE, 1978, SURGERY, V83, P521; FOWLER NO, 1964, AM HEART J, V67, P135, DOI 10.1016/0002-8703(64)90409-0; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HARRISON MJG, 1984, BRIT J HOSP MED, V32, P80; HAYNES RB, 1992, CLIN RES, V40, pA184; HEYMAN A, 1980, NEW ENGL J MED, V302, P838, DOI 10.1056/NEJM198004103021504; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; HURST JW, 1980, NEW ENGL J MED, V302, P862, DOI 10.1056/NEJM198004103021512; INGALL TJ, 1989, ARCH NEUROL-CHICAGO, V46, P418, DOI 10.1001/archneur.1989.00520400078023; IVEY TD, 1984, J THORAC CARDIOV SUR, V87, P183; JONES FL, 1962, NEW ENGL J MED, V267, P658, DOI 10.1056/NEJM196209272671307; MATTHEWS WB, 1961, J NEUROL NEUROSUR PS, V24, P161, DOI 10.1136/jnnp.24.2.161; MESSERT B, 1977, ANN NEUROL, V2, P535, DOI 10.1002/ana.410020616; RATCHESON RA, 1982, CLIN NEUR, V29, P464; ROPPER AH, 1982, NEW ENGL J MED, V307, P1388, DOI 10.1056/NEJM198211253072207; SAUVE S, 1992, CLIN RES, V40, pA304; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; VANRUISWYK J, 1990, ANN INTERN MED, V112, P340, DOI 10.7326/0003-4819-112-5-340; WADIA NH, 1957, BRAIN, V80, P492, DOI 10.1093/brain/80.4.492; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WIEBERS DO, 1990, STROKE, V21, P984, DOI 10.1161/01.STR.21.7.984; WOLF PA, 1981, JAMA-J AM MED ASSOC, V245, P1442, DOI 10.1001/jama.245.14.1442; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZIEGLER DK, 1971, NEUROLOGY, V21, P860, DOI 10.1212/WNL.21.8.860	27	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2843	2845		10.1001/jama.270.23.2843	http://dx.doi.org/10.1001/jama.270.23.2843			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK941	8133624				2022-12-01	WOS:A1993MK94100035
J	BUSCHARD, K; JOSEFSEN, K; HORN, T; FREDMAN, P				BUSCHARD, K; JOSEFSEN, K; HORN, T; FREDMAN, P			SULFATIDE AND SULFATIDE ANTIBODIES IN INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Note							SULFATIDE	Insulin-dependent diabetes mellitus (IDDM) is associated with neurological disorders. Sulph I, a monoclonal antibody to sulphatide (a neural epitope), stained secretory granules in alpha and beta cells of rat islets of Langerhans, but not exocrine tissue. Sera from 88% of 57 newly diagnosed IDDM patients was anti-sulphatide positive, and 76% were positive 6 months later. All 135 healthy controls were negative. Sulphatide antibody may be an IDDM marker.	MOLNDALS SJUKHUS,DEPT CLIN NEUROSCI,PSYCHIAT & NEUROCHEM SECT,MOLNDAL,SWEDEN; HERLEV HOSP,DEPT PATHOL,DK-2730 HERLEV,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital	BUSCHARD, K (corresponding author), KOMMUNE HOSP COPENHAGEN,BARTHOLIN INST,DK-1399 COPENHAGEN K,DENMARK.			Buschard, Karsten/0000-0002-0126-7423				BUSCHARD K, 1983, DIABETOLOGIA, V24, P42; DEAN BM, 1986, DIABETOLOGIA, V29, P339, DOI 10.1007/BF00452073; FREDMAN P, 1991, J NEUROL, V238, P75, DOI 10.1007/BF00315684; FREDMAN P, 1988, BIOCHEM J, V251, P17, DOI 10.1042/bj2510017; FREDMAN P, 1993, J NEUROL, V240, P382; GLEICHMANN H, 1987, DIABETES, V36, P578, DOI 10.2337/diabetes.36.5.578; MARSHALL MO, 1992, J IMMUNOL METHODS, V149, P63, DOI 10.1016/S0022-1759(12)80049-4; RABINOWE SL, 1990, DIABETES METAB REV, V6, P169, DOI 10.1002/dmr.5610060304	8	53	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					840	840		10.1016/0140-6736(93)92697-R	http://dx.doi.org/10.1016/0140-6736(93)92697-R			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104274				2022-12-01	WOS:A1993MA02500011
J	JUDICE, JK; GAMBLE, TR; MURPHY, EC; DEVOS, AM; SCHULTZ, PG				JUDICE, JK; GAMBLE, TR; MURPHY, EC; DEVOS, AM; SCHULTZ, PG			PROBING THE MECHANISM OF STAPHYLOCOCCAL NUCLEASE WITH UNNATURAL AMINO-ACIDS - KINETIC AND STRUCTURAL STUDIES	SCIENCE			English	Article							ACTIVE-SITE; MAGNETIC-RESONANCE; CRYSTAL-STRUCTURE; DOUBLE MUTANT; SUBSTITUTIONS; RESOLUTION; CATALYSIS; PROTEINS; COMPLEX	Staphylococcal nuclease is an enzyme with enormous catalytic power, accelerating phosphodiester bond hydrolysis by a factor of 10(16) over the spontaneous rate. The mechanistic basis for this rate acceleration was investigated by substitution of the active site residues Glu43, Arg35, and Arg87 With unnatural amino acid analogs. Two Glu43 mutants, one containing the nitro analog of glutamate and the other containing homoglutamate, retained high catalytic activity at pH 9.9, but were less active than the wild-type enzyme at lower pH values. The x-ray crystal structure of the homoglutamate mutant revealed that the carboxylate side chain of this residue occupies a position and orientation similar to that of Glu43 in the wild-type enzyme. The increase in steric bulk is accommodated by a backbone shift and altered torsion angles. The nitro and the homoglutamate mutants display similar pH versus rate profiles, which differ from that of the wild-type enzyme. Taken together, these studies suggest that Glu43 may not act as a general base, as previously thought, but may play a more complex structural role during catalysis.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, GRAD GRP BIOPHYS, SAN FRANCISCO, CA 94143 USA; GENENTECH INC, DEPT PROT ENGN, S SAN FRANCISCO, CA 94080 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco; Roche Holding; Genentech					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008388, F32GM014012, R01GM049220] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM-08388, R01 GM49220, GM 14012-02S1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNETT EM, 1963, PROG PHYS ORG CHEM, V1, P223, DOI 10.1002/9780470171806.ch5; BRUNGER AT, 1992, XPLOR MANUAL; COTTON FA, 1979, P NATL ACAD SCI USA, V76, P2551, DOI 10.1073/pnas.76.6.2551; CUATRECA.P, 1967, J BIOL CHEM, V242, P1541; DUNN BM, 1973, J BIOL CHEM, V248, P4769; ELLMAN J, 1991, METHOD ENZYMOL, V202, P301; HALE SP, IN PRESS BIOCHEMISTR; HERMANN P, 1968, H-S Z PHYSIOL CHEM, V349, P390, DOI 10.1515/bchm2.1968.349.1.390; HIBLER DW, 1987, BIOCHEMISTRY-US, V26, P6278, DOI 10.1021/bi00393a048; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; JOESTEN MD, 1974, HYDROGEN BONDING, P309; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LESLEY SA, UNPUB; LOLL PJ, 1990, BIOCHEMISTRY-US, V29, P6866, DOI 10.1021/bi00481a016; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; MEHDI S, 1982, J AM CHEM SOC, V104, P3223, DOI 10.1021/ja00375a053; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; POURMOTABBED T, 1990, BIOCHEMISTRY-US, V29, P3677, DOI 10.1021/bi00467a013; SAMPSON NS, 1992, BIOCHEMISTRY-US, V31, P8488, DOI 10.1021/bi00151a015; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; Schowen R. L., 1977, ISOTOPE EFFECTS ENZY, P64; SERPERSU EH, 1987, BIOCHEMISTRY-US, V26, P1289, DOI 10.1021/bi00379a014; SERPERSU EH, 1986, BIOCHEMISTRY-US, V25, P68, DOI 10.1021/bi00349a011; SHORTLE D, 1983, GENE, V22, P181, DOI 10.1016/0378-1119(83)90102-6; SLATER CD, 1981, J ORG CHEM, V46, P2173, DOI 10.1021/jo00323a041; SUICH DJ, 1993, THESIS U CALIFORNIA; TAKAHARA M, 1985, J BIOL CHEM, V260, P2670; WEBER DJ, 1990, BIOCHEMISTRY-US, V29, P8632, DOI 10.1021/bi00489a020; WEBER DJ, 1991, BIOCHEMISTRY-US, V30, P6103, DOI 10.1021/bi00239a004; WEBER DJ, 1992, PROTEINS, V13, P275, DOI 10.1002/prot.340130402; WILDE JA, 1988, BIOCHEMISTRY-US, V27, P4127, DOI 10.1021/bi00411a033	31	80	81	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1993	261	5128					1578	1581		10.1126/science.8103944	http://dx.doi.org/10.1126/science.8103944			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8103944				2022-12-01	WOS:A1993LX47400030
J	FREI, E				FREI, E			GENE DELETION - A NEW TARGET FOR CANCER-CHEMOTHERAPY	LANCET			English	Article							CELL LUNG-CANCER; RETINOBLASTOMA; 5-FLUOROURACIL; INACTIVATION; TOXICITY				FREI, E (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,44 BINNEY ST,BOSTON,MA 02115, USA.							BERTINO JR, 1993, CANC MED, P698; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRENT TP, 1985, P NATL ACAD SCI USA, V82, P2985, DOI 10.1073/pnas.82.9.2985; DIASIO RB, 1989, CLIN PHARMACOKINET, V16, P215, DOI 10.2165/00003088-198916040-00002; FREI E, 1993, CANCER MED, P631; GELEHRTER TD, 1990, PRINCIPLERS MED GENE, P255; HARRIS BE, 1991, CANCER, V68, P499, DOI 10.1002/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LEE WH, 1987, HUM GENET, V76, P33; LILENBAUM RC, 1992, P AM SOC CLIN ONCOL, V33, P11; Meyer U A, 1990, Prog Liver Dis, V9, P307; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; OWENS TK, 1992, CANCER RES, V82, P2389; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; REMICK SC, 1990, CANCER RES, V50, P2667; SAGER R, 1984, CANCER SURV, V3, P321; TUCHMAN M, 1985, NEW ENGL J MED, V313, P245, DOI 10.1056/NEJM198507253130407; WAXMAN DJ, 1990, CANCER RES, V50, P6449; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WOLFENDEN R, 1975, BIOCHEMISTRY-US, V14, P599; 1987, CYTOGENET CELL GENET, V46, P1	23	17	18	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					662	664		10.1016/0140-6736(93)91764-D	http://dx.doi.org/10.1016/0140-6736(93)91764-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103151				2022-12-01	WOS:A1993LX27200015
J	KAMEOKA, J; TANAKA, T; NOJIMA, Y; SCHLOSSMAN, SF; MORIMOTO, C				KAMEOKA, J; TANAKA, T; NOJIMA, Y; SCHLOSSMAN, SF; MORIMOTO, C			DIRECT ASSOCIATION OF ADENOSINE-DEAMINASE WITH A T-CELL ACTIVATION ANTIGEN, CD26	SCIENCE			English	Article							DIPEPTIDYL PEPTIDASE-IV; AMINO-ACID-SEQUENCE; COMPLEXING PROTEIN; MONOCLONAL-ANTIBODIES; BINDING-PROTEIN; SURFACE; EXPRESSION; 1F7; CHROMOSOME-2; ASSIGNMENT	CD26, the T cell activation molecule dipeptidyl peptidase IV (DPPIV), associates with a 43-kilodalton protein. Amino acid sequence analysis and immunoprecipitation studies demonstrated that this 43-kilodalton protein was adenosine deaminase (ADA). ADA was coexpressed with CD26 on the Jurkat T cell lines, and an in vitro binding assay showed that the binding was through the extracellular domain of CD26. ADA deficiency causes severe combined immunodeficiency disease (SCID) in humans. Thus, ADA and CD26 (DPPIV) interact on the T cell surface, and this interaction may provide a clue to the pathophysiology of SCID caused by ADA deficiency.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NIAID NIH HHS [AI29530, AI12069] Funding Source: Medline; NIAMS NIH HHS [AR33713] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012069, R01AI012069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033713] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDY RJ, 1982, J BIOL CHEM, V257, P7922; ARAN JM, 1991, J HISTOCHEM CYTOCHEM, V39, P1001, DOI 10.1177/39.8.1856451; BARANKIEWICZ J, 1988, J BIOL CHEM, V263, P7094; BLAESE RM, 1993, PEDIATR RES, V33, pS49, DOI 10.1203/00006450-199304001-00010; BUC HA, 1990, EUR J IMMUNOL, V20, P611, DOI 10.1002/eji.1830200322; CAMM AJ, 1991, NEW ENGL J MED, V325, P1621, DOI 10.1056/NEJM199112053252306; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DADDONA PE, 1984, J BIOL CHEM, V259, P2101; DANG NH, 1991, J IMMUNOL, V147, P2825; DANG NH, 1990, J IMMUNOL, V145, P3963; DANG NH, 1990, J EXP MED, V172, P649, DOI 10.1084/jem.172.2.649; DANG NH, 1990, J IMMUNOL, V144, P4092; DARMOUL D, 1990, ANN HUM GENET, V54, P191, DOI 10.1111/j.1469-1809.1990.tb00377.x; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DINJENS WNM, 1989, J BIOL CHEM, V264, P19215; FLEISCHER B, 1987, J IMMUNOL, V138, P1346; FOX DA, 1984, J IMMUNOL, V133, P1250; HEGEN M, 1990, J IMMUNOL, V144, P2908; HERBSCHLEBVOOGT E, 1981, HUM GENET, V59, P317, DOI 10.1007/BF00295464; HIRSCHHORN R, 1993, PEDIATR RES, V33, pS35; HIRSCHHORN R, 1990, Immunodeficiency Reviews, V2, P175; KAMEOKA J, UNPUB; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; MOORE KA, 1990, BLOOD, V75, P2085; MORIMOTO C, 1989, J IMMUNOL, V143, P3430; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; SCHARENBERG JGM, 1990, INT J IMMUNOPHARMACO, V12, P113, DOI 10.1016/0192-0561(90)90074-W; SCHRADER WP, 1988, J HISTOCHEM CYTOCHEM, V36, P1481, DOI 10.1177/36.12.2461411; SCHRADER WP, 1990, J BIOL CHEM, V265, P19312; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P4586, DOI 10.1073/pnas.90.10.4586; TANAKA T, 1992, J IMMUNOL, V149, P481; Tanaka T., UNPUB; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; TORIMOTO Y, 1992, MOL IMMUNOL, V29, P183, DOI 10.1016/0161-5890(92)90099-J; ULMER AJ, 1990, SCAND J IMMUNOL, V31, P429, DOI 10.1111/j.1365-3083.1990.tb02789.x	35	458	477	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					466	469		10.1126/science.8101391	http://dx.doi.org/10.1126/science.8101391			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8101391				2022-12-01	WOS:A1993LN62300034
J	WATTERSON, A				WATTERSON, A			CHEMICAL HAZARDS AND PUBLIC CONFIDENCE	LANCET			English	Editorial Material											WATTERSON, A (corresponding author), NOTTINGHAM TRENT UNIV,CTR OCCUPAT SAFETY & HLTH,NOTTINGHAM,ENGLAND.							[Anonymous], 1992, RISK ANAL PERCEPTION; Avery N., 1993, CRACKING CODEX ANAL; KRAUS N, 1992, RISK ANAL, V12, P215, DOI 10.1111/j.1539-6924.1992.tb00669.x; 1976, ENV HLTH CRITERIA, V1; 1993, DRAFT ENV HLTH CRITE; 1991, ENV HLTH CRITERIA, V126	6	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					131	132		10.1016/0140-6736(93)91341-I	http://dx.doi.org/10.1016/0140-6736(93)91341-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101252				2022-12-01	WOS:A1993LN04200007
J	FISHER, PJ; PRENDERGAST, FG; EHRHARDT, MR; URBAUER, JL; WAND, AJ; SEDAROUS, SS; MCCORMICK, DJ; BUCKLEY, PJ				FISHER, PJ; PRENDERGAST, FG; EHRHARDT, MR; URBAUER, JL; WAND, AJ; SEDAROUS, SS; MCCORMICK, DJ; BUCKLEY, PJ			CALMODULIN INTERACTS WITH AMPHIPHILIC PEPTIDES COMPOSED OF ALL D-AMINO ACIDS	NATURE			English	Article							LIGHT-CHAIN KINASE; MULTIDIMENSIONAL NMR; COMPLEX-FORMATION; BINDING DOMAIN; PROTEINS; MELITTIN; RECOGNITION; SEQUENCE; SPECTRA; ENZYME	CALMODULIN binds to amphiphilic, helical peptides of a variety of amino-acid sequences1-8. These peptides are usually positively charged, although there is spectroscopic evidence that at least one neutral peptide binds5. The complex between calmodulin and one of its natural target peptides, the binding site for calmodulin on smooth muscle myosin light-chain kinase (RS20)9, has been investigated by crystallography10 and NMR11-13 which have characterized the interactions between the ligand and the protein. From these data, it appears that the calmodulin-binding surface is sterically malleable and van der Waals forces probably dominate the binding. To explore further this apparently permissive binding, we investigated the chiral selectivity of calmodulin using synthesized analogues of melittin and RS20 that consisted of only D-amino acids. Fluorescence and NMR measurements show that D-melittin and D-RS20 both bind avidly to calmodulin, probably in the same general binding site as that for peptides having all L-amino acids. The calmodulin-peptide binding surface is therefore remarkably tolerant sterically. Our results suggest a potentially useful approach to the design of non-hydrolysable or slowly hydrolysable intracellular inhibitors of calmodulin.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,200 1ST ST SW,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; UNIV ILLINOIS,SCH CHEM SCI,DEPT BIOCHEM,URBANA,IL 61801	Mayo Clinic; Mayo Clinic; University of Illinois System; University of Illinois Urbana-Champaign								BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; COMTE M, 1983, BIOCHEM J, V209, P269, DOI 10.1042/bj2090269; CORIGLIANOMURPHY MA, 1985, INT J PEPT PROT RES, V25, P225; COX JA, 1985, J BIOL CHEM, V260, P2527; DEGRADO WF, 1985, J CELL BIOCHEM, V29, P83, DOI 10.1002/jcb.240290204; DINTZIS HM, 1993, PROTEINS, V16, P306, DOI 10.1002/prot.340160309; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; HUANG CY, 1982, METHOD ENZYMOL, V87, P509; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1991, BIOCHEMISTRY-US, V30, P5498, DOI 10.1021/bi00236a024; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MALENCIK DA, 1984, BIOCHEMISTRY-US, V23, P2420, DOI 10.1021/bi00306a016; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MAULET Y, 1983, BIOCHEMISTRY-US, V22, P5680, DOI 10.1021/bi00293a035; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; NOMIZU M, 1992, J BIOL CHEM, V267, P14118; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ROTH SM, 1991, BIOCHEMISTRY-US, V30, P10078, DOI 10.1021/bi00106a003; ROTH SM, 1992, BIOCHEMISTRY-US, V31, P1433; Seeholzer S.H., 1987, CALCIUM BINDING PROT, P360; SEEHOLZER SH, 1989, BIOCHEMISTRY-US, V28, P4011, DOI 10.1021/bi00435a057; TERWILLIGER TC, 1982, BIOPHYS J, V37, P353, DOI 10.1016/S0006-3495(82)84683-3; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; TOMITA U, 1991, BIOCHEM BIOPH RES CO, V178, P400, DOI 10.1016/0006-291X(91)91827-Y; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761	28	59	62	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					651	653		10.1038/368651a0	http://dx.doi.org/10.1038/368651a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145853				2022-12-01	WOS:A1994NF39200065
J	ZHONG, Z; WEN, ZL; DARNELL, JE				ZHONG, Z; WEN, ZL; DARNELL, JE			STAT3 - A STAT FAMILY MEMBER ACTIVATED BY TYROSINE PHOSPHORYLATION IN RESPONSE TO EPIDERMAL GROWTH-FACTOR AND INTERLEUKIN-6	SCIENCE			English	Article							INTERFERON-ALPHA; TRANSCRIPTIONAL ACTIVATOR; BINDING PROTEIN; PROMOTER; ISGF-3; GAMMA	The STAT family of proteins carries out a dual function: signal transduction and activation of transcription. A new family member, Stat3, becomes activated through phosphorylation on tyrosine as a DNA binding protein in response to epidermal growth factor (EGF) and interleukin-6 (IL-6) but not interferon gamma (IFN-gamma). It is likely that this phosphoprotein forms homodimers as well as heterodimers with the first described member of the STAT family, Stat91 (renamed Stat1alpha), which is activated by the IFNs and EGF. Differential activation of different STAT proteins in response to different ligands should help to explain specificity in nuclear signaling from the cell surface.			ZHONG, Z (corresponding author), ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021, USA.				NIAID NIH HHS [AI32489] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; RUFFJAMISONS, 1993, SCIENCE, V261, P1733; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAI K, IN PRESS CELL; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YAMAMOTO K, UNPUB; ZHONG Z, IN PRESS P NATL ACAD	23	1751	1816	3	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					95	98		10.1126/science.8140422	http://dx.doi.org/10.1126/science.8140422			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	8140422				2022-12-01	WOS:A1994ND53600038
J	WADDLE, DM				WADDLE, DM			MATRIX CORRELATION TESTS SUPPORT A SINGLE ORIGIN FOR MODERN HUMANS	NATURE			English	Article							HOMINID BURIAL SITE; ESR DATES; ISRAEL; EVOLUTION	THE debate over human origins has focused on two competing theories. The single African origin model holds that anatomically modern Homo sapiens evolved in Africa 100,000-200,000 years ago. Members of this population migrated out of Africa, replacing archaic human groups through Asia and Europe, with racial differentiation occurring within the past 100,000 years1-3. The alternative regional continuity model proposes continuous evolution over the past million years, with racial variation developing early, and similar modern human traits developing in all regions as the result of worldwide gene flow4-6. The persistence of specific morphological features within regions over the past million years supports regional continuity, whereas the identification of anatomically modern fossil specimens from Africa and the Levant 50-60,000 years before they are found elsewhere, provides support for a single origin. I give here the first quantitative test of the fossil evidence for each of these models. Results support a single African and/or Levantine origin for modern humans.	SUNY STONY BROOK,DOCTORAL PROGRAM ANTHROPOL SCI,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								Clarke R.J., 1985, P301; Cooke HBS, 1945, MAN, V45, P6, DOI 10.2307/2793006; DELSON E, 1988, NATURE, V332, P206, DOI 10.1038/332206a0; GRUN R, 1991, ARCHAEOMETRY, V33, P153, DOI 10.1111/j.1475-4754.1991.tb00696.x; GRUN R, 1990, NATURE, V344, P537, DOI 10.1038/344537a0; HAY RL, 1987, RESULTS LAETOLI EXPE, P23; Howells WW., 1973, PAP PEABODY MUS ARCH, V67, P1; Leakey M. D., 1982, HOMO ERECTUS PLACE H, P753; MANTEL N, 1967, CANCER RES, V27, P209; MERCIER N, 1993, J ARCHAEOL SCI, V20, P169, DOI 10.1006/jasc.1993.1012; SCHWARCZ HP, 1988, J HUM EVOL, V17, P733, DOI 10.1016/0047-2484(88)90063-2; SMOUSE PE, 1992, YEARB PHYS ANTHROPOL, V35, P187; Sneath Peter HA., 1973, NUMERICAL TAXONOMY P, DOI 10.2307/2412767; SOKAL RR, 1991, NATURE, V351, P143, DOI 10.1038/351143a0; STRINGER C, 1988, SCIENCE, V241, P773, DOI 10.1126/science.241.4867.773; Stringer C.B., 1985, P289; STRINGER CB, 1989, NATURE, V338, P756, DOI 10.1038/338756a0; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; THORNE AG, 1992, SCI AM, V266, P76, DOI 10.1038/scientificamerican0492-76; VALLADAS H, 1988, NATURE, V331, P614, DOI 10.1038/331614a0; Vandermeersch B., 1985, P306; Vandermeersch B., 1981, HOMMES FOSSILES QAFZ; WADDLE DM, 1993, THESIS STATE U NEW Y; WOLPOFF MH, 1988, SCIENCE, V241, P772, DOI 10.1126/science.3136545; WOLPOFF MH, 1989, HUMAN REVOLUTION, P62	25	75	76	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 31	1994	368	6470					452	454		10.1038/368452a0	http://dx.doi.org/10.1038/368452a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ND120	8133890				2022-12-01	WOS:A1994ND12000062
J	WEBB, PM; KNIGHT, T; GREAVES, S; WILSON, A; NEWELL, DG; ELDER, J; FORMAN, D				WEBB, PM; KNIGHT, T; GREAVES, S; WILSON, A; NEWELL, DG; ELDER, J; FORMAN, D			RELATION BETWEEN INFECTION WITH HELICOBACTER-PYLORI AND LIVING-CONDITIONS IN CHILDHOOD - EVIDENCE FOR PERSON-TO-PERSON TRANSMISSION IN EARLY-LIFE	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER-PYLORI; SEROPREVALENCE; EPIDEMIOLOGY; FAMILIES	Objectives-To relate the prevalence of infection with Helicobacter pylori in adults to their living conditions in childhood to identify risk factors for infection. Design-Prevalence study of IgG antibodies to H pylori (> 10 mu g IgG/ml, determined by enzyme linked immunosorbent assay (ELISA)) and reported living conditions and other socioeconomic factors in childhood. Setting-Three factories in Stoke on Trent. Subjects-471 male volunteers aged 18 to 65 years. Main outcome measures-Seroprevalence and variables in childhood. Results-Seroprevalence of H pylori increased with age (22/74 (29.7%) at < 30 years v 29/46 (63%) at 55-65 years; P < 0.001 for trend) and was related to manual occupation (14/65 (21.5%) for non-manual v 162/406 (39.9%) for manual; P = 0.003). After data were adjusted for age and occupation subjects from large families, whose childhood homes were crowded or who regularly shared a bed in childhood, were significantly more likely to be seropositive (adjusted odds ratio (95% confidence interval) 2.15 (1.41 to 3.30) for crowding and 2.13 (1.38 to 3.30) for sharing a bed), but there was no relation with possession of a bathroom, inside toilet, refrigerator, or household pets in childhood. Conclusions-Close person to person contact in childhood is an important determinant of seroprevalence of H pylori in adulthood, suggesting that the infection is transmitted directly from one person to another and may be commonly acquired in early life.	UNIV KEELE,DEPT SURG,STOKE ON TRENT,STAFFS,ENGLAND; CENT VET LABS,APPL & MOLEC IMMUNOL UNIT,WEYBRIDGE KT15 4NB,SURREY,ENGLAND	Keele University	WEBB, PM (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,OXON,ENGLAND.		Webb, Penelope/D-5736-2013	Webb, Penelope/0000-0003-0733-5930				[Anonymous], 1980, CLASSIFICATION OCCUP; BANATVALA N, 1993, J INFECT DIS, V168, P219, DOI 10.1093/infdis/168.1.219; BERKOWICZ J, 1987, LANCET, V2, P680; DIXON MF, 1992, HELICOBACTER PYLORI, P124; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; FORMAN D, 1992, EUR J GASTROEN HEPAT, V4, pS31; GALPIN OP, 1992, LANCET, V339, P619, DOI 10.1016/0140-6736(92)90907-K; HAMMERMEISTER I, 1992, EUR J CLIN MICROBIOL, V11, P9, DOI 10.1007/BF01971264; KRAJDEN S, 1989, J CLIN MICROBIOL, V27, P1397, DOI 10.1128/JCM.27.6.1397-1398.1989; MALATY HM, 1991, SCAND J GASTROENTERO, V26, P927, DOI 10.3109/00365529108996244; MEGRAUD F, 1992, HELICOBACTER PYLORI, P107; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; MITCHELL HM, 1987, LANCET, V2, P681; PEREZPEREZ GI, 1991, J CLIN MICROBIOL, V29, P642, DOI 10.1128/JCM.29.3.642-644.1991; PEREZPEREZ GI, 1990, J INFECT DIS, V161, P1237, DOI 10.1093/infdis/161.6.1237; SOBALA GM, 1992, HELICOBACTER PYLORI, P150; STEER HW, 1987, SERODIAGN IMMUNOTHER, V1, P253; TALLEY NJ, 1991, J CLIN MICROBIOL, V29, P1635, DOI 10.1128/JCM.29.8.1635-1639.1991; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L; WHITAKER CJ, 1993, EPIDEMIOL INFECT, V111, P63, DOI 10.1017/S0950268800056685; WYATT JI, 1992, HELICOBACTER PYLORI, P140; 1986, BRITAINS HOUSEHOLDS, V4	24	298	307	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					750	753		10.1136/bmj.308.6931.750	http://dx.doi.org/10.1136/bmj.308.6931.750			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142828	Green Published			2022-12-01	WOS:A1994NC34800017
J	SEBZDA, E; WALLACE, VA; MAYER, J; YEUNG, RSM; MAK, TW; OHASHI, PS				SEBZDA, E; WALLACE, VA; MAYER, J; YEUNG, RSM; MAK, TW; OHASHI, PS			POSITIVE AND NEGATIVE THYMOCYTE SELECTION INDUCED BY DIFFERENT CONCENTRATIONS OF A SINGLE PEPTIDE	SCIENCE			English	Article							CYTOTOXIC LYMPHOCYTES-T; CELL ANTIGEN RECEPTOR; CLONAL DELETION; THYMIC SELECTION; TRANSGENIC MICE; TOLERANCE INDUCTION; MHC; CD8; COMPLEX; MOLECULES	T lymphocyte maturation is dependent on interactions between the T cell receptor (TCR) expressed on the developing thymocyte and intrathymic major histocompatibility complex (MHC)-peptide ligands. The relation between the peptide-MHC complex that results in negative or positive selection has not been identified. Here, the requirements for the maturation of thymocytes expressing a defined transgenic TCR specific for a viral peptide are studied in fetal thymic organ culture. Low concentrations of the viral peptide antigen recognized by this transgenic TCR can mediate positive selection, whereas high concentrations result in thymocyte tolerance. These findings support the affinity-avidity model of thymocyte selection.	ONTARIO CANC INST, DEPT MED BIOPHYS, TORONTO M4X 1K9, ON, CANADA; ONTARIO CANC INST, DEPT IMMUNOL, TORONTO M4X 1K9, ON, CANADA; AMGEN INST, TORONTO M4X 1K9, ON, CANADA; AMGEN INC, BOULDER, CO 80301 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Amgen				Ohashi, Pamela S./0000-0003-2915-9317				ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; APASOV S, 1993, P NATL ACAD SCI USA, V90, P2837, DOI 10.1073/pnas.90.7.2837; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DAVIS MM, 1990, ANNU REV BIOCHEM, V59, P475, DOI 10.1146/annurev.biochem.59.1.475; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; FUNGLEUNG WP, 1993, EUR J IMMUNOL, V23, P212, DOI 10.1002/eji.1830230133; GLAS R, 1992, P NATL ACAD SCI USA, V89, P11381, DOI 10.1073/pnas.89.23.11381; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HUGO P, 1993, IMMUNOL REV, V135, P133, DOI 10.1111/j.1600-065X.1993.tb00647.x; KAYE J, 1992, J IMMUNOL, V148, P3342; KILEEN N, 1992, J EXP MED, V176, P89; KNOBLOCH M, 1992, INT IMMUNOL, V4, P1169, DOI 10.1093/intimm/4.10.1169; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; MARRACK P, 1993, J EXP MED, V178, P2173, DOI 10.1084/jem.178.6.2173; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; OHASHI PS, 1993, INT IMMUNOL, V5, P131, DOI 10.1093/intimm/5.2.131; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1993, EUR J IMMUNOL, V23, P669, DOI 10.1002/eji.1830230315; PIRCHER H, 1992, EUR J IMMUNOL, V22, P399, DOI 10.1002/eji.1830220217; PIRCHER H, 1992, INT IMMUNOL, V4, P1065, DOI 10.1093/intimm/4.9.1065; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SHA WC, 1989, NATURE, V341, P746; SHERMAN LA, 1992, SCIENCE, V258, P815, DOI 10.1126/science.1439792; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SINGER A, 1986, PROG IMMUNOL, V6, P60; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; VASQUEZ NJ, 1992, J EXP MED, V175, P1307, DOI 10.1084/jem.175.5.1307; YAGI J, 1990, INT IMMUNOL, V2, P83, DOI 10.1093/intimm/2.1.83; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085	48	471	482	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 18	1994	263	5153					1615	1618		10.1126/science.8128249	http://dx.doi.org/10.1126/science.8128249			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128249				2022-12-01	WOS:A1994NB67300033
J	PHILLIPS, KA; LOWE, RA; KAHN, JG; LURIE, P; AVINS, AL; CICCARONE, D				PHILLIPS, KA; LOWE, RA; KAHN, JG; LURIE, P; AVINS, AL; CICCARONE, D			THE COST-EFFECTIVENESS OF HIV TESTING OF PHYSICIANS AND DENTISTS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS; PERFORMING INVASIVE PROCEDURES; DENTAL PROFESSIONALS; SURGICAL-PROCEDURES; OPERATING-ROOM; BLOOD CONTACT; INFECTION; RISK; AIDS	Objective.-To evaluate the cost-effectiveness of alternative policies for human immunodeficiency testing (HIV) testing of physicians and dentists. Methods.-Decision analysis and cost-effectiveness analysis from a societal perspective were used. Data were derived from extensive literature review and consultation with experts. We conducted sensitivity analyses and also performed a cost-benefit analysis. Analyses.-We analyzed policies for mandatory or voluntary testing of all physicians, surgeons, and dentists; for those testing positive, we analyzed mandatory or voluntary exclusion from practice, restriction from performance of invasive procedures, or requirements to inform patients of serostatus. Main Outcome Measure.-Cost per patient infection averted. Results.-Although one-time mandatory testing of surgeons and dentists with mandatory restriction of those found to be HIV-positive is more cost-effective than other policies, the cost-effectiveness varies tremendously under different scenarios. Results were highly sensitive to several data inputs, especially HIV seroprevalence of surgeons and dentists and transmission risk. For example, under a medium seroprevalence and transmission risk scenario, mandatory testing of all surgeons might avert 25 infections at a total cost of $27.9 million or $1 115 000 per infection averted and an incremental cost of $291 000 compared with current testing; however, the incremental cost-effectiveness per patient infection averted ranges from $29 807 000 under a low-risk scenario to a savings of $81 000 under a high-risk scenario. Conclusion.-Our analysis neither justifies nor precludes a mandatory testing policy. Further research on the key data inputs is needed. Given the ethical, social, and public health implications, mandatory testing policies should not be implemented without greater certainty as to their cost-effectiveness.	UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA; UNIV CALIF BERKELEY,CTR STUDENT HLTH,BERKELEY,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California Berkeley	PHILLIPS, KA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,CTR AIDS PREVENT STUDIES,PREVENT SCI GRP,SAN FRANCISCO,CA 94143, USA.		Lowe, Robert A/A-4926-2008; Ciccarone, Daniel/I-5404-2013	Lowe, Robert A/0000-0002-4732-9634; Ciccarone, Daniel/0000-0002-2355-5477	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS007373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459, T32MH019105] Funding Source: NIH RePORTER; AHRQ HHS [HSO7373-01] Funding Source: Medline; NIMH NIH HHS [MH19105-02, P50 MH42459] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 1990, MMWR MORB MORTAL WKL, V39, P380; [Anonymous], 1989, GUIDE CLIN PREVENTIV; ARMSTRONG FP, 1987, MIL MED, V152, P414; ARNO PS, 1991, SEP IMP REG GUID LEG; BARTLETT JG, 1992, INFECT DIS CLIN PRAC, V1, P11; BELL DM, 1992, INFECT AGENTS DIS, V1, P253; BIDDLECOM AE, 1992, J ACQ IMMUN DEF SYND, V5, P1131; BOWLEG L, 1992, INTERGOVERNMENTA JUN, P1; CHAMBERLAND ME, 1991, JAMA-J AM MED ASSOC, V266, P3459, DOI 10.1001/jama.266.24.3459; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; CLEARY PD, 1987, JAMA-J AM MED ASSOC, V258, P1757, DOI 10.1001/jama.258.13.1757; COLOMBOTOS J, 1991, PHYSICIANS NURSES AI; COWAN DN, 1991, JAMA-J AM MED ASSOC, V265, P2826, DOI 10.1001/jama.265.21.2826; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; DICKINSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1802, DOI 10.1001/jama.269.14.1802; FLYNN NM, 1987, WESTERN J MED, V146, P439; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERDING JL, 1991, INFECT CONT HOSP EP, V12, P443, DOI 10.1086/646376; GERBERT B, 1993, ARCH INTERN MED, V153, P313, DOI 10.1001/archinte.153.3.313; GRUNINGER SE, 1992, J AM DENT ASSOC, V123, P57, DOI 10.14219/jada.archive.1992.0075; HARDY AM, 1991, ADV DATA VITAL HLTH, V204; HEDLUND K, 1990, 6TH INT C AIDS SAN F; HELLINGER FJ, 1992, INQUIRY-J HEALTH CAR, V29, P356; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HENDERSON DK, 1990, PRINCIPLES PRACTICE, P2221; HOLLENBERG J, 1989, SMLTREE 2 90 VERSION; HOLTGRAVE DR, 1993, ARCH INTERN MED, V153, P1225, DOI 10.1001/archinte.153.10.1225; HUSSAIN SA, 1988, BRIT J SURG, V75, P324; KAHN JG, 1992, UPDATED ESTIMATES IM; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; KRAHN M, 1993, MED CARE, V31, P403, DOI 10.1097/00005650-199305000-00003; LETTAU LA, 1992, INFECT CONT HOSP EP, V13, P336, DOI 10.1086/646541; MARGOLIS TE, 1992, J LEGAL MED, V13, P357, DOI 10.1080/01947649209510888; MCKAY NL, 1991, INQUIRY-J HEALTH CAR, V28, P236; MIIKE L, 1991, HIV HLTH CARE WORKPL; MISHU B, 1993, JAMA-J AM MED ASSOC, V269, P1843, DOI 10.1001/jama.269.14.1843; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; PANLILIO AL, 1990, 6TH INT C AIDS SAN F; PETERSEN LR, 1990, AM J PUBLIC HEALTH, V80, P1087, DOI 10.2105/AJPH.80.9.1087; POPEJOY SL, 1991, SURG GYNECOL OBSTET, V172, P480; QUEBBEMAN EJ, 1991, ANN SURG, V214, P614, DOI 10.1097/00000658-199111000-00012; RAYHAWK P, 1991, INTERGOVERNMENTA DEC, P4; REYNOLDS RA, 1985, SOCIOECONOMIC CHARAC; ROBERT L, 1993, PROGRAM ABSTRACTS SO; ROGERS AS, 1993, JAMA-J AM MED ASSOC, V269, P1795, DOI 10.1001/jama.269.14.1795; RUSSO G, 1992, INFECT CONT HOSP EP, V13, P107, DOI 10.1086/646482; SCHATZ B, 1991, AIDS PUBLIC POLICY J, V7, P71; SCHOCHETMAN G, 1989, ANNU REV MICROBIOL, V43, P629; SCHOCHETMAN G, 1992, AIDS TESTING METHODO; SCHWARTZ JS, 1988, JAMA-J AM MED ASSOC, V259, P2574, DOI 10.1001/jama.259.17.2574; SCHWARTZ JS, 1990, JAMA-J AM MED ASSOC, V264, P1704, DOI 10.1001/jama.264.13.1704; SIEW C, 1992, Journal of the American Dental Association, V123, P37; SLOAND EM, 1991, JAMA-J AM MED ASSOC, V266, P2861, DOI 10.1001/jama.266.20.2861; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V268, P489, DOI 10.1001/jama.268.4.489; TURNOCK BJ, 1989, JAMA-J AM MED ASSOC, V261, P3415, DOI 10.1001/jama.261.23.3415; VERRUSIO AC, 1989, J AM DENT ASSOC, V118, P553, DOI 10.14219/jada.archive.1989.0082; VONREYN CF, 1993, JAMA-J AM MED ASSOC, V269, P1807, DOI 10.1001/jama.269.14.1807; 1991, MMWR MORB MORTAL WKL, V40, P1; 1991, REVISED RECOMENDATIO; 1991, ESTIMATES RISK ENDEM; 1990, MMWR MORB MORTAL WKL, V39, P117; 1989, GUIDELINES PREVENTIO; 1991, HIV SCREENING PREGNA; 1992, PHYSICIAN CHARACTERI; 1993, MMWR MORB MORTAL WKL, V42, P329; 1992, STATISTICAL ABSTRACT; 1990, MMWR MORB MORTAL WKL, V39, P110; 1992, PREVENTING HIV TRANS; 1987, DISTRIBUTION DENTIST; 1990, SURVEY DENTAL PRACTI; 1991, MMWR MORB MORTAL WKL, V40, P377	74	28	29	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					851	858		10.1001/jama.271.11.851	http://dx.doi.org/10.1001/jama.271.11.851			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MZ498	8114240				2022-12-01	WOS:A1994MZ49800032
J	MUTA, T; KUROSAKI, T; MISULOVIN, Z; SANCHEZ, M; NUSSENZWEIG, MC; RAVETCH, JV				MUTA, T; KUROSAKI, T; MISULOVIN, Z; SANCHEZ, M; NUSSENZWEIG, MC; RAVETCH, JV			A 13-AMINO-ACID MOTIF IN THE CYTOPLASMIC DOMAIN OF FC-GAMMA-RIIB MODULATES B-CELL RECEPTOR SIGNALING	NATURE			English	Article							LYMPHOCYTES-B; TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTORS; ZETA-CHAIN; ACTIVATION; HETEROGENEITY; IMMUNOGLOBULIN; COMPLEX; TAIL; BETA	THE FC receptor on B lymphocytes, Fc gamma RIIB (beta 1 isoform), helps to modulate B-cell activation triggered by the surface immuno-globulin complex(1,2). Crosslinking of membrane immunoglobulin by antigen or anti-IG F(ab')(2) antibody induces a transient increase in cytosolic free Ca2+, a rise in inositol-3-phosphate, activation of protein kinase C, and enhanced protein tyrosine phosphorylation(3-5). Crosslinking Fc gamma RIIB with the surface immunoglobulin complex confers a dominant signal that prevents or aborts lymphocyte activation triggered through the ARH-1 motifs of the signal transduction subunits Ig-alpha and Ig-beta. Here we show that Fc gamma RIIB modulates membrane immunoglobulin-induced Ca2+ mobilization by; inhibiting Ca2+ influx, without changing the pattern of tyrosine phosphorylation. A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB is both necessary and sufficient for this effect. Tyrosine at residue 309 in this motif is phosphorylated upon co-crosslinking with surface immunoglobulin; mutation of this residue aborts the inhibitory effect of Fc gamma RIIB. This inhibition is directly coupled to signalling mediated through Ig-alpha and Ig-beta as evidenced by chimaeric IgM/alpha and IgM/beta molecules. The 13-residue motif in Fc gamma RIIB controls lymphocyte activation by inhibiting a Ca2+ signalling pathway triggered through ARH-1 motifs as a result of recruitment of novel SH2-containing proteins that interact with this Fc gamma RIIB cytoplasmic motif.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Rockefeller University	MUTA, T (corresponding author), SLOAN KETTERING INST, DEWITT WALLACE RES LAB, 1275 YORK AVE, NEW YORK, NY 10021 USA.		Nussenzweig, Michel/AAE-7292-2019; Kurosaki, Tomohiro/D-1306-2009; Ravetch, Jeffrey/Z-1596-2019	Kurosaki, Tomohiro/0000-0002-6352-304X; Ravetch, Jeffrey/0000-0003-2024-9041				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DESIDERIO SV, 1992, CURR OPIN IMMUNOL, V4, P252, DOI 10.1016/0952-7915(92)90073-N; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JONES B, 1986, J IMMUNOL, V136, P348; KAMEYAMA M, 1985, PFLUG ARCH EUR J PHY, V405, P285, DOI 10.1007/BF00582573; KOLANUS W, 1992, EMBO J, V11, P4861, DOI 10.1002/j.1460-2075.1992.tb05592.x; LAI MZ, 1987, J IMMUNOL, V139, P3973; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MELLMAN I, 1988, CURR OPIN IMMUNOL, V1, P16, DOI 10.1016/0952-7915(88)90046-5; RANSOM JT, 1988, J IMMUNOL, V140, P3150; RANSOM JT, 1986, J IMMUNOL, V137, P708; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.immunol.10.1.97; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WILSON HA, 1987, J IMMUNOL, V138, P1712; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	26	426	448	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 3	1994	368	6466					70	73		10.1038/368070a0	http://dx.doi.org/10.1038/368070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	8107887				2022-12-01	WOS:A1994MY56900056
J	KAFFMAN, A; HERSKOWITZ, I; TJIAN, R; OSHEA, EK				KAFFMAN, A; HERSKOWITZ, I; TJIAN, R; OSHEA, EK			PHOSPHORYLATION OF THE TRANSCRIPTION FACTOR-PHO4 BY A CYCLIN-CDK COMPLEX, PHO80-PHO85	SCIENCE			English	Article							ACID-PHOSPHATASE SYNTHESIS; REGULATORY GENE PHO4; SACCHAROMYCES-CEREVISIAE; NEGATIVE REGULATORS; PROTEIN; YEAST; EXPRESSION; SYSTEM; SEQUENCE; ACTIVATION	Induction of the yeast gene PHO5 is mediated by the transcription factors PHO2 and PHO4. PHO5 transcription is not detectable in high phosphate; it is thought that the negative regulators PHO80 and PHO85 inactivate PHO2 and PHO4. Here it is reported that PHO80 has homology to yeast cyclins and interacts with PHO85, a p34cdc2/CDC28-related protein kinase. The PHO80-PHO85 complex phosphorylates PHO4; this phosphorylation is correlated with negative regulation of PHO5. These results demonstrate the existence of a cyclin-cdk complex that is used for a regulatory process other than cell-cycle control and identify a physiologically relevant substrate for this complex.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley								BERBEN G, 1988, GENE, V66, P307, DOI 10.1016/0378-1119(88)90367-8; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGLIN TR, 1988, CELL, V53, P339, DOI 10.1016/0092-8674(88)90153-5; CREASY CL, 1993, NUCLEIC ACIDS RES, V21, P1975, DOI 10.1093/nar/21.8.1975; ESPINOZA FH, COMMUNICATION; FISHER F, 1991, ONCOGENE, V6, P1099; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GILLIQUET V, 1990, GENE, V96, P181, DOI 10.1016/0378-1119(90)90251-L; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; KOREN R, 1986, GENE, V41, P271, DOI 10.1016/0378-1119(86)90107-1; LEGRAIN M, 1986, NUCLEIC ACIDS RES, V14, P3059, DOI 10.1093/nar/14.7.3059; LEMIRE JM, 1985, MOL CELL BIOL, V5, P2131, DOI 10.1128/MCB.5.8.2131; MURRAY A, 1993, CELL CYCLE INTRO, P114; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; OFARRELL P, 1991, COLD SH Q B, V56, P83; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OGAWA N, 1993, MOL GEN GENET, V238, P444, DOI 10.1007/BF00292004; OKADA H, 1992, CURR GENET, V21, P95, DOI 10.1007/BF00318466; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUBIN GM, 1973, J BIOL CHEM, V248, P3860; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; Toh-e A, 1986, Yeast, V2, P129, DOI 10.1002/yea.320020209; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TOHE A, 1974, J BACTERIOL, V120, P608, DOI 10.1128/JB.120.2.608-617.1974; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; UEDA Y, 1975, J BACTERIOL, V122, P911, DOI 10.1128/JB.122.3.911-922.1975; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; UESONO Y, 1992, MOL GEN GENET, V231, P426, DOI 10.1007/BF00292712; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940; YOSHIDA K, 1989, MOL GEN GENET, V217, P31, DOI 10.1007/BF00330939	36	323	333	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 25	1994	263	5150					1153	1156		10.1126/science.8108735	http://dx.doi.org/10.1126/science.8108735			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108735				2022-12-01	WOS:A1994MX75900037
J	HOWARD, RS; LIVELY, CM				HOWARD, RS; LIVELY, CM			PARASITISM, MUTATION ACCUMULATION AND THE MAINTENANCE OF SEX	NATURE			English	Article							RECOMBINATION; REPRODUCTION	Two classes of models attempt to explain why obligate parthenogenesis only rarely replaces sexual reproduction in natural populations, in spite of the apparent reproductive advantage that parthenogens gain by producing only female offspring1. The mutation-accumulation models suggest that sex is adaptive because it purges the genome of harmful recurrent mutations2,3. The ecological genetic models postulate that sex is adaptive in variable environments, particularly when the relevant variation is generated by coevolutionary interactions with parasites4-7. Both of these models have considerable merit, but would seem to have limitations. The mutation-accumulation models require high rates of mutation3,8; the coevolutionary models require that parasites have severe fitness effects on their hosts9. In addition, parasites could select for clonal diversity and thereby erode any advantage that sex gains by producing variable progeny10. Here we consider the interaction between mutation accumulation and host-parasite cevolution. The results suggest that even moderate effects by parasites combined with reasonable rates of mutation could render sex evolutionarily stable against repeated invasion by clones.			HOWARD, RS (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.		Lively, Curtis M/A-8057-2011; Howard, Robert/O-3137-2017					Bell G., 1982, MASTERPIECE NATURE; CLARKE B, 1976, GENETIC ASPECTS HOST, V14, P87; FELSENSTEIN J, 1974, GENETICS, V78, P737; HAIGH J, 1978, THEOR POPUL BIOL, V14, P251, DOI 10.1016/0040-5809(78)90027-8; HAMILTON WD, 1980, OIKOS, V35, P282, DOI 10.2307/3544435; HAMILTON WD, 1990, P NATL ACAD SCI USA, V87, P3566, DOI 10.1073/pnas.87.9.3566; HOWARD RS, IN PRESS THEOR POPUL; HUTSON V, 1981, PROC R SOC SER B-BIO, V213, P345, DOI 10.1098/rspb.1981.0070; JAENIKE J, 1978, Evolutionary Theory, V3, P191; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; LEVIN DA, 1975, AM NAT, V109, P437, DOI 10.1086/283012; LIVELY CM, 1992, EVOLUTION, V46, P907, DOI [10.2307/2409745, 10.1111/j.1558-5646.1992.tb00608.x]; LYNCH M, 1990, EVOLUTION, V44, P1725, DOI 10.1111/j.1558-5646.1990.tb05244.x; MAY RM, 1983, PROC R SOC SER B-BIO, V219, P281, DOI 10.1098/rspb.1983.0075; Maynard-Smith J., 1978, MODELS ECOLOGY; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8	16	250	252	2	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					554	557		10.1038/367554a0	http://dx.doi.org/10.1038/367554a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	8107824				2022-12-01	WOS:A1994MV86300057
J	JOOSTEN, MHAJ; COZIJNSEN, TJ; DEWIT, PJGM				JOOSTEN, MHAJ; COZIJNSEN, TJ; DEWIT, PJGM			HOST-RESISTANCE TO A FUNGAL TOMATO PATHOGEN LOST BY A SINGLE BASE-PAIR CHANGE IN AN AVIRULENCE GENE	NATURE			English	Article							BACTERIAL SPOT DISEASE; SYRINGAE PV GLYCINEA; CLADOSPORIUM-FULVUM; RACE; PROTEINS; AVR9	HOST genotype specificity in interactions between biotrophic pathogens and plants in most cases complies with the gene-for-gene model1; success or failure of infection is determined by absence or presence of complementary genes, avirulence and resistance genes, in the pathogen and host plant, respectively. Resistance, expressed by the induction of a hypersensitive response in the host, is envisaged to be based on recognition of the pathogen, mediated through direct interaction between products of pathogen avirulence genes (the so-called race-specific elicitors) and receptors in the host plant, the putative products of resistance genes1. The interaction between the biotrophic fungus Cladosporium fulvum and its only host, tomato (Lycopersicon esculentum), is a well-established model system for studying fungus-plant gene-for-gene relationships1. Here we report the isolation of race-specific elicitor AVR4 of C. fulvum and the cloning of its encoding avirulence gene. We present evidence that, in nature, a single base-pair change in this avirulence gene leads to virulence of races previously avirulent on tomato genotypes carrying the complementary Cf4 resistance gene.	WAGENINGEN UNIV AGR,DEPT PHYTOPATHOL,POB 8025,6700 EE WAGENINGEN,NETHERLANDS	Wageningen University & Research			de Wit, Pierre/A-1998-2013; de Wit, Pierre J. G.M./CAI-9966-2022; Joosten, Matthieu/AAB-5131-2022; Joosten, Matthieu/AAB-5150-2022	de Wit, Pierre/0000-0002-4208-288X; Joosten, Matthieu/0000-0002-6243-4547; 				DEWIT PJGM, 1992, ANNU REV PHYTOPATHOL, V30, P391, DOI 10.1146/annurev.py.30.090192.002135; DEWIT PJGM, 1982, PHYSIOL PLANT PATHOL, V21, P1, DOI 10.1016/0048-4059(82)90002-9; HERBERS K, 1992, NATURE, V356, P172, DOI 10.1038/356172a0; JOOSTEN MHAJ, 1990, PLANT PHYSIOL, V94, P585, DOI 10.1104/pp.94.2.585; KEARNEY B, 1988, NATURE, V332, P541, DOI 10.1038/332541a0; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KOBAYASHI DY, 1990, MOL PLANT MICROBE IN, V3, P103, DOI 10.1094/MPMI-3-103; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; VANDENACKERVEKEN GFJM, 1993, PLANT PHYSIOL, V103, P91, DOI 10.1104/pp.103.1.91; VANDENACKERVEKEN GFJM, 1992, PLANT J, V2, P359, DOI 10.1111/j.1365-313X.1992.00359.x; VANKAN JAL, 1992, PLANT MOL BIOL, V20, P513, DOI 10.1007/BF00040610; VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	13	301	317	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					384	386		10.1038/367384a0	http://dx.doi.org/10.1038/367384a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114941				2022-12-01	WOS:A1994MT54000073
J	MORLA, A; ZHANG, ZH; RUOSLAHTI, E				MORLA, A; ZHANG, ZH; RUOSLAHTI, E			SUPERFIBRONECTIN IS A FUNCTIONALLY DISTINCT FORM OF FIBRONECTIN	NATURE			English	Article							CELL-ADHESION; METASTATIC CELLS; RECEPTOR; MATRIX; VITRONECTIN; MIGRATION; INTEGRINS; PEPTIDE; SURFACE; LAMININ	FIBRONECTIN is an extracellular matrix protein that is important in development, wound healing and tumorigenesis1-5. In the blood it is dimeric, but in tissues forms disulphide crosslinked fibrils Here we show that a fragment from the first type-III repeat of fibronectin binds to fibronectin and induces spontaneous disulphide crosslinking of the molecule into multimers of high relative molecular mass which resemble matrix fibrils. Treatment of fibronectin with this inducing fragment also converts fibronectin into a form that has greatly enhanced adhesive properties (hence the term superfibronectin) and which suppresses cell migration. Whereas cells attach to fibronectin through integrins, cell attachment to superfibronectin is mediated both by integrins and by receptors with properties distinct from those of integrins. Superfibronectin may be closely related to the natural matrix form of fibronectin.	LA JOLLA CANC RES FDN,CTR CANC,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,SCH MED,MOLEC PATHOL PROGRAM,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego								ALI IU, 1978, BIOCHIM BIOPHYS ACTA, V510, P140, DOI 10.1016/0005-2736(78)90136-0; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; FURCHT LT, 1984, CIBA F SYMP, V108, P130; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOODMAN SL, 1985, CELL, V41, P1029, DOI 10.1016/S0092-8674(85)80083-0; Hynes R. O., 1990, FIBRONECTINS; HYNES RO, 1977, P NATL ACAD SCI USA, V74, P2855, DOI 10.1073/pnas.74.7.2855; KESKIOJA J, 1977, BIOCHEM BIOPH RES CO, V74, P699, DOI 10.1016/0006-291X(77)90359-X; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LACOVARA J, 1984, CANCER RES, V44, P1657; MCCARTHY JB, 1985, CANCER METAST REV, V4, P125, DOI 10.1007/BF00050692; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; PASQUALINI R, 1993, J CELL SCI, V105, P101; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	26	262	274	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 13	1994	367	6459					193	196		10.1038/367193a0	http://dx.doi.org/10.1038/367193a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114919				2022-12-01	WOS:A1994MQ78000067
J	VAINIO, S; KARAVANOVA, I; JOWETT, A; THESLEFF, I				VAINIO, S; KARAVANOVA, I; JOWETT, A; THESLEFF, I			IDENTIFICATION OF BMP-4 AS A SIGNAL MEDIATING SECONDARY INDUCTION BETWEEN EPITHELIAL AND MESENCHYMAL TISSUES DURING EARLY TOOTH DEVELOPMENT	CELL			English	Article							BONE MORPHOGENETIC PROTEIN; GROWTH-FACTOR-BETA; HOMEOBOX GENE; EMBRYONIC-DEVELOPMENT; MOUSE EMBRYO; EXPRESSION PATTERNS; MESODERM INDUCTION; CELL-PROLIFERATION; DENTAL MESENCHYME; RNA EXPRESSION	Growth factor-mediated signaling has been implicated in the regulation of epithelial-mesenchymal interactions during organogenesis. Bone morphogenetic protein 4 (BMP-4), a member of the transforming growth factor beta superfamily, is expressed in the presumptive dental epithelium at the initiation of tooth development. Subsequently, epithelial signaling leads to mesenchymal induction of BMP-4 expression. To address the role of this factor, BMP-4-releasing agarose beads were added to dental mesenchyme in culture. These beads induced a translucent mesenchymal zone similar to that induced by dental epithelium. Moreover, three transcription factors (Msx-1, Msx-2, and Egr-1) whose expression is governed by epithelial signaling were induced in response to BMP-4. In addition, BMP-4 induced its own mesenchymal expression. These findings support the hypothesis that BMP-4 mediates epithelial-mesenchymal interactions during early tooth development.	UNIV HELSINKI,INST DENT,DEPT PEDODONT & ORTHODONT,SF-00014 HELSINKI,FINLAND	University of Helsinki				Vainio, Seppo/0000-0001-9319-3566	NIDCR NIH HHS [DE-09399] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTABA ARI, 1989, NATURE, V341, P945; BEQUEKIRN C, 1992, INT J DEV BIOL, V36, P491; BESSHO K, 1990, J ORAL MAXIL SURG, V48, P162, DOI 10.1016/S0278-2391(10)80204-6; Bienz Mariann, 1992, Current Opinion in Cell Biology, V4, P955, DOI 10.1016/0955-0674(92)90124-U; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; DOLLE P, 1992, DIFFERENTIATION, V49, P93, DOI 10.1111/j.1432-0436.1992.tb00773.x; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRENZ DA, 1992, DEV BIOL, V153, P324, DOI 10.1016/0012-1606(92)90117-Y; GILBERT S, 1992, DEV BIOL; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GROBSTEIN C, 1953, NATURE, V172, P869, DOI 10.1038/172869a0; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; GURDON JB, 1992, CURR BIOL, V3, P1; HAYAMIZU TF, 1991, DEV BIOL, V145, P164, DOI 10.1016/0012-1606(91)90222-O; HAYEK A, 1987, BIOCHEM BIOPH RES CO, V147, P876, DOI 10.1016/0006-291X(87)91011-4; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; INGHAM P, 1992, CURR BIOL, V9, P465; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JONES CM, 1991, DEVELOPMENT, V111, P531; JONES CM, 1992, DEVELOPMENT, V115, P639; JOWETT AK, 1993, DEVELOPMENT, V117, P461; KARAVANOVA I, 1992, MECH DEVELOP, V39, P41, DOI 10.1016/0925-4773(92)90024-E; KAWAI T, 1989, J DENT RES, V68, P1069, DOI 10.1177/00220345890680060301; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; LEHNERT SA, 1988, DEVELOPMENT, V104, P263; LUMSDEN AGS, 1979, J BIOL BUCCALE, V7, P77; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MACKENZIE A, 1991, DEVELOPMENT, V111, P269; MACKENZIE A, 1992, DEVELOPMENT, V115, P403; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MINA M, 1987, ARCH ORAL BIOL, V32, P123, DOI 10.1016/0003-9969(87)90055-0; MOON RT, 1992, CELL, V71, P709, DOI 10.1016/0092-8674(92)90545-N; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PELTON RW, 1990, DEVELOPMENT, V110, P609; ROS MA, 1992, DEVELOPMENT, V116, P811; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; Ruch J V, 1987, Revis Biol Celular, V14, P1; RUNYAN RB, 1992, MOL REPROD DEV, V32, P152, DOI 10.1002/mrd.1080320211; SAXEN L, 1976, NATURE, V259, P662, DOI 10.1038/259662a0; SAXEN L, 1980, DEV MAMMALS, V4, P161; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; THESLEFF I, 1988, DEV BIOL, V129, P565, DOI 10.1016/0012-1606(88)90401-0; THESLEFF I, 1990, J BIOL BUCCALE, V18, P179; THESLEFF I, 1981, DIFFERENTIATION, V18, P75, DOI 10.1111/j.1432-0436.1981.tb01107.x; THESLEFF I, 1979, DEV BIOL, V70, P116, DOI 10.1016/0012-1606(79)90011-3; THESLEFF I, 1992, CHEM BIOL MINERALIZE, P369; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TREMML G, 1992, DEVELOPMENT, V116, P447; VAAHTOKARI A, 1991, DEVELOPMENT, V113, P985; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945; VAINIO S, 1992, DIFFERENTIATION, V50, P97, DOI 10.1111/j.1432-0436.1992.tb00490.x; VAINIO S, 1992, DEV DYNAM, V194, P105, DOI 10.1002/aja.1001940204; VAINIO S, 1992, THESIS U HELSINKI HE; VAINIO S, 1991, DEV BIOL, V147, P323; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; Williams J, 1991, CURR OPIN CELL BIOL, V3, P925, DOI 10.1016/0955-0674(91)90108-B; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212	71	819	847	0	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					45	58		10.1016/0092-8674(93)90678-J	http://dx.doi.org/10.1016/0092-8674(93)90678-J			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8104708				2022-12-01	WOS:A1993MB66700007
J	HANNUM, C; CULPEPPER, J; CAMPBELL, D; MCCLANAHAN, T; ZURAWSKI, S; BAZAN, JF; KASTELEIN, R; HUDAK, S; WAGNER, J; MATTSON, J; LUH, J; DUDA, G; MARTINA, N; PETERSON, D; MENON, S; SHANAFELT, A; MUENCH, M; KELNER, G; NAMIKAWA, R; RENNICK, D; RONCAROLO, MG; ZLOTNIK, A; ROSNET, O; DUBREUIL, P; BIRNBAUM, D; LEE, F				HANNUM, C; CULPEPPER, J; CAMPBELL, D; MCCLANAHAN, T; ZURAWSKI, S; BAZAN, JF; KASTELEIN, R; HUDAK, S; WAGNER, J; MATTSON, J; LUH, J; DUDA, G; MARTINA, N; PETERSON, D; MENON, S; SHANAFELT, A; MUENCH, M; KELNER, G; NAMIKAWA, R; RENNICK, D; RONCAROLO, MG; ZLOTNIK, A; ROSNET, O; DUBREUIL, P; BIRNBAUM, D; LEE, F			LIGAND FOR FLT3 FLK2 RECEPTOR TYROSINE KINASE REGULATES GROWTH OF HEMATOPOIETIC STEM-CELLS AND IS ENCODED BY VARIANT RNAS	NATURE			English	Article							COLONY-STIMULATING FACTOR; MOUSE	THE FLT3/FLK2 receptor tyrosine kinase is closely related to two receptors, c-Kit and c-Fms, which function with their respective ligands, Kit ligand and macrophage colony-stimulating factor to control differentiation of haematopoietic and non-haematopoietic cells1-5. FLT3/FLK2 is thought to be present on haematopoietic stem cells and found in brain, placenta and testis3-5. We have purified to homogeneity and partially sequenced a soluble form of the FLT3/FLK2 ligand produced by mouse thymic stromal cells. We isolated several mouse and human complementary DNAs that encode polypeptide with identical N termini and different C termini. Some variants contain hydrophobic transmembrane segments, suggesting that processing may be required to release soluble ligand. The purified ligand enhances the response of mouse stem cells and a primitive human progenitor cell population to other growth factors such as interleukins IL-3 and IL-6 and to granulocyte-macrophage colony-stimulating factor, and also stimulates fetal thymocytes.	INSERM, U119, F-13009 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	HANNUM, C (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC, 901 CALIF AVE, PALO ALTO, CA 94304 USA.		Rosnet, Olivier/G-3536-2013; Zlotnik, Albert/C-3791-2011; dubreuil, patrice/F-5346-2011; Bazan, J. Fernando/B-4562-2010; Dubreuil, Patrice/V-4816-2019; Muench, Marcus O./C-5025-2009	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; Muench, Marcus O./0000-0001-8946-6605; Rosnet, Olivier/0000-0002-3020-910X; RONCAROLO, Maria Grazia/0000-0002-2193-9186; Birnbaum, Daniel/0000-0001-7920-9883				BARCENA A, IN PRESS BLOOD; DOVER GA, 1991, CELL, V65, P9, DOI 10.1016/0092-8674(91)90401-J; GALY AHM, 1993, THYMUS, V22, P13; GODFREY DI, 1992, J IMMUNOL, V149, P2281; HEIMFELD S, 1991, P NATL ACAD SCI USA, V88, P9902, DOI 10.1073/pnas.88.21.9902; MAROC N, 1993, ONCOGENE, V8, P909; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHERR CJ, 1990, BLOOD, V75, P1; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1992, EMBO J, V11, P3905, DOI 10.1002/j.1460-2075.1992.tb05483.x	21	404	450	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	1994	368	6472					643	648		10.1038/368643a0	http://dx.doi.org/10.1038/368643a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145851				2022-12-01	WOS:A1994NF39200063
J	MARENBERG, ME; RISCH, N; BERKMAN, LF; FLODERUS, B; DEFAIRE, U				MARENBERG, ME; RISCH, N; BERKMAN, LF; FLODERUS, B; DEFAIRE, U			GENETIC SUSCEPTIBILITY TO DEATH FROM CORONARY HEART-DISEASE IN A STUDY OF TWINS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDEPENDENT RISK FACTOR; MYOCARDIAL-INFARCTION; FAMILY HISTORY; PARENTAL HISTORY; ARTERY DISEASE; AGGREGATION; ONSET; AGE; RELATIVES; MORTALITY	Background. A family history of premature coronary heart disease has long been thought to be a risk factor for coronary heart disease. Using data from 26 years of follow-up of 21,004 Swedish twins born between 1886 and 1925, we investigated this issue further by assessing the risk of death from coronary heart disease in pairs of monozygotic and dizygotic twins. Methods. The study population consisted of 3298 monozygotic and 5964 dizygotic male twins and 4012 monozygotic and 7730 dizygotic female twins. The age at which one twin died of coronary heart disease was used as the primary independent variable to predict the risk of death from coronary heart disease in the other twin. Information about other risk factors was obtained from questionnaires administered in 1961 and 1963. Actuarial life-table analysis was used to estimate the cumulative probability of death from coronary heart disease. Relative-hazard estimates were obtained from a multivariate survival analysis. Results. Among the men, the relative hazard of death from coronary heart disease when one's twin died of coronary heart disease before the age of 55 years, as compared with the hazard when one's twin did not die before 55, was 8.1 (95 percent confidence interval, 2.7 to 24.5) for monozygotic twins and 3.8 (1.4 to 10.5) for dizygotic twins. Among the women, when one's twin died of coronary heart disease before the age of 65 years, the relative hazard was 15.0 (95 percent confidence interval, 7.1 to 31.9) for monozygotic twins and 2.6 (1.0 to 7.1) for dizygotic twins. Among both the men and the women, whether monozygotic or dizygotic twins, the magnitude of the relative hazard decreased as the age at which one's twin died of coronary heart disease increased. The ratio of the relative-hazard estimate for the monozygotic twins to the estimate for the dizygotic twins approached 1 with increasing age. These relative hazards were little influenced by other risk factors for coronary heart disease. Conclusions. Our findings suggest that at younger ages, death from coronary heart disease is influenced by genetic factors in both women and men. The results also imply that the genetic effect decreases at older ages.	KAROLINSKA INST, DEPT ENVIRONM HYG, S-10401 STOCKHOLM, SWEDEN; KAROLINSKA HOSP, DEPT INTERNAL MED, DIV CARDIOVASC MED, S-10401 STOCKHOLM, SWEDEN; KAROLINSKA INST, INST ENVIRONM MED, DIV EPIDEMIOL, S-10401 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	MARENBERG, ME (corresponding author), YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, 60 COLL ST, NEW HAVEN, CT 06510 USA.		Girelli, Domenico/B-1183-2008	Girelli, Domenico/0000-0001-9684-1899	NHGRI NIH HHS [HG-00348] Funding Source: Medline; NIMH NIH HHS [2-T32-MH-14235] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH014235] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON AJ, 1979, PREV MED, V8, P419, DOI 10.1016/0091-7435(79)90019-7; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; BARRETTCONNOR E, 1984, CIRCULATION, V69, P1065, DOI 10.1161/01.CIR.69.6.1065; BLOTH B, 1976, ACTA MED SCAND, V200, P281; BONNEY GE, 1987, BIOMETRICS, V43, P951, DOI 10.2307/2531548; BRESLOW JL, 1991, ANNU REV MED, V42, P357, DOI 10.1146/annurev.me.42.020191.002041; BRITTON M, 1974, ACTA MED SCAND, V196, P203; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Cederlof R, 1977, Acta Med Scand Suppl, V612, P1; CEDERLOF R, 1967, ARCH ENVIRON HEALTH, V14, P397, DOI 10.1080/00039896.1967.10664761; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; DEFAIRE U, 1975, PREV MED, V4, P509, DOI 10.1016/0091-7435(75)90036-5; DEUTSCHER S, 1970, AM J EPIDEMIOL, V91, P233, DOI 10.1093/oxfordjournals.aje.a121133; FRIEDLANDER Y, 1985, BRIT HEART J, V53, P382; GOLDBOURT U, 1986, ARTERIOSCLEROSIS, V6, P357, DOI 10.1161/01.ATV.6.4.357; HAMSTEN A, 1987, AM J CARDIOL, V59, P14, DOI 10.1016/S0002-9149(87)80061-9; HARVALD B, 1970, ACTA GENET MED GEMEL, V19, P248, DOI 10.1017/S1120962300025609; HELLER DA, 1993, NEW ENGL J MED, V328, P1150, DOI 10.1056/NEJM199304223281603; HOPKINS PN, 1989, ANNU REV NUTR, V9, P303; Hosmer DW, 1989, APPL LOGISTIC REGRES, P238; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; NEALE MC, 1989, AM J HUM GENET, V45, P226; NERBRAND C, 1991, SCAND J SOC MED, V19, P154, DOI 10.1177/140349489101900303; NORA JJ, 1980, CIRCULATION, V61, P503, DOI 10.1161/01.CIR.61.3.503; PHILLIPS RL, 1974, AM J EPIDEMIOL, V100, P87, DOI 10.1093/oxfordjournals.aje.a112021; RISCH N, 1990, AM J HUM GENET, V46, P222; RISSANEN AM, 1979, BRIT HEART J, V42, P294, DOI 10.1136/hrt.42.3.294; ROSE G, 1964, BRIT J PREV SOC MED, V18, P75; SCHILDKRAUT JM, 1989, AM J CARDIOL, V64, P555, DOI 10.1016/0002-9149(89)90477-3; SHEA S, 1984, J AM COLL CARDIOL, V4, P793, DOI 10.1016/S0735-1097(84)80408-8; SHOLTZ RI, 1975, AM J EPIDEMIOL, V102, P350, DOI 10.1093/oxfordjournals.aje.a112171; SING CF, 1990, ANNU REV GENET, V24, P171; SING CF, 1989, INT J EPIDEMIOL, V18, pS183; SLACK J., 1966, J MED GENET, V3, P239, DOI 10.1136/jmg.3.4.239; SNOWDEN CB, 1982, AM J EPIDEMIOL, V115, P217, DOI 10.1093/oxfordjournals.aje.a113293; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; TENKATE LP, 1982, AM J CARDIOL, V50, P945, DOI 10.1016/0002-9149(82)90400-3; THORDARSON O, 1979, ACTA MED SCAND, V205, P493; TSAI WY, 1987, BIOMETRIKA, V74, P883; 1991, OFFICIAL STATISTICS	41	955	989	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 14	1994	330	15					1041	1046		10.1056/NEJM199404143301503	http://dx.doi.org/10.1056/NEJM199404143301503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF022	8127331				2022-12-01	WOS:A1994NF02200003
J	SUKI, B; BARABASI, AL; HANTOS, Z; PETAK, F; STANLEY, HE				SUKI, B; BARABASI, AL; HANTOS, Z; PETAK, F; STANLEY, HE			AVALANCHES AND POWER-LAW BEHAVIOR IN LUNG-INFLATION	NATURE			English	Article							AIRWAY-CLOSURE; MODEL	WHEN lungs are emptied during exhalation, peripheral airways close up1. For people with lung disease, they may not reopen for a significant portion of inhalation, impairing gas exchange2,3. A knowledge of the mechanisms that govern reinflation of collapsed regions of lungs is therefore central to the development of ventilation strategies for combating respiratory problems. Here we report measurements of the terminal airway resistance, R(t), during the opening of isolated dog lungs. When inflated by a constant flow, R(t) decreases in discrete jumps. We find that the probability distribution of the sizes of the jumps and of the time intervals between them exhibit power-law behaviour over two decades. We develop a model of the inflation process in which 'avalanches' of airway openings are seen-with power-law distributions of both the size of avalanches and the time intervals between them-which agree quantitatively with those seen experimentally, and are reminiscent of the power-law behaviour observed for self-organized critical systems4. Thus power-law distributions, arising from avalanches associated with threshold phenomena propagating down a branching tree structure, appear to govern the recruitment of terminal airspaces.	BOSTON UNIV,CTR POLYMER STUDIES,BOSTON,MA 02215; BOSTON UNIV,DEPT PHYS,BOSTON,MA 02215; ALBERT SZENT GYORGYI MED UNIV,DEPT MED INFORMAT,SZEGED,HUNGARY; ALBERT SZENT GYORGY MED UNIV,DEPT EXPTL SURG,SZEGED,HUNGARY	Boston University; Boston University; Szeged University; Szeged University	SUKI, B (corresponding author), BOSTON UNIV,DEPT BIOMED ENGN,RESP RES LAB,BOSTON,MA 02215, USA.		Hantos, Zoltan/D-2692-2011; Barabasi, Albert-Laszlo/S-6474-2017	Barabasi, Albert/0000-0002-4028-3522				BAK P, 1989, NATURE, V342, P780, DOI 10.1038/342780a0; BAK P, 1994, FRACTALS SCI; CRAWFORD ABH, 1989, J APPL PHYSIOL, V66, P2511, DOI 10.1152/jappl.1989.66.6.2511; DAVEY BLK, 1993, RESP PHYSIOL, V91, P165, DOI 10.1016/0034-5687(93)90097-T; ENGEL LA, 1975, J APPL PHYSIOL, V38, P1117, DOI 10.1152/jappl.1975.38.6.1117; GAVER DP, 1990, J APPL PHYSIOL, V69, P74, DOI 10.1152/jappl.1990.69.1.74; HORSFIELD K, 1982, J APPL PHYSIOL, V52, P21, DOI 10.1152/jappl.1982.52.1.21; HUGHES JMB, 1970, J APPL PHYSIOL, V29, P340, DOI 10.1152/jappl.1970.29.3.340; LAMBERT RK, 1982, J APPL PHYSIOL, V52, P44, DOI 10.1152/jappl.1982.52.1.44; MACKLEM PT, 1970, RESP PHYSIOL, V8, P191, DOI 10.1016/0034-5687(70)90015-0; PETAK F, 1993, EUR RESPIR J, V6, pS403; SALAZAR E, 1964, J APPL PHYSIOL, V19, P97, DOI 10.1152/jappl.1964.19.1.97; SHLESINGER MF, 1991, PHYS REV LETT, V67, P2106, DOI 10.1103/PhysRevLett.67.2106; Vicsek T., 1992, FRACTAL GROWTH PHENO, DOI DOI 10.1142/1407; West B.J., 1990, FRACTAL PHYSL CHAOS, DOI [10.1142/8577, DOI 10.1142/8577]; WEST BJ, 1990, AM SCI, V78, P40	16	216	220	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					615	618		10.1038/368615a0	http://dx.doi.org/10.1038/368615a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145846				2022-12-01	WOS:A1994NF39200054
J	GOLDSTEIN, LB; MATCHAR, DB				GOLDSTEIN, LB; MATCHAR, DB			CLINICAL-ASSESSMENT OF STROKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSIENT ISCHEMIC ATTACKS; CEREBRAL INFARCTION; INTEROBSERVER AGREEMENT; INTERRATER RELIABILITY; PROGNOSTIC SCORE; MOOD DISORDERS; DIAGNOSIS; SCALE; RECOVERY; PREVENTION		DEPT VET AFFAIRS MED CTR, DURHAM, NC USA; DUKE UNIV, MED CTR, DEPT MED, DIV NEUROL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DIV GEN INTERNAL MED, DURHAM, NC 27710 USA	Duke University; Duke University	GOLDSTEIN, LB (corresponding author), DUKE UNIV, MED CTR, CTR HLTH POLICY RES, BOX 3651, DURHAM, NC 27710 USA.		Matchar, David/M-3951-2019	Matchar, David/0000-0003-3020-2108	PHS HHS [282-91-0028] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; ADAMS RD, 1985, PRINCIPLES NEUROLOGY; ADAMS RJ, 1987, STROKE, V18, P665, DOI 10.1161/01.STR.18.3.665; ALLEN CMC, 1983, Q J MED, V52, P515; ALLEN CMC, 1984, J NEUROL NEUROSUR PS, V47, P475, DOI 10.1136/jnnp.47.5.475; [Anonymous], 1989, STROKE, V20, P1407; ASPLUND K, 1987, STROKE, V18, P528, DOI 10.1161/01.STR.18.2.528; BARER DH, 1989, Q J MED, V70, P27; BARNETT HJM, 1990, STROKE, V21, P40; BOZZAO L, 1989, AM J NEURORADIOL, V10, P1215; BRITTON M, 1984, NEUROLOGY, V34, P1504, DOI 10.1212/WNL.34.11.1504; BRITTON M, 1980, ACTA MED SCAND, V207, P37; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; CALANCHINI PR, 1977, JAMA-J AM MED ASSOC, V238, P2029, DOI 10.1001/jama.238.19.2029; CAPLAN LR, 1991, JAMA-J AM MED ASSOC, V266, P2413, DOI 10.1001/jama.266.17.2413; COTE R, 1989, NEUROLOGY, V39, P638, DOI 10.1212/WNL.39.5.638; DUNCAN PW, 1992, STROKE, V23, P1084, DOI 10.1161/01.STR.23.8.1084; FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9; FORD AB, 1966, MEDICINE, V45, P223; FRITHZ G, 1976, ACTA MED SCAND, V199, P133; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; FULLERTON KJ, 1988, Q J MED, V66, P147; GARRAWAY WM, 1983, STROKE, V14, P699, DOI 10.1161/01.STR.14.5.699; GELMERS HJ, 1988, STROKE, V19, P709, DOI 10.1161/01.STR.19.6.709; GENT M, 1989, LANCET, V1, P1215, DOI 10.1016/S0140-6736(89)92327-1; GLASS TA, 1993, STROKE, V24, P64, DOI 10.1161/01.STR.24.1.64; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; GRANGER CV, 1990, STROKE, V21, P66; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P14; GRESHAM GE, 1979, ARCH PHYS MED REHAB, V60, P487; GROSS CR, 1986, ARCH NEUROL-CHICAGO, V43, P893, DOI 10.1001/archneur.1986.00520090031012; Hachinski V, 1985, ACUTE STROKE; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; HENLEY S, 1985, J NEUROL NEUROSUR PS, V48, P1, DOI 10.1136/jnnp.48.1.1; HOWARD G, 1985, JAMA-J AM MED ASSOC, V253, P226, DOI 10.1001/jama.253.2.226; JONGBLOED L, 1986, STROKE, V17, P765, DOI 10.1161/01.STR.17.4.765; KINSELLA G, 1980, MED J AUSTRALIA, V2, P663; KOUDSTAAL PJ, 1986, STROKE, V17, P723, DOI 10.1161/01.STR.17.4.723; KRAAIJEVELD CL, 1984, STROKE, V15, P723, DOI 10.1161/01.STR.15.4.723; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; LEE H, 1990, NEUROLOGY, V40, P165, DOI 10.1212/WNL.40.1.165; LINCOLN NB, 1989, J NEUROL NEUROSUR PS, V52, P493, DOI 10.1136/jnnp.52.4.493; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; LINDMARK B, 1988, SCAND J REHABIL MED, V20, P103; LOEWEN SC, 1990, STROKE, V21, P78, DOI 10.1161/01.STR.21.1.78; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; NORRIS JW, 1982, LANCET, V1, P328; OLSEN J, 1988, J NEUROL REHABIL, V2, P59; OXBURY JM, 1975, BRIT MED J, V3, P125, DOI 10.1136/bmj.3.5976.125; PANZER RJ, 1985, ARCH INTERN MED, V145, P1800, DOI 10.1001/archinte.145.10.1800; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; PRESCOTT RJ, 1982, STROKE, V13, P641, DOI 10.1161/01.STR.13.5.641; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; ROBINSON RG, 1985, J NERV MENT DIS, V173, P221, DOI 10.1097/00005053-198504000-00003; ROSS RT, 1983, ARCH NEUROL-CHICAGO, V40, P633, DOI 10.1001/archneur.1983.04050090069011; ROTHMAN ML, 1989, MED CARE, V27, pS157, DOI 10.1097/00005650-198903001-00013; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2_Supplement.2S; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SHINAR D, 1985, ARCH NEUROL-CHICAGO, V42, P557, DOI 10.1001/archneur.1985.04060060059010; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Sisk C, 1970, STROKE, V1, P14, DOI 10.1161/01.STR.1.1.14; SUZUKI I, 1992, NEUROLOGY, V42, P2207, DOI 10.1212/WNL.42.11.2207; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TOMASELLO F, 1982, STROKE, V13, P32, DOI 10.1161/01.STR.13.1.32; TUTHILL JE, 1969, AM HEART J, V78, P53, DOI 10.1016/0002-8703(69)90258-0; VOGEL HP, 1992, NEUROLOGY, V42, P2076, DOI 10.1212/WNL.42.11.2076; VONARBIN M, 1981, STROKE, V12, P288, DOI 10.1161/01.STR.12.3.288; VONARBIN M, 1980, J CHRON DIS, V33, P215, DOI 10.1016/0021-9681(80)90066-1; WADE DT, 1983, J NEUROL NEUROSUR PS, V46, P521, DOI 10.1136/jnnp.46.6.521; WADE DT, 1985, J NEUROL NEUROSUR PS, V48, P7, DOI 10.1136/jnnp.48.1.7; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WERDELIN L, 1988, NEUROLOGY, V38, P677, DOI 10.1212/WNL.38.5.677; WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707; Ziegler DK, 1973, STROKE, V4, P666, DOI 10.1161/01.STR.4.4.666; 1992, 1993 SROKE FACTS	77	31	31	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1114	1120		10.1001/jama.271.14.1114	http://dx.doi.org/10.1001/jama.271.14.1114			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151856				2022-12-01	WOS:A1994NE22800036
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FLUOXETINE LABELING REVISED TO IDENTIFY PHENYTOIN INTERACTION AND TO RECOMMEND AGAINST USE IN NURSING MOTHERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1067	1067		10.1001/jama.271.14.1067	http://dx.doi.org/10.1001/jama.271.14.1067			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151837				2022-12-01	WOS:A1994NE22800007
J	LIU, F; GREEN, MR				LIU, F; GREEN, MR			PROMOTER TARGETING BY ADENOVIRUS-E1A THROUGH INTERACTION WITH DIFFERENT CELLULAR DNA-BINDING DOMAINS	NATURE			English	Article							EUKARYOTIC TRANSCRIPTIONAL ACTIVATORS; RETINOBLASTOMA GENE-PRODUCT; E1A PROTEINS; MAMMALIAN-CELLS; FACTOR FAMILY; TRANSACTIVATION; ELEMENT; IDENTIFICATION; TRANSFORMATION; EXPRESSION	A puzzling property of the transcriptional activators encoded by several animal viruses is their ability to function promiscuously. The adenovirus E1a protein, for example, stimulates transcription of adenoviral genes as well as a wide variety of other viral and cellular genes. We show that E1a can interact with several classes of cellular DNA-binding domains and thereby be recruited to diverse promoters. Our results explain how a single protein can regulate transcription of multiple genes that lack a common promoter element.	UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	LIU, F (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.							BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BUCKBINDER L, 1989, EMBO J, V8, P4239, DOI 10.1002/j.1460-2075.1989.tb08609.x; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DU W, 1993, NATURE, V74, P887; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FLINT KJ, 1991, ONCOGENE, V6, P2019; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEWIS ED, 1985, MOL CELL BIOL, V5, P2433, DOI 10.1128/MCB.5.9.2433; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1991, ONCOGENE, V6, P627; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RICHTER JD, 1988, J VIROL, V62, P1948, DOI 10.1128/JVI.62.6.1948-1955.1988; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHENK T, 1991, ADV CANCER RES, V57, P47; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; Tao Jianshi, 1993, V3, P3; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P176, DOI 10.1128/MCB.10.1.176; TENESE N, 1991, GEES DEV, V5, P2212; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG WD, 1991, MOL CELL BIOL, V11, P4561, DOI 10.1128/MCB.11.9.4561; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZU YL, 1991, J BIOL CHEM, V266, P24134	44	244	253	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	1994	368	6471					520	525		10.1038/368520a0	http://dx.doi.org/10.1038/368520a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139685				2022-12-01	WOS:A1994NE33500045
J	MEYER, A; MORRISSEY, JM; SCHARTL, M				MEYER, A; MORRISSEY, JM; SCHARTL, M			RECURRENT ORIGIN OF A SEXUALLY SELECTED TRAIT IN XIPHOPHORUS FISHES INFERRED FROM A MOLECULAR PHYLOGENY	NATURE			English	Article							MATING PREFERENCES; FEMALE PREFERENCES; MALE SWORDS; EVOLUTION	DARWIN1 believed that sexual selection accounts for the evolution of exaggerated male ornaments, such as the sword-like caudal fin extensions of male fishes of the genus Xiphophorus, that appear detrimental to survival. Swordtails continue to feature prominently in empirical work and theories of sexual selection; the pre-existing bias hypothesis has been offered as an explanation for the evolution of swords in these fishes2,3. Based upon a largely morphological phylogeny, this hypothesis suggests that female preference to mate with sworded males arose in ancestrally swordless species, thus pre-dating the origin of the sword itself and directly driving its evolution. Here we present a molecular phylogeny (based on mitochondrial and nuclear DNA sequences) of Xiphophorus which differs from the traditional one: it indicates that the sword originated and was lost repeatedly. Our phylogeny suggests that the ancestor of the genus is more likely to have possessed a sword than not, thus questioning the applicability of the pre-existing bias hypothesis as an explanation for the evolution of this sexually selected trait.	SUNY STONY BROOK,PROGRAM GENET,STONY BROOK,NY 11794; UNIV WURZBURG,BIOZENTRUM,THEODOR BOVERI INST BIOWISSENSCH,D-97074 WURZBURG,GERMANY	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; University of Wurzburg	MEYER, A (corresponding author), SUNY STONY BROOK,DEPT ECOL & EVOLUT,STONY BROOK,NY 11794, USA.		Meyer, Axel/C-9826-2009	Meyer, Axel/0000-0002-0888-8193; Schartl, Manfred/0000-0001-9882-5948				ALCOCK J, 1993, ANIMAL BEHAVIOR EVOL; [Anonymous], 1993, MEGA MOL EVOLUTIONAR; BAKKER TCM, 1993, NATURE, V363, P255, DOI 10.1038/363255a0; BASOLO A L, 1990, Animal Behaviour, V40, P332, DOI 10.1016/S0003-3472(05)80928-5; BASOLO AL, 1990, SCIENCE, V250, P808, DOI 10.1126/science.250.4982.808; BASOLO AL, 1991, SCIENCE, V253, P1426, DOI 10.1126/science.253.5026.1426-b; BRADBURY JW, 1987, SEXUAL SELECTION TES; Darwin C., 1871, P423; DOWLING TE, 1993, NATURE, V362, P444, DOI 10.1038/362444a0; DZWILLO M, 1963, VERH DT ZOOL GES, P152; ENDLER JA, 1992, AM NAT, V139, pS125, DOI 10.1086/285308; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fisher R., 2005, TEACHING CHILDREN TH; Gordon M, 1943, AM NAT, V77, P569, DOI 10.1086/281162; HAAS V, 1993, TRENDS ICHTHYOLOGY, P279; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOUDE AE, 1990, SCIENCE, V248, P1405, DOI 10.1126/science.248.4961.1405; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; KIRKPATRICK M, 1987, SEXUAL SELECTION TES, P67; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KREBS JR, 1993, INTRO BEHAVIOURAL EC; MADDISON WP, 1992, MACCLADER VER 3 0 AN; MEYER A, 1993, P ROY SOC B-BIOL SCI, V254, P153, DOI 10.1098/rspb.1993.0140; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; MEYER M K, 1980, Senckenbergiana Biologica, V60, P147; Meyer M.K., 1987, Courier Forschungsinstitut Senckenberg, V94, P123; MORIZOT DC, 1982, GENETICS, V102, P539; PARTRIDGE L, 1987, NATURE, V328, P377, DOI 10.1038/328377a0; RAUCHENBERGER M, 1990, AM MUS NOVIT, P1; ROBERTSON SM, 1989, THESIS LUDWIGS MAXIM; Rosen D. E., 1963, Bulletin of the American Museum of Natural History, V126, P1; Rosen D. E., 1969, American Museum Novitates, VNo. 2379, P1; Rosen D. E., 1979, B AM MUS NAT HIST, V162, P268; Ryan M.J., 1990, Oxford Surveys in Evolutionary Biology, V7, P157; RYAN MJ, 1990, NATURE, V343, P66, DOI 10.1038/343066a0; RYAN MJ, 1993, PHILOS T ROY SOC B, V340, P187, DOI 10.1098/rstb.1993.0057; RYAN MJ, 1987, SCIENCE, V236, P595, DOI 10.1126/science.236.4801.595; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SMITH JM, 1991, TRENDS ECOL EVOL, V6, P146, DOI 10.1016/0169-5347(91)90055-3; SMITH JM, 1987, SEXUAL SELECTION TES, P9; Swofford D, 1993, PHYLOGENETIC ANAL US; WINQUIST ST, 1991, SCIENCE, V253, P1426, DOI 10.1126/science.253.5026.1426-a; ZANDER C D, 1969, Zeitschrift fuer Wissenschaftliche Zoologie, V178, P276	43	228	233	2	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					539	542		10.1038/368539a0	http://dx.doi.org/10.1038/368539a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139686	Green Published, Green Submitted			2022-12-01	WOS:A1994NE33500052
J	COSTA, M; WILSON, ET; WIESCHAUS, E				COSTA, M; WILSON, ET; WIESCHAUS, E			A PUTATIVE CELL SIGNAL ENCODED BY THE FOLDED GASTRULATION GENE COORDINATES CELL-SHAPE CHANGES DURING DROSOPHILA GASTRULATION	CELL			English	Article							LARVAL CUTICLE; ZYGOTIC LOCI; 3RD CHROMOSOME; X-CHROMOSOME; MELANOGASTER; EMBRYOS; PATTERN; PROTEIN; MUTATIONS; REQUIREMENTS	The folded gastrulation (fog) gene is required during Drosophila gastrulation for two morphogenetic movements, formation of the ventral furrow and invagination of the posterior midgut primordium. fog coordinates cell shape changes during these invaginations by inducing apical constriction of cells in spatially and temporally defined manners. fog is expressed in the invagination primordia in a pattern that precisely precedes the pattern of constrictions. Overexpression of fog in the dorsoanterior region of the embryo induces ectopic constrictions, indicating localization of fog transcripts may define domains of cell shape changes. fog encodes a novel protein with a putative signal sequence but no potential transmembrane domains. We suggest fog functions as a secreted signal that activates the G protein alpha subunit encoded by concertina in neighboring cells. Our analyses indicate that cell-cell communication ensures the rapid, orderly progression of constriction initiations from the middle of invagination primordia out toward the margins.	UNIV UTAH,SCH MED,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah	COSTA, M (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012480, T32GM007388] Funding Source: NIH RePORTER; NICHD NIH HHS [5RO1HD22780] Funding Source: Medline; NIGMS NIH HHS [1F32GM12480-01, 5T32GM07388-14] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CASANOVA J, 1990, DEVELOPMENT, V110, P621; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; COSTA M, 1992, DEV DROSOPHILA MELAN; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ERDELYI M, 1989, GENETICS, V122, P111; ETTENSOHN CA, 1985, Q REV BIOL, V60, P289, DOI 10.1086/414426; FOE VE, 1989, DEVELOPMENT, V107, P1; FRISTROM D, 1988, TISSUE CELL, V20, P645, DOI 10.1016/0040-8166(88)90015-8; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; GONZALEZCRESPO S, 1993, GENE DEV, V7, P1703, DOI 10.1101/gad.7.9.1703; GOVIND S, 1993, DEVELOPMENT, V117, P135; HARDIN J, 1988, DEVELOPMENT, V103, P211; HINTON CW, 1959, GENETICS, V44, P923; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KAM Z, 1991, DEVELOPMENT, V112, P365; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANE MC, 1993, DEVELOPMENT, V117, P1049; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEPTIN M, 1990, DEVELOPMENT, V110, P73; LEPTIN M, 1991, GASTRULATION MOVEMEN, P198; MANOUKIAN AS, 1992, GENE DEV, V6, P1740, DOI 10.1101/gad.6.9.1740; MERRILL PT, 1988, DEVELOPMENT, V104, P495; MIKLOS GLG, 1988, P NATL ACAD SCI USA, V85, P2051, DOI 10.1073/pnas.85.7.2051; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; NUSSLEINVOLHARD C, 1979, S SOC DEV BIOL, V37, P185; ODELL GM, 1981, DEV BIOL, V85, P446, DOI 10.1016/0012-1606(81)90276-1; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PERRIMON N, 1989, GENETICS, V121, P313; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEJTER ED, 1993, CELL, V75, P373, DOI 10.1016/0092-8674(93)80078-S; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SIMPSON L, 1990, DEVELOPMENT, V110, P851; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; Sturtevant AH, 1936, GENETICS, V21, P554; SWEETON D, 1991, DEVELOPMENT, V112, P775; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WIESCHAUS E, 1988, DEVELOPMENT, V104, P483; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; YOUNG PE, 1990, DEVELOPMENT, V111, P1; ZUSMAN SB, 1987, GENETICS, V115, P725; ZUSMAN SB, 1985, DEV BIOL, V111, P359, DOI 10.1016/0012-1606(85)90490-7	52	232	233	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1075	1089		10.1016/0092-8674(94)90384-0	http://dx.doi.org/10.1016/0092-8674(94)90384-0			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137424				2022-12-01	WOS:A1994ND24600013
J	GOODMAN, RA; THACKER, SB; SOLOMON, SL; OSTERHOLM, MT; HUGHES, JM				GOODMAN, RA; THACKER, SB; SOLOMON, SL; OSTERHOLM, MT; HUGHES, JM			INFECTIOUS-DISEASES IN COMPETITIVE SPORTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HERPES-GLADIATORUM; ASEPTIC-MENINGITIS; FOOTBALL PLAYERS; HIV-INFECTION; OUTBREAK; TRANSMISSION; WRESTLERS; EPIDEMIC; MEASLES; TEAM	Objective.-Participation in competitive sports is popular and widely encouraged throughout the United States. Reports of infectious disease outbreaks among competitive athletes and recent publicity regarding infectious disease concerns in sports underscore the need to better characterize the occurrence of these problems. Data Sources.-To identify reports of infectious diseases in sports, we performed a comprehensive search of the medical literature (MEDLINE) and newspaper databases in two on-line services (NEXIS and DIALOG PAPERS). Study Selection.-Articles selected from the literature review included those describing cases or outbreaks of disease in which exposure to an infectious agent was likely to have occurred during training for competitive sports or during actual competition. Articles from the newspaper review included reports of outbreaks, exposures, or preventive measures that directly or indirectly involved teams or spectators. Data Synthesis.-The literature review identified 38 reports of infectious disease outbreaks or other instances of transmission through person-to-person (24 reports), common-source (nine reports), or airborne (five reports) routes; the newspaper search identified 28 reports. Infectious agents included predominantly viruses but also a variety of fungi and gram-positive and gram-negative bacteria. Conclusions.-Our findings indicate that strategies to prevent transmission of infectious diseases in sports must recognize risks at three levels: the individual athlete, the team, and spectators or others who may become exposed to infectious diseases as a result of sports-related activities. Team physicians and others who are responsible for the health of athletes should be especially familiar with the features of infectious diseases that occur in sports and measures for the prevention of these problems.	CTR DIS CONTROL,NATL CTR INFECT DIS,ATLANTA,GA 30333; MINNESOTA DEPT HLTH,MINNEAPOLIS,MN	Centers for Disease Control & Prevention - USA; Minnesota Department of Health (MHD)	GOODMAN, RA (corresponding author), CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333, USA.							ALEXANDER JP, 1993, J INFECT DIS, V167, P1201, DOI 10.1093/infdis/167.5.1201; ALFANO P, 1989, NY TIMES, pD17; AREY N, 1992, ATLANTA CONSTIT 0409, V1, P6; Atkinson William L., 1992, Morbidity and Mortality Weekly Report, V41, P1; BARON RC, 1982, JAMA-J AM MED ASSOC, V248, P1724, DOI 10.1001/jama.248.14.1724; BARTLETT PC, 1982, AM J SPORT MED, V10, P371, DOI 10.1177/036354658201000611; BASLER RSW, 1983, PRIMARY CARE, V10, P479; BECKER TM, 1988, AM J SPORT MED, V16, P665, DOI 10.1177/036354658801600620; BELONGIA EA, 1991, NEW ENGL J MED, V325, P906, DOI 10.1056/NEJM199109263251302; BONDY F, 1992, NY TIMES        1117, pA1; BONDY F, 1992, NY TIMES        1117, pB11; BROWN LS, IN PRESS MED SCI SPO; BROWN LS, 1993, 9TH INT C AIDS BERL; CALABRESE LH, 1993, SPORTS MED, V15, P6, DOI 10.2165/00007256-199315010-00002; COHEN BA, 1992, NEW ENGL J MED, V327, P820, DOI 10.1056/NEJM199209103271121; COMMENS CA, 1987, MED J AUSTRALIA, V146, P117, DOI 10.5694/j.1326-5377.1987.tb136293.x; DAVIS RM, 1987, AM J EPIDEMIOL, V126, P438, DOI 10.1093/oxfordjournals.aje.a114675; DECKER MD, 1986, AM J EPIDEMIOL, V124, P969, DOI 10.1093/oxfordjournals.aje.a114486; DORMAN JM, 1981, NEW ENGL J MED, V305, P467; DYKE LM, 1965, JAMA-J AM MED ASSOC, V194, P153; EHRESMANN KR, 1992, 32ND INT C ANT AG CH; FREEMAN MJ, 1977, CUTIS, V20, P333; FRISK A, 1966, ACTA DERM-VENEREOL, V46, P453; GLEZEN WP, 1972, LANCET, V1, P301; GOLD A, 1992, NY TIMES        0204, pB11; GOLDSMITH MF, 1992, JAMA-J AM MED ASSOC, V267, P1311, DOI 10.1001/jama.267.10.1311; GRAY C, 1992, CAN MED ASSOC J, V146, P1437; GRAY C, 1992, CAN MED ASSOC J, V146, P1440; HEDBERG CW, 1992, JAMA-J AM MED ASSOC, V268, P3208, DOI 10.1001/jama.268.22.3208; IKEDA RM, 1993, JAMA-J AM MED ASSOC, V270, P2205, DOI 10.1001/jama.270.18.2205; JOHNSON F, 1992, Morbidity and Mortality Weekly Report, V41, P109; JOHNSON M, 1991, SPORTS ILLUSTRAT NOV, V18, P16; KASHIWAGI S, 1982, JAMA-J AM MED ASSOC, V248, P213, DOI 10.1001/jama.248.2.213; LAYMAN C, 1993, STATE ALASKA EPIDEMI, V9, P1; LEVINE N, 1980, J AM ACAD DERMATOL, V3, P415, DOI 10.1016/S0190-9622(80)80337-9; LUDLAM H, 1986, LANCET, V2, P331; MARE JB, 1978, S AFR MED J, V54, P752; MOORE M, 1983, JAMA-J AM MED ASSOC, V249, P2039, DOI 10.1001/jama.249.15.2039; MORSE LJ, 1972, J AMER MED ASSOC, V219, P706, DOI 10.1001/jama.219.6.706; NEMECHEK PM, 1991, NEW ENGL J MED, V325, P357; OSTERBACK L, 1987, ACTA PAEDIATR SCAND, V76, P944, DOI 10.1111/j.1651-2227.1987.tb17269.x; PETERS EM, 1983, S AFR MED J, V64, P582; POLLARD JG, 1967, J AMER COLL HEALTH A, V15, P234; PORTER PS, 1965, JAMA-J AM MED ASSOC, V194, P150; REID TMS, 1981, J HYG-CAMBRIDGE, V86, P357, DOI 10.1017/S0022172400069114; RISSER WL, 1992, PHYSICIAN SPORTSMED, V20, P190; ROBERTSON SE, 1992, PUBLIC HEALTH REP, V107, P24; ROSENBAUM GS, 1990, INT J DERMATOL, V29, P141, DOI 10.1111/j.1365-4362.1990.tb04088.x; SCOTT MJ, 1989, JAMA-J AM MED ASSOC, V262, P207, DOI 10.1001/jama.1989.03430020049017; SELLING B, 1964, NEW ENGL J MED, V270, P979, DOI 10.1056/NEJM196405072701903; SHUTE P, 1979, LANCET, V2, P1629; SNOOK GA, 1980, AM J SPORT MED, V8, P450, DOI 10.1177/036354658000800616; SOSIN DM, 1989, AM J SPORT MED, V17, P828, DOI 10.1177/036354658901700618; STILLER MJ, 1992, J AM ACAD DERMATOL, V27, P632, DOI 10.1016/S0190-9622(08)80205-8; STRAUSS RH, 1989, NEW ENGL J MED, V320, P598; SUDMAN JH, 1988, 8809 CDC, P1; THOMAS JC, 1990, J SCHOOL HEALTH, V60, P11; TORRE D, 1990, LANCET, V335, P1105, DOI 10.1016/0140-6736(90)92684-A; VERBOV J, 1974, LANCET, V2, P1523; WHEELER CE, 1965, JAMA-J AM MED ASSOC, V194, P145; WHITE WB, 1984, JAMA-J AM MED ASSOC, V252, P533; 1992, NATIONAL FEDERATION; 1987, NY TIMES        0506, pD32; 1989, NY TIMES        0319, P4; 1982, NY TIMES        0531, pC2; 1989, WORLD HEALTH FORUM, V10, P287; 1981, MMWR MORB MORTAL WKL, V29, P631; 1991, PEDIATRICS, V88, P640; 1991, DHHS PHS9150212 PUBL, P93; 1993, NCAA SPORTS MED HDB, P24; 1981, MMWR MORB MORTAL WKL, V29, P637	71	52	54	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					862	867		10.1001/jama.271.11.862	http://dx.doi.org/10.1001/jama.271.11.862			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114242				2022-12-01	WOS:A1994MZ49800034
J	DAWE, RK; SEDAT, JW; AGARD, DA; CANDE, WZ				DAWE, RK; SEDAT, JW; AGARD, DA; CANDE, WZ			MEIOTIC CHROMOSOME PAIRING IN MAIZE IS ASSOCIATED WITH A NOVEL CHROMATIN ORGANIZATION	CELL			English	Article							SYNAPTONEMAL COMPLEX; SACCHAROMYCES-CEREVISIAE; LILIUM-LONGIFLORUM; MEIOSIS; CONDENSATION; PROPHASE; STAGE; GENE	Three-dimensional light microscopy and the excellent cytological features of maize meiotic chromosomes are used to analyze the early events of chromosome synapsis. We demonstrate that the chromosomes undergo a dramatic structural reorganization prior to synapsis in zygotene. The unique features of prezygotene chromosomes are a partial separation of sister chromatids, an elongation of knob heterochromatin, an increase in surface complexity, a 50% increase in total chromosome volume, and a peripheral localization and alignment of telomeric, but not proximal, loci. At zygotene, chromosome volume decreases and chromosomes appear as single fibers. The specialized prezygotene chromosome morphology may facilitate homology recognition once the homologs have been brought together.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	DAWE, RK (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.				NIGMS NIH HHS [GM23238] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023238] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARD DA, 1989, METHOD CELL BIOL, V30, P353; BELMONT A, 1984, J CELL SCI, V65, P123; BELMONT AS, 1987, J CELL BIOL, V105, P77, DOI 10.1083/jcb.105.1.77; BOJKO M, 1983, CARLSBERG RES COMMUN, V48, P457, DOI 10.1007/BF02911920; BURNHAM CR, 1972, GENETICS, V71, P111; Carlson W. R., 1988, Corn and corn improvement. Third edition., P259; CHANG MT, 1989, GENOME, V32, P232, DOI 10.1139/g89-434; CHEN H, 1989, HDB BIOL CONFOCAL MI, P153; Chughtai S. R., 1989, Sabrao Journal, V21, P21; Creighton HB, 1931, P NATL ACAD SCI USA, V17, P492, DOI 10.1073/pnas.17.8.492; CRONENWETT C, 1967, MAIZE GENET COOP NEW, V41, P179; DAWE RK, 1992, MAIZE GENET COOP NEW, V66, P23; GILLIES CB, 1975, CR TRAV LAB CARLSB, V40, P135; GOLUBOVSKAYA IN, 1989, ADV GENET, V26, P149; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; HAN CD, 1992, EMBO J, V11, P4037, DOI 10.1002/j.1460-2075.1992.tb05497.x; HAWLEY RS, 1993, CELL, V72, P301, DOI 10.1016/0092-8674(93)90108-3; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; HOLM PB, 1977, CARLSBERG RES COMMUN, V42, P249, DOI 10.1007/BF02910453; HOLM PB, 1977, CARLSBERG RES COMMUN, V42, P103, DOI 10.1007/BF02906489; HSU S-Y, 1981, Iowa State Journal of Research, V55, P351; Huskins CL, 1934, J GENET, V28, P397, DOI 10.1007/BF02981762; JENKINS G, 1983, CARLSBERG RES COMMUN, V48, P255, DOI 10.1007/BF02907772; JOHN B, 1974, CHROMOSOMA, V46, P181, DOI 10.1007/BF00332516; John B., 1990, MEIOSIS; KLECKNER N, 1991, COLD SH Q B, V56, P729; LOIDL J, 1990, GENOME, V33, P759, DOI 10.1139/g90-115; LU BC, 1970, CHROMOSOMA, V29, P305, DOI 10.1007/BF00325945; MAGUIRE MP, 1984, J THEOR BIOL, V106, P605, DOI 10.1016/0022-5193(84)90010-9; MAGUIRE MP, 1983, CYTOLOGIA, V48, P811, DOI 10.1508/cytologia.48.811; MAGUIRE MP, 1985, GENET RES, V46, P273, DOI 10.1017/S0016672300022771; MAGUIRE MP, 1988, CHROMOSOME STRUCTURE, P117; McClintock B., 1978, Maize breeding and genetics. Section 2. Evolution., P159; MOENS PB, 1969, CHROMOSOMA, V28, P1, DOI 10.1007/BF00325986; OEHLKERS F, 1957, CHROMOSOMA, V8, P351; PADDY MR, 1990, CELL, V62, P89, DOI 10.1016/0092-8674(90)90243-8; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PARVINEN M, 1976, NATURE, V260, P534, DOI 10.1038/260534a0; PEACOCK WJ, 1981, P NATL ACAD SCI-BIOL, V78, P4490, DOI 10.1073/pnas.78.7.4490; PEII T, 1982, OPT ENG, V21, P108; RHOADES MM, 1950, J HERED, V41, P58, DOI 10.1093/oxfordjournals.jhered.a106089; Rhoades MM, 1961, CELL, VIII, P1; Robertson WRB, 1931, J MORPHOL PHYSIOL, V51, P119, DOI 10.1002/jmor.1050510103; RUSS CJ, 1992, IMAGE PROCESSING HDB; SALONEN K, 1982, CHROMOSOMA, V85, P611, DOI 10.1007/BF00330775; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; STAIGER CJ, 1990, DEV BIOL, V138, P231, DOI 10.1016/0012-1606(90)90193-M; STERN H, 1975, P NATL ACAD SCI USA, V72, P961, DOI 10.1073/pnas.72.3.961; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; THOMAS JB, 1976, HEREDITY, V36, P155, DOI 10.1038/hdy.1976.19; VINCENT JE, 1993, CHROMOSOMA, V102, P195, DOI 10.1007/BF00387734; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WESTERGA.M, 1970, CR TRAV LAB CARLSB, V37, P239	54	140	144	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 11	1994	76	5					901	912		10.1016/0092-8674(94)90364-6	http://dx.doi.org/10.1016/0092-8674(94)90364-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124724				2022-12-01	WOS:A1994NA89000015
J	POZNANSKY, MC; TORKINGTON, J; TURNER, G; BANKES, MJK; PARRY, JV; CONNELL, JA; TOUQUET, R; WEBER, J				POZNANSKY, MC; TORKINGTON, J; TURNER, G; BANKES, MJK; PARRY, JV; CONNELL, JA; TOUQUET, R; WEBER, J			PREVALENCE OF HIV-INFECTION IN PATIENTS ATTENDING AN INNER-CITY ACCIDENT AND EMERGENCY DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY		ST MARYS HOSP,DEPT ACCID & EMERGENCY MED,LONDON W2 1NY,ENGLAND; CENT PUBL HLTH LAB,DIV VIRUS REFERENCE,LONDON NW9 5HT,ENGLAND; ST MARYS HOSP,SCH MED,DEPT GENITOURINARY MED & COMMUNICABLE DIS,LONDON W2 1NY,ENGLAND	Imperial College London; Public Health England; Imperial College London			Poznansky, Mark C/M-4996-2015	Poznansky, Mark C/0000-0003-1344-7103				CONNELL JA, 1990, LANCET, V335, P1366, DOI 10.1016/0140-6736(90)91245-6; CONNELL JA, IN PRESS J MED VIOL; KELEN GD, 1988, NEW ENGL J MED, V318, P1645, DOI 10.1056/NEJM198806233182503; KELEN GD, 1989, ANN EMERG MED, V18, P378, DOI 10.1016/S0196-0644(89)80574-8; 1993, CDR REV, V3, P1	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1994	308	6929					636	636		10.1136/bmj.308.6929.636	http://dx.doi.org/10.1136/bmj.308.6929.636			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148714	Green Published			2022-12-01	WOS:A1994MZ69800025
J	BENJACOB, E; SCHOCHET, O; TENENBAUM, A; COHEN, I; CZIROK, A; VICSEK, T				BENJACOB, E; SCHOCHET, O; TENENBAUM, A; COHEN, I; CZIROK, A; VICSEK, T			GENERIC MODELING OF COOPERATIVE GROWTH-PATTERNS IN BACTERIAL COLONIES	NATURE			English	Article							FRACTAL GROWTH	BACTERIAL colonies must often cope with unfavourable environmental conditions(1,2). To do so, they have developed sophisticated modes of cooperative behaviour(3-10). It has been found that such behaviour can cause bacterial colonies to exhibit complex growth patterns similar to those observed during non-equilibrium growth processes in non-living systems(11) some of the qualitative features of the latter may be invoked to account for the complex patterns of bacterial growth(12-18). Here we show that a simple model of bacterial growth can reproduce the salient features of the observed growth patterns. The model incorporates random walkers, representing aggregates of bacteria, which move in response to gradients in nutrient concentration and communicate with each other by means of chemotactic 'feedback'. These simple features allow the colony to respond efficiently to adverse growth conditions, and generate self-organization over a wide range of length scales.	EOTVOS LORAND UNIV, DEPT ATOM PHYS, H-1088 BUDAPEST, HUNGARY	Eotvos Lorand University	BENJACOB, E (corresponding author), TEL AVIV UNIV, RAYMOND & BEVERLY SACKLER FAC EXACT SCI, SCH PHYS & ASTRON, IL-69978 TEL AVIV, ISRAEL.		Vicsek, Tamas/A-3305-2009; Czirok, Andras/E-4253-2014	Czirok, Andras/0000-0002-2694-5163				ADLER J, 1969, SCIENCE, V166, P1588, DOI 10.1126/science.166.3913.1588; ALLISON C, 1991, SCI PROG, V75, P403; BENJACOB E, 1994, PHYSICA A, V202, P1, DOI 10.1016/0378-4371(94)90165-1; BENJACOB E, 1992, PHYSICA A, V187, P378, DOI 10.1016/0378-4371(92)90002-8; BENJACOB E, 1990, NATURE, V343, P523, DOI 10.1038/343523a0; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BUDRENE EO, 1991, NATURE, V349, P630, DOI 10.1038/349630a0; COOPER AL, 1968, PROC R SOC SER B-BIO, V171, P175, DOI 10.1098/rspb.1968.0063; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; FUJIKAWA H, 1989, J PHYS SOC JPN, V58, P3875, DOI 10.1143/JPSJ.58.3875; HENRICHSEN J, 1972, BACTERIOL REV, V36, P478, DOI 10.1128/MMBR.36.4.478-503.1972; HENRICI TH, 1948, BIOL BACTERIA; KESSLER D, IN PRESS PHYS REV E; KESSLER JO, 1985, CONTEMP PHYS, V26, P147, DOI 10.1080/00107518508210745; LACKIIE JM, 1981, BIOL CHEMOTACTIC RES; MATSUYAMA T, 1993, CRIT REV MICROBIOL, V19, P117, DOI 10.3109/10408419309113526; NOSSAL R, 1972, EXP CELL RES, V75, P138, DOI 10.1016/0014-4827(72)90529-0; SANDER LM, 1986, NATURE, V322, P789, DOI 10.1038/322789a0; SCHINDLER J, 1992, Binary Computing in Microbiology, V4, P66; Shapiro J. A., 1988, SCI AM, V258, P62; SHAPIRO JA, 1991, PHYSICA D, V49, P214, DOI 10.1016/0167-2789(91)90209-R; STANIER RY, 1957, MICROBIAL WORLD	22	441	449	2	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					46	49		10.1038/368046a0	http://dx.doi.org/10.1038/368046a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	8107881				2022-12-01	WOS:A1994MY56900047
J	COSTE, J; DELECOEUILLERIE, G; DELARA, AC; LEPARC, JM; PAOLAGGI, JB				COSTE, J; DELECOEUILLERIE, G; DELARA, AC; LEPARC, JM; PAOLAGGI, JB			CLINICAL COURSE AND PROGNOSTIC FACTORS IN ACUTE LOW-BACK-PAIN - AN INCEPTION COHORT STUDY IN PRIMARY-CARE PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							LUMBAR SPINE RADIOGRAPHS; DISABILITY; RELIABILITY	Objective-To describe the natural course of recent acute low back pain in terms of both morbidity (pain, disability) and absenteeism from work and to evaluate the prognostic factors for these outcomes. Design-Inception cohort study. Setting-Primary care. Patients-103 patients with acute localised nonspecific back pain lasting less than 72 hours. Main outcome measures-Complete recovery (disappearance of both pain and disability) and return to work. Results-90% of patients recovered within two weeks and only two developed chronic low back pain. Only 49 of 100 patients for whom data were available had bed rest and 40% of 75 employed patients lost no time from work. Proportional hazards regression analysis showed that previous chronic episodes of low back pain, initial disability level, initial pain worse when standing, initial pain worse when lying, and compensation status were significantly associated with delayed episode recovery. These factors were also related to absenteeism from work. Absenteeism from work was also influenced by job satisfaction and gender. Conclusions-The recovery rate from acute low back pain was much higher than reported in other studies. Those studies, however, did not investigate groups of patients enrolled shortly after the onset of symptoms and often mixed acute low back pain patients with patients with exacerbations of chronic pain or sciatica. Several sociodemographic and clinical factors were of prognostic value in acute low back pain. Factors which influenced the outcome in terms of episode recovery (mainly physical severity factors) were only partly predictive of absenteeism from work. Time off work and return to work depended more on sociodemographic and job related influences.	LABS CASSENNE 1,F-92800 PUTEAUX,FRANCE; HOP AMBROISE PARE,SERV RHUMATOL,F-92104 BOULOGNE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	COSTE, J (corresponding author), HOP BICETRE,INSERM,U292,F-94275 LE KREMLIN BICETR,FRANCE.							ANDERSSON GBJ, 1981, SPINE, V6, P53, DOI 10.1097/00007632-198101000-00013; ANDERSSON GBJ, 1983, SPINE, V8, P880, DOI 10.1097/00007632-198311000-00011; BERGQUISTULLMAN M, 1977, ACTA ORTHOP SCAND S, V170, P1; CATSBARIL WL, 1991, SPINE, V16, P605, DOI 10.1097/00007632-199106000-00001; COSTE J, 1991, SPINE, V16, P426, DOI 10.1097/00007632-199104000-00006; COSTE J, 1991, J CLIN EPIDEMIOL, V44, P1233, DOI 10.1016/0895-4356(91)90156-4; Coste J, 1993, REV RHUM, V60, P295; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1987, ARTHRITIS RHEUM, V30, P1247, DOI 10.1002/art.1780301107; DEYO RA, 1986, SPINE, V11, P951, DOI 10.1097/00007632-198611000-00017; DEYO RA, 1983, SPINE, V8, P635, DOI 10.1097/00007632-198309000-00009; DEYO RA, 1988, J RHEUMATOL, V15, P1557; DEYO RA, 1985, ARTHRITIS RHEUM, V28, P1066, DOI 10.1002/art.1780280916; DILLANE JB, 1966, BRIT MED J, V2, P82, DOI 10.1136/bmj.2.5505.82; DIXON WJ, 1989, BMDP STATISTICAL SOF; FRANK A, 1993, BMJ-BRIT MED J, V306, P901, DOI 10.1136/bmj.306.6882.901; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; GOERTZ MN, 1990, SPINE, V15, P1307, DOI 10.1097/00007632-199012000-00013; GUELFI JD, 1989, MANUEL DIAGNOSTIQUE; Hull F M, 1982, J R Coll Gen Pract, V32, P352; LEAVITT F, 1982, SPINE, V7, P398, DOI 10.1097/00007632-198207000-00010; MAGNI G, 1984, ACTA PSYCHIAT SCAND, V70, P614, DOI 10.1111/j.1600-0447.1984.tb01256.x; NACHEMSON A L, 1976, Spine, V1, P59, DOI 10.1097/00007632-197603000-00009; NACHEMSON AL, 1985, CLIN ORTHOPAEDICS, V200, P266; Pedersen P A, 1981, J R Coll Gen Pract, V31, P209; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROLAND MO, 1983, BRIT MED J, V286, P523, DOI 10.1136/bmj.286.6364.523; Sackett D, 1991, CLIN EPIDEMIOLOGY BA; WADDELL G, 1982, BMJ-BRIT MED J, V284, P1519, DOI 10.1136/bmj.284.6328.1519; WHITE AWM, 1966, CAN MED ASSOC J, V95, P50; WIESEL SW, 1980, SPINE, V5, P324, DOI 10.1097/00007632-198007000-00006; 1987, DIAGNOSTIC STATISTIC; 1987, SPINE S, V21, pS17	33	288	294	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	1994	308	6928					577	580		10.1136/bmj.308.6928.577	http://dx.doi.org/10.1136/bmj.308.6928.577			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY714	8148683	Green Published			2022-12-01	WOS:A1994MY71400025
J	STEARNS, T; KIRSCHNER, M				STEARNS, T; KIRSCHNER, M			IN-VITRO RECONSTITUTION OF CENTROSOME ASSEMBLY AND FUNCTION - THE CENTRAL ROLE OF GAMMA-TUBULIN	CELL			English	Article							MICROTUBULE-ORGANIZING CENTERS; CELL-FREE-EXTRACTS; SPISULA-SOLIDISSIMA OOCYTES; HAMSTER OVARY CELLS; ASPERGILLUS-NIDULANS; NUCLEATING ACTIVITY; CYTOPLASMIC EXTRACTS; DROSOPHILA EMBRYO; MITOTIC SPINDLE; PROTEIN-KINASE	The centrosome nucleates microtubule polymerization, affecting microtubule number, polarity, and structure. We use an in vitro system based on extracts of Xenopus eggs to examine the role of gamma-tubulin in centrosome assembly and function. gamma-Tubulin is present in the cytoplasm of frog eggs and vertebrate somatic cells in a large similar to 25S complex. The egg extracts assemble centrosomes around sperm centrioles. Formation of a centrosome in the extract requires both the gamma-tubulin complex and ATP and can take place in the absence of microtubules. gamma-Tubulin is not present on the sperm prior to incubation in extract, but is recruited from the cytoplasm during centrosome assembly. The gamma-tubulin complex also binds to microtubules, likely the minus end, independent of the centrosome. These results suggest that gamma-tubulin is an essential component of the link between the centrosome and the microtubule, probably playing a direct role in microtubule nucleation.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco				Stearns, Tim/0000-0002-0671-6582				BARON AT, 1988, J CELL BIOL, V107, P2669, DOI 10.1083/jcb.107.6.2669; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; BUENDIA B, 1992, J CELL BIOL, V116, P1431, DOI 10.1083/jcb.116.6.1431; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CENTONZE VE, 1990, J CELL SCI, V95, P405; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GARD DL, 1987, J CELL BIOL, V105, P2191, DOI 10.1083/jcb.105.5.2191; GOULD RR, 1977, J CELL BIOL, V73, P601, DOI 10.1083/jcb.73.3.601; HEIDEMANN SR, 1975, J CELL BIOL, V57, P105; HELDEMANN SR, 1980, NATURE, V286, P517; HILLER G, 1978, CELL, V14, P795, DOI 10.1016/0092-8674(78)90335-5; HORIO T, 1991, J CELL SCI, V99, P693; HUANG B, 1988, J CELL BIOL, V107, P133, DOI 10.1083/jcb.107.1.133; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; KERYER G, 1990, J CELL SCI, V97, P553; KURIYAMA R, 1981, J CELL BIOL, V91, P822, DOI 10.1083/jcb.91.3.822; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; MASUDA H, 1992, J CELL BIOL, V117, P1055, DOI 10.1083/jcb.117.5.1055; MCDONALD KL, 1992, J CELL BIOL, V118, P369, DOI 10.1083/jcb.118.2.369; MCNIVEN MA, 1988, J CELL BIOL, V106, P1593, DOI 10.1083/jcb.106.5.1593; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NUMATA O, 1983, EXP CELL RES, V148, P207, DOI 10.1016/0014-4827(83)90200-8; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; OHTA K, 1993, J CELL SCI, V104, P125; PALAZZO RE, 1992, SCIENCE, V256, P219, DOI 10.1126/science.1566068; RAFF JW, 1993, J CELL BIOL, V121, P823, DOI 10.1083/jcb.121.4.823; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; SUPRENANT KA, 1991, CELL MOTIL CYTOSKEL, V19, P207, DOI 10.1002/cm.970190308; TAO W, 1988, J CELL BIOL, V107, P1025, DOI 10.1083/jcb.107.3.1025; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; WEIL CF, 1986, MOL CELL BIOL, V6, P2963, DOI 10.1128/MCB.6.8.2963; Wilson E.B., 1928, CELL DEV HEREDITY; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZABALA JC, 1992, CELL MOTIL CYTOSKEL, V23, P222, DOI 10.1002/cm.970230306; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	56	414	420	3	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					623	637		10.1016/0092-8674(94)90503-7	http://dx.doi.org/10.1016/0092-8674(94)90503-7			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124706				2022-12-01	WOS:A1994MZ28500006
J	KATZ, PS; GETTING, PA; FROST, WN				KATZ, PS; GETTING, PA; FROST, WN			DYNAMIC NEUROMODULATION OF SYNAPTIC STRENGTH INTRINSIC TO A CENTRAL PATTERN GENERATOR CIRCUIT	NATURE			English	Article							CENTRAL NERVOUS-SYSTEM; MOTOR ORGANIZATION; NEURAL NETWORKS; TRITONIA; NEURONS; BEHAVIOR; APLYSIA; MODULATION; INTERNEURONS; MECHANISMS	MOTOR circuits are often thought to be physically separate from their neuromodulatory systems1,2. We report here a counter example, where neurons within a circuit appear to modulate synaptic properties of that same circuit during its normal operation. The dorsal swim interneurons (DSIs) are members of the central pattern generator circuit for escape swimming in the mollusc Tritonia diomedea3. However, DSI stimulation also rapidly enhances the synaptic potentials evoked by another neuron in the same circuit onto its follower cells. This modulatory action appears to be mediated by serotonin (5-hydroxytryptamine); the DSIs are serotonin-immunoreactive4, and bath-application of serotonin mimics and occludes the effect of DSIs. These results indicate that during the escape swim, circuit connection strengths are dynamically controlled by the activity of neurons within the circuit itself. This 'intrinsic neuromodulation' may be important for the animal's initial decision to swim, the generation of the swim motor programme itself, and certain types of learning.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa	KATZ, PS (corresponding author), UNIV TEXAS, SCH MED, DEPT NEUROBIOL & ANAT, HOUSTON, TX 77225 USA.							ABRAHAM F D, 1971, Communications in Behavioral Biology Part A Original Articles, V6, P271; BISHOP CA, 1987, J NEUROSCI, V7, P1769; BROWN G D, 1991, Society for Neuroscience Abstracts, V17, P549; CHIEL HJ, 1990, TRENDS NEUROSCI, V13, P223, DOI 10.1016/0166-2236(90)90164-6; CROLL RP, 1989, J COMP NEUROL, V280, P122, DOI 10.1002/cne.902800109; CROPPER EC, 1987, P NATL ACAD SCI USA, V84, P3486, DOI 10.1073/pnas.84.10.3486; FROST W N, 1989, Society for Neuroscience Abstracts, V15, P1118; FROST W N, 1988, Society for Neuroscience Abstracts, V14, P607; Getting P.A., 1985, P3; GETTING P A, 1985, Society for Neuroscience Abstracts, V11, P1023; GETTING PA, 1989, ANNU REV NEUROSCI, V12, P185, DOI 10.1146/annurev.neuro.12.1.185; GETTING PA, 1985, J NEUROPHYSIOL, V53, P466, DOI 10.1152/jn.1985.53.2.466; GETTING PA, 1980, J NEUROPHYSIOL, V44, P151, DOI 10.1152/jn.1980.44.1.151; GETTING PA, 1981, J NEUROPHYSIOL, V46, P65, DOI 10.1152/jn.1981.46.1.65; GETTING PA, 1983, SYM SOC EXP BIOL, P89; HARRISWARRICK RM, 1991, ANNU REV NEUROSCI, V14, P39, DOI 10.1146/annurev.ne.14.030191.000351; HAWKINS RD, 1981, J NEUROPHYSIOL, V45, P315, DOI 10.1152/jn.1981.45.2.315; HUME RI, 1982, J NEUROPHYSIOL, V47, P60, DOI 10.1152/jn.1982.47.1.60; HUME RI, 1982, J NEUROPHYSIOL, V47, P75, DOI 10.1152/jn.1982.47.1.75; Jordan L M, 1992, Curr Opin Neurobiol, V2, P794, DOI 10.1016/0959-4388(92)90136-9; Kaczmarek LK, 1987, NEUROMODULATION BIOC; Katz P. S., 1993, Society for Neuroscience Abstracts, V19, P1700; KATZ PS, 1990, TRENDS NEUROSCI, V13, P367, DOI 10.1016/0166-2236(90)90021-2; KATZ PS, 1989, J NEUROPHYSIOL, V62, P571, DOI 10.1152/jn.1989.62.2.571; NUSBAUM MP, 1992, J NEUROSCI, V12, P2706; TAGHERT PH, 1978, J COMP PHYSIOL, V123, P253, DOI 10.1007/BF00656878; WEINREICH D, 1973, J NEUROCHEM, V20, P969, DOI 10.1111/j.1471-4159.1973.tb00067.x; WHIM MD, 1990, J NEUROSCI, V10, P3313; WILLOWS AOD, 1973, J NEUROBIOL, V4, P207, DOI 10.1002/neu.480040306; [No title captured]	30	119	120	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	1994	367	6465					729	731		10.1038/367729a0	http://dx.doi.org/10.1038/367729a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107867				2022-12-01	WOS:A1994MX63100056
J	WILLIAMS, RW; HOGAN, D; GARRAGHTY, PE				WILLIAMS, RW; HOGAN, D; GARRAGHTY, PE			TARGET RECOGNITION AND VISUAL MAPS IN THE THALAMUS OF ACHIASMATIC DOGS	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; BINOCULAR COMPETITION; SIAMESE CAT; PROJECTIONS; ORGANIZATION; PATHWAYS; FIELD	VISION is dependent on ordered neuronal representations or maps of visual space. These maps depend on precise connections between retinal axons and their targets cells. In mammals, nerve fibres from right and left eyes produce congruent maps of contralateral visual space in adjacent layers of the lateral geniculate nucleus (LGN)(1). We have identified an autosomal recessive mutation in Belgian sheepdogs(2,3) that eliminates the optic chiasm. In these mutants, all retinal axons project into the ipsilateral optic tract, including those originating in the nasal hemiretina that normally cross midline. These animals exhibit a pronounced horizontal nystagmus(4,5). The abnormal ipsilaterally directed nasal fibres innervate the LGN as if they had successfully crossed the midline, terminating in the appropriate layer of the nucleus. As a consequence, the LGN contains non-congruent, mirror-image maps of visual space in adjacent layers. These results show that there is a robust affinity between nasal and temporal retinal axons and,specific LGN layers even when all retinal axons originate from a single eye.	INDIANA UNIV, DEPT PSYCHOL, PROGRAM NEURAL SCI, BLOOMINGTON, IN 47405 USA	Indiana University System; Indiana University Bloomington	WILLIAMS, RW (corresponding author), UNIV TENNESSEE, SCH MED, DEPT ANAT & NEUROBIOL, 855 MONROE AVE, MEMPHIS, TN 38163 USA.		Williams, Robert W./H-8789-2016	Williams, Robert W./0000-0001-8924-4447				APKARIAN P, IN PRESS EUR J NEURO; BALKEMA GW, 1990, VISUAL NEUROSCI, V4, P595, DOI 10.1017/S0952523800005794; BERMAN N, 1972, J PHYSIOL-LONDON, V224, P363, DOI 10.1113/jphysiol.1972.sp009900; BONHOEFFER F, 1985, NATURE, V315, P408, DOI 10.1038/315409a0; CHALUPA LM, 1984, HUM NEUROBIOL, V3, P103; COOPER ML, 1979, J COMP NEUROL, V187, P313, DOI 10.1002/cne.901870205; DELLOSSO LF, 1988, CURR NEURO OPHTHALMO, V1, P139; GARRAGHTY PE, 1988, VISUAL NEUROSCI, V1, P93, DOI 10.1017/S0952523800001048; GUILLERY RW, 1971, J COMP NEUROL, V143, P73, DOI 10.1002/cne.901430106; GUILLERY RW, 1986, TRENDS NEUROSCI, V9, P364, DOI 10.1016/0166-2236(86)90115-3; GUILLERY RW, 1985, J NEUROSCI, V5, P1370; Hogan D., 1993, Society for Neuroscience Abstracts, V19, P524; HUANG K, 1985, DEV BRAIN RES, V20, P213, DOI 10.1016/0165-3806(85)90108-7; HUBEL DH, 1971, J PHYSIOL-LONDON, V218, P33, DOI 10.1113/jphysiol.1971.sp009603; KAAS JH, 1973, BRAIN BEHAV EVOLUT, V6, P253; LEVENTHAL AG, 1985, J NEUROSCI, V5, P795; RAKIC P, 1981, SCIENCE, V214, P928, DOI 10.1126/science.7302569; Rioch DM, 1929, J COMP NEUROL, V49, P1, DOI 10.1002/cne.900490102; SANDERSON KJ, 1971, J COMP NEUROL, V143, P101, DOI 10.1002/cne.901430107; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STONE J, 1978, J COMP NEUROL, V180, P783, DOI 10.1002/cne.901800409; WALSH C, 1983, NATURE, V302, P611, DOI 10.1038/302611a0; WILLIAMS R W, 1991, Society for Neuroscience Abstracts, V17, P187; WILLIAMS RW, 1993, INVEST OPHTH VIS SCI, V34, P1125	24	68	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	1994	367	6464					637	639		10.1038/367637a0	http://dx.doi.org/10.1038/367637a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107846				2022-12-01	WOS:A1994MW68800051
J	HONG, KS; DRISCOLL, M				HONG, KS; DRISCOLL, M			A TRANSMEMBRANE DOMAIN OF THE PUTATIVE CHANNEL SUBUNIT MEC-4 INFLUENCES MECHANOTRANSDUCTION AND NEURODEGENERATION IN C-ELEGANS	NATURE			English	Article							TOUCH RECEPTOR NEURONS; CAENORHABDITIS-ELEGANS; GENE	ABERRANT ion channel activity plays a causative role in several human disorders1-3. Inappropriately regulated channel activity also appears to be the basis for neurodegeneration induced by dominant mutations of Caenorhabditis elegans mec-4 (mec-4(d)), a member of the degenerin gene family postulated to encode a subunit of a mechanosensory channel4. The degenerin gene family has been defined by two C. elegans genes, mec-4 and deg-1 (ref. 5), which can mutate to gain-of-function alleles that induce degeneration of specific groups of neurons. A related mammalian gene, rat alpha-rENaC, induces an amiloride-sensitive Na+ current when introduced to Xenopus oocytes6, strongly suggesting that degenerin genes encode ion channel proteins. Deduced amino-acid sequences of the degenerins include two predicted membrane-spanning domains6,7. Here we show that conserved amino acids within the second membrane-spanning domain (MSDII) are critical for MEC-4 activity and that specific substitutions within MSDII, whether encoded in cis or in trans to a mec-4(d) mutation, block or delay the onset of degeneration. Remarkably, MSDII from two other family members, C. elegans deg-1 (ref. 5) and rat alpha-rENaC (ref. 6), can functionally substitute for MEC-4 MSDII in chimaeric proteins. Our results support a structural model for a mechanosensory channel in which multiple MEC-4 subunits are oriented such that MSDII lines the channel pore, and a neurodegeneration model in which aberrant ion flow through this channel is a key event.	RUTGERS UNIV,CTR ADV BIOTECHNOL & MED,DEPT MOLEC BIOL & BIOCHEM,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick								BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; BRENNER S, 1974, GENETICS, V77, P71; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; CHALFIE M, 1993, NATURE, V361, P504, DOI 10.1038/361504a0; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; DRISCOLL M, 1992, J NEUROBIOL, V23, P1327, DOI 10.1002/neu.480230919; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FRENCH AS, 1992, ANNU REV PHYSIOL, V54, P135, DOI 10.1146/annurev.physiol.54.1.135; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; PTACEK LJ, 1993, ANN NEUROL, V33, P300, DOI 10.1002/ana.410330312; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; 1991, GENETICS COMPUTER GR	23	183	193	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					470	473		10.1038/367470a0	http://dx.doi.org/10.1038/367470a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107806				2022-12-01	WOS:A1994MU67900057
J	NAGY, LM; CARROLL, S				NAGY, LM; CARROLL, S			CONSERVATION OF WINGLESS PATTERNING FUNCTIONS IN THE SHORT-GERM EMBRYOS OF TRIBOLIUM-CASTANEUM	NATURE			English	Article							SEGMENT-POLARITY GENE; WHOLE DROSOPHILA EMBRYOS; LOCALIZATION; EXPRESSION	DURING embryogenesis, all insects reach a conserved, or phylotypic, stage at which all future segments are present1,2. Different insects, however, arrive at this stage by overtly different pathways. In the long-germ insect Drosophila melanogaster, segmentation of the entire embryo occurs nearly simultaneosly and results from the action of a cascade of transcriptional regulatory factors that operate in the acellular environment of the syncytial blastoderm3,4. In short-germ insects, segmentation occurs in an anterior-to-posterior sequence, within a cellular environment1, and might then be dependent on intercellular signalling5,6. To compare the molecular mechanisms of segmentation, we have isolated a homologue of the Drosophila wingless gene, a mediator of cell-cell communications7-9, from the short-germ beetle Tribolium castaneum. The principal features of wingless expression patterns in Drosophila are conserved in Tribolium, including its early deployment in rostral and caudal domains in the blastoderm, its segmental iteration in cells immediately anterior to cells expressing the engrailed gene, and its later restriction to a ventral sector of the developing appendages.			NAGY, LM (corresponding author), UNIV WISCONSIN, HOWARD HUGHES MED INST, MOLEC BIOL LAB, MADISON, WI 53706 USA.							AKAM M, 1992, Current Biology, V2, P395, DOI 10.1016/0960-9822(92)90313-Y; AKAM M, 1987, DEVELOPMENT, V101, P1; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEVELOPMENT, V103, P289; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; KNIPPLE DC, 1985, NATURE, V317, P40, DOI 10.1038/317040a0; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PATEL NH, 1994, NATURE, V367, P429, DOI 10.1038/367429a0; PATEL NH, 1989, DEVELOPMENT, V107, P201; PATEL NH, 1993, EVOLUTIONARY CONSERVATION OF DEVELOPMENTAL MECHANISMS, P85; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; SANDERK, 1983, DEV EVOLUTION, P137; SIMCOX AA, 1989, DEVELOPMENT, V107, P715; SOMMER RJ, 1993, NATURE, V361, P448, DOI 10.1038/361448a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STUART JJ, 1993, DEVELOPMENT, V117, P233; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2	29	131	132	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	1994	367	6462					460	463		10.1038/367460a0	http://dx.doi.org/10.1038/367460a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107804				2022-12-01	WOS:A1994MU67900054
J	PEKAREK, KJ; JACOB, JS; MATHIOWITZ, E				PEKAREK, KJ; JACOB, JS; MATHIOWITZ, E			DOUBLE-WALLED POLYMER MICROSPHERES FOR CONTROLLED DRUG-RELEASE	NATURE			English	Article							POLYANHYDRIDE MICROSPHERES; SOLVENT REMOVAL; MICROENCAPSULATION; MORPHOLOGY; SYSTEMS; COACERVATION	ONE approach to the controlled release of drugs involves incorporation of the drug molecules into the matrix of microscopic polymer spheres or capsules1-10. Existing methods for preparing such microparticles do not, however, always guarantee a constant release rate, for example because drug molecules may be trapped preferentially at the surface, because they have to diffuse through an increasing thickness of polymer when the particles are non-eroding or because the surface area changes for eroding particles. In other situations pulsed release may be required-an application to which simple polymer microspheres do not readily lend themselves. Multi-walled microspheres might solve some of these problems. Here we describe a one-step process for preparing double-walled polymer microspheres with diameters ranging from about 20 to 1,000 micrometres. Our technique11 involves the phase separation of a polymer mixture owing to solvent evaporation: with an appropriate choice of interfacial tensions and evaporation rate, a spherical droplet of one polymer becomes coated with a highly uniform layer of the other. This process, which might be adapted to yield multi-walled microspheres, should make possible the engineering of highly specific drug-release properties.	BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912	Brown University								Green B. K., 1957, US, Patent No. [US 2800458 A, 2800458, 2800458A]; Green B.K., 1957, Patent Brevet, Patent No. [2,800,457, 2800457, US 2800457]; HARKIN WD, 1952, PYSICAL CHEM SURFACE; HEISTAND EN, 1836, Patent No. 24899; HELLER J, 1985, J CONTROL RELEASE, V1, P87; MADAN PL, 1978, DRUG DEV IND PHARM, V4, P95, DOI 10.3109/03639047809055641; MADAN PL, 1972, J PHARM SCI, V61, P1586, DOI 10.1002/jps.2600611008; MATHIOWITZ E, 1990, POLYMER, V31, P547, DOI 10.1016/0032-3861(90)90401-J; MATHIOWITZ E, 1988, J APPL POLYM SCI, V35, P755, DOI 10.1002/app.1988.070350316; MATHIOWITZ E, 1992, J APPL POLYM SCI, V45, P125, DOI 10.1002/app.1992.070450115; MATHIOWITZ E, 1990, SCANNING MICROSCOPY, V4, P329; Mathiowitz E, 1989, US Patent, Patent No. 4861627; MISSELBROOK J, 1976, Patent No. 3960757; PARROTT EL, 1970, PHARM TECHNOLOGY, P86; TORZA S, 1970, J COLLOID INTERF SCI, V33, P67, DOI 10.1016/0021-9797(70)90073-1; Vrancken MN., 1970, U.S. Patent, Patent No. [3523906, 3,523,906]	16	230	267	2	101	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					258	260		10.1038/367258a0	http://dx.doi.org/10.1038/367258a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121490				2022-12-01	WOS:A1994MR49400051
J	GUZDER, SN; QIU, HF; SOMMERS, CH; SUNG, P; PRAKASH, L; PRAKASH, S				GUZDER, SN; QIU, HF; SOMMERS, CH; SUNG, P; PRAKASH, L; PRAKASH, S			DNA-REPAIR GENE RAD3 OF SACCHAROMYCES-CEREVISIAE IS ESSENTIAL FOR TRANSCRIPTION BY RNA POLYMERASE-II	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; XERODERMA-PIGMENTOSUM; NUCLEOTIDE-SEQUENCE; DEPENDENT ATPASE; YEAST HOMOLOG; INITIATION; REQUIREMENT; HELICASE; PROTEIN; ENCODES	THE RAD3 gene of Saccharomyces cerevisiae is required for excision repair of ultraviolet-damaged DNA and is essential for cell viability1. The RAD3-encoded protein shares a high degree of homology with the human ERCC2(XPD) gene product2. Mutations in XPD, besides causing the cancer-prone syndrome xeroderma pigmentosum, can also result in Cockayne's syndrome and trichothiodystrophy3. To investigate the role of RAD3 in viability, we examine here the effect of a recessive, temperature-sensitive (ts) conditional lethal mutation of the gene on transcription by RNA polymerase II. Upon transfer to the restrictive temperature, the rad3-ts mutant rapidly ceases growth and poly(A)+ RNA synthesis is inhibited drastically. Messenger RNA levels of all the genes examined, HIS3, TRP3, STE2, MET19, RAD23, CDC7, CDC9 and ACT1, decline rapidly upon loss of RAD3 activity. The synthesis of heat-shock-inducible HSP26 mRNA and galactose-inducible GAL7 and GAL10 mRNAs is also drastically inhibited in the rad3-ts mutant at the restrictive temperature. The RNA polymerase II transcriptional activity in extract from the rad3-ts14 strain is thermolabile, and this in vitro transcriptional defect can be fully corrected by the addition of homogeneous RAD3 protein. These findings indicate that RAD3 protein has a direct and essential role in RNA polymerase II transcription.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOPHYS,ROCHESTER,NY 14642; UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Rochester; University of Rochester; University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261				BAILLY V, 1991, P NATL ACAD SCI USA, V88, P9712, DOI 10.1073/pnas.88.21.9712; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; JOHNSON RT, 1992, MUTAT RES, V273, P97, DOI 10.1016/0921-8777(92)90072-B; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LEHMANN A R, 1987, Cancer Reviews, V7, P82; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; OGDEN RC, 1984, NUCLEIC ACIDS RES, V12, P9367, DOI 10.1093/nar/12.24.9367; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; REYNOLDS P, 1985, NUCLEIC ACIDS RES, V13, P2357, DOI 10.1093/nar/13.7.2357; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; VENEMA J, 1991, THESIS STATE U LEIDE; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	30	135	137	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					91	94		10.1038/367091a0	http://dx.doi.org/10.1038/367091a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107780				2022-12-01	WOS:A1994MP86500067
J	BREO, DL				BREO, DL			THE DENTAL AIDS CASES - MURDER OR AN UNSOLVABLE MYSTERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1990, MORBIDITY MORTA 0727	1	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2732	2734		10.1001/jama.270.22.2732	http://dx.doi.org/10.1001/jama.270.22.2732			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MJ821	8133594				2022-12-01	WOS:A1993MJ82100036
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR NON-INSULIN-DEPENDENT DIABETES-MELLITUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2669	2669						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133573				2022-12-01	WOS:A1993MJ82100005
J	MARIAN, AJ; YU, QT; WORKMAN, R; GREVE, G; ROBERTS, R				MARIAN, AJ; YU, QT; WORKMAN, R; GREVE, G; ROBERTS, R			ANGIOTENSIN-CONVERTING ENZYME POLYMORPHISM IN HYPERTROPHIC CARDIOMYOPATHY AND SUDDEN CARDIAC DEATH	LANCET			English	Note							INSERTION DELETION POLYMORPHISM; HEAVY-CHAIN GENE; MUTATION	We determined the distribution frequency of angiotensin converting enzyme (ACE) polymorphism in 100 patients with hypertrophic cardiomyopathy and 106 of their unaffected siblings and offspring. The distribution of ACE genotypes was different in the two groups: allele D frequency of 0.69 in patients and 0 57 in relatives (p = 0.021). The frequency of allele D was also higher in hypertrophic cardiomyopathy families with a high incidence of sudden cardiac death than those with a low incidence (0.74 vs 0.55, p = 0.011). In 25 hypertrophic cardiomyopathy patients with a strong family history of sudden cardiac death the frequency of allele D was 0.82 (p = 0.001 vs normals).	BAYLOR COLL MED,6535 FANNIN,MS F905,HOUSTON,TX 77030	Baylor College of Medicine				Marian, AJ/0000-0002-1252-7120	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL42267-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAN R, IN PRESS J CLIN INVE; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; HEJTMANCIK JF, 1991, CIRCULATION, V83, P1592, DOI 10.1161/01.CIR.83.5.1592; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; MARIAN AJ, 1992, CIRCULATION, V86, P16; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SCHUNKERT H, 1993, CIRCULATION, V87, P1328, DOI 10.1161/01.CIR.87.4.1328	9	350	362	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1085	1086		10.1016/0140-6736(93)92064-Z	http://dx.doi.org/10.1016/0140-6736(93)92064-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105312				2022-12-01	WOS:A1993ME82200010
J	PETRICCIANI, JC				PETRICCIANI, JC			ONGOING TRAGEDY OF RABIES	LANCET			English	Editorial Material											PETRICCIANI, JC (corresponding author), GENET INST INC,CAMBRIDGE,MA, USA.							BROWN A, 1974, J VIROL, V14, P840, DOI 10.1128/JVI.14.4.840-845.1974; Grachev V, 1989, Dev Biol Stand, V70, P215; MORGEAUX S, 1993, VACCINE, V11, P82, DOI 10.1016/0264-410X(93)90343-V; NICHOLSON KG, 1990, LANCET, V335, P1201, DOI 10.1016/0140-6736(90)92710-Y; PETRICCIANI JC, 1991, DEV BIOL STAND, V76, P5; PETRICCIANI JC, 1979, CELL SUBSTRATES, P9; SEHGAL S, 1992, GELBEN HELTE, V38, P126; SWADDIWUTHIPONG W, 1988, T ROY SOC TROP MED H, V82, P472, DOI 10.1016/0035-9203(88)90167-8; 1992, WORLD SURVEY RABIES	9	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1067	1068		10.1016/0140-6736(93)92058-2	http://dx.doi.org/10.1016/0140-6736(93)92058-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105306				2022-12-01	WOS:A1993ME82200004
J	WOTHERSPOON, AC; DOGLIONI, C; DISS, TC; PAN, LX; MOSCHINI, A; DEBONI, M; ISAACSON, PG				WOTHERSPOON, AC; DOGLIONI, C; DISS, TC; PAN, LX; MOSCHINI, A; DEBONI, M; ISAACSON, PG			REGRESSION OF PRIMARY LOW-GRADE B-CELL GASTRIC LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE TYPE AFTER ERADICATION OF HELICOBACTER-PYLORI	LANCET			English	Article							CAMPYLOBACTER-PYLORI; IMMUNE-RESPONSE; MONOCLONALITY	Certain features of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue (MALT) suggest the tumour is antigen-responsive. Given the close association between gastric MALT lymphoma and Helicobacter pylori, these organisms might be evoking the immunological response, and eradication of H pylori might inhibit the tumour. 6 patients in whom biopsies showed histological and molecular-genetic evidence of low-grade gastric B-cell MALT lymphoma with H pylori infection were treated with antibiotics. In all cases H pylori was eradicated and in 5, repeated biopsies showed no evidence of lymphoma. These results suggest that eradication of H pylori causes regression of low-grade B-cell gastric MALT lymphoma, and that anti-H-pylori treatment should be given for this lymphoma.	UCL,SCH MED,DEPT HISTOPATHOL,UNIV ST,LONDON WC1E 6JJ,ENGLAND; OSPED CIVILE,FELTRE,ITALY	University of London; University College London; UCL Medical School				DOGLIONI, Claudio/0000-0002-4969-5216				BENAYED F, 1989, CANCER, V63, P1251, DOI 10.1002/1097-0142(19890401)63:7<1251::AID-CNCR2820630704>3.0.CO;2-H; DISS TC, 1993, J PATHOL, V169, P291, DOI 10.1002/path.1711690303; GENTA RM, 1993, HUM PATHOL, V24, P577, DOI 10.1016/0046-8177(93)90235-9; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON PG, 1991, AM J SURG PATHOL, V15, P819, DOI 10.1097/00000478-199109000-00001; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; Maniatis T., 1982, MOL CLONING; RAMASAMY I, 1992, J CLIN PATHOL, V45, P770, DOI 10.1136/jcp.45.9.770; STOLTE M, 1992, LANCET, V339, P745, DOI 10.1016/0140-6736(92)90645-J; STOLTE M, 1989, J CLIN PATHOL, V42, P1269, DOI 10.1136/jcp.42.12.1269; TRAINOR KJ, 1990, BLOOD, V75, P2220; WAN JH, 1990, J CLIN PATHOL, V43, P888, DOI 10.1136/jcp.43.11.888; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712	14	1756	1802	0	32	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					575	577		10.1016/0140-6736(93)91409-F	http://dx.doi.org/10.1016/0140-6736(93)91409-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102719				2022-12-01	WOS:A1993LV96300009
J	MEYER, KS; URBAN, C; EAGAN, JA; BERGER, BJ; RAHAL, JJ				MEYER, KS; URBAN, C; EAGAN, JA; BERGER, BJ; RAHAL, JJ			NOSOCOMIAL OUTBREAK OF KLEBSIELLA INFECTION RESISTANT TO LATE-GENERATION CEPHALOSPORINS	ANNALS OF INTERNAL MEDICINE			English	Article						CROSS INFECTION; KLEBSIELLA PNEUMONIAE; CEPHALOSPORINS; DRUG RESISTANCE, MICROBIAL; CEFTAZIDIME	MEDIATED BETA-LACTAMASE; BROAD-SPECTRUM CEPHALOSPORINS; TRANSFERABLE ENZYMATIC RESISTANCE; 3RD-GENERATION CEPHALOSPORINS; CEFTAZIDIME RESISTANCE; ESCHERICHIA-COLI; PNEUMONIAE STRAINS; ENTEROBACTERIACEAE; DISSEMINATION; COLONIZATION	Objective: To describe the epidemiology, antimicrobial susceptibility, and control of widespread ceftazidime-resistant Klebsiella pneumoniae infections in a North American hospital and circumstances that led to delayed detection. Design: A 2-year epidemiologic, microbiologic, and clinical cohort study. Setting: A 487-bed general hospital in New York City. Patients and Clinical Isolates: Patient records were reviewed retrospectively and prospectively. Isolates were obtained from the Clinical Microbiology Laboratory. Results: Four hundred thirty-two isolates of ceftazidime-resistant Klebsiella pneumoniae were recovered during a 19-month study period. The peak incidence reached 17.3% of all Klebsiella isolates. One hundred fifty-five patients were colonized or infected, representing more than 70 per 1000 average daily census. Infections occurred in 39% of patients from whom ceftazidime-resistant Klebsiella was isolated. These included 14 bacteremias and 17 pulmonary infections among 52 infected patients. The outbreak coincided with increasing use of ceftazidime therapy for multiresistant Acinetobacter infections. Reduction in ceftazidime use and barrier precautions markedly reduced the incidence of colonization and infection. Ceftriaxone, ceftizoxime, cefotaxime, and cephamycins were inhibitory, but not bactericidal, against ceftazidime-resistant Klebsiella and appeared effective by routine disc diffusion tests. In contrast, imipenem provided consistent bactericidal activity. Preliminary studies indicated that the outbreak was caused by one or more plasmid-mediated beta lactamases. Conclusions. Nosocomial ceftazidime-resistant Klebsiella pneumoniae may be resistant to the bactericidal activity of all cephalosporins and cephamycins. Such isolates appear susceptible to cephalosporins other than ceftazidime by routine disc diffusion testing. Ineffective therapy, delayed detection of resistance, and epidemic spread are potential consequences. Imipenem provides consistent bactericidal activity. Ceftazidime restriction and barrier precautions for colonized and infected patients are effective control measures.	NEW YORK HOSP, MED CTR QUEENS, 56-45 MAIN ST, FLUSHING, NY 11355 USA; NYU, SCH MED, NEW YORK, NY 10003 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, BRONX, NY 10461 USA	NewYork-Presbyterian Hospital; New York University; Yeshiva University; Albert Einstein College of Medicine								ADLER JL, 1970, J PEDIATR-US, V77, P376, DOI 10.1016/S0022-3476(70)80004-X; BENREDJEB S, 1988, J ANTIMICROB CHEMOTH, V21, P263; BRUNBUISSON C, 1987, LANCET, V2, P302; BULGER RJ, 1967, ANN INTERN MED, V67, P523, DOI 10.7326/0003-4819-67-3-523; BURE A, 1988, EUR J CLIN MICROBIOL, V7, P780, DOI 10.1007/BF01975048; CHANAL C, 1988, J ANTIMICROB CHEMOTH, V22, P81, DOI 10.1093/jac/22.1.81; CHANAL CM, 1989, ANTIMICROB AGENTS CH, V33, P1915, DOI 10.1128/AAC.33.11.1915; DECHAMPS C, 1989, J CLIN MICROBIOL, V27, P2887, DOI 10.1128/JCM.27.12.2887-2890.1989; DONOWITZ GR, 1990, PRINCIPLES PRACTICE, P246; GARDNER P, 1969, ANN INTERN MED, V71, P1, DOI 10.7326/0003-4819-71-1-1; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GUTMANN L, 1989, ANTIMICROB AGENTS CH, V33, P951, DOI 10.1128/AAC.33.6.951; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JARLIER V, 1988, REV INFECT DIS, V10, P867; KITZIS MD, 1988, ANTIMICROB AGENTS CH, V32, P9, DOI 10.1128/AAC.32.1.9; KNOTHE H, 1983, INFECTION, V11, P315, DOI 10.1007/BF01641355; MARTIN CM, 1971, J INFECT DIS, V124, pS24, DOI 10.1093/infdis/124.Supplement_1.S24; MATTHEW M, 1979, J BACTERIOL, V138, P657, DOI 10.1128/JB.138.3.657-662.1979; NAUMOVSKI L, 1992, ANTIMICROB AGENTS CH, V36, P1991, DOI 10.1128/AAC.36.9.1991; NOREIGA ER, 1975, J INFECT DIS S, V131, pS45; PANGON B, 1989, J INFECT DIS, V159, P1005, DOI 10.1093/infdis/159.5.1005; PAPANICOLAOU GA, 1990, ANTIMICROB AGENTS CH, V34, P2200, DOI 10.1128/AAC.34.11.2200; PETIT A, 1988, ANTIMICROB AGENTS CH, V32, P626, DOI 10.1128/AAC.32.5.626; QUINN JP, 1989, ANTIMICROB AGENTS CH, V33, P1451, DOI 10.1128/AAC.33.9.1451; RICE LB, 1990, ANTIMICROB AGENTS CH, V34, P2193, DOI 10.1128/AAC.34.11.2193; SANDERS CC, 1984, ANTIMICROB AGENTS CH, V26, P797, DOI 10.1128/AAC.26.6.797; SCHABERG DR, 1976, J INFECT DIS, V133, P363, DOI 10.1093/infdis/133.3.363; SCHABERG DR, 1981, AM J MED, V70, P445, DOI 10.1016/0002-9343(81)90786-5; SHAH PM, 1983, J ANTIMICROB CHEMOTH, V11, P597, DOI 10.1093/jac/11.6.597; SIROT D, 1987, J ANTIMICROB CHEMOTH, V20, P323, DOI 10.1093/jac/20.3.323; SIROT J, 1988, REV INFECT DIS, V10, P850; SMITH CE, 1990, ANTIMICROB AGENTS CH, V34, P1290, DOI 10.1128/AAC.34.6.1290; SPENCER RC, 1987, J ANTIMICROB CHEMOTH, V20, P919, DOI 10.1093/jac/20.6.919; TERMAN JW, 1972, AM J MED SCI, V264, P191; THOMAS FE, 1977, ARCH INTERN MED, V137, P581, DOI 10.1001/archinte.137.5.581; URBAN C, 1993, J INFECT DIS, V167, P448, DOI 10.1093/infdis/167.2.448; URBAN CM, 1991, 31ST P INT C ANT AG; VERSCHRAEGEN G, 1988, ACTA CLIN BELG, V43, P356; WEBER DA, 1990, J INFECT DIS, V162, P460, DOI 10.1093/infdis/162.2.460; 1987, ANTIMICROBIAL SUSCEP, V5, P589	40	477	497	2	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					353	358		10.7326/0003-4819-119-5-199309010-00001	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8135915				2022-12-01	WOS:A1993LZ47600001
J	OKA, Y; KATAGIRI, H; YAZAKI, Y; MURASE, T; KOBAYASHI, T				OKA, Y; KATAGIRI, H; YAZAKI, Y; MURASE, T; KOBAYASHI, T			MITOCHONDRIAL GENE MUTATION IN ISLET-CELL-ANTIBODY-POSITIVE PATIENTS WHO WERE INITIALLY NON-INSULIN-DEPENDENT DIABETICS	LANCET			English	Note							MELLITUS	Autoimmunity is thought to lead to islet-cell-antibody (ICA) formation in diabetes mellitus. However, we found a mitochondrial gene mutation at nucleotide pair 3243 in 3 of 27 Japanese ICA-positive, initially non-insulin-dependent diabetic patients. All 3 progressed to insulin-dependency within 13-31 months, whereas 5 of the other 24 are non-insulin-dependent after 54-90 months. ICA, at least in these 3 patients, may follow gradual beta-cell destruction due to mitochondrial gene mutation, although the possibility of beta-cells with the mutation being susceptible to autoimmune destruction cannot be excluded.	TORANOMON GEN HOSP,DEPT ENDOCRINOL & METAB,TOKYO 107,JAPAN	Toranomon Hospital	OKA, Y (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN.							GERBITZ KD, 1993, FEBS LETT, V321, P194, DOI 10.1016/0014-5793(93)80106-5; KOBAYASHI T, 1993, DIABETES CARE, V16, P780, DOI 10.2337/diacare.16.5.780; KOBAYASHI T, 1987, DIABETES, V36, P510, DOI 10.2337/diabetes.36.4.510; LOHR M, 1987, DIABETOLOGIA, V30, P757; NAKANISHI K, 1993, METABOLISM, V42, P196, DOI 10.1016/0026-0495(93)90035-M; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; SRIKANTA S, 1983, NEW ENGL J MED, V308, P322, DOI 10.1056/NEJM198302103080607; SRIKANTA S, 1985, NEW ENGL J MED, V313, P4611; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; WARRAM JH, 1984, NEW ENGL J MED, V311, P149, DOI 10.1056/NEJM198407193110304	10	109	111	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					527	528		10.1016/0140-6736(93)91649-7	http://dx.doi.org/10.1016/0140-6736(93)91649-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102670				2022-12-01	WOS:A1993LU58200012
J	NEVEN, P				NEVEN, P			TAMOXIFEN AND ENDOMETRIAL LESIONS	LANCET			English	Editorial Material							BODY-FAT DISTRIBUTION; BREAST-CANCER				NEVEN, P (corresponding author), ALGEMENE KLIN ST JAN,DEPT OBSTET & GYNAECOL,BRUSSELS,BELGIUM.							COHEN I, 1993, BRIT J OBSTET GYNAEC, V100, P567, DOI 10.1111/j.1471-0528.1993.tb15310.x; COHEN I, 1992, LANCET, V340, P312, DOI 10.1016/0140-6736(92)92409-9; FORNANDER T, 1989, LANCET, V1, P117; LAHTI E, 1993, OBSTET GYNECOL, V81, P660; NEVEN P, 1990, EUR J OBSTET GYN R B, V35, P235, DOI 10.1016/0028-2243(90)90167-Y; SCHAPIRA DV, 1991, CANCER, V67, P523, DOI 10.1002/1097-0142(19910115)67:2<523::AID-CNCR2820670234>3.0.CO;2-O; SCHAPIRA DV, 1991, JAMA-J AM MED ASSOC, V266, P1808, DOI 10.1001/jama.266.13.1808	7	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					452	452		10.1016/0140-6736(93)91590-I	http://dx.doi.org/10.1016/0140-6736(93)91590-I			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102426				2022-12-01	WOS:A1993LU07500007
J	BRODSKY, M; KAMENKER, E; ORLOV, M; ALLEN, B				BRODSKY, M; KAMENKER, E; ORLOV, M; ALLEN, B			CARDIAC EFFECT OF PROLONGED BETA-BLOCKER THERAPY FOR MIGRAINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BRODSKY, M (corresponding author), UNIV CALIF IRVINE,IRVINE MED CTR,ORANGE,CA 92668, USA.							FRISHMAN WH, 1988, MED CLIN N AM, V72, P37, DOI 10.1016/S0025-7125(16)30786-6; GORDON NF, 1991, MED SCI SPORT EXER, V23, P668; ROSEN JA, 1983, ANN NEUROL, V13, P92, DOI 10.1002/ana.410130119; SABLE DL, 1982, CIRCULATION, V65, P679, DOI 10.1161/01.CIR.65.4.679; WALDEN RJ, 1982, AM HEART J, V104, P515, DOI 10.1016/0002-8703(82)90149-1	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					880	880						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8101882				2022-12-01	WOS:A1993LR61200041
J	OGRADY, JG; SCHALM, SW; WILLIAMS, R				OGRADY, JG; SCHALM, SW; WILLIAMS, R			ACUTE LIVER-FAILURE - REDEFINING THE SYNDROMES	LANCET			English	Article							HEPATIC-FAILURE; FULMINANT; PROGNOSIS	Existing definitions of clinical syndromes in acute liver failure do not accurately reflect important differences in clinical features and prognosis. Based on a large series of patients with acute liver failure treated at King's College Hospital, London between 1972 and 1985, we propose a new terminology. Hyperacute liver failure is our suggested term for cases in which encephalopathy occurs within 7 days of the onset of jaundice; this group includes the sizeable cohort likely to survive with medical management despite the high incidence of cerebral oedema. We suggest the term acute liver failure for cases with an interval of between 8 and 28 days from jaundice to encephalopathy; they also have a high incidence of cerebral oedema, but have a much poorer prognosis without liver transplantation. The term subacute liver failure is suggested to describe cases with encephalopathy that occurs within 5 to 12 weeks of the onset of jaundice; these patients are characterised by a law incidence of cerebral oedema, but have a poor prognosis. Adoption of this terminology should help in the management of these patients, in addition to standardising the structure and interpretation of controlled trials of therapies.	KINGS COLL,SCH MED & DENT,INST LIVER STUDIES,LONDON SE5 8RS,ENGLAND; ST JAMES UNIV HOSP,LIVER UNIT,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; UNIV HOSP ROTTERDAM,DEPT INTERNAL MED 2,ROTTERDAM,NETHERLANDS	University of London; King's College London; Saint James's University Hospital; Erasmus University Rotterdam; Erasmus MC				opoku, anita/0000-0001-7243-8157				BERNUAU J, 1993, LANCET, V342, P252, DOI 10.1016/0140-6736(93)91809-Z; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; GIMSON AES, 1986, HEPATOLOGY, V6, P288, DOI 10.1002/hep.1840060222; LUCKE B, 1946, AM J PATHOL, V22, P867; MATHIESEN LR, 1980, GUT, V21, P72, DOI 10.1136/gut.21.1.72; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; TAKAHASHI Y, 1991, J GASTROEN HEPATOL, V6, P159, DOI 10.1111/j.1440-1746.1991.tb01458.x; Trey C, 1970, Prog Liver Dis, V3, P282; 1989, GUT, V20, P620	9	627	644	0	24	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					273	275						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101303				2022-12-01	WOS:A1993LQ16300011
J	WANG, BB; MULLERIMMERGLUCK, MM; AUSTIN, J; ROBINSON, NT; CHISHOLM, A; KENYON, C				WANG, BB; MULLERIMMERGLUCK, MM; AUSTIN, J; ROBINSON, NT; CHISHOLM, A; KENYON, C			A HOMEOTIC GENE-CLUSTER PATTERNS THE ANTEROPOSTERIOR BODY AXIS OF C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA HEAD DEVELOPMENT; ANTERIOR POSTERIOR AXIS; HOMEOBOX GENES; EMBRYONIC EXPRESSION; BITHORAX COMPLEX; EMPTY SPIRACLES; DISTAL-LESS; HOMEODOMAIN; SEQUENCE	In insects and vertebrates, clusters of Antennapedia class homeobox (HOM-C) genes specify anteroposterior body pattern. The nematode C. elegans also contains a small cluster of HOM-C genes, one of which has been shown to specify positional identity. Here we show that two additional C. elegans HOM-C genes also specify positional identity and that together these three HOM-C genes function along the anteroposterior axis in the same order as their homologs in other organisms. Thus, HOM-C-based pattern formation has been conserved in nematodes despite the many differences in morphology and embryology that distinguish them from other phyla. Each C. elegans HOM-C gene is responsible for a distinct body region; however, where their domains overlap, two HOM-C genes can act together to specify the fates of individual cells.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	WANG, BB (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Chisholm, Andrew/0000-0001-5091-0537				AKAM M, 1988, DEVELOPMENT, V104, P123; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; CHALFIE M, 1983, SCIENCE, V221, P61, DOI 10.1126/science.6857263; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; COWING DW, 1992, DEVELOPMENT, V116, P481; CRIBBS DL, 1992, EMBO J, V11, P1437, DOI 10.1002/j.1460-2075.1992.tb05188.x; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DIEDERICH RJ, 1989, GENE DEV, V3, P399, DOI 10.1101/gad.3.3.399; ELLIS H, 1985, THESIS MIT CAMBRIDGE; FIBI M, 1988, DEVELOPMENT, V102, P349; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3; HAWKINS NC, 1990, NUCLEIC ACIDS RES, V18, P6101, DOI 10.1093/nar/18.20.6101; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HORVITZ HR, 1982, NEUROSCI COMMENT, V1, P56; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KENYON C, 1991, SCIENCE, V253, P516, DOI 10.1126/science.1677487; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KORNFELD K, 1989, GENE DEV, V3, P243, DOI 10.1101/gad.3.2.243; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; LEMOTTE PK, 1989, EMBO J, V8, P219, DOI 10.1002/j.1460-2075.1989.tb03367.x; LOER CM, 1993, IN PRESS NEUROSCIENC; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEIJLINK F, 1987, NUCLEIC ACIDS RES, V15, P6773, DOI 10.1093/nar/15.17.6773; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SCHALLER D, 1990, NUCLEIC ACIDS RES, V18, P2033, DOI 10.1093/nar/18.8.2033; SCHUGHART K, 1988, P NATL ACAD SCI USA, V85, P5582, DOI 10.1073/pnas.85.15.5582; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TAN DP, 1992, P NATL ACAD SCI USA, V89, P6280, DOI 10.1073/pnas.89.14.6280; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WOOD WB, 1988, NEMATODE CAENORHABDI, P491	50	283	294	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					29	42		10.1016/0092-8674(93)90292-X	http://dx.doi.org/10.1016/0092-8674(93)90292-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8101474				2022-12-01	WOS:A1993LN62500005
J	HINRICHS, W; KISKER, C; DUVEL, M; MULLER, A; TOVAR, K; HILLEN, W; SAENGER, W				HINRICHS, W; KISKER, C; DUVEL, M; MULLER, A; TOVAR, K; HILLEN, W; SAENGER, W			STRUCTURE OF THE TET REPRESSOR TETRACYCLINE COMPLEX AND REGULATION OF ANTIBIOTIC-RESISTANCE	SCIENCE			English	Article							TURN-HELIX MOTIF; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; DNA-BINDING; ESCHERICHIA-COLI; OPERATOR COMPLEX; MACROMOLECULAR CRYSTALLOGRAPHY; PROTEIN STRUCTURES; LAC-REPRESSOR; TN10	The most frequently occurring resistance of Gram-negative bacteria against tetracyclines is triggered by drug recognition of the Tet repressor. This causes dissociation of the repressor-operator DNA complex and enables expression of the resistance protein TetA, which is responsible for active efflux of tetracycline. The 2.5 angstrom resolution crystal structure of the homodimeric Tet repressor complexed with tetracycline-magnesium reveals detailed drug recognition. The orientation of the operator-binding helix-turn-helix motifs of the repressor is inverted in comparison with other DNA binding proteins. The repressor-drug complex is unable to interact with DNA because the separation of the DNA binding motifs is 5 angstroms wider than usually observed.	UNIV ERLANGEN NURNBERG,INST MIKROBIOL & BIOCHEM,D-91058 ERLANGEN,GERMANY	University of Erlangen Nuremberg	HINRICHS, W (corresponding author), FREE UNIV BERLIN,INST KRISTALLOG,D-14195 BERLIN,GERMANY.			Hinrichs, Winfried/0000-0002-0435-4565; Kisker, Caroline/0000-0002-0216-6026				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BAUMEISTER R, 1992, PROTEINS, V14, P168, DOI 10.1002/prot.340140204; BAUMEISTER R, 1992, J MOL BIOL, V226, P1257, DOI 10.1016/0022-2836(92)91065-W; BERENS C, 1992, J BIOL CHEM, V267, P1945; BERTRAND KP, 1983, GENE, V23, P149, DOI 10.1016/0378-1119(83)90046-X; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DAUTER Z, 1990, ACTA CRYSTALLOGR B, V46, P833, DOI 10.1107/S0108768190008059; DEGENKOLB J, 1991, ANTIMICROB AGENTS CH, V35, P1591, DOI 10.1128/AAC.35.8.1591; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HECHT B, 1993, J BACTERIOL, V175, P1206, DOI 10.1128/JB.175.4.1206-1210.1993; HEUER C, 1988, J MOL BIOL, V202, P407, DOI 10.1016/0022-2836(88)90274-4; HILLEN W, 1984, J MOL BIOL, V172, P185, DOI 10.1016/S0022-2836(84)80037-6; HILLEN W, 1983, J MOL BIOL, V169, P707, DOI 10.1016/S0022-2836(83)80166-1; HLAVKA JJ, 1985, HDB EXPT PHARM, V78, P332; ISACKSON PJ, 1985, P NATL ACAD SCI USA, V82, P6226, DOI 10.1073/pnas.82.18.6226; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; KOSTREWA D, 1992, J MOL BIOL, V226, P209, DOI 10.1016/0022-2836(92)90134-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMERICHS RMJN, 1990, EUR J BIOCHEM, V194, P629, DOI 10.1111/j.1432-1033.1990.tb15662.x; LEHMING N, 1988, P NATL ACAD SCI USA, V85, P7947, DOI 10.1073/pnas.85.21.7947; LESK AM, 1982, SCIENCE, V216, P539, DOI 10.1126/science.7071602; LEVY SB, 1984, ANTIMICROBIAL DRUG R, P191; MENDEZ B, 1980, PLASMID, V3, P99, DOI 10.1016/0147-619X(80)90101-8; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PARGE HE, 1984, J MOL BIOL, V180, P1189, DOI 10.1016/0022-2836(84)90279-1; POSTLE K, 1984, NUCLEIC ACIDS RES, V12, P4849, DOI 10.1093/nar/12.12.4849; SCHULTZ SC, 1990, J MOL BIOL, V213, P159, DOI 10.1016/S0022-2836(05)80128-7; SIZEMORE C, 1990, NUCLEIC ACIDS RES, V18, P2875, DOI 10.1093/nar/18.10.2875; SMITH LD, 1988, J MOL BIOL, V203, P949, DOI 10.1016/0022-2836(88)90120-9; SUZUKI S, 1992, SCIENCE, V257, P942, DOI 10.1126/science.257.5072.942; TAKAHASHI M, 1986, J MOL BIOL, V187, P341, DOI 10.1016/0022-2836(86)90437-7; TOVAR K, 1989, NUCLEIC ACIDS RES, V17, P6515, DOI 10.1093/nar/17.16.6515; TOVAR K, 1988, MOL GEN GENET, V215, P76, DOI 10.1007/BF00331306; UNGER B, 1984, NUCLEIC ACIDS RES, V12, P7693, DOI 10.1093/nar/12.20.7693; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WISSMANN A, 1991, EMBO J, V10, P4145, DOI 10.1002/j.1460-2075.1991.tb04992.x; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0; ZHAO J, 1992, MICROBIOL IMMUNOL, V36, P1051, DOI 10.1111/j.1348-0421.1992.tb02109.x; [No title captured]	46	332	354	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					418	420		10.1126/science.8153629	http://dx.doi.org/10.1126/science.8153629			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153629				2022-12-01	WOS:A1994NG19400038
J	SALZMAN, CD; NEWSOME, WT				SALZMAN, CD; NEWSOME, WT			NEURAL MECHANISMS FOR FORMING A PERCEPTUAL DECISION	SCIENCE			English	Article							TEMPORAL VISUAL AREA; SUPERIOR COLLICULUS; FUNCTIONAL-PROPERTIES; EYE-MOVEMENTS; TOPOGRAPHIC ORGANIZATION; NEURONAL POPULATION; MACAQUE MONKEY; RHESUS-MONKEY; DIRECTION; MOTION	Cognitive and behavioral responses to environmental stimuli depend on an evaluation of sensory signals within the cerebral cortex. The mechanism by which this occurs in a specific visual task was investigated with a combination of physiological and psychophysical techniques. Rhesus monkeys discriminated among eight possible directions of motion while directional signals were manipulated in visual area MT. One directional signal was generated by a visual stimulus and a second signal was introduced by electrically stimulating neurons that encoded a specific direction of motion. The decisions made by the monkeys in response to the two signals allowed a distinction to be made between two possible mechanisms for interpreting directional signals in MT. The monkeys tended to cast decisions in favor of one or the other signal, indicating that the signals exerted independent effects on performance and that an interactive mechanism such as vector averaging of the two signals was not operative. Thus, the data suggest a mechanism in which monkeys chose the direction encoded by the largest signal in the representation of motion direction, a ''winner-take-all'' decision process.	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Newsome, William T./W-7171-2019		NEI NIH HHS [EY 5603] Funding Source: Medline; NINDS NIH HHS [NS 07158-14] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005603, R37EY005603] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V51, P16, DOI 10.1152/jn.1984.51.1.16; ALBRIGHT TD, 1987, EXP BRAIN RES, V65, P582; ALBRIGHT TD, 1993, VISUAL MOTION ITS RO, P177; BAKER JF, 1981, J NEUROPHYSIOL, V45, P397, DOI 10.1152/jn.1981.45.3.397; BECKER W, 1979, VISION RES, V19, P967, DOI 10.1016/0042-6989(79)90222-0; BORN RT, 1992, NATURE, V357, P497, DOI 10.1038/357497a0; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; BRITTEN KH, UNPUB; Cox D.R., 1989, MONOGRAPHS STAT APPL, V2nd ed.; CRIST CF, 1988, J NEUROSCI METH, V26, P117, DOI 10.1016/0165-0270(88)90160-4; FINDLAY JM, 1982, VISION RES, V22, P1033, DOI 10.1016/0042-6989(82)90040-2; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Graham N. V., 1989, VISUAL PATTERN ANAL; HENN V, 1976, BRAIN RES, V108, P307, DOI 10.1016/0006-8993(76)90188-8; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; LEE CK, 1988, NATURE, V332, P357, DOI 10.1038/332357a0; MARSHAK W, 1979, SCIENCE, V205, P1399, DOI 10.1126/science.472756; MAUNSELL JHR, 1987, J COMP NEUROL, V266, P535, DOI 10.1002/cne.902660407; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; McIlwain J. T., 1976, INT REV PHYSIOL, Vii, P223; MCILWAIN JT, 1991, VISUAL NEUROSCI, V6, P3, DOI 10.1017/S0952523800000857; MCILWAIN JT, 1982, J NEUROPHYSIOL, V47, P167, DOI 10.1152/jn.1982.47.2.167; Movshon J. A., 1985, PATTERN RECOGNITION; MURASUGI CM, 1993, J NEUROSCI, V13, P1719; NEWSOME WT, IN PRESS COGNITIVE N; OTTES FP, 1984, VISION RES, V24, P1169, DOI 10.1016/0042-6989(84)90172-X; ROBINSON DA, 1972, VISION RES, V12, P1795, DOI 10.1016/0042-6989(72)90070-3; ROBINSON DA, 1969, J NEUROPHYSIOL, V32, P637, DOI 10.1152/jn.1969.32.5.637; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; RODMAN HR, 1989, EXP BRAIN RES, V75, P53; SALZMAN CD, 1990, NATURE, V346, P174, DOI 10.1038/346174a0; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; SCHILLER PH, 1983, EXP BRAIN RES, V49, P381; SCHOR RH, 1984, J NEUROPHYSIOL, V51, P136, DOI 10.1152/jn.1984.51.1.136; SHADLEN MN, 1992, ABSTR SOC NEUROSCI, V18, P1101; SPARKS DL, 1976, BRAIN RES, V113, P21, DOI 10.1016/0006-8993(76)90003-2; SPARKS DL, 1983, J NEUROPHYSIOL, V49, P45, DOI 10.1152/jn.1983.49.1.45; STEINMETZ MA, 1987, J NEUROSCI, V7, P177; STONER GR, 1992, NATURE, V358, P412, DOI 10.1038/358412a0; SUZUKI I, 1985, J NEUROPHYSIOL, V54, P123, DOI 10.1152/jn.1985.54.1.123; VANESSEN DC, 1981, J COMP NEUROL, V199, P293, DOI 10.1002/cne.901990302; WILLIAMS DW, 1984, VISION RES, V24, P55, DOI 10.1016/0042-6989(84)90144-5; WILSON HR, 1992, VISUAL NEUROSCI, V9, P79, DOI 10.1017/S0952523800006386; WILSON VJ, 1984, J NEUROPHYSIOL, V51, P567, DOI 10.1152/jn.1984.51.3.567; ZEKI SM, 1974, J PHYSIOL-LONDON, V236, P549, DOI 10.1113/jphysiol.1974.sp010452	49	188	188	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					231	237		10.1126/science.8146653	http://dx.doi.org/10.1126/science.8146653			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146653				2022-12-01	WOS:A1994NE41000028
J	MORRIS, P; SHAMAN, J; ATTAYA, M; AMAYA, M; GOODMAN, S; BERGMAN, C; MONACO, JJ; MELLINS, E				MORRIS, P; SHAMAN, J; ATTAYA, M; AMAYA, M; GOODMAN, S; BERGMAN, C; MONACO, JJ; MELLINS, E			AN ESSENTIAL ROLE FOR HLA-DM IN ANTIGEN PRESENTATION BY CLASS-II MAJOR HISTOCOMPATIBILITY MOLECULES	NATURE			English	Article							INVARIANT CHAIN PEPTIDES; PROCESSING MUTANT; DR MOLECULES; BINDING-SITE; CELL LINE; COMPLEX; REGION; GENE; EXPRESSION; RESPONSES	IN antigen-presenting cells, class II molecules of the major histocompatibility complex (MHC) bind peptides derived from endocytosed proteins1. In certain B-lymphoblastoid cell mutants, MHC class II molecule-peptide complex formation is impaired, resulting in deficient antigen-presenting function2. MHC deletion mutants with this defect map the responsible gene(s) to the class II region of the MHC3-5. Here we report that multiple independent mutants with the class II presentation defect harbour lesions in HLA-DMB, an MHC-linked gene encoding a class II-like beta-chain6,7. Expression of DMB complementary DNA in mutants lacking DMB messenger RNA restores the wild-type phenotype. These results establish HLA-DM as a critical regulatory molecule in class II-restricted antigen presentation and suggest that it functions at an intracellular site to promote class II molecule-peptide association.	UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298	University of Pennsylvania; Virginia Commonwealth University				Mellins, Elizabeth/0000-0003-2577-139X				BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CAMPBELL RD, 1993, IMMUNOL TODAY, V14, P349, DOI 10.1016/0167-5699(93)90234-C; CEMAN S, 1992, J IMMUNOL, V149, P754; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; GLADSTONE P, 1982, P NATL ACAD SCI-BIOL, V79, P1235, DOI 10.1073/pnas.79.4.1235; GLADSTONE P, 1978, NATURE, V271, P459, DOI 10.1038/271459a0; GRIFFITH IJ, 1988, J EXP MED, V167, P541, DOI 10.1084/jem.167.2.541; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JOHNSON AH, 1984, IMMUNOBIOLGOY HLA, P202; JOHNSON JP, 1982, J EXP MED, V156, P104, DOI 10.1084/jem.156.1.104; KELLY AP, 1991, NATURE, V353, P5741; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; LAMPSON LA, 1980, J IMMUNOL, V125, P293; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MELLINS E, 1987, HUM IMMUNOL, V18, P211, DOI 10.1016/0198-8859(87)90086-3; PIOUS D, 1985, J EXP MED, V162, P1193, DOI 10.1084/jem.162.4.1193; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SANT AJ, 1993, HUM IMMUNOL, V37, P3; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHAW S, 1980, J EXP MED, V152, P565, DOI 10.1084/jem.152.3.565; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; XIE W, 1991, BIOTECHNIQUES, V11, P325	29	361	367	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					551	554		10.1038/368551a0	http://dx.doi.org/10.1038/368551a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139689				2022-12-01	WOS:A1994NE33500056
J	UYEDA, TQP; RUPPEL, KM; SPUDICH, JA				UYEDA, TQP; RUPPEL, KM; SPUDICH, JA			ENZYMATIC-ACTIVITIES CORRELATE WITH CHIMERIC SUBSTITUTIONS AT THE ACTIN-BINDING FACE OF MYOSIN	NATURE			English	Article							HEAVY-CHAIN GENE; ADENOSINE-TRIPHOSPHATASE; SUBFRAGMENT-1; MEROMYOSIN; ACTOMYOSIN; SITE; ATP; DISRUPTION; HYDROLYSIS; MECHANISM	MYOSINS are a functionally divergent group of mechanochemical enzymes involved in various motile activities in cells1. Despite a high degree of conservation in the amino-acid sequence of the 130K motor domain2,3 (head region) of the molecule, there are large differences in the enzymatic and motile activities (Tables 1 and 2) of myosins from diverse species and cell types. However, the degree of conservation is not uniform throughout the head sequence4; therefore, one reasonable hypothesis is that the functional differences between myosins derive from the poorly conserved areas. The most prominent divergent region occurs at the 50K/20K junction, a region of the molecule sensitive to proteolytic digestion5 and a binding site for actin6-12. We have now constructed chimaeras of this region of myosin by substituting the 9-amino-acid Dictyostelium junction region with those from myosins from other species and find that the actin-activated ATPase correlates well with the activity of the myosin from which the junction region was derived. Our results suggest that this region, likely to be part of the myosin head that interacts directly with actin10,13,14, is important in deter mining the enzymatic activity of myosin.	STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University; Stanford University								BALINT M, 1978, ARCH BIOCHEM BIOPHYS, V190, P793, DOI 10.1016/0003-9861(78)90339-9; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BOTTS J, 1982, BIOCHEMISTRY-US, V21, P6903, DOI 10.1021/bi00269a043; DASGUPTA G, 1989, J MOL BIOL, V207, P833, DOI 10.1016/0022-2836(89)90249-0; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Kniesmeijer Joke, 1987, PAROOL 1109; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MCNALLY EM, 1989, J MOL BIOL, V210, P665, DOI 10.1016/0022-2836(89)90141-1; MORNET D, 1979, BIOCHEM BIOPH RES CO, V89, P925, DOI 10.1016/0006-291X(79)91867-9; POPE B, 1980, FEBS LETT, V118, P205, DOI 10.1016/0014-5793(80)80219-5; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1920; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SCHWARTZ K, 1981, J MOL CELL CARDIOL, V13, P1071, DOI 10.1016/0022-2828(81)90297-2; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; SPUDICH JA, 1989, CELL REGUL, V1, P1; STEIN LA, 1979, BIOCHEMISTRY-US, V18, P3895, DOI 10.1021/bi00585a009; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cellbio.3.1.379; WARSHAW D, 1991, BIOPHYS J, V58, pA186; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WHITE HD, 1993, J BIOL CHEM, V268, P10039; YAMAMOTO K, 1979, J BIOCHEM-TOKYO, V86, P1863, DOI 10.1093/oxfordjournals.jbchem.a132709; YAMAMOTO K, 1989, BIOCHEMISTRY-US, V28, P5573, DOI 10.1021/bi00439a035	30	183	189	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					567	569		10.1038/368567a0	http://dx.doi.org/10.1038/368567a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139694				2022-12-01	WOS:A1994NE33500061
J	COHENTANNOUDJI, M; BABINET, C; WASSEF, M				COHENTANNOUDJI, M; BABINET, C; WASSEF, M			EARLY DETERMINATION OF A MOUSE SOMATOSENSORY CORTEX MARKER	NATURE			English	Article							CEREBRAL-CORTEX; VISUAL-CORTEX; SPECIFICATION; NEOCORTEX; NEURONS; RAT; ORGANIZATION; UNITS; LACZ	THE mammalian neocortex is subdivided into functionally distinct areas differing in cytoarchitecture and connectivity. Areal specification is thought to occur late in development1-3 and to be controlled by extrinsic cues, particularly thalamic afferents4. We have produced a transgenic mouse line in which beta-galactosidase expression in the neocortex is largely restricted to layer-IV neurons of the somatosensory area. Transgene expression in these mice may be considered as an intrinsic marker of a somatosensory cortex identity. We investigated whether the fate of pieces of embryonic cortex from transgenic embryos is modified after transplantation to ectopic locations. Parietal or occipital cortex obtained on embryonic days 14-16 maintained their characteristics with respect to transgene expression after heterotopic transplantation to the cerebellum or neocortex of newborn hosts. This shows that the specification of neocortical areas involves a previously unsuspected early step of areal determination.	HOP LA PITIE SALPETRIERE,INSERM,U106,F-75651 PARIS 13,FRANCE; INST PASTEUR,F-75724 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Cohen-Tannoudji, Michel/0000-0002-6405-2657				ARIMATSU Y, 1992, P NATL ACAD SCI USA, V89, P8879, DOI 10.1073/pnas.89.19.8879; BARBE MF, 1991, J NEUROSCI, V11, P519; CATALANO SM, 1991, P NATL ACAD SCI USA, V88, P2999, DOI 10.1073/pnas.88.8.2999; COHENTANNOUDJI M, 1992, MOL REPROD DEV, V33, P149, DOI 10.1002/mrd.1080330206; DAWSON DR, 1987, J COMP NEUROL, V256, P246, DOI 10.1002/cne.902560205; FAIREN A, 1986, J COMP NEUROL, V251, P67, DOI 10.1002/cne.902510105; FERRI RT, 1993, CEREB CORTEX, V3, P187, DOI 10.1093/cercor/3.3.187; KENNEDY H, 1993, CEREB CORTEX, V3, P171, DOI 10.1093/cercor/3.3.171; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; OLEARY DDM, 1992, EXP NEUROL, V115, P121, DOI 10.1016/0014-4886(92)90234-H; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1991, P NATL ACAD SCI USA, V88, P2083, DOI 10.1073/pnas.88.6.2083; SCHLAGGAR BL, 1991, SCIENCE, V252, P1556, DOI 10.1126/science.2047863; SHATZ CJ, 1992, SCIENCE, V258, P237, DOI 10.1126/science.1357747; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WOOLSEY CN, 1958, BIOL BIOCH BASES BEH, P62; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	18	174	175	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 31	1994	368	6470					460	463		10.1038/368460a0	http://dx.doi.org/10.1038/368460a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133892				2022-12-01	WOS:A1994ND12000065
J	TODD, KH; LEE, T; HOFFMAN, JR				TODD, KH; LEE, T; HOFFMAN, JR			THE EFFECT OF ETHNICITY ON PHYSICIAN ESTIMATES OF PAIN SEVERITY IN PATIENTS WITH ISOLATED EXTREMITY TRAUMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY	Objective.-To determine whether physician estimates of pain severity are influenced by patient ethnicity. Design.-Prospective cohort study. Setting.-UCLA Emergency Medicine Center, a level I trauma center, Los Angeles, Calif. Participants.-Hispanic and non-Hispanic white patients presenting to the emergency department with extremity trauma when research assistants were present. Exclusion criteria were patient refusal, altered mentation, or severe injury interfering with the interview process. Main Outcome Measures.-The difference between patient and physician estimates of pain severity as assessed on a visual analog scale for Hispanics and non-Hispanic whites. Results.-A total of 138 non-Hispanic white and 69 Hispanic patients participated in the study. The groups differed in language use, insurance status, and proportions suffering occupational injury. There were no differences between non-Hispanic white and Hispanic patients in patient pain assessments (mean, 39.8 mm vs 39.0 mm, respectively; P=.86), physician pain assessments (mean, 33.6 mm vs 29.7 mm; P=.23), or the disparity between patient and physician pain assessments (mean 6.1 mm vs 9.4 mm; P=.38). The degree of disparity between patient and physician pain assessments remained similar for both groups even after controlling for multiple potential confounders. Conclusions.-Physician ability to assess pain severity does not differ for Hispanic and non-Hispanic white patients. Other explanations for a difference in analgesic practice as a function of ethnicity should be explored.	UNIV CALIF LOS ANGELES, SCH MED, CTR EMERGENCY MED, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	TODD, KH (corresponding author), EMORY UNIV, SCH MED, DIV EMERGENCY MED, 69 BUTLER ST SE, ATLANTA, GA 30303 USA.							GREENWALD HP, 1991, PAIN, V44, P157, DOI 10.1016/0304-3959(91)90130-P; KELSEY JL, 1986, METHODS OBSERVATIONA; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; SELBST SM, 1990, ANN EMERG MED, V19, P1010, DOI 10.1016/S0196-0644(05)82565-X; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; WILSON JE, 1989, AM J EMERG MED, V7, P620, DOI 10.1016/0735-6757(89)90286-6; ZATZICK DF, 1990, PSYCHOSOM MED, V52, P544, DOI 10.1097/00006842-199009000-00007; 1992, PHS920032 US DEP HLT; 1992, STATA REFERENCE MANU	9	188	189	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	1994	271	12					925	928		10.1001/jama.271.12.925	http://dx.doi.org/10.1001/jama.271.12.925			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA743	8120961				2022-12-01	WOS:A1994NA74300028
J	PERRETT, DI; MAY, KA; YOSHIKAWA, S				PERRETT, DI; MAY, KA; YOSHIKAWA, S			FACIAL SHAPE AND JUDGMENTS OF FEMALE ATTRACTIVENESS	NATURE			English	Article							PHYSICAL ATTRACTIVENESS; FACES; PERCEPTION; AVERAGE; BEAUTY	THE finding that photographic(1-4) and digital(5) composites (blends) of faces are considered to be attractive has led to the claim that attractiveness is averageness(5). This would encourage stabilizing selection, favouring phenotypes with an average facial structure(5). The 'averageness hypothesis' would account for the low distinctiveness of attractive faces(6) but is difficult to reconcile with the finding that some facial measurements correlate with attractiveness(7,8). An average face shape is attractive but may not be optimally attractive(9). Human preferences may exert directional selection pressures, as with the phenomena of optimal outbreeding and sexual selection for extreme characteristics(10-14). Using composite faces, we show here that, contrary to the averageness hypothesis, the mean shape of a set of attractive faces is preferred to the mean shape of the sample from which the faces were selected. In addition, attractive composites can be made more attractive by exaggerating the shape differences from the sample mean. Japanese and caucasian observers showed the same direction of preferences for the same facial composites, suggesting that aesthetic judgements of face shape are similar across different cultural backgrounds. Our finding that highly attractive facial configurations are not average shows that preferences could exert a directional selection pressure on the evolution of human face shape.	OTEMON GAKUIN UNIV,FAC LETTERS,DEPT PSYCHOL,IBARAKI,OSAKA 567,JAPAN		PERRETT, DI (corresponding author), UNIV ST ANDREWS,SCH PSYCHOL,ST ANDREWS KY16 9JU,FIFE,SCOTLAND.		May, Keith/F-8686-2011	May, Keith/0000-0001-8114-5989; d, muthu/0000-0003-3996-3333; Perrett, David/0000-0002-6025-0939				ALLEY TR, 1991, PSYCHOL SCI, V2, P123, DOI 10.1111/j.1467-9280.1991.tb00113.x; ANDERSSON M, 1982, NATURE, V299, P818, DOI 10.1038/299818a0; BENSON PJ, 1993, PERCEPTION, V22, P257, DOI 10.1068/p220257; BENSON PJ, 1991, IMAGE VISION COMPUT, V9, P123, DOI 10.1016/0262-8856(91)90022-H; BERNSTEIN IH, 1982, PERCEPT PSYCHOPHYS, V32, P495, DOI 10.3758/BF03204202; BRENNAN SE, 1985, LEONARDO, V18, P170, DOI 10.2307/1578048; CROSS JF, 1971, DEV PSYCHOL, V5, P433, DOI 10.1037/h0031591; CUNNINGHAM MR, 1990, J PERS SOC PSYCHOL, V59, P61, DOI 10.1037/0022-3514.59.1.61; CUNNINGHAM MR, 1986, J PERS SOC PSYCHOL, V50, P925, DOI 10.1037/0022-3514.50.5.925; ENQUIST M, 1993, NATURE, V361, P446, DOI 10.1038/361446a0; Galton F, 1878, NATURE, V18, P97, DOI [DOI 10.1038/018686A0, DOI 10.1038/018097A0]; Galton F., 1878, J ANTHR I GREAT BRIT, V18, P97, DOI 10.2307/2841021; Jastrow J, 1885, Science, V6, P165, DOI 10.1126/science.ns-6.134.165; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LANGLOIS JH, 1990, PSYCHOL SCI, V1, P115, DOI 10.1111/j.1467-9280.1990.tb00079.x; Light L.L., 1981, PERSONALITY SOCIAL P, V7, P269, DOI [10.1177/014616728172014, DOI 10.1177/014616728172014]; MOLLER AP, 1992, NATURE, V357, P238, DOI 10.1038/357238a0; Stoddard J T, 1886, Science, V8, P89, DOI 10.1126/science.ns-8.182.89-a; Symons D., 1979, EVOLUTION HUMAN SEXU; TENCATE C, 1988, EVOLUTION, V42, P1355, DOI 10.1111/j.1558-5646.1988.tb04196.x	20	522	534	2	138	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					239	242		10.1038/368239a0	http://dx.doi.org/10.1038/368239a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NA870	8145822				2022-12-01	WOS:A1994NA87000054
J	LENFANT, C				LENFANT, C			REDUCING THE DELAYS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LENFANT, C (corresponding author), NHLBI,BETHESDA,MD 20892, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					738	738						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	8114202				2022-12-01	WOS:A1994MY28800009
J	AMREIN, H; HEDLEY, ML; MANIATIS, T				AMREIN, H; HEDLEY, ML; MANIATIS, T			THE ROLE OF SPECIFIC PROTEIN-RNA AND PROTEIN-PROTEIN INTERACTIONS IN POSITIVE AND NEGATIVE CONTROL OF PRE-MESSENGER-RNA SPLICING BY TRANSFORMER-2	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; DROSOPHILA DOUBLESEX GENE; SEX DETERMINATION GENE; BINDING PROTEINS; U1 RNA; CLONED GENES; A-PROTEIN; MELANOGASTER; EXPRESSION; DIFFERENTIATION	We have investigated the function of different structural domains of the Drosophila splicing regulator Transformer 2 (Tra2). We find that the ribonucleoprotein consensus sequence (RNP-CS) of Tra2 is required for male fertility and positive and negative control of alternative splicing in transgenic flies, as well as for in vitro binding of recombinant Trail to doublesex and tra2 pre-mRNAs. Thus, all of the known functions of Tra2 require specific protein-RNA interactions. We also show that one of the two arginine-serine (RS)-rich domains of Tra2 is dispensable, while the other is essential for all of the in vivo functions. Part of this domain is also required for RNA binding in vitro. Significantly, the essential RS domain is also required for specific protein-protein interactions. We find that Tra2 interacts with itself, with the splicing regulator Transformer, and with the general splicing factor SF2 in vitro and in the yeast two-hybrid system. These results demonstrate that both protein-RNA and protein-protein interactions are involved in tra2-dependent activation and repression of alternative splicing.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University	AMREIN, H (corresponding author), COLUMBIA UNIV, HOWARD HUGHES MED INST, 701 W 168TH ST, NEW YORK, NY 10032 USA.		Amrein, Hubert/AAG-9480-2021	Amrein, Hubert/0000-0001-8799-7250				AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1990, EMBO J, V9, P3619, DOI 10.1002/j.1460-2075.1990.tb07573.x; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BECKER DM, 1991, GUDIE YEAST GENETICS, P186; BELOTE JM, 1982, P NATL ACAD SCI-BIOL, V79, P1568, DOI 10.1073/pnas.79.5.1568; BELOTE JM, 1983, DEV BIOL, V95, P512, DOI 10.1016/0012-1606(83)90054-4; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P4611, DOI 10.1093/nar/19.17.4611; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HABETS WJ, 1987, P NATL ACAD SCI USA, V84, P2421, DOI 10.1073/pnas.84.8.2421; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MATTOX W, 1990, GENE DEV, V4, P789, DOI 10.1101/gad.4.5.789; MATTOX W, 1992, J BIOL CHEM, V267, P19023; MATTOX W, 1991, GENE DEV, V5, P786, DOI 10.1101/gad.5.5.786; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; McKeown M, 1990, Genet Eng (N Y), V12, P139; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Rio Donald C., 1992, Gene Expression, V2, P1; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; Sambrook J., 1989, MOL CLONING LAB MANU; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WATANABE TK, 1975, JPN J GENET, V50, P269, DOI 10.1266/jjg.50.269; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5; [No title captured]	64	174	181	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					735	746		10.1016/0092-8674(94)90512-6	http://dx.doi.org/10.1016/0092-8674(94)90512-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124712				2022-12-01	WOS:A1994MZ28500015
J	ASHTONRICKARDT, PG; BANDEIRA, A; DELANEY, JR; VANKAER, L; PIRCHER, HP; ZINKERNAGEL, RM; TONEGAWA, S				ASHTONRICKARDT, PG; BANDEIRA, A; DELANEY, JR; VANKAER, L; PIRCHER, HP; ZINKERNAGEL, RM; TONEGAWA, S			EVIDENCE FOR A DIFFERENTIAL AVIDITY MODEL OF T-CELL SELECTION IN THE THYMUS	CELL			English	Article							CLASS-I MOLECULES; RESTRICTED ANTIGEN PRESENTATION; POSITIVE SELECTION; TRANSGENIC MICE; LYMPHOCYTES-T; VIRAL PEPTIDES; SELF-PEPTIDES; MHC MOLECULES; H-2 ANTIGENS; RECEPTOR	Positive and negative selection of a lymphocytic choriomeningitis virus (LCMV) peptide-specific, H-2D(b)-restricted T cell clone (P14) was studied using TAP1(-) and TAP1(+) mice transgenic for P14 T cell receptor (TCR) alpha and beta genes. Positive selection of transgenic CD8(+) P14 cells was impaired in TAP1- mice. Addition of the LCMV peptide to TAP1(-) fetal thymic organ cultures (FTOCs) at low and high concentrations induced positive and negative selection of CD8(+) P14 cells, respectively, while addition of the same peptide to TAP1(+) FTOCs induced negative selection even at low concentrations. Both types of selection were peptide specific. Thus, a critical parameter that controls the fate of a thymocyte seems to be the number of TCRs engaged with complexes of peptide and major histocompatibility complex. When this number is low, positive selection occurs, and when it is high, negative selection takes place. These findings support a differential avidity model of T cell selection.	UNIV ZURICH,DEPT PATHOL,INST EXPTL IMMUNOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich	ASHTONRICKARDT, PG (corresponding author), MIT,DEPT BIOL,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.		Van Kaer, Luc/H-1033-2015	Van Kaer, Luc/0000-0001-5275-2309; Bandeira Ferreira, Antonio/0000-0002-8054-8716	NCI NIH HHS [CA53874] Funding Source: Medline; NIAID NIH HHS [AI17879] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA053874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017879, R37AI017879] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1989, SCIENCE; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HOGQUIST KA, 1993, J EXP MED, V177, P1464; HUGO P, 1993, IMMUNOL REV, V135, P133, DOI 10.1111/j.1600-065X.1993.tb00647.x; JACOBS H, 1990, EUR J IMMUNOL, V20, P2333, DOI 10.1002/eji.1830201024; JANEWAY C, 1992, Current Biology, V2, P26, DOI 10.1016/0960-9822(92)90419-B; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LO D, 1986, NATURE, V319, P672, DOI 10.1038/319672a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OHASHI PS, 1993, INT IMMUNOL, V5, P131, DOI 10.1093/intimm/5.2.131; PAWLOWSKI T, 1993, NATURE, V364, P642, DOI 10.1038/364642a0; PIRCHER H, 1993, EUR J IMMUNOL, V23, P669, DOI 10.1002/eji.1830230315; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER HP, 1990, NATURE, V346, P624; ROBEY EA, 1992, CELL, V64, P1084; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; ZIEGLER K, 1981, J IMMUNOL, V127, P1869; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	46	639	648	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 25	1994	76	4					651	663		10.1016/0092-8674(94)90505-3	http://dx.doi.org/10.1016/0092-8674(94)90505-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124708				2022-12-01	WOS:A1994MZ28500008
J	ZHANG, FM; STRAND, A; ROBBINS, D; COBB, MH; GOLDSMITH, EJ				ZHANG, FM; STRAND, A; ROBBINS, D; COBB, MH; GOLDSMITH, EJ			ATOMIC-STRUCTURE OF THE MAP KINASE ERK2 AT 2.3-ANGSTROM RESOLUTION	NATURE			English	Article							SIGNAL-REGULATED KINASES; DEPENDENT PROTEIN-KINASE; ADENOSINE-MONOPHOSPHATE; CATALYTIC SUBUNIT; GROWTH-FACTOR; SUBSTRATE RECOGNITION; PHOSPHORYLATION; INSULIN; ACTIVATION; TYROSINE	The structure of the MAP kinase ERK2, a ubiquitous protein kinase target for regulation by Ras and Raf, has been solved in its unphosphorylated low-activity conformation to a resolution of 2.3 angstrom. The two domains of unphosphorylated ERK2 are farther apart than in the active conformation of cAMP-dependent protein kinase and the peptide-binding site is blocked by tyrosine 185, one of the two residues that are phosphorylated in the active enzyme. Activation of ERK2 is thus likely to involve both global and local conformational changes.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute				Cobb, Melanie/0000-0003-0833-5473				AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARLSSON R, 1993, ACTA CRYSTALLOGR D, V49, P381, DOI 10.1107/S0907444993002306; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE RM, 1992, J BIOL CHEM, V267, P1088; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RINGE D, 1985, PROG BIOPHYS MOL BIO, V45, P197, DOI 10.1016/0079-6107(85)90002-1; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5779, DOI 10.1073/pnas.89.13.5779; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; Schulz GE, 1991, CURR OPIN STRUC BIOL, V1, P883, DOI 10.1016/0959-440X(91)90082-5; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SPRANG SR, 1991, SCIENCE, V254, P1367, DOI 10.1126/science.1962195; STEIGEMANN W, 1989, PROTEIN PROGRAM SYST; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSAO H, 1990, J BIOL CHEM, V265, P15471; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WANG BC, 1985, METHOD ENZYMOL, V115, P90; ZHANG FM, 1993, J MOL BIOL, V233, P550, DOI 10.1006/jmbi.1993.1532; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	54	523	542	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					704	711		10.1038/367704a0	http://dx.doi.org/10.1038/367704a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107865				2022-12-01	WOS:A1994MX63100048
J	ARENAS, E; PERSSON, H				ARENAS, E; PERSSON, H			NEUROTROPHIN-3 PREVENTS THE DEATH OF ADULT CENTRAL NORADRENERGIC NEURONS IN-VIVO	NATURE			English	Article							NERVE GROWTH-FACTOR; CHOLINERGIC NEURONS; LOCUS-CERULEUS; MESSENGER-RNA; FACTOR FAMILY; RAT-BRAIN; MOLECULAR-CLONING; CELL-DEATH; TRK FAMILY; EXPRESSION	NEUROTROPHIN-3 (NT-3)1-4 and neurotrophin-4/5 (NT4)5-7, together with nerve growth factor and brain-derived neurotrophic factor, are members of the neurotrophin family of proteins8,9 which supports the survival of vertebrate neurons. However, no function in vivo has been described for NT4 and limited information is available on the role of the other neurotrophins in the central nervous system in vivo. Nerve growth factor prevents the degeneration of lesioned septal cholinergic neurons in the adult brain10-13, whereas brain-derived neurotrophic factor prevents the death of developing motor neurons14-16 and a subpopulation of adult septal cholinergic neurons17. Finally, NT-3 partially prevents the death of facial motor neurons in newborn rats16. To assess the role of NT-3 and NT4 in the adult brain in vivo, we implanted genetically modified fibroblasts that constitutively express high levels of NT-3 or NT-4. The results show that NT-3, but no other neurotrophin, prevents the degeneration of noradrenergic neurons of the locus coeruleus in a 6-hydroxydopamine lesion model that resembles the pattern of cell loss found in Alzheimer's disease18,19. These results imply that NT-3 may have therapeutic potential for preventing the death of noradrenergic neurons in the locus coeruleus.			ARENAS, E (corresponding author), KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MOLEC NEUROBIOL LAB,S-17177 STOCKHOLM,SWEDEN.		Arenas, Ernest/AAO-5231-2020	Arenas, Ernest/0000-0003-0197-6577				ALTAR CA, 1993, J NEUROSCI, V13, P733; BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; CHANPALAY V, 1991, PROG BRAIN RES, V88, P625; ERNFORS P, 1989, P NATL ACAD SCI USA, V86, P4756, DOI 10.1073/pnas.86.12.4756; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; FRIEDMAN WJ, 1993, EXP NEUROL, V119, P72, DOI 10.1006/exnr.1993.1007; FRIEDMAN WJ, 1991, J NEUROSCI, V11, P1577; GERMAN DC, 1992, ANN NEUROL, V32, P667, DOI 10.1002/ana.410320510; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HARLEY C, 1991, PROG BRAIN RES, V88, P307; HEFTI F, 1986, J NEUROSCI, V6, P2155; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; KNUSEL B, 1992, J NEUROSCI, V12, P4391; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; PERSSON H, 1993, CURR OPIN NEUROL NEU, V6, P11; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; ROSENBERG MB, 1988, SCIENCE, V242, P1575, DOI 10.1126/science.3201248; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	33	192	203	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					368	371		10.1038/367368a0	http://dx.doi.org/10.1038/367368a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114936				2022-12-01	WOS:A1994MT54000067
J	GOUNNI, AS; LAMKHIOUED, B; OCHIAI, K; TANAKA, Y; DELAPORTE, E; CAPRON, A; KINET, JP; CAPRON, M				GOUNNI, AS; LAMKHIOUED, B; OCHIAI, K; TANAKA, Y; DELAPORTE, E; CAPRON, A; KINET, JP; CAPRON, M			HIGH-AFFINITY IGE RECEPTOR ON EOSINOPHILS IS INVOLVED IN DEFENSE AGAINST PARASITES	NATURE			English	Article							EPIDERMAL LANGERHANS CELLS; FC-EPSILON-RI; IMMUNOGLOBULIN-E; ALPHA-SUBUNIT; 2ND RECEPTOR; CHAIN; GENE; RESISTANCE; EXPRESSION; PRODUCTS	PARASITIC infections are often associated with eosinophilia and high levels of immunoglobulin E (IgE). This observation has led to speculation that eosinophils and IgE may act together in the immune response against parasites. In support of this hypothesis, IgE and eosinophils participate in cytotoxic reactions directed against Schistosoma mansoni larvae in vitro1,2. Furthermore, epidemiological studies have shown an inverse correlation between levels of specific IgE and rates of infection with Schistosoma3-5. The low-affinity IgE receptor (FcepsilonRII/CD23) was first incriminated in eosinophil activation 6,7. The fact that the high-affinity IgE receptor (FcepsilonRI)8,9 is not only expressed on mast cells and basophils but also on Langerhans cells10,11 led us to investigate the presence of FcepsilonRI on eosinophils. Here we show that FcepsilonRI is expressed on eosinophils from hypereosinophilic patients, is involved in eosinophil degranulation, and participates in eosinophil-mediated cytotoxicity against S. mansoni. Our results indicate that FcepsilonRI may play a major part in immune defence against parasites.	INST PASTEUR, CTR IMMUNOL & BIOL PARASITAIRE,UNITE MIXTE,INSERM, U167,CNRS 624, F-59019 LILLE, FRANCE; NIAID, MOLEC ALLERGY & IMMUNOL SECT, BETHESDA, MD 20892 USA; CTR HOSP REG UNIV LILLE, SERV DERMATOL A, F-59000 LILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Universite de Lille - ISITE; CHU Lille			LAMKHIOUED, Bouchaib/AAL-4201-2021; Gounni, Abdelilah Soussi/AAH-3456-2020	Gounni, Abdelilah/0000-0003-1265-6560; Soussi Gounni, Abdelilah/0000-0002-7282-0388				BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BLANK U, 1991, J BIOL CHEM, V266, P2639; CAPRON A, 1986, IMMUNOL TODAY, V7, P15, DOI 10.1016/0167-5699(86)90184-2; CAPRON A, 1987, SCIENCE, V238, P1065, DOI 10.1126/science.3317823; CAPRON M, 1989, CHEM IMMUNOL, V47, P128; CAPRON M, 1991, EUR J IMMUNOL, V21, P2423, DOI 10.1002/eji.1830211019; CAPRON M, 1986, J EXP MED, V164, P72, DOI 10.1084/jem.164.1.72; DUNNE DW, 1992, EUR J IMMUNOL, V22, P1483, DOI 10.1002/eji.1830220622; FISCHKOFF SA, 1984, J EXP MED, V160, P179, DOI 10.1084/jem.160.1.179; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; KHALIFE J, 1986, J IMMUNOL, V137, P1659; KINET JP, 1992, INFLAMMATION BASIC P, P701; KOCHAN J, 1988, NUCLEIC ACIDS RES, V16, P3584, DOI 10.1093/nar/16.8.3584; KUSTER H, 1992, J BIOL CHEM, V267, P12782; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RIHET P, 1991, EUR J IMMUNOL, V21, P2679, DOI 10.1002/eji.1830211106; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; TOMASSINI M, 1991, J ALLERGY CLIN IMMUN, V88, P365, DOI 10.1016/0091-6749(91)90099-A; TRUONG MJ, 1993, J EXP MED, V177, P243, DOI 10.1084/jem.177.1.243; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353	23	447	454	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 13	1994	367	6459					183	186		10.1038/367183a0	http://dx.doi.org/10.1038/367183a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114916				2022-12-01	WOS:A1994MQ78000064
J	ACHARYA, KR; PASSALACQUA, EF; JONES, EY; HARLOS, K; STUART, DI; BREHM, RD; TRANTER, HS				ACHARYA, KR; PASSALACQUA, EF; JONES, EY; HARLOS, K; STUART, DI; BREHM, RD; TRANTER, HS			STRUCTURAL BASIS OF SUPERANTIGEN ACTION INFERRED FROM CRYSTAL-STRUCTURE OF TOXIC-SHOCK SYNDROME TOXIN-1	NATURE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; RECEPTOR BETA-CHAIN; V-BETA; T-CELLS; BINDING; IDENTIFICATION; RESIDUES; STIMULATION; RESPONSES; MOLECULES	SUPERANTIGENS stimulate T cells bearing particular T-cell receptor Vbeta sequences1,2, so they are extremely potent polyclonal T-cell mitogens. T-cell activation is preceded by binding of superantigens to class II major histocompatibility complex (MHC) molecules3. To further the structural characterization of these interactions, the crystal structure of a toxin associated with toxic-shock syndrome, TSST-1, which is a microbial superantigen, has been determined at 2.5 angstrom resolution. The N- and C-terminal domains of the structure both contain regions involved in MHC class II association; the C-terminal domain is also implicated in binding the T-cell receptor. Despite low sequence conservation, the TSST-1 topology is similar to the structure reported for the superantigen staphylococcal enterotoxin B4. But TSST-1 lacks several of the structural features highlighted as central to superantigen activity in the staphylococcal enterotoxin B and we therefore reappraise the structural basis of superantigen action.	OXFORD CTR MOLEC SCI, OXFORD OX1 3QU, ENGLAND; LAB MOLEC BIOPHYS, OXFORD OX1 3QU, ENGLAND; PUBL HLTH LAB SERV, CTR APPL MICROBIOL & RES, DIV BIOL, SALISBURY SP4 0JG, ENGLAND	University of Oxford; University of Oxford	ACHARYA, KR (corresponding author), UNIV BATH, SCH BIOL & BIOCHEM, CLAVERTON DOWN, BATH BA2 7AY, AVON, ENGLAND.		Jones, Yvonne/J-2293-2016; Jones, Yvonne/N-8111-2019	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210; Acharya, K. Ravi/0000-0002-3009-4058				BJORKMAN PJ, 1989, COLD SH Q B, V54, P365; BLANCO L, 1990, INFECT IMMUN, V58, P3020, DOI 10.1128/IAI.58.9.3020-3028.1990; BONVENTRE PF, 1988, INFECT IMMUN, V56, P135, DOI 10.1128/IAI.56.1.135-141.1988; BONVENTRE PF, 1993, INFECT IMMUN, V61, P793, DOI 10.1128/IAI.61.3.793-799.1993; BRAUNSTEIN NS, 1992, J EXP MED, V175, P1301, DOI 10.1084/jem.175.5.1301; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; EDWIN C, 1989, INFECT IMMUN, V57, P2230, DOI 10.1128/IAI.57.7.2230-2236.1989; EDWIN C, 1991, J INFECT DIS, V163, P524, DOI 10.1093/infdis/163.3.524; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; GRIGGS ND, 1992, J IMMUNOL, V148, P2516; IRWIN MJ, 1992, NATURE, V359, P841, DOI 10.1038/359841a0; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JONES EY, 1991, ACTA CRYSTALLOGR A, V47, P753, DOI 10.1107/S0108767391006839; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAPPLER JW, 1992, J EXP MED, V175, P387, DOI 10.1084/jem.175.2.387; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MURRAY DL, 1993, 93RD GEN M AM SOC MI, P64; MURZIN AG, 1992, NATURE, V360, P635, DOI 10.1038/360635a0; PANINABORDIGNON P, 1992, J EXP MED, V176, P1779, DOI 10.1084/jem.176.6.1779; PASSALACQUA EF, 1992, J MOL BIOL, V228, P983, DOI 10.1016/0022-2836(92)90882-K; PONTZER CH, 1991, P NATL ACAD SCI USA, V88, P125, DOI 10.1073/pnas.88.1.125; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1991, J EXP MED, V173, P1183, DOI 10.1084/jem.173.5.1183; SOOS JM, 1993, BIOCHEM BIOPH RES CO, V191, P1211, DOI 10.1006/bbrc.1993.1346; SPERO L, 1988, HDB NATURAL TOXINS, V4, P131; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND DL, 1993, IMMUNOL TODAY, V14, P208, DOI 10.1016/0167-5699(93)90164-G	30	147	157	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	1994	367	6458					94	97		10.1038/367094a0	http://dx.doi.org/10.1038/367094a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107781				2022-12-01	WOS:A1994MP86500068
J	KASS, DA; WOLFF, MR; TING, CT; LIU, CP; CHANG, MS; LAWRENCE, W; MAUGHAN, WL				KASS, DA; WOLFF, MR; TING, CT; LIU, CP; CHANG, MS; LAWRENCE, W; MAUGHAN, WL			DIASTOLIC COMPLIANCE OF HYPERTROPHIED VENTRICLE IS NOT ACUTELY ALTERED BY PHARMACOLOGICAL AGENTS INFLUENCING ACTIVE PROCESSES	ANNALS OF INTERNAL MEDICINE			English	Article						VENTRICULAR FUNCTION, LEFT; HYPERTROPHY, LEFT VENTRICULAR; VERAPAMIL; ESMOLOL; COMPLIANCE	PRESSURE-VOLUME RELATIONS; CONDUCTANCE CATHETER; HEART-FAILURE; SHORT-TERM; CARDIOMYOPATHY; VERAPAMIL; RELAXATION; DYSFUNCTION; NIFEDIPINE; DETERMINANTS	Objective: To test, by studying the acute effects of drugs that influence active processes, the hypothesis that in humans with marked ventricular hypertrophy, reduced chamber compliance is primarily caused by passive structural changes. Design: An uncontrolled (before-after) study. Setting: University Medical Center. Patients: Fourteen patients with ventricular hypertrophy (19 +/- 4.5-mm diastolic-wall thickness) and normal resting systolic function were studied while they had invasive cardiac catheterization. Intervention: Intravenous beta-blocker (esmolol) or calcium channel blocker (verapamil) or both. Measurements: Left ventricular function was determined by pressure-volume relations. Volume was measured using conductance catheter, providing a continuous voltage signal proportional to chamber volume. Pressure was measured by micromanometer. Cardiac-specific assessment of change in chamber contractility and diastolic compliance due to each drug was determined. Results: Both drugs lowered contractility by approximately 30% (P < 0.01). Esmolol slowed relaxation and reduced early peak filling rate, whereas verapamil delayed the time to peak filling (all P < 0.05). In contrast to the effects of both drugs on active contraction and early diastole, late-diastolic compliance was unaltered, and end-diastolic pressure-volume relations were almost identical. Conclusion: Neither beta-receptor nor calcium channel blockade acutely alters left ventricular compliance despite substantial active effects manifest in systole and early diastole. This supports the notion that chamber compliance is principally determined by passive structural elements in the heart rather than by active processes.	JOHNS HOPKINS MED INST, BALTIMORE, MD 21205 USA; VET GEN HOSP, TAIPEI, TAIWAN	Johns Hopkins University; Johns Hopkins Medicine					NHLBI NIH HHS [HL-33243, HL-01610, HL-01820] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033243, K11HL001820] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPLEGATE RJ, 1990, CIRCULATION, V81, P638, DOI 10.1161/01.CIR.81.2.638; BAAN J, 1984, CIRCULATION, V70, P812, DOI 10.1161/01.CIR.70.5.812; BETOCCHI S, 1986, J AM COLL CARDIOL, V7, P74, DOI 10.1016/S0735-1097(86)80262-5; BONOW RO, 1985, CIRCULATION, V72, P853, DOI 10.1161/01.CIR.72.4.853; BONOW RO, 1983, CIRCULATION, V68, P1062, DOI 10.1161/01.CIR.68.5.1062; BONOW RO, 1981, CIRCULATION, V64, P787, DOI 10.1161/01.CIR.64.4.787; BURKHOFF D, 1985, CIRCULATION, V72, P440, DOI 10.1161/01.CIR.72.2.440; COHEN LS, 1967, CIRCULATION, V35, P847, DOI 10.1161/01.CIR.35.5.847; EPSTEIN SE, 1965, J CLIN INVEST, V44, P1745, DOI 10.1172/JCI105282; GILBERT JC, 1989, CIRC RES, V64, P827, DOI 10.1161/01.RES.64.5.827; Glantz SA, 1990, PRIMER APPL REGRESSI, P381; GROSSMAN W, 1991, NEW ENGL J MED, V325, P1557; GWATHMEY JK, 1991, J CLIN INVEST, V87, P1023, DOI 10.1172/JCI115061; HESS OM, 1986, CIRCULATION, V74, P530, DOI 10.1161/01.CIR.74.3.530; KASS DA, 1988, CIRCULATION, V77, P1203, DOI 10.1161/01.CIR.77.6.1203; KASS DA, 1988, CATHETER CARDIO DIAG, V15, P192, DOI 10.1002/ccd.1810150314; KASS DA, 1990, CIRCULATION, V81, P447, DOI 10.1161/01.CIR.81.2.447; LIU CP, 1992, CIRCULATION, V85, P1447, DOI 10.1161/01.CIR.85.4.1447; LORELL BH, 1987, J AM COLL CARDIOL, V9, P1189, DOI 10.1016/S0735-1097(87)80326-1; LORELL BH, 1980, NEW ENGL J MED, V303, P801, DOI 10.1056/NEJM198010023031407; LORELL BH, 1982, CIRCULATION, V65, P499, DOI 10.1161/01.CIR.65.3.499; LUDBROOK PA, 1977, CIRCULATION, V56, P937, DOI 10.1161/01.CIR.56.6.937; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MORGAN JP, 1990, CIRCULATION, V81, P21; PAULUS WJ, 1983, J AM COLL CARDIOL, V2, P879, DOI 10.1016/S0735-1097(83)80235-6; REFSUM H, 1981, CIRCULATION, V64, P997, DOI 10.1161/01.CIR.64.5.997; SCHULMAN SP, 1990, NEW ENGL J MED, V322, P1350, DOI 10.1056/NEJM199005103221904; Speiser K W, 1981, Eur Heart J, V2, P21; STEWART S, 1968, CIRCULATION, V37, P8, DOI 10.1161/01.CIR.37.1.8; SUGA H, 1974, CIRC RES, V35, P117, DOI 10.1161/01.RES.35.1.117; SWANTON RH, 1977, EUR J CARDIOL, V5, P327; TENCATE FJ, 1983, CIRCULATION, V68, P1274, DOI 10.1161/01.CIR.68.6.1274; WEBER KT, 1987, CIRCULATION, V75, P40; WEBER KT, 1989, AM J HYPERTENS, V2, P931, DOI 10.1093/ajh/2.12.931; WEISS JL, 1976, J CLIN INVEST, V58, P751, DOI 10.1172/JCI108522	35	58	60	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					466	473		10.7326/0003-4819-119-6-199309150-00004	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8102838				2022-12-01	WOS:A1993LZ27500004
J	BU, XD; ROTTER, JI				BU, XD; ROTTER, JI			WOLFRAM-SYNDROME - A MITOCHONDRIAL-MEDIATED DISORDER	LANCET			English	Article							PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; HEREDITARY OPTIC NEUROPATHY; KEARNS-SAYRE SYNDROME; DIABETES-MELLITUS; DNA MUTATION; DELETIONS; DEAFNESS; PEDIGREE; GENES	Mitochondrial DNA mutations cause several human diseases, (eg, Leber's hereditary optic neuropathy). Wolfram syndrome (characterised by diabetes insipidus, diabetes mellitus, optic atrophy, and deafness) also has, in some cases, a mitochondrial origin. The disease, often familial, has been well documented as an autosomal recessive disorder, and most of the clinical phenotypes are consistent with an ATP supply defect that is often seen in mitochondrial-mediated disorders. We propose a dual genome defect model for Wolfram syndrome in which nuclear genetic defects or mitochondrial genetic defects can independently lead to the disease. This model suggests that besides a mitochondrial gene defect alone, a nuclear gene defect, which interferes with the normal function of mitochondria (probably with a normal mitochondrial genome), can also be the underlying explanation for the pleiotropic features of Wolfram syndrome. This hypothesis explains how an autosomal recessive disorder can result in mitochondrial dysfunction, and has a general application in the identification of candidate genes for the various important phenotypes (eg, deafness and diabetes mellitus) seen in mitochondrial disorders.	CEDARS SINAI MED CTR, DEPT PEDIAT, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	BU, XD (corresponding author), CEDARS SINAI MED CTR, DEPT MED, DIV MED GENET, SSB-3, 8700 W BEVERLY BLVD, LOS ANGELES, CA 90048 USA.				NHLBI NIH HHS [HL28481] Funding Source: Medline; NIDCD NIH HHS [DCO1402] Funding Source: Medline; NIDDK NIH HHS [DK07426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001402] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALCOLADO JC, 1991, BRIT MED J, V302, P1178, DOI 10.1136/bmj.302.6786.1178; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BELCOUR L, 1991, P NATL ACAD SCI USA, V88, P3579, DOI 10.1073/pnas.88.9.3579; BU XD, 1993, GENET EPIDEMIOL, V10, P3, DOI 10.1002/gepi.1370100102; BU XD, 1991, P NATL ACAD SCI USA, V88, P8198, DOI 10.1073/pnas.88.18.8198; BU XD, 1992, GENET EPIDEMIOL, V9, P27, DOI 10.1002/gepi.1370090105; BUNDEY S, 1992, J INHERIT METAB DIS, V15, P315, DOI 10.1007/BF02435965; CAVELIER L, 1993, CLIN GENET, V43, P69, DOI 10.1111/j.1399-0004.1993.tb04429.x; CORMIER V, 1991, AM J HUM GENET, V48, P643; GERBITZ KD, 1992, DIABETOLOGIA, V35, P1181, DOI 10.1007/BF00401375; JABER L, 1992, J MED GENET, V29, P86, DOI 10.1136/jmg.29.2.86; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P1333; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; PREZANT TR, 1992, AM J MED GENET, V44, P465, DOI 10.1002/ajmg.1320440416; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; ROTIG A, 1993, J CLIN INVEST, V91, P1095, DOI 10.1172/JCI116267; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SINGH G, 1989, NEW ENGL J MED, V320, P1300, DOI 10.1056/NEJM198905183202002; SWIFT RG, 1990, LANCET, V336, P667, DOI 10.1016/0140-6736(90)92157-D; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VANDENOUWELAND JMW, 1992, NUCLEIC ACIDS RES, V20, P679, DOI 10.1093/nar/20.4.679; VILKKI J, 1991, American Journal of Human Genetics, V48, P486; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; ZEVIANI M, 1988, NEUROLOGY, V38, P1339; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0	27	55	56	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					598	600		10.1016/0140-6736(93)91416-J	http://dx.doi.org/10.1016/0140-6736(93)91416-J			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102726				2022-12-01	WOS:A1993LV96300016
J	CHIKASHIGE, Y; DING, DQ; FUNABIKI, H; HARAGUCHI, T; MASHIKO, S; YANAGIDA, M; HIRAOKA, Y				CHIKASHIGE, Y; DING, DQ; FUNABIKI, H; HARAGUCHI, T; MASHIKO, S; YANAGIDA, M; HIRAOKA, Y			TELOMERE-LED PREMEIOTIC CHROMOSOME MOVEMENT IN FISSION YEAST	SCIENCE			English	Article							SCHIZOSACCHAROMYCES-POMBE; CENTROMERES; MEIOSIS	The movement of chromosomes that precedes meiosis was observed in living cells of fission yeast by fluorescence microscopy. Further analysis by in situ hybridization revealed that the telomeres remain clustered at the leading end of premeiotic chromosome movement, unlike mitotic chromosome movement in which the centromere leads. Once meiotic chromosome segregation starts, however, centromeres resume the leading position in chromosome movement, as they do in mitosis. Although the movement of the telomere first has not been observed before, the clustering of telomeres is reminiscent of the bouquet structure of meiotic-prophase chromosomes observed in higher eukaryotes, which suggests that telomeres perform specific functions required for premeiotic chromosomal events generally in eukaryotes.	KYOTO UNIV, FAC SCI, DEPT BIOPHYS, KYOTO 606, JAPAN	Kyoto University	CHIKASHIGE, Y (corresponding author), KANSAI ADV RES CTR, COMMUN RES LAB, 588-2 IWAOKA, IWAOKA CHO, NISHI KU, KOBE 65124, JAPAN.		Hiraoka, Yasushi/B-5111-2009	Hiraoka, Yasushi/0000-0001-9407-8228; Funabiki, Hironori/0000-0003-4831-4087; Ding, Da-Qiao/0000-0003-4403-2760				BAHLER J, 1993, J CELL BIOL, V121, P241, DOI 10.1083/jcb.121.2.241; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; DING DQ, UNPUB; EGEL R, 1973, MOL GEN GENET, V121, P277, DOI 10.1007/BF00267055; EGEL R, 1974, EXP CELL RES, V88, P127, DOI 10.1016/0014-4827(74)90626-0; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; FUSSELL C P, 1987, P275; HAGAN I, UNPUB; HAGAN IM, 1988, J CELL SCI, V89, P343; HILLIKER AJ, 1989, EXP CELL RES, V185, P297, DOI 10.1016/0014-4827(89)90301-7; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; HIRATA A, 1982, J GEN APPL MICROBIOL, V28, P263, DOI 10.2323/jgam.28.263; HTERMAN E, 1992, HUMAN CHROMOSOMES, P165; Hughes-Schrader S, 1943, BIOL BULL-US, V85, P265, DOI 10.2307/1538227; John B., 1990, MEIOSIS; MAGUIRE MP, 1984, J THEOR BIOL, V106, P605, DOI 10.1016/0022-5193(84)90010-9; MORENO S, 1991, METHOD ENZYMOL, V194, P795; OLSON LW, 1978, HEREDITAS, V89, P189; ROBINOW CF, 1977, GENETICS, V87, P491; UZAWA S, 1992, J CELL SCI, V101, P267	21	397	401	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 8	1994	264	5156					270	273		10.1126/science.8146661	http://dx.doi.org/10.1126/science.8146661			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146661				2022-12-01	WOS:A1994NE41000040
J	SUZUKI, CK; SUDA, K; WANG, N; SCHATZ, G				SUZUKI, CK; SUDA, K; WANG, N; SCHATZ, G			REQUIREMENT FOR THE YEAST GENE LON IN INTRAMITOCHONDRIAL PROTEOLYSIS AND MAINTENANCE OF RESPIRATION	SCIENCE			English	Article							ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; INTERMEMBRANE SPACE; LIVER-MITOCHONDRIA; PROTEINS; MECHANISM; IMPORT; CELLS; ION	The role of protein degradation in mitochondrial homeostasis was explored by cloning of a gene from Saccharomyces cerevisiae that encodes a protein resembling the adenosine triphosphate (ATP)-dependent bacterial protease Lon. The predicted yeast protein has a typical mitochondrial matrix-targeting sequence at its amino terminus. Yeast cells lacking a functional LON gene contained a nonfunctional mitochondrial genome, were respiratory-deficient, and lacked an ATP-dependent proteolytic activity present in the mitochondria of Lon+ cells. Lon- cells were also impaired in their ability to catalyze the energy-dependent degradation of several mitochondrial matrix proteins and they accumulated electron-dense inclusions in their mitochondrial matrix.	NCI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SUZUKI, CK (corresponding author), UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND.							CHIN DT, 1988, J BIOL CHEM, V263, P11718; DAUM G, 1982, J BIOL CHEM, V257, P3075; DESAUTELS M, 1982, P NATL ACAD SCI-BIOL, V79, P1869, DOI 10.1073/pnas.79.6.1869; DESAUTELS M, 1982, J BIOL CHEM, V257, P1673; DICE JF, 1975, P NATL ACAD SCI USA, V72, P3893, DOI 10.1073/pnas.72.10.3893; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; FLETCHER MJ, 1961, BIOCHIM BIOPHYS ACTA, V51, P356, DOI 10.1016/0006-3002(61)90177-9; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; ITO K, 1992, J BACTERIOL, V174, P2281, DOI 10.1128/JB.174.7.2281-2287.1992; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KUTEJOVA E, 1993, FEBS LETT, V329, P47, DOI 10.1016/0014-5793(93)80190-6; RUSSELL SM, 1980, BIOCHEM J, V256, P8652; Stevens B., 1981, MOL BIOL YEAST SACCH, V1, P471; SUZUKI C, UNPUB; TOJO N, 1993, J BACTERIOL, V175, P2271, DOI 10.1128/JB.175.8.2271-2277.1993; VANDYCK L, 1994, J BIOL CHEM, V269, P238; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	22	209	213	3	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					273	276		10.1126/science.8146662	http://dx.doi.org/10.1126/science.8146662			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146662				2022-12-01	WOS:A1994NE41000041
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PROPOSES RULE TO PROTECT IDENTITIES OF REPORTERS OF ADVERSE EVENTS AND PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					812	812						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114223				2022-12-01	WOS:A1994MZ49800039
J	BUYS, H; PEAD, L; HALLETT, R; MASKELL, R				BUYS, H; PEAD, L; HALLETT, R; MASKELL, R			SUPRAPUBIC ASPIRATION UNDER ULTRASOUND GUIDANCE IN CHILDREN WITH FEVER OF UNDIAGNOSED CAUSE	BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT INFECTIONS	Objectives-To assess the ease of use of suprapubic aspiration of urine under ultrasound guidance in babies with fever of uncertain cause and to assess the importance of bacterial counts and pyuria in relation to abnormalities of the urinary tract and the importance of pyuria in the absence of bacteriuria. Design-Analysis of urine samples obtained by suprapubic aspiration in babies and children from July 1991 to June 1992. The clinical records of the children with bacteriuria and sterile pyuria were examined retrospectively. Setting-Neonatal and paediatric wards of a district general hospital. Subjects-508 babies and children who had fever of uncertain cause or were seriously ill. Results-No difficulties arose in the collection of 545 specimens. Bacteria were isolated from the specimens of 44 children, 24 of whom had abnormalities of the urinary tract. The bacterial count was <10(8)/1 in 18 of the children with bacteriuria, 10 of whom had abnormalities. No white cells were seen in 22 of the 46 bacteriuric specimens; nine of the children with no pyuria had vesicoureteric reflux. 439 of the 499 non-bacteriuric specimens showed no white cells. 60 children had pyuria without bacteriuria. Conclusions-The use of ultrasound guidance simplifies suprapubic aspiration of urine in babies. Low bacterial counts may be associated with abnormalities of the urinary tract. Laboratory techniques capable of detecting such counts reliably should be used. Pyuria is absent in half of babies and very young children with bacteriuria. It rarely occurs without bacteriuria, and if it does an explanation should be sought.	ST MARYS HOSP,DEPT PAEDIATR,PORTSMOUTH PO3 6AD,HANTS,ENGLAND; ST MARYS HOSP,PUBL HLTH LAB,PORTSMOUTH PO3 6AD,HANTS,ENGLAND				Buys, Heloise/I-6051-2017	Buys, Heloise/0000-0001-9778-8233				AHMAD T, 1991, LANCET, V338, P674, DOI 10.1016/0140-6736(91)91242-M; AIREDE AI, 1992, J INFECTION, V25, P55, DOI 10.1016/0163-4453(92)93513-P; AUSTIN N, 1992, LANCET, V339, P65; BERGSTRO.T, 1972, J PEDIATR-US, V80, P858; CHIU N-C, 1989, Acta Paediatrica Sinica, V30, P225; KELLOGG JA, 1987, AM J MED, V83, P739, DOI 10.1016/0002-9343(87)90907-7; LEE P, 1991, ARCH DIS CHILD, V66, P1287, DOI 10.1136/adc.66.11.1287; MASKELL R, 1982, URINARY TRACT INFECT, P24; OCALLAGHAN C, 1987, ARCH DIS CHILD, V62, P1072, DOI 10.1136/adc.62.10.1072; POWELL HR, 1987, ARCH DIS CHILD, V62, P138, DOI 10.1136/adc.62.2.138; Smellie Jean M, 1967, J R Coll Physicians Lond, V1, P189; SMELLIE JM, 1991, J UROLOGY, V146, P665, DOI 10.1016/S0022-5347(17)37889-8; WOODWARD MN, 1993, BRIT MED J, V306, P1512, DOI 10.1136/bmj.306.6891.1512	13	33	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					690	692		10.1136/bmj.308.6930.690	http://dx.doi.org/10.1136/bmj.308.6930.690			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142792	Green Published			2022-12-01	WOS:A1994NA86900019
J	WARNER, KE; FULTON, GA				WARNER, KE; FULTON, GA			THE ECONOMIC-IMPLICATIONS OF TOBACCO PRODUCT SALES IN A NONTOBACCO STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-The tobacco industry claims that tobacco makes a significant economic contribution to each of the states in the United States. We sought to determine whether Michigan, a nontobacco state, would reap more economic benefits from the presence or absence of tobacco product sales. Design.-Computer simulation of the Michigan economy, with and without tobacco product sales, for the years 1992 through 2005. Intervention.-We simulated Michigan's economy with tobacco expenditures eliminated or reduced and the equivalent spending redistributed to other goods and services, according to consumers' normal spending patterns. We compare these results with baseline forecasts of the economy. Main Outcome Measures.-Numbers of jobs and tax revenues. Results.-Michigan would have had 5600 more jobs in 1992 had there been no expenditure on tobacco products, with equivalent spending redistributed to other goods and services (and to other taxes, to replace half of lost cigarette excise tax revenues). By the year 2005, a tobacco-free Michigan would still have almost 1500 more jobs than it will have if sales trends for tobacco products continue tie, gradually declining over time). If, instead of tobacco expenditures ceasing, the contemporary rate of decline in tobacco consumption had doubled, the state would have had over 300 more jobs in 1992 and would have nearly 800 more in 2005. With cigarette excise tax revenues not replaced, the elimination of spending on tobacco products would have decreased Michigan's tax revenues by $254 million in 1992. The more realistic doubling of the expected decline in smoking would have decreased revenues by $14 million that year. Conclusions.-Reducing or eliminating tobacco product spending in Michigan will increase employment in the state, as well as health.	UNIV MICHIGAN,DEPT ECON,ANN ARBOR,MI 48109; UNIV MICHIGAN,INST LABOR & IND RELAT,ANN ARBOR,MI	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	WARNER, KE (corresponding author), UNIV MICHIGAN,SCH PUBL HLTH,DEPT PUBL HLTH POLICY & ADM,1420 WASHINGTON HTS,ANN ARBOR,MI 48109, USA.			Warner, Kenneth/0000-0002-8214-1776				[Anonymous], 1992, EC REPORT PRESIDENT; HODGSON TA, 1992, MILBANK Q, V70, P81, DOI 10.2307/3350086; SCHELLING TC, 1986, PREV MED, V15, P549, DOI 10.1016/0091-7435(86)90030-7; Treyz G. I., 1993, REGIONAL EC MODELING; TREYZ GI, 1992, INT REGIONAL SCI REV, V14, P221, DOI 10.1177/016001769201400301; WARNER KE, 1987, JAMA-J AM MED ASSOC, V258, P2080, DOI 10.1001/jama.258.15.2080; 1993, MMWR MORB MORTAL WKL, V42, P645; 1993, EC LOSSES US EC SPEC; 1993, TAX BURDEN TOBACCO H; 1979, STUDY TOBACCO IND EC; 1993, SAVING LIVES RAISING; 1990, DHHS CDC878396 DEP H; 1992, MICHIGAN ASSIST PROJ; 1985, EC IMPACT TOBACCO IN, pCH5; 1990, EC IMPACT TOBACCO IN; 1992, EC IMPACT TOBACCO IN	16	34	34	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					771	776		10.1001/jama.271.10.771	http://dx.doi.org/10.1001/jama.271.10.771			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MY288	8114214				2022-12-01	WOS:A1994MY28800032
J	CHEN, JH; IYENGAR, R				CHEN, JH; IYENGAR, R			SUPPRESSION OF RAS-INDUCED TRANSFORMATION OF NIH 3T3 CELLS BY ACTIVATED G-ALPHA(S)	SCIENCE			English	Article							MAP KINASE; G-PROTEINS; PROLIFERATION; STIMULATION	Conversion of external signals into proliferative responses may be mediated by interactions between signaling pathways that control cell proliferation. Interactions between G alpha(s), the alpha subunit of the heterotrimeric guanine nucleotide binding protein that stimulates adenylyl cyclase, and Ras, an important element in growth factor signaling, were studied. Expression of activated G alpha(s), in NIH 3T3 cells increased intracellular concentrations of adenosine 3',5'-monophosphate (cAMP) and inhibited H-Ras-stimulated DNA synthesis and mitogen-activated protein kinase activity. Activated G alpha(s) and 8-Br-cAMP suppressed H-Ras-induced transformation of NIH 3T3 cells. Apparently, G alpha(s) inhibits proliferative signals from Ras by stimulating cAMP production and activating protein kinase A.	CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA-44998] Funding Source: Medline; NIDDK NIH HHS [DK-38761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHEN J, 1994, THESIS CITY U NEW YO; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; KROLL SD, 1992, J BIOL CHEM, V267, P23183; LAMORTE VJ, 1993, J CELL BIOL, V245, P1146; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARX J, 1993, SCIENCE, V260, P1588, DOI 10.1126/science.8503004; MCCORMICK F, 1989, NATURE, V340, P678, DOI 10.1038/340678a0; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RIGBY PWJ, 1982, NATURE, V297, P451, DOI 10.1038/297451a0; RUBIN H, 1989, P NATL ACAD SCI USA, V86, P1860, DOI 10.1073/pnas.86.6.1860; SPADA A, 1992, TRENDS ENDOCRIN MET, V3, P355, DOI 10.1016/1043-2760(92)90001-H; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WINITZ S, 1993, J BIOL CHEM, V268, P19196	24	113	114	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1278	1281		10.1126/science.8122111	http://dx.doi.org/10.1126/science.8122111			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122111				2022-12-01	WOS:A1994MY57000036
J	MORRIS, SW; KIRSTEIN, MN; VALENTINE, MB; DITTMER, KG; SHAPIRO, DN; SALTMAN, DL; LOOK, AT				MORRIS, SW; KIRSTEIN, MN; VALENTINE, MB; DITTMER, KG; SHAPIRO, DN; SALTMAN, DL; LOOK, AT			FUSION OF A KINASE GENE, ALK, TO A NUCLEOLAR PROTEIN GENE, NPM, IN NON-HODGKINS-LYMPHOMA	SCIENCE			English	Article							LARGE-CELL LYMPHOMA; CLINICAL-FEATURES; GROWTH; HYBRIDIZATION; INTERPHASE; ACTIVATION; NUMATRIN; LEUKEMIA; CLONING; FAMILY	The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes. This rearrangement was shown to fuse the NPM nucleolar phosphoprotein:gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23. In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK). Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases. Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.	ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; GENELABS INC, REDWOOD CITY, CA 94063 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	MORRIS, SW (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38105 USA.				NCI NIH HHS [KO8 CA 01702, P01 CA 20180, CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, K08CA001702, P01CA020180] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BITTER MA, 1990, AM J SURG PATHOL, V14, P305, DOI 10.1097/00000478-199004000-00001; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRINKMAN A, 1988, EMBO J, V7, P2417, DOI 10.1002/j.1460-2075.1988.tb03087.x; BURNETT RC, 1991, GENE CHROMOSOME CANC, V3, P461, DOI 10.1002/gcc.2870030608; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1991, EXP CELL RES, V194, P289, DOI 10.1016/0014-4827(91)90367-4; GREER JP, 1991, J CLIN ONCOL, V9, P539, DOI 10.1200/JCO.1991.9.4.539; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KADIN ME, 1991, J CLIN ONCOL, V9, P533, DOI 10.1200/JCO.1991.9.4.533; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; MASON DY, 1990, BRIT J HAEMATOL, V74, P161; MORGAN R, 1989, BLOOD, V73, P2155; MORRIS SC, UNPUB; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; SALTMAN DL, 1992, NUCLEIC ACIDS RES, V20, P1401, DOI 10.1093/nar/20.6.1401; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STANSFELD AG, 1988, LANCET, V1, P292; STEIN H, 1992, NEOPLASTIC HEMATOPAT, P675; TRASK BJ, 1991, AM J HUM GENET, V48, P1; TYCKO B, 1991, J EXP MED, V174, P867, DOI 10.1084/jem.174.4.867	29	1752	1824	4	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1281	1284		10.1126/science.8122112	http://dx.doi.org/10.1126/science.8122112			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122112				2022-12-01	WOS:A1994MY57000037
J	WANG, ZG; SVEJSTRUP, JQ; FEAVER, WJ; WU, XH; KORNBERG, RD; FRIEDBERG, EC				WANG, ZG; SVEJSTRUP, JQ; FEAVER, WJ; WU, XH; KORNBERG, RD; FRIEDBERG, EC			TRANSCRIPTION FACTOR-B (TFIIH) IS REQUIRED DURING NUCLEOTIDE-EXCISION REPAIR IN YEAST	NATURE			English	Article							HUMAN CELL-EXTRACTS; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; XERODERMA-PIGMENTOSUM; GENE; MUTAGENESIS; POLYMERASE; HELICASE; HOMOLOG; CLONING	NUCLEOTIDE-excision repair (NER)(1) is an important cellular defence mechanism against mutagenesis and carcinogenesis. The essential yeast genes RAD3 (ref 2) and SSL2 (RAD25)(3,4), homologues of the human xeroderma pigmentosum genes XPD(5,6) and XPB(7) respectively, have been implicated in NER in yeast. The products of these genes are also subunits of (Rad3 protein) or associate with (Ssl2 protein) purified yeast RNA polymerase II transcription initiation factor b, the counterpart of human TFIIH8. Rad3 and Ssl2 proteins may participate directly in NER. Alternatively, they may function exclusively as transcription factors that support NER by influencing the expression of other NER genes. Here we show that defective NER in rad3 mutant extracts can be specifically complemented by purified transcription factor b. Similarly, defective NER in ssl2 mutant extracts is corrected by purified factor b/Ssl2 complex. These results support a direct role of factor b during NER in yeast. Hence, factor b (TFlIH) has a dual role in transcription and NER.	STANFORD UNIV,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305	Stanford University	WANG, ZG (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PATHOL,MOLEC PATHOL LAB,DALLAS,TX 75235, USA.			Svejstrup, Jesper/0000-0003-4964-6147				[Anonymous], 1985, DNA REPAIR; BARDWELL L, IN PESS P NATN ACAD; DOWNES CS, 1993, BIOESSAYS, V15, P209, DOI 10.1002/bies.950150311; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; FUCHS RPP, 1984, EMBO J, V3, P757, DOI 10.1002/j.1460-2075.1984.tb01880.x; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HANSSON J, 1989, J BIOL CHEM, V264, P21788; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; NAEGELI H, 1992, J BIOL CHEM, V267, P392; NAUMOVSKI L, 1986, MOL CELL BIOL, V6, P1218, DOI 10.1128/MCB.6.4.1218; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; Qui H., 1993, GENE DEV, V7, P2161; SANCAR A, 1985, J MOL BIOL, V184, P725, DOI 10.1016/0022-2836(85)90316-X; SWEDER KS, 1994, J BIOL CHEM, V269, P1852; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; TERLETH C, 1991, MUTAGENESIS, V6, P103, DOI 10.1093/mutage/6.2.103; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907; WANG ZG, 1991, J BIOL CHEM, V266, P22472; WANG ZG, 1992, BIOCHEMISTRY-US, V31, P3694, DOI 10.1021/bi00129a019; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463	27	155	156	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					74	76		10.1038/368074a0	http://dx.doi.org/10.1038/368074a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	8107888				2022-12-01	WOS:A1994MY56900057
J	NAKAYAMA, K; NAKAYAMA, K; NEGISHI, I; KUIDA, K; LOUIE, MC; KANAGAWA, O; NAKAUCHI, H; LOH, DY				NAKAYAMA, K; NAKAYAMA, K; NEGISHI, I; KUIDA, K; LOUIE, MC; KANAGAWA, O; NAKAUCHI, H; LOH, DY			REQUIREMENT FOR CD8 BETA-CHAIN IN POSITIVE SELECTION OF CD8-LINEAGE T-CELLS	SCIENCE			English	Article							CLASS-I MOLECULES; MHC CLASS; ALPHA-3 DOMAIN; MOUSE CD8; SURFACE EXPRESSION; LYMPHOCYTES-T; RECEPTOR; GENES; RECOGNITION; THYMOCYTES	CD8 is either an alphaalpha homodimer or an alphabeta heterodimer, although most peripheral CD8-lineage T cells express only the CD8alphabeta heterodimer. The physiological function of CD8beta was elucidated with mice that were chimeric for the homozygous disruption of the CD8beta gene. The CD8beta-/- T cells developed normally to CD4-CD8+ stage, but did not efficiently differentiate further, which resulted in few peripheral CD8+ T cells. The number of peripheral CD8+ T cells was restored by transfer of an exogenous CD8beta gene into CD8beta-deficient T cells. Thus, CD8beta is necessary for the maturation of CD8+ T cells.	WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; INST PHYS & CHEM RES, CELL GROWTH & DIFFERENTIAT LAB, TSUKUBA, IBARAKI 305, JAPAN; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); RIKEN; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NIAID NIH HHS [AI 34580] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034580, U01AI034580] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLANC D, 1988, EUR J IMMUNOL, V18, P613, DOI 10.1002/eji.1830180419; BLUE ML, 1988, CELL, V54, P413, DOI 10.1016/0092-8674(88)90204-8; CHAN IT, 1993, SCIENCE, V261, P1581, DOI 10.1126/science.8372352; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; FUNGLEUNG WP, 1993, EUR J IMMUNOL, V23, P2834, DOI 10.1002/eji.1830231117; FUNGLEUNG WP, 1993, EUR J IMMUNOL, V23, P212, DOI 10.1002/eji.1830230133; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; GORMAN SD, 1988, J IMMUNOL, V140, P3646; KARAKI S, 1992, J IMMUNOL, V149, P1613; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LIN T, 1993, EUR J IMMUNOL, V23, P1968, DOI 10.1002/eji.1830230836; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LOH DY, 1991, NEW BIOL, V3, P924; NAKAUCHI H, 1987, P NATL ACAD SCI USA, V84, P4210, DOI 10.1073/pnas.84.12.4210; NAKAYAMA K, 1993, INT IMMUNOL, V5, P419, DOI 10.1093/intimm/5.4.419; NAKAYAMA K, 1992, SCIENCE, V257, P94, DOI 10.1126/science.1621101; NAKAYAMA K, 1989, J IMMUNOL, V142, P2540; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NAKAYAMA K, 1991, IMMUNOGENETICS, V33, P206, DOI 10.1007/BF01719243; NAKAYAMA K, UNPUB; NAKAYAMA KI, 1992, J IMMUNOL, V148, P1919; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SHERMAN LA, 1992, SCIENCE, V258, P815, DOI 10.1126/science.1439792; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TORRESNAGEL N, 1992, EUR J IMMUNOL, V22, P2841, DOI 10.1002/eji.1830221113; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WHEELER CJ, 1992, NATURE, V357, P247, DOI 10.1038/357247a0	37	113	116	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 25	1994	263	5150					1131	1133		10.1126/science.8108731	http://dx.doi.org/10.1126/science.8108731			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108731				2022-12-01	WOS:A1994MX75900030
J	DECOCK, KM; ZADI, F; ADJORLOLO, G; DIALLO, MO; SASSANMOROKRO, M; EKPINI, E; SIBAILLY, T; DOORLY, R; BATTER, V; BRATTEGAARD, K; GAYLE, H				DECOCK, KM; ZADI, F; ADJORLOLO, G; DIALLO, MO; SASSANMOROKRO, M; EKPINI, E; SIBAILLY, T; DOORLY, R; BATTER, V; BRATTEGAARD, K; GAYLE, H			RETROSPECTIVE STUDY OF MATERNAL HIV-1 AND HIV-2 INFECTIONS AND CHILD SURVIVAL IN ABIDJAN, COTE-DIVOIRE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POLYMERASE CHAIN-REACTION; IVORY-COAST; VERTICAL TRANSMISSION; WEST-AFRICA; PREVALENCE; TYPE-2; AIDS; MORTALITY; INFANTS; BISSAU	Objectives-To compare the effects of maternal HIV-1 and HIV-2 infections on outcome of pregnancy, infant mortality, and child survival, and to measure serological concordance between mothers and children. Design-Retrospective cohort study with cross sectional study of concordance for HIV antibodies. Setting-Hospital, tuberculosis clinic, and maternal and child health centre in Abidjan, Cote d'Ivoire, west Africa. Subjects-986 women who had had a total of 2758 pregnancies since 1980, The last born children of 194 of these women. Main outcome measures-Pregnancy outcomes; mortality for all children born since 1980; and outcome for last born children. Serological concordance between mothers and last born children. Results-Women with HIV-1 and HIV-2 infections had higher rates of spontaneous abortion and stillbirth than uninfected women (86/769 in HIV-1 positive women, 48/421 in HIV-2 positive, 31/234 in dually reactive, and 96/1131 in uninfected). Compared with children born to uninfected mothers (mortality 10.3%), greater proportions of children of HIV-1 positive (20.6%) and dually reactive (20.3%) mothers had died; mortality in children of HIV-2 infected women (13.1%) was not significantly increased. Infant mortalities for the last born children of HIV-1 positive, dually reactive, HTV3 positive, and seronegative women were, respectively, 133, 82, 32, and 40 per 1000 live births. Nine of 77 last born children of HIV-1 positive mothers were concordantly seropositive compared with none of 21 children of HIV-2 infected mothers. Conclusions-Maternal HIV-2 infection has less influence on child survival than infection with HIV-1, probably because of a lower vertical transmission rate.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV HIV AIDS, ATLANTA, GA USA; PROJET RETRO CI, DATA MANAGEMENT SECT, ABIDJAN, COTE IVOIRE; PROJET RETRO CI, LAB SECT, ABIDJAN, COTE IVOIRE	Centers for Disease Control & Prevention - USA								ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1991, AIDS, V5, pS21; DECOCK KM, 1990, AIDS, V4, P443, DOI 10.1097/00002030-199005000-00010; DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013; DECOCK KM, 1989, LANCET, V2, P408; DECOCKKM, 1993, JAMA-J AM MED ASSOC, V270, P2083; DELMISTRO A, 1992, J ACQ IMMUN DEF SYND, V5, P19; GAYLE HD, 1992, J ACQ IMMUN DEF SYND, V5, P513; GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X; GNAORE E, 1989, LANCET, V2, P513; HALSEY NA, 1990, JAMA-J AM MED ASSOC, V264, P2088, DOI 10.1001/jama.264.16.2088; LALLEMANT M, 1989, AIDS, V3, P643, DOI 10.1097/00002030-198910000-00004; MATHERON S, 1990, LANCET, V335, P1103, DOI 10.1016/0140-6736(90)92682-8; MIOTTI PG, 1992, INT J EPIDEMIOL, V21, P792; MIOTTI PG, 1990, AIDS, V4, P733, DOI 10.1097/00002030-199008000-00003; MORGAN G, 1990, AIDS, V4, P879, DOI 10.1097/00002030-199009000-00008; PEETERS M, 1992, LANCET, V340, P339, DOI 10.1016/0140-6736(92)91407-Y; POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; ROSSI P, 1992, J ACQ IMMUN DEF SYND, V5, P1019; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; TEMMERMAN M, 1990, AIDS, V4, P1087, DOI 10.1097/00002030-199011000-00006	25	41	42	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	1994	308	6926					441	443		10.1136/bmj.308.6926.441	http://dx.doi.org/10.1136/bmj.308.6926.441			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW976	8124173	Green Published			2022-12-01	WOS:A1994MW97600020
J	IGARASHI, K; KATAOKA, K; ITOH, K; HAYASHI, N; NISHIZAWA, M; YAMAMOTO, M				IGARASHI, K; KATAOKA, K; ITOH, K; HAYASHI, N; NISHIZAWA, M; YAMAMOTO, M			REGULATION OF TRANSCRIPTION BY DIMERIZATION OF ERYTHROID FACTOR NF-E2 P45 WITH SMALL MAF PROTEINS	NATURE			English	Article							LEUCINE ZIPPERS; MESSENGER-RNA; DNA-BINDING; DIFFERENTIATION; EXPRESSION; PROMOTER; SYNTHASE; CELLS; GENE; FOS	TRANSCRIPTION factor NF-E2 is crucial for regulating erythroid-specific gene expression1. Cloning of the NF-E2 p45 protein has revealed that it contains a basic region-leucine zipper (b-zip) domain which associates with another unidentified protein (of relative molecular mass 18,000) to form functional NF-E2 (ref. 2). We show here that products of the maf proto-oncogene family3-5, MafF, MafG and MafK (the small Maf proteins) which possess a b-zip DNA-binding domain but lack a canonical transactivation domain3, directly control the DNA-binding properties of p45 by heterodimeric association with p45. Whereas homodimers of the small Maf proteins act as negative regulators, heterodimers composed of Maf and p45 support active transcription in vivo. These results indicate that one (or all) of the small Maf proteins is the second constituent chain required for NF-E2 activity, and that negative as well as positive regulation can be achieved through an NF-E2 site, depending on the equilibrium concentrations of p45 and the Maf proteins inside erythroid cells.	TOHOKU UNIV,SCH MED,DEPT BIOCHEM,2-1 SEIRYOMACHI,AOBA KU,SENDAI,MIYAGI 980,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,TOSHIMA KU,TOKYO 170,JAPAN	Tohoku University; Japanese Foundation for Cancer Research			Itoh, Ken/B-9506-2013; Yamamoto, Masayuki/A-4873-2010	Itoh, Ken/0000-0002-5518-0729; Yamamoto, Masayuki/0000-0002-9073-9436; Igarashi, Kazuhiko/0000-0002-2470-2475				AKIYAMA Y, 1974, BIKEN J, V17, P195; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; FUJITA H, 1991, J BIOL CHEM, V266, P17494; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; Maniatis T, 1989, DECONTAMINATION DILU; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	22	403	408	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					568	572		10.1038/367568a0	http://dx.doi.org/10.1038/367568a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	8107826				2022-12-01	WOS:A1994MV86300062
J	ALGAZI, M; ANCELLEPARK, R; ASJO, B; BARIN, F; BARME, M; BARRESINOUSSI, F; BAYLON, H; BENICHOU, J; BENICHOU, G; BEZEAUD, A; BLANCHER, A; BLATTNER, WA; BLOT, P; BOURROUILLOU, G; BOUTTIER, D; BOVEN, B; BRUNET, JB; CADROY, Y; CAEN, J; CAHAN, C; CALVAS, P; CARANOBE, C; CARRELL, RW; CHANZY, M; CHAOUAT, G; CHIODI, F; COLOMBIES, P; COUTINHO, A; DAUSSET, J; DEVINCENTI, I; DEBRE, P; DENIS, F; DESMYTER, J; DEUBEL, V; DEVERGIE, A; DODIN, A; DORE, JF; DREYFUS, JC; DREYFUSBRISAC, C; DUCOS, J; DURAND, H; FENYO, EM; FLEURY, H; FOURNEL, JJ; FROTTIER, J; GAILLARD, J; GALANAUD, P; GARCON, P; GAZZOLO, L; GEORGES, AJ; GEORGESCOURBOT, MC; GIRARD, M; GLUCKMAN, E; GLUCKMAN, JC; GOLDBERG, M; GOUBAU, P; GUILLIN, MC; HERRAULT, A; JENNINGS, M; JUHANVAGUE, I; KANKI, PJ; KAZATCHKINE, M; KIRN, A; KLATZMANN, D; KOHEN, JP; KREIS, H; KRUH, J; LEMINOR, L; LESOURD, G; LIDEREAU, R; LORTHOLARY, P; LOWENSTEIN, W; LOYGUE, J; MARCOVICH, H; MARTY, M; MATHIOT, C; MONODBROCA, P; ORTH, G; DASILVA, LP; PERES, G; PILLOT, J; POLICARD, C; REYNES, J; ROZENBAUM, W; SCARLATTI, G; SCHAISON, G; SCHUPBACH, J; SIE, P; SMILOVICI, W; SOURNIA, JC; TARANTOLA, D; TAVITIAN, A; TEDGUI, A; TESTAS, P; TIOLLAIS, P; ULLMAN, A; WOLLMAN, E; WOLLMAN, A				ALGAZI, M; ANCELLEPARK, R; ASJO, B; BARIN, F; BARME, M; BARRESINOUSSI, F; BAYLON, H; BENICHOU, J; BENICHOU, G; BEZEAUD, A; BLANCHER, A; BLATTNER, WA; BLOT, P; BOURROUILLOU, G; BOUTTIER, D; BOVEN, B; BRUNET, JB; CADROY, Y; CAEN, J; CAHAN, C; CALVAS, P; CARANOBE, C; CARRELL, RW; CHANZY, M; CHAOUAT, G; CHIODI, F; COLOMBIES, P; COUTINHO, A; DAUSSET, J; DEVINCENTI, I; DEBRE, P; DENIS, F; DESMYTER, J; DEUBEL, V; DEVERGIE, A; DODIN, A; DORE, JF; DREYFUS, JC; DREYFUSBRISAC, C; DUCOS, J; DURAND, H; FENYO, EM; FLEURY, H; FOURNEL, JJ; FROTTIER, J; GAILLARD, J; GALANAUD, P; GARCON, P; GAZZOLO, L; GEORGES, AJ; GEORGESCOURBOT, MC; GIRARD, M; GLUCKMAN, E; GLUCKMAN, JC; GOLDBERG, M; GOUBAU, P; GUILLIN, MC; HERRAULT, A; JENNINGS, M; JUHANVAGUE, I; KANKI, PJ; KAZATCHKINE, M; KIRN, A; KLATZMANN, D; KOHEN, JP; KREIS, H; KRUH, J; LEMINOR, L; LESOURD, G; LIDEREAU, R; LORTHOLARY, P; LOWENSTEIN, W; LOYGUE, J; MARCOVICH, H; MARTY, M; MATHIOT, C; MONODBROCA, P; ORTH, G; DASILVA, LP; PERES, G; PILLOT, J; POLICARD, C; REYNES, J; ROZENBAUM, W; SCARLATTI, G; SCHAISON, G; SCHUPBACH, J; SIE, P; SMILOVICI, W; SOURNIA, JC; TARANTOLA, D; TAVITIAN, A; TEDGUI, A; TESTAS, P; TIOLLAIS, P; ULLMAN, A; WOLLMAN, E; WOLLMAN, A			APPEAL TO MITTERRAND IN BLOOD SCANDAL	NATURE			English	Letter													scarlatti, gabriella/H-1482-2018; ORTH, Gérard C/C-2518-2009; eliane, Gluckman/AAA-5024-2021; Barre-Sinoussi, Françoise/G-8355-2011	scarlatti, gabriella/0000-0003-2316-2689; 					0	1	1	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					312	312						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114928				2022-12-01	WOS:A1994MT54000029
J	EDERY, P; LYONNET, S; MULLIGAN, LM; PELET, A; DOW, E; ABEL, L; HOLDER, S; NIHOULFEKETE, C; PONDER, BAJ; MUNNICH, A				EDERY, P; LYONNET, S; MULLIGAN, LM; PELET, A; DOW, E; ABEL, L; HOLDER, S; NIHOULFEKETE, C; PONDER, BAJ; MUNNICH, A			MUTATIONS OF THE RET PROTOONCOGENE IN HIRSCHSPRUNGS-DISEASE	NATURE			English	Article								HIRSCHSPRUNG'S disease (HSCR)1 is a common condition (1 in 5,000 live births) resulting in intestinal obstruction in neonates2 and megacolon in infants and adults3. This disease has been ascribed to the absence of autonomic ganglion cells, which are derived from the neural crest, in the terminal hindgut4. Segregation analyses have suggested incompletely penetrant dominant inheritance in familial HSCR5. Recently, a gene for HSCR has been mapped to chromosome 10q11.2 (refs 6, 7). No recombination was observed between the disease locus and the locus for the RET proto-oncogene8, a protein tyrosine kinase gene expressed in the cells derived from the neural crest9,10. Here we report nonsense and missense mutations in the extracellular domain of RET protein (exons, 2, 3, 5, and 6) in six unrelated probands and show that the mutant genotypes segregate with the disease in HSCR families. Mutations of RET have been previously reported in multiple endocrine neoplasia type 2A (MEN 2A)11,12. Thus, germ-line mutations of the RET gene may contribute either to developmental anomalies in HSCR or to inherited predisposition to cancer in MEN 2A.	HOP NECKER ENFANTS MALAD,CHIRURG INFANTILE CLIN,SERV GENET MED,149 RUE SEVRES,F-75743 PARIS 15,FRANCE; HOP NECKER ENFANTS MALAD,INSERM,U393,UNITE RECH HANDICAPS GENET ENFANT,F-75743 PARIS 15,FRANCE; UNIV CAMBRIDGE,DEPT PATHOL,CRC HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 1QP,ENGLAND; ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND; HOP LA PITIE SALPETRIERE,INSERM,U194,F-75634 PARIS 13,FRANCE; INST CHILD HLTH,MOTHERCARE UNIT CLIN GENET,LONDON WC1N 1EH,ENGLAND	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Cambridge; Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of London; University College London			Dow, Eleanor/A-7927-2012; Abel, Laurent/H-8888-2017; Lyonnet, Stanislas/H-5483-2017	PELET, Anastella/0000-0002-8353-1725; Abel, Laurent/0000-0001-7016-6493; Lyonnet, Stanislas/0000-0001-5426-9417				ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; BADNER JA, 1990, AM J HUM GENET, V46, P568; BODIAN M, 1963, ANN HUM GENET, V26, P261, DOI 10.1111/j.1469-1809.1963.tb01983.x; BOTTANI A, 1991, HUM GENET, V87, P748; COOPER DN, 1990, HUM GENET, V85, P55; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1993, AM J HUM GEMET S, V53, pA996; EMANUEL B, 1965, J PEDIATR-US, V66, P437, DOI 10.1016/S0022-3476(65)80201-3; FEWTRELL MS, IN PRESS J MED GENET; HAYASHI K, 1993, HUM MUTAT, V2, P338, DOI 10.1002/humu.1380020503; Hirschsprung H., 1888, JAHRBUCHF RKINDERHEI, V27, P1; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KWOK JBJ, 1993, ONCOGENE, V8, P2575; LANE PW, 1966, J HERED, V57, P29, DOI 10.1093/oxfordjournals.jhered.a107457; LEDOUARI.NM, 1973, J EMBRYOL EXP MORPH, V30, P31; LESSER PB, 1979, JAMA-J AM MED ASSOC, V242, P747, DOI 10.1001/jama.242.8.747; LIPSON AH, 1987, CLIN GENET, V32, P175; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MARTUCCIELLO G, 1992, PEDIATR SURG INT, V7, P308; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, IN PRESS NATURE GENE; Okamoto E, 1967, J PEDIATR SURG, V2, P437; PASSARGE E, 1972, Birth Defects Original Article Series, V8, P63; PASSARGE E, 1987, NEW ENGL J MED, V276, P138; Polley, 1986, PEDIATR SURG INT, V1, P80, DOI 10.1007/BF00166865; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; WHITEHOUSE FR, 1948, ARCH INTERN MED, V82, P75, DOI 10.1001/archinte.1948.00220250085005	30	639	652	2	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					378	380		10.1038/367378a0	http://dx.doi.org/10.1038/367378a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114939				2022-12-01	WOS:A1994MT54000071
J	SCHUCHARDT, A; DAGATI, V; LARSSONBLOMBERG, L; COSTANTINI, F; PACHNIS, V				SCHUCHARDT, A; DAGATI, V; LARSSONBLOMBERG, L; COSTANTINI, F; PACHNIS, V			DEFECTS IN THE KIDNEY AND ENTERIC NERVOUS-SYSTEM OF MICE LACKING THE TYROSINE KINASE RECEPTOR RET	NATURE			English	Article							MOUSE EMBRYO; PROTEIN; CELLS; DIFFERENTIATION; GENES	RECEPTOR tyrosine kinases (RTKs) are cell-surface molecules that transduce signals for cell growth and differentiation1. The RTK encoded by the c-ret proto-oncogene2-5 is rearranged and constitutively activated in a large proportion of thyroid papillary carcinomas6, and germ-line point mutations in c-ret seem to be responsible for the dominantly inherited cancer syndromes multiple endocrine neoplasia (MEN) types 2A7,8 and B-9. The gene is expressed in the developing central and peripheral nervous systems (sensory, autonomic and enteric ganglia) and the excretory system (Wolffian duct and ureteric bud epithelium) of mice, indicating that it may play a role in normal development5. Here we show that mice homozygous for a targeted mutation in c-ret develop to term, but die soon after birth, showing renal agenesis or severe dysgenesis, and lacking enteric neurons throughout the digestive tract. Ret is thus an essential component of a signalling pathway required for renal organogenesis and enteric neurogenesis.	NATL INST MED RES,GENE STRUCT & EXPRESS LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	MRC National Institute for Medical Research; Columbia University; Columbia University				Pachnis, Vassilis/0000-0001-9733-7686				ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; Bernstein J, 1989, RENAL PATHOLOGY CLIN, P1278; BISHOP AE, 1985, HISTOCHEMISTRY, V82, P93, DOI 10.1007/BF00502095; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CARLSON KM, IN PRESS P NATN ACAD; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ERICKSON RA, 1968, J EXP ZOOL, V169, P33, DOI 10.1002/jez.1401690105; FONTAINEPERUS JC, 1982, CELL DIFFER DEV, V11, P183, DOI 10.1016/0045-6039(82)90065-3; GERSHON MD, 1993, J NEUROBIOL, V24, P199, DOI 10.1002/neu.480240207; GROBSTEIN C, 1953, SCIENCE, V118, P52, DOI 10.1126/science.118.3054.52; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEDOUARI.NM, 1973, J EMBRYOL EXP MORPH, V30, P31; LEDOUARIN NM, 1975, P NATL ACAD SCI USA, V72, P728; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROODHOOFT M, 1984, NEW ENGL J MED, V310, P1341, DOI 10.1056/NEJM198405243102101; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TROY CM, 1990, NEUROSCIENCE, V36, P217, DOI 10.1016/0306-4522(90)90364-A; WHITEHOUSE FR, 1948, ARCH INTERN MED, V82, P75, DOI 10.1001/archinte.1948.00220250085005; WILSON RD, 1985, AM J MED GENET, V21, P153, DOI 10.1002/ajmg.1320210123; YIN L, IN PRESS HUMAN MOL G; YNTEMA CL, 1954, J COMP NEUROL, V101, P515, DOI 10.1002/cne.901010212	34	1313	1350	2	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					380	383		10.1038/367380a0	http://dx.doi.org/10.1038/367380a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114940				2022-12-01	WOS:A1994MT54000072
J	HANKINSON, SE; HUNTER, DJ; COLDITZ, GA; WILLETT, WC; STAMPFER, MJ; ROSNER, B; HENNEKENS, CH; SPEIZER, FE				HANKINSON, SE; HUNTER, DJ; COLDITZ, GA; WILLETT, WC; STAMPFER, MJ; ROSNER, B; HENNEKENS, CH; SPEIZER, FE			TUBAL-LIGATION, HYSTERECTOMY, AND RISK OF OVARIAN-CANCER - A PROSPECTIVE-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STERILIZATION; TALC	Objective.-To assess whether tubal ligation and hysterectomy affect subsequent risk of ovarian cancer. Design.-Prospective cohort study with 12 years of follow-up. Setting.-United States, multistate. Participants.-A total of 121 700 female registered nurses who were 30 to 55 years of age in 1976; the follow-up rate was 90% as of 1988. Main Outcome Measure.-Ovarian cancer of epithelial origin confirmed by medical record review. Results.-We observed a strong inverse association between tubal ligation and ovarian cancer, which persisted after adjustment for age, oral contraceptive use, parity, and other ovarian cancer risk factors (multivariate relative risk [RR], 0.33; 95% confidence interval [CI], 0.16 to 0.64). The association was similar when we assessed tubal ligation status at the baseline questionnaire and excluded cases in the first 4 years to eliminate any possible short-term decrease in risk due to screening of the ovaries during ligation surgery. We noted a weaker inverse association between simple hysterectomy and ovarian cancer (RR, 0.67; 95% CI, 0.45 to 1.00). Neither vasectomy nor condom use by a partner was associated with risk of ovarian cancer. Conclusions.-These data indicate that tubal ligation, and perhaps hysterectomy, may substantially reduce risk of epithelial ovarian cancer.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	HANKINSON, SE (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356, 5T32CA09001] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356, T32CA009001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZSANCHEZ F, 1981, FERTIL STERIL, V36, P606; ANNEGERS JF, 1979, CANCER, V43, P723, DOI 10.1002/1097-0142(197902)43:2<723::AID-CNCR2820430248>3.0.CO;2-1; BACHMANN GA, 1990, J REPROD MED, V35, P839; BOOTH M, 1989, BRIT J CANCER, V60, P592, DOI 10.1038/bjc.1989.320; CATTANACH J, 1985, LANCET, V1, P847; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; CORSON SL, 1981, J REPROD MED, V26, P333; COX DR, 1972, J R STAT SOC B, V34, P187; CRAMER DW, 1982, CANCER-AM CANCER SOC, V50, P372, DOI 10.1002/1097-0142(19820715)50:2<372::AID-CNCR2820500235>3.0.CO;2-S; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DESTEFANO F, 1983, OBSTET GYNECOL, V62, P673; DESTEFANO F, 1985, AM J OBSTET GYNECOL, V152, P835, DOI 10.1016/S0002-9378(85)80073-9; DONNEZ J, 1981, OBSTET GYNECOL, V57, P65; DOYLE LL, 1971, AM J OBSTET GYNECOL, V110, P92, DOI 10.1016/0002-9378(71)90221-3; EGLI GE, 1961, FERTIL STERIL, V12, P151; FATHALLA MF, 1971, LANCET, V2, P163; HANKINSON SE, 1992, OBSTET GYNECOL, V80, P708; HARTGE P, 1988, AM J EPIDEMIOL, V127, P990, DOI 10.1093/oxfordjournals.aje.a114902; HELM G, 1983, ACTA OBSTET GYN SCAN, V62, P63, DOI 10.3109/00016348309155761; HENDERSON WJ, 1979, LANCET, V1, P499; HUGGINS GR, 1984, FERTIL STERIL, V41, P337; IRWIN KL, 1991, AM J EPIDEMIOL, V134, P362, DOI 10.1093/oxfordjournals.aje.a116098; JANSON PO, 1977, AM J OBSTET GYNECOL, V127, P349; KOCH M, 1984, CANCER DETECT PREV, V7, P241; KOCH M, 1988, CANCER DETECT PREV, V13, P131; MCGOWAN L, 1979, GYNECOL ONCOL, V7, P325, DOI 10.1016/0090-8258(79)90111-2; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MORI M, 1988, AM J EPIDEMIOL, V128, P771, DOI 10.1093/oxfordjournals.aje.a115030; Moses V I, 1983, MMWR CDC Surveill Summ, V32, p9SS; RADWANSKA E, 1979, OBSTET GYNECOL, V54, P189; RADWANSKA E, 1982, J REPROD MED, V27, P376; RIVERA R, 1989, CONTRACEPTION, V40, P157, DOI 10.1016/0010-7824(89)90003-6; RULIN MC, 1989, OBSTET GYNECOL, V74, P149; SCOTTENFELD D, 1982, CANCER EPIDEMIOL, P871; SHU XO, 1989, CANCER RES, V49, P3670; SIMON WE, 1983, J NATL CANCER I, V70, P839; SORENSEN T, 1981, ACTA OBSTET GYN SCAN, V60, P559, DOI 10.3109/00016348109155486; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STEIN KF, 1949, ANAT REC, V82, P1; STONE SC, 1975, AM J OBSTET GYNECOL, V121, P193, DOI 10.1016/0002-9378(75)90638-9; WEISS NS, 1986, AM J EPIDEMIOL, V124, P856, DOI 10.1093/oxfordjournals.aje.a114463; WHITTEMORE AS, 1988, AM J EPIDEMIOL, V128, P1228, DOI 10.1093/oxfordjournals.aje.a115077; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; WYNDER EL, 1969, CANCER, V23, P352, DOI 10.1002/1097-0142(196902)23:2<352::AID-CNCR2820230212>3.0.CO;2-4; 1990, NIH902789 US DEP HLT, P128	47	235	247	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2813	2818		10.1001/jama.270.23.2813	http://dx.doi.org/10.1001/jama.270.23.2813			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK941	8133619				2022-12-01	WOS:A1993MK94100029
J	KARLSTROM, E; ABEL, GG				KARLSTROM, E; ABEL, GG			BIOFEEDBACK FOR MUSCULOSKELETAL PAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											KARLSTROM, E (corresponding author), BEHAV MED INST ATLANTA,ATLANTA,GA, USA.							FOGEL ER, 1987, BIOFEEDBACK PRACTITI, P390; SHERMAN PA, 1991, AM PAIN SOC B, V1, P11; SHERMAN RA, 1992, SPINAL MANIPULATIVE, P177	3	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2736	2736		10.1001/jama.270.22.2736	http://dx.doi.org/10.1001/jama.270.22.2736			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133597				2022-12-01	WOS:A1993MJ82100039
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW LABEL WOULD ADVISE CONSUMERS TO CONSULT PHYSICIAN BEFORE TAKING ASPIRIN FOR THE HEART	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1993, FED REGISTER, V58, P54224	1	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2669	2669						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MJ821	8133573				2022-12-01	WOS:A1993MJ82100004
J	GREENWOOD, D				GREENWOOD, D			LACKING BLOOD FOR CULTURE	LANCET			English	Editorial Material							BACTEREMIA				GREENWOOD, D (corresponding author), UNIV NOTTINGHAM HOSP,DEPT MICROBIOL,NOTTINGHAM NG7 2UH,ENGLAND.							ISPAHANI P, 1989, MED LAB SCI, V46, P295; ISPAHANI P, 1987, Q J MED, V63, P427; MERMEL LA, 1993, ANN INTERN MED, V119, P270, DOI 10.7326/0003-4819-119-4-199308150-00003; Pulvertaft RJV, 1930, LANCET, V1, P821; SHANSON DC, 1984, J CLIN PATHOL, V37, P568, DOI 10.1136/jcp.37.5.568; SHANSON DC, 1989, SEPTICAEMIA ENDOCARD; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P54	7	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1006	1006		10.1016/0140-6736(93)92875-T	http://dx.doi.org/10.1016/0140-6736(93)92875-T			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105261				2022-12-01	WOS:A1993MD06600006
J	MACMILLAN, JC; SNELL, RG; TYLER, A; HOULIHAN, GD; FENTON, I; CHEADLE, JP; LAZAROU, LP; SHAW, DJ; HARPER, PS				MACMILLAN, JC; SNELL, RG; TYLER, A; HOULIHAN, GD; FENTON, I; CHEADLE, JP; LAZAROU, LP; SHAW, DJ; HARPER, PS			MOLECULAR ANALYSIS AND CLINICAL CORRELATIONS OF THE HUNTINGTONS-DISEASE MUTATION	LANCET			English	Article							MYOTONIC-DYSTROPHY; ANTICIPATION; REPEAT	The genetic mutation underlying Huntington's disease (HD) has been identified as an expansion and instability of a specific CAG repeat sequence in a gene (IT15) on chromosome 4. We have investigated the relation of the phenotype of HD to this molecular defect and assessed the feasibility of HD mutation analysis in diagnosis and prediction. Analysis of DNA from 449 HD patients (351 familial and 98 apparently isolated cases) revealed the mutation in more than 95% of patients from both groups. No molecular difference was found between patients presenting with psychiatric symptoms and those in whom chorea or other motor defects were the principal features; additionally, there was a wide range of age at onset for any specific repeat number, though the small group with juvenile onset and presenting with rigidity showed the largest expansions. The findings suggest that molecular analysis will be an accurate and specific diagnostic test for HD and valuable in presymptomatic detection in individuals at risk. However, such testing will require considerable caution to avoid serious difficulties; the well-established guidelines developed for the use of linked markers in relation to the prediction of HD should continue to be followed, though they will require reassessment in relation to use in diagnosis.	UNIV WALES COLL MED, INST MED GENET, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University			MacMillan, John C/C-9591-2011	Snell, Russell/0000-0002-8166-4014	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CRAUFURD D, 1992, J MED GENET, V29, P915, DOI 10.1136/jmg.29.12.915; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HARLEY HG, 1992, LANCET, V339, P1125, DOI 10.1016/0140-6736(92)90729-M; HARPER PS, 1992, AM J HUM GENET, V51, P10; Harper PS, 1991, HUNTINGTONS DISEASE; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; QUARRELL OWJ, 1988, J MED GENET, V25, P191, DOI 10.1136/jmg.25.3.191; QUARRELL OWJ, 1986, CLIN GENET, V30, P433; RIDLEY RM, 1991, J MED GENET, V28, P224, DOI 10.1136/jmg.28.4.224; SHAW DJ, 1992, NEUROMUSCULAR DISORD, V2, P241, DOI 10.1016/0960-8966(92)90055-B; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; VANDIJK JG, 1986, HUM GENET, V73, P235, DOI 10.1007/BF00401235; WENT L, 1990, J MED GENET, V27, P34, DOI 10.1136/jmg.27.1.34	16	84	89	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1993	342	8877					954	958		10.1016/0140-6736(93)92002-B	http://dx.doi.org/10.1016/0140-6736(93)92002-B			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105214				2022-12-01	WOS:A1993MC00500009
J	ALMIND, K; BJORBAEK, C; VESTERGAARD, H; HANSEN, T; ECHWALD, S; PEDERSEN, O				ALMIND, K; BJORBAEK, C; VESTERGAARD, H; HANSEN, T; ECHWALD, S; PEDERSEN, O			AMINO-ACID POLYMORPHISMS OF INSULIN-RECEPTOR SUBSTRATE-1 IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Article							C-PEPTIDE; PROTEIN; GLUCOSE; EXPRESSION; GENETICS; MUSCLE; NIDDM; SERUM; RNA	Since relative or absolute insulin deficiency and insulin insensitivity are involved in the aetiology of non-insulin-dependent diabetes mellitus (NIDDM), we examined whether patients with NIDDM exhibit genetic variability in the coding region of insulin receptor substrate-1 (IRS-1), a candidate gene that is ubiquitous in insulin-sensitive and insulin-like growth factor 1 (IGF1) sensitive tissues, including those that determine glucose production and clearance and those with regulatory effects on pancreatic beta-cell function. IRS-1 has a central role as an adaptor molecule that links the insulin-receptor and IGF1-receptor kinases with enzymes that regulate cellular metabolism and growth. Single-stranded conformation polymorphism analysis and direct nucleotide sequencing were applied to genomic DNA from 86 unrelated patients with NIDDM and 76 normoglycaemic controls. 10 of the patients with NIDDM and 3 of the controls were heterozygous at codon 972 for a polymorphism in which glycine was substituted with arginine. Moreover, at codon 513, 6 patients with NIDDM and 2 controls had a heterozygous polymorphism with a transition from alanine to proline. None of the polymorphism carriers had both aminoacid variants and the total allelic frequency of IRS-1 polymorphisms was about three times higher in patients with NIDDM than in controls (p=0.02). Both aminoacid substitutions were located close to tyrosine phosphorylation motifs that are putative recognition sites for insulin and IGF1 signal transmission proteins. Analysis of the phenotypes showed that patients with NIDDM who had IRS-1 variants did not differ in their degree of insulin resistance compared with patients without known IRS-1 polymorphisms. However, carriers of the codon 972 variant had significantly lower plasma levels of fasting insulin and C-peptide. Our results suggest that aminoacid polymorphisms in IRS-1 may be involved in the aetiology of a subset of late-onset NIDDM.	STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK; HAGEDORN RES INST,DK-2820 GENTOFTE,DENMARK	Steno Diabetes Center; Novo Nordisk; Hagedorn Research Institute			Pedersen, Oluf/Z-1731-2019; Pedersen, Oluf/AAG-8015-2020; Bjorbaek, Christian/S-4727-2019	Pedersen, Oluf/0000-0002-3321-3972; Vestergaard, Henrik/0000-0003-3090-269X; Hansen, Torben/0000-0001-8748-3831				CERASI E, 1972, DIABETES, V21, P224, DOI 10.2337/diab.21.4.224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAMSGAARD EM, 1987, DIABETES CARE, V10, P26, DOI 10.2337/diacare.10.1.26; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HEDING LG, 1975, DIABETOLOGIA, V11, P541, DOI 10.1007/BF01222104; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; HITMAN GA, 1991, BAILLIERE CLIN ENDOC, V5, P455, DOI 10.1016/S0950-351X(05)80142-9; HOLLENBECK C, 1987, J CLIN ENDOCR METAB, V64, P1169, DOI 10.1210/jcem-64-6-1169; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAYLOR SI, 1991, J CLIN ENDOCR METAB, V73, P1158, DOI 10.1210/jcem-73-6-1158; VESTERGAARD H, 1991, DIABETES, V40, P1740, DOI 10.2337/diabetes.40.12.1740; 1979, DIABETES, V28, P1039	22	302	316	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					828	832		10.1016/0140-6736(93)92694-O	http://dx.doi.org/10.1016/0140-6736(93)92694-O			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104271				2022-12-01	WOS:A1993MA02500008
J	HAMILTON, JA				HAMILTON, JA			RHEUMATOID-ARTHRITIS - OPPOSING ACTIONS OF HEMATOPOIETIC GROWTH-FACTORS AND SLOW-ACTING ANTIRHEUMATIC DRUGS	LANCET			English	Article							COLONY-STIMULATING FACTOR; CHRONIC INFLAMMATORY ARTHRITIS; TUMOR-NECROSIS-FACTOR; BONE-MARROW ADJACENT; D-PENICILLAMINE; GM-CSF; FACTOR-ALPHA; GOLD SALTS; CELLS; INTERLEUKIN-1	The pathogenesis of rheumatoid arthritis and the mode of action of anti-rheumatic drugs are unknown. This hypothesis proposes that haemopoietic growth factors (colony stimulating factors [CSFs]) have an important role in rheumatoid arthritis as regulators of myelopoiesis and as activators of inflammatory leucocytes. It also suggests that slow-acting anti-rheumatic drugs may work by inhibiting myelopoiesis. This opposition to one of the actions of the CSFs would result in fewer inflammatory cells in the inflamed joints.			HAMILTON, JA (corresponding author), UNIV MELBOURNE, ROYAL MELBOURNE HOSP, DEPT MED, PARKVILLE, VIC 3050, AUSTRALIA.			Hamilton, John A/0000-0002-9493-9224				ABD AHA, 1991, LYMPHOKINE CYTOK RES, V10, P43; ALLISON AC, IN PRESS AG ACT; ALVAROGRACIA JM, 1991, J IMMUNOL, V146, P3365; BRANDES ME, 1991, J CLIN INVEST, V87, P1108, DOI 10.1172/JCI115073; BUCHAN GS, 1985, J LEUKOCYTE BIOL, V37, P221, DOI 10.1002/jlb.37.2.221; CAMPBELL IK, 1991, J IMMUNOL, V147, P1238; CAMPBELL IK, IN PRESS BIOCH BIOPH; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; DREHER R, 1986, IMMUN INFEKT, V14, P100; FIRESTEIN GS, 1988, J EXP MED, V168, P1573, DOI 10.1084/jem.168.5.1573; FIRESTEIN GS, 1990, ARTHRITIS RHEUM, V33, P768, DOI 10.1002/art.1780330602; GERATZ JD, 1988, ARTHRITIS RHEUM, V31, P1156; HAMILTON JA, 1993, IMMUNOL TODAY, V14, P18, DOI 10.1016/0167-5699(93)90319-G; HAMILTON JA, 1991, J RHEUMATOL, V18, P106; HAMILTON JA, 1985, J RHEUMATOL, V12, P892; HAMILTON JA, 1987, J RHEUMATOL, V14, P216; HAMILTON JA, IN PRESS GROWTH FACT; HAYASHIDA K, 1992, ARTHRITIS RHEUM, V35, P241, DOI 10.1002/art.1780350219; HAZENBERG BPC, 1989, BLOOD, V74, P2769, DOI 10.1182/blood.V74.8.2769.2769; HOWELL A, 1975, BRIT MED J, V1, P432, DOI 10.1136/bmj.1.5955.432; KAY AGL, 1979, ANN RHEUM DIS, V38, P232, DOI 10.1136/ard.38.3.232; KAY AGL, 1976, BRIT MED J, V1, P1266, DOI 10.1136/bmj.1.6020.1266; KOTAKE S, 1992, J RHEUMATOL, V19, P1511; KUIPERS EJ, 1992, J RHEUMATOL, V19, P621; LEIZER T, 1990, BLOOD, V76, P1989, DOI 10.1182/blood.V76.10.1989.1989; LIPSKY PE, 1989, SPRINGER SEMIN IMMUN, V11, P123; LIPSKY PE, 1982, ADV INFLAMMAT RES, V3, P219; LOWENTHAL RM, 1993, J RHEUMATOL, V20, P137; METCALF D, 1987, EXP HEMATOL, V15, P1; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; OCHI T, 1988, J RHEUMATOL, V15, P1609; OWAKI H, 1989, J RHEUMATOL, V16, P572; SEITZ M, 1982, CLIN IMMUNOL IMMUNOP, V25, P405, DOI 10.1016/0090-1229(82)90205-7; SEITZ M, 1992, J RHEUMATOL, V19, P1038; THOMAS D, 1984, ANN RHEUM DIS, V43, P402, DOI 10.1136/ard.43.3.402; VERNONROBERTS B, 1979, J RHEUMATOL, V6, P120; WIKTORJEDRZEJCZAK W, 1991, EXP HEMATOL, V19, P1049; XU WD, 1989, J CLIN INVEST, V83, P876, DOI 10.1172/JCI113971; YANNI G, 1992, ARTHRITIS RHEUM, V35, pS108; ZSEBO KM, 1988, BLOOD, V71, P99	40	93	98	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1993	342	8870					536	539		10.1016/0140-6736(93)91653-4	http://dx.doi.org/10.1016/0140-6736(93)91653-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102674				2022-12-01	WOS:A1993LU58200016
J	HARRISON, P				HARRISON, P			ANTISENSE - INTO THE BRAIN	LANCET			English	Editorial Material							EXPRESSION; INVIVO		RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary	HARRISON, P (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7J,ENGLAND.			Harrison, Paul/0000-0002-6719-1126				Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2; CHIASSON BJ, 1992, EUR J PHARM-MOLEC PH, V227, P451, DOI 10.1016/0922-4106(92)90167-T; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; JIRIKOWSKI GF, 1992, SCIENCE, V255, P996, DOI 10.1126/science.1546298; PRUSINER SB, 1992, CURR OPINION NEUROBI, V5, P638; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; WAHLESTEDT C, 1993, SCIENCE, V259, P528, DOI 10.1126/science.8380941; WHITESELL L, 1993, P NATL ACAD SCI USA, V90, P4665, DOI 10.1073/pnas.90.10.4665; 1991, LANCET, V338, P1427	11	9	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					254	255		10.1016/0140-6736(93)91812-Z	http://dx.doi.org/10.1016/0140-6736(93)91812-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101297				2022-12-01	WOS:A1993LQ16300005
J	DURANDZALESKI, I; RYMER, JC; ROUDOTTHORAVAL, F; REVUZ, J; ROSA, J				DURANDZALESKI, I; RYMER, JC; ROUDOTTHORAVAL, F; REVUZ, J; ROSA, J			REDUCING UNNECESSARY LABORATORY USE WITH NEW TEST REQUEST FORM - EXAMPLE OF TUMOR-MARKERS	LANCET			English	Article							CLINICAL DECISION-MAKING; TEST-ORDERING BEHAVIOR; CONTROLLED TRIAL; COST; STRATEGIES; EDUCATION; PHYSICIANS; FAILURE; MODIFY	To limit the ordering of serum tumour marker tests that are clinically irrelevant, we designed a new request form. This is a matrix of boxes, rows being individual markers and columns body organs. The box at the intersection of line and column is colour-coded to indicate whether the test is appropriate or not. These ratings were allocated on the basis of published data and local consensus. This new form replaced the form in use at our hospital at the beginning of 1992, and resulted in a 25% decrease in the ordering of tumour markers. Adapting the design of the test request form is a low-cost intervention that combines both economic and clinical requirements in reducing the prescription of tests that are useless in a given clinical situation.	HOP HENRI MONDOR,DEPT BIOCHEM,F-94010 CRETEIL,FRANCE; HOP HENRI MONDOR,DERMATOL SERV,F-94010 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	DURANDZALESKI, I (corresponding author), HOP HENRI MONDOR,PUBL HLTH SERV,51 AVE MARECHAL DE LATTRE DE TASSIGNY,F-94010 CRETEIL,FRANCE.							BATES SE, 1991, ANN INTERN MED, V115, P623, DOI 10.7326/0003-4819-115-8-623; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; DAVIDOFF F, 1989, MED CARE, V27, P45, DOI 10.1097/00005650-198901000-00005; DEVINE GW, 1989, J GEN INTERN MED, V7, P623; EVERITT DE, 1990, INFECT CONT HOSP EP, V11, P578; FOWKES FGR, 1986, BRIT MED J, V292, P883, DOI 10.1136/bmj.292.6524.883; FRASER CG, 1987, ANN CLIN BIOCHEM, V24, P223, DOI 10.1177/000456328702400301; GOLDMAN L, 1990, NEW ENGL J MED, V322, P1524, DOI 10.1056/NEJM199005243222110; GORTMAKER SL, 1988, MED CARE, V26, P631, DOI 10.1097/00005650-198806000-00011; GRINER PF, 1982, NEW ENGL J MED, V307, P1336, DOI 10.1056/NEJM198211183072109; GRINER PF, 1979, ANN INTERN MED, V90, P243, DOI 10.7326/0003-4819-90-2-243; GROSSMAN RM, 1983, MED CARE, V21, P783, DOI 10.1097/00005650-198308000-00003; HARRINGTON JT, 1985, NEW ENGL J MED, V312, P785; HENDERSON AR, 1982, J CLIN PATHOL, V35, P986, DOI 10.1136/jcp.35.9.986; HERSHEY JC, 1987, MED DECIS MAKING, V7, P212, DOI 10.1177/0272989X8700700403; KASSIRER JP, 1986, JAMA-J AM MED ASSOC, V256, P256, DOI 10.1001/jama.256.2.256; LEPAGE EF, 1992, TRANSFUSION, V32, P253, DOI 10.1046/j.1537-2995.1992.32392213810.x; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; SCHROEDER S, 1973, JAMA-J AM MED ASSOC, V225, P996; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P225, DOI 10.1001/jama.252.2.225; SILVER H, 1992, TRANSFUSION, V32, P260, DOI 10.1046/j.1537-2995.1992.32392213811.x; SOMERAI SB, 1990, QUAL ASSUR HLTH CARE, V2, P37; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; WICKENNS R, 1992, BMJ, V304, P1093; WONES RG, 1987, MED CARE, V25, P78, DOI 10.1097/00005650-198701000-00009; WONG ET, 1983, JAMA-J AM MED ASSOC, V249, P3076, DOI 10.1001/jama.249.22.3076; WONG ET, 1983, JAMA-J AM MED ASSOC, V250, P2510, DOI 10.1001/jama.250.18.2510; YOUNG D, 1981, BMJ, V282, P1610; ZAAT JOM, 1992, MED CARE, V30, P189, DOI 10.1097/00005650-199203000-00001	31	56	56	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					150	153		10.1016/0140-6736(93)91349-Q	http://dx.doi.org/10.1016/0140-6736(93)91349-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101259				2022-12-01	WOS:A1993LN04200015
J	LARSEN, GC; STUPEY, MR; WALANCE, CG; GRIFFITH, KK; CUTLER, JE; KRON, J; MCANULTY, JH				LARSEN, GC; STUPEY, MR; WALANCE, CG; GRIFFITH, KK; CUTLER, JE; KRON, J; MCANULTY, JH			RECURRENT CARDIAC EVENTS IN SURVIVORS OF VENTRICULAR-FIBRILLATION OR TACHYCARDIA - IMPLICATIONS FOR DRIVING RESTRICTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; MORTALITY	Objective-To determine when survivors of ventricular tachycardia (VT) or ventricular fibrillation (VF) might most safely return to driving. Design.-Consecutive case series of 501 VT and VF survivors discharged alive between August 1978 and October 1989 and followed from 0 to 117 months (mean, 26 months). Setting.-Cardiac arrhythmia service of a university hospital. Patients.-The study group comprised 290 consecutive patients with sustained VT and 211 patients with VF who underwent electrophysiological studies and were discharged alive (78% male; mean age, 59 years). The mean ejection fraction (available in 338 patients) was 0.42. Interventions-Antiarrhythmic drug testing for all patients was guided by serial electrophysiological testing. Overall, 227 patients (45%) were discharged on conventional antiarrhythmic agents, 115 (23%) on amiodarone, 39 (8%) received an implantable defibrillator, and 120 (24%) received no specific antiarrhythmic therapy. Main Outcome Measures.-Main outcomes included any event that could hamper a patient's ability to operate a motor vehicle. Specifically, these events included recurrent VF, poorly tolerated, hemodynamically unstable VT, syncope, sudden cardiac death, and implantable defibrillator discharge. Results.-Event risks were assessed during the first year after hospital discharge because that is when most patients decide whether to begin driving again. The 1-year outcome event rate for all 501 patients was 17%. Three distinct periods of risk were identified. The monthly hazard rate was highest in the first month after hospital discharge (4.22% per month), intermediate in months 2 through 7 (1.81% per month), and lowest in months 8 through 12 (0.63% per month). The 191 patients for whom no successful conventional antiarrhythmic drug could be found during electrophysiological testing experienced a persistently high monthly event risk (1.6%) during months 8 through 12. Conclusions.-All survivors of VT or VF should refrain from driving during the first month after hospital discharge when the hazard for events that could impair their ability to drive is greatest. Our data would support restricting driving for most patients until the eighth month after hospital discharge, when risk becomes lowest. Restriction might be lengthened in patients for whom electrophysiological testing finds no satisfactory conventional antiarrhythmic agent because their risk remains higher than average even after 7 months. Individualized recommendations should be allowed because the accident rate for patients who actually suffer sudden death is low.	OREGON HLTH SCI UNIV,DEPT MED,DIV CARDIOL,ARRHYTHMIA SERV,PORTLAND,OR 97201	Oregon Health & Science University	LARSEN, GC (corresponding author), VET AFFAIRS MED CTR,CARDIOL SECT 111B,PORTLAND,OR 97201, USA.							BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; Cox DR., 1984, ANAL SURVIVAL DATA; DENNISS AR, 1986, CIRCULATION, V74, P731, DOI 10.1161/01.CIR.74.4.731; DICARLO LA, 1992, PACE, V15, P1131, DOI 10.1111/j.1540-8159.1992.tb03115.x; DIXON WJ, 1988, BMDP STATISTICAL SOF; FINCH NJ, 1993, JAMA-J AM MED ASSOC, V270, P1587, DOI 10.1001/jama.270.13.1587; FURUKAWA T, 1989, CIRCULATION, V80, P599, DOI 10.1161/01.CIR.80.3.599; KERWIN AJ, 1984, CAN MED ASSOC J, V131, P312; MASON JW, 1993, NEW ENGL J MED, V329, P445, DOI 10.1056/NEJM199308123290701; MYERBURG RJ, 1992, CIRCULATION, V85, P2; MYERBURG RJ, 1964, AM HEART J, V68, P586, DOI 10.1016/0002-8703(64)90266-2; OLSSON G, 1985, J AM COLL CARDIOL, V5, P1428, DOI 10.1016/S0735-1097(85)80360-0; STRICKBERGER SA, 1991, ANN INTERN MED, V115, P560, DOI 10.7326/0003-4819-115-7-560; 1989, OREGON DRIVERS 1989; 1982, JAMA-J AM MED ASSOC, V247, P1707; 1981, NEW ENGL J MED, V304, P801	16	49	50	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	1994	271	17					1335	1339		10.1001/jama.271.17.1335	http://dx.doi.org/10.1001/jama.271.17.1335			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH487	8158818				2022-12-01	WOS:A1994NH48700025
J	JARDETZKY, TS; BROWN, JH; GORGA, JC; STERN, LJ; URBAN, RG; CHI, YI; STAUFFACHER, C; STROMINGER, JL; WILEY, DC				JARDETZKY, TS; BROWN, JH; GORGA, JC; STERN, LJ; URBAN, RG; CHI, YI; STAUFFACHER, C; STROMINGER, JL; WILEY, DC			3-DIMENSIONAL STRUCTURE OF A HUMAN CLASS-II HISTOCOMPATIBILITY MOLECULE COMPLEXED WITH SUPERANTIGEN	NATURE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-B; SHOCK SYNDROME TOXIN-1; RECEPTOR BETA-CHAIN; HIGH-AFFINITY BINDING; T-CELL RECOGNITION; HLA-DR; V-BETA; ALPHA; IDENTIFICATION; POLYMORPHISM	The structure of a bacterial superantigen, Staphylococcus aureus enterotoxin B, bound to a human class II histocompatibility complex molecule (HLA-DR1) has been determined by X-ray crystallography. The superantigen binds as an intact protein outside the conventional peptide antigen-binding site of the class II major histocompatibility complex (MHC) molecule. No large conformational changes occur upon complex formation in either the DR1 or the enterotoxin B molecules. The structure of the complex helps explain how different class II molecules and superantigens associate and suggests a model for ternary complex formation with the T-cell antigen receptor (TCR), in which unconventional TCR-MHC contacts are possible.	HARVARD UNIV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA; BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02154 USA; CHILDRENS HOSP PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15213 USA; PURDUE UNIV, DEPT BIOL, W LAFAYETTE, IN 47907 USA	Harvard University; Howard Hughes Medical Institute; Brandeis University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Purdue University System; Purdue University; Purdue University West Lafayette Campus								ACHARYA KR, 1994, NATURE, V367, P94, DOI 10.1038/367094a0; BLACKMAN MA, 1993, J IMMUNOL, V151, P556; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRAUNSTEIN NS, 1992, J EXP MED, V175, P1301, DOI 10.1084/jem.175.5.1301; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUELOW R, 1992, J IMMUNOL, V148, P1; CAZENAVE PA, 1990, CELL, V63, P717, DOI 10.1016/0092-8674(90)90138-5; CCP4, 1979, CCP4 SUITE PROGRAMS; CHINTAGUMPALA MM, 1991, J IMMUNOL, V147, P3876; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; FRASER JD, 1993, RES IMMUNOL, V144, P188, DOI 10.1016/0923-2494(93)80116-G; GASCOIGNE NR, 1993, J SEMIN IMMUN, V5, P13; GASCOIGNE NRJ, 1991, P NATL ACAD SCI USA, V88, P613, DOI 10.1073/pnas.88.2.613; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GROSSMAN D, 1991, J IMMUNOL, V147, P3274; HARRIS TO, 1993, INFECT IMMUN, V61, P3175, DOI 10.1128/IAI.61.8.3175-3183.1993; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HERMAN A, 1991, P NATL ACAD SCI USA, V88, P9954, DOI 10.1073/pnas.88.22.9954; HERRMANN T, 1990, J IMMUNOL, V144, P1181; HERRMANN T, 1989, EUR J IMMUNOL, V19, P2171, DOI 10.1002/eji.1830191131; HUDSON KR, 1993, J EXP MED, V177, P175, DOI 10.1084/jem.177.1.175; IRWIN MJ, 1993, IMMUNOL REV, V131, P61, DOI 10.1111/j.1600-065X.1993.tb01530.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KAPPLER JW, 1992, J EXP MED, V175, P387, DOI 10.1084/jem.175.2.387; KARP DR, 1992, J EXP MED, V175, P415, DOI 10.1084/jem.175.2.415; KARP DR, 1990, NATURE, V346, P474, DOI 10.1038/346474a0; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARRACK P, 1993, IMMUNOL REV, V131, P79, DOI 10.1111/j.1600-065X.1993.tb01531.x; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; Micusan V V, 1993, Semin Immunol, V5, P3, DOI 10.1006/smim.1993.1002; MIETHKE T, 1992, J EXP MED, V175, P91, DOI 10.1084/jem.175.1.91; MOLLICK JA, 1991, J IMMUNOL, V146, P463; MOLLICK JA, 1993, J EXP MED, V177, P283, DOI 10.1084/jem.177.2.283; NAVAZA J, 1987, ACTA CRYSTALLOGR A, V43, P645, DOI 10.1107/S0108767387098787; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; PANINABORDIGNON P, 1992, J EXP MED, V176, P1779, DOI 10.1084/jem.176.6.1779; PRASAD GS, 1993, BIOCHEMISTRY-US, V32, P13762, DOI 10.1021/bi00213a001; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1991, J EXP MED, V173, P1183, DOI 10.1084/jem.173.5.1183; SCHOLL PR, 1990, J IMMUNOL, V144, P226; SCHOLL PR, 1989, J IMMUNOL, V143, P2583; SMITH HP, 1992, J IMMUNOL, V149, P887; SOOS JM, 1993, J IMMUNOL, V150, pA192; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; THIBODEAU J, 1994, J EXP MED, V179, P1029, DOI 10.1084/jem.179.3.1029; VACCHIO MS, 1992, J EXP MED, V175, P1405, DOI 10.1084/jem.175.5.1405; WAANDERS GA, 1993, INT IMMUNOL, V5, P55, DOI 10.1093/intimm/5.1.55; WHITE J, 1993, J EXP MED, V177, P119, DOI 10.1084/jem.177.1.119; WOODLAND DL, 1993, J EXP MED, V177, P433, DOI 10.1084/jem.177.2.433; YAGI JJ, 1991, J IMMUNOL, V147, P1398	65	516	542	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 21	1994	368	6473					711	718		10.1038/368711a0	http://dx.doi.org/10.1038/368711a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152483				2022-12-01	WOS:A1994NG55300049
J	BEARD, KC; QI, T; DAWSON, MR; WANG, BY; LI, CK				BEARD, KC; QI, T; DAWSON, MR; WANG, BY; LI, CK			A DIVERSE NEW PRIMATE FAUNA FROM MIDDLE EOCENE FISSURE-FILLINGS IN SOUTHEASTERN CHINA	NATURE			English	Article							ADAPIS-PARISIENSIS; EARLY TERTIARY; AFFINITIES; DISCOVERY; DENTITION; AFRICA; TARSIIDAE; PAKISTAN; ALTANIUS; MONGOLIA	We report the discovery of a fauna of primates from Eocene (approximately 45 Myr) deposits in China having a diversity greater than in European and North American localities of similar antiquity. From the many forms that will illuminate questions of primate phylogeny comes evidence for a basal radiation of primitive simians.	ACAD SINICA, INST VERTEBRATE PALEONTOL & PALEOANTHROPOL, BEIJING 100044, PEOPLES R CHINA	Chinese Academy of Sciences; Institute of Vertebrate Paleontology & Paleoanthropology, CAS	BEARD, KC (corresponding author), CARNEGIE MUSEUM NAT HIST, VERTEBRATE PALEONTOL SECT, 4400 FORBES AVE, PITTSBURGH, PA 15213 USA.		Klein, Richard G/B-5910-2009; Beard, K. Christopher/AAQ-4438-2021	Beard, K. Christopher/0000-0002-6279-9837				BEARD KC, 1988, NATURE, V331, P712, DOI 10.1038/331712a0; BEARD KC, 1991, NATURE, V349, P64, DOI 10.1038/349064a0; BEARD KC, 1991, AM J PHYS ANTHROPOL, V85, P159, DOI 10.1002/ajpa.1330850205; CHOW MINCHEN, 1961, VERTEBR PALASIAT, V5, P1; CIOCHON RL, 1985, SCIENCE, V229, P756, DOI 10.1126/science.229.4715.756; COLBERT EDWIN H., 1937, AMER MUS NOVITATES, V951., P1; CONROY GC, 1987, INT J PRIMATOL, V8, P115, DOI 10.1007/BF02735160; COVERT HH, 1991, J HUM EVOL, V21, P463, DOI 10.1016/0047-2484(91)90096-E; DAGOSTO M, 1983, FOLIA PRIMATOL, V41, P49, DOI 10.1159/000156119; DASHZEVEG D, 1977, Acta Palaeontologica Polonica, V22, P119; DEBONIS L, 1988, CR ACAD SCI II, V306, P929; Delson E., 1980, P445; FLEAGLE JG, 1987, J HUM EVOL, V16, P483, DOI 10.1016/0047-2484(87)90036-4; Franzen J.L., 1987, Courier Forschungsinstitut Senckenberg, V91, P151; Franzen J.L., 1986, Modern Geology, V10, P159; Gingerich P.D., 1980, P123; GINGERICH PD, 1981, AM J PHYS ANTHROPOL, V56, P235, DOI 10.1002/ajpa.1330560304; GINGERICH PD, 1991, GEOBIOS-LYON, V24, P637, DOI 10.1016/0016-6995(91)80029-Y; GINGERICH PD, 1984, INT J PRIMATOL, V5, P63, DOI 10.1007/BF02735148; GINSBURG L, 1987, CR ACAD SCI II, V304, P1213; GODINOT M, 1992, NATURE, V357, P324, DOI 10.1038/357324a0; GODINOT M, 1984, CR ACAD SCI II, V299, P1291; Godinot M, 1984, ACTES S PALEONTOLOGI, P221; KELLY TS, 1990, NAT HIST MUS LOS ANG, V419, P1; KRISHTALKA L, 1978, Annals of Carnegie Museum, V47, P335; MARTIN RD, 1993, NATURE, V363, P223, DOI 10.1038/363223a0; MAW B, 1979, NATURE, V282, P65, DOI 10.1038/282065a0; Musser GG., 1987, AM MUS NOVIT, V2867, P1; NORELL MA, 1992, SCIENCE, V255, P1690, DOI 10.1126/science.255.5052.1690; PAN YR, 1988, J HUM EVOL, V17, P359; PILGRIM GUY E., 1927, MEM GEOL SURV INDIA PALAEONT INDICA NEW SERIES, V14, P1; Prothero D.R., 1992, EOCENE OLIGOCENE CLI, P46, DOI DOI 10.1515/9781400862924.46; Qi Tao, 1991, Vertebrata Palasiatica, V29, P59; RASMUSSEN DT, 1990, INT J PRIMATOL, V11, P439, DOI 10.1007/BF02196131; RASMUSSEN DT, 1988, FOLIA PRIMATOL, V51, P182; ROSE KD, 1991, P NATL ACAD SCI USA, V88, P98, DOI 10.1073/pnas.88.1.98; ROSE KD, 1984, J MAMMAL, V65, P721, DOI 10.2307/1380867; RUSSELL D E, 1987, Memoires du Museum National d'Histoire Naturelle Serie C Sciences de la Terre, V52, P1; RUSSELL DE, 1980, CR ACAD SCI D NAT, V291, P621; RUSSELL DE, 1987, CR ACAD SCI II, V304, P209; SIMONS EL, 1990, SCIENCE, V247, P1567, DOI 10.1126/science.2108499; SIMONS EL, 1985, NATURE, V313, P475, DOI 10.1038/313475a0; SIMONS EL, 1992, P NATL ACAD SCI USA, V89, P10743, DOI 10.1073/pnas.89.22.10743; SIMONS EL, 1988, AM J PRIMATOL, V15, P337, DOI 10.1002/ajp.1350150407; SIMONS EL, 1989, P NATL ACAD SCI USA, V86, P9956, DOI 10.1073/pnas.86.24.9956; Szalay F.S., 1979, EVOLUTIONARY HIST PR; Wang Banyue, 1990, Vertebrata Palasiatica, V28, P165; WILSON JA, 1976, FOLIA PRIMATOL, V25, P294, DOI 10.1159/000155722; WILSON JA, 1986, U WYOMING CONTRIB GE, V3, P221; Zdansky O., 1930, Palaeontologia Sinica, V6C, P1	50	147	162	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 14	1994	368	6472					604	609		10.1038/368604a0	http://dx.doi.org/10.1038/368604a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145845				2022-12-01	WOS:A1994NF39200051
J	GERSZTEN, RE; CHEN, J; ISHII, M; ISHII, K; WANG, L; NANEVICZ, T; TURCK, CW; VU, TKH; COUGHLIN, SR				GERSZTEN, RE; CHEN, J; ISHII, M; ISHII, K; WANG, L; NANEVICZ, T; TURCK, CW; VU, TKH; COUGHLIN, SR			SPECIFICITY OF THE THROMBIN RECEPTOR FOR AGONIST PEPTIDE IS DEFINED BY ITS EXTRACELLULAR SURFACE	NATURE			English	Article							NEUROKININ-1 RECEPTOR; ACTIVATION; MECHANISM; BINDING; DOMAINS; CLONING	G-PROTEIN-COUPLED receptors for catecholamines and some other small ligands are activated when agonists bind to the transmembrane region of the receptor1. The docking interactions through which peptide agonists activate their receptors are less well characterized2-7. The thrombin receptor is a specialized peptide receptor. it is activated by binding its tethered ligand domain, which is unmasked upon receptor cleavage by thrombin8,9. Human and Xenopus thrombin receptor homologues are each selectively activated by the agonist peptide representing their respective tethered ligand domains. Here we identify receptor domains that confer this agonist specificity by replacing the Xenopus receptor's amino-terminal exodomain and three extracellular loops with the corresponding human structures. This switches receptor specificity from Xenopus to human. The specificity of these thrombin receptors for their respective peptide agonists is thus determined by their extracellular surfaces. Our results indicate that agonist interaction with extracellular domains is important for thrombin receptor activation.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DOHLMAN HG, 1992, ANNU REV BIOCHEM, V60, P651; FATHI Z, 1993, J BIOL CHEM, V268, P14622; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; ISHII K, 1993, J BIOL CHEM, V268, P9780; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANZA F, 1991, J BIOL CHEM, V266, P10638; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	19	195	204	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					648	651		10.1038/368648a0	http://dx.doi.org/10.1038/368648a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145852				2022-12-01	WOS:A1994NF39200064
J	BOWLER, C; NEUHAUS, G; YAMAGATA, H; CHUA, NH				BOWLER, C; NEUHAUS, G; YAMAGATA, H; CHUA, NH			CYCLIC-GMP AND CALCIUM MEDIATE PHYTOCHROME PHOTOTRANSDUCTION	CELL			English	Article							A/B-BINDING POLYPEPTIDE; OXYGEN-EVOLVING COMPLEX; MESSENGER-RNA LEVELS; CAB GENE FAMILY; PHOTOSYSTEM-II; CHROMOSOMAL LOCATION; CHALCONE SYNTHASE; KDA POLYPEPTIDE; PROTEIN-KINASE; CDNA CLONE	We have previously used single-cell assays in a phytochrome-deficient tomato mutant to demonstrate that phytochrome signaling involves heterotrimeric G proteins, calcium, and calmodulin. While G protein activation could stimulate full chloroplast development and anthocyanin pigment biosynthesis, calcium and calmodulin could not induce anthocyanins and were only able to stimulate the development of immature chloroplasts tacking cytochrome b(6)f and photosystem I core components. We now report that cyclic GMP is able to trigger the production of anthocyanins, and that a combination of cyclic GMP with calcium can induce the development of fully mature chloroplasts containing all the photosynthetic machinery. Furthermore, using reporter genes for these different pathways (cab-gus, chs-gus and fnr-gus) we demonstrate that cGMP and calcium act primarily by modulating gene expression.	ETH ZENTRUM,INST PFLANZENWISSENSCH,CH-8092 ZURICH,SWITZERLAND; ROCKEFELLER UNIV,PLANT MOLEC BIOL LAB,NEW YORK,NY 10021	Swiss Federal Institutes of Technology Domain; ETH Zurich; Rockefeller University			Bowler, Chris/AAC-6256-2019	Bowler, Chris/0000-0003-3835-6187	PHS HHS [44640] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON JM, 1986, ANNU REV PLANT PHYS, V37, P93, DOI 10.1146/annurev.arplant.37.1.93; BENNOUN P, 1986, PLANT MOL BIOL, V6, P151, DOI 10.1007/BF00021484; BENTLEY J K, 1992, Current Opinion in Cell Biology, V4, P233; BOWLER C, 1989, EMBO J, V8, P31, DOI 10.1002/j.1460-2075.1989.tb03345.x; BUSH DS, 1987, CELL CALCIUM, V8, P455, DOI 10.1016/0143-4160(87)90029-7; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; COTE RH, 1984, J BIOL CHEM, V259, P9635; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; ESTABROOK EM, 1991, PLANT CELL, V3, P299, DOI 10.1105/tpc.3.3.299; FEINBAUM RL, 1991, MOL GEN GENET, V226, P449, DOI 10.1007/BF00260658; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; GILMARTIN PM, 1992, PLANT CELL, V4, P839, DOI 10.1105/tpc.4.7.839; GILMARTIN PM, 1990, PLANT CELL, V2, P369, DOI 10.1105/tpc.2.5.369; GIRARDBASCOU J, 1987, CURR GENET, V12, P489, DOI 10.1007/BF00419557; HOFFMAN NE, 1988, PLANT MOL BIOL, V10, P435, DOI 10.1007/BF00014949; HORN ME, 1983, PLANT PHYSIOL, V72, P426, DOI 10.1104/pp.72.2.426; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; JEFFERSON RA, 1987, EMBO J, V6, P3901; Koornneef M., 1981, Induced mutations -- a tool in plant research. Proceedings of an international symposium. Vienna, 9-13 March 1981, P227; LAM E, 1989, MOL CELL BIOL, V9, P4819, DOI 10.1128/MCB.9.11.4819; LARSSON KH, 1992, PLANT MOL BIOL, V19, P343, DOI 10.1007/BF00027359; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; MELIS A, 1991, BIOCHIM BIOPHYS ACTA, V1058, P87, DOI 10.1016/S0005-2728(05)80225-7; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; NEWTON RP, 1991, ANAL CHIM ACTA, V247, P161, DOI 10.1016/S0003-2670(00)83811-8; PARKS BM, 1987, PLANT MOL BIOL, V9, P97, DOI 10.1007/BF00015642; PICHERSKY E, 1988, PLANT MOL BIOL, V11, P69, DOI 10.1007/BF00016015; PICHERSKY E, 1989, PLANT MOL BIOL, V12, P257, DOI 10.1007/BF00043203; PIECHULLA B, 1991, MOL GEN GENET, V230, P413, DOI 10.1007/BF00280298; PUGH EN, 1993, NATURE, V364, P389, DOI 10.1038/364389a0; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; ROMERO LC, 1993, P NATL ACAD SCI USA, V90, P1465, DOI 10.1073/pnas.90.4.1465; SHARMA R, 1993, PLANT J, V4, P1035, DOI 10.1046/j.1365-313X.1993.04061035.x; SHIRLEY BW, 1990, PLANT MOL BIOL, V14, P909, DOI 10.1007/BF00019389; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STOCKHAUS J, 1989, EMBO J, V8, P2445, DOI 10.1002/j.1460-2075.1989.tb08379.x; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUSEK RE, 1993, CELL, V74, P787, DOI 10.1016/0092-8674(93)90459-4; VONWETTSTEINKNO.P, 1968, HEREDITAS, V60, P318; WALES R, 1989, PLANT MOL BIOL, V12, P439, DOI 10.1007/BF00017583; WALES R, 1989, PLANT MOL BIOL, V13, P573, DOI 10.1007/BF00027317; WALLING L, 1986, P NATL ACAD SCI USA, V83, P2123, DOI 10.1073/pnas.83.7.2123; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; ZIMMERMAN AL, 1985, P NATL ACAD SCI USA, V82, P8813, DOI 10.1073/pnas.82.24.8813	45	428	454	1	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					73	81		10.1016/0092-8674(94)90236-4	http://dx.doi.org/10.1016/0092-8674(94)90236-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156599				2022-12-01	WOS:A1994NF21100011
J	PAPADOPOULOS, N; NICOLAIDES, NC; WEI, YF; RUBEN, SM; CARTER, KC; ROSEN, CA; HASELTINE, WA; FLEISCHMANN, RD; FRASER, CM; ADAMS, MD; VENTER, JC; HAMILTON, SR; PETERSEN, GM; WATSON, P; LYNCH, HT; PELTOMAKI, P; MECKLIN, JP; DELACHAPELLE, A; KINZLER, KW; VOGELSTEIN, B				PAPADOPOULOS, N; NICOLAIDES, NC; WEI, YF; RUBEN, SM; CARTER, KC; ROSEN, CA; HASELTINE, WA; FLEISCHMANN, RD; FRASER, CM; ADAMS, MD; VENTER, JC; HAMILTON, SR; PETERSEN, GM; WATSON, P; LYNCH, HT; PELTOMAKI, P; MECKLIN, JP; DELACHAPELLE, A; KINZLER, KW; VOGELSTEIN, B			MUTATION OF A MUTL HOMOLOG IN HEREDITARY COLON-CANCER	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-SEQUENCE; COLORECTAL-CANCER; MISMATCH REPAIR; CLONING; K-12; PMS1; HEXB	Some cases of hereditary nonpolyposis colorectal cancer (HNPCC) are due to alterations in a mutS-related mismatch repair gene. A search of a large database of expressed sequence tags derived from random complementary DNA clones revealed three additional human mismatch repair genes, all related to the bacterial mutL gene. One of these genes (hMLH1) resides on chromosome 3p21, within 1 centimorgan of markers previously linked to cancer susceptibility in HNPCC kindreds. Mutations of hMLH1 that would disrupt the gene product were identified in such kindreds, demonstrating that this gene is responsible for the disease. These results suggest that defects in any of several mismatch repair genes can cause HNPCC.	JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; INST GENOM RES,GAITHERSBURG,MD 20878; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH PUBL HLTH & HYG,DEPT EPIDEMIOL,BALTIMORE,MD 21205; CREIGHTON UNIV,SCH MED,DEPT PREVENT MED,OMAHA,NE 68178; CREIGHTON UNIV,SCH MED,DEPT PUBL HLTH,OMAHA,NE 68178; UNIV HELSINKI,DEPT MED GENET,SF-00290 HELSINKI,FINLAND	Johns Hopkins University; Johns Hopkins Medicine; GlaxoSmithKline; Human Genome Sciences Inc; J. Craig Venter Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Creighton University; Creighton University; University of Helsinki			Mecklin, Jukka-Pekka/AAC-9650-2019; Papadopoulos, Nickolas/K-7272-2012	Peltomaki, Paivi/0000-0001-8819-2980; Fraser, Claire/0000-0003-1462-2428	NATIONAL CANCER INSTITUTE [R01CA035494, R01CA047527, R37CA035494] Funding Source: NIH RePORTER; NCI NIH HHS [CA35494, CA47527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JASS JR, 1992, GUT, V33, P783, DOI 10.1136/gut.33.6.783; JASS JR, UNPUB; JOHNSON CV, 1991, GENET ANAL-BIOMOL E, V8, P75, DOI 10.1016/1050-3862(91)90052-S; JOHNSON CV, 1991, METHOD CELL BIOL, V35, P73; KNUDSON AG, 1985, CANCER RES, V45, P1437; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Maniatis T., 1982, MOL CLONING; MANKOVICH JA, 1989, J BACTERIOL, V171, P5325, DOI 10.1128/jb.171.10.5325-5331.1989; NYSTROMLAHTI M, IN PRESS P NATL ACAD; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PARSONS R, UNPUB; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; PRUDHOMME M, 1989, J BACTERIOL, V171, P7196; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TSUI HCT, 1992, NUCLEIC ACIDS RES, V20, P2379, DOI 10.1093/nar/20.9.2379; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; VERMA R, 1989, HUMAN CHROMOSOMES MA, P115; WEI Y, UNPUB	35	1727	1793	0	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 18	1994	263	5153					1625	1629		10.1126/science.8128251	http://dx.doi.org/10.1126/science.8128251			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128251				2022-12-01	WOS:A1994NB67300036
J	JANSSON, A; GILLIN, F; KAGARDT, U; HAGBLOM, P				JANSSON, A; GILLIN, F; KAGARDT, U; HAGBLOM, P			CODING OF HEMOLYSINS WITHIN THE RIBOSOMAL-RNA REPEAT ON A PLASMID IN ENTAMOEBA-HISTOLYTICA	SCIENCE			English	Article							CIRCULAR DNA; PATHOGENESIS; DIFFERENTIATION; TROPHOZOITES; MECHANISMS; AMEBIASIS; PROTEIN; PROBES; ACIDS; GENES	The pathogenesis of amoebic dysentery is a result of cytolysis of the colonic mucosa by the parasitic protozoan Entamoeba histolytica. The cytolysis results in extensive local ulceration and allows the amoeba to penetrate and metastasize to distant sites. Factors involved in this process were defined with three clones that express hemolytic activities in Escherichia coli. These potential amoebic virulence determinants were also toxic to human colonic epithelial cells, the primary cellular targets in amoebal invasion of the large intestine. The coding sequences for the hemolysins were close to each other on a 2.6-kilobase segment of a 25-kilobase extrachromosomal DNA element. The structural genes for the hemolysins were within inverted repeats that encode ribosomal RNAs.	UPPSALA UNIV,CTR BIOMED,DEPT MICROBIOL,S-75123 UPPSALA,SWEDEN; UNIV CALIF SAN DIEGO,DEPT PATHOL,SAN DIEGO,CA 92103	Uppsala University; University of California System; University of California San Diego								AGRAWAL A, 1990, B SOC FRANCAISE PARA; ANDERBERG EK, 1992, J PHARM SCI, V81, P879, DOI 10.1002/jps.2600810908; AVILA EE, 1985, J PROTOZOOL, V32, P163; BHATTACHARYA S, 1989, J PROTOZOOL, V36, P455, DOI 10.1111/j.1550-7408.1989.tb01080.x; BOER PH, 1988, CELL, V55, P399, DOI 10.1016/0092-8674(88)90026-8; BRACHA R, 1990, J CLIN MICROBIOL, V28, P680, DOI 10.1128/JCM.28.4.680-684.1990; CAVALLOS MA, 1993, NUCLEIC ACIDS RES, V21, P355; CLARK CG, 1991, MOL BIOCHEM PARASIT, V49, P297, DOI 10.1016/0166-6851(91)90073-F; GARFINKEL LI, 1989, INFECT IMMUN, V57, P926, DOI 10.1128/IAI.57.3.926-931.1989; GRUZREYES JA, 1992, PARASITOLOGY, V104, P239; HAGBLOM P, UNPUB; HUBER M, 1989, MOL BIOCHEM PARASIT, V32, P285, DOI 10.1016/0166-6851(89)90077-7; Jarumilinta R., 1960, Transactions of the Royal Society of Tropical Medicine and Hygiene, V54, P5; LEIPPE M, 1992, EMBO J, V11, P3501, DOI 10.1002/j.1460-2075.1992.tb05432.x; LOHIA A, 1993, GENE, V127, P203, DOI 10.1016/0378-1119(93)90720-N; LONGKRUG SA, 1985, J INFECT DIS, V152, P536, DOI 10.1093/infdis/152.3.536; LOPEZREVILLA R, 1980, AM J TROP MED HYG, V29, P209, DOI 10.4269/ajtmh.1980.29.209; MARTINEZPALOMO A, 1987, PARASITOL TODAY, V3, P111, DOI 10.1016/0169-4758(87)90048-2; MUNOZ MD, 1982, J EXP MED, V155, P42, DOI 10.1084/jem.155.1.42; QUE X, 1991, NUCLEIC ACIDS RES, V19, P5438, DOI 10.1093/nar/19.19.5438; RAMACHANDRAN S, 1993, NUCLEIC ACIDS RES, V21, P2011, DOI 10.1093/nar/21.8.2011; RAVDIN JI, 1986, REV INFECT DIS, V8, P247; RAVDIN JI, 1982, REV INFECT DIS, V4, P1185; REED S, 1993, J CLIN INVEST, V91, P1532, DOI 10.1172/JCI116359; REED SL, 1989, J IMMUNOL, V143, P189; Rosales-Encina J L, 1992, Arch Med Res, V23, P243; ROSALESENCINA JL, 1987, J INFECT DIS, V156, P790, DOI 10.1093/infdis/156.5.790; ROSENBERG I, 1989, MOL BIOCHEM PARASIT, V33, P237, DOI 10.1016/0166-6851(89)90085-6; SAIDFERNANDEZ S, 1988, INFECT IMMUN, V56, P874; SAMBROCK J, 1989, MOL CLONING LABORATO; TANNICH E, 1989, P NATL ACAD SCI USA, V86, P5118, DOI 10.1073/pnas.86.13.5118; UDEZULU IA, 1987, INFECT IMMUN, V55, P181, DOI 10.1128/IAI.55.1.181-186.1987; UPCROFT JA, 1990, NUCLEIC ACIDS RES, V18, P7077, DOI 10.1093/nar/18.23.7077; YOUNG JDE, 1985, J CELL BIOCHEM, V29, P299, DOI 10.1002/jcb.240290404	34	30	30	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1440	1443		10.1126/science.8128227	http://dx.doi.org/10.1126/science.8128227			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128227				2022-12-01	WOS:A1994MZ92700033
J	ORR, WC; SOHAL, RS				ORR, WC; SOHAL, RS			EXTENSION OF LIFE-SPAN BY OVEREXPRESSION OF SUPEROXIDE-DISMUTASE AND CATALASE IN DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							OXYGEN RADICALS; AGE	The hypothesis that oxygen free radicals are causally involved in the aging process was tested by a study of the effects of simultaneous overexpression of copper-zinc superoxide dismutase and catalase. As compared to diploid controls, transgenic flies carrying three copies of each of these genes exhibited as much as a one-third extension of life-span, a longer mortality rate doubling time, a lower amount of protein oxidative damage, and a delayed loss in physical performance. Results provide direct support for the free radical hypothesis of aging.			ORR, WC (corresponding author), SO METHODIST UNIV,DEPT BIOL SCI,DALLAS,TX 75275, USA.				NIA NIH HHS [R01AG8459] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG008459] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1987, SCIENCE, V236, P271, DOI 10.1126/science.3563506; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Finch C. E., 1990, SENESCENCE GENOME; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LEFFELAAR D, 1984, DEV GENET, V4, P211; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Luck H., 1974, ESTIMATION CATALASE, V885; MCARTHUR MC, 1982, J GERONTOL, V37, P268, DOI 10.1093/geronj/37.3.268; MIQUEL J, 1976, MECH AGEING DEV, V5, P347, DOI 10.1016/0047-6374(76)90034-8; MISRA HP, 1977, ANAL BIOCHEM, V79, P553, DOI 10.1016/0003-2697(77)90429-8; ORR WC, 1992, ARCH BIOCHEM BIOPHYS, V297, P35, DOI 10.1016/0003-9861(92)90637-C; ORR WC, 1993, ARCH BIOCHEM BIOPHYS, V301, P34, DOI 10.1006/abbi.1993.1111; PAGE EB, 1963, J AM STAT ASSOC, V58, P216, DOI 10.2307/2282965; Pryor W. A., 1987, MODERN BIOL THEORIES, P89; ROBERTSON HM, 1988, GENETICS, V118, P461; SACHER GA, 1977, HDB BIOL AGING, P582; SMITH J, 1979, COMP BIOCHEM PHYS B, V63, P39, DOI 10.1016/0305-0491(79)90231-1; SOHAL RS, 1982, AGE, V5, P21, DOI 10.1007/BF02431719; SOHAL RS, 1990, MECH AGEING DEV, V56, P223, DOI 10.1016/0047-6374(90)90084-S; SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616	26	1205	1252	0	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1128	1130		10.1126/science.8108730	http://dx.doi.org/10.1126/science.8108730			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108730				2022-12-01	WOS:A1994MX75900029
J	RAO, VR; COHEN, GB; OPRIAN, DD				RAO, VR; COHEN, GB; OPRIAN, DD			RHODOPSIN MUTATION G90D AND A MOLECULAR MECHANISM FOR CONGENITAL NIGHT BLINDNESS	NATURE			English	Article							DOMINANT RETINITIS-PIGMENTOSA; BOVINE RHODOPSIN; GENE	MUTATIONS in the gene for the visual pigment rhodopsin cause retinitis pigmentosa (RP) and congenital night blindness(1-7). Inheritance of the diseases is generally autosomal dominant and about 40 different rhodopsin mutations have been documented. Although the cell death and retinal degeneration associated with RP have been suggested to result from improper folding and accumulation of the mutant proteins in rod photoreceptor cells(8), this may not account for the disease in all cases. For example, RP mutations at Lys 296, site of Schiff base linkage to the retinal chromophore, result in constitutive;activation of the protein in vitro(9-11); that is, the mutants can catalytically activate the G protein transducin in the absence of chromophore and in the absence of light. Similarly, mutation of Ala 292 --> Glu activates opsin in vitro and causes night blindness(7). We show here that the mutation Gly 90 --> Asp (G90D) in the second transmembrane segment of rhodopsin, which causes congenital night blindness(12), also constitutively activates opsin. Furthermore, we show that Asp 90 can substitute for the Schiff base counterion, Glu 113, which is located in the third transmembrane segment of the protein. This demonstrates the proximity of Asp 90 and Lys 296 in the three-dimensional structure of rhodopsin and suggests that the constitutively activating mutations operate by a common molecular mechanism, disrupting a salt bridge between Lys 296 and the Schiff base counterion, Glu 113.			RAO, VR (corresponding author), BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254, USA.				NATIONAL EYE INSTITUTE [R01EY007965] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY007965] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FAIN GL, 1993, EXP EYE RES, V57, P335, DOI 10.1006/exer.1993.1132; FARRAR GJ, 1990, AM J HUM GENET, V47, P941; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; KEEN TJ, 1991, GENOMICS, V11, P199, DOI 10.1016/0888-7543(91)90119-Y; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; MORTON RA, 1955, BIOCHEM J, V59, P128, DOI 10.1042/bj0590128; NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RANDO RR, 1990, ANGEW CHEM INT EDIT, V29, P461, DOI 10.1002/anie.199004611; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SIEVING PA, 1992, INVEST OPHTH VIS SCI, V33, P1397; SULLIVAN JM, 1993, INVEST OPHTH VIS SCI, V34, P1149; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	31	318	323	2	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 17	1994	367	6464					639	642		10.1038/367639a0	http://dx.doi.org/10.1038/367639a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107847				2022-12-01	WOS:A1994MW68800052
J	ROMEO, G; RONCHETTO, P; LUO, Y; BARONE, V; SERI, M; CECCHERINI, I; PASINI, B; BOCCIARDI, R; LERONE, M; KAARIAINEN, H; MARTUCCIELLO, G				ROMEO, G; RONCHETTO, P; LUO, Y; BARONE, V; SERI, M; CECCHERINI, I; PASINI, B; BOCCIARDI, R; LERONE, M; KAARIAINEN, H; MARTUCCIELLO, G			POINT MUTATIONS AFFECTING THE TYROSINE KINASE DOMAIN OF THE RET PROTOONCOGENE IN HIRSCHPRUNGS DISEASE	NATURE			English	Article							ACTIVATION; RECEPTOR	HIRSCHSPRUNG'S disease is a genetic disorder of neural crest development affecting 1 in 5,000 births. It is characterized by the absence of intramural ganglion cells in the hindgut, which often results in partial to complete intestinal obstruction during the first years of life. An autosomal dominant gene causing this disease was recently mapped to chromosome 10q11.2 (refs 1, 2), using an interstitial deletion of this region isolated in a cell hybrid3,4. It was subsequently localized to a 250-kilobase interval which contains the RET proto-oncogene5. Using flanking intronic sequences as primers6 to amplify 12 of the 20 exons of RET from genomic DNA of 27 Hirschsprung's disease patients, we have now identified four mutations (one frameshift and three missense) that totally disrupt or partially change the structure of the tyrosine kinase domain of the RET protein (Ret). Mutations in the extracellular cysteine-rich domain of Ret have been identified previously7,8 in patients with multiple endocrine neoplasia type 2A, and a targeted mutation in the tyrosine kinase domain of the same gene produces intestinal aganglionosis and kidney agenesis in homozygous transgenic mice9. Our results support the hypothesis that RET, in addition to its potential role in tumorigenesis, plays a critical role in the embryogenesis of the mammalian enteric nervous system.	UNIV HELSINKI,DEPT MED GENET,SF-00014 HELSINKI,FINLAND	University of Helsinki	ROMEO, G (corresponding author), IST GIANNINA GASLINI,I-16148 GENOA,ITALY.		lerone, margherita/AAC-1583-2021; Ronchetto, Patrizia/AAA-7742-2020; Barone, Virginia/K-8782-2015; Bocciardi, Renata/J-8577-2016; Ceccherini, Isabella/P-8195-2014; Martucciello, Giuseppe/J-6543-2018; Pasini, Barbara/AHI-2004-2022; Seri, Marco/A-4339-2014	lerone, margherita/0000-0003-0666-4740; Barone, Virginia/0000-0001-8794-9291; Bocciardi, Renata/0000-0001-8415-3802; Ceccherini, Isabella/0000-0001-8732-1955; Martucciello, Giuseppe/0000-0002-7709-8937; Pasini, Barbara/0000-0002-4373-1212; Ronchetto, Patrizia/0000-0002-2606-3398; Seri, Marco/0000-0003-2425-2176				ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P1085; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KWOK JBJ, 1993, ONCOGENE, V8, P2575; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MARTUCCIELLO G, 1992, PEDIATR SURG INT, V7, P308; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PULITI A, 1993, CYTOGENET CELL GENET, V63, P102, DOI 10.1159/000133510; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; YIN L, 1993, HUM MOL GENET, V2, P1803	25	621	636	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					377	378		10.1038/367377a0	http://dx.doi.org/10.1038/367377a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114938				2022-12-01	WOS:A1994MT54000070
J	RIVARA, FP; KOEPSELL, TD; JURKOVICH, GJ; GURNEY, JG; SODERBERG, R				RIVARA, FP; KOEPSELL, TD; JURKOVICH, GJ; GURNEY, JG; SODERBERG, R			THE EFFECTS OF ALCOHOL-ABUSE ON READMISSION FOR TRAUMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SCREENING-TEST; INJURIES; INTOXICATION; EMERGENCY; ACCIDENTS	Objective.-To determine the effect of admission for trauma with concurrent acute alcohol intoxication or chronic alcohol abuse on the risk of subsequent recurrence of trauma. Design.-Prospective cohort study. Setting.-Level I regional trauma center. Patients.-A total of 2578 patients 18 years or older admitted with blunt or penetrating trauma within 24 hours of injury and surviving to discharge. All patients had a blood alcohol concentration (BAC) test, a gamma-glutamyltransferase (GGT) test, and the short Michigan Alcohol Screening Test (SMAST) performed on admission. Main Outcome Measurement.-Readmission to the trauma center for new trauma. Average follow-up was 28 months (range, 16 to 40 months). Results.-The overall rate of readmission for new injuries was 1.3 per 1000 patient-months of follow-up. Patients who were intoxicated on the initial admission (BAC >22 mmol/L [100 mg/dL]) were 2.5-fold as likely to be readmitted than those not intoxicated (95% confidence limits, 1.6, 3.9). The relative risks for patients with positive SMAST scores and abnormal GGT values were 2.2 (95% confidence limits, 1.4, 3.5) and 3.5 (95% confidence limits, 2.2, 5.5), respectively. The increased risks remained significant for intoxication and abnormal GGT values after adjustment for gender, race, Medicaid status, and mechanism of injury. Conclusion.-Alcohol abuse is associated with an increased risk of readmission for new trauma. Trauma patients should be screened for alcohol problems; referral of problem drinkers for appropriate care may decrease their risk of admission for subsequent trauma.	UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT SURG, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	RIVARA, FP (corresponding author), HARBORVIEW INJURY PREVENT & RES CTR, 325 9TH AVE, ZX-10, SEATTLE, WA 98104 USA.							BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; CESARE J, 1990, J TRAUMA, V30, P176, DOI 10.1097/00005373-199002000-00007; CHANG G, 1988, JAMA-J AM MED ASSOC, V260, P2533, DOI 10.1001/jama.260.17.2533; COX DR, 1972, J R STAT SOC B, V34, P187; DEVGUN MS, 1985, ALCOHOL CLIN EXP RES, V9, P235, DOI 10.1111/j.1530-0277.1985.tb05742.x; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; JURKOVICH GJ, 1992, ANN EMERG MED, V21, P704, DOI 10.1016/S0196-0644(05)82783-0; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; MACKENZIE EJ, 1988, ICDMAP DETERMINING I; PAPOZ L, 1986, BRIT MED J, V292, P1234, DOI 10.1136/bmj.292.6530.1234; PATEL S, 1975, J CLIN PATHOL, V28, P414, DOI 10.1136/jcp.28.5.414; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; ROSKALI S, 1974, CLIN CHEM, V20, P1121; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SMITH GS, 1988, ANNU REV PUBL HEALTH, V9, P99; SODERSTROM CA, 1987, ARCH SURG-CHICAGO, V122, P1067; SODERSTROM CA, 1989, ADV TRAUMA, V4, P211; Swan KG, 1989, J TRAUMA, V29, P947; WATSON RR, 1986, ALCOHOL CLIN EXP RES, V10, P364, DOI 10.1111/j.1530-0277.1986.tb05108.x; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; 1990, BROADENING BASE TREA; 1985, INJURY AM CONTINUING	26	172	174	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1962	1964		10.1001/jama.270.16.1962	http://dx.doi.org/10.1001/jama.270.16.1962			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC513	8105114				2022-12-01	WOS:A1993MC51300028
J	DEBRE, M; BONNET, MC; FRIDMAN, WH; CAROSELLA, E; PHILIPPE, N; REINERT, P; VILMER, E; KAPLAN, C; TEILLAUD, JL; GRISCELLI, C				DEBRE, M; BONNET, MC; FRIDMAN, WH; CAROSELLA, E; PHILIPPE, N; REINERT, P; VILMER, E; KAPLAN, C; TEILLAUD, JL; GRISCELLI, C			INFUSION OF FC-GAMMA-FRAGMENTS FOR TREATMENT OF CHILDREN WITH ACUTE IMMUNE THROMBOCYTOPENIC PURPURA	LANCET			English	Article							IMMUNOGLOBULIN-BINDING FACTORS; INTRAVENOUS IMMUNOGLOBULIN; ANTIBODY-PRODUCTION; GLOBULIN; RECEPTORS; CELLS; IGG; CHILDHOOD	Treatment of acute immune thrombocytopenic purpura (ITP) with intravenous immunoglobulin (IVIG) induces partial or complete responses, shown by transient or persistent increases in platelet count. The clinical benefit could be due to blockade of the Fcgamma receptor (FcgammaR); platelets sensitised by IgG could not be cleared by cells of the reticuloendothelial system if FcgammaR on these cells was blocked with IVIG. To find out whether this putative mechanism is correct, we treated twelve children who had acute ITP with intravenous infusions of Fcgamma fragments. Eleven children showed rapid increases in platelet counts to above the critical value of 50 x 10(9)/L, thereby avoiding major haemorrhagic risk. The response was stable in six patients and transient in five. No adverse reactions were observed. In responders who had detectable platelet-associated IgG before treatment (> 1500 IgG per platelet), platelet IgG fell substantially with treatment. Serum soluble CD16 (sCD16 or sFcgammaRIII) concentrations, measured in five children, showed transient or stable increases that correlated with the rise in platelet count. No sCD16 was detected in the Fcgamma preparation used. We conclude that the infusion of Fcgamma fragments is an efficient treatment of acute ITP in children. The efficacy of Fcgamma fragments strengthens the hypothesis that FcgammaR blockade is the main mechanism of action of IVIG in ITP, although other immunoregulatory mechanisms triggered by the presence of increased sCD16 concentrations in serum could be involved in the clinical benefit observed.	DIRECT MED IMMUNOPROT PASTEUR MERLEUX SERUMS & VAC, MARCY LETOILE, FRANCE; INST CURIE, INSERM, U255, F-75231 PARIS 05, FRANCE; HOP INTERCOMMUNAL CRETEIL, CRETEIL, FRANCE; HOP ROBERT DEBRE, PARIS, FRANCE; HOP ST LOUIS, CTR HAYEM, CEA, DSV, F-75475 PARIS 10, FRANCE; HOP DEBROUSSE, F-69005 LYON, FRANCE; INST NATL TRANSFUS SANGUINE, PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; CEA; UDICE-French Research Universities; Universite Paris Cite; CHU Lyon	DEBRE, M (corresponding author), HOP NECKER ENFANTS MALAD, UNITE IMMUNOHEMATOL, 149 RUE SEVRES, F-75748 PARIS, FRANCE.			Teillaud, Jean-Luc/0000-0003-4442-9565; fridman, wolf herman/0000-0002-1332-0973				ANDERSON CL, 1989, CHEM IMMUNOL, V47, P1; ASTIER A, IN PRESS J IMMUNOL M; BARANDUN S, 1975, VOX SANG, V28, P157, DOI 10.1111/j.1423-0410.1975.tb02755.x; BEARDSLEY DS, 1993, HEMATOLOGY INFANCY C, P1561; BURDACH SEG, 1986, J PEDIATR-US, V109, P770, DOI 10.1016/S0022-3476(86)80691-6; BUSSEL JB, 1987, VOX SANG, V52, P206, DOI 10.1111/j.1423-0410.1987.tb03029.x; BUSSEL JB, 1989, J ALLERGY CLIN IMMUN, V84, P566, DOI 10.1016/0091-6749(89)90193-0; CLARKSON SB, 1986, NEW ENGL J MED, V314, P1236, DOI 10.1056/NEJM198605083141907; COHN EJ, 1946, J AM CHEM SOC, V68, P459, DOI 10.1021/ja01207a034; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; FOLLEA G, 1985, NOUV REV FR HEMATOL, V27, P5; FRIDMAN WH, 1986, MOL IMMUNOL, V23, P1141, DOI 10.1016/0161-5890(86)90144-6; FRIDMAN WH, 1988, NOUV REV FR HEMATOL, V30, P311; FRIDMAN WH, 1974, J IMMUNOL, V113, P1008; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P3189; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; IMBACH P, 1981, LANCET, V1, P1228; KAVERI SV, 1991, CLIN EXP IMMUNOL, V86, P192; KHAYAT D, 1987, J IMMUNOL METHODS, V100, P235, DOI 10.1016/0022-1759(87)90194-3; LANIER LL, 1989, EUR J IMMUNOL, V19, P775, DOI 10.1002/eji.1830190431; LOWY I, 1983, P NATL ACAD SCI-BIOL, V80, P2323, DOI 10.1073/pnas.80.8.2323; MULLER JY, 1983, REV FR TRANSFUS IMMU, V26, P173, DOI 10.1016/S0338-4535(83)80091-9; ONCLEY JL, 1949, J AM CHEM SOC, V71, P541, DOI 10.1021/ja01170a048; SALAMA A, 1983, LANCET, V2, P193; SOLALCELIGNY P, 1983, SCAND J HAEMATOL, V31, P39; SOUBRANE C, 1993, BLOOD, V81, P15; TEILLAUD JL, 1990, MOL IMMUNOL, V27, P1209, DOI 10.1016/0161-5890(90)90024-T; VARIN N, 1989, EUR J IMMUNOL, V19, P2263, DOI 10.1002/eji.1830191213	29	274	282	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1993	342	8877					945	949		10.1016/0140-6736(93)92000-J	http://dx.doi.org/10.1016/0140-6736(93)92000-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105212				2022-12-01	WOS:A1993MC00500007
J	RIGGS, JE				RIGGS, JE			SMOKING AND ALZHEIMERS-DISEASE - PROTECTIVE EFFECT OR DIFFERENTIAL SURVIVAL BIAS	LANCET			English	Editorial Material							CIGARETTE-SMOKING				RIGGS, JE (corresponding author), W VIRGINIA UNIV,HLTH SCI CTR,DEPT NEUROL,POB 9180,MORGANTOWN,WV 26506, USA.							AU WW, 1991, MUTAT RES, V260, P137, DOI 10.1016/0165-1218(91)90001-3; BARON JA, 1986, NEUROLOGY, V36, P1490, DOI 10.1212/WNL.36.11.1490; BOERRIGTER ME, 1992, J GERONTOL, V47, P177; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; CONNEALLY PM, 1991, ADV NEUROL, V56, P233; FARRER LA, 1984, AM J MED GENET, V18, P115, DOI 10.1002/ajmg.1320180115; FIELDING JE, 1985, NEW ENGL J MED, V313, P555, DOI 10.1056/NEJM198508293130906; GRAVES AB, 1991, INT J EPIDEMIOL S2, V20, P48; Gusella J F, 1991, Adv Hum Genet, V20, P125; PINCHEIRA J, 1993, MUTAT RES, V295, P55, DOI 10.1016/0921-8734(93)90001-J; RIGGS JE, 1992, CLIN NEUROPHARMACOL, V15, P88, DOI 10.1097/00002826-199204000-00002; RIGGS JE, 1992, MECH AGEING DEV, V65, P217, DOI 10.1016/0047-6374(92)90037-E; RIGGS JE, 1993, MECH AGEING DEV, V66, P249, DOI 10.1016/0047-6374(93)90012-G; VANDUIJN CM, 1991, BRIT MED J, V302, P1491, DOI 10.1136/bmj.302.6791.1491	14	71	71	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 25	1993	342	8874					793	794		10.1016/0140-6736(93)91547-Y	http://dx.doi.org/10.1016/0140-6736(93)91547-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103882				2022-12-01	WOS:A1993LY86800016
J	CAMPBELL, G; WEAVER, T; TOMLINSON, A				CAMPBELL, G; WEAVER, T; TOMLINSON, A			AXIS SPECIFICATION IN THE DEVELOPING DROSOPHILA APPENDAGE - THE ROLE OF WINGLESS, DECAPENTAPLEGIC, AND THE HOMEOBOX GENE ARISTALESS	CELL			English	Article							SEGMENT-POLARITY GENE; IMAGINAL DISKS; XENOPUS EMBRYOS; HALTERE DEVELOPMENT; ECTOPIC EXPRESSION; FROG EMBRYOS; BETA FAMILY; PATTERN; ORGANIZER; WNT	The wingless (wg) and decapentaplegic (dpp) genes of Drosophila encode homologs of secreted growth factors and are required for the correct patterning of the appendages. We show that the presumptive tips of both the leg and wing, the distal extreme of the proximodistal axis, are characterized by the close association of cells expressing wg, dpp, and the homeobox gene aristaless (al). Ectopic expression of wg can induce both ectopic al expression and a duplication of the proximodistal axis (the development of supernumerary legs), but only in regions expressing high levels of dpp. Ectopic al expression can induce a duplication of the proximodistal axis in the wing, suggesting that it may also be directly involved in axis specification. The proximodistal axis may be specified via a mechanism involving a direct interaction between cells expressing wg, dpp, and possibly al.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology				Campbell, Gerard/0000-0002-7631-4394				ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; BAKER NE, 1988, DEVELOPMENT, V102, P489; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BATE M, 1991, DEVELOPMENT, V112, P755; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; Bryant P.J., 1978, P230; Bryant PJ, 1987, GENETIC REGULATION D, P339; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; CONDIC ML, 1991, DEVELOPMENT, V111, P23; DAVIS LG, 1986, METHODS MOL BIOL; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GELBART WM, 1989, DEVELOPMENT, V107, P65; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; Grigliati T., 1986, DROSOPHILA PRACTICAL, P39; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LEWIS EB, 1945, GENETICS, V30, P137; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MEINHARDT H, 1982, DEV ORDER ITS ORIGIN, P439; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; POODRY CA, 1970, ROUX ARCH DEV BIOL, V166, P1, DOI 10.1007/BF00576805; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; POSTLETHWAIT JH, 1978, GENETICS BIOL DROS C, V2, P359; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; SCHUBIGER G, 1968, ROUX ARCH DEV BIOL, V160, P9; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; SMITH JC, 1989, DEVELOPMENT, V107, P149; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SOKOL SY, 1992, DEV BIOL, V154, P348, DOI 10.1016/0012-1606(92)90073-P; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Stern C, 1926, GENETICS, V11, P503; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481	59	246	247	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					1113	1123		10.1016/0092-8674(93)90732-6	http://dx.doi.org/10.1016/0092-8674(93)90732-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8104704				2022-12-01	WOS:A1993LY49300017
J	STEINHOFF, MC				STEINHOFF, MC			DEVELOPING AND DEPLOYING PNEUMOCOCCAL AND HAEMOPHILUS VACCINES	LANCET			English	Editorial Material											STEINHOFF, MC (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21218, USA.							FUNKHOUSER A, 1991, REV INFECT DIS, V13, P542; MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5; RILEY ID, 1991, REV INFECT DIS, V13, P535; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; STEINHOFF MC, 1992, 32ND INT C ANT AG CH, P325; 1986, NEW VACCINE DEV ESTA, V2, P357	6	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					630	631		10.1016/0140-6736(93)91754-A	http://dx.doi.org/10.1016/0140-6736(93)91754-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103141				2022-12-01	WOS:A1993LX27200005
J	XUE, D; TU, Y; CHALFIE, M				XUE, D; TU, Y; CHALFIE, M			COOPERATIVE INTERACTIONS BETWEEN THE CAENORHABDITIS-ELEGANS HOMEOPROTEINS UNC-86 AND MEC-3	SCIENCE			English	Article							DROSOPHILA HOMEODOMAIN PROTEINS; DNA-BINDING SPECIFICITY; TOUCH RECEPTOR NEURONS; POU-DOMAIN PROTEINS; C-ELEGANS; RNA-POLYMERASE; TRANSCRIPTION FACTORS; CELL IDENTITY; GENE; EXPRESSION	The POU-type homeodomain protein UNC-86 and the LIM-type homeodomain protein MEC-3, which specify neuronal cell fate in the nematode Caenorhabditis elegans, bind cooperatively as a heterodimer to the mec-3 promoter. Heterodimer formation increases DNA binding stability and, therefore, increases DNA binding specificity. The in vivo significance of this heterodimer formation in neuronal differentiation is suggested by (i) a loss-of-function mec-3 mutation whose product in vitro binds DNA well but forms heterodimers with UNC-86 poorly and (ii) a mec-3 mutation with wild-type function whose product binds DNA poorly but forms heterodimers well.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University				XUE, DING/0000-0002-8429-8136	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030997, R01GM030997] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30997] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; FRITSCH EFJ, 1989, MOL CLONING LABORATO; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MITANI S, IN PRESS DEVELOPMENT; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TREISMAN J, 1989, CELL, V59, P553; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WAY JC, 1991, GENE DEV, V5, P2199, DOI 10.1101/gad.5.12a.2199; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WILLIAMS BD, 1992, GENETICS, V131, P609; XUE D, 1992, EMBO J, V11, P4969, DOI 10.1002/j.1460-2075.1992.tb05604.x; XUE DF, UNPUB; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	51	194	201	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1324	1328		10.1126/science.8103239	http://dx.doi.org/10.1126/science.8103239			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	8103239				2022-12-01	WOS:A1993LV65600029
J	CINQUE, P; BRYTTING, M; VAGO, L; CASTAGNA, A; PARRAVICINI, C; ZANCHETTA, N; MONFORTE, AD; WAHREN, B; LAZZARIN, A; LINDE, A				CINQUE, P; BRYTTING, M; VAGO, L; CASTAGNA, A; PARRAVICINI, C; ZANCHETTA, N; MONFORTE, AD; WAHREN, B; LAZZARIN, A; LINDE, A			EPSTEIN-BARR-VIRUS DNA IN CEREBROSPINAL-FLUID FROM PATIENTS WITH AIDS-RELATED PRIMARY LYMPHOMA OF THE CENTRAL-NERVOUS-SYSTEM	LANCET			English	Article							POLYMERASE CHAIN-REACTION; AMPLIFICATION; DIAGNOSIS	Epstein-Barr virus (EBV) is constantly associated with AIDS-related primary lymphomas of the central nervous system (CNS). To assess whether EBV DNA in cerebrospinal fluid (CSF) could be used as a tumour marker, CSF samples that had been taken within 180 days before death from 85 patients with HIV infection and neurological disorders at necropsy were examined retrospectively by nested polymerase chain reaction (PCR) for EBV. Histologically evident primary CNS lymphomas were found in 17 patients, and EBV was shown in tissue by in-situ hybridisation in 16 of the 16 cases examined. All 17 patients with primary CNS lymphoma had EBV DNA in CSF. EBV DNA was found in CSF from 1 of 68 HIV-infected patients without histologically detectable lymphoma at necropsy. PCR for EBV DNA in CSF was 100% sensitive and 98.5% specific for AIDS-associated primary CNS lymphoma, and may be useful as a diagnostic tumour marker.	UNIV MILAN,S RAFFAELE HOSP,DEPT INFECT DIS,I-20122 MILAN,ITALY; NATL BACTERIOL LAB,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN; KAROLINSKA INST,S-10401 STOCKHOLM 60,SWEDEN; UNIV MILAN,L SACCO HOSP,DEPT PATHOL 5,I-20122 MILAN,ITALY; UNIV MILAN,L SACCO HOSP,CENT ANAL LAB,I-20122 MILAN,ITALY; UNIV MILAN,L SACCO HOSP,INFECT DIS CLIN,I-20122 MILAN,ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Karolinska Institutet; University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital			Castagna, Antonella/K-3280-2018; Cinque, Paola/AAA-1227-2019; LAZZARIN, Adriano/K-3607-2018	Castagna, Antonella/0000-0002-8338-9714; Cinque, Paola/0000-0003-2448-5957; LAZZARIN, Adriano/0000-0003-2551-7754				[Anonymous], 1982, CANCER, V49, P2112; AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BRYTTING M, 1992, J CLIN MICROBIOL, V30, P1937, DOI 10.1128/JCM.30.8.1937-1941.1992; CHAPPELL ET, 1992, NEUROSURGERY, V30, P825, DOI 10.1227/00006123-199206000-00001; CINQUE P, 1992, J INFECT DIS, V166, P1408, DOI 10.1093/infdis/166.6.1408; CINQUE P, 1993, 4TH INT C CYT PAR; GULLEY ML, 1992, CANCER, V70, P185, DOI 10.1002/1097-0142(19920701)70:1<185::AID-CNCR2820700129>3.0.CO;2-J; HAMILTONDUTOIT SJ, 1991, AM J PATHOL, V138, P149; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HSIA K, 1989, J CLIN MICROBIOL, V27, P1802, DOI 10.1128/JCM.27.8.1802-1809.1989; KATZ BZ, 1992, AM J PATHOL, V140, P1247; MACMAHON EME, 1991, LANCET, V338, P969, DOI 10.1016/0140-6736(91)91837-K; Maniatis T., 1982, MOL CLONING; PARRAVICINI CL, 1988, AIDS, V2, P171; SUMAYA CV, 1986, J INFECT DIS, V154, P864, DOI 10.1093/infdis/154.5.864	16	263	272	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					398	401		10.1016/0140-6736(93)92814-A	http://dx.doi.org/10.1016/0140-6736(93)92814-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101902				2022-12-01	WOS:A1993LR90000010
J	JAMESON, BA; MCDONNELL, JM; MARINI, JC; KORNGOLD, R				JAMESON, BA; MCDONNELL, JM; MARINI, JC; KORNGOLD, R			A RATIONALLY DESIGNED CD4 ANALOG INHIBITS EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS	NATURE			English	Article							MONOCLONAL-ANTIBODY	EXPERIMENTAL allergic encephalomyelitis (EAE) is an acute inflammatory autoimmune disease of the central nervous system that can be elicited in rodents and is the major animal model for the study of multiple sclerosis (MS)(1,2). The pathogenesis of both EAE and MS directly involves the CD4(+) helper T-cell subset(3-5) Anti-CD4 monoclonal antibodies inhibit the development of EAE in rodents(6-9), and are currently being used in human clinical trials for MS. We report here that similar therapeutic effects can be achieved in mice using a small (rationally designed) synthetic analogue of the CD4 protein surface. It greatly inhibits both clinical incidence and severity of EAE with a single injection, but does so without depletion of the CD4(+) subset and without the inherent immunogenicity of an antibody. Furthermore, this analogue is capable of exerting its effects on disease even after the onset of symptoms.			JAMESON, BA (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA.			McDonnell, James/0000-0001-9037-2980				BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BERNARD CCA, 1976, EUR J IMMUNOL, V6, P655, DOI 10.1002/eji.1830060912; BROSTOFF SW, 1984, J IMMUNOL, V133, P1938; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; HAFLER DA, 1989, IMMUNOL TODAY, V10, P104, DOI 10.1016/0167-5699(89)90236-3; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MCDONNELL JM, 1992, J IMMUNOL, V149, P1626; MCDONNELL JM, 1992, IMMUNOMETHODS, V1, P33; ONEILL JK, 1993, NEUROIMMUNOLOGY, V45, P1; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; SRIRAM S, 1986, J IMMUNOL, V136, P4464; SU CM, 1991, HORM METAB RES, V23, P15, DOI 10.1055/s-2007-1003601; TRAUGOTT U, 1983, SCIENCE, V219, P308, DOI 10.1126/science.6217550; WALDOR MK, 1985, SCIENCE, V227, P415, DOI 10.1126/science.3155574	14	134	202	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 21	1994	368	6473					744	746		10.1038/368744a0	http://dx.doi.org/10.1038/368744a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152486				2022-12-01	WOS:A1994NG55300059
J	NORRIS, DP; PATEL, D; KAY, GF; PENNY, GD; BROCKDORFF, N; SHEARDOWN, SA; RASTAN, S				NORRIS, DP; PATEL, D; KAY, GF; PENNY, GD; BROCKDORFF, N; SHEARDOWN, SA; RASTAN, S			EVIDENCE THAT RANDOM AND IMPRINTED XIST EXPRESSION IS CONTROLLED BY PREEMPTIVE METHYLATION	CELL			English	Article							X-CHROMOSOME INACTIVATION; CPG-RICH ISLANDS; DNA METHYLATION; MOUSE EMBRYOS; SEQUENCE SPECIFICITY; CELLS; GENE; DIFFERENTIATION; TRANSGENE; NUCLEUS	The mouse Xist gene is expressed exclusively from the inactive X chromosome and may control the initiation of X inactivation. We show that in somatic tissues the 5' end of the silent Xist allele on the active X chromosome is fully methylated, while the expressed allele on the inactive X is completely unmethylated. In tissues that undergo imprinted paternal Xist expression and imprinted X inactivation, the paternal Xist allele is unmethylated, and the silent maternal allele is fully methylated. In the male germline, a developmentally regulated demethylation of Xist occurs at the onset of meiosis and is retained in mature spermatozoa. This may be the cause of imprinted expression of the paternal Xist allele. A role for methylation in the control of Xist expression is further supported by the finding that in differentiating embryonic stem cells during the initiation of X inactivation, differential methylation of Xist alleles precedes the onset of Xist expression.			NORRIS, DP (corresponding author), MRC,CLIN RES CTR,COMPARAT BIOL SECT,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.		Kay, Graham F/A-4130-2011	Brockdorff, Neil/0000-0003-4838-2653				ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1993, CURR BIOL, V3, P275, DOI 10.1016/0960-9822(93)90177-P; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; GOETZ P, 1984, J CELL SCI, V65, P249; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HOGAN BLM, 1981, J EMBRYOL EXP MORPH, V62, P379; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JOHNSTON PG, 1981, GENET RES, V37, P151, DOI 10.1017/S0016672300020127; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; LEVAKSVA.B, 1969, EXPERIENTIA, V25, P1311, DOI 10.1007/BF01897519; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LYON MF, 1993, TRENDS GENET, V9, P123, DOI 10.1016/0168-9525(93)90206-W; LYON MF, 1964, CYTOGENETICS, V3, P306, DOI 10.1159/000129820; LYON MF, 1984, DIFFERENTIATION, V26, P63, DOI 10.1111/j.1432-0436.1984.tb01375.x; LYON MF, 1961, NATURE, V190, P373; LYON MF, 1989, GENETIC VARIANTS STA; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; MCCARREY JR, 1992, NAT GENET, V2, P200, DOI 10.1038/ng1192-200; MCLAREN A, 1984, SOC EXP BIOL S, V38, P2; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; MONK M, 1991, DEVELOPMENT, V112, P189; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; MONK M, 1987, P139; MONK M, 1987, DEVELOPMENT, V99, P371; MONK M, 1990, PHILOS T ROY SOC B, V326, P179; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; NORRIS DP, 1991, MAMM GENOME, V1, P78, DOI 10.1007/BF02443782; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RICHLER C, 1992, NAT GENET, V2, P192, DOI 10.1038/ng1192-192; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SALIDO EC, 1992, NAT GENET, V2, P196, DOI 10.1038/ng1192-196; SCHEDL A, 1992, GENOMICS, V14, P288, DOI 10.1016/S0888-7543(05)80218-6; SMITH AG, 1992, CELL BIOL, V3, P385; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SURANI MA, 1988, DEVELOPMENT, V103, P171; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; TADA T, 1994, IN PRESS DEVELOPMENT; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; VENOLIA L, 1982, P NATL ACAD SCI-BIOL, V79, P2352, DOI 10.1073/pnas.79.7.2352; WEST JD, 1977, CELL, V12, P873, DOI 10.1016/0092-8674(77)90151-9; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0	58	223	225	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					41	51		10.1016/0092-8674(94)90233-X	http://dx.doi.org/10.1016/0092-8674(94)90233-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156596				2022-12-01	WOS:A1994NF21100008
J	WALTUCK, J; BUYON, JP				WALTUCK, J; BUYON, JP			AUTOANTIBODY-ASSOCIATED CONGENITAL HEART-BLOCK - OUTCOME IN MOTHERS AND CHILDREN	ANNALS OF INTERNAL MEDICINE			English	Article						HEART BLOCK; AUTOANTIBODIES; AUTOIMMUNE DISEASES; RHEUMATIC DISEASES; PACEMAKER, ARTIFICIAL	SYSTEMIC LUPUS-ERYTHEMATOSUS; CONNECTIVE-TISSUE DISEASE; COMPLETE ATRIOVENTRICULAR-BLOCK; SS-A ANTIBODIES; NEONATAL LUPUS; RO; LA; ANTIGEN; PREDNISOLONE; EXPERIENCE	Objective: To determine the initial clinical status and the long-term outcome of mothers and their children with autoantibody-associated congenital heart block. Design: Dynamic, longitudinal cohort study. Patients: 55 children with isolated congenital heart block, their 52 mothers, and 5 other women currently carrying fetuses with congenital heart block. All maternal sera contained antibodies to SSA/Ro alone or to both SSA/Ro and SSB/La. Measurements: Clinical information obtained from mailed questionnaires, telephone interviews, primary physicians, and chart reviews. Results: When congenital heart block was identified in the children, 23 women were asymptomatic, 15 had systemic lupus erythematosus, 8 had the Sjogren syndrome, and 11 had an undifferentiated autoimmune syndrome. Follow-up ranged from 1 week to 20 years (median, 3.7 years). Eleven (48%) of the 23 initially asymptomatic mothers developed symptoms of a rheumatic disease (0.15 status changes/patient-year of follow-up; 6 (26%) developed an undifferentiated autoimmune syndrome, 2 (9%) developed the Sjogren syndrome, and 3 (13%) developed systemic lupus erythematosus. One mother with the Sjogren syndrome progressed to systemic lupus erythematosus. Four (16%) of 25 subsequent pregnancies in 22 women were complicated by heart block. Seventeen affected children died, 12 within 1 month of birth. Pacemakers were implanted in 37 (67%) of the 55 children, 27 within 3 months after birth. Conclusion: The development of rheumatic disease in asymptomatic mothers identified by the birth of a child with congenital heart block is common but not universal. The risk for congenital heart block in subsequent pregnancies is low. One third of the children with autoantibody-associated congenital heart block die in the early neonatal period and, of those who survive, most require pacemakers.	NYU, HOSP JOINT DIS, SCH MED, NEW YORK, NY 10003 USA	New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC				Buyon, Jill/0000-0002-3852-7129				ALEXANDER E, 1992, ARTHRITIS RHEUM-US, V35, P176, DOI 10.1002/art.1780350209; ALEXANDER EL, 1989, J INVEST DERMATOL, V93, P751, DOI 10.1111/1523-1747.ep12284404; [Anonymous], ARCH MED ENFANTS; BABOONIAN C, 1989, CLIN EXP IMMUNOL, V78, P454; BEITINS IZ, 1972, J PEDIATR-US, V81, P936, DOI 10.1016/S0022-3476(72)80547-X; BIERMAN FZ, 1988, J PEDIATR-US, V112, P646, DOI 10.1016/S0022-3476(88)80189-6; BLANFORD AT, 1977, AM J OBSTET GYNECOL, V127, P264, DOI 10.1016/0002-9378(77)90466-5; BUYON JP, 1990, ARTHRITIS RHEUM, V33, P609, DOI 10.1002/art.1780330502; BUYON JP, 1989, J CLIN INVEST, V84, P627, DOI 10.1172/JCI114208; BUYON JP, 1993, ARTHRITIS RHEUM, V36, P1263, DOI 10.1002/art.1780360911; BUYON JP, 1987, ARTHRITIS RHEUM, V30, P44, DOI 10.1002/art.1780300106; BUYON JP, 1990, J IMMUNOL METHODS, V129, P207, DOI 10.1016/0022-1759(90)90440-7; CARREIRA PE, 1993, J RHEUMATOL, V20, P1204; CARTER JB, 1974, ARCH PATHOL, V97, P51; CHAMEIDES L, 1977, NEW ENGL J MED, V297, P1204, DOI 10.1056/NEJM197712012972203; DENG JS, 1985, J INVEST DERMATOL, V85, P412, DOI 10.1111/1523-1747.ep12277079; DERKSEN RHWM, 1992, ARTHRITIS RHEUM, V35, P953, DOI 10.1002/art.1780350817; DEWEY RC, 1987, NEW ENGL J MED, V316, P835, DOI 10.1056/NEJM198704023161403; ELKAYAM U, 1990, CARDIAC PROBLEMS PRE, P611; ESSCHER E, 1983, PEDIATR CARDIOL, V4, P121, DOI 10.1007/BF02076336; FOX RI, 1986, SCAND J RHEUMATOL, P28; FOX RJ, 1979, ARCH DERMATOL, V115, P340, DOI 10.1001/archderm.115.3.340; HARLEY JB, 1985, ARTHRITIS RHEUM, V28, P1321, DOI 10.1002/art.1780281202; HERREMAN G, 1985, NEW ENGL J MED, V312, P1329; HORSFALL AC, 1991, J AUTOIMMUN, V4, P165, DOI 10.1016/0896-8411(91)90015-5; JACKSON R, 1979, BRIT J DERMATOL, V101, P81, DOI 10.1111/j.1365-2133.1979.tb15297.x; JORDAN JM, 1989, PEDIATRICS, V84, P574; KEPHART DC, 1981, J INVEST DERMATOL, V77, P331, DOI 10.1111/1523-1747.ep12482531; LAXER RM, 1990, J PEDIATR-US, V116, P238, DOI 10.1016/S0022-3476(05)82880-X; LEE L A, 1983, Arthritis and Rheumatism, V26, pS24; LITSEY SE, 1985, NEW ENGL J MED, V312, P98, DOI 10.1056/NEJM198501103120206; LOCKSHIN MD, 1988, ARTHRITIS RHEUM, V31, P697, DOI 10.1002/art.1780310601; MACHADO MV, 1988, BRIT HEART J, V60, P512; MADISON JP, 1979, AM HEART J, V98, P505, DOI 10.1016/0002-8703(79)90257-6; MANTHORPE R, 1986, SCAND J RHEUMATOL, P19; MCCUE CM, 1977, CIRCULATION, V56, P82, DOI 10.1161/01.CIR.56.1.82; MCCUISTION CH, 1954, AMA ARCH DERM SYPH, V70, P782, DOI 10.1001/archderm.1954.01540240088009; MCCUNE AB, 1987, ANN INTERN MED, V106, P518, DOI 10.7326/0003-4819-106-4-518; Michaelsson M, 1972, Cardiovasc Clin, V4, P85; PINSKY WW, 1982, PEDIATRICS, V69, P728; PLANT RK, 1945, AM HEART J, V30, P615, DOI 10.1016/0002-8703(45)90220-1; PROVOST TT, 1987, J RHEUMATOL, V14, P199; RAMSEYGOLDMAN R, 1986, ARTHRITIS RHEUM, V29, P1269, DOI 10.1002/art.1780291013; RIDER LG, 1993, J RHEUMATOL, V20, P1208; SCHMIDT KG, 1991, J AM COLL CARDIOL, V17, P1360, DOI 10.1016/S0735-1097(10)80148-2; SCHOENLEBE J, 1993, AM J DIS CHILD, V147, P1072, DOI 10.1001/archpedi.1993.02160340058014; SCOTT JS, 1983, NEW ENGL J MED, V309, P209, DOI 10.1056/NEJM198307283090403; SINGSEN BH, 1985, AM J OBSTET GYNECOL, V152, P655, DOI 10.1016/S0002-9378(85)80039-9; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VITALI C, 1993, ARTHRITIS RHEUM, V36, P340, DOI 10.1002/art.1780360309; WASICEK CA, 1982, J CLIN INVEST, V69, P835, DOI 10.1172/JCI110523; WATSON R, 1988, ARCH DERMATOL, V124, P560, DOI 10.1001/archderm.124.4.560; WATSON RM, 1984, MEDICINE, V63, P362, DOI 10.1097/00005792-198411000-00003; WINKLER RB, 1977, CIRCULATION, V56, P1103, DOI 10.1161/01.CIR.56.6.1103	54	241	259	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					544	551		10.7326/0003-4819-120-7-199404010-00003	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116991				2022-12-01	WOS:A1994NC76400003
J	KELLY, DP; STRAUSS, AW				KELLY, DP; STRAUSS, AW			MECHANISMS OF DISEASE - INHERITED CARDIOMYOPATHIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; A DEHYDROGENASE-DEFICIENCY; IDIOPATHIC DILATED CARDIOMYOPATHY; DUCHENNE MUSCULAR-DYSTROPHY; MYOSIN HEAVY-CHAIN; CARNITINE PALMITOYLTRANSFERASE-II; SUDDEN CHILD-DEATH; MITOCHONDRIAL-DNA; MOLECULAR-BASIS; GENETIC-HETEROGENEITY		WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	KELLY, DP (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,DIV CARDIOVASC,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.							ALMAHDAWI S, 1993, BRIT HEART J, V69, P136; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ARAHATA K, 1988, NATURE, V333, P861, DOI 10.1038/333861a0; BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5; BERKO BA, 1987, NEW ENGL J MED, V316, P1186, DOI 10.1056/NEJM198705073161904; BIES RD, 1992, CIRCULATION, V86, P147, DOI 10.1161/01.CIR.86.1.147; CARRIER L, 1993, NAT GENET, V4, P311, DOI 10.1038/ng0793-311; CIRO E, 1983, CIRCULATION, V67, P1227, DOI 10.1161/01.CIR.67.6.1227; COATES PM, 1992, NEW DEV FATTY ACID O, P409; CORR PB, 1989, J CLIN INVEST, V83, P927, DOI 10.1172/JCI113978; CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; DURAN M, 1986, PEDIATRICS, V78, P1052; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; EPSTEIN ND, 1992, CIRCULATION, V85, P635, DOI 10.1161/01.CIR.85.2.635; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FANANAPAZIR L, 1994, CIRCULATION, V89, P22, DOI 10.1161/01.CIR.89.1.22; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GRABER HL, 1986, CIRCULATION, V74, P21, DOI 10.1161/01.CIR.74.1.21; GREGERSEN N, 1991, HUM GENET, V86, P545; HALE DE, 1985, PEDIATR RES, V19, P666, DOI 10.1203/00006450-198507000-00006; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; HUG G, 1991, NEW ENGL J MED, V325, P1862, DOI 10.1056/NEJM199112263252607; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; KELLY DP, 1990, P NATL ACAD SCI USA, V87, P9236, DOI 10.1073/pnas.87.23.9236; KELLY DP, 1992, J INHERIT METAB DIS, V15, P171, DOI 10.1007/BF01799626; KELLY DP, 1993, AM J CARDIOL, V71, P731; KO YL, 1992, HUM GENET, V89, P597; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; MARIAN AJ, 1992, J CLIN INVEST, V90, P2156, DOI 10.1172/JCI116101; MARIAN AJ, 1992, CIRCULATION S1, V86, P1; MARON BJ, 1984, AM J CARDIOL, V53, P1087, DOI 10.1016/0002-9149(84)90643-X; MASTAGLIA FL, 1982, SKELETAL MUSCLE PATH; MATSUBARA Y, 1990, LANCET, V335, P1589, DOI 10.1016/0140-6736(90)91413-5; MATSUBARA Y, 1991, LANCET, V338, P552, DOI 10.1016/0140-6736(91)91110-G; MESTRONI L, 1990, AM J CARDIOL, V65, P1449, DOI 10.1016/0002-9149(90)91353-8; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; NAITO E, 1990, J CLIN INVEST, V85, P1575, DOI 10.1172/JCI114607; NAITO E, 1989, J CLIN INVEST, V83, P1605, DOI 10.1172/JCI114058; NEELY J R, 1972, Progress in Cardiovascular Diseases, V15, P289, DOI 10.1016/0033-0620(72)90029-1; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; PERLOFF JK, 1966, CIRCULATION, V33, P625, DOI 10.1161/01.CIR.33.4.625; ROCCHICCIOLI F, 1990, PEDIATR RES, V28, P657, DOI 10.1203/00006450-199012000-00023; ROE CR, 1989, METABOLIC BASIS INHE, V1, P889; SCHWARTZ K, 1992, CIRC RES, V71, P3, DOI 10.1161/01.RES.71.1.3; SOLOMON SD, 1990, J CLIN INVEST, V86, P993, DOI 10.1172/JCI114802; STANLEY CA, 1992, NEW ENGL J MED, V327, P19, DOI 10.1056/NEJM199207023270104; SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3; Tanaka K., 1992, Human Mutation, V1, P271, DOI 10.1002/humu.1380010402; TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9; TARONI F, 1992, P NATL ACAD SCI USA, V89, P8429, DOI 10.1073/pnas.89.18.8429; TEIN I, 1990, PEDIATR RES, V28, P247, DOI 10.1203/00006450-199009000-00020; THIERFELDER L, 1993, P NATL ACAD SCI USA, V90, P6270, DOI 10.1073/pnas.90.13.6270; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; WALLACE DC, 1986, SOMAT CELL MOLEC GEN, V12, P41, DOI 10.1007/BF01560726; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WATKINS H, 1993, NAT GENET, V3, P333, DOI 10.1038/ng0493-333; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; WATKINS H, 1992, J CLIN INVEST, V90, P1666, DOI 10.1172/JCI116038; YOKOTA I, 1990, J CLIN INVEST, V86, P1000, DOI 10.1172/JCI114761; ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D	65	284	289	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	1994	330	13					913	919						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC608	8114864				2022-12-01	WOS:A1994NC60800008
J	ANDERSSON, L; HALEY, CS; ELLEGREN, H; KNOTT, SA; JOHANSSON, M; ANDERSSON, K; ANDERSSONEKLUND, L; EDFORSLILJA, I; FREDHOLM, M; HANSSON, I; HAKANSSON, J; LUNDSTROM, K				ANDERSSON, L; HALEY, CS; ELLEGREN, H; KNOTT, SA; JOHANSSON, M; ANDERSSON, K; ANDERSSONEKLUND, L; EDFORSLILJA, I; FREDHOLM, M; HANSSON, I; HAKANSSON, J; LUNDSTROM, K			GENETIC-MAPPING OF QUANTITATIVE TRAIT LOCI FOR GROWTH AND FATNESS IN PIGS	SCIENCE			English	Article							MENDELIAN FACTORS; IDENTIFICATION; MARKERS	The European wild boar was crossed with the domesticated Large White pig to genetically dissect phenotypic differences between these populations for growth and fat deposition. The most important effects were clustered on chromosome 4, with a single region accounting for a large part of the breed difference in growth rate, fatness, and length of the small intestine. The study is an advance in genome analyses and documents the usefulness of crosses between divergent outbred populations for the detection and characterization of quantitative trait loci. The genetic mapping of a major locus for fat deposition in the pig could have implications for understanding human obesity.	AFRC,ROSLIN INST EDINBURGH,ROSLIN EH25 9PS,MIDLOTHIAN,SCOTLAND; INRA,GENET QUANTITAT & APPL STN,F-78350 JOUY EN JOSAS,FRANCE; UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,EDINBURGH EH9 3JT,SCOTLAND; ROYAL VET & AGR UNIV,DEPT ANIM PROD & ANIM HLTH,DIV ANIM GENET,DK-1870 FREDERIKSBERG C,DENMARK; SWEDISH UNIV AGR SCI,DEPT FOOD SCI,S-75007 UPPSALA,SWEDEN; SWEDISH UNIV AGR SCI,DEPT ANIM NUTR & MANAGEMENT,S-75007 UPPSALA,SWEDEN	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of Edinburgh; University of Copenhagen; Swedish University of Agricultural Sciences; Swedish University of Agricultural Sciences	ANDERSSON, L (corresponding author), SWEDISH UNIV AGR SCI,DEPT ANIM BREEDING & GENET,BOX 7023,S-75007 UPPSALA,SWEDEN.		Knott, Sara A/H-2466-2013; Haley, Chris S/F-3110-2013; Giuffra, Elisabetta/J-8080-2014; Kijas, James W/A-4656-2011	Knott, Sara A/0000-0002-4568-2928; Kijas, James W/0000-0002-1417-8278; Haley, Chris/0000-0002-9811-0210; Fredholm, Merete/0000-0002-3563-7648; Moller, Maria/0000-0001-9750-6101				ABBOTT CM, 1993, MAMM GENOME, V4, pS58, DOI 10.1007/BF00360830; ANDERSSON L, 1993, ANIM GENET, V24, P205, DOI 10.1111/j.1365-2052.1993.tb00290.x; ANDERSSON L, UNPUB; BOUCHARD C, 1993, ANNU REV NUTR, V13, P337, DOI 10.1146/annurev.nu.13.070193.002005; CECI JD, 1993, MAMM GENOME, V4, pS121, DOI 10.1007/BF00360834; DARWIN C, 1882, VARIATION ANIMALS PL, V1, P77; ELLEGREN H, IN PRESS GENETICS; HALEY CS, 1992, HEREDITY, V69, P315, DOI 10.1038/hdy.1992.131; HALEY CS, IN PRESS; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JOHANSSON M, 1992, GENOMICS, V14, P965, DOI 10.1016/S0888-7543(05)80118-1; LANDER ES, 1989, GENETICS, V121, P185; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; PEARSON, 1988, SAS PROCEDURES GUIDE; PETERSSON H, 1979, SWED J AGR RES, V9, P75; PETERSSON H, 1990, THESIS SWEDISH U AGR, P57; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; SOLLER M, 1983, THEOR APPL GENET, V67, P25, DOI 10.1007/BF00303917; STUBER CW, 1992, GENETICS, V132, P823; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; VANOOIJEN JW, 1992, THEOR APPL GENET, V84, P803, DOI 10.1007/BF00227388; Wiseman J, 1986, HIST BRIT PIG	23	545	604	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1771	1774		10.1126/science.8134840	http://dx.doi.org/10.1126/science.8134840			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	8134840				2022-12-01	WOS:A1994NC04000038
J	ROCHAT, A; KOBAYASHI, K; BARRANDON, Y				ROCHAT, A; KOBAYASHI, K; BARRANDON, Y			LOCATION OF STEM-CELLS OF HUMAN HAIR-FOLLICLES BY CLONAL ANALYSIS	CELL			English	Article							OUTER ROOT SHEATH; HUMAN EPIDERMAL-KERATINOCYTES; DERMAL PAPILLA CELLS; SERIAL CULTIVATION; INVITRO; GROWTH; CULTURE; CYCLE; UNIT	We have examined the growth capacity of keratinocytes isolated from human scalp hair follicles. Like the keratinocytes of glabrous epidermis, most of the colony-forming cells are classified as holoclones or meroclones when analyzed in a clonal assay. Some of them have extensive growth potential, as they are able to undergo at least 130 doublings. Therefore, the hair follicle, like the epidermis, contains keratinocytes with the expected property of stem cells: an extensive proliferative capacity permitting the generation of a large amount of epithelium. We have also examined the distribution of clonogenic keratinocytes within the hair follicle. Several hundred colony-forming cells are concentrated at a region below the midpoint of the follicle and outside the hair bulb. This region lies deeper than the site of insertion of the arrector pili muscle, which corresponds with the position of the bulge when the latter can be identified. In contrast, few colony-forming cells are present in the hair bulb, where most of the mitotic activity is observed during the active growth phase of the follicle. Paraclones, which are present both in the midregion and in the bulb of hair follicles, are unlikely to be the transient amplifying cells expected from kinetic studies.			ROCHAT, A (corresponding author), ECOLE NORMALE SUPER, DEPT BIOL, 46 RUE ULM, F-75230 PARIS 05, FRANCE.							ALBARWARI SE, 1976, INT J RADIAT BIOL, V30, P201, DOI 10.1080/09553007614550981; ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BARRANDON Y, 1985, P NATL ACAD SCI USA, V82, P5390, DOI 10.1073/pnas.82.16.5390; BARRANDON Y, 1988, J INVEST DERMATOL, V91, P315, DOI 10.1111/1523-1747.ep12475646; BERGSTRESSER PR, 1978, J INVEST DERMATOL, V70, P280, DOI 10.1111/1523-1747.ep12541516; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; HEID HW, 1986, DIFFERENTIATION, V32, P101, DOI 10.1111/j.1432-0436.1986.tb00562.x; HOLBROOK KA, 1979, INT J DERMATOL, V18, P329, DOI 10.1111/ijd.1979.18.5.329; HOLECEK BU, 1993, AM J DERMATOPATH, V15, P235, DOI 10.1097/00000372-199306000-00007; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KOBAYASHI K, 1993, P NATL ACAD SCI USA, V90, P7391, DOI 10.1073/pnas.90.15.7391; LAJTHA LG, 1979, DIFFERENTIATION, V14, P23, DOI 10.1111/j.1432-0436.1979.tb01007.x; LAVKER RM, 1991, ANN NY ACAD SCI, V642, P214; LAVKER RM, 1983, J INVEST DERMATOL, V81, pS121, DOI 10.1111/1523-1747.ep12540880; LAVKER RM, 1982, SCIENCE, V215, P1239, DOI 10.1126/science.7058342; LENOIR MC, 1988, DEV BIOL, V130, P610, DOI 10.1016/0012-1606(88)90356-9; LENOIRVIALE MC, 1993, ARCH DERMATOL RES, V285, P197, DOI 10.1007/BF00372009; LIMAT A, 1991, EXP CELL RES, V194, P218, DOI 10.1016/0014-4827(91)90357-Z; LIMAT A, 1986, J INVEST DERMATOL, V87, P485, DOI 10.1111/1523-1747.ep12455548; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; MONTAGNA W, 1958, BIOL HAIR GROWTH, P39; MORRIS RJ, 1985, J INVEST DERMATOL, V84, P277, DOI 10.1111/1523-1747.ep12265358; MYERS RJ, 1951, ANN NY ACAD SCI, V53, P562, DOI 10.1111/j.1749-6632.1951.tb31957.x; PENNEYS NS, 1970, ARCH DERMATOL, V101, P323, DOI 10.1001/archderm.101.3.323; PHILPOTT MP, 1990, J CELL SCI, V97, P463; PINKUS F, 1910, MANUAL HUMAN EMBRYOL, P243; PINKUS H., 1958, BIOL HAIR GROWTH, P1; POTTEN CS, 1973, INT J RADIAT BIOL, V24, P537, DOI 10.1080/09553007314551441; POTTEN CS, 1983, STEM CELLS THEIR IDE, P200; REYNOLDS AJ, 1993, J INVEST DERMATOL, V101, P634, DOI 10.1111/1523-1747.ep12366095; REYNOLDS AJ, 1991, J CELL SCI, V99, P373; REYNOLDS AJ, 1992, DEVELOPMENT, V115, P587; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; UNNA PG, 1876, ARCH MIKROSK ANAT, V12, P665; VANNESTE D, 1983, BRIT J DERMATOL, V108, P433; VANSCOTT EJ, 1963, J INVEST DERMATOL, V41, P269, DOI 10.1038/jid.1963.110; WEINSTEIN GD, 1984, J INVEST DERMATOL, V82, P623, DOI 10.1111/1523-1747.ep12261462; YANG JS, 1993, J INVEST DERMATOL, V101, P652, DOI 10.1111/1523-1747.ep12371671	44	422	456	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	1994	76	6					1063	1073		10.1016/0092-8674(94)90383-2	http://dx.doi.org/10.1016/0092-8674(94)90383-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137423				2022-12-01	WOS:A1994ND24600012
J	GAO, SW; DROUIN, R; HOLMQUIST, GP				GAO, SW; DROUIN, R; HOLMQUIST, GP			DNA-REPAIR RATES MAPPED ALONG THE HUMAN PGK1 GENE AT NUCLEOTIDE RESOLUTION	SCIENCE			English	Article							LIGATION-MEDIATED PCR; PYRIMIDINE DIMERS; DHFR GENE; REMOVAL; CELLS	The repair of cyclobutane pyrimidine dimers (CPDs), DNA lesions induced by ultraviolet light, was studied at nucleotide resolution. Human fibroblasts were irradiated with ultraviolet light and allowed to repair. The DNA was enzymatically cleaved at the CPDs, and the induced breaks along the promoter and exon 1 of the PGK1 gene were mapped by ligation-mediated polymerase chain reaction. Repair rates within the nontranscribed strand varied as much as 15-fold, depending on nucleotide position. Preferential repair of the transcribed strand began just downstream of the transcription start site but was most pronounced beginning at nucleotide +140 in exon 1. The promoter contained two slowly repaired regions that coincided with two transcription factor binding sites.	BECKMAN RES INST CITY HOPE,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NCI NIH HHS [CA54773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; GORDON LK, 1980, J BIOL CHEM, V255, P2047; KANTOR GJ, 1981, CANCER RES, V41, P819; KUNALA S, 1992, P NATL ACAD SCI USA, V89, P11031, DOI 10.1073/pnas.89.22.11031; Maxam A M, 1980, Methods Enzymol, V65, P499; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PFEIFER GP, 1991, MOL CELL BIOL, V12, P1798; PFEIFER GP, 1993, METHOD ENZYMOL, V225, P557; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SINGERSAM J, 1984, GENE, V32, P409, DOI 10.1016/0378-1119(84)90016-7; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANZEELAND AA, 1990, MUTATION ENV A, P249	17	121	121	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1438	1440		10.1126/science.8128226	http://dx.doi.org/10.1126/science.8128226			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128226				2022-12-01	WOS:A1994MZ92700032
J	LENFANT, C				LENFANT, C			HOSPITAL DELAYS COMPOUND PATIENT AND TRANSPORT DELAYS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LENFANT, C (corresponding author), NHLBI,BETHESDA,MD 20892, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					738	738						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	8114202				2022-12-01	WOS:A1994MY28800008
J	LEE, DY; MALPELI, JG				LEE, DY; MALPELI, JG			GLOBAL FORM AND SINGULARITY - MODELING THE BLIND SPOTS ROLE IN LATERAL GENICULATE MORPHOGENESIS	SCIENCE			English	Article							VISUAL-FIELD; NUCLEUS; MONKEY	Optic nerve terminals segregate by functional class into distinct layers in the lateral geniculate nucleus, the thalamic relay nucleus of the visual system. In the rhesus monkey, the number of geniculate layers changes abruptly from six posteriorly (central vision) to four anteriorly (peripheral vision). The plane of transition between these patterns passes through small laminar gaps corresponding to the perceptual blind spot caused by the exit of the optic nerve from the eyeball. However, this plane of transition has no apparent functional link to the blind spot. A thermodynamic model of geniculate morphogenesis supports the hypothesis that the blind spot traps the transition in its stereotypic position by introducing a singularity in an otherwise smooth gradient in forces guiding the development of geniculate morphogenesis. This relation suggests that small-scale anomalies may be important in the determination of large-scale patterns in biological structure.	UNIV ILLINOIS,DEPT PSYCHOL,CHAMPAIGN,IL 61820; UNIV ILLINOIS,NEUROSCI PROGRAM,CHAMPAIGN,IL 61820	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Lee, Daeyeol/A-6794-2008	Lee, Daeyeol/0000-0003-3474-019X	NEI NIH HHS [EY02695] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002695] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aarts E., 1989, SIMULATED ANNEALING; BISHOP PO, 1962, J PHYSIOL-LONDON, V163, P503, DOI 10.1113/jphysiol.1962.sp006991; Clark WEL, 1941, J ANAT, V75, P419; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P219, DOI 10.1113/jphysiol.1984.sp015498; KAAS J H, 1972, Brain Behavior and Evolution, V6, P253, DOI 10.1159/000123713; KAAS JH, 1973, J COMP NEUROL, V147, P163, DOI 10.1002/cne.901470203; MALPELI JG, 1975, J COMP NEUROL, V161, P569, DOI 10.1002/cne.901610407; MALPELI JG, 1993, INVEST OPHTH VIS SCI, V34, P812; MICHAEL CR, 1988, P NATL ACAD SCI USA, V85, P4914, DOI 10.1073/pnas.85.13.4914; RAKIC P, 1981, SCIENCE, V214, P923; SANDERSON KJ, 1971, EXP BRAIN RES, V13, P159; SCHILLER PH, 1978, J NEUROPHYSIOL, V41, P788, DOI 10.1152/jn.1978.41.3.788; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P115	13	18	18	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1292	1294		10.1126/science.8122115	http://dx.doi.org/10.1126/science.8122115			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122115				2022-12-01	WOS:A1994MY57000041
J	ROSE, L				ROSE, L			HOMOPHOBIA AMONG DOCTORS	BRITISH MEDICAL JOURNAL			English	Article								Homophobia creates stress for gay men and women. An interview study of 28 doctors, 20 gay and eight non-gay, was performed to assess whether homophobia is strong among the medical profession, the stress it causes, and whether the advent of AIDS and HIV infection has increased the stress. The doctors, recruited by word of mouth and by a letter in the medical and gay press, were asked about their own attitudes to homosexuality and AIDS. Only one (non-gay) doctor thought that there was no prejudice against gay doctors in the medical profession. The gay doctors certainly perceived prejudice, which they claimed caused them extra stress; the advent of AIDS had increased this stress to an extent. Doctors who had not openly declared themselves to be gay feared doing so because of the effect on their job prospects, but those who had declared themselves openly reported less stress than previously. Homophobia clearly exists within the medical profession. Non-gay doctors should use the power of the profession to challenge homophobia in the profession and in society. HIV infection could then be treated as a purely medical condition; sufferers would receive wider understanding and the pressures of extra workload could be more equally shared.			ROSE, L (corresponding author), FDN AIDS COUNSELLING TREATMENT & SUPPORT,LONDON N8 9SY,ENGLAND.							BOLLING DR, 1987, JAMA-J AM MED ASSOC, V258, P474; Feyerabend P., 1993, METHOD; FOX DM, 1988, AIDS BURDEN HIST; GILLON R, 1987, BRIT MED J, V2, P1332; Goffman E., 1963, BEHAV PUBLIC PLACES; Goffman E., 1969, REPRESENTATION SELF; TONKS A, 1994, BRIT MED J, V308, P289, DOI 10.1136/bmj.308.6924.289; Turner B., 1987, MED POWER SOCIAL KNO; 1992, STRESS MED PROFESSIO	9	53	54	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	1994	308	6928					586	587		10.1136/bmj.308.6928.586	http://dx.doi.org/10.1136/bmj.308.6928.586			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY714	8148685	Green Published			2022-12-01	WOS:A1994MY71400029
J	MURFETT, J; ATHERTON, TL; MOU, B; GASSER, CS; MCCLURE, BA				MURFETT, J; ATHERTON, TL; MOU, B; GASSER, CS; MCCLURE, BA			S-RNASE EXPRESSED IN TRANSGENIC NICOTIANA CAUSES S-ALLELE-SPECIFIC POLLEN REJECTION	NATURE			English	Article							SELF-INCOMPATIBILITY LOCUS; SEQUENCE VARIABILITY; RIBONUCLEASE-ACTIVITY; PETUNIA-INFLATA; ALATA; GENE; PROTEINS; TRANSFORMATION; BRASSICA; PLANTS	MANY angiosperms employ self-incompatibility systems to prevent inbreeding1,2. The simple genetics of such systems3-6 have made them attractive models of plant cellular communication. Implicit in the single locus genetics is that only one or a few gene products are necessary for recognition and rejection of incompatible pollen. Results in the sporophytic system of the Brassicaceae suggest that different S-locus products are responsible for the pollen and pistil parts of the recognition and rejection response7,8. In solanaceous plants, which have a gametophytic self-incompatibility system, the S-locus product responsible for the pollen portion of the interaction has not been identified, but ribonucleases encoded by the S-locus (S-RNases) are strongly implicated in the style part of the recognition and rejection reaction9-14. In Nicotiana alata, pollen r cognition and rejection occur if its S-allele matches either S-allele in the style. The putative stylar S-RNase is abundant in the transmitting tract15, and pollen rejection may be related to action of S-RNaSe on pollen RNAs10. Efforts to understand the molecular basis for pollen recognition and rejection have been limited by the lack of a system for manipulating and expressing S-RNases4-6,16. Here we use the promoter of a style-expressed gene from tomato to obtain high levels of S-RNase expression in transgenic Nicotiana. Recognition and rejection of N. alata pollen S-alleles occur faithfully in the transgenic plants. Our results show that S-RNases alone are sufficient for pollen rejection in this system.	UNIV MISSOURI,DEPT BIOCHEM,117 SCHWEITZER HALL,COLUMBIA,MO 65211; UNIV CALIF DAVIS,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of Missouri System; University of Missouri Columbia; University of California System; University of California Davis				Gasser, Charles/0000-0001-5735-8175				AI YJ, 1990, SEX PLANT REPROD, V3, P130, DOI 10.1007/BF00198857; ANDERSON MA, 1989, PLANT CELL, V1, P483, DOI 10.1105/tpc.1.5.483; ANDERSON MA, 1986, NATURE, V321, P38, DOI 10.1038/321038a0; BERNATZKY R, 1986, THEOR APPL GENET, V72, P314, DOI 10.1007/BF00288567; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BROOTHAERTS W, 1991, SEX PLANT REPROD, V4, P258, DOI 10.1007/BF00200545; CLARK KR, 1990, PLANT CELL, V2, P815, DOI 10.1105/tpc.2.8.815; COLEMAN CE, 1992, PLANT MOL BIOL, V18, P725, DOI 10.1007/BF00020014; de Nettancourt D., 1977, INCOMPATIBILITY ANGI, DOI DOI 10.1007/BF00276804; EBERT PR, 1990, PLANT MOL BIOL, V14, P815, DOI 10.1007/BF00016514; GASSER CS, 1989, PLANT CELL, V1, P15, DOI 10.1105/tpc.1.1.15; GASSER CS, 1993, MOL BIOL TOMATO, P161; GORING DR, 1993, PLANT CELL, V5, P531, DOI 10.1105/tpc.5.5.531; HARING V, 1990, SCIENCE, V250, P937, DOI 10.1126/science.2237440; IOERGER TR, 1991, SEX PLANT REPROD, V4, P81; JAHNEN W, 1989, PLANT CELL, V1, P493, DOI 10.1105/tpc.1.5.493; KAUFMANN H, 1991, MOL GEN GENET, V226, P457, DOI 10.1007/BF00260659; KHEYRPOUR A, 1990, SEX PLANT REPROD, V3, P88, DOI 10.1007/BF00198851; KHO YO, 1968, EUPHYTICA, V17, P299; MCCLURE BA, 1989, SCIENCE, V243, P91, DOI 10.1126/science.11540631; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; MURFETT J, 1992, PLANT CELL, V4, P1063, DOI 10.2307/3869475; MURFETT J, 1993, MOL BIOL TOMATO, P139; NASRALLAH JB, 1991, ANNU REV PLANT PHYS, V42, P393, DOI 10.1146/annurev.pp.42.060191.002141; SIMS TL, 1993, CRIT REV PLANT SCI, V12, P129, DOI 10.1080/07352689309382359; SINGH A, 1991, PLANT PHYSIOL, V96, P61, DOI 10.1104/pp.96.1.61; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; Stevens WL, 1942, J GENET, V43, P301, DOI 10.1007/BF02982905; THOMPSON RD, 1992, TRENDS GENET, V8, P381, DOI 10.1016/0168-9525(92)90299-J	30	310	339	2	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					563	566		10.1038/367563a0	http://dx.doi.org/10.1038/367563a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	8107825				2022-12-01	WOS:A1994MV86300060
J	HE, Y; LAM, TH; LI, LS; LI, LS; DU, RY; JIA, GL; HUANG, JY; ZHENG, JS				HE, Y; LAM, TH; LI, LS; LI, LS; DU, RY; JIA, GL; HUANG, JY; ZHENG, JS			PASSIVE SMOKING AT WORK AS A RISK FACTOR FOR CORONARY HEART-DISEASE IN CHINESE WOMEN WHO HAVE NEVER SMOKED	BRITISH MEDICAL JOURNAL			English	Article								Objective-To study whether passive smoking at work is a risk factor for coronary heart disease. Design-Case-control study. Setting-Xi'an, China. Subject-59 patients with coronary heart disease and 126 controls, all Chinese women with full time jobs, who had never smoked cigarettes. Results-The crude odds ratio for passive smoking from husband was 2.12 (95% confidence interval 1.06 to 4.25) and at work was 2.45 (1.23 to 4.88). The final logistic regression model, with passive smoking from husband and at work as the base, included age, history of hypertension, type A personality, and total cholesterol and high density lipoprotein cholesterol concentrations; the adjusted odds ratios for passive smoking from husband and at work were 1.24 (0.56 to 2.72) and 1.85 (0.86 to 4.00) respectively. For passive smoking at work, statistically significant linear trends of increasing risks (for both crude and adjusted odds ratios) with increasing exposures (amount exposed daily, number of smokers, number of hours exposed daily, and cumulative exposure) were observed. When these exposure variables were analysed as continuous variables, the crude and adjusted odds ratios were also significant. Conclusion-Passive smoking at work is a risk factor for coronary heart disease. Urgent public health measures are needed to reduce smoking and to protect non-smokers from passive smoking in China.	UNIV HONG KONG,DEPT COMMUNITY MED,5 SASSOON RD,HONG KONG,HONG KONG; MIL MED UNIV 4,DEPT EPIDEMIOL,XIAN,PEOPLES R CHINA; MIL MED UNIV,DEPT CARDIOL,XIAN,PEOPLES R CHINA	University of Hong Kong; Air Force Military Medical University; Air Force Military Medical University; Army Medical University; Naval Medical University			; Lam, Tai Hing/C-4317-2009	He, Yao/0000-0001-6205-7895; Lam, Tai Hing/0000-0002-2033-9971				BRESLOW N. E., 1980, STATISTICAL METHODS; CUMMINGS KM, 1989, AM J EPIDEMIOL, V130, P122, DOI 10.1093/oxfordjournals.aje.a115303; DOBSON AJ, 1991, MED J AUSTRALIA, V154, P793, DOI 10.5694/j.1326-5377.1991.tb121366.x; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HE Y, 1989, CHIN J PREV MED, V23, P19; JUDKINS MP, 1967, RADIOLOGY, V89, P815, DOI 10.1148/89.5.815; LEE PN, 1986, BRIT J CANCER, V54, P97, DOI 10.1038/bjc.1986.157; MACKAY J, 1993, TOB CONTROL, V2, P7; Nomenclature and criteria for diagnosis of ischemic heart disease, 1979, CIRCULATION, V59, P607; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V267, P94, DOI 10.1001/jama.267.1.94; TAYLOR AE, 1992, CIRCULATION, V86, P699, DOI 10.1161/01.CIR.86.2.699; VECCHIA CL, 1993, LANCET, V341, P505; WENG XZ, 1987, COLLECTION DATA 1984; 1992, RESPIRATORY HLTH EFF	14	66	71	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	1994	308	6925					380	384		10.1136/bmj.308.6925.380	http://dx.doi.org/10.1136/bmj.308.6925.380			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV862	8124145	Green Published			2022-12-01	WOS:A1994MV86200020
J	KASHANCHI, F; PIRAS, G; RADONOVICH, MF; DUVALL, JF; FATTAEY, A; CHIANG, CM; ROEDER, RG; BRADY, JN				KASHANCHI, F; PIRAS, G; RADONOVICH, MF; DUVALL, JF; FATTAEY, A; CHIANG, CM; ROEDER, RG; BRADY, JN			DIRECT INTERACTION OF HUMAN TFIID WITH THE HIV-1 TRANSACTIVATOR TAT	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; III TRANSCRIPTION FACTOR; RNA POLYMERASE-II; BINDING PROTEIN; ELONGATION; COMPONENTS; ACTIVATION; COMPLEXES; PROMOTER; INVITRO	THE tat gene of the human immunodeficiency virus (HIV) plays a central role in the activation and life cycle of HIV. The tat protein (Tat) specifically transactivates HIV transcription in vivo and in vitro1-8, exerting its effects at the level of transcriptional initiation and elongation. Here we report that Tat binds directly to the basal transcription factor TFIID. The transcriptional activity of HeLa extracts was depleted after chromatography on a rat affinity column, which specifically retained the polymerase II-specific factor TFIID: Direct interaction of Tat with holo-TFIID, composed of TATA-binding protein (TBP) and associated factors (TAFs), was observed. Tat binds, through amino acids 36-50, directly to the TBP subunit of TFIID. Our results suggest that Tat may transduce upstream or downstream regulatory signals by direct interaction with the basal transcription factor TFIID.	MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129; ROCKEFELLER UNIV,NEW YORK,NY 10021	Harvard University; Massachusetts General Hospital; Rockefeller University	KASHANCHI, F (corresponding author), NCI,MOLEC VIROL LAB,BETHESDA,MD 20892, USA.							BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Bohan Cindy A., 1992, Gene Expression, V2, P391; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CLLE BR, 1992, MICROBIOL REV, V56, P375; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KASHANCHI F, 1992, NUCLEIC ACIDS RES, V20, P4673, DOI 10.1093/nar/20.17.4673; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V7, P3551; LASPIA MF, 1990, GENE DEV, V4, P2397, DOI 10.1101/gad.4.12b.2397; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TILEY LS, 1990, VIROLOGY, V178, P560, DOI 10.1016/0042-6822(90)90354-T; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V	30	245	249	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					295	299		10.1038/367295a0	http://dx.doi.org/10.1038/367295a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121496				2022-12-01	WOS:A1994MR49400063
J	TAKAHASHI, H; SNOW, BJ; BHATT, MH; PEPPARD, R; EISEN, A; CALNE, DB				TAKAHASHI, H; SNOW, BJ; BHATT, MH; PEPPARD, R; EISEN, A; CALNE, DB			EVIDENCE FOR A DOPAMINERGIC DEFICIT IN SPORADIC AMYOTROPHIC-LATERAL-SCLEROSIS ON POSITRON EMISSION SCANNING	LANCET			English	Article							ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; HYPOTHESIS; DEMENTIA; DISORDERS; GUAM	Although rare, the chronic neurodegenerative disorders amyotrophic lateral sclerosis (ALS) and idiopathic parkinsonism coexist to a greater degree than expected by chance. This suggests that patients with ALS may have subclinical lesions of the nigrostriatal dopaminergic pathway. To study this hypothesis, we did positron emission tomography with 6-fluorodopa on 16 patients with sporadic ALS and without extrapyramidal disease, and compared the results with age-matched controls. We found a significant progressive fall in 6-fluorodopa uptake with time since diagnosis, and reduced dopaminergic function in 3 patients with ALS of long duration. This supports the hypothesis that ALS and IP may share pathogenesis and, perhaps, aetiology.	UNIV BRITISH COLUMBIA,CTR NEURODEGENERAT DISORDERS,VANCOUVER V6T 1W5,BC,CANADA; UBC,TRIUMF,PET PROGRAM,VANCOUVER,BC,CANADA	University of British Columbia; University of British Columbia				Bhatt, Mohit/0000-0002-5233-3371; Eisen, Andrew/0000-0002-1447-2725				APPEL SH, 1981, ANN NEUROL, V10, P499, DOI 10.1002/ana.410100602; BURROW JNC, 1992, AUST NZ J MED, V22, P469; CALNE DB, 1986, LANCET, V2, P1067, DOI 10.1016/S0140-6736(86)90469-1; CALNE DB, 1992, ANN NEUROL, V32, P799, DOI 10.1002/ana.410320615; EISEN A, 1993, MUSCLE NERVE, V16, P27, DOI 10.1002/mus.880160107; EISEN A, 1992, CAN J NEUROL SCI, V19, P117, DOI 10.1017/S0317167100041482; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; HAMMERSTAD J P, 1991, Neurology, V41, P192; HANSEN L, 1990, NEUROLOGY, V40, P1; HEATHFIELD MT, 1990, NEUROSCI LETT, V110, P216; HUDSON AJ, 1981, BRAIN, V104, P217, DOI 10.1093/brain/104.2.217; JELLINGER K, 1989, PARKINSONISM AGING, P35; MARTIN WRW, 1989, ANN NEUROL, V26, P535, DOI 10.1002/ana.410260407; Mendell J R, 1971, Trans Am Neurol Assoc, V96, P284; PATE BD, 1993, ANN NEUROL, V34, P331, DOI 10.1002/ana.410340306; RODGERSJOHNSON P, 1986, NEUROLOGY, V36, P7, DOI 10.1212/WNL.36.1.7; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROWLAND LP, 1991, AMYOTROPH LATERAL SC, P3; SNOW BJ, 1993, ANN NEUROL, V34, P324, DOI 10.1002/ana.410340304; SNOW BJ, 1990, ARCH NEUROL-CHICAGO, V47, P870, DOI 10.1001/archneur.1990.00530080052010	20	83	86	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1016	1018		10.1016/0140-6736(93)92878-W	http://dx.doi.org/10.1016/0140-6736(93)92878-W			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105264				2022-12-01	WOS:A1993MD06600009
J	BUKRINSKY, MI; HAGGERTY, S; DEMPSEY, MP; SHAROVA, N; ADZHUBEI, A; SPITZ, L; LEWIS, P; GOLDFARB, D; EMERMAN, M; STEVENSON, M				BUKRINSKY, MI; HAGGERTY, S; DEMPSEY, MP; SHAROVA, N; ADZHUBEI, A; SPITZ, L; LEWIS, P; GOLDFARB, D; EMERMAN, M; STEVENSON, M			A NUCLEAR-LOCALIZATION SIGNAL WITHIN HIV-1 MATRIX PROTEIN THAT GOVERNS INFECTION OF NONDIVIDING CELLS	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; RETROVIRAL DNA; COMPLEX; GENE; INTEGRATION; MONOCYTES; INVITRO; VIRIONS	PERMISSIVENESS of the host cell to productive infection by onco-retroviruses is cell-cycle dependent1, and nuclear localization of viral nucleoprotein preintegration complexes will occur only after cells have passed through mitosis2. In contrast, establishment of an integrated provirus after infection by the lentivirus HIV-1 is independent of host cell proliferation3-5. The ability of HIV-1 to replicate in non-dividing cells is partly accounted for by the karvophilic properties of the viral preintegration complex which, after virus infection, is actively transported to the host cell nucleus. Here we report that the gag matrix protein of HIV-1 contains a nuclear localization sequence which, when conjugated to a heterologous protein, directs its nuclear import. In addition, HIV-1 mutants containing amino-acid substitutions in this nuclear localization signal integrate and replicate within dividing but not growth-arrested cells, and thus display a phenotype more representative of an onco-retrovirus.	UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198; IMPERIAL CANC RES FUND,BIOMOLEC MODELLING LAB,LONDON WC2A 3PX,ENGLAND; UNIV NEBRASKA,MED CTR,EPPLEY INST RES,OMAHA,NE 68198; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627; FRED HUTCHINSON CANC RES CTR,PROGRAM MOLEC MED,SEATTLE,WA 98104	University of Nebraska System; University of Nebraska Medical Center; Cancer Research UK; University of Nebraska System; University of Nebraska Medical Center; University of Rochester; Fred Hutchinson Cancer Center					NCRR NIH HHS [R01 RR011589] Funding Source: Medline; NIAID NIH HHS [R21 AI127091, R37 AI037475] Funding Source: Medline; NIMH NIH HHS [R01 MH093306, R01 MH064411] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; ELIOPOULOS E, 1982, INT J BIOL MACROMOL, V4, P263, DOI 10.1016/0141-8130(82)90053-8; FARNET CM, 1991, J VIROL, V65, P1990; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GENDELMAN HE, 1986, J VIROL, V58, P67, DOI 10.1128/JVI.58.1.67-74.1986; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; HAASE AT, 1982, VIROLOGY, V119, P399, DOI 10.1016/0042-6822(82)90099-X; HSU WS, 1990, SCIENCE, V250, P1227; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; MEYERS G, 1992, HUMAN RETROVIRUSES A; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; STEVENSON M, 1990, J VIROL, V64, P3792, DOI 10.1128/JVI.64.8.3792-3803.1990; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089	27	708	740	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					666	669		10.1038/365666a0	http://dx.doi.org/10.1038/365666a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	8105392	Green Accepted			2022-12-01	WOS:A1993MB84600065
J	MORRISON, PJ				MORRISON, PJ			TRINUCLEOTIDE REPEAT REPEAT REPEAT	LANCET			English	Editorial Material											MORRISON, PJ (corresponding author), NO IRELAND GENET SERV,BELFAST,NORTH IRELAND.							BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MANDEL JL, 1993, NAT GENET, V4, P8, DOI 10.1038/ng0593-8; NELSON DL, 1993, NAT GENET, V4, P107, DOI 10.1038/ng0693-107; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; REIK W, 1993, J MED GENET, V30, P175; SCHALLING M, 1993, NAT GENET, V4, P135, DOI 10.1038/ng0693-135; SHAW DJ, 1993, J MED GENET, V30, P189, DOI 10.1136/jmg.30.3.189; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; 1993, CELL, V72, P971	10	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					385	386						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101897				2022-12-01	WOS:A1993LR90000005
J	FLING, SP; ARP, B; PIOUS, D				FLING, SP; ARP, B; PIOUS, D			HLA-DMA AND HLA-DMB GENES ARE BOTH REQUIRED FOR MHC CLASS-II PEPTIDE COMPLEX-FORMATION IN ANTIGEN-PRESENTING CELLS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN PEPTIDES; MONOCLONAL-ANTIBODY; PROCESSING MUTANT; DR MOLECULES; EXPRESSION; POPULATIONS; REGION; VECTOR; LINE	MAJOR histocompatibility complex (MHC) class II molecules are highly polymorphic cell-surface glycoproteins that present antigenic peptides to CD4+ T lymphocytes. The normal assembly of class II molecules with cognate peptides for antigen presentation requires an accessory function provided by a gene mapping to the class II region of the HLA complex1,2. The isolation of somatic cell mutants of antigen-presenting cells (APC) has shown that at least one gene which maps between HLA-DP and HLA-DQ, provisionally designated c2p-1 (ref. 3), mediates this process1,2,4. Here we describe a unique new mutant 2.2.93, which manifests defective formation of class II/peptide complexes like that described in c2p-1 mutants. We show that (1) mutant 2.2.93 contains a mutation in HLA-DMA5, and a representative c2p-1 mutant, 9.5.3, contains a mutation in HLA-DMB5; and (2) transfection and expression of DMA complementary DNA in 2.2.93, and DMB cDNA in 9.5.3, reverses their mutant phenotypes. These results show that HLA-DMA and -DMB, genes of previously unknown function mapping between HLA-DP and HLA-DQ5, are required for the normal assembly of peptides with MHC class II molecules. They suggest that HLA-DMA and -DMB encode subunits of a functional heterodimer which is critical in the pathway of class II antigen presentation.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ANTONELLI P, 1984, HUM IMMUNOL, V11, P11, DOI 10.1016/0198-8859(84)90052-1; BODMER JG, 1985, HISTOCOMPATIBILITY T; CAMPBELL DR, 1993, IMMUNOL TODAY, V14, P349; CEMAN S, 1992, J IMMUNOL, V149, P754; CLARK EA, 1989, J IMMUNOL, V143, P3873; CLARK EA, 1984, LEUCOCYTE TYPING; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GLADSTONE P, 1982, P NATL ACAD SCI-BIOL, V79, P1235, DOI 10.1073/pnas.79.4.1235; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; JOHNSON JP, 1982, J EXP MED, V156, P104, DOI 10.1084/jem.156.1.104; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; KONING F, 1984, HUM IMMUNOL, V9, P221, DOI 10.1016/0198-8859(84)90027-2; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LEVINE F, 1985, J IMMUNOL, V134, P637; LEVINE F, 1985, P NATL ACAD SCI USA, V82, P3741, DOI 10.1073/pnas.82.11.3741; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1994, J EXP MED, V179, P541, DOI 10.1084/jem.179.2.541; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PIOUS D, 1985, J EXP MED, V162, P1193, DOI 10.1084/jem.162.4.1193; PIOUS D, 1977, IMMUNOGENETICS, V4, P437, DOI 10.1007/BF01575679; PIOUS D, IN PRESS ANTIGEN PRO; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STOCKSCHLAEDER MAR, 1991, HUM GENE THER, V2, P33, DOI 10.1089/hum.1991.2.1-33; VIKEN HD, 1989, TISSUE ANTIGENS, V34, P250, DOI 10.1111/j.1399-0039.1989.tb02100.x	30	282	283	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					554	558		10.1038/368554a0	http://dx.doi.org/10.1038/368554a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139690				2022-12-01	WOS:A1994NE33500057
J	TAX, FE; YEARGERS, JJ; THOMAS, JH				TAX, FE; YEARGERS, JJ; THOMAS, JH			SEQUENCE OF C-ELEGANS LAG-2 REVEALS A CELL-SIGNALING DOMAIN SHARED WITH DELTA AND SERRATE OF DROSOPHILA	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; EGF-LIKE REPEATS; CAENORHABDITIS-ELEGANS; TRANSMEMBRANE PROTEIN; HOMOLOGOUS GENES; NEUROGENIC GENE; LIN-12; GLP-1; ENCODES; NOTCH	THE lin-12 and glp-1 genes of Caenorhabditis elegans encode members of the Notch family of transmembrane proteins(1,2). Genetic studies indicate that the lin-12 and glp-1 proteins act as receptors in specific developmental cell interactions(3-6) and that their functions are partially redundant(7). lin-12 glp-1 double mutants display certain embryonic defects not found in either single mutant(7,8). The phenotype of this double mutant is called Lag, and recessive mutations in either of the genes lag-1 or lag-2 can also result in the Lag phenotype(7), indicating that these two genes may participate in the same cell interactions that require lin-12 or glp-1. We report here that lag-2 encodes a predicted transmembrane protein of 402 amino acids. The predicted extracellular region of lag-2 is similar to amino-terminal regions of Delta and Serrate, two Drosophila proteins that are thought to function as ligands for Notch(9-14). The region of similarity includes sequences related to epidermal growth factor (EGF) repeats. We have isolated lag-2(sa37), a dominant allele that shows specific genetic interactions with lin-12. The sa37 mutation causes a Gly-->Asp change in a conserved residue of an EGF motif. Because of its overall structure, its sequence similarity to Delta and Serrate, and its genetic interactions, ne suggest that lag-2 encodes an intercellular signal for the lin-12 and glp-1 receptors.			TAX, FE (corresponding author), UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195, USA.			Tax, Frans/0000-0002-1386-3310				ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BOWERMAN B, 1992, DEVELOPMENT, V116, P1113; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DELONG L, 1987, GENETICS, V117, P657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HEITZLER P, 1993, DEVELOPMENT, V117, P1113; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; JOHNSEN RC, 1991, GENETICS, V129, P735; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBLUTH RE, 1981, GENETICS, V99, P415; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; THOMAS U, 1991, DEVELOPMENT, V111, P749; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	31	232	263	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					150	154		10.1038/368150a0	http://dx.doi.org/10.1038/368150a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139658				2022-12-01	WOS:A1994NA03000067
J	LEHMAN, W; CRAIG, R; VIBERT, P				LEHMAN, W; CRAIG, R; VIBERT, P			CA2+-INDUCED TROPOMYOSIN MOVEMENT IN LIMULUS THIN-FILAMENTS REVEALED BY 3-DIMENSIONAL RECONSTRUCTION	NATURE			English	Article							ELECTRON-MICROSCOPY; MUSCLE; TROPONIN; ACTIN; MYOSIN; BINDING	THE steric model of muscle regulation holds that tropomyosin strands running along thin filaments move away from myosin-binding sites on actin when muscle is activated. Exposing these sites would permit actomyosin interaction and contraction to proceed. This compelling and widely cited model is based on changes observed in X-ray diffraction patterns of skeletal muscle following activation(1-3) Although analysis of X-ray patterns can suggest models of filament structure, unambiguous interpretation is not possible. In contrast, three-dimensional reconstruction of thin-filament electron micrographs could, in principle, offer direct confirmation of the predicted tropomyosin movement, but so far tropomyosin in skeletal muscle has been resolved definitively only in the 'on' state but not in the 'off' state(4). Thin filaments from the arthropod Limulus have a similar composition to those from vertebrate skeletal muscle(5), and troponin-tropomyosin is distributed in both species with the same characteristic 38-nm periodicity(6) Limulus thin filaments activate skeletal muscle myosin ATPase at micromolar Ca2+ concentrations and confer a high calcium dependence on the enzyme. Arthropod and vertebrate troponin subunits form functional hybrids in vitro(7) and the respective tropomyosins are functionally interchangeable(8,9), arguing for a common mechanism of thin-filament-linked regulation in the two phyla. Here we report that tropomyosin is readily resolved in native filaments of troponin-regulated Limulus muscle in both the 'on' and 'off' states, and demonstrate tropomyosin movement, providing support for the importance of steric effects in muscle activation.	UNIV MASSACHUSETTS,SCH MED,DEPT CELL BIOL,WORCESTER,MA 01655; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	University of Massachusetts System; University of Massachusetts Worcester; Brandeis University	LEHMAN, W (corresponding author), BOSTON UNIV,SCH MED,DEPT PHYSIOL,80 E CONCORD ST,BOSTON,MA 02118, USA.			Lehman, William/0000-0002-9430-9521				AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; CHALOVICH JM, 1981, J BIOL CHEM, V256, P575; COHEN C, 1972, COLD SPRING HARB SYM, V37, P287; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; HASELGROVE JC, 1972, COLD SPRING HARB SYM, V37, P225; Holmes KC, 1991, CURR OPIN STRUC BIOL, V1, P270, DOI 10.1016/0959-440X(91)90073-3; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; LEHMAN W, 1975, NATURE, V255, P424, DOI 10.1038/255424a0; LEHMAN W, 1982, J MOL BIOL, V154, P385, DOI 10.1016/0022-2836(82)90071-7; LEHMAN W, 1976, BIOCHIM BIOPHYS ACTA, V434, P215, DOI 10.1016/0005-2795(76)90053-2; LEHMAN W, 1975, J GEN PHYSIOL, V59, P375; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOODY C, 1990, J MUSCLE RES CELL M, V11, P176, DOI 10.1007/BF01766496; OBRIEN EJ, 1983, ACTIN STRUCTURE FUNC, P3; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; REGENSTEIN JM, 1975, BIOCHEMISTRY-US, V14, P917, DOI 10.1021/bi00676a007; SEYMOUR J, 1980, NATURE, V283, P680, DOI 10.1038/283680a0; SQUIRE JM, 1993, J CHEM SOC FARADAY T, V89, P2717, DOI 10.1039/ft9938902717; TOYOSHIMA C, 1985, J BIOCHEM-TOKYO, V97, P245, DOI 10.1093/oxfordjournals.jbchem.a135049; TRACHTENBERG S, 1987, J MOL BIOL, V195, P581, DOI 10.1016/0022-2836(87)90184-7; VIBERT P, 1993, J CELL BIOL, V123, P313, DOI 10.1083/jcb.123.2.313	25	277	280	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					65	67		10.1038/368065a0	http://dx.doi.org/10.1038/368065a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	8107884				2022-12-01	WOS:A1994MY56900054
J	JOHANSEN, S; VOGT, VM				JOHANSEN, S; VOGT, VM			AN INTRON IN THE NUCLEAR RIBOSOMAL DNA OF DIDYMIUM-IRIDIS CODES FOR A GROUP-I RIBOZYME AND A NOVEL RIBOZYME THAT COOPERATE IN SELF-SPLICING	CELL			English	Article							PHYSARUM-POLYCEPHALUM; SECONDARY STRUCTURE; SEQUENCE-ANALYSIS; SUBUNIT RNA; GENE; SITE; RDNA; EVOLUTION; SUGGESTS; VIROIDS	We have discovered a unique group I intron-like insertion (DiSSU) in the nuclear small subunit ribosomal RNA gene of the myxomycete Didymium iridis. By sequence, DiSSU consists of a group I ribozyme at the 5' end, an open reading frame (ORF) in the middle, and a novel element at the 3' end. Intron RNA self-splices in vitro to yield ten major processed RNAs, including a full-length circle. The group I ribozyme can efficiently cleave at an internal processing site, which separates the group I ribozyme from the ORF. Surprisingly, deletions that remove the entire group I ribozyme do not impair cleavage at the 3' splice site, implying that the 3' element itself is a catalytic RNA. Deletions that remove portions of the 3' element prevent utilization of the 5' splice site, suggesting that this element cooperates with the upstream group I ribozyme in splicing. DiSSU appears to be the first example for the cooperative interaction of distinct ribozymes in RNA splicing.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University	JOHANSEN, S (corresponding author), UNIV TROMSO,INST MED BIOL,DEPT CELL BIOL,N-9037 TROMSO,NORWAY.				NIGMS NIH HHS [GM-31577] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031577] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BEEN MD, 1985, NUCLEIC ACIDS RES, V13, P8389, DOI 10.1093/nar/13.23.8389; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1992, J BIOL CHEM, V267, P17479; COLLINS OR, 1976, AM J BOT, V63, P138, DOI 10.2307/2441693; DAVILAAPONTE JA, 1991, NUCLEIC ACIDS RES, V19, P4429, DOI 10.1093/nar/19.16.4429; DEPRIEST PT, 1992, J MOL BIOL, V228, P315, DOI 10.1016/0022-2836(92)90819-6; DEWACHTER R, 1992, NUCLEIC ACIDS RES, V20, P1251; DIENER TO, 1989, P NATL ACAD SCI USA, V86, P9370, DOI 10.1073/pnas.86.23.9370; DINTERGOTTLIEB G, 1986, P NATL ACAD SCI USA, V83, P6250, DOI 10.1073/pnas.83.17.6250; EMBLEY TM, 1992, NUCLEIC ACIDS RES, V20, P6411, DOI 10.1093/nar/20.23.6411; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HADIDI A, 1986, PLANT MOL BIOL, V7, P129, DOI 10.1007/BF00040139; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JAKUBCZAK JL, 1991, P NATL ACAD SCI USA, V88, P3295, DOI 10.1073/pnas.88.8.3295; JOHANSEN S, 1992, CURR GENET, V22, P305, DOI 10.1007/BF00317926; JOHANSEN S, 1992, CURR GENET, V22, P297, DOI 10.1007/BF00317925; JOHANSEN S, 1993, NUCLEIC ACIDS RES, V21, P4405, DOI 10.1093/nar/21.18.4405; JOHANSEN T, 1988, CURR GENET, V14, P265, DOI 10.1007/BF00376747; JOHANSEN T, 1988, DNA PROT ENG TECH, V1, P57; LIN H, 1992, GENE, V119, P163, DOI 10.1016/0378-1119(92)90268-T; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MUSCARELLA DE, 1990, MOL CELL BIOL, V10, P3386, DOI 10.1128/MCB.10.7.3386; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; NEEFS JM, 1990, NUCLEIC ACIDS RES, V18, P2237, DOI 10.1093/nar/18.suppl.2237; OBERBAUMER I, 1992, NUCLEIC ACIDS RES, V20, P671; PERLMAN PS, 1990, INTERVENING SEQUENCE, P112; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROGERS SO, 1993, CURR GENET, V23, P338, DOI 10.1007/BF00310896; RUOFF B, 1992, NUCLEIC ACIDS RES, V20, P5899, DOI 10.1093/nar/20.22.5899; SAVILLE BJ, 1990, CELL, V61, P685, DOI 10.1016/0092-8674(90)90480-3; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; THOMPSON AJ, 1991, NUCLEIC ACIDS RES, V19, P661; VANDERHORST G, 1993, J MOL BIOL, V229, P685, DOI 10.1006/jmbi.1993.1072; WILCOX LW, 1992, MOL BIOL EVOL, V9, P1103	41	66	70	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 25	1994	76	4					725	734		10.1016/0092-8674(94)90511-8	http://dx.doi.org/10.1016/0092-8674(94)90511-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124711				2022-12-01	WOS:A1994MZ28500014
J	ISACSSON, G; HOLMGREN, P; WASSERMAN, D; BERGMAN, U				ISACSSON, G; HOLMGREN, P; WASSERMAN, D; BERGMAN, U			USE OF ANTIDEPRESSANTS AMONG PEOPLE COMMITTING SUICIDE IN SWEDEN	BRITISH MEDICAL JOURNAL			English	Article							DRUGS; PRESCRIPTION; POPULATION; OVERDOSE; RISK	Objective-To analyse the outcome of depression in the Swedish population as reflected by the detection of antidepressants in a national forensic toxicological screening programme of unnatural deaths. Design-Antidepressants detected by the National Laboratory of Forensic Chemistry were related to data on use expressed in person years of exposure. Subjects-All 7000 cases of unnatural death with results from forensic toxicological screening in 199O-1; this included 3400 (85%) of the 4000 cases of suicide in Sweden. Main outcome measures-Number of findings of antidepressants in the screening programme and number of findings of different antidepressants in relation to their use. Results-Antidepressants were found in 585 screening tests, corresponding to 542 subjects or less than 16% of the 3400 cases of suicide. Newer, less toxic antidepressants were found more often than the older compounds. Toxic concentrations of antidepressants were found in only 190 cases (5.6%). Conclusion-A consistent finding in surveys of suicide is that about half of the patients who commit suicide are depressed. The current data suggest that most depressed patients who commit suicide are not taking antidepressants immediately before death. Therapeutic failure may be a greater problem with antidepressants than toxicity as the results did not indicate any advantage of the newer, less toxic antidepressants. Ah causes of death should be included in risk analyses, thereby providing an estimate of effectiveness as web as toxicity of antidepressants.	NATL LAB FORENS CHEM,DEPT TOXICOL,LINKOPING,SWEDEN; KAROLINSKA HOSP,CTR SUICIDE RES & PREVENT,STOCKHOLM,SWEDEN; KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT MED LAB SCI & TECHNOL,DIV CLIN PHARMACOL,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	ISACSSON, G (corresponding author), KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT CLIN NEUROSCI & FAMILY MED,PSYCHIAT SECT,S-14186 HUDDINGE,SWEDEN.		anand, amit/A-7222-2009					BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BERGMAN U, 1992, J CLIN EPIDEMIOL, V45, P313, DOI 10.1016/0895-4356(92)90092-2; BESKOW J, 1979, ACTA PSYCHIATR SCA S, V277; CASSIDY S, 1987, BRIT MED J, V295, P1021, DOI 10.1136/bmj.295.6605.1021; DERBY LE, 1992, J CLIN PSYCHOPHARM, V12, P235; EKLUND A, 1983, J ANAL TOXICOL, V7, P24, DOI 10.1093/jat/7.1.24; FORSTER DP, 1985, ACTA PSYCHIAT SCAND, V71, P567, DOI 10.1111/j.1600-0447.1985.tb02550.x; GUESS HA, 1987, AM J EPIDEMIOL, V125, P340, DOI 10.1093/oxfordjournals.aje.a114535; HANZLICK R, 1989, AM J FOREN MED PATH, V10, P326, DOI 10.1097/00000433-198912000-00009; HORTE LG, 1983, HYGIEA, V92, P251; ISACSSON G, 1992, ACTA PSYCHIAT SCAND, V85, P444, DOI 10.1111/j.1600-0447.1992.tb03209.x; JOHNSON DAW, 1986, INT MED S, V11, P14; KELLEHER MJ, 1992, BRIT J PSYCHIAT, V161, P625, DOI 10.1192/bjp.161.5.625; Moffat A., 1986, CLARKES ISOLATION ID, V2nd, P1248, DOI [10.1002/jps.2600760520, DOI 10.1002/JPS.2600760520]; MONTGOMERY SA, 1988, INT CLIN PSYCHOPHARM, V3, P15; REGIER DA, 1988, AM J PSYCHIAT, V145, P1351; RORSMAN B, 1982, NEUROPSYCHOBIOLOGY, V8, P233, DOI 10.1159/000117904; WESSLING A, 1991, EUR J CLIN PHARMACOL, V40, P495, DOI 10.1007/BF00315229; 1992, LANCET, V340, P700; 1993, J AFFECT DISORDERS, V28, P105; 1993, CAUSES DEATH 1989 19	21	122	122	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	1994	308	6927					506	509		10.1136/bmj.308.6927.506	http://dx.doi.org/10.1136/bmj.308.6927.506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MX814	8136668	Green Published			2022-12-01	WOS:A1994MX81400021
J	LEVINE, RS; HENNEKENS, CH; JESSE, MJ				LEVINE, RS; HENNEKENS, CH; JESSE, MJ			BLOOD-PRESSURE IN PROSPECTIVE POPULATION-BASED COHORT OF NEWBORN AND INFANT TWINS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-BIRTH-WEIGHT; GENETIC VARIANCE; ADULT LIFE; FETAL; GROWTH; RISK	Objective-To describe blood pressure in twins during infancy. Design-Prospective study of cohort of twins. Setting-Teaching hospital in Florida. Subjects-166 viable twin pairs born between July 1976 and December 1989. Main outcome measures-Blood pressure and body weight at birth, at 14 days, and at 1, 3, 6, 9, and 12 months. Results-Both systolic and diastolic pressure correlated with body weight throughout infancy (at birth r = 0.41, P < 0.001 and r = 0.42, P < 0.001 respectively; at 1 year r=0.23, P < 0.001 and r=0.26, P < 0.001 respectively). In infants weighing < 1500 g at birth mean blood pressure rose from about 45/25 mm Hg to 101/55 mm Hg from birth to the age of 1 year, while in infants weighing > 3000 g at birth it rose from 63/39 mm Hg to 100/61 mm Hg; corresponding mean body weights at 1 year were 7.86 kg and 9.58 kg. Differences in birth weight within pairs of monozygotic twins were negatively correlated with such differences in systolic blood pressure at 1 year (r = -0.37, P < 0.01). Conclusions-Blood pressure and body weights in twins showed strongly positive but generally declining correlations throughout infancy. Twins Of lower birth weight showed a more rapid rate of rise in blood pressure during infancy. At 1 year the catch up in blood pressure exceeded that in body weight. Greater differences in birth weights between monozygotic twins were associated with smaller differences in systolic blood pressure at 1 year, suggesting that intrauterine environmental factors related to birth weight are important in determining blood pressure in infancy.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; UNIV CINCINNATI, SCH MED, CINCINNATI, OH 45221 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Cincinnati	LEVINE, RS (corresponding author), MEHARRY MED COLL, DEPT FAMILY & PREVENT MED, NASHVILLE, TN 37208 USA.				NHLBI NIH HHS [HL 00286, HL 19930] Funding Source: Medline; PHS HHS [52119-6] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARMITAGE P, 1971, STATISTICAL METHODS; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; BURKE GL, 1987, PEDIATRICS, V80, P784; CHRISTIAN JC, 1977, ACTA GENET MED GEMEL, V26, P49, DOI 10.1017/S0001566000010187; DESWIET M, 1992, BRIT MED J, V304, P23, DOI 10.1136/bmj.304.6818.23; GEMELLI M, 1990, EUR J PEDIATR, V149, P318, DOI 10.1007/BF02171556; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; HIGGINS M, 1980, AM J EPIDEMIOL, V111, P142, DOI 10.1093/oxfordjournals.aje.a112882; KRAMER AA, 1984, AM J EPIDEMIOL, V119, P651, DOI 10.1093/oxfordjournals.aje.a113785; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LEVINE RS, 1978, PEDIATRICS, V61, P121; LEVINE RS, 1987, AM J EPIDEMIOL, V126, P929, DOI 10.1093/oxfordjournals.aje.a114730; LEVINE RS, 1982, AM J EPIDEMIOL, V116, P759, DOI 10.1093/oxfordjournals.aje.a113465; LOGGIE J, 1988, PEDIATRICS, V81, P328; MCGARVEY ST, 1991, HYPERTENSION, V17, P218, DOI 10.1161/01.HYP.17.2.218; PARK MK, 1989, AM J DIS CHILD, V143, P860, DOI 10.1001/archpedi.1989.02150190110034; PERSSON E, 1992, ACTA PHYSIOL SCAND, V145, P195, DOI 10.1111/j.1748-1716.1992.tb09356.x; PIAZZA SF, 1985, AM J DIS CHILD, V139, P797, DOI 10.1001/archpedi.1985.02140100059030; RANKOVA S, 1989, Tokai Journal of Experimental and Clinical Medicine, V14, P181; SCHACHTER J, 1982, AM J EPIDEMIOL, V116, P29, DOI 10.1093/oxfordjournals.aje.a113400; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; SPINAZZOLA RM, 1990, J PERINATOL, V11, P147; TAN KL, 1988, J PEDIATR-US, V112, P266, DOI 10.1016/S0022-3476(88)80068-4; UHARI M, 1980, ACTA PAEDIATR SCAND, V69, P613, DOI 10.1111/j.1651-2227.1980.tb07331.x; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L; ZINNER SH, 1985, HYPERTENSION, V7, P411, DOI 10.1161/01.HYP.7.3_Pt_1.411; 1992, HLTH PEOPLE 2000 SUM, P110	30	70	71	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 29	1994	308	6924					298	302		10.1136/bmj.308.6924.298	http://dx.doi.org/10.1136/bmj.308.6924.298			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU492	8124117	Green Published			2022-12-01	WOS:A1994MU49200019
J	KETLEY, D; WOODS, KL				KETLEY, D; WOODS, KL			IMPACT OF CLINICAL-TRIALS ON CLINICAL-PRACTICE - EXAMPLE OF THROMBOLYSIS FOR ACUTE MYOCARDIAL-INFARCTION	LANCET			English	Article							INFLUENCE MEDICAL-PRACTICE; THERAPY	Little is known about incorporation of new knowledge from randomised clinical trials into clinical practice. Thrombolytic therapy was shown to reduce the mortality of acute myocardial infarction in several large trials published during 1986-88. To examine the effect of these data on clinical practice, we analysed the supply of thrombolytic drugs in a representative English region (population 4.7 million) in 1987-92. During the study period there were over 10 000 hospital admissions per year in the region for acute myocardial infarction. From a very low initial level, thrombolytic drug use rose slowly for several years after publication of the trial results and reached a plateau in 1991-92. Rates of use per 1000 patients admitted with myocardial infarction varied almost six-fold between districts in 1989-90 and over two-fold in 1991-92. Level of use attained by districts in the latter period was strongly associated with the extent of their previous participation in multicentre trials of thrombolysis (p = 0.003); we estimate that 35-50% of patients admitted with acute myocardial infarction were receiving thrombolytics. The full potential of thrombolytic treatment has still not been achieved in routine care and the limiting factors need to be defined.	LEICESTER ROYAL INFIRM, DEPT PHARMACOL & THERAPEUT, CLIN SCI BLDG, LEICESTER LE2 7LX, ENGLAND; LEICESTER ROYAL INFIRM, DEPT PHARM, LEICESTER LE2 7LX, ENGLAND	University of Leicester; University of Leicester								[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; BOISSEL JP, 1989, CONTROL CLIN TRIALS, V10, pS120; BOISSEL JP, 1990, ARCH MAL COEUR VAISS, V83, P1777; BRAUNWALD E, 1990, CIRCULATION, V82, P1510, DOI 10.1161/01.CIR.82.4.1510; BURRELL CJ, 1990, BMJ-BRIT MED J, V300, P237, DOI 10.1136/bmj.300.6719.237; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COLLINS R, 1991, BRIT HEART J, V66, P250; FINEBERG HV, 1987, B CANCER, V74, P333; FRIEDMAN L, 1983, CONTROL CLIN TRIALS, V4, P513, DOI 10.1016/0197-2456(83)90032-6; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; Haigh R, 1991, Health Trends, V23, P154; HENDRA TJ, 1992, BMJ-BRIT MED J, V304, P423, DOI 10.1136/bmj.304.6824.423; HLATKY MA, 1988, AM J CARDIOL, V61, P510, DOI 10.1016/0002-9149(88)90755-2; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; WILCOX RG, 1988, LANCET, V2, P525; 1986, LANCET, V1, P398; 1987, LANCET, V1, P502	20	204	204	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1993	342	8876					891	894		10.1016/0140-6736(93)91945-I	http://dx.doi.org/10.1016/0140-6736(93)91945-I			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105166				2022-12-01	WOS:A1993MA96300009
J	DIXON, M				DIXON, M			ACID, ULCERS, AND HELICOBACTER-PYLORI	LANCET			English	Editorial Material							HELICOBACTER-PYLORI				DIXON, M (corresponding author), UNIV LEEDS,ACAD UNIT PATHOL SCI,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.							CARD WI, 1960, CLIN SCI, V19, P147; DIXON MF, 1991, J GASTROEN HEPATOL, V6, P125, DOI 10.1111/j.1440-1746.1991.tb01451.x; DIXON MF, 1992, IRISH J MED SCI S10, V161, P11; ELOMAR E, 1993, GUT, V34, P1060, DOI 10.1136/gut.34.8.1060; ELOMAR E, 1993, GASTROENTEROLOGY, V104, pA75; Kramling H J, 1987, Adv Exp Med Biol, V216A, P427; MCCOLL KEL, 1993, GUT, V34, P762, DOI 10.1136/gut.34.6.762; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; MOSS SF, 1993, GUT, V34, P888, DOI 10.1136/gut.34.7.888; MOSS SF, 1992, LANCET, V340, P930, DOI 10.1016/0140-6736(92)92816-X; MULHOLLAND G, 1993, GUT, V34, P757, DOI 10.1136/gut.34.6.757; SIPPONEN P, 1989, GUT, V30, P922, DOI 10.1136/gut.30.7.922; WYATT JI, 1987, J CLIN PATHOL, V40, P841, DOI 10.1136/jcp.40.8.841; WYATT JI, 1990, J CLIN PATHOL, V43, P981, DOI 10.1136/jcp.43.12.981; 1992, GUT, V34, P604	15	34	34	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					384	385						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101896				2022-12-01	WOS:A1993LR90000004
J	SHAPER, AG				SHAPER, AG			WHATS NEW IN ENDOMYOCARDIAL FIBROSIS	LANCET			English	Editorial Material											SHAPER, AG (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON,ENGLAND.							VALIATHAN MS, 1993, ENDOMYOCARDIAL FIBRO, P302	1	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					255	256		10.1016/0140-6736(93)91813-2	http://dx.doi.org/10.1016/0140-6736(93)91813-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101298				2022-12-01	WOS:A1993LQ16300006
J	CIAPA, B; PESANDO, D; WILDING, M; WHITAKER, M				CIAPA, B; PESANDO, D; WILDING, M; WHITAKER, M			CELL-CYCLE CALCIUM TRANSIENTS DRIVEN BY CYCLIC CHANGES IN INOSITOL TRISPHOSPHATE LEVELS	NATURE			English	Article							NUCLEAR-ENVELOPE BREAKDOWN; INTRACELLULAR FREE CALCIUM; SEA-URCHIN EMBRYOS; TRANSLATIONAL CONTROL; EGGS; FERTILIZATION; ANAPHASE; CA2+	TRANSIENT changes in intracellular calcium ([Ca2+](i)) have been shown to punctuate the cell cycle in various types of cells in culture(1-5) and in early embryos(6-12). The [Ca2+](i) transients are correlated with cell-cycle events: pronuclear migration, nuclear envelope breakdown, the metaphase-anaphase transition of mitosis, and cytokinesis. Mitotic events fan be induced by injecting calcium and prevented by injecting calcium chelators into the sea urchin embryo(10,13). Cell-cycle calcium transients differ from the transients linked to membrane signal transduction pathways: they are generated by an endogenous mechanism, not by plasma membrane receptor complexes, and their trigger is unknown. We report here that the phosphoinositide messenger system oscillates during the early embryonic cell cycle in the sea urchin, leading to cyclic increases in inositol trisphosphate that trigger cell-cycle [Ca2+](i) transients and mitosis by calcium release from intracellular stores.	FAC SCI NICE,PHYSIOL CELLULAIRE & COMPAREE LAB,F-06108 NICE,FRANCE; INSERM,U303,F-06230 VILLEFRANCHE MER,FRANCE; UNIV LONDON UNIV COLL,DEPT PHYSIOL,LONDON WC1E 6BT,ENGLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); University of London; University College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWNE CL, 1992, BIOL BULL, V183, P270; Chatfield C, 1980, ANAL TIME SERIES INT; CIAPA B, 1993, DEV BIOL, V159, P114, DOI 10.1006/dbio.1993.1225; CIAPA B, 1992, DEVELOPMENT, V115, P187; CIAPA B, 1986, FEBS LETT, V195, P347, DOI 10.1016/0014-5793(86)80191-0; EDGECOMBE M, 1991, EMBO J, V10, P3769, DOI 10.1002/j.1460-2075.1991.tb04946.x; FLUCK RA, 1991, J CELL BIOL, V115, P1259, DOI 10.1083/jcb.115.5.1259; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GRANDIN N, 1991, J CELL SCI, V99, P5; HAN JK, 1992, J CELL BIOL, V116, P147, DOI 10.1083/jcb.116.1.147; HEPLER PK, 1987, J CELL BIOL, V105, P2137, DOI 10.1083/jcb.105.5.2137; HEPLER PK, 1992, INT REV CYTOL, V138, P239, DOI 10.1016/S0074-7696(08)61590-9; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LI LH, 1984, CANCER LETT, V23, P279, DOI 10.1016/0304-3835(84)90095-8; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; RATAN RR, 1986, P NATL ACAD SCI USA, V83, P5136, DOI 10.1073/pnas.83.14.5136; RATAN RR, 1988, J CELL BIOL, V107, P993, DOI 10.1083/jcb.107.3.993; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SOLOMON MJ, 1990, CELL, V63, P113; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; STITH BJ, 1993, MOL BIOL CELL, V4, P435, DOI 10.1091/mbc.4.4.435; TOMBES RM, 1992, J CELL BIOL, V117, P799, DOI 10.1083/jcb.117.4.799; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; UNO I, 1988, NATURE, V333, P366; WHITAKER MJ, 1990, DEVELOPMENT, V105, P525	28	165	166	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					875	878		10.1038/368875a0	http://dx.doi.org/10.1038/368875a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159248				2022-12-01	WOS:A1994NH71700077
J	STRYNADKA, NCJ; JENSEN, SE; JOHNS, K; BLANCHARD, H; PAGE, M; MATAGNE, A; FRERE, JM; JAMES, MNG				STRYNADKA, NCJ; JENSEN, SE; JOHNS, K; BLANCHARD, H; PAGE, M; MATAGNE, A; FRERE, JM; JAMES, MNG			STRUCTURAL AND KINETIC CHARACTERIZATION OF A BETA-LACTAMASE-INHIBITOR PROTEIN	NATURE			English	Article							CLAVULANIC ACID; RESOLUTION; RESISTANCE; REFINEMENT	THE past decade has seen an alarming worldwide increase in resistance to beta-lactam antibiotics among many pathogenic bacteria1, which is due mainly to plasmid- or chromosomally encoded beta-lactamases that specifically cleave penicillin and cephalosporins, rendering them inactive. There is therefore a need to develop new strategies in the design of effective inhibitors of beta-lactamase. All the small-molecule inhibitors in clinical use are not very effective and are rapidly degraded2,3. Furthermore, newly characterized mutants of the plasmid-mediated beta-lactamase TEM-1 are highly resistant to these small-molecule inhibitors, including clavulanic acid and tazobactam4. It has been shown that Streptomyces clavuligerus produces an exocellular beta-lactamase inhibitory protein (BLIP; M(r) 17.5 K)5. Here we present data defining BLIP as the most effective known inhibitor of a variety of beta-lactamases, with K(i) values in the subnanomolar to picomolar range. To identify those features in BLIP that make it such a potent inhibitor, we have determined its molecular structure at 2.1 angstrom resolution. BLIP is a relatively flat molecule with a unique fold, comprising a tandem repeat of a 76-amino-acid domain. Each domain consists of a helix-loop-helix motif that packs against a four-stranded antiparallel beta-sheet (Fig. 1a). To our knowledge, BLIP is the first example of a protein inhibitor having two similarly folded domains that interact with and inhibit a single target enzyme.	UNIV ALBERTA,DEPT BIOCHEM,MRC,PROT STRUCT & FUNCT GRP,EDMONTON T6G 2G7,ALBERTA,CANADA; UNIV ALBERTA,DEPT MICROBIOL,EDMONTON T6G 2E9,ALBERTA,CANADA; F HOFFMANN LA ROCHE & CO LTD,DEPT PRECLIN RES PHARMADIV INFECT DIS,CH-4002 BASEL,SWITZERLAND; STATE UNIV LIEGE,ENZYMOL LAB,B-4000 LIEGE,BELGIUM; STATE UNIV LIEGE,CTR PROT ENGN,B-4000 LIEGE,BELGIUM	University of Alberta; University of Alberta; Roche Holding; University of Liege; University of Liege			Jensen, Susan/C-8701-2013; Blanchard, Helen/A-4681-2009	Blanchard, Helen/0000-0003-3372-5027; Matagne, Andre/0000-0001-6417-6791				BLAZQUEZ J, 1993, ANTIMICROB AGENTS CH, V37, P2059, DOI 10.1128/AAC.37.10.2059; BRUNGER AT, 1987, XPLOR MANUAL VERSION; BUSH K, 1989, ANTIMICROB AGENTS CH, V33, P264, DOI 10.1128/AAC.33.3.264; DORAN JC, 1990, J BACTERIOL, V172, P4904; Frere J M, 1976, Methods Enzymol, V45, P610; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KNOX JR, 1991, J MOL BIOL, V220, P435, DOI 10.1016/0022-2836(91)90023-Y; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; READ RJ, 1986, PROTEINASE INHIBITOR, P301; READING C, 1979, BIOCHEM J, V179, P67, DOI 10.1042/bj1790067; READING C, 1977, ANTIMICROB AGENTS CH, V11, P852, DOI 10.1128/AAC.11.5.852; SOUGAKOFF W, 1988, REV INFECT DIS, V10, P879; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0	22	109	117	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					657	660		10.1038/368657a0	http://dx.doi.org/10.1038/368657a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145854				2022-12-01	WOS:A1994NF39200067
J	GOODRICH, JA; TJIAN, R				GOODRICH, JA; TJIAN, R			TRANSCRIPTION FACTORS IIE AND IIH AND ATP HYDROLYSIS DIRECT PROMOTER CLEARANCE BY RNA-POLYMERASE-II	CELL			English	Article							MAJOR LATE PROMOTER; PREINITIATION COMPLEX; INITIATION-FACTOR; ABORTIVE INITIATION; TERMINAL-DOMAIN; FACTOR-DELTA; MECHANISM; BINDING; PURIFICATION; ACTIVATION	Using a defined RNA polymerase II(pol II) transcription system, we have investigated the roles of basal factors at discrete stages during the transcription cycle (e.g., initiation, promoter clearance, and transcript elongation). Abortive initiation assays revealed that TATA-binding protein, transcription factors TFIIB and TFIIF, and pol II were necessary and sufficient to form functional initiation complexes on both linear and supercoiled templates. By contrast, TFIIE, TFIIH, and ATP hydrolysis were additionally required during promoter clearance from linear templates, while negative supercoiling obviated the need for these auxiliary factors. Furthermore, TFIIE, TFIIH, and supercoiling were not required during elongation. Our results suggest a role for TFIIH-associated helicase activity or supercoiling during promoter clearance rather than open complex formation. These results establish abortive initiation as a useful assay for studying functional initiation complex formation in defined eukaryotic transcription systems and provide a framework for investigating regulation at different stages of the eukaryotic transcription cycle.			GOODRICH, JA (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							ARIAS JA, 1989, J BIOL CHEM, V264, P3223; ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHANG CH, 1993, J BIOL CHEM, V268, P20482; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; GOODRICH JA, 1992, J MOL BIOL, V224, P15, DOI 10.1016/0022-2836(92)90573-3; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; JIANG Y, 1993, J BIOL CHEM, V268, P6535; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	49	301	302	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					145	156		10.1016/0092-8674(94)90242-9	http://dx.doi.org/10.1016/0092-8674(94)90242-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156590				2022-12-01	WOS:A1994NF21100017
J	SIOMI, H; CHOI, MY; SIOMI, MC; NUSSBAUM, RL; DREYFUSS, G				SIOMI, H; CHOI, MY; SIOMI, MC; NUSSBAUM, RL; DREYFUSS, G			ESSENTIAL ROLE FOR KH DOMAINS IN RNA-BINDING - IMPAIRED RNA-BINDING BY A MUTATION IN THE KH DOMAIN OF FMR1 THAT CAUSES FRAGILE-X SYNDROME	CELL			English	Article							PROTEIN; GENE; REPEAT; DNA; INSTABILITY; SEQUENCE; SITE	The KH domain is an evolutionarily conserved sequence motif present in many RNA-binding proteins, including the pre-mRNA-binding (hnRNP) K protein and the fragile X mental retardation gene product (FMR1). We assessed the role of KH domains in RNA binding by mutagenesis of KH domains in hnRNP K and FMR1. Conserved residues of all three hnRNP K KH domains are required for its wild-type RNA binding. Interestingly, while fragile X syndrome is usually caused by lack of FMR1 expression, a previously reported mutation in a highly conserved residue of one of its two KH domains (lle-304-->Asn) also results in mental retardation. We found that the binding of this mutant protein to RNA is severely impaired. These results demonstrate an essential role for KH domains in RNA binding. Furthermore, they strengthen the connection between fragile X syndrome and loss of the RNA binding activity of FMR1.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania	SIOMI, H (corresponding author), UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104, USA.		Dreyfuss, Gideon/D-1218-2013; Siomi, Haruhiko/A-7020-2015	Dreyfuss, Gideon/0000-0001-8129-8774; Siomi, Haruhiko/0000-0001-8690-3822				ABITBOL M, 1993, NAT GENET, V4, P147, DOI 10.1038/ng0693-147; ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BACHNER D, 1993, NAT GENET, V4, P115, DOI 10.1038/ng0693-115; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; BURD CG, 1994, IN PRESS EMBO J; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DELAHODDE A, 1986, NUCLEIC ACIDS RES, V14, P9213, DOI 10.1093/nar/14.22.9213; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GEDEON AK, 1992, NAT GENET, V1, P341, DOI 10.1038/ng0892-341; GIBSON TJ, 1993, TRENDS BIOCHEM SCI, V18, P331, DOI 10.1016/0968-0004(93)90068-X; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; NUSSBAUM RL, 1994, METABOLIC BASIS INHE; OOSTRA BA, 1992, CHROMOSOMA, V101, P381, DOI 10.1007/BF00582832; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1992, TRENDS GENET, V8, P249, DOI 10.1016/0168-9525(92)90124-M; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMIDT C, 1992, EUR J BIOCHEM, V206, P625, DOI 10.1111/j.1432-1033.1992.tb16967.x; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; VERKERK AJMH, 1993, HUM MOL GENET, V2, P399, DOI 10.1093/hmg/2.4.399; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WOHRLE D, 1992, AM J HUM GENET, V51, P299; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	39	393	401	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					33	39		10.1016/0092-8674(94)90232-1	http://dx.doi.org/10.1016/0092-8674(94)90232-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156595				2022-12-01	WOS:A1994NF21100007
J	SMITH, CL; DELOTTO, R				SMITH, CL; DELOTTO, R			VENTRALIZING SIGNAL DETERMINED BY PROTEASE ACTIVATION IN DROSOPHILA EMBRYOGENESIS	NATURE			English	Article							SERINE PROTEASE; DORSAL; PATTERN; EMBRYO; POLARITY; EASTER; GENES	SPECIFICATION of dorsal-ventral cell fate during Drosophila embryogenesis is mediated by a signal transduction pathway1-4. Asymmetry of cell fates arises through the spatially restricted production of a ligand in an extracellular compartment called the perivitelline space5. The snake and easter genes are required for the production of the ligand17 and they encode the proenzyme form of secreted extracellular serine proteases6,7. We have examined the effect of producing a preactivated form of the snake protease on the generation of dorsal-ventral polarity. SP6 RNA microinjection experiments reveal that different cell fates acquired at cellular blastoderm can be specified by the amount and spatial distribution of activated snake protein. Our results support a protease cascade model in which localized activation of uniformly distributed protease proenzymes leads to the spatially restricted production of ligand in the perivitelline space on the ventral side of the embryo.	CORNELL UNIV,GRAD SCH MED SCI,DEPT CELL BIOL,NEW YORK,NY 10021	Cornell University	SMITH, CL (corresponding author), SLOAN KETTERING INST CANC RES,DEPT MICROBIOL,1275 YORK AVE,NEW YORK,NY 10021, USA.		Smith, Cynthia/AAY-6219-2020; Smith, Cynthia L/A-5646-2009	Smith, Cynthia/0000-0003-3691-0324; Smith, Cynthia L/0000-0003-3691-0324				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEPTIN M, 1990, DEVELOPMENT, V110, P73; ROTH S, 1991, DEVELOPMENT, V112, P371; Rushlow C, 1990, Semin Cell Biol, V1, P137; Sambrook J., 1989, MOL CLONING LAB MANU; SANTAMARIA P, 1983, EMBO J, V2, P1695, DOI 10.1002/j.1460-2075.1983.tb01644.x; Santamaria P., 1986, DROSOPHILA PRACTICAL, P159; SMITH C, 1994, GENETICS, V136, P1355; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STJOHNSTON D, 1992, CELL, V68, P201; Wieschaus E., 1986, P199	17	67	67	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					548	551		10.1038/368548a0	http://dx.doi.org/10.1038/368548a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139688				2022-12-01	WOS:A1994NE33500055
J	ZAGELBAUM, BM; HERSH, PS; DONNENFELD, ED; PERRY, HD; HOCHMAN, MA				ZAGELBAUM, BM; HERSH, PS; DONNENFELD, ED; PERRY, HD; HOCHMAN, MA			OCULAR TRAUMA IN MAJOR-LEAGUE BASEBALL PLAYERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							EYE INJURY		BRONX LEBANON HOSP CTR,BRONX,NY 10457	BronxCare Health System	ZAGELBAUM, BM (corresponding author), N SHORE UNIV HOSP,LIONS EYE BANK LONG ISL,300 COMMUNITY DR,MANHASSET,NY 11030, USA.							JONES NP, 1989, SPORTS MED, V7, P163, DOI 10.2165/00007256-198907030-00003; Parver L M, 1986, Arch Ophthalmol, V104, P1452; STOCK JG, 1991, AM FAM PHYSICIAN, V44, P515; ZAGELBAUM BM, 1993, PHYSICIAN SPORTSMED, V21, P25, DOI 10.1080/00913847.1993.11710413; 1992, 1991 EYE INJURIES AS; 1991, 1990 SPORTS RECREATI; 1990, 1989 SPORTS RECREATI; 1992, ESTIMATES REPORT BAS	8	15	15	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	1994	330	14					1021	1023		10.1056/NEJM199404073301421	http://dx.doi.org/10.1056/NEJM199404073301421			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND793	8121457				2022-12-01	WOS:A1994ND79300039
J	KIMBEL, WH; JOHANSON, DC; RAK, Y				KIMBEL, WH; JOHANSON, DC; RAK, Y			THE 1ST SKULL AND OTHER NEW DISCOVERIES OF AUSTRALOPITHECUS-AFARENSIS AT HADAR, ETHIOPIA	NATURE			English	Article							FUNCTIONAL-MORPHOLOGY; CRANIAL MORPHOLOGY; HOMINIDS; POSITION	THE Hadar Formation in Ethiopia is a prolific source of Pliocene Hominidae attributed to the species Australopithecus afarensis1. Since 1990, three seasons of field work have contributed 53 new specimens to the hominid inventory from Hadar, including the first fairly complete adult skull. Ranging from 3.0 to 3.4 million years in age (Fig. 1)2-4 , the new specimens bear on key debates in hominid palaeontology, including the taxonomic implications of sample variation and the reconstruction of locomotor behaviour. They confirm the taxonomic unity of A. afarensis and constitute the largest body of evidence for about 0.9 million years of stasis in the earliest known hominid species.	TEL AVIV UNIV, SACKLER SCH MED, DEPT ANAT, TEL AVIV, ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	KIMBEL, WH (corresponding author), INST HUMAN ORIGINS, 2453 RIDGE RD, BERKELEY, CA 94709 USA.		Klein, Richard G/B-5910-2009					ASFAW B, 1987, J HUM EVOL, V16, P611, DOI 10.1016/0047-2484(87)90016-9; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P403, DOI 10.1002/ajpa.1330570403; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P373, DOI 10.1002/ajpa.1330570402; JOHANSON DC, 1979, SCIENCE, V203, P321, DOI 10.1126/science.104384; JOHANSON DC, 1978, KIRTLANDIA, V28, P1; JUNGERS WL, 1983, J HUM EVOL, V12, P673, DOI 10.1016/S0047-2484(83)80007-4; KIMBEL WH, 1982, AM J PHYS ANTHROPOL, V57, P453, DOI 10.1002/ajpa.1330570404; KIMBEL WH, 1988, J HUM EVOL, V17, P545, DOI 10.1016/0047-2484(88)90042-5; KIMBEL WH, 1984, AM J PHYS ANTHROPOL, V64, P337, DOI 10.1002/ajpa.1330640403; KIMBEL WH, 1985, AM J PHYS ANTHROPOL, V66, P31, DOI 10.1002/ajpa.1330660104; KIMBEL WH, 1985, ANCESTORS HARD EVIDE, P122; Latimer B., 1991, P169; LOVEJOY CO, 1988, SCI AM, V259, P118, DOI 10.1038/scientificamerican1188-118; LOVEJOY CO, 1982, AM J PHYS ANTHROPOL, V57, P637, DOI 10.1002/ajpa.1330570409; MCHENRY HM, 1980, SCIENCE, V207, P1103, DOI 10.1126/science.207.4435.1103; MCKEE JK, 1989, AM J PHYS ANTHROPOL, V80, P1, DOI 10.1002/ajpa.1330800102; Olson T.R., 1985, P102; Rak Y, 1983, AUSTRALOPITHECINE FA, P1; RENNE P, 1993, J GEOPHYS RES, V20, P1067; SHIPMAN P, 1986, DISCOVER, V7, P87; STERN JT, 1983, AM J PHYS ANTHROPOL, V60, P279, DOI 10.1002/ajpa.1330600302; STRN JT, 1991, ORIGINES BIPEDIE HOM, P99; SUSMAN RL, 1984, FOLIA PRIMATOL, V43, P113, DOI 10.1159/000156176; WALTER RC, 1993, J HUM EVOL, V25, P229, DOI 10.1006/jhev.1993.1046; WALTER RC, 1994, GEOLOGY, V22, P6, DOI 10.1130/0091-7613(1994)022<0006:AOLATF>2.3.CO;2; WARD SC, 1983, AM J PHYS ANTHROPOL, V61, P157, DOI 10.1002/ajpa.1330610204; WHITE TD, 1993, NATURE, V366, P261, DOI 10.1038/366261a0; WHITE TD, 1981, S AFR J SCI, V77, P445; WHITE TD, 1982, AM J PHYS ANTHROPOL, V57, P501, DOI 10.1002/ajpa.1330570405; White TD, 1984, J VERTEBR PALEONTOL, V4, P575, DOI DOI 10.1080/02724634.1984.10012033; WOOD BA, 1991, J ANAT, V174, P185	31	142	143	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	1994	368	6470					449	451		10.1038/368449a0	http://dx.doi.org/10.1038/368449a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133889				2022-12-01	WOS:A1994ND12000061
J	CROWLEY, C; SPENCER, SD; NISHIMURA, MC; CHEN, KS; PITTSMEEK, S; ARMANINI, MP; LING, LH; MCMAHON, SB; SHELTON, DL; LEVINSON, AD; PHILLIPS, HS				CROWLEY, C; SPENCER, SD; NISHIMURA, MC; CHEN, KS; PITTSMEEK, S; ARMANINI, MP; LING, LH; MCMAHON, SB; SHELTON, DL; LEVINSON, AD; PHILLIPS, HS			MICE LACKING NERVE GROWTH-FACTOR DISPLAY PERINATAL LOSS OF SENSORY AND SYMPATHETIC NEURONS YET DEVELOP BASAL FOREBRAIN CHOLINERGIC NEURONS	CELL			English	Article							ROOT GANGLION NEURONS; NEUROTROPHIC FACTOR; BIOLOGICAL-ACTIVITY; FACTOR DEPRIVATION; MOLECULAR-CLONING; EXPRESSION; BRAIN; TRK; NGF; PROTOONCOGENE	Homologous recombination was utilized to generate mice with a deletion in the coding sequence of the nerve growth factor (NGF) gene. Animals homozygous for NGF disruption failed to respond to noxious mechanical stimuli, and histological analysis revealed profound cell loss in both sensory and sympathetic ganglia. Within dorsal root ganglia, effects of the mutation appeared to be restricted to small and medium peptidergic neurons. These observations confirm the critical dependence of sensory and sympathetic neurons on NGF and demonstrate that other neurotrophins are not able to compensate for the loss of NGF action on these cells. Examination of the central nervous system revealed that, in marked contrast with neurons of sensory and sympathetic ganglia, basal forebrain cholinergic neurons differentiate and continue to express phenotypic markers for the life span of the null mutant mice. Thus, differentiation and initial survival of central NGF-responsive neurons can occur in the absence of NGF.	UNITED MED & DENT SCH,DEPT PHYSIOL,LONDON SE1 7EH,ENGLAND; GENENTECH INC,DEPT ENDOCRINE RES,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080	University of London; King's College London; Roche Holding; Genentech; Roche Holding; Genentech	CROWLEY, C (corresponding author), GENENTECH INC,DEPT CELL GENET,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.			McMahon, Stephen/0000-0003-4656-5536				BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CARROLL SL, 1992, NEURON, V9, P779, DOI 10.1016/0896-6273(92)90040-K; CHUN LLY, 1977, J CELL BIOL, V75, P694, DOI 10.1083/jcb.75.3.694; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DAVIES AM, 1985, DEV BIOL, V111, P62, DOI 10.1016/0012-1606(85)90435-X; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GAGE FH, 1989, NEURON, V2, P1177, DOI 10.1016/0896-6273(89)90184-0; GORIN PD, 1979, P NATL ACAD SCI USA, V76, P5382, DOI 10.1073/pnas.76.10.5382; GORIN PD, 1980, DEV BIOL, V80, P13; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HAMBURGER V, 1993, J NEUROBIOL, V24, P893, DOI 10.1002/neu.480240702; HARTIKKA J, 1988, J NEUROSCI RES, V21, P352, DOI 10.1002/jnr.490210227; HEFTI F, 1985, NEUROSCIENCE, V14, P55, DOI 10.1016/0306-4522(85)90163-0; HEFTI F, 1989, NEUROBIOL AGING, V10, P515, DOI 10.1016/0197-4580(89)90118-8; JOHNSON EM, 1983, NEUROSCIENCE, V8, P631, DOI 10.1016/0306-4522(83)90204-X; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LEVIMONTALCINI R, 1966, PHARMACOL REV, V10, P619; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; OTTEN U, 1980, NATURE, V287, P158, DOI 10.1038/287158a0; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; ROSE RD, 1987, J COMP NEUROL, V263, P365, DOI 10.1002/cne.902630305; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; RUIT KG, 1992, NEURON, V8, P1; SELBY MJ, 1987, MOL CELL BIOL, V7, P3057, DOI 10.1128/MCB.7.9.3057; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; VANTINI G, 1989, NEURON, V3, P267, DOI 10.1016/0896-6273(89)90251-1; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; Willis WD, 1991, SENSORY MECH SPINAL	41	874	910	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1001	1011		10.1016/0092-8674(94)90378-6	http://dx.doi.org/10.1016/0092-8674(94)90378-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137419				2022-12-01	WOS:A1994ND24600007
J	LODI, PJ; GARRETT, DS; KUSZEWSKI, J; TSANG, MLS; WEATHERBEE, JA; LEONARD, WJ; GRONENBORN, AM; CLORE, GM				LODI, PJ; GARRETT, DS; KUSZEWSKI, J; TSANG, MLS; WEATHERBEE, JA; LEONARD, WJ; GRONENBORN, AM; CLORE, GM			HIGH-RESOLUTION SOLUTION STRUCTURE OF THE BETA-CHEMOKINE HMIP-1-BETA BY MULTIDIMENSIONAL NMR	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; RESTRAINED MOLECULAR-DYNAMICS; HUMAN INTERLEUKIN-8 RECEPTOR; MULTIPLE QUANTUM COHERENCE; 3-DIMENSIONAL STRUCTURE; DISTANCE GEOMETRY; MONOCYTE CHEMOATTRACTANT; CYTOKINE FAMILY; LARGER PROTEINS; ACT-2 CYTOKINE	The three-dimensional structure of a member of the beta subfamily of chemokines, human macrophage inflammatory protein-1 beta (hMIP-1 beta), has been determined with the use of solution multidimensional heteronuclear magnetic resonance spectroscopy. Human MIP-1 beta is a symmetric homodimer with a relative molecular mass of similar to 16 kilodaltons. The structure of the hMIP-1 beta monomer is similar to that of the related alpha chemokine interleukin-8 (IL-8). However, the quaternary structures of the two proteins are entirely distinct, and the dimer interfaceis formed by a completely different set of residues. Whereas the IL-8 dimer is globular, the hMIP-1 beta dimer is elongated and cylindrical. This provides a rational explanation for the absence of cross-binding and reactivity between the alpha and beta chemokine subfamilies. Calculation of the solvation free energies of dimerization suggests that the formation and stabilization of the two different types of dimers arise from the burial of hydrophobic residues.	NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892; R&D SYST INC,MINNEAPOLIS,MN 55413; NHLBI,PULM & MOLEC IMMUNOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Clore, G Marius/L-2546-2018; Leonard, Warren/AAA-1397-2022; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1992, J AM CHEM SOC, V114, P6923, DOI 10.1021/ja00043a052; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROWN KD, 1989, J IMMUNOL, V142, P679; BRUNGER AT, 1993, SCIENCE, V261, P328, DOI 10.1126/science.8332897; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1993, J MOL BIOL, V231, P82, DOI 10.1006/jmbi.1993.1259; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; CLORE GM, IN PRESS METHODS ENZ; DECASTRO E, 1992, VISP 1 0 USERS GUIDE; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GRAHAM GJ, 1993, CELL GROWTH DIFFER, V4, P137; GRONENBORN AM, 1991, PROTEIN ENG, V4, P263, DOI 10.1093/protein/4.3.263; GRZESIEK S, 1992, J MAGN RESON, V96, P215, DOI 10.1016/0022-2364(92)90307-S; GRZESIEK S, 1993, J BIOMOL NMR, V3, P627; GRZESIEK S, 1993, J BIOMOL NMR, V3, P487; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JONES TA, 1990, O VERSION 5 MANUAL; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; KUSZEWSKI J, UNPUB; LIPES MA, 1988, P NATL ACAD SCI USA, V85, P9704, DOI 10.1073/pnas.85.24.9704; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NAPOLITANO M, 1990, J EXP MED, V172, P285, DOI 10.1084/jem.172.1.285; NAPOLITANO M, 1991, J BIOL CHEM, V266, P17531; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; ROYER WE, 1985, NATURE, V316, P277, DOI 10.1038/316277a0; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; STEVENS AAE, UNPUB; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; VANKIMMENADE A, 1988, EUR J BIOCHEM, V173, P109; VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; VUISTER GW, IN PRESS METHODS ENZ; VULSTER GW, 1993, J AM CHEM SOC, V115, P7772; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; YOSHIMURA T, 1990, J IMMUNOL, V145, P292; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	60	217	234	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1762	1767		10.1126/science.8134838	http://dx.doi.org/10.1126/science.8134838			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	8134838	Green Submitted			2022-12-01	WOS:A1994NC04000036
J	NEDERGAARD, M				NEDERGAARD, M			DIRECT SIGNALING FROM ASTROCYTES TO NEURONS IN CULTURES OF MAMMALIAN BRAIN-CELLS	SCIENCE			English	Article							CALCIUM WAVES; JUNCTION; TRANSIENTS; GLUTAMATE; GROWTH; GLIA	Although astrocytes have been considered to be supportive, rather than transmissive, in the adult nervous system, recent studies have challenged this assumption by demonstrating that astrocytes possess functional neurotransmitter receptors. Astrocytes are now shown to directly modulate the free cytosolic calcium, and hence transmission characteristics, of neighboring neurons. When a focal electric field potential was applied to single astrocytes in mixed cultures of rat forebrain astrocytes and neurons, a prompt elevation of calcium occurred in the target cell. This in turn triggered a wave of calcium increase, which propagated from astrocyte to astrocyte. Neurons resting on these astrocytes responded with large increases in their concentration of cytosolic calcium. The gap junction blocker octanol attenuated the neuronal response, which suggests that the astrocytic-neuronal signaling is mediated through intercellular connections rather than synaptically. This neuronal response to local astrocytic stimulation may mediate local intercellular communication within the brain.			NEDERGAARD, M (corresponding author), CORNELL UNIV,COLL MED,DEPT SURG,DIV NEUROSURG,1300 YORK AVE,NEW YORK,NY 10021, USA.							CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CSERR HF, 1986, ANN NY ACAD SCI, V1, P481; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DAVENPORT RW, 1992, NEURON, V9, P405, DOI 10.1016/0896-6273(92)90179-H; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; FLAGGNEWTON JL, 1980, SCIENCE, V207, P771, DOI 10.1126/science.7352287; GOLDMAN SA, 1989, J CEREBR BLOOD F MET, V9, P471, DOI 10.1038/jcbfm.1989.70; HANSEN AJ, 1985, PHYSIOL REV, V65, P101, DOI 10.1152/physrev.1985.65.1.101; JENSEN AM, 1990, J NEUROSCI, V10, P1165; KATZ B, 1967, J PHYSIOL-LONDON, V192, P407, DOI 10.1113/jphysiol.1967.sp008307; KRIEGLER S, 1993, J NEUROSCI, V13, P4229, DOI 10.1523/jneurosci.13-10-04229.1993; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; MANTZ J, 1993, ANESTHESIOLOGY, V78, P892, DOI 10.1097/00000542-199305000-00014; MURPHY TH, 1992, J NEUROSCI, V12, P4834; MURPHY TH, 1993, J NEUROSCI, V13, P2672, DOI 10.1523/JNEUROSCI.13-06-02672.1993; NEDERGAARD M, 1991, J NEUROSCI, V11, P2489; PATEL NB, 1984, J NEUROSCI, V4, P2939; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; REIST NE, 1992, P NATL ACAD SCI USA, V89, P7625, DOI 10.1073/pnas.89.16.7625; ROBINSON SR, 1993, SCIENCE, V262, P1072; Saito R, 1993, J CEREB BLOOD FLO S1, V13, pS86; SHIOSAKA S, 1989, J COMP NEUROL, V281, P282, DOI 10.1002/cne.902810210; TOBIASZ C, 1982, BRAIN RES, V241, P329, DOI 10.1016/0006-8993(82)91071-X; WADE MH, 1986, SCIENCE, V232, P525, DOI 10.1126/science.3961495	28	823	846	0	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1768	1771		10.1126/science.8134839	http://dx.doi.org/10.1126/science.8134839			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	8134839				2022-12-01	WOS:A1994NC04000037
J	COSSON, P; LETOURNEUR, F				COSSON, P; LETOURNEUR, F			COATOMER INTERACTION WITH DI-LYSINE ENDOPLASMIC-RETICULUM RETENTION MOTIFS	SCIENCE			English	Article							TRANSMEMBRANE PROTEINS; SECRETORY PATHWAY; RECEPTOR; TRANSPORT; COMPLEX; SIGNAL; GOLGI	Although signals for retention in the endoplasmic reticulum (ER) have been identified in the cytoplasmic domain of various ER-resident type I transmembrane proteins, the mechanisms responsible for ER retention are still unknown. Yeast and mammalian ER retention motifs interacted specifically in cell lysates with the coatomer, a polypeptide complex implicated in membrane traffic. Mutations that affect the ER retention capacity of the motifs also abolished binding of the coatomer. These results suggest a role for the coatomer in the retrieval of transmembrane proteins to the ER in both yeast and mammals.	BASEL INST IMMUNOL, CH-4005 BASEL, SWITZERLAND					Letourneur, Francois/0000-0003-2232-6127				BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; COSSON P, UNPUB; EMR S, COMMUNICATION; FRANZUSOFF A, 1991, METHOD ENZYMOL, V194, P662; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	24	486	492	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 18	1994	263	5153					1629	1631		10.1126/science.8128252	http://dx.doi.org/10.1126/science.8128252			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128252				2022-12-01	WOS:A1994NB67300037
J	OHTO, H; TERAZAWA, S; SASAKI, N; SASAKI, N; HINO, K; ISHIWATA, C; KAKO, M; UJIIE, N; ENDO, C; MATSUI, A; OKAMOTO, H; MISHIRO, S; KOJIMA, M; AIKAWA, T; SHIMODA, K; SAKAMOTO, M; AKAHANE, Y; YOSHIZAWA, H; TANAKA, T; TOKITA, H; TSUDA, F				OHTO, H; TERAZAWA, S; SASAKI, N; SASAKI, N; HINO, K; ISHIWATA, C; KAKO, M; UJIIE, N; ENDO, C; MATSUI, A; OKAMOTO, H; MISHIRO, S; KOJIMA, M; AIKAWA, T; SHIMODA, K; SAKAMOTO, M; AKAHANE, Y; YOSHIZAWA, H; TANAKA, T; TOKITA, H; TSUDA, F			TRANSMISSION OF HEPATITIS-C VIRUS FROM MOTHERS TO INFANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; ASYMPTOMATIC CARRIER MOTHERS; POLYMERASE CHAIN-REACTION; PUTATIVE CORE GENE; NON-A-HEPATITIS; E-ANTIGEN; NEONATAL TRANSMISSION; VERTICAL TRANSMISSION; INFECTION; ANTIBODIES	Background. Although there are case reports of vertical transmission of hepatitis C virus (HCV), it remains uncertain to what extent infected mothers transmit this virus to their infants. Methods. We investigated the transmission of HCV from infected mothers to their babies by analyzing HCV RNA in the blood. Three independent studies were performed. First, 7698 parturient women were tested for anti-HCV antibodies; 53 were positive. Their 54 infants (including one set of twins) were followed prospectively for at least six months and tested for HCV infection. Second, the babies of six women with known HCV disease were prospectively studied. Third, the families of three HCV-infected infants were examined retrospectively. Results. Of the 53 antibody-positive mothers, 31 were also positive for serum HCV RNA, Three of the 54 babies born to these mothers (5.6 percent) became positive for HCV RNA during the follow-up period. None of the babies of the 22 women who were antibody-positive but HCV RNA-negative became positive for HCV RNA. In the second study, HCV RNA was detected in one of the six infants of infected mothers. In the third study, HCV RNA was detected in the mothers of the three HCV-infected infants. In each of the seven infected infants we studied, the genomic sequence of HCV was almost identical to that from the mother. These seven mothers had significantly higher titers of HCV RNA than did the mothers of infants with no evidence of infection (mean [+/-SD], 10(6.4+/-0.5) VS. 10(4.4+/-1.5) per milliliter; P<0.001). Conclusions. HCV is vertically transmitted from mother to infant, and the risk of transmission is correlated with the titer of HCV RNA in the mother.	INST IMMUNOL,BUNKYO KU,TOKYO,TOKYO 112,JAPAN; FUKUSHIMA MED COLL,BLOOD TRANSFUS SERV,FUKUSHIMA,FUKUSHIMA,JAPAN; FUKUSHIMA MED COLL,DEPT PEDIAT,FUKUSHIMA,FUKUSHIMA,JAPAN; FUKUSHIMA MED COLL,DEPT OBSTET & GYNECOL,FUKUSHIMA,FUKUSHIMA,JAPAN; GIFU KOUSEIREN GIHOKU HOSP,DIV PEDIAT,GIFU,GIFU,JAPAN; JICHI MED SCH,DEPT PEDIAT,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; JICHI MED SCH,DIV IMMUNOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; ONOMICHI GEN HOSP,DEPT PEDIAT,HIROSHIMA,HIROSHIMA,JAPAN; NATL DEF MED COLL,DEPT INTERNAL MED 2,TOKOROZAWA,SAITAMA,JAPAN; ISHIWATA OBSTET & GYNECOL HOSP,IBARAKI,OSAKA,JAPAN; TEIKYO UNIV,SCH MED,DEPT MED 4,SAGAMIKO,KANAGAWA,JAPAN; TEIKYO UNIV,SCH MED,DEPT MED 4,SAGAMIKO,KANAGAWA,JAPAN; AIKAWA INTERNAL HOSP,IBARAKI,OSAKA,JAPAN; YAMANASHI MED COLL,KOFU,YAMANASHI,JAPAN; HIROSHIMA UNIV,SCH MED,HIROSHIMA,HIROSHIMA,JAPAN; JAPANESE RED CROSS,SAITAMA BLOOD CTR,URAWA,SAITAMA,JAPAN; VIRAL HEPATITIS RES FDN JAPAN,TOKYO,TOKYO,JAPAN	Fukushima Medical University; Fukushima Medical University; Fukushima Medical University; Jichi Medical University; Jichi Medical University; National Defense Medical College - Japan; Teikyo University; Teikyo University; University of Yamanashi; Hiroshima University; Japanese Red Cross Medical Center			Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964; Mishiro, Shunji/0000-0001-9618-6468				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1976, NEW ENGL J MED, V295, P909, DOI 10.1056/NEJM197610212951701; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DEGOS F, 1991, LANCET, V338, P758, DOI 10.1016/0140-6736(91)91477-C; HIJIKATA M, 1991, BIOCHEM BIOPH RES CO, V175, P220, DOI 10.1016/S0006-291X(05)81223-9; INOUE Y, 1991, NATURE, V353, P609, DOI 10.1038/353609a0; KATO N, 1991, HEPATOLOGY, V14, pA67; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KOFF RS, 1992, ANN INTERN MED, V117, P967, DOI 10.7326/0003-4819-117-11-967; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAM JPH, 1993, J INFECT DIS, V167, P572, DOI 10.1093/infdis/167.3.572; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; MURATA S, 1977, NEW ENGL J MED, V296, P692; OKADA K, 1976, NEW ENGL J MED, V294, P746, DOI 10.1056/NEJM197604012941402; OKADA K, 1975, J PEDIATR-US, V87, P360, DOI 10.1016/S0022-3476(75)80635-4; OKADA S, 1992, HEPATOLOGY, V16, P619, DOI 10.1002/hep.1840160302; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1992, VIROLOGY, V190, P894, DOI 10.1016/0042-6822(92)90933-G; OKAMOTO H, 1992, HEPATOLOGY, V15, P180, DOI 10.1002/hep.1840150203; OKAMOTO H, 1990, JPN J EXP MED, V60, P223; REESINK HW, 1990, LANCET, V335, P1216, DOI 10.1016/0140-6736(90)92734-Y; REINUS JF, 1992, ANN INTERN MED, V117, P881, DOI 10.7326/0003-4819-117-11-881; ROUDOTTHORAVAL F, 1993, HEPATOLOGY, V17, P772, DOI 10.1002/hep.1840170504; SHIKATA T, 1977, J INFECT DIS, V136, P571, DOI 10.1093/infdis/136.4.571; TAKAHASHI K, 1992, J GEN VIROL, V73, P667, DOI 10.1099/0022-1317-73-3-667; TANIGUCHI S, 1993, VIROLOGY, V195, P297, DOI 10.1006/viro.1993.1378; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; VANDENHOEK JAR, 1990, J INFECT DIS, V162, P823, DOI 10.1093/infdis/162.4.823; WEINER AJ, 1993, J VIROL, V67, P4365, DOI 10.1128/JVI.67.7.4365-4368.1993; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; Wejstal R, 1992, ANN INTERN MED, V117, P887, DOI 10.7326/0003-4819-117-11-887	33	545	552	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					744	750		10.1056/NEJM199403173301103	http://dx.doi.org/10.1056/NEJM199403173301103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	8107740				2022-12-01	WOS:A1994NA74200003
J	COLE, TJ				COLE, TJ			DO GROWTH CHART CENTILES NEED A FACE LIFT	BMJ-BRITISH MEDICAL JOURNAL			English	Article								European height and weight growth charts commonly extend from the 3rd to the 97th centile, whereas in North America the extremes are usually the 5th and 95th centiles. There is no good reason for the difference, and neither chart is particularly useful for screening owing to the high false positive rate associated with a cut off based on the lowest centile. The World Health Organisation's international growth reference uses cut offs based on standard deviation scores rather than centiles, which are more suitable for the extremes of growth status seen in the developing world. This chart, however, is incompatible with charts based on centiles. sere a unified growth chart is proposed: it has nine rather than seven centiles, and they are spaced two thirds of a standard deviation score apart rather than the more usual unit spacing. This gives a set of curves very like the conventional 3rd to 97th centiles, but with additional curves at 2.67 standard deviation below and above the mean (roughly the 0.4th and 99.6th centiles). The 0.4th centile is a more practical cut off for screening purposes than the 3rd or 5th centile.			COLE, TJ (corresponding author), MRC, DUNN NUTR UNIT, CAMBRIDGE CB4 1XJ, ENGLAND.		Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200				COLE TJ, 1988, J R STAT SOC A STAT, V151, P385, DOI 10.2307/2982992; DIDLEY MJ, 1987, AM J CLIN NUTR, V46, P736; HAMILL PVV, 1977, VITAL HLTH STATISTIC, V11; HEALY MJR, 1988, ANN HUM BIOL, V15, P17, DOI 10.1080/03014468800009421; ROEDE MJ, 1985, TIJDSCHR SOC GEZON S, V63, P1, DOI DOI 10.1007/978-1-4471-1721-6_10; STUART HC, 1950, MITCHELL NELSONS TXB, P14; TANNER JM, 1966, ARCH DIS CHILD, V41, P454, DOI 10.1136/adc.41.219.454	7	83	85	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 5	1994	308	6929					641	642		10.1136/bmj.308.6929.641	http://dx.doi.org/10.1136/bmj.308.6929.641			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148716	Green Published, Green Submitted			2022-12-01	WOS:A1994MZ69800029
J	RHIM, JA; SANDGREN, EP; DEGEN, JL; PALMITER, RD; BRINSTER, RL				RHIM, JA; SANDGREN, EP; DEGEN, JL; PALMITER, RD; BRINSTER, RL			REPLACEMENT OF DISEASED MOUSE-LIVER BY HEPATIC CELL TRANSPLANTATION	SCIENCE			English	Article							TRANSGENIC MICE; STEM-CELL; HEPATOCYTES; EXPRESSION; REGENERATION; RABBIT	Adult liver has the unusual ability to fully regenerate after injury. Although regeneration is accomplished by the division of mature hepatocytes, the replicative potential of these cells is unknown. Here, the replicative capacity of adult liver cells and their medical usefulness as donor cells for transplantation were investigated by transfer of adult mouse liver cells into transgenic mice that display an endogenous defect in hepatic growth potential and function. The transplanted liver cell populations replaced up to 80 percent of the diseased recipient liver. These findings demonstrate the enormous growth potential of adult hepatocytes, indicating the feasibility of liver cell transplantation as a method to replace lost or diseased hepatic parenchyma.	UNIV PENN,SCH VET MED,DEPT ANIM BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Pennsylvania; University of Pennsylvania; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Brinster, Ralph/0000-0003-1408-7656	NICHD NIH HHS [HD09172, HD-23657] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD009172, R37HD023657, R01HD009172] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMENTANO D, 1990, P NATL ACAD SCI USA, V87, P6141, DOI 10.1073/pnas.87.16.6141; FAUSTO N, 1990, HEPATOLOGY TXB LIVER, P49; FAUSTO N, 1987, CELL SEPARATION METH, V4, P45; JONES EA, 1990, HEPATOLOGY TXB LIVER, P460; KAY MA, 1992, P NATL ACAD SCI USA, V89, P89, DOI 10.1073/pnas.89.1.89; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; RHIM JS, UNPUB; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; SELL S, 1990, CANCER RES, V50, P3811; SIGAL SH, 1992, AM J PHYSIOL, V263, pG139, DOI 10.1152/ajpgi.1992.263.2.G139; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P8437, DOI 10.1073/pnas.87.21.8437; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P4421, DOI 10.1073/pnas.85.12.4421	18	482	511	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1149	1152		10.1126/science.8108734	http://dx.doi.org/10.1126/science.8108734			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108734				2022-12-01	WOS:A1994MX75900036
J	SUZUKI, M; TAKAHASHI, K; IKEDA, M; HAYAKAWA, H; OGAWA, A; KAWAGUCHI, Y; SAKAI, O				SUZUKI, M; TAKAHASHI, K; IKEDA, M; HAYAKAWA, H; OGAWA, A; KAWAGUCHI, Y; SAKAI, O			CLONING OF A PH-SENSITIVE K+ CHANNEL POSSESSING 2 TRANSMEMBRANE SEGMENTS	NATURE			English	Article							POTASSIUM CHANNELS; TEA BLOCKADE; DROSOPHILA; SHAKER; MODULATION; COMPONENT; CALCIUM; TUBULE; LOCUS; BRAIN	THE mammalian renal collecting ducts are responsible for secreting potassium ions into the urine and are a major regulatory site for potassium homeostasis(1), in which a voltage-independent pH-sensitive K+ channel in the apical membrane plays a central role(2,3). Here we describe a complementary DNA encoding a novel K+ channel from rabbit renal cortical collecting tubule cells (RACTK1). RACTK1 has the functional characteristics of the apical K+-permeable channel and consists of 284 amino acids, putatively with two transmembrane segments. The sequence of RACTK1, however, shows no homology to known voltage-dependent or -independent K+ channels, and has a different K+-driving path and regulatory sites, The study of this protein should provide insight into K+ homeostasis and diseases of K+ metabolism.	JIKEIKAI UNIV, SCH MED, MINATO KU, TOKYO, TOKYO 105, JAPAN	Jikei University	SUZUKI, M (corresponding author), JICHI MED SCH, DEPT PHARMACOL, 3311-1 MINAMIKAWACHI, KAWACHI, TOCHIGI 32904, JAPAN.		Ikeda, Masato/AHD-4141-2022	Ikeda, Masato/0000-0003-3583-5975				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHANDY KG, 1990, SCIENCE, V247, P943; GIEBISCH G, 1987, POTASSIUM TRANSPORT, P133; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LEVITAN ES, 1990, NATURE, V348, P545, DOI 10.1038/348545a0; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; Maniatis T., 1982, MOL CLONING; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; MISLER S, 1989, J MEMBRANE BIOL, V109, P135, DOI 10.1007/BF01870852; PAK MD, 1991, J NEUROSCI, V11, P869; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROSE GD, 1978, NATURE, V272, P586, DOI 10.1038/272586a0; SUZUKI M, 1993, J MEMBRANE BIOL, V134, P31; SUZUKI M, 1991, J CLIN INVEST, V88, P735, DOI 10.1172/JCI115370; TAKUMI T, 1988, SCIENCE, V242, P1024; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; THREVENOD F, 1992, J MEMBRANE BIOL, V129, P253; WANG WH, 1991, J GEN PHYSIOL, V98, P35, DOI 10.1085/jgp.98.1.35; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494	28	68	68	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	1994	367	6464					642	645		10.1038/367642a0	http://dx.doi.org/10.1038/367642a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107848				2022-12-01	WOS:A1994MW68800053
J	LIU, ZG; SMITH, SW; MCLAUGHLIN, KA; SCHWARTZ, LM; OSBORNE, BA				LIU, ZG; SMITH, SW; MCLAUGHLIN, KA; SCHWARTZ, LM; OSBORNE, BA			APOPTOTIC SIGNALS DELIVERED THROUGH THE T-CELL RECEPTOR OF A T-CELL HYBRID REQUIRE THE IMMEDIATE-EARLY GENE NUR77	NATURE			English	Article							MONOCLONAL-ANTIBODY; ACTIVATION; DEATH; ANTIGEN; THYMOCYTES; FRAGMENTATION; DEGRADATION; INDUCTION	ENGAGEMENT of the T-cell antigen receptor (TCR) on immature thymic T cells induces death by apoptosis1-3. Although several lines of evidence indicate that apoptosis requires de novo gene expression, little is known about the molecular pathways that mediate this response. Here we show that nur77 (refs 4-7), a zinc-finger transcription factor, is expressed in response to TCR engagement in immature T cells and T-cell hybrids. Antisense inhibition of nur77 expression prevents apoptosis in TCR-stimulated cells. nur 7 is also expressed in response to mitogens, but in this case transcription is regulated by 5' upstream elements that are distinct from those used for induction of apoptosis. In addition, polyadenylation is only observed on nur77 transcripts found in condemned cells. These data support a role for nur77 in cell death that may be distinct from that of activation.	UNIV MASSACHUSETTS,DEPT VET & ANIM SCI,AMHERST,MA 01003; UNIV MASSACHUSETTS,DEPT BIOL,AMHERST,MA 01003; UNIV MASSACHUSETTS,PROGRAM MOLEC & CELLULAR BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst								ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; AUSEBEL FM, 1987, CURRENT PROTOCOLS MO; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MONROE D, 1990, MOL CELL BIOL, V10, P3441; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1990, J IMMUNOL, V144, P3326; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; UCKER DS, 1989, J IMMUNOL, V143, P3461; VARNUM BC, 1989, ONCOGENE, V4, P1263; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	22	495	513	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					281	284		10.1038/367281a0	http://dx.doi.org/10.1038/367281a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121494				2022-12-01	WOS:A1994MR49400059
J	MORENO, S; NURSE, P				MORENO, S; NURSE, P			REGULATION OF PROGRESSION THROUGH THE G1 PHASE OF THE CELL-CYCLE BY THE RUM1(+) GENE	NATURE			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; S-PHASE; MITOSIS; DIVISION; SEQUENCE; P34CDC2	The rum1+ gene is identified as a new regulator of G1 progression in fission yeast. It influences three aspects of G1 regulation: determination of the length of G1, dependence of S phase upon completion of mitosis, and restraint of mitosis until G1 is finished. We propose that it has a central role in regulating the G1 phase of the cell cycle.	ICRF, LONDON WCZA 3PX, ENGLAND; UNIV OXFORD, DEPT BIOCHEM, ICRF, CELL CYCLE GRP, OXFORD OX1 1QU, ENGLAND	University of Oxford			Moreno, Sergio/K-3671-2014	Moreno, Sergio/0000-0002-8039-1413				BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BOSTOCK CJ, 1970, EXP CELL RES, V60, P16, DOI 10.1016/0014-4827(70)90484-2; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CALIGIURI M, 1993, CELL, V72, P607, DOI 10.1016/0092-8674(93)90079-6; CARR AM, 1989, MOL GEN GENET, V218, P41, DOI 10.1007/BF00330563; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; EGEL R, 1990, TRENDS GENET, V6, P369, DOI 10.1016/0168-9525(90)90279-F; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; GENDIMENICO GJ, 1988, ANAL BIOCHEM, V173, P45, DOI 10.1016/0003-2697(88)90156-X; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HOFER F, 1979, CURR GENET, V1, P45, DOI 10.1007/BF00413306; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1979, J CELL SCI, V39, P215; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; NURSE P, 1977, EXP CELL RES, V107, P365, DOI 10.1016/0014-4827(77)90358-5; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SAZER S, 1990, J CELL SCI, V97, P509; SMITH AV, 1991, DEVELOPMENT, V112, P997; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; THURIAUX P, 1980, J GEN MICROBIOL, V116, P525; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x	44	310	315	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	1994	367	6460					236	242		10.1038/367236a0	http://dx.doi.org/10.1038/367236a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121488				2022-12-01	WOS:A1994MR49400045
J	ELLIS, SJ				ELLIS, SJ			FUNCTIONAL MAGNETIC-RESONANCE - NEUROLOGICAL ENLIGHTENMENT	LANCET			English	Editorial Material							POSITRON EMISSION TOMOGRAPHY; BRAIN				ELLIS, SJ (corresponding author), UNIV OXFORD, DEPT CLIN NEUROL, OXFORD, ENGLAND.			Ellis, Simon/0000-0002-9131-6427				FRACKOWIAK RSJ, 1989, SEMIN NEUROL, V9, P275, DOI 10.1055/s-2008-1041334; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; JAMIESON DG, 1989, COMPUT MED IMAG GRAP, V13, P61, DOI 10.1016/0895-6111(89)90079-7; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Poeck K, 1984, Adv Neurol, V42, P71; SMITH FW, 1988, J CEREBRAL BLOOD FLO, V8, pS166; WEISSLEDER R, 1992, Magnetic Resonance Quarterly, V8, P55	7	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1993	342	8876					882	882		10.1016/0140-6736(93)91942-F	http://dx.doi.org/10.1016/0140-6736(93)91942-F			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105163				2022-12-01	WOS:A1993MA96300006
J	POIRIER, J; DAVIGNON, J; BOUTHILLIER, D; KOGAN, S; BERTRAND, P; GAUTHIER, S				POIRIER, J; DAVIGNON, J; BOUTHILLIER, D; KOGAN, S; BERTRAND, P; GAUTHIER, S			APOLIPOPROTEIN-E POLYMORPHISM AND ALZHEIMERS-DISEASE	LANCET			English	Article							RAT SCIATIC-NERVE; CHOLESTEROL TRANSPORT; IMMUNOREACTIVITY; PROTEIN; CORTEX; LOCUS	Apolipoprotein E (apoE) is associated with Alzheimer's neurofibrillary tangles and beta-amyloid protein in senile plaques. It also appears to play an important part in the redistribution of lipids that follows deafferentation and neurodegeneration in the brain. The gene for apoE is on chromosome 19, within the genomic region previously associated with late-onset familial Alzheimer's disease (AD). We have studied apoE phenotype expression and the corresponding allele frequencies (epsilon2, epsilon3, epsilon4) in 91 patients with sporadic AD and 74 controls. There was a significant association between epsilon4 and sporadic AD (epsilon4 frequency 0.380 in AD and 0.122 in controls, p <0.01). Analysis of epsilon4 allele frequency as a function of age revealed a bimodal distribution, with peaks at 65 and 75 years. In bearers of epsilon4 in whom AD develops this tended to happen earlier in life than in those with epsilon3 or epsilon2. The epsilon4/AD association was more pronounced in women. Octogenarians with AD had an epsilon4 allele frequency that was 3 times higher than one reported, in a different study, in healthy octogenarians. ApoE may be an important susceptibility factor in the aetiopathology of sporadic AD.	MCGILL UNIV,DEPT PSYCHIAT,MONTREAL H3A 2T5,QUEBEC,CANADA; CLIN RES INST MONTREAL,MONTREAL H2W 1R7,QUEBEC,CANADA; UNIV MONTREAL,MONTREAL H3C 3J7,QUEBEC,CANADA	McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal	POIRIER, J (corresponding author), DOUGLAS HOSP,RES CTR,MCGILL CTR STUDIES AGING,6575 LASALLE BLVD,VERDUN H4H 1R3,PQ,CANADA.				NATIONAL INSTITUTE ON AGING [R01AG010003] Funding Source: NIH RePORTER; NIA NIH HHS [AG-10003] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOUTHILLIER D, 1983, J LIPID RES, V24, P1060; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; CUMMING AM, 1984, CLIN GENET, V25, P310; DAVIES CA, 1987, J NEUROL SCI, V78, P151, DOI 10.1016/0022-510X(87)90057-8; Davignon J, 1988, Trans Am Clin Climatol Assoc, V99, P100; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; GUIBILEI F, 1989, ACTA NEUROL SCAND, V81, P84; HALLMAN DM, 1991, AM J HUM GENET, V49, P338; HONER WG, 1992, NEUROBIOL AGING, V13, P375, DOI 10.1016/0197-4580(92)90111-A; LEBLANC AC, 1990, J NEUROSCI RES, V25, P162, DOI 10.1002/jnr.490250203; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MASLIAH E, 1989, NEUROSCI LETT, V103, P234, DOI 10.1016/0304-3940(89)90582-X; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MUCJKLE TJ, 1985, LANCET, V1, P1191; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; POIRIER J, 1991, BASIC THERAPEUTIC ST, P191; RANSMAYR G, 1989, NEUROSCIENCE, V32, P701, DOI 10.1016/0306-4522(89)90291-1; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1992, ANN NEUROL, V31, P223, DOI 10.1002/ana.410310214; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; YAMADA N, 1980, BIOCHEM BIOPH RES CO, V94, P710, DOI 10.1016/0006-291X(80)91290-5	25	1141	1175	3	52	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					697	699		10.1016/0140-6736(93)91705-Q	http://dx.doi.org/10.1016/0140-6736(93)91705-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103819				2022-12-01	WOS:A1993LX46900006
J	SOUTHALL, DP; SAMUELS, MP				SOUTHALL, DP; SAMUELS, MP			ETHICAL USE OF COVERT VIDEOING FOR POTENTIALLY LIFE-THREATENING CHILD-ABUSE - A RESPONSE	BRITISH MEDICAL JOURNAL			English	Article							MUNCHAUSEN-SYNDROME; PROXY; SURVEILLANCE				SOUTHALL, DP (corresponding author), UNIV KEELE,N STAFFORDSHIRE HOSP,ACAD DEPT PAEDIATR,STOKE ON TRENT ST4 6QG,ENGLAND.							ALEXANDER R, 1990, PEDIATRICS, V86, P581; EPSTEIN MA, 1987, PEDIATRICS, V80, P220; MEADOW R, 1990, J PEDIATR-US, V117, P351, DOI 10.1016/S0022-3476(05)81072-8; ROSEN CL, 1983, PEDIATRICS, V71, P715; SAMUELS MP, 1992, ARCH DIS CHILD, V67, P162, DOI 10.1136/adc.67.2.162; SOUTHALL DP, 1987, BRIT MED J, V294, P1637, DOI 10.1136/bmj.294.6588.1637; WALLER DA, 1983, J AM ACAD CHILD PSY, V22, P80, DOI 10.1097/00004583-198301000-00013; WILLIAMS C, 1988, LANCET, V1, P780	8	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					613	614		10.1136/bmj.307.6904.613	http://dx.doi.org/10.1136/bmj.307.6904.613			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LW149	8129811	Bronze, Green Published			2022-12-01	WOS:A1993LW14900024
J	DALBAGNI, G; PRESTI, J; REUTER, V; FAIR, WR; CORDONCARDO, C				DALBAGNI, G; PRESTI, J; REUTER, V; FAIR, WR; CORDONCARDO, C			GENETIC ALTERATIONS IN BLADDER-CANCER	LANCET			English	Note							ALTERED EXPRESSION; ALLELOTYPE; CARCINOMA	To see whether genetic alterations follow a sequence of events leading to bladder cancer progression, 60 paired bladder tumours and normal tissues were analysed with polymorphic DNA markers, correlating loss of heterozygosity (LOH) at candidate tumour suppressor gene sites with pathological indices of poor clinical outcome. Distinct genotypic patterns were associated with early and late stages of bladder cancer. 9q deletions were observed in all superficial papillary tumours (Ta) and almost all tumours invading the lamina propria (T1), suggesting that this event associates with the development of superficial bladder tumours. However, 3p, 5q, and 17p deletions were absent in the Ta tumours but were identified in invasive bladder cancers. Two genetic pathways characterise the evolution of superficial bladder tumours. 9qLOH was detected in most Ta tumours, but in only 43% of muscle invasive neoplasms. Our hypothesis is that certain chromosomal abnormalities have a defined role in bladder tumour development, whereas others correlate with pathological indices of poor clinical outcome.	MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,1275 YORK AVE,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT SURG,UROL SERV,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [NCI CA-47538] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA047538, R01CA047538] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; DEVILEE P, 1991, ONCOGENE, V6, P1705; FARNDON PA, 1992, LANCET, V339, P581, DOI 10.1016/0140-6736(92)90868-4; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOSS L, 1992, DIAGNOSTIC CYTOLOGY, P934; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; PRESTI JC, 1991, CANCER RES, V51, P5405; TYRKUS M, 1992, J UROLOGY, V148, P44, DOI 10.1016/S0022-5347(17)36504-7; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	10	220	221	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					469	471		10.1016/0140-6736(93)91595-D	http://dx.doi.org/10.1016/0140-6736(93)91595-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102431				2022-12-01	WOS:A1993LU07500012
J	KARASUYAMA, H; ROLINK, A; SHINKAI, Y; YOUNG, F; ALT, FW; MELCHERS, F				KARASUYAMA, H; ROLINK, A; SHINKAI, Y; YOUNG, F; ALT, FW; MELCHERS, F			THE EXPRESSION OF V-PRE-B/LAMBDA-5 SURROGATE LIGHT-CHAIN IN EARLY BONE-MARROW PRECURSOR B-CELLS OF NORMAL AND B-CELL-DEFICIENT MUTANT MICE	CELL			English	Article							LYMPHOCYTES-PRE-B; HEAVY-CHAIN; LAMBDA-5; MOUSE; GENE; SURFACE; PROTEIN; VPREB; LOCUS; LINES	Precursor B (pre-B) cells in bone marrow of normal and B cell-deficient mutant mice were analyzed for the expression of V-pre-B/lambda 5 surrogate light chain (SL). The surface expression of SL is confined to the early stages (pro-B and pre-B-I) of pre-B cell development and becomes undetectable once C heavy chain (pH) is produced. The cell-cycle analysis revealed that cytoplasmic mu H+ large cells (large pre-B-II), similar to 30% of which coexpressed SL in the cytoplasm, were most actively cycling, whereas cytoplasmic mu H+ small cells (small pre-b-II) were SL(-) and not in cycle. The analysis of pre-B cells in B cell-deficient mice suggests that the large pre-B-II stage is a critical step for the selection and amplification of cells carrying functionally rearranged mu H genes.	CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	KARASUYAMA, H (corresponding author), BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND.		Karasuyama, Hajime/A-7966-2011; Shinkai, Yoichi/N-3909-2014	Karasuyama, Hajime/0000-0003-0689-0836; Shinkai, Yoichi/0000-0002-6051-2484	NIAID NIH HHS [AI20047] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020047, R37AI020047] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOSSY D, 1993, INT IMMUNOL, V5, P467, DOI 10.1093/intimm/5.5.467; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; GROETTRUP M, 1993, CELL, V75, P238; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARLOW E, 1988, ANTIBODIES LABORATOR; IGLESIAS A, 1993, EUR J IMMUNOL, V23, P2622, DOI 10.1002/eji.1830231036; KARASUYAMA H, 1993, J EXP MED, V178, P469, DOI 10.1084/jem.178.2.469; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KERR WG, 1989, INT IMMUNOL, V7, P354; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KLEINFIELD R, 1986, NATURE, V322, P843, DOI 10.1038/322843a0; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; KUDO A, 1992, INT IMMUNOL, V4, P831, DOI 10.1093/intimm/4.8.831; KUDO A, 1989, PROGR IMMUNOLOGY, V7, P339; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MATSUO T, 1993, J IMMUNOL, V150, P3766; MELCHERS F, 1993, IMMUNOL TODAY, V14, P60, DOI 10.1016/0167-5699(93)90060-X; MISENER V, 1990, J IMMUNOL, V145, P905; MISENER V, 1991, INT IMMUNOL, V3, P1129, DOI 10.1093/intimm/3.11.1129; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; NISHIMOTO N, 1991, P NATL ACAD SCI USA, V88, P6284, DOI 10.1073/pnas.88.14.6284; OSMOND DG, 1991, CURR OPIN IMMUNOL, V3, P179, DOI 10.1016/0952-7915(91)90047-5; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PILLAI S, 1988, CURR TOP MICROBIOL, V137, P136; REICHMANFRIED M, 1993, INT IMMUNOL, V5, P303, DOI 10.1093/intimm/5.3.303; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; ROLINK A, 1993, BLOOD, V81, P2290; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROLINK A, 1993, EUR J IMMUNOL, V23, P1284, DOI 10.1002/eji.1830230614; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SAKAGUCHI N, 1986, EMBO J, V5, P2139, DOI 10.1002/j.1460-2075.1986.tb04477.x; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973	41	230	236	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					133	143		10.1016/0092-8674(94)90241-0	http://dx.doi.org/10.1016/0092-8674(94)90241-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156589				2022-12-01	WOS:A1994NF21100016
J	LU, W; HAN, DS; YUAN, J; ANDRIEU, JM				LU, W; HAN, DS; YUAN, J; ANDRIEU, JM			MULTITARGET PCR ANALYSIS BY CAPILLARY ELECTROPHORESIS AND LASER-INDUCED FLUORESCENCE	NATURE			English	Article							POLYMERASE CHAIN-REACTION				LU, W (corresponding author), UNIV PARIS 05,HOP LAENNEC,TUMOR IMMUNOL LAB,F-75007 PARIS,FRANCE.							ALBIN M, 1991, ANAL CHEM, V63, P417, DOI 10.1021/ac00005a006; ANDRIEU JM, 1991, VIRAL QUANTITATION H, P191; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; HORSBURGH CR, 1989, LANCET, V2, P637; ISAACS ST, 1991, NUCLEIC ACIDS RES, V19, P109, DOI 10.1093/nar/19.1.109; LEFRERE JJ, 1992, LANCET, V339, P999, DOI 10.1016/0140-6736(92)91585-V; LU W, 1993, J INFECT DIS, V167, P1498, DOI 10.1093/infdis/167.6.1498; LU W, 1993, AIDS, V7, pS111, DOI 10.1097/00002030-199311002-00021; LU W, 1993, J INFECT DIS, V167, P1014, DOI 10.1093/infdis/167.5.1014; Lu Wei, 1993, Lancet (North American Edition), V341, P113, DOI 10.1016/0140-6736(93)92589-L; LUCKEY JA, 1990, NUCLEIC ACIDS RES, V18, P4417, DOI 10.1093/nar/18.15.4417; OU CY, 1991, BIOTECHNIQUES, V10, P442; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SHULDINER AR, 1991, BIOTECHNIQUES, V11, P760; SIMONDS RJ, 1993, AIDS, V7, pS35, DOI 10.1097/00002030-199311002-00008	15	78	84	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					269	271		10.1038/368269a0	http://dx.doi.org/10.1038/368269a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145828				2022-12-01	WOS:A1994NA87000063
J	SELHUB, J; JACQUES, PF; WILSON, PWF; RUSH, D; ROSENBERG, IH				SELHUB, J; JACQUES, PF; WILSON, PWF; RUSH, D; ROSENBERG, IH			VITAMIN STATUS AND INTAKE AS PRIMARY DETERMINANTS OF HOMOCYSTEINEMIA IN AN ELDERLY POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMA HOMOCYST(E)INE; VASCULAR-DISEASE; RISK FACTOR; INFARCTION; HEALTH; ASSAY	Objective.-To describe the distribution of plasma homocysteine concentrations in an elderly population and to analyze the relationship between homocysteine level and intake of vitamins and serum levels of vitamins that serve as coenzymes in homocysteine metabolism. Design.-Cross-sectional analysis of homocysteine levels and vitamin blood levels and intake in elderly participants in the Framingham Study. Setting.-Population-based cohort in Framingham, Mass. Participants.-A total of 1160 adult survivors, aged 67 to 96 years, from the original Framingham Heart Study cohort. Main Outcome Measures.-Plasma homocysteine concentration correlated with plasma folate, vitamin B-12, pyridoxal-5'-phosphate (PLP), and oral intakes of these vitamins, and the contribution of these vitamins to the prevalence of elevated homocysteine in the population. Results.-Homocysteine levels were positively correlated with age after controlling for vitamin concentrations. After controlling for age, sex, and levels of other vitamins, homocysteine exhibited a strong inverse association with plasma folate. When subjects were grouped by deciles of plasma folate, mean homocysteine was significantly higher in the lowest two folate deciles (1 5.6 and 1 3.7 mumol/L, respectively) than in the highest decile (11.0 mumol/L). Homocysteine demonstrated weaker, inverse associations with plasma vitamin B-12 and PLP. Similar inverse associations were demonstrated between homocysteine and intakes of folate and vitamin B-6, but not vitamin B-12. Prevalence of high homocysteine (> 14 mumol/L) was 29.3% in this cohort, and was greatest among subjects with low folate status. Inadequate plasma concentrations of one or more B vitamins appear to contribute to 67% of the cases of high homocysteine. Conclusions.-These results indicate a strong association between homocysteine concentration and folate, vitamin B-12, and vitamin B-6 status, as well as age. It is possible that a substantial majority of the cases of high homocysteine in this older population can be attributed to vitamin status.	FRAMINGTON MASS HEART STUDY, FRAMINGHAM, MA USA		SELHUB, J (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, 711 WASHINGTON ST, BOSTON, MA 02111 USA.		Wilson, Peter W.F./J-2455-2016					ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; ARAKI A, 1989, ATHEROSCLEROSIS, V79, P139, DOI 10.1016/0021-9150(89)90118-4; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; CAMP VM, 1983, CLIN CHEM, V29, P642; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; DAWBER T. R., 1957, AMER JOUR PUBL HEALTH, V47, P4, DOI 10.2105/AJPH.47.4_Pt_2.4; GARTLER SM, 1981, P NATL ACAD SCI-BIOL, V78, P1916, DOI 10.1073/pnas.78.3.1916; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; JACQUES PF, 1993, AM J CLIN NUTR, V57, P182, DOI 10.1093/ajcn/57.2.182; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; MCCULLY KS, 1969, AM J PATHOL, V56, P111; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; ROTHHMAN KJ, 1986, MODERN EPIDEMIOLOGY; RUSSELL RM, 1992, AM J CLIN NUTR, V55, P1203; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAMURA T, 1990, CLIN CHEM, V36, P1993; UELAND PM, 1989, J LAB CLIN MED, V114, P473; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; Willett W, 1990, NUTR EPIDEMIOLOGY, P92	20	1599	1660	1	44	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2693	2698		10.1001/jama.270.22.2693	http://dx.doi.org/10.1001/jama.270.22.2693			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133587				2022-12-01	WOS:A1993MJ82100028
J	DOLLE, P; DIERICH, A; LEMEUR, M; SCHIMMANG, T; SCHUHBAUR, B; CHAMBON, P; DUBOULE, D				DOLLE, P; DIERICH, A; LEMEUR, M; SCHIMMANG, T; SCHUHBAUR, B; CHAMBON, P; DUBOULE, D			DISRUPTION OF THE HOXD-13 GENE INDUCES LOCALIZED HETEROCHRONY LEADING TO MICE WITH NEOTENIC LIMBS	CELL			English	Article							HOMEOBOX GENE; PATTERN-FORMATION; HOMEOTIC TRANSFORMATIONS; POSITIONAL INFORMATION; DEVELOPMENTAL DEFECTS; TARGETED DISRUPTION; ECTOPIC EXPRESSION; VERTEBRATE LIMB; HOX-4 GENES; STEM-CELLS	Vertebrate Hoxd genes are sequentially activated during the morphogenesis and pattern formation of the limb. Using the approach of gene disruption via homologous recombination in embryonic stem cells, we have assessed the function of the last gene of the complex, Hoxd-13. Mutant mice displayed skeletal alterations along all body axes suggesting the existence of a general multiaxial patterning system. In limbs, abnormalities such as a reduction in the length of some bony elements, loss of phalanges, bone fusions, and the presence of an extra element were observed. We propose that the mutation induces local heterochrony, as illustrated by an important retardation in limb-morphogenesis. The relevance of these observations to our understanding of the development and evolution of the tetrapod limb is discussed.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG 1,GERMANY	European Molecular Biology Laboratory (EMBL)	DOLLE, P (corresponding author), FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE.		Schimmang, Thomas/Z-2834-2019; Dolle, Pascal/A-8037-2010	Schimmang, Thomas/0000-0002-3801-1640; Dolle, Pascal/0000-0002-9294-9090; duboule, denis/0000-0001-9961-2960				ALBERCH P, 1983, J EMBRYOL EXP MORPH, V76, P177; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BASTIAN H, 1992, MAMM GENOME, V3, P241, DOI 10.1007/BF00355726; BURKE AC, 1985, J MORPHOL, V186, P119, DOI 10.1002/jmor.1051860111; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; DOLLE P, 1991, MECH DEVELOP, V36, P3, DOI 10.1016/0925-4773(91)90067-G; DOLLE P, 1991, GENE DEV, V5, P1767, DOI 10.1101/gad.5.10.1767; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DOLLE P, 1993, IN PRESS ADV DEV BIO, V2; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; Garstang W., 1922, Journal of the Linnean Society Zoology, V35, P81; GAUNT SJ, 1988, DEVELOPMENT S, V104, P71; GLUCKSMANN A, 1976, J ANAT, V121, P363; Gould S.J., 1977, ONTOGENY PHYLOGENY; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HARDING K, 1985, SCIENCE, V229, P1236, DOI 10.1126/science.3898362; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; HINCHLIFFE JR, 1983, DEV EVOLUTION, P99; Holland P.W.H., 1990, Seminars in Developmental Biology, V1, P135; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; HURIE JM, 1991, DEV PATTERNING VERTE; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; IZPISUABELMONTE JC, 1992, DEVELOPMENT, V115, P553; IZPISUABELMONTE JC, 1992, EMBO J, V11, P1451, DOI 10.1002/j.1460-2075.1992.tb05189.x; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS J, 1989, NATURE, V342, P734, DOI 10.1038/342734a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORGANBA, 1992, NATURE, V358, P236; Muller G., 1991, DEV PATTERNING VERTE; MULLER GB, 1990, J MORPHOL, V203, P151, DOI 10.1002/jmor.1052030204; OLIVER G, 1989, GENE DEV, V3, P641, DOI 10.1101/gad.3.5.641; OSTER GF, 1985, J EMBRYOL EXP MORPH, V89, P93; OSTER GF, 1983, J EMBRYOL EXP MORPH, V78, P83; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SHUBIN N, 1991, DEV PATTERNING VERTE; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SOLURSH M, 1984, CELL DIFFER DEV, V15, P17, DOI 10.1016/0045-6039(84)90025-3; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TABIN CJ, 1992, DEVELOPMENT, V116, P289; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; Wolpert L, 1975, Ciba Found Symp, V0, P95; WOLPERT L, 1989, DEVELOPMENT, V107, P3; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0; [No title captured]	62	405	412	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 5	1993	75	3					431	441		10.1016/0092-8674(93)90378-4	http://dx.doi.org/10.1016/0092-8674(93)90378-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8106170				2022-12-01	WOS:A1993MF83000006
J	SMIRNOVA, T; STINNAKRE, J; MALLET, J				SMIRNOVA, T; STINNAKRE, J; MALLET, J			CHARACTERIZATION OF A PRESYNAPTIC GLUTAMATE-RECEPTOR	SCIENCE			English	Article							AMINO-ACID RECEPTORS; NMDA RECEPTOR; XENOPUS OOCYTES; BOVINE BRAIN; PROTEIN; CLONING; NEURONS; CHANNEL; PHARMACOLOGY; SELECTIVITY	Glutamate receptors mediate excitatory neurotransmission in the brain and are important in the formation of memory and in some neurodegenerative disorders. A complementary DNA clone that encoded a 33-kilodalton protein (GR33) was obtained by screening a library with an antibody generated against glutamate binding proteins. The sequence of GR33 is identical to that of the recently reported presynaptic protein syntaxin. When GR33 was expressed in Xenopus oocytes, it formed glutamate-activated ion channels that are pharmacologically similar to those of N-methyl-D-aspartate receptors but with different electrophysiological properties. Mutation of the leucine 278 residue in the single putative transmembrane segment of GR33 affects the properties of the channel. Thus, in vivo GR33 may be a presynaptic glutamate receptor.	LAB GENET MOLEC NEUROTRANSMISS & PROC, NEURODEGENERAT, CNRS, C9923, F-91198 GIF SUR YVETTE, FRANCE; LAB NEUROBIOL CELLULAIRE & MOLEC, CNRS, F-91198 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BUSTOS G, 1992, BRAIN RES, V585, P105, DOI 10.1016/0006-8993(92)91195-K; CHERNEVSKAYA NI, 1991, NATURE, V349, P418, DOI 10.1038/349418a0; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; CROUCHER MJ, 1982, SCIENCE, V216, P899, DOI 10.1126/science.7079744; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GROSS RA, 1989, J PHYSIOL-LONDON, V411, P585, DOI 10.1113/jphysiol.1989.sp017592; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; INOUE A, 1992, BIOCHEM BIOPH RES CO, V187, P1144, DOI 10.1016/0006-291X(92)91316-I; INOUE A, 1992, J BIOL CHEM, V267, P10613; KURE S, 1991, BIOCHEM BIOPH RES CO, V179, P39, DOI 10.1016/0006-291X(91)91330-F; MICHAELIS EK, 1984, J NEUROCHEM, V42, P397, DOI 10.1111/j.1471-4159.1984.tb02691.x; MILEDI R, 1982, BIOMED RES-TOKYO, V3, P390, DOI 10.2220/biomedres.3.390; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLNEY JW, 1990, ANNU REV PHARMACOL, V30, P47; PFEIFFERLINN C, 1991, SYNAPSE, V9, P35, DOI 10.1002/syn.890090106; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; VERDOORN TA, 1988, MOL PHARMACOL, V34, P298	24	99	104	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					430	433		10.1126/science.8105537	http://dx.doi.org/10.1126/science.8105537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	8105537				2022-12-01	WOS:A1993MB85900061
J	KUMAR, L				KUMAR, L			EPIPODOPHYLLOTOXINS AND SECONDARY LEUKEMIA	LANCET			English	Editorial Material							LEUKEMIA; ETOPOSIDE; CISPLATIN; RADIATION; RISK				KUMAR, L (corresponding author), ALL INDIA INST MED SCI,INST ROTARY CANC HOSP,NEW DELHI 110016,INDIA.							AMYLON MD, 1992, BLOOD S, V80, pA206; BAJORIN DF, 1993, J NATL CANCER I, V85, P60, DOI 10.1093/jnci/85.1.60; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HAWKINS MM, 1992, BRIT MED J, V304, P951, DOI 10.1136/bmj.304.6832.951; LEVINE EG, 1992, SEMIN ONCOL, V19, P47; NICHOLS CR, 1993, J NATL CANCER I, V85, P36, DOI 10.1093/jnci/85.1.36; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RATAIN MJ, 1987, BLOOD, V70, P1412; THACHUK DC, 1992, CELL, V71, P691; WHITLOCK JA, 1991, CANCER, V68, P600, DOI 10.1002/1097-0142(19910801)68:3<600::AID-CNCR2820680326>3.0.CO;2-F; WINICK NJ, 1993, J CLIN ONCOL, V11, P209, DOI 10.1200/JCO.1993.11.2.209	12	31	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					819	820		10.1016/0140-6736(93)92692-M	http://dx.doi.org/10.1016/0140-6736(93)92692-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104269				2022-12-01	WOS:A1993MA02500006
J	PALMER, CR				PALMER, CR			PROBABILITY OF RECURRENCE OF EXTREME DATA - AN AID TO DECISION-MAKING	LANCET			English	Article								Those, such as public health specialists, who have to assess routinely collected data often find it difficult to decide whether or not extreme results are a matter of chance. I describe here a simple method of measuring one's ''degree of surprise'' for noticeable patterns in ranked data, classified by time and place, to help detect significant departures from random variation. A table of exact probability values is the key to this approach. Designed primarily for reviewing post-hoc data, the method is relevant to published ''league tables'' of performance indicators. The table has to be used cautiously and the method is intended as a preliminary screen where data are limited or as a supplement to traditional analyses where there is more. Areas of application include public health, audit, and health services management and performance monitoring.			PALMER, CR (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,ROBINSON WAY,CAMBRIDGE CB2 2SR,ENGLAND.							Agresti A., 1992, STAT SCI, V7, P131, DOI 10.1214/ss/1177011454; Fisher RA, 1934, STAT METHODS RES WOR, V5; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; 1991, STATXACT STATISTICAL; 1993, LANCET, V341, P1183	7	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					845	847		10.1016/0140-6736(93)92699-T	http://dx.doi.org/10.1016/0140-6736(93)92699-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104276				2022-12-01	WOS:A1993MA02500013
J	DALEY, CL				DALEY, CL			TUBERCULOSIS RECURRENCE IN AFRICA - TRUE RELAPSE OR REINFECTION	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS				DALEY, CL (corresponding author), SAN FRANCISCO GEN HOSP, DIV PULM & CRIT CARE MED, SAN FRANCISCO, CA 94110 USA.		Daley, Charles L./AAC-3231-2021					ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; MUKADI Y, 1991, 7 P INT C AIDS FLOR; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503	9	23	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1993	342	8874					756	757		10.1016/0140-6736(93)91535-T	http://dx.doi.org/10.1016/0140-6736(93)91535-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103871				2022-12-01	WOS:A1993LY86800004
J	JUDSON, IR; THREADGILL, MD				JUDSON, IR; THREADGILL, MD			POLY(ADP-RIBOSYLATION) AS TARGET FOR CANCER-CHEMOTHERAPY	LANCET			English	Editorial Material							INHIBITORS; SYNTHETASE		UNIV BATH,SCH PHARM & PHARMACOL,BATH BA2 7AY,AVON,ENGLAND	University of Bath	JUDSON, IR (corresponding author), INST CANC RES,SUTTON SM2 5PX,SURREY,ENGLAND.		Threadgill, Michael/C-3925-2009					ALDERSON T, 1990, BIOL REV, V65, P623, DOI 10.1111/j.1469-185X.1990.tb01240.x; ALDERSON T, 1993, BIOL REV, V68, P265, DOI 10.1111/j.1469-185X.1993.tb00997.x; BANASIK M, 1992, J BIOL CHEM, V267, P1569; PURNELL MR, 1980, BIOCHEM J, V185, P775, DOI 10.1042/bj1850775; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SUTO MJ, 1991, ANTI-CANCER DRUG DES, V7, P107; SWINNEN LJ, 1989, CANCER RES, V49, P1383; TSENG A, 1987, P NATL ACAD SCI USA, V84, P1107, DOI 10.1073/pnas.84.4.1107; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.bi.54.070185.000445	9	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					632	632		10.1016/0140-6736(93)91756-C	http://dx.doi.org/10.1016/0140-6736(93)91756-C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103143				2022-12-01	WOS:A1993LX27200007
J	BLASI, J; CHAPMAN, ER; LINK, E; BINZ, T; YAMASAKI, S; DECAMILLI, P; SUDHOF, TC; NIEMANN, H; JAHN, R				BLASI, J; CHAPMAN, ER; LINK, E; BINZ, T; YAMASAKI, S; DECAMILLI, P; SUDHOF, TC; NIEMANN, H; JAHN, R			BOTULINUM NEUROTOXIN-A SELECTIVELY CLEAVES THE SYNAPTIC PROTEIN SNAP-25	NATURE			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; MOTOR-NERVE TERMINALS; MEMBRANE-PROTEIN; CLOSTRIDIAL NEUROTOXINS; SECRETORY PATHWAY; VESICLES; IDENTIFICATION; SYNAPTOBREVIN; EXOCYTOSIS; RECEPTOR	NEUROTRANSMITTER release is potently blocked by a group of structurally related toxin proteins produced by Clostridium botulinum1. Botulinum neurotoxin type B (BoNT/B) and tetanus toxin (TeTx) are zinc-dependent proteases that specifically cleave synaptobrevin (VAMP), a membrane protein of synaptic vesicles2,3. Here we report that inhibition of transmitter release from synaptosomes caused by botulinum neurotoxin A (BoNT/A) is associated with the selective proteolysis of the synaptic protein SNAP-25. Furthermore, isolated or recombinant L chain of BoNT/A cleaves SNAP-25 in vitro. Cleavage occurred near the carboxyterminus and was sensitive to divalent cation chelators. In addition, a glutamate residue in the BoNT/A L chain, presumably required to stabilize a water molecule in the zinc-containing catalytic centre, was required for proteolytic activity. These findings demonstrate that BoNT/A acts as a zinc-dependent protease that selectively cleaves SNAP-25. Thus, a second component of the putative fusion complex mediating synaptic vesicle exocytosis is targeted by a clostridial neurotoxin.	FED RES CTR VIRUS DIS ANIM,INST MICROBIOL,W-7400 TUBINGEN,GERMANY; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED CTR,DALLAS,TX 75235; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; UNIV BARCELONA,SCH MED,DEPT CELL BIOL & PATHOL,BARCELONA 7,SPAIN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Yale University; Yale University; Yale University; University of Barcelona			Blasi, Juan/K-7943-2014	Blasi, Juan/0000-0002-0482-9444; Chapman, Edwin/0000-0001-9787-8140; Jahn, Reinhard/0000-0003-1542-3498				BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BINZ T, 1990, J BIOL CHEM, V265, P9153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CATSICAS S, 1991, P NATL ACAD SCI USA, V88, P785, DOI 10.1073/pnas.88.3.785; CHAPMAN ER, 1992, J BIOL CHEM, V267, P25233; DREYER F, 1987, N-S ARCH PHARMACOL, V335, P1, DOI 10.1007/BF00165027; GANSEL M, 1987, PFLUG ARCH EUR J PHY, V409, P533, DOI 10.1007/BF00583812; HESS DT, 1992, J NEUROSCI, V12, P4634; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; OLMSTEDT JB, 1987, METHOD ENZYMOL, V134, P467; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUGII S, 1975, INFECT IMMUN, V12, P1262, DOI 10.1128/IAI.12.6.1262-1270.1975; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; [No title captured]	30	959	997	2	87	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					160	163		10.1038/365160a0	http://dx.doi.org/10.1038/365160a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8103915				2022-12-01	WOS:A1993LW44200048
J	KUIPERS, EJ; PENA, AS; VANKAMP, G; UYTERLINDE, AM; PALS, G; PELS, NFM; KURZPOHLMANN, E; MEUWISSEN, SGM				KUIPERS, EJ; PENA, AS; VANKAMP, G; UYTERLINDE, AM; PALS, G; PELS, NFM; KURZPOHLMANN, E; MEUWISSEN, SGM			SEROCONVERSION FOR HELICOBACTER-PYLORI	LANCET			English	Article							CAMPYLOBACTER-PYLORIDIS; GASTRIC-CARCINOMA; DUODENAL-ULCER; INFECTION; ERADICATION; ANTIBODY; RISK; SEROLOGY; CHILDREN; HUMANS	The prevalence of Helicobacter pylori antibodies increases with age, but it is unknown whether this is due to a constant rate of infection in different age groups, or whether most infection occurs in childhood. Follow-up data on infection rates and the course of infection in an untreated population are scarce. We measured H pylori IgG antibody concentrations in patients who were seen at our endoscopy unit between 1979 and 1983. 115 of 164 eligible patients (70%) participated in the study. H pylori IgG antibody concentrations were measured in two serum samples taken with a mean interval of 11.5 years. 56 patients tested positive at the first visit. During follow-up, 2 patients became infected (annual infection rate 0.30%, 95% CI 0.04-1.08%). Evidence of infection disappeared in 6 patients: after gastric surgery in 3 and due to an unknown cause in the remaining 3 patients. A non-significant decrease of infection was shown in different age cohorts during follow-up. Antibody concentrations did not increase with age. These results strongly support the concept of dominant infection rates in childhood. Elimination of infection may occur in a few patients without eradication therapy.	FREE UNIV AMSTERDAM HOSP,DEPT CLIN CHEM,1081 HV AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,1081 HV AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT HUMAN GENET,1081 HV AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	KUIPERS, EJ (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT GASTROENTEROL,DE BOELELAAN 1117,1081 HV AMSTERDAM,NETHERLANDS.		Pals, Gerard/A-5198-2011; Kuipers, Ernst J/H-3293-2019	Kuipers, Ernst J/0000-0002-0633-3098; Pals, Gerard/0000-0003-4091-7115				FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; GEORGE LL, 1990, MED J AUSTRALIA, V153, P145, DOI 10.5694/j.1326-5377.1990.tb136833.x; GOODWIN CS, 1987, J INFECT DIS, V155, P488, DOI 10.1093/infdis/155.3.488; HO SA, 1991, J CLIN MICROBIOL, V29, P2543, DOI 10.1128/JCM.29.11.2543-2549.1991; JONES DM, 1986, J MED MICROBIOL, V22, P57, DOI 10.1099/00222615-22-1-57; KARNES WE, 1991, GASTROENTEROLOGY, V101, P167, DOI 10.1016/0016-5085(91)90474-Y; KOSUNEN TU, 1992, LANCET, V339, P893, DOI 10.1016/0140-6736(92)90929-W; KUIPERS EJ, 1993, SCAND J GASTROENTERO, V28, P433, DOI 10.3109/00365529309098245; KUIPERS EJ, IN PRESS SCAND J GAS; LOFFELD RJLF, 1992, GUT, V33, P1680, DOI 10.1136/gut.33.12.1680; MEYER B, 1991, GUT, V32, P347, DOI 10.1136/gut.32.4.347; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; ODERDA G, 1992, GUT, V33, P1328, DOI 10.1136/gut.33.10.1328; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PENA AS, 1989, DIGESTION, V44, P131, DOI 10.1159/000199902; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SIERRA R, 1992, CANCER EPIDEM BIOMAR, V1, P449; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4; STEER HW, 1987, SERODIAGN IMMUNOTHER, V1, P253; VANZANTEN SV, 1992, GASTROENTEROLOGY, V102, pA184; VEENENDAAL RA, 1991, GUT, V32, P1291, DOI 10.1136/gut.32.11.1291; VEENENDAAL RA, 1992, GUT, V33, P452, DOI 10.1136/gut.33.4.452	24	208	209	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					328	331		10.1016/0140-6736(93)91473-Y	http://dx.doi.org/10.1016/0140-6736(93)91473-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101585				2022-12-01	WOS:A1993LQ86800011
J	BRUMMEL, CL; LEE, INW; ZHOU, Y; BENKOVIC, SJ; WINOGRAD, N				BRUMMEL, CL; LEE, INW; ZHOU, Y; BENKOVIC, SJ; WINOGRAD, N			A MASS-SPECTROMETRIC SOLUTION TO THE ADDRESS PROBLEM OF COMBINATORIAL LIBRARIES	SCIENCE			English	Article							SIMS	The molecular weights of femtomole quantities of small peptides attached to polystyrene beads have been determined with imaging time-of-flight secondary ion mass spectrometry. The analysis is made possible by the selective clipping of the bond linking the peptide to a bead with trifluoroacetic acid vapor before the secondary ion mass spectrometry assay. The approach can be applied to large numbers of 30- to 60-micrometer polystyrene beads for the direct characterization of massive combinatorial libraries.	PENN STATE UNIV,DEPT CHEM,152 DAVEY LAB,UNIV PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University			Lee, Irene/C-6104-2011	Winograd, Nicholas/0000-0002-2690-7714				BARANY BG, 1980, PEPTIDES; BEAVIS R, 1983, INT J MASS SPECTROM, V46, P471, DOI 10.1016/0020-7381(83)80154-5; BENNINGHOVEN A, 1978, ANAL CHEM, V50, P1180, DOI 10.1021/ac50030a043; BENNINGHOVEN A, 1993, ANAL CHEM, V65, pA630, DOI 10.1021/ac00062a002; BERNNER S, 1992, P NATL ACAD SCI USA, V89, P5381; BIEMANN K, 1987, MASS SPECTROM REV, V6, P1, DOI 10.1002/mas.1280060102; BRIGGS D, 1982, SURF INTERFACE ANAL, V4, P109, DOI 10.1002/sia.740040306; BUNIN BA, 1992, J AM CHEM SOC, V114, P10997, DOI 10.1021/ja00053a067; CHAIT BT, 1993, SCIENCE, V262, P89, DOI 10.1126/science.8211132; CHAIT BT, 1981, INT J MASS SPECTROM, V40, P185, DOI 10.1016/0020-7381(81)80041-1; DAVIES MC, 1988, SURF INTERFACE ANAL, V11, P591, DOI 10.1002/sia.740111202; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GARDELLA JA, 1980, ANAL CHEM, V52, P226, DOI 10.1021/ac50052a003; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P367, DOI 10.1002/anie.199203673; KERR JM, 1993, J AM CHEM SOC, V115, P2529, DOI 10.1021/ja00059a070; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEGGETT GJ, 1992, J CHEM SOC FARADAY T, V88, P297, DOI 10.1039/ft9928800297; MANTUS DS, 1993, ANAL CHEM, V65, P1431, DOI 10.1021/ac00058a021; MEGLER M, 1988, TETRAHEDRON LETT, V29, P4009; MEGLER M, 1988, TETRAHEDRON LETT, V29, P4002; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; STEFFENS P, 1985, J VAC SCI TECHNOL A, V3, P1322, DOI 10.1116/1.573058; TAYLOR R, IN PRESS J AM CHEM S; WINOGRAD N, 1993, ANAL CHEM, V65, pA622, DOI 10.1021/ac00062a001; WINOGRAD N, 1992, I PHYS C SER, V128, P259; YOUNGQUIST RS, 1994, RAPID COMMUN MASS SP, V8, P77	27	137	167	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					399	402		10.1126/science.8153627	http://dx.doi.org/10.1126/science.8153627			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153627				2022-12-01	WOS:A1994NG19400031
J	JONES, KR; FARINAS, I; BACKUS, C; REICHARDT, LF				JONES, KR; FARINAS, I; BACKUS, C; REICHARDT, LF			TARGETED DISRUPTION OF THE BDNF GENE PERTURBS BRAIN AND SENSORY NEURON DEVELOPMENT BUT NOT MOTOR-NEURON DEVELOPMENT	CELL			English	Article							NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; MESSENGER-RNAS; SYSTEM; NGF; DIFFERENTIATION; EXPRESSION; RECEPTORS; BINDING	Brain-derived neurotrophic factor (BDNF), a neurotrophin, enhances the survival and differentiation of several classes of neurons in vitro. To determine its essential functions, we have mutated the BDNF gene. Most homozygote mutants die within 2 days after birth, but a fraction live for 2-4 weeks. These develop symptoms of nervous system dysfunction, including ataxia. The BDNF mutant homozygotes have substantially reduced numbers of cranial and spinal sensory neurons. Although their central nervous systems show no gross structural abnormalities, expression of neuropeptide Y and calcium-binding proteins is altered in many neurons, suggesting they do not function normally. In contrast with mice lacking the BDNF receptor TrkB, motor neurons appear normal in the BDNF mutant.	UNIV CALIF SAN FRANCISCO,SCH MED,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	JONES, KR (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.		Farinas, Isabel/L-7118-2014	Farinas, Isabel/0000-0003-2903-4960; JONES, KEVIN/0000-0002-3802-7562	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016033] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48200] Funding Source: Medline; NINDS NIH HHS [P01 NS016033-17A10014, P01 NS016033] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1993, J NEUROSCI, V13, P3394; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; Joyner AL, 1993, GENE TARGETING PRACT; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; NAMBA T, 1967, AM J CLIN PATHOL, V47, P74; NAWA H, 1993, J NEUROCHEM, V60, P772, DOI 10.1111/j.1471-4159.1993.tb03216.x; PIRVOLA U, 1992, P NATL ACAD SCI USA, V89, P9915, DOI 10.1073/pnas.89.20.9915; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; Scott SA, 1992, SENSORY NEURONS DIVE; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; ZIAI MR, 1988, J NEUROCHEM, V51, P1771, DOI 10.1111/j.1471-4159.1988.tb01158.x	23	906	915	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					989	999		10.1016/0092-8674(94)90377-8	http://dx.doi.org/10.1016/0092-8674(94)90377-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137432	Green Accepted			2022-12-01	WOS:A1994ND24600006
J	LENFANT, C				LENFANT, C			SPEED URGED FOR THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL-INFARCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LENFANT, C (corresponding author), NHLBI,BETHESDA,MD 20892, USA.							1994, ANN EMERG MED, V23, P311; 1993, JAMA-J AM MED ASSOC, V270, P1211	2	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					738	738						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	8114202				2022-12-01	WOS:A1994MY28800007
J	STRUHL, K				STRUHL, K			DUALITY OF TBP, THE UNIVERSAL TRANSCRIPTION FACTOR	SCIENCE			English	Editorial Material							TATA-BINDING PROTEIN; RNA POLYMERASE-II; DNA-SEQUENCES; PROMOTER; YEAST; ACTIVATION; INITIATION; COMPONENTS; INVITRO; TFIIIB				STRUHL, K (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.							AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BURATOWSKI S, 1992, TRANSCRIPTIONAL REGU, P227; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Geiduschek E.P., 1992, TRANSCRIPTIONAL REGU, P247; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INOSTROZA JA, 1992, CELL, V70, P477; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLUG A, 1979, J MOL BIOL, V131, P669, DOI 10.1016/0022-2836(79)90196-7; LEE WS, 1991, CELL, V67, P367; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LOBO SM, 1992, CELL, V71, P1041; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; REEDER RH, 1992, TRANSCRIPTIONAL REGU, P315; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9	34	70	71	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1103	1104		10.1126/science.8108728	http://dx.doi.org/10.1126/science.8108728			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108728				2022-12-01	WOS:A1994MX75900021
J	HARTMANN, E; SOMMER, T; PREHN, S; GORLICH, D; JENTSCH, S; RAPOPORT, TA				HARTMANN, E; SOMMER, T; PREHN, S; GORLICH, D; JENTSCH, S; RAPOPORT, TA			EVOLUTIONARY CONSERVATION OF COMPONENTS OF THE PROTEIN TRANSLOCATION COMPLEX	NATURE			English	Article							SIGNAL RECOGNITION PARTICLE; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; 4.5S RNA; YEAST; RIBONUCLEOPROTEIN; RECONSTITUTION; SUFFICIENT; INSERTION	PROTEIN translocation into the mammalian endoplasmic reticulum requires the Sec61p complex, which consists of three membrane proteins(1). The alpha-subunit, the homologue of Sec61p of yeast(2-4), shows some similarity to SecYp(5), a key component of the protein export apparatus of bacteria(6,7). In Escherichia coli, SecYp is also associated with two other proteins (SecEp and band-1 protein)(8,9). We have now determined the sequences of the beta- and gamma-subunits of the mammalian Sec61p complex. Sec61-gamma is homologous to SSS1p, a suppressor of sec61 mutants in Saccharomyces cerevisiae, and can functionally replace it in yeast cells. Moreover, Sec61-gamma and SSSIp are structurally related to SecEp of E. coli and to putative homologues in various other bacteria. At least two subunits of the Sec61/SecYp complex therefore seem to be keg components of the protein translocation apparatus in all classes of organisms.	MAX DELBRUCK CTR MOLEC MED, D-12135 BERLIN, GERMANY; HUMBOLDT UNIV BERLIN, INST BIOCHEM, D-10115 BERLIN, GERMANY; UNIV HEIDELBERG, CTR MOLEC BIOL, ZMBH, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Ruprecht Karls University Heidelberg			Görlich, Dirk/B-8296-2017; Hartmann, Enno/C-5687-2013	Görlich, Dirk/0000-0002-4343-5210; 				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Guthrie C, 1991, GUIDE YEAST GENETICS; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	26	226	232	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	1994	367	6464					654	657		10.1038/367654a0	http://dx.doi.org/10.1038/367654a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107851				2022-12-01	WOS:A1994MW68800057
J	KUJALA, UM; KAPRIO, J; SARNA, S				KUJALA, UM; KAPRIO, J; SARNA, S			OSTEOARTHRITIS OF WEIGHT-BEARING JOINTS OF LOWER-LIMBS IN FORMER ELITE MALE-ATHLETES	BRITISH MEDICAL JOURNAL			English	Article							OSTEO-ARTHRITIS; HIP; DISEASE; KNEE	Objective-To compare the cumulative 21 year incidence of admission to hospital for osteoarthritis of the hip, knee, and ankle in former elite athletes and control subjects. Design-National population based study. Setting-Finland. Subjects-2049 male athletes who had represented Finland in international events during 1920-65 and 1403 controls who had been classified healthy at the age of 20. Main outcome measures-Hospital admissions for osteoarthritis of the hip, knee, and ankle joints identified from the national hospital discharge registry between 1970 and 1990. Results-Athletes doing endurance sports, mixed sports, and power sports all had higher incidences of admission to hospital for osteoarthritis than controls. Age adjusted odds ratios compared with controls were 1.3 (95% confidence interval 0.99 to 3.01, P=0.063) in endurance, 1.90 (1.24 to 2.92, P=0.003) in mixed sports athletes, and 2.17 (1.41 to 3.32, P=0.0003) in power sports athletes. The mean age at first admission to hospital was higher in endurance athletes (70.6) than in other groups (58.2 in mixed sports, 61.9 in power sports, and 61.2 in controls). Among the 2046 respondents to a questionnaire in 1985, the odds ratios for admission to hospital were similar in all three groups after adjusting for age, occupation, and body mass index at 20 (2.37, 2.42, 2.68). Conclusions-Athletes from all types of competitive sports are at slightly increased risk of requiring hospital care because of osteoarthritis of the hip, knee, or ankle. Mixed sports and power sports lead to increased admissions for premature osteoarthritis, but in endurance athletes the admissions are at an older age.	UNIV HELSINKI,DEPT PUBL HLTH,SF-00290 HELSINKI 29,FINLAND	University of Helsinki	KUJALA, UM (corresponding author), HELSINKI RES INST SPORTS & EXERCISE MED,TOOLO SPORTS HALL,MANNERHEIMINTIE 17,SF-00250 HELSINKI,FINLAND.		Kaprio, Jaakko/A-1820-2008; Kujala, Urho/AAP-2547-2020	Kaprio, Jaakko/0000-0002-3716-2455; Sarna, Seppo/0000-0003-3458-1627; Kujala, Urho/0000-0002-9262-1992				ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; Aro S, 1990, Duodecim, V106, P1443; CROFT P, 1992, BRIT MED J, V304, P1269, DOI 10.1136/bmj.304.6837.1269; DEHAVEN KE, 1985, CLIN SPORT MED, V4, P267; FAIRBANK TJ, 1948, J BONE JOINT SURG BR, V30, P664, DOI 10.1302/0301-620X.30B4.664; FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003-4819-109-1-18; JOHNSON RJ, 1984, CLIN ORTHOP RELAT R, V183, P122; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KANNUS P, 1987, J BONE JOINT SURG AM, V69A, P1007, DOI 10.2106/00004623-198769070-00008; KLUNDER KB, 1980, ACTA ORTHOP SCAND, V51, P925, DOI 10.3109/17453678008990896; KONRADSEN L, 1990, AM J SPORT MED, V18, P379, DOI 10.1177/036354659001800408; LANE NE, 1986, JAMA-J AM MED ASSOC, V255, P1147; LINDBERG H, 1993, ACTA ORTHOP SCAND, V64, P165, DOI 10.3109/17453679308994561; MARTI B, 1989, BRIT MED J, V299, P91, DOI 10.1136/bmj.299.6691.91; PANUSH RS, 1986, JAMA-J AM MED ASSOC, V255, P1152, DOI 10.1001/jama.255.9.1152; PURANEN J, 1975, BRIT MED J, V2, P424, DOI 10.1136/bmj.2.5968.424-a; SARNA S, 1993, MED SCI SPORT EXER, V25, P237; Solonen K A, 1966, Ann Chir Gynaecol Fenn, V55, P176; VINGARD E, 1993, AM J SPORT MED, V21, P195, DOI 10.1177/036354659302100206; VINGARD E, 1991, ARBETE HALSA, V25, P1; 1972, TILASTOKESKUS AAKOSE	21	200	203	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	1994	308	6923					231	234		10.1136/bmj.308.6923.231	http://dx.doi.org/10.1136/bmj.308.6923.231			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT539	8111258	Green Published			2022-12-01	WOS:A1994MT53900018
J	IWASHITA, Y; KAWAGUCHI, S; MURATA, M				IWASHITA, Y; KAWAGUCHI, S; MURATA, M			RESTORATION OF FUNCTION BY REPLACEMENT OF SPINAL-CORD SEGMENTS IN THE RAT	NATURE			English	Article							CENTRAL NERVOUS-SYSTEM; AXONAL REGENERATION; CORTICOSPINAL TRACT; PLASTICITY; TRANSPLANTATION; TRANSECTION; MECHANISMS; PROJECTION; RECOVERY; GUIDANCE	RECONSTRUCTiON Of 2 Severed mammalian spinal cord with restoration of function has so far not been achieved1-12, although structural and functional restitution after spinal transection has been successful in some lower vertebrates12-14. In quail hick nd chick chick chimaeras, spinal cord segments were found to be functional after replacement by isotopic and isochronic grafting of the neural tube15,16. Here we achieve such a replacement in neonatal rats under less restricted topological and temporal conditions than were necessary for the avian chimaeras. The replaced segments united with the host spinal cord and promoted robust growth and regrowth of axons across the graft, enabling neural connections to be reconstructed that were hardly distinguishable from normal. The animals with replaced segments could walk, run and climb with almost normal hind-forelimb coordination. This functional restoration in these animals appeared to be permanent, raising the possibility of therapeutic application in humans.	KYOTO UNIV, FAC MED, DEPT ORTHOPAED SURG, KYOTO 606, JAPAN	Kyoto University	IWASHITA, Y (corresponding author), KYOTO UNIV, FAC MED, DEPT INTEGRAT BRAIN SCI, KYOTO 606, JAPAN.							AMASSIAN VE, 1964, ANN NY ACAD SCI, V112, P5, DOI 10.1111/j.1749-6632.1964.tb26740.x; [Anonymous], 1959, DEGENERATION REGENER; BERNSTEIN DR, 1983, J COMP NEUROL, V221, P382, DOI 10.1002/cne.902210403; BJORKLUND A, 1991, TRENDS NEUROSCI, V14, P319, DOI 10.1016/0166-2236(91)90154-M; BOLZ J, 1993, TRENDS NEUROSCI, V16, P310, DOI 10.1016/0166-2236(93)90107-W; BREGMAN BS, 1991, EXP NEUROL, V112, P49, DOI 10.1016/0014-4886(91)90113-Q; BREGMAN BS, 1989, J COMP NEUROL, V282, P355, DOI 10.1002/cne.902820304; DAS GD, 1986, NEURAL TRANSPLANTATI, P1; GIESLER GJ, 1981, J COMP NEUROL, V195, P243, DOI 10.1002/cne.901950205; GRILLNER S, 1975, PHYSIOL REV, V55, P247, DOI 10.1104/pp.55.2.247; GUTH L, 1983, TRENDS NEUROSCI, V6, P20, DOI 10.1016/0166-2236(83)90009-7; HARRIS WA, 1989, NATURE, V339, P218, DOI 10.1038/339218a0; ITASAKI N, 1992, NEURON, V8, P787, DOI 10.1016/0896-6273(92)90099-Y; KALIL K, 1979, SCIENCE, V205, P1158, DOI 10.1126/science.472734; KAO CC, 1977, EXP NEUROL, V54, P591, DOI 10.1016/0014-4886(77)90259-X; KAWAGUCHI S, 1986, J COMP NEUROL, V245, P258, DOI 10.1002/cne.902450208; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KINUTANI M, 1985, DEV BIOL, V111, P243, DOI 10.1016/0012-1606(85)90449-X; KUNKELBAGDEN E, 1990, EXP BRAIN RES, V81, P25; LEDOUARIN NM, 1993, TRENDS NEUROSCI, V16, P64, DOI 10.1016/0166-2236(93)90019-I; MATSUSHITA M, 1979, BRAIN RES, V173, P185, DOI 10.1016/0006-8993(79)90620-6; REIER PJ, 1986, J COMP NEUROL, V247, P275, DOI 10.1002/cne.902470302; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHREYER DJ, 1982, NEUROSCIENCE, V7, P1837, DOI 10.1016/0306-4522(82)90001-X; SELZER ME, 1978, J PHYSIOL-LONDON, V277, P395, DOI 10.1113/jphysiol.1978.sp012280; SENG KL, 1984, J COMP NEUROL, V228, P18, DOI 10.1002/cne.902280104; SIERADZAN K, 1989, NEUROSCIENCE, V31, P115, DOI 10.1016/0306-4522(89)90034-1; SINGER M, 1979, J COMP NEUROL, V185, P1, DOI 10.1002/cne.901850102; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0	30	197	203	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	1994	367	6459					167	170		10.1038/367167a0	http://dx.doi.org/10.1038/367167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114911				2022-12-01	WOS:A1994MQ78000059
J	MIKO, TL; LEMAITRE, C; KINFU, Y				MIKO, TL; LEMAITRE, C; KINFU, Y			DAMAGE AND REGENERATION OF PERIPHERAL-NERVES IN ADVANCED TREATED LEPROSY	LANCET			English	Article							REPAIR; GRAFT	Despite the rapidly falling prevalence of leprosy, the disability and handicap resulting from loss of protective sensation, due to irreversible nerve damage, will remain a huge medical problem for many years. To elucidate the location and consequences of permanent nerve damage in treated leprosy, a prospective study involving nine patients who underwent leg amputation was conducted. Full-length nerves dissected from amputated legs were studied with histological and immunohistochemical methods. Our main findings were that: in both lepromatous and tuberculoid leprosy nerve damage increased distally, culminating in total destruction of dermal nerves and sensory nerve endings; after the therapy-related decrease of inflammation large-scale nerve regeneration took place; and that regenerating axons persisted for decades and in tuberculoid leprosy they might reach the subcutaneous fat of the plantar skin. We conclude that nerve regeneration was blocked by fibrous replacement of the distal-most nerves and nerve endings, and that the theoretical basis of nerve grafting in leprosy is in need of further clarification. In some patients, autologous transplantation of skin flaps, probably irrespective of the duration of loss of sensation, might help in regaining protective sensation.	ALL AFRICA LEPROSY & REHABIL TRAINING CTR,ARMAUER HANSEN RES INST,ADDIS ABABA,ETHIOPIA; UNIV ADDIS ABABA,FAC MED,DEPT ANAT,ADDIS ABABA,ETHIOPIA	Addis Ababa University								ADEYMO O, 1957, TRANSPLAN B, V4, P152; Carayon A, 1970, J Chir (Paris), V99, P235; Dastur D K, 1970, Int J Lepr Other Mycobact Dis, V38, P30; Dastur D K, 1983, Neurosurg Rev, V6, P139, DOI 10.1007/BF01742765; DASTUR DK, 1955, BRAIN, V78, P615, DOI 10.1093/brain/78.4.615; DAYAN AD, 1970, J NEUROL NEUROSUR PS, V33, P586, DOI 10.1136/jnnp.33.5.586; ERMAKOVA NINA, 1936, INTERNAL JOUR LEPROSY, V4, P325; FAWCETT JW, 1986, J NEUROSURG, V65, P354, DOI 10.3171/jns.1986.65.3.0354; HASTINGS R C, 1968, Leprosy Review, V39, P71; Job C K, 1968, Int J Lepr Other Mycobact Dis, V36, P257; KARANTH SS, 1989, J PATHOL, V157, P15, DOI 10.1002/path.1711570104; MACKINNON SE, 1988, SURGERY PERIPHERAL N; MANNERFELT L, 1962, Br J Plast Surg, V15, P136, DOI 10.1016/S0007-1226(62)80019-8; MIKO TL, IN PRESS BIOTECHNIC; MIKO TL, IN PRESS LEPR REV; NOORDEEN SK, 1992, B WORLD HEALTH ORGAN, V70, P7; NORRIS RW, 1988, J BONE JOINT SURG BR, V70, P530, DOI 10.1302/0301-620X.70B4.3403592; PEREIRA JH, 1991, LANCET, V338, P1239, DOI 10.1016/0140-6736(91)92105-B; PFALTZGRAFF RE, 1985, LEPROSY; REDDY DG, 1962, INDIAN J MED RES, V50, P692; Ridley DS., 1988, PATHOGENESIS LEPROSY; SABIN TD, 1969, ARCH NEUROL-CHICAGO, V20, P257, DOI 10.1001/archneur.1969.00480090045006; SABIN TD, 1984, PERIPHERAL NEUROPATH; SMITH WCS, 1993, LANCET, V341, P89, DOI 10.1016/0140-6736(93)92563-9; SMITH WCS, 1992, LEPROSY REV, V63, P23; SUNDERLAND S, 1973, BRAIN, V96, P865, DOI 10.1093/brain/96.4.865; VIEREGGE P, 1985, LEPROSY REV, V56, P5; WATERS MFR, 1993, LANCET, V341, P489, DOI 10.1016/0140-6736(93)90238-C; 1991, ELIMINATION LEPROSY	29	22	22	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					521	525		10.1016/0140-6736(93)91647-5	http://dx.doi.org/10.1016/0140-6736(93)91647-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102668				2022-12-01	WOS:A1993LU58200010
J	FELICIELLO, A; PORCELLINI, A; CIULLO, I; BONAVOLONTA, G; AVVEDIMENTO, EV; FENZI, G				FELICIELLO, A; PORCELLINI, A; CIULLO, I; BONAVOLONTA, G; AVVEDIMENTO, EV; FENZI, G			EXPRESSION OF THYROTROPIN-RECEPTOR MESSENGER-RNA IN HEALTHY AND GRAVES-DISEASE RETRO-ORBITAL TISSUE	LANCET			English	Note							MOLECULAR-CLONING; OPHTHALMOPATHY; FIBROBLASTS	It is not clear whether the ophthalmopathy present in Graves' disease is related to autoimmune reactions to common thyroid/orbit components or is due to specific ocular antigens unrelated to the thyroid. In Graves' disease, serum antibodies to the thyrotropin receptor (TSH-R) can stimulate thyroid function, but no link between the TSH-R and ocular tissues has been found. We have shown, by polymerase chain reaction amplification of specific cDNA, that mature TSH-R mRNA is expressed in the retro-orbital tissue of both healthy subjects and patients with Graves' disease. Of other tissues and cells tested (fibroblasts, lymphocytes, muscle, and thyroid), only thyroid tissue expressed the TSH-R mRNA.	UNIV NAPLES,FAC MED,CATTEDRA ENDOCRINOL,VIA S PANSINI 5,I-80131 NAPLES,ITALY; UNIV NAPLES,FAC MED,CATTEDRA PATOL ORBITARIA,I-80131 NAPLES,ITALY; UNIV NAPLES,FAC MED,DIPARTIMENTO BIOL & PATOL MOLEC & CELLULARE,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,CATANZARO,ITALY	University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria			Porcellini, Antonio/E-1900-2011; Porcellini, Antonio/AAC-6097-2019	Porcellini, Antonio/0000-0001-6882-9518; Feliciello, Antonio/0000-0002-7932-2170				ATKINSON S, 1984, LANCET, V2, P374; Francis T, 1991, Thyroid, V1, P223, DOI 10.1089/thy.1991.1.223; HEUFELDER AE, 1991, J CLIN ENDOCR METAB, V73, P307, DOI 10.1210/jcem-73-2-307; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; SMITH TJ, 1989, J CLIN ENDOCR METAB, V69, P1019, DOI 10.1210/jcem-69-5-1019; WEETMAN AP, 1991, LANCET, V338, P25, DOI 10.1016/0140-6736(91)90013-F	7	241	249	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					337	338		10.1016/0140-6736(93)91475-2	http://dx.doi.org/10.1016/0140-6736(93)91475-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101586				2022-12-01	WOS:A1993LQ86800013
J	HENDERSON, AH; JONES, CJH				HENDERSON, AH; JONES, CJH			REVERSIBLE ENDOTHELIAL DYSFUNCTION IN EPICARDIAL CORONARY-ARTERIES	LANCET			English	Editorial Material							RESISTANCE VESSELS; MICROCIRCULATION; ATHEROSCLEROSIS				HENDERSON, AH (corresponding author), UNIV WALES COLL MED,DEPT CARDIOL,CARDIFF CF4 4XN,S GLAM,WALES.							CHILIAN WM, 1990, AM J PHYSIOL, V258, pH529, DOI 10.1152/ajpheart.1990.258.2.H529; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; GRIFFITH TM, 1987, NATURE, V329, P442, DOI 10.1038/329442a0; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; HENDERSON AH, 1991, BRIT HEART J, V65, P116; LEUNG WH, 1993, LANCET, V341, P1496, DOI 10.1016/0140-6736(93)90634-S; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0	8	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					253	253		10.1016/0140-6736(93)91810-9	http://dx.doi.org/10.1016/0140-6736(93)91810-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101295				2022-12-01	WOS:A1993LQ16300003
J	LOGAN, S; STANTON, A				LOGAN, S; STANTON, A			SCREENING FOR BILIARY ATRESIA	LANCET			English	Editorial Material									MARSTON GREEN HOSP,COMMUNITY MENTAL HLTH SERV UNIT,BIRMINGHAM,ENGLAND		LOGAN, S (corresponding author), INST CHILD HLTH,DIV PUBL HLTH,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND.			Logan, Stuart/0000-0002-9279-261X				DICK MC, 1985, ARCH DIS CHILD, V60, P512, DOI 10.1136/adc.60.6.512; HENRIKSEN NT, 1981, ARCH DIS CHILD, V56, P622, DOI 10.1136/adc.56.8.622; KIVLAHAN C, 1984, PEDIATRICS, V74, P364; MACKINLAY GA, 1993, BRIT MED J, V306, P1426, DOI 10.1136/bmj.306.6890.1426; MATTHEW PM, 1981, ARCH DIS CHILD, V56, P949; MIELIVERGANI G, 1989, LANCET, V1, P421; WILSON JMG, 1968, 34 PUBL HLTH PAP	7	10	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					256	256		10.1016/0140-6736(93)91814-3	http://dx.doi.org/10.1016/0140-6736(93)91814-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101299				2022-12-01	WOS:A1993LQ16300007
J	GIOVANNUCCI, E; TOSTESON, TD; SPEIZER, FE; ASCHERIO, A; VESSEY, MP; COLDITZ, GA				GIOVANNUCCI, E; TOSTESON, TD; SPEIZER, FE; ASCHERIO, A; VESSEY, MP; COLDITZ, GA			A RETROSPECTIVE COHORT STUDY OF VASECTOMY AND PROSTATE-CANCER IN UNITED-STATES MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN SEMINAL PLASMA; MYOCARDIAL-INFARCTION; SPERM ANTIGENS; RISK; ETIOLOGY; DISEASE; EPIDEMIOLOGY; HEALTH; MOUSE; AGE	Objective.-To examine the relationship between vasectomy and prostate cancer. Design.-Retrospective cohort study. Setting.-Husbands of nurses in 11 large states in the United States. Participants.-In questionnaires administered in 1976 and 1978, 14 607 married female participants of the Nurses' Health Study reported vasectomy as the couple's form of contraception. In 1989, we contacted these 14607 women and 14607 age-matched participants whose husbands had not had a vasectomy prior to 1978 to ascertain their husband's disease status between 1976 and 1989. Main Outcome Measure.-Diagnosis of prostate cancer. Results.-During the study period, from 1976 through 1989, 96 new cases of prostate cancer were diagnosed in the cohort. Vasectomy was associated with an increased risk of prostate cancer (age-adjusted relative risk, 1.56; 95% confidence interval, 1.03 to 2.37; P=.04). The relative risk of prostate cancer increased overtime since vasectomy. Among men who had their vasectomy 20 or more years in the past, the relative risk of prostate cancer was 1.89 (95% confidence interval, 1.14 to 3.14; P=.005), and after excluding stage A and B cases, the relative risk was 2.06 (95% confidence interval, 0.95 to 4.43; P=.07). This elevated risk of prostate cancer among vasectomized men persisted when we adjusted for smoking, alcohol consumption, educational level, body mass index, and geographical area of residence. Conclusions.-These results support evidence from other epidemiologic studies that vasectomy increases risk of prostate cancer. A biological mechanism whereby vasectomy influences the rate of prostate cancer may be related to a diminished secretory rate of prostatic fluid following vasectomy, or, alternatively, to the postvasectomy immune response to sperm antigens, which may cross-react with tumor-associated antigens and suppress tumor immunosurveillance mechanisms.	DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,BIOSTAT & EPIDEMIOL GRP,HANOVER,NH 03756; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD,ENGLAND	Dartmouth College; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; University of Oxford	GIOVANNUCCI, E (corresponding author), HARVARD UNIV,SCH MED,CHANNING LAB,DEPT MED,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD092913] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA040935] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40935] Funding Source: Medline; NICHD NIH HHS [N01-HD-09-2913] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adamopoulos D A, 1976, Acta Eur Fertil, V7, P219; ALEXANDER NJ, 1980, J ANDROL, V1, P40; ANDERSON DJ, 1982, J NATL CANCER I, V69, P551; ANDERSON DJ, 1983, AM J PATHOL, V111, P129; ANSBACHE.R, 1972, FERTIL STERIL, V23, P640; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; CASTRO JE, 1974, CANCER RES, V34, P2055; CHI IC, 1990, INT J EPIDEMIOL, V19, P1113, DOI 10.1093/ije/19.4.1113; CHISM SE, 1976, J IMMUNOL, V117, P1870; Coggin J H Jr, 1974, Adv Cancer Res, V19, P105, DOI 10.1016/S0065-230X(08)60053-6; Cox DR., 1984, ANAL SURVIVAL DATA; DELATORRE B, 1983, INT J ANDROL, V6, P125; FREUND M, 1969, FERTIL STERIL, V20, P163; GACHELIN G, 1977, DEV BIOL, V57, P199, DOI 10.1016/0012-1606(77)90365-7; GIOVANNUCCI E, 1992, NEW ENGL J MED, V326, P1392, DOI 10.1056/NEJM199205213262104; GOLDACRE MJ, 1983, NEW ENGL J MED, V308, P805, DOI 10.1056/NEJM198304073081403; GOLDBERG EH, 1977, TRANSPLANT P, V9, P1363; GUANGHUA T, 1988, INT J EPIDEMIOL, V17, P608; HONDA GD, 1988, BRIT J CANCER, V57, P326, DOI 10.1038/bjc.1988.74; ISAACS JT, 1983, PROSTATE, V4, P351, DOI 10.1002/pros.2990040405; JAKOBSEN H, 1988, PROSTATE, V13, P57, DOI 10.1002/pros.2990130107; JAKOBSEN H, 1989, J REPROD FERTIL, V87, P39; JOHNSONBAUGH RE, 1975, FERTIL STERIL, V26, P329; JOSHI UM, 1981, ARCH ANDROLOGY, V7, P187, DOI 10.3109/01485018108999306; JOUANNET P, 1978, FERTIL STERIL, V29, P435; KINSON GA, 1977, RES COMMUN CHEM PATH, V18, P561; LAUSCH RN, 1974, PROG EXP TUMOR RES, V19, P48; LELANNOU D, 1980, INT J ANDROL, V3, P502; LINNET L, 1978, CLIN EXPT IMMUNOLOGY, V30, P413; LOHIYA N K, 1987, Acta Europaea Fertilitatis, V18, P207; MASSEY FJ, 1984, JAMA-J AM MED ASSOC, V252, P1023, DOI 10.1001/jama.252.8.1023; MENDIRATTA R, 1980, INDIAN J EXP BIOL, V18, P409; MENGE AC, 1978, DEV BIOL, V63, P111, DOI 10.1016/0012-1606(78)90117-3; METTLIN C, 1990, AM J EPIDEMIOL, V132, P1056, DOI 10.1093/oxfordjournals.aje.a115747; NAG DSK, 1984, ANDROLOGIA, V16, P451; NAIK VK, 1980, J REPROD FERTIL, V58, P289; NIENHUIS H, 1992, BRIT MED J, V304, P743, DOI 10.1136/bmj.304.6829.743; NOMURA A, 1988, CANCER RES, V48, P3515; PARMIANI G, 1974, INT J CANCER, V14, P555, DOI 10.1002/ijc.2910140416; PERLMAN JA, 1991, AM J EPIDEMIOL, V134, P107, DOI 10.1093/oxfordjournals.aje.a115985; PERRIN EB, 1984, AM J PUBLIC HEALTH, V74, P128, DOI 10.2105/AJPH.74.2.128; PETITTI DB, 1982, AM J PUBLIC HEALTH, V72, P476, DOI 10.2105/AJPH.72.5.476; PIERREPOINT CG, 1975, J REPROD FERTIL, V44, P395; PURVIS K, 1976, CLIN ENDOCRINOL, V5, P263, DOI 10.1111/j.1365-2265.1976.tb01952.x; ROSENBERG L, 1990, AM J EPIDEMIOL, V132, P1051, DOI 10.1093/oxfordjournals.aje.a115746; ROSENBERG L, 1986, AM J EPIDEMIOL, V123, P1049, DOI 10.1093/oxfordjournals.aje.a114333; ROSS RK, 1983, PROSTATE, V4, P333, DOI 10.1002/pros.2990040403; RUI H, 1986, J ANDROL, V7, P93; SAMUEL T, 1975, CLIN EXP IMMUNOL, V21, P65; SHETH AR, 1982, MED HYPOTHESES, V8, P237, DOI 10.1016/0306-9877(82)90118-9; SIDNEY S, 1991, CANCER CAUSE CONTROL, V2, P113, DOI 10.1007/BF00053130; SKEGG DCG, 1976, BRIT MED J, V1, P621, DOI 10.1136/bmj.1.6010.621; SKINNER JD, 1968, J ENDOCRINOL, V42, P355, DOI 10.1677/joe.0.0420355; SOLTER D, 1977, DEV BIOL, V57, P199; SPITZ MR, 1991, AM J EPIDEMIOL, V134, P108, DOI 10.1093/oxfordjournals.aje.a115986; SRIVASTAVA A, 1986, ACTA ENDOCRINOL-COP, V113, P440, DOI 10.1530/acta.0.1130440; VARMA MM, 1975, J CLIN ENDOCR METAB, V40, P868, DOI 10.1210/jcem-40-5-868; WALKER AM, 1981, LANCET, V1, P13; YING W, 1983, INT J ANDROL, V6, P116, DOI 10.1111/j.1365-2605.1983.tb00330.x; ZARIDZE DG, 1987, BRIT J UROL, V59, P493, DOI 10.1111/j.1464-410X.1987.tb04862.x	60	124	126	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					878	882		10.1001/jama.269.7.878	http://dx.doi.org/10.1001/jama.269.7.878			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL474	8123059				2022-12-01	WOS:A1993KL47400025
J	HALL, WA; LUCIANO, MG; DOPPMAN, JL; PATRONAS, NJ; OLDFIELD, EH				HALL, WA; LUCIANO, MG; DOPPMAN, JL; PATRONAS, NJ; OLDFIELD, EH			PITUITARY MAGNETIC-RESONANCE-IMAGING IN NORMAL HUMAN VOLUNTEERS - OCCULT ADENOMAS IN THE GENERAL-POPULATION	ANNALS OF INTERNAL MEDICINE			English	Article						ADENOMA; PITUITARY NEOPLASMS; MAGNETIC RESONANCE IMAGING; GADOLINIUM; CUSHINGS SYNDROME	SECRETING MICROADENOMAS; CUSHING DISEASE; GLAND; APPEARANCE; EXPERIENCE; 1.5-T; AGE	Objective: To determine the prevalence of focal lesions of the pituitary gland that suggest the presence of a pituitary adenoma in asymptomatic persons. Design: 100 normal volunteers (70 women, 30 men; age range, 18 to 60 years old) were studied by high-resolution magnetic resonance imaging (MRI) of the pituitary gland before and after administration of gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA). Setting: Occult pituitary adenomas are identified at autopsy in 3% to 27% of unselected asymptomatic patients. The frequency of incidental pituitary adenomas detected by MRI in normal persons is unknown. Measurements: The MRI scans from volunteers were randomly mixed with scans of 57 patients with Cushing disease and interpreted independently by three blinded reviewers. Results: Seven women (10%) and three men (10%) had focal areas of decreased signal intensity in the pituitary gland after administration of Gd-DTPA. The lesions ranged from 3 to 6 mm in greatest diameter and were diagnosed as pituitary adenomas by at least two of the three reviewers. When similar lesions were detected on MRI scans in patients with Cushing disease, the positive predictive value for identification of an adenoma at that site was 86%. Conclusions: About 10% of the normal adult population have pituitary abnormalities on MRI scans that are compatible with the diagnosis of asymptomatic pituitary adenomas. Most pituitary adenomas remain asymptomatic and do not require treatment.	NIH, CTR CLIN, SURG NEUROL BRANCH, BETHESDA, MD 20892 USA; NIH, CTR CLIN, DEPT DIAGNOST RADIOL, BETHESDA, MD 20892 USA; NINCDS, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								AHMADI H, 1990, RADIOLOGY, V177, P389, DOI 10.1148/radiology.177.2.2217774; BROWN SB, 1983, NEURORADIOLOGY, V24, P259, DOI 10.1007/BF00333177; BURROW GN, 1981, NEW ENGL J MED, V304, P156, DOI 10.1056/NEJM198101153040306; CHAMBERS EF, 1982, RADIOLOGY, V144, P109, DOI 10.1148/radiology.144.1.7089241; Costello RT, 1936, AM J PATHOL, V12, P205; DAVIS PC, 1985, AM J NEURORADIOL, V6, P711; DOPPMAN JL, 1989, RADIOLOGY, V172, P115, DOI 10.1148/radiology.172.1.2544919; DOPPMAN JL, 1988, J COMPUT ASSIST TOMO, V12, P728, DOI 10.1097/00004728-198809010-00002; DWYER AJ, 1987, RADIOLOGY, V163, P421, DOI 10.1148/radiology.163.2.3562821; ELSTER AD, 1990, RADIOLOGY, V174, P681, DOI 10.1148/radiology.174.3.2305049; FINDLING JW, 1991, J CLIN ENDOCR METAB, V73, P408, DOI 10.1210/jcem-73-2-408; GOLD EB, 1981, EPIDEMIOL REV, V3, P163, DOI 10.1093/oxfordjournals.epirev.a036232; HEMMINGHYTT S, 1983, RADIOLOGY, V146, P65, DOI 10.1148/radiology.146.1.6294733; KAUFMAN B, 1987, J LAB CLIN MED, V109, P308; KULKARNI MV, 1988, AM J NEURORADIOL, V9, P5; LURIE SN, 1990, J CLIN ENDOCR METAB, V71, P505, DOI 10.1210/jcem-71-2-505; MUHR C, 1981, NEURORADIOLOGY, V21, P55, DOI 10.1007/BF00342982; NEWTON DR, 1989, AM J NEURORADIOL, V10, P949; PARENT AD, 1981, J NEUROSURG, V54, P228, DOI 10.3171/jns.1981.54.2.0228; PECK WW, 1989, AM J ROENTGENOL, V152, P145, DOI 10.2214/ajr.152.1.145; PEYSTER RG, 1983, AM J NEURORADIOL, V4, P411; SARIS SC, 1987, RADIOLOGY, V162, P775, DOI 10.1148/radiology.162.3.3809493; SWANSON HA, 1975, BRIT J RADIOL, V48, P366, DOI 10.1259/0007-1285-48-569-366; SWARTZ JD, 1983, RADIOLOGY, V147, P115, DOI 10.1148/radiology.147.1.6828714; WILSON CB, 1984, J NEUROSURG, V61, P814, DOI 10.3171/jns.1984.61.5.0814; WOLPERT SM, 1984, AM J ROENTGENOL, V143, P377, DOI 10.2214/ajr.143.2.377	26	404	423	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1994	120	10					817	820		10.7326/0003-4819-120-10-199405150-00001	http://dx.doi.org/10.7326/0003-4819-120-10-199405150-00001			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK458	8154641				2022-12-01	WOS:A1994NK45800001
J	LONBERG, N; TAYLOR, LD; HARDING, FA; TROUNSTINE, M; HIGGINS, KM; SCHRAMM, SR; KUO, CC; MASHAYEKH, R; WYMORE, K; MCCABE, JG; MUNOZOREGAN, D; ODONNELL, SL; LAPACHET, ESG; BENGOECHEA, T; FISHWILD, DM; CARMACK, CE; KAY, RM; HUSZAR, D				LONBERG, N; TAYLOR, LD; HARDING, FA; TROUNSTINE, M; HIGGINS, KM; SCHRAMM, SR; KUO, CC; MASHAYEKH, R; WYMORE, K; MCCABE, JG; MUNOZOREGAN, D; ODONNELL, SL; LAPACHET, ESG; BENGOECHEA, T; FISHWILD, DM; CARMACK, CE; KAY, RM; HUSZAR, D			ANTIGEN-SPECIFIC HUMAN-ANTIBODIES FROM MICE COMPRISING 4 DISTINCT GENETIC MODIFICATIONS	NATURE			English	Article							CELL-SPECIFIC ENHANCER; MONOCLONAL-ANTIBODY; IMMUNOGLOBULIN; RECOMBINATION; REJECTION; LOCUS	HUMAN sequence monoclonal antibodies, which in theory combine high specificity with low immunogenicity, represent a class of potential therapeutic agents. But nearly 20 years after Kohler and Milstein first developed methods for obtaining mouse antibodies(1), no comparable technology exists for reliably obtaining high-affinity human antibodies directed against selected targets. Thus, rodent antibodies(2), and in vitro modified derivatives of rodent antibodies(3-5), are still being used and tested in the clinic. The rodent system has certain clear advantages; mice are easy to immunize, are not tolerant to most human antigens, and their B cells form stable hybridoma cell lines. To exploit these advantages, we have developed transgenic mice that express human IgM, IgG and Ig kappa in the absence of mouse IgM or Ig kappa. We report here that these mice contain human sequence transgenes that undergo V(D)J joining, heavy-chain class switching, and somatic mutation to generate a repertoire of human sequence immunoglobulins. They are also homozygous for targeted mutations that disrupt V(D)J rearrangement at the endogenous heavy- and kappa light-chain loci. We have immunized the mice with human proteins and isolated hybridomas secreting human IgG kappa antigen-specific antibodies.	GENPHARM INT,MT VIEW,CA 94043									CHEN JZ, 1993, EMBO J, V12, P821, DOI 10.1002/j.1460-2075.1993.tb05722.x; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; DURDIK J, 1989, P NATL ACAD SCI USA, V86, P2346, DOI 10.1073/pnas.86.7.2346; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GOLDSTEIN G, 1985, NEW ENGL J MED, V313, P337; HOGAN B, 1986, METHODS MANIPULATING; HYAKAWA K, 1986, EUR J IMMUNOL, V16, P1313; JUDDE JG, 1992, MOL CELL BIOL, V12, P5206, DOI 10.1128/MCB.12.11.5206; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MOREL P, 1992, CLIN IMMUNOL IMMUNOP, V64, P248, DOI 10.1016/0090-1229(92)90207-5; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; PIEPER FR, 1992, NUCLEIC ACIDS RES, V20, P1259, DOI 10.1093/nar/20.6.1259; QUEEN C, 1991, NATURE, V351, P501; TAYLOR LD, 1994, INT IMMUNOL, V6, P579, DOI 10.1093/intimm/6.4.579; TAYLOR LD, 1992, NUCLEIC ACIDS RES, V20, P6287, DOI 10.1093/nar/20.23.6287; WALDMANN TA, 1992, ANNU REV IMMUNOL, V10, P675, DOI 10.1146/annurev.immunol.10.1.675; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	18	266	1259	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					856	859		10.1038/368856a0	http://dx.doi.org/10.1038/368856a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159246				2022-12-01	WOS:A1994NH71700072
J	GU, W; BHATIA, K; MAGRATH, IT; DANG, CV; DALLAFAVERA, R				GU, W; BHATIA, K; MAGRATH, IT; DANG, CV; DALLAFAVERA, R			BINDING AND SUPPRESSION OF THE MYC TRANSCRIPTIONAL ACTIVATION DOMAIN BY P107	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; HELIX ZIPPER PROTEIN; LARGE T-ANTIGEN; C-MYC; CYCLIN-A; MAX; E2F; EXPRESSION; IDENTIFICATION; SEQUENCE	An amino-terminal transactivation domain is required for Myc to function as a transcription factor controlling cell proliferation, differentiation, and apoptosis. A complementary DNA expression library was screened with a Myc fusion protein to identify proteins interacting with this domain, and a clone encoding the Rb-related p107 protein was isolated. The p107 protein was shown to associate with Myc in vivo and to suppress the activity of the Myc transactivation domain. However, mutant forms of Myc from Burkitt lymphoma cells, which contain sequence alterations in the transactivation domain, were resistant to p107-mediated suppression. Thus, disruption of a regulatory interaction between Myc and p107 may be important in tumorigenesis.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; NCI,PEDIAT ONCOL BRANCH,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21205	Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine			Dang, Chi/Y-3375-2019	Dang, Chi/0000-0002-4031-2522	NCI NIH HHS [CA 51497, CA 37165] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051497, R37CA051497, R01CA051497, R01CA037165] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BHATIA K, 1993, NATURE GENET, V56; BHATIA K, UNPUB; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CZIEPLUCH C, 1993, ONCOGENE, V8, P2833; DALLAFAVERA R, 1993, CAUSES CONSEQUENCES, P313; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Gu W.Q., UNPUB; HATEBOER J, 1993, P NATL ACAD SCI USA, V90, P8489; HERCHBACH BM, 1993, ANN REV CELL BIOL, V9, P479; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LOMBARDI L, 1987, CELL, V49, P101; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MURPHY JW, UNPUB; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SET A, 1993, MOL CELL BIOL, V13, P4125; SETH A, 1991, J BIOL CHEM, V266, P23521; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; YANO T, 1993, ONCOGENE, V8, P2741; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZMANANIAN M, 1992, EMBO J, V11, P2603	41	212	216	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					251	254		10.1126/science.8146655	http://dx.doi.org/10.1126/science.8146655			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146655				2022-12-01	WOS:A1994NE41000034
J	LE, DT; WEIBERT, RT; SEVILLA, BK; DONNELLY, KJ; RAPAPORT, SI				LE, DT; WEIBERT, RT; SEVILLA, BK; DONNELLY, KJ; RAPAPORT, SI			THE INTERNATIONAL NORMALIZED RATIO (INR) FOR MONITORING WARFARIN THERAPY - RELIABILITY AND RELATION TO OTHER MONITORING METHODS	ANNALS OF INTERNAL MEDICINE			English	Article						DRUG MONITORING; PROTHROMBIN TIME; WARFARIN; INTERNATIONAL NORMALIZED RATIO; THROMBOPLASTIN	NATIVE PROTHROMBIN ANTIGEN; ORAL ANTICOAGULANT-THERAPY; SENSITIVITY INDEX ISI; THROMBOPLASTIN REAGENTS; TIME; PRECISION	Objective: To enhance understanding of the reliability of the international normalized ratio (INR) for monitoring warfarin therapy and its relation to other monitoring techniques. Design: Prospective cohort study. Setting: A university hospital. Patients: 79 patients attending an anticoagulation clinic. Measurements: International normalized ratios obtained with a portable capillary monitor (Coumatrak) and the following from a simultaneous plasma sample: INRs from prothrombin times done with six thromboplastins, prothrombin-proconvertin (P&P) test activity, specific prothrombin activity, and native prothrombin antigen. Results: Converting to INRs failed to standardize prothrombin time results obtained with high- and low-sensitivity thromboplastins. Coumatrak INRs correlated best with INRs obtained with high-sensitivity thromboplastins. The INR range of 2.0 to 3.0 corresponded to a P&P range of 30% to 13%, a native plasma prothrombin antigen range of 56 to 24 mu g/mL, and a specific prothrombin activity range of 43% to 21%. Conclusions: Low-sensitivity thromboplastins may give erroneously high INRs in the upper therapeutic range. Plasma prothrombin times should be done with a high-sensitivity thromboplastin, particularly in patients maintained at the upper limit of the therapeutic range. An INR so obtained correlated well with an INR obtained with a portable capillary blood monitor.	UNIV CALIF SAN DIEGO, LA JOLLA, CA USA	University of California System; University of California San Diego					NHLBI NIH HHS [HL 27234] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL027234] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKER DM, 1993, ARCH PATHOL LAB MED, V117, P602; BJERKLUND CJ, 1957, THESIS OSLO U OSLO; BLANCHARD RA, 1983, J LAB CLIN MED, V101, P242; BRAUN PJ, 1992, THROMB HAEMOSTASIS, V68, P160; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278, DOI 10.1001/archinte.152.2.278; FURIE B, 1984, BLOOD, V64, P445; FURIE B, 1990, BLOOD, V75, P344; HIRSH J, 1992, ARCH INTERN MED, V152, P257, DOI 10.1001/archinte.152.2.257; HIRSH J, 1992, CHEST, V102, pS312, DOI 10.1378/chest.102.4.312S; HIRSH J, 1987, ARCH INTERN MED, V147, P769, DOI 10.1001/archinte.147.4.769; KAZAMA M, 1990, THROMB HAEMOSTASIS, V64, P535; LEWIS SM, 1985, J CLIN PATHOL, V38, P133; LOELIGER EA, 1992, ANN HEMATOL, V64, P60, DOI 10.1007/BF01715346; MCCURDY SA, 1992, ARCH INTERN MED, V152, P589, DOI 10.1001/archinte.152.3.589; NG VL, 1993, AM J CLIN PATHOL, V99, P689, DOI 10.1093/ajcp/99.6.689; OWREN PA, 1951, SCAND J CLIN LAB INV, V3, P201, DOI 10.3109/00365515109060600; OWREN PA, 1955, 1954 INT C THROMB EM, P1085; POGGIO M, 1989, THROMB HAEMOSTASIS, V62, P868; POLLER L, 1989, J CLIN PATHOL, V42, P97, DOI 10.1136/jcp.42.1.97; SISE HS, 1958, NEW ENGL J MED, V259, P266, DOI 10.1056/NEJM195808072590603; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; TABERNER DA, 1989, J CLIN PATHOL, V42, P92, DOI 10.1136/jcp.42.1.92; VANRIJN JLML, 1989, CLIN CHEM, V35, P840; XI M, 1989, THROMB HAEMOSTASIS, V62, P788; ZIVELIN A, 1993, J CLIN INVEST, V92, P2131, DOI 10.1172/JCI116814; 1983, TECHNICAL REPORT SER, V687, P81	26	64	66	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					552	558		10.7326/0003-4819-120-7-199404010-00004	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116992				2022-12-01	WOS:A1994NC76400004
J	ROSENBERG, SA; YANG, JC; TOPALIAN, SL; SCHWARTZENTRUBER, DJ; WEBER, JS; PARKINSON, DR; SEIPP, CA; EINHORN, JH; WHITE, DE				ROSENBERG, SA; YANG, JC; TOPALIAN, SL; SCHWARTZENTRUBER, DJ; WEBER, JS; PARKINSON, DR; SEIPP, CA; EINHORN, JH; WHITE, DE			TREATMENT OF 283 CONSECUTIVE PATIENTS WITH METASTATIC MELANOMA OR RENAL-CELL CANCER USING HIGH-DOSE BOLUS INTERLEUKIN-2	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVATED KILLER CELLS; ESTABLISHED PULMONARY METASTASES; TUMOR-INFILTRATING LYMPHOCYTES; RECOMBINANT INTERLEUKIN-2; AUTOLOGOUS TUMOR; INVITRO GROWTH; IMMUNOTHERAPY; REGRESSION; RESPONSES; LYSIS	Objective.-To determine the efficacy of treatment using high-dose bolus interleukin 2 (IL-2) in patients with metastatic melanoma or renal cell cancer. Design and Setting.-Consecutive series of all patients treated with high-dose IL-2 in the Surgery Branch of the National Cancer Institute from September 1985 through December 1992. Patients.-Two hundred eighty-three patients with metastatic melanoma or metastatic renal cell cancer who had failed standard treatment for their cancers. Interventions.-Patients received IL-2 at a dose of 720 000 IU/kg intravenously every 8 hours for a maximum of 15 doses per cycle. Two cycles constituted a treatment course, and patients with stable or responding disease received additional treatment courses. A total of 447 courses of treatment were administered. Main Outcome Measures.-Regression of measurable tumor, durability of response to treatment, and survival. Results.-Nine patients (7%) with metastatic melanoma achieved complete regression of all disease and 14 patients (10%) had partial regression. Ten patients (7%) with metastatic renal cell cancer experienced complete regression and 20 patients (13%) had partial regression. Of the 19 patients with complete regression, 15 have remained in complete remission from 7 to 91 months aftertreatment. Three treatment-related deaths (1.1%) occurred early in this series, but as experience with the administration of this IL-2 regimen increased, no treatment-related deaths occurred in 214 patients treated during the last 5 years of the study. Conclusion.-Biologic therapy with IL-2 can cause significant antitumor effects in patients with advanced metastatic melanoma or renal cell cancer. Because IL-2 does not have a direct effect on cancer cells but rather mediates its antitumor activity by altering host immune reactions, these data represent the best available evidence that immunologic therapy for cancer can be effective in selected patients.			ROSENBERG, SA (corresponding author), NCI,DIV CANC TREATMENT,SURG BRANCH,9000 ROCKVILLE PIKE,BLDG 10,ROOM 2B42,BETHESDA,MD 20892, USA.							ATKINS MB, 1988, NEW ENGL J MED, V318, P1557, DOI 10.1056/NEJM198806163182401; BALCH CM, 1993, CANC PRINCIPLES PRAC, P1612; BELLDEGRUN A, 1987, ANN INTERN MED, V106, P817, DOI 10.7326/0003-4819-106-6-817; BOCK SN, 1990, J CLIN ONCOL, V8, P161, DOI 10.1200/JCO.1990.8.1.161; DENICOFF KD, 1987, ANN INTERN MED, V107, P293, DOI 10.7326/0003-4819-107-2-293; DEVITA VT, 1993, CANCER PRINCIPLES PR; ELSON PJ, 1988, CANCER RES, V48, P7310; ETTINGHAUSEN SE, 1987, BLOOD, V69, P1654; ETTINGHAUSEN SE, 1986, CANCER RES, V46, P2784; FAIRLAMB DJ, 1981, CANCER, V47, P2102, DOI 10.1002/1097-0142(19810415)47:8<2102::AID-CNCR2820470833>3.0.CO;2-K; FISHER B, 1989, J CLIN ONCOL, V7, P1852, DOI 10.1200/JCO.1989.7.12.1852; GASPARI AA, 1987, JAMA-J AM MED ASSOC, V258, P1624, DOI 10.1001/jama.258.12.1624; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; ITOH K, 1988, J EXP MED, V168, P1419, DOI 10.1084/jem.168.4.1419; KIRKWOOD JM, 1993, PRINCIPLES PRACTICE, P1; KLEMPNER MS, 1990, NEW ENGL J MED, V322, P959, DOI 10.1056/NEJM199004053221404; KURZROCK R, 1991, BIOL THERAPY CANCER, P247; LEE RE, 1989, J CLIN ONCOL, V7, P7, DOI 10.1200/JCO.1989.7.1.7; LOTZE MT, 1981, CANCER RES, V41, P4420; LOTZE MT, 1981, J IMMUNOL, V126, P2215; LOTZE MT, 1986, JAMA-J AM MED ASSOC, V256, P3117, DOI 10.1001/jama.256.22.3117; LOTZE MT, 1985, J IMMUNOL, V135, P2865; LOTZE MT, 1991, BIOL THERAPY CANCER, P159; MALKOVSKA V, 1993, THERAPEUTIC APPLICAT, V2, P143; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; MULE JJ, 1984, SCIENCE, V225, P1487, DOI 10.1126/science.6332379; MUUL LM, 1987, J IMMUNOL, V138, P989; OGNIBENE FP, 1988, CHEST, V94, P750, DOI 10.1378/chest.94.4.750; POCKAJ BA, 1993, J CLIN ONCOL, V22, P136; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1992, J CLIN ONCOL, V10, P180, DOI 10.1200/JCO.1992.10.2.180; ROSENBERG SA, 1984, SCIENCE, V223, P1412, DOI 10.1126/science.6367046; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; ROSENBERG SA, 1985, J EXP MED, V161, P1169, DOI 10.1084/jem.161.5.1169; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; ROSENBERG SA, 1991, BIOL THERAPY CANCER, P214; ROSENSTEIN M, 1986, J IMMUNOL, V137, P1735; SCHWARTZENTRUBER DJ, 1992, J IMMUNOTHER, V12, P1, DOI 10.1097/00002371-199207000-00001; SCHWARTZENTRUBER DJ, 1991, J IMMUNOL, V146, P3674; SCHWARTZENTRUBER DJ, 1991, CANCER, V68, P2384, DOI 10.1002/1097-0142(19911201)68:11<2384::AID-CNCR2820681109>3.0.CO;2-A; SPARANO JA, 1993, THERAPEUTIC APPLICAT, V2, P99; STRAUSSER JL, 1978, J IMMUNOL, V121, P1491; SUNDERLAND MC, 1993, THERAPEUTIC APPLICAT, V2, P119; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; TOPALIAN SL, 1989, J IMMUNOL, V142, P3714; WEBB DE, 1988, CLIN NEPHROL, V30, P141; YRON I, 1980, J IMMUNOL, V125, P238	47	959	993	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	1994	271	12					907	913		10.1001/jama.271.12.907	http://dx.doi.org/10.1001/jama.271.12.907			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA743	8120958				2022-12-01	WOS:A1994NA74300025
J	PFARR, CM; MECHTA, F; SPYROU, G; LALLEMAND, D; CARILLO, S; YANIV, M				PFARR, CM; MECHTA, F; SPYROU, G; LALLEMAND, D; CARILLO, S; YANIV, M			MOUSE JUND NEGATIVELY REGULATES FIBROBLAST GROWTH AND ANTAGONIZES TRANSFORMATION BY RAS	CELL			English	Article							C-JUN; DNA-BINDING; FOS PROTEINS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM; G0-TO-G1 TRANSITION; ACTIVATION DOMAIN; ESTROGEN-RECEPTOR	As NIH 3T3 fibroblasts become quiescent, the level of c-Jun protein decreases while JunD accumulates. When resting cells are stimulated with fresh serum, nuclear-localized JunD is rapidly degraded, followed by resynthesis of both c-Jun and JunD later in G1. Overexpression of JunD results in slower growth and an increase in the percentage of cells in G0/G1 while c-Jun overexpression produces larger S/G2 and M phase populations. In addition, JunD partially suppresses transformation by an activated ras gene whereas c-Jun cooperates with ras to transform cells. These data indicate that two closely related transcription factors can function in an opposing manner.	INST GENET MOLEC MONTPELLIER, UNITE MIXTE RECH 9942, F-34033 MONTPELLIER 01, FRANCE; INST PASTEUR, DEPT BIOTECHNOL, CNRS, UNITE VIRUS ONCOGENES 1644, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite			MECHTA-GRIGORIOU, Fatima/C-5253-2017; lallemand, dominique/O-7445-2017	MECHTA-GRIGORIOU, Fatima/0000-0002-3751-6989; lallemand, dominique/0000-0002-0212-7342				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, NEW BIOL, V3, P870; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARTY L, 1990, BIOCHIMIE, V72, P885, DOI 10.1016/0300-9084(90)90007-4; MCCOY MS, 1986, MOL CELL BIOL, V6, P1326, DOI 10.1128/MCB.6.4.1326; MECHTA F, 1989, New Biologist, V1, P297; MILLER AD, 1984, CELL, V36, P51; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	77	298	301	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					747	760		10.1016/0092-8674(94)90513-4	http://dx.doi.org/10.1016/0092-8674(94)90513-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124713				2022-12-01	WOS:A1994MZ28500016
J	ARNASON, U; GULLBERG, A				ARNASON, U; GULLBERG, A			RELATIONSHIP OF BALEEN WHALES ESTABLISHED BY CYTOCHROME-B GENE SEQUENCE COMPARISON	NATURE			English	Article							FIN WHALE; BALAENOPTERA-MUSCULUS; MITOCHONDRIAL-DNA; PHYSALUS; MAMMALS	A RECENT revision1 of whale phylogeny suggested that the sperm whale was more closely related to rorquals than to other toothed whales. This made the suborder Odontoceti (toothed whales) paraphyletic, and implied that the latest common ancestor of rorquals and sperm whales may have lived only 10-13 million years ago. This is at variance with palaeontological evidence for the greater antiquity for both mysticetes (baleen whales) and sperm whales, so the Mysticeti, as well as the Odontoceti, must also be paraphyletic if the dates implied in ref. 1 were correct. Here we present a more comprehensive phylogenetic analysis that demonstrates the monophyly of mysticetes and identifies no particular affinity between the sperm whales and rorquals.			ARNASON, U (corresponding author), LUND UNIV, DEPT GENET, DIV EVOLUT MOLEC SYST, SOLVEGATAN 29, S-22362 LUND, SWEDEN.							ADEGOKE JA, 1993, CHROMOSOMA, V102, P382, DOI 10.1007/BF00360402; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ARNASON U, 1992, MOL BIOL EVOL, V9, P1018; ARNASON U, 1993, J MOL EVOL, V37, P312; ARNASON U, 1981, HEREDITAS, V95, P277; ARNASON U, 1993, BIOCHEM SYST ECOL, V21, P115, DOI 10.1016/0305-1978(93)90016-K; ARNASON U, 1993, MOL BIOL EVOL, V10, P960; ARNASON U, 1991, J MOL EVOL, V33, P556, DOI 10.1007/BF02102808; ARNASON U, 1991, HEREDITAS, V114, P263, DOI 10.1111/j.1601-5223.1991.tb00333.x; ARNASON U, 1991, HEREDITAS, V115, P183, DOI 10.1111/j.1601-5223.1991.tb03554.x; ARNASON U, 1973, HEREDITAS, V75, P67; Barnes L.G., 1978, P582; BARNES LG, 1985, MAR MAMMAL SCI, V1, P15, DOI 10.1111/j.1748-7692.1985.tb00530.x; Barnes LG, 1984, GRAY WHALE ESCHRICHT, P3; Czelusniak J., 1990, Current Mammalogy, V2, P545; FELSENSTEIN J, 1991, PHYLIP VERSION 3 4 1; GOODMAN M, 1989, INT CONGR SER, V824, P43; Gray JE, 1874, T P NZ I, V6, P93; GRETARSDOTTIR S, 1993, MOL BIOL EVOL, V10, P306; HEYNING JE, 1990, NATO ADV SCI I A-LIF, V196, P67; HEYNING JE, 1989, CONTRIBUTIONS SCI NA, V405, P1; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; MED JG, 1993, MAMMAL SPECIES WORLD, P349; MILINKOVITCH MC, 1993, NATURE, V361, P346, DOI 10.1038/361346a0; Miller G. S., 1923, Smithsonian Miscellaneous Collections, V76, P1; NOVACEK M, 1993, NATURE, V361, P298, DOI 10.1038/361298a0; RICE DW, 1977, NOAA NMFS SSRF711 TE; SPILLIAERT R, 1991, J HERED, V82, P269, DOI 10.1093/oxfordjournals.jhered.a111085; Swofford D, 1993, PHYLOGENETIC ANAL US	29	103	120	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					726	728		10.1038/367726a0	http://dx.doi.org/10.1038/367726a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107866				2022-12-01	WOS:A1994MX63100055
J	KUHLBRANDT, W; WANG, DN; FUJIYOSHI, Y				KUHLBRANDT, W; WANG, DN; FUJIYOSHI, Y			ATOMIC MODEL OF PLANT LIGHT-HARVESTING COMPLEX BY ELECTRON CRYSTALLOGRAPHY	NATURE			English	Article							PHOTOSYNTHETIC REACTION CENTER; A/B-PROTEIN COMPLEX; CHLOROPHYLL-A; RHODOPSEUDOMONAS-VIRIDIS; ENERGY-TRANSFER; 3A RESOLUTION; DENSITY MAPS; MEMBRANE; MICROSCOPY; PHOSPHORYLATION	The structure of the light-harvesting chlorophyll a/b-protein complex, an integral membrane protein, has been determined at 3.4 Angstrom resolution by electron crystallography of two-dimensional crystals. Two of the three membrane-spanning alpha-helices are held together by ion pairs formed by charged residues that also serve as chlorophyll ligands. In the centre of the complex, chlorophyll a is in close contact with chlorophyll b for rapid energy transfer, and with two carotenoids that prevent the formation of toxic singlet oxygen.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN		KUHLBRANDT, W (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Fujiyoshi, Yoshinori/E-5989-2012	Fujiyoshi, Yoshinori/0000-0002-8070-1493; Wang, Da-Neng/0000-0002-6496-4699; Kuhlbrandt, Werner/0000-0002-2013-4810				BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BENNETT J, 1979, EUR J BIOCHEM, V99, P133, DOI 10.1111/j.1432-1033.1979.tb13239.x; BOOY FP, 1993, ULTRAMICROSCOPY, V48, P273, DOI 10.1016/0304-3991(93)90101-3; BORN M, 1975, PRINCIPLES OPTICS, P333; BOWERS PG, 1967, PROC R SOC LON SER-A, V296, P435, DOI 10.1098/rspa.1967.0036; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUTT HJ, 1991, ULTRAMICROSCOPY, V36, P307, DOI 10.1016/0304-3991(91)90123-N; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CESKA TA, 1994, J APPL CRYSTALLOGR, V27, P200, DOI 10.1107/S0021889893009537; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; DEMMIGADAMS B, 1992, REV PLANT PHYSL, V43, P599; DEXTER DL, 1953, J CHEM PHYS, V21, P836, DOI 10.1063/1.1699044; EADS DD, 1989, J PHYS CHEM-US, V93, P8271, DOI 10.1021/j100363a001; ECCLES J, 1983, P NATL ACAD SCI-BIOL, V80, P4959, DOI 10.1073/pnas.80.16.4959; EVANS PR, 1991, CRYSTALLOGRAPHIC COM, V5, P136; FUJIYOSHI Y, 1980, ULTRAMICROSCOPY, V5, P459, DOI 10.1016/0304-3991(80)90046-7; FUJIYOSHI Y, 1991, ULTRAMICROSCOPY, V38, P241, DOI 10.1016/0304-3991(91)90159-4; GLAESER RM, 1989, ULTRAMICROSCOPY, V27, P307, DOI 10.1016/0304-3991(89)90021-1; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HILLER RG, 1993, J PHOTOCHEM PHOTOBIO, V57, P125; HOFFMANN NE, 1986, P NATL ACAD SCI USA, V84, P8844; IDE JP, 1987, BIOCHIM BIOPHYS ACTA, V893, P349, DOI 10.1016/0005-2728(87)90056-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUHLER RK, 1993, PHOTOSYNTH RES, V35, P171, DOI 10.1007/BF00014747; KEARNS DR, 1971, CHEM REV, V71, P395, DOI 10.1021/cr60272a004; KRAMER H, 1980, BIOCHIM BIOPHYS ACTA, V593, P319, DOI 10.1016/0005-2728(80)90069-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; KUHLBRANDT W, 1989, J MOL BIOL, V207, P823, DOI 10.1016/0022-2836(89)90247-7; MATTHEWS BW, 1979, J MOL BIOL, V131, P259, DOI 10.1016/0022-2836(79)90076-7; MAURING K, 1987, SPECTROCHIM ACTA A, V43, P507, DOI 10.1016/0584-8539(87)80052-1; MICHEL H, 1991, J BIOL CHEM, V266, P17584; MULLET JE, 1983, J BIOL CHEM, V258, P9941; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; PALSSON LO, IN PRESS FEBS LETT; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PETER GF, 1991, J BIOL CHEM, V266, P16745; PICOREL R, 1992, PHOTOCHEM PHOTOBIOL, V56, P263, DOI 10.1111/j.1751-1097.1992.tb02156.x; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; SIEFERMANNHARMS D, 1985, BIOCHIM BIOPHYS ACTA, V811, P325, DOI 10.1016/0304-4173(85)90006-0; STERLING C, 1964, ACTA CRYSTALLOGR, V17, P1224, DOI 10.1107/S0365110X64003152; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; van der Vos R, 1991, APPL MAGN RESON, V2, P179, DOI 10.1007/BF03166035; WANG DN, 1991, J MOL BIOL, V217, P691, DOI 10.1016/0022-2836(91)90526-C; WANG DN, 1992, BIOPHYS J, V61, P287, DOI 10.1016/S0006-3495(92)81836-2; 1974, INT TABLES XRAY CRYS, V4, P71	53	1543	1607	4	201	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 17	1994	367	6464					614	621		10.1038/367614a0	http://dx.doi.org/10.1038/367614a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107845				2022-12-01	WOS:A1994MW68800044
J	BARRES, BA; RAFF, MC; GAESE, F; BARTKE, I; DECHANT, G; BARDE, YA				BARRES, BA; RAFF, MC; GAESE, F; BARTKE, I; DECHANT, G; BARDE, YA			A CRUCIAL ROLE FOR NEUROTROPHIN-3 IN OLIGODENDROCYTE DEVELOPMENT	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; GLIAL PROGENITOR-CELL; GROWTH-FACTOR; MONOCLONAL-ANTIBODY; NEURONAL DEATH; DIFFERENTIATION; ASTROCYTE; CULTURE; INVITRO; ANTIGEN	THE neurotrophins nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin4/5 promote the survival of subpopulations of vertebrate neurons in vitro, but so far only nerve growth factor has been demonstrated to be essential for normal neuronal development1-4; no neurotrophin has previously been shown to function in normal glial cell development. We found recently that neurotrophin-3 promotes the survival of pure oligodendrocyte precursor cells in vitro, and although by itself it induces only a small percentage of these cells to synthesize DNA, in combination with platelet-derived growth factor it induces the majority of them to do so5. Neither of these factors, however, has been shown to contribute to oligodendrocytes precursor cell proliferation in vivo or to stimulate pure populations of these cells to proliferate (as opposed to synthesize DNA) in vitro. Here we show that neurotrophin-3 and platelet-derived growth factor collaborate to promote clonal expansion of oligodendrocyte precursor cells in vitro and to drive the intrinsic clock that times oligodendrocyte development6. We also show that neurotrophin-3 helps stimulate the proliferation of oligodendrocyte precursor cells in vivo and is thus required for normal oligodendrocyte development.	UNIV LONDON UNIV COLL,DEPT BIOL,MRC,DEV NEUROBIOL PROGRAMME,LONDON WC1E 6BT,ENGLAND; MAX PLANCK INST PSYCHIAT,DEPT NEUROBIOCHEM,D-82152 PLANEGG,GERMANY; BOEHRINGER MANNHEIM,D-82377 PENZBERG,GERMANY	University of London; University College London; Max Planck Society			Messier, Claude/A-2322-2008; Barde, Yves/F-6019-2011	Messier, Claude/0000-0002-4791-1763; Barde, Yves/0000-0002-7627-461X				BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B; BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1993, DEVELOPMENT, V118, P283; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; ELKABES S, 1993, ABSTR SOC NEUROSCI, V19, P251; GOBLET C, 1992, METHOD ENZYMOL, V216, P160; GONCHOROFF NJ, 1985, CYTOMETRY, V6, P506, DOI 10.1002/cyto.990060604; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; MAGAUD JP, 1988, J IMMUNOL METHODS, V106, P95, DOI 10.1016/0022-1759(88)90276-1; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MILLER RH, 1985, DEV BIOL, V111, P35, DOI 10.1016/0012-1606(85)90432-4; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; RAFF MC, 1985, CELL, V42, P61, DOI 10.1016/S0092-8674(85)80101-X; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; TEMPLE S, 1985, NATURE, V313, P223, DOI 10.1038/313223a0	29	318	325	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					371	375		10.1038/367371a0	http://dx.doi.org/10.1038/367371a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114937				2022-12-01	WOS:A1994MT54000068
J	CUNDY, T; CORNISH, J; EVANS, MC; ROBERTS, H; REID, IR				CUNDY, T; CORNISH, J; EVANS, MC; ROBERTS, H; REID, IR			RECOVERY OF BONE-DENSITY IN WOMEN WHO STOP USING MEDROXYPROGESTERONE ACETATE	BRITISH MEDICAL JOURNAL			English	Article									FAMILY PLANNING ASSOC NEW ZEALAND,AUCKLAND,NEW ZEALAND		CUNDY, T (corresponding author), UNIV AUCKLAND,DEPT MED,AUCKLAND 1,NEW ZEALAND.			Cundy, Timothy/0000-0003-4890-9400; Roberts, Helen/0000-0002-8107-5746				CUNDY T, 1991, BRIT MED J, V303, P13, DOI 10.1136/bmj.303.6793.13; JOHANSEN JS, 1988, J CLIN ENDOCR METAB, V67, P701, DOI 10.1210/jcem-67-4-701; SCHLECHTE J, 1989, J CLIN ENDOCR METAB, V68, P412, DOI 10.1210/jcem-68-2-412; WARREN MP, 1986, NEW ENGL J MED, V314, P1348, DOI 10.1056/NEJM198605223142104	4	118	121	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	1994	308	6923					247	248		10.1136/bmj.308.6923.247	http://dx.doi.org/10.1136/bmj.308.6923.247			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT539	8111260	Green Published			2022-12-01	WOS:A1994MT53900022
J	KATO, K; CLARK, GD; BAZAN, NG; ZORUMSKI, CF				KATO, K; CLARK, GD; BAZAN, NG; ZORUMSKI, CF			PLATELET-ACTIVATING-FACTOR AS A POTENTIAL RETROGRADE MESSENGER IN CA1 HIPPOCAMPAL LONG-TERM POTENTIATION	NATURE			English	Article							NITRIC-OXIDE; ARACHIDONIC-ACID; DENTATE GYRUS; RAT; RECEPTOR; INHIBITION; CURRENTS; RELEASE; NEURONS; BRAIN	LONG-term potentiation (LTP) refers to a persisting enhancement of neurotransmission that follows high-frequency activation of certain synapses1. Although both pre- and postsynaptic mechanisms contribute to LTP2,3, it is believed that the enhanced release of neurotransmitter that accompanies this process results from the production of a diffusible messenger in postsynaptic neurons which traverses the synaptic cleft and alters the function of presynaptic terminals4,5. One candidate for such a messenger is arachidonic acid, a metabolite produced by phospholipase A2 which augments synaptic transmission when coupled with presynaptic stimulations. However, the effects of arachidonic acid require activation of the postsynaptic receptor for N-methyl-D-aspartate6. Previously we found that platelet-activating factor (1 O-alkyl-2-acetyl-sn-glycero-3-phosphocholine), another phospholipase A2-derived messenger7, selectively enhances excitatory postsynaptic currents in hippocampal neurons by a presynaptic mechanism8. We now present evidence that platelet-activating factor, acting at a receptor localized to synaptic regions, participates in LTP in the CA1 region of rat hippocampal slices and may serve as part of a retrograde signalling cascade.	WASHINGTON UNIV, SCH MED, DEPT PSYCHIAT, 4940 CHILDRENS PL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROBIOL, ST LOUIS, MO 63110 USA; LOUISIANA STATE UNIV, MED CTR, SCH MED, CTR NEUROSCI, NEW ORLEANS, LA 70112 USA; LOUISIANA STATE UNIV, MED CTR, SCH MED, DEPT NEUROL, NEW ORLEANS, LA 70112 USA; LOUISIANA STATE UNIV, MED CTR, SCH MED, DEPT OPHTHALMOL, NEW ORLEANS, LA 70112 USA	Washington University (WUSTL); Washington University (WUSTL); Louisiana State University System; Louisiana State University System; Louisiana State University System			Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444				ARAI A, 1992, EUR J NEUROSCI, V4, P411, DOI 10.1111/j.1460-9568.1992.tb00890.x; BAZAN NG, 1989, ANN NY ACAD SCI, V559, P1; BAZAN NG, 1992, EMERGING STRATEGIES, P238; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; DELCERRO S, 1990, BEHAV NEURAL BIOL, V54, P213, DOI 10.1016/0163-1047(90)90595-W; DOUCET JP, 1992, MOL NEUROBIOL, V6, P407, DOI 10.1007/BF02757944; GRIBKOFF VK, 1992, J NEUROPHYSIOL, V68, P639, DOI 10.1152/jn.1992.68.2.639; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KANDEL ER, 1992, SCIENCE, V258, P243, DOI 10.1126/science.1411522; KATO K, 1993, NEUROSCIENCE, V53, P39, DOI 10.1016/0306-4522(93)90282-K; KATO K, 1991, BRAIN RES, V563, P94, DOI 10.1016/0006-8993(91)91519-7; KUBA K, 1990, PROG NEUROBIOL, V34, P197, DOI 10.1016/0301-0082(90)90012-6; LI YG, 1992, SOC NEUR ABSTR, V18, P343; LYNCH MA, 1991, J NEUROCHEM, V56, P113, DOI 10.1111/j.1471-4159.1991.tb02569.x; LYNCH MA, 1989, NEUROSCIENCE, V30, P693, DOI 10.1016/0306-4522(89)90162-0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MARCHESELLI VL, 1990, J BIOL CHEM, V265, P9140; MARCHESELLI VL, IN PRESS J NEUROSCI; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; YUE TL, 1990, J NEUROCHEM, V54, P1809, DOI 10.1111/j.1471-4159.1990.tb01239.x; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	30	225	230	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	1994	367	6459					175	179		10.1038/367175a0	http://dx.doi.org/10.1038/367175a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114914				2022-12-01	WOS:A1994MQ78000062
J	SCHNELL, L; SCHNEIDER, R; KOLBECK, R; BARDE, YA; SCHWAB, ME				SCHNELL, L; SCHNEIDER, R; KOLBECK, R; BARDE, YA; SCHWAB, ME			NEUROTROPHIN-3 ENHANCES SPROUTING OF CORTICOSPINAL TRACT DURING DEVELOPMENT AND AFTER ADULT SPINAL-CORD LESION	NATURE			English	Article							NEURITE GROWTH-INHIBITORS; NERVOUS-SYSTEM; MESSENGER-RNA; RAT; AXONS; BRAIN; MOTONEURONS; EXPRESSION; EXTENSION; SURVIVAL	THE number of neurotrophic factors found in the central nervous system is rapidly growing, but their functions in vivo are largely unknown. In the peripheral nervous system they promote the survival of developing and lesioned neurons and enhance nerve fibre growth and regeneration1-6. Here we study the effects of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) on the largest tract system leading from the brain to the spinal cord, the corticospinal tract (CST)7. The developing CST grows down the spinal cord during the first postnatal days and innervates its targets after a waiting period by collateral sprouting8-10. We find that NT-3 injected locally specifically enhances this sprouting, whereas BDNF has no effect. In adult rats, injection of NT-3 (but not BDNF) into the lesioned spinal cord increases the regenerative sprouting of the transected CST. The distance of growth of the sprouts is very restricted, but application of an antibody that neutralizes myelin-associated neurite growth inhibitory proteins'' results in long-distance regeneration of CST fibres.	MAX PLANCK INST PSYCHIAT,DEPT NEUROBIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society	SCHNELL, L (corresponding author), UNIV ZURICH,BRAIN RES INST,AUGUST FOREL STR 1,CH-8029 ZURICH,SWITZERLAND.		Barde, Yves/F-6019-2011; Schwab, Martin E/B-6818-2016	Barde, Yves/0000-0002-7627-461X				ALTAR CA, 1993, J NEUROSCI, V13, P733; [Anonymous], 1959, DEGENERATION REGENER; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BREGMAN BS, 1989, J COMP NEUROL, V282, P355, DOI 10.1002/cne.902820304; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CASALE EJ, 1988, J COMP NEUROL, V278, P275, DOI 10.1002/cne.902780210; DAVIES AM, 1990, ANNU REV NEUROSCI, V13, P61, DOI 10.1146/annurev.neuro.13.1.61; DCHANT G, 1993, DEVELOPMENT, V119, P545; DIAMOND J, 1992, J NEUROSCI, V12, P1454; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; FRIEDMAN WJ, 1991, EUR J NEUROSCI, V3, P688, DOI 10.1111/j.1460-9568.1991.tb00854.x; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; KUNKELBAGDEN E, 1993, NEUR ABSTR, V19, P681; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; NUDO RJ, 1988, J COMP NEUROL, V277, P53, DOI 10.1002/cne.902770105; OLEARY DDM, 1988, NEURON, V1, P901, DOI 10.1016/0896-6273(88)90147-X; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; RINGSTEDT T, 1993, DEV BRAIN RES, V72, P119, DOI 10.1016/0165-3806(93)90165-7; ROMANES G. J., 1964, PROGR BRAIN RES, V11, P93; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1993, EUR J NEUROSCI, V5, P1156, DOI 10.1111/j.1460-9568.1993.tb00970.x; SCHREYER DJ, 1982, NEUROSCIENCE, V7, P1837, DOI 10.1016/0306-4522(82)90001-X; SCHWAB ME, 1991, J NEUROSCI, V11, P709; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0	28	774	813	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 13	1994	367	6459					170	173		10.1038/367170a0	http://dx.doi.org/10.1038/367170a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114912				2022-12-01	WOS:A1994MQ78000060
J	FRADKIN, JE; MILLS, JL; SCHONBERGER, LB; WYSOWSKI, DK; THOMSON, R; DURAKO, SJ; ROBISON, LL				FRADKIN, JE; MILLS, JL; SCHONBERGER, LB; WYSOWSKI, DK; THOMSON, R; DURAKO, SJ; ROBISON, LL			RISK OF LEUKEMIA AFTER TREATMENT WITH PITUITARY GROWTH-HORMONE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; MEDULLOBLASTOMA; EPIDEMIOLOGY; CHILDREN; HISTORY	Objective.-To determine whether pituitary-derived human growth hormone treatment increases the subsequent risk of developing leukemia and lymphoma. Design.-Cohort study. Setting.-United States. Participants.-A total of 6284 recipients of pituitary-derived human growth hormone distributed by the National Hormone and Pituitary Program between 1963 and 1985. Main Outcome Measures.-Leukemia and lymphoma. Results.-Three cases of leukemia occurred in 59736 patient-years of follow-up from the start of growth hormone therapy to case ascertainment at interview; this number was not significantly higher (P=.23) than the 1.66 cases expected in the US age-, race-, and gender-matched general population. Three additional cases, found in an extended follow-up that provided 83 917 person-years of risk, yielded a minimum rate of leukemia that was significantly increased (six cases found, 2.26 expected; P=.028). The relative risk of leukemia in pituitary growth hormone recipients compared with the general population was 1.8 (90% confidence interval [CI], 0.82 to 7.5) for the defined follow-up and 2.6 (90% CI, 1.2 to 5.2) for the extended follow-up. Five of the six subjects who developed leukemia had antecedent cranial tumors (four craniopharyngioma, one astrocytoma) as the cause of growth hormone deficiency, and four had received radiotherapy. There was no increase in leukemia in patients with idiopathic growth hormone deficiency. The association of leukemia and craniopharyngioma was significant (P<.001). There was no excess of lymphoma in the cohort. Conclusions.-This cohort of growth hormone recipients had a significantly increased rate of leukemia compared with the age-, race-, and gender-matched general population. However, the upper bound CI of the relative risk in our population (5.2) is well below the other estimates (7.6). Compared with the general population, our study population had more possible risk factors for leukemia (radiation, tumor) that may have contributed to the excess observed. The clustering of cases of leukemia in craniopharyngioma patients should be further evaluated.	NICHHD, BETHESDA, MD 20892 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA; US FDA, ROCKVILLE, MD 20857 USA; WESTAT CORP, ROCKVILLE, MD USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Centers for Disease Control & Prevention - USA; US Food & Drug Administration (FDA); Westat; University of Minnesota System; University of Minnesota Twin Cities	FRADKIN, JE (corresponding author), NIDDKD, DIV DIABET ENDOCRINOL & METAB DIS, WESTWOOD BLDG, ROOM 621, BETHESDA, MD 20892 USA.		Robison, Leslie/N-8122-2018	Mills, James/0000-0003-4496-332X				BLATT J, 1991, PEDIATR HEMAT ONCOL, V8, P77, DOI 10.3109/08880019109033430; BOICE JD, 1987, J NATL CANCER I, V79, P1295; COLTMAN CA, 1990, NEW ENGL J MED, V322, P52, DOI 10.1056/NEJM199001043220109; DANOFF BF, 1982, CANCER, V48, P1580, DOI 10.1002/1097-0142(19820415)49:8<1580::AID-CNCR2820490810>3.0.CO;2-7; DARBY S, 1989, NEW CANCERS MED TREA; DOLL R, 1989, J ROY STAT SOC A STA, V152, P341, DOI 10.2307/2983131; ENDO M, 1988, MED PEDIATR ONCOL, V16, P45, DOI 10.1002/mpo.2950160111; ESTROV Z, 1991, J CLIN ONCOL, V9, P394, DOI 10.1200/JCO.1991.9.3.394; Finlay J L, 1987, Hematol Oncol Clin North Am, V1, P753; FISHER DA, 1988, LANCET, V1, P1159; FORBES GM, 1992, MED J AUSTRALIA, V157, P27, DOI 10.5694/j.1326-5377.1992.tb121603.x; FRADKIN JE, 1991, JAMA-J AM MED ASSOC, V265, P880, DOI 10.1001/jama.265.7.880; KELLEY KW, 1989, BIOCHEM PHARMACOL, V38, P705, DOI 10.1016/0006-2952(89)90222-0; LAMPKIN BC, 1988, PEDIATR CLIN N AM, V35, P743; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MEADOWS AT, 1991, PEDIATR HEMAT ONCOL, V8, pR7, DOI 10.3109/08880019109033419; MILLS JL, 1990, HORM RES, V33, P116, DOI 10.1159/000181494; MORI S, 1986, HORMONE CLIN, V34, P549; NEGLIA JP, 1988, PEDIATR CLIN N AM, V35, P675; OGAWA M, 1988, JPN J CLIN ONCOL, V18, P255; REDMOND G P, 1992, Pediatric Research, V31, p83A; RIES LAG, 1991, NIH912789 PUBL; RON E, 1988, AM J EPIDEMIOL, V127, P713, DOI 10.1093/oxfordjournals.aje.a114852; SASAKI U, 1988, JPN J CLIN ONCOL, V18, P81, DOI 10.1093/jjco/18.1.81; WADA E, 1989, JPN J CLIN ONCOL, V19, P36; WATANABE S, 1989, JPN J CANCER RES, V80, P822, DOI 10.1111/j.1349-7006.1989.tb01721.x; WATANABE S, 1993, J PEDIATR ENDOCRINOL, V6, P99; 1989, NCI892789 PUBL	28	104	104	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2829	2832		10.1001/jama.270.23.2829	http://dx.doi.org/10.1001/jama.270.23.2829			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK941	8133622				2022-12-01	WOS:A1993MK94100032
J	ROSCH, PJ				ROSCH, PJ			STRESSFUL LIFE EVENTS AND GRAVES-DISEASE	LANCET			English	Editorial Material											ROSCH, PJ (corresponding author), AMER INST STRESS,NEW YORK,NY, USA.							HADDEN DR, 1974, LANCET, V2, P577; MEANS JH, 1948, THYROID ITS DISEASES, P295; ORTHGOMER K, 1990, PSYCHOSOM MED, V52, P59, DOI 10.1097/00006842-199001000-00005; ROSCH PJ, 1992, LANCET, V339, P428; SONINO N, 1993, ACTA ENDOCRINOL-COP, V128, P293, DOI 10.1530/acta.0.1280293; UTIGER RD, 1991, NEW ENGL J MED, V325, P278, DOI 10.1056/NEJM199107253250410; WINSA B, 1991, LANCET, V338, P1475, DOI 10.1016/0140-6736(91)92298-G	7	12	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					566	567		10.1016/0140-6736(93)91402-8	http://dx.doi.org/10.1016/0140-6736(93)91402-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102712				2022-12-01	WOS:A1993LV96300002
J	HARRIES, AD				HARRIES, AD			MALARIA - KEEPING THE MOSQUITOS AT BAY	LANCET			English	Editorial Material							TREATED BED NETS; GAMBIAN CHILDREN; AFRICA				HARRIES, AD (corresponding author), UNIV MALAWI, DEPT MED, BLANTYRE, MALAWI.							ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; GREENWOOD BM, 1988, LANCET, V1, P1121; GREENWOOD BM, 1993, T R SOC TROP MED S2, V87; SNOW RW, 1988, T ROY SOC TROP MED H, V82, P212, DOI 10.1016/0035-9203(88)90414-2; SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4; SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9; SPENCER H C, 1987, Annals of Tropical Medicine and Parasitology, V81, P36; STURCHLER D, 1989, PARASITOL TODAY, V5, P39, DOI 10.1016/0169-4758(89)90188-9	8	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1993	342	8870					506	507		10.1016/0140-6736(93)91639-4	http://dx.doi.org/10.1016/0140-6736(93)91639-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102660				2022-12-01	WOS:A1993LU58200002
J	SIMON, GE; DANIELL, W; STOCKBRIDGE, H; CLAYPOOLE, K; ROSENSTOCK, L				SIMON, GE; DANIELL, W; STOCKBRIDGE, H; CLAYPOOLE, K; ROSENSTOCK, L			IMMUNOLOGICAL, PSYCHOLOGICAL, AND NEUROPSYCHOLOGICAL FACTORS IN MULTIPLE CHEMICAL-SENSITIVITY - A CONTROLLED-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						ANXIETY; ENVIRONMENTAL EXPOSURE; HYPERSENSITIVITY; IMMUNOLOGICAL FACTORS; DEPRESSION	ENVIRONMENTAL ILLNESS; 20TH-CENTURY DISEASE; IMMUNE PROFILES; FORMALDEHYDE; ANTIBODIES; FOOD; EXPOSURE	Objective: To examine the role of immunologic, psychological, and neuropsychological factors in multiple chemical sensitivity. Design: Case-control comparison. Setting: Community allergy practice (cases), university-based clinics for musculoskeletal injuries (controls). Participants: Forty-one patients with chemical sensitivity and 34 control patients with chronic musculoskeletal injuries. Main Outcome Measures: Immunologic measures included autoantibody titers, lymphocyte surface markers, and interleukin-1 generation by monocytes. Psychological evaluation included standardized measures of anxiety, depression, and somatization. Results: Immunologic testing did not differentiate patients with chemical sensitivity from controls. The only difference noted (lower interleukin-1 generation among cases) appeared attributable to laboratory methods. Patients with chemical sensitivity reported greater prevalence of current anxiety or depressive disorder (44% versus 15%, P = 0.006). This difference, however, did not appear to precede the onset of chemical sensitivity, and 25% of chemically sensitive patients showed no significant current psychological disturbance. Cases reported significantly more ''medically unexplained'' physical symptoms before and after the onset of chemical sensitivity. When considering only symptoms that preceded chemical sensitivity, 25% of cases (and no controls) satisfied criteria for somatization disorder. Neuropsychological testing revealed no significant case-control differences. Conclusions: Immunologic testing failed to confirm findings from earlier uncontrolled studies, militating against proposed immunologic mechanisms. The decreased memory and concentration frequently described in multiple chemical sensitivity were not confirmed by brief neuropsychological testing. Psychological symptoms, although not necessarily etiologic, are a central component of chemical sensitivity.	UNIV WASHINGTON, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	SIMON, GE (corresponding author), GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, 1730 MINOR AVE, SEATTLE, WA 98101 USA.							ANESHENSEL CS, 1987, J HEALTH SOC BEHAV, V28, P232, DOI 10.2307/2136843; BLACK DW, 1990, JAMA-J AM MED ASSOC, V264, P3166, DOI 10.1001/jama.264.24.3166; BRODSKY CM, 1983, PSYCHOSOMATICS, V24, P731, DOI 10.1016/S0033-3182(83)73168-3; BROUGHTON A, 1988, AM J IND MED, V13, P463, DOI 10.1002/ajim.4700130406; CULLEN MR, 1987, OCCUP MED, V2, P655; DEROGATIS LR, 1977, SCL90R ADM SCORING P; FIEDLER N, 1992, J OCCUP ENVIRON MED, V34, P529; JEWETT DL, 1990, NEW ENGL J MED, V323, P429, DOI 10.1056/NEJM199008163230701; KATON W, 1990, Journal of Clinical Psychiatry, V51, P3; LEVIN AS, 1987, OCCUP MED, V2, P669; MCGOVERN JJ, 1983, ARCH OTOLARYNGOL, V109, P292; MEANS B, 1989, VITAL HLTH STATISTIC, V6; REA WJ, 1978, ANN ALLERGY, V41, P101; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; SCHOTTENFELD RS, 1985, AM J PSYCHIAT, V142, P198; SIMON GE, 1990, AM J PSYCHIAT, V147, P901; SIMON GE, 1991, AM J PSYCHIAT, V148, P1494; STEWART DE, 1985, CAN MED ASSOC J, V133, P1001; TERR AI, 1986, ARCH INTERN MED, V146, P145, DOI 10.1001/archinte.146.1.145; TERR AI, 1989, J OCCUP ENVIRON MED, V31, P257, DOI 10.1097/00043764-198903000-00012; THRASHER JD, 1988, AM J IND MED, V14, P479, DOI 10.1002/ajim.4700140411; THRASHER JD, 1987, ARCH ENVIRON HEALTH, V42, P347, DOI 10.1080/00039896.1987.9934357; THRASHER JD, 1990, ARCH ENVIRON HEALTH, V45, P217, DOI 10.1080/00039896.1990.9940805; THRASHER JD, 1989, AM J IND MED, V15, P187, DOI 10.1002/ajim.4700150207; VONKORFF M, 1988, PAIN, V32, P173, DOI 10.1016/0304-3959(88)90066-8; White LJ, 1989, ANN INTERN MED, V111, P168, DOI 10.7326/0003-4819-111-2-168; 1991, CLIN ECOLOGY CSA REP; 1987, DIAGNOSTIC STATISTIC; 1981, J ALLERGY CLIN IMMUN, V67, P333; 1986, W J MED, V144, P239	30	163	165	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1993	119	2					97	103		10.7326/0003-4819-119-2-199307150-00001	http://dx.doi.org/10.7326/0003-4819-119-2-199307150-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU902	8129805				2022-12-01	WOS:A1993LU90200001
J	ORTMANN, B; ANDROLEWICZ, MJ; CRESSWELL, P				ORTMANN, B; ANDROLEWICZ, MJ; CRESSWELL, P			MHC CLASS I/BETA(2)-MICROGLOBULIN COMPLEXES ASSOCIATE WITH TAP TRANSPORTERS BEFORE PEPTIDE BINDING	NATURE			English	Article							CLASS-I MOLECULES; HLA CLASS-I; ENDOPLASMIC-RETICULUM; T-CELL; ANTIGEN; BETA-2-MICROGLOBULIN; PROTEIN; LINE	MAJOR histocompatibility complex: class I molecules bind antigenic peptides in the endoplasmic reticulum (ER) and transport them to the cell surface for recognition by cytotoxic T lymphocytes. The peptides are predominantly generated from cytoplasmic proteins, probably by the action of the multicatalytic proteinase complex, or proteasome(1,2). They are transported into the ER by the transporters associated with antigen processing (TAP), a complex formed from two subunits, TAP.1 and TAP.2 (refs 3-5). Here we show that the TAP molecules are intimately involved in the assembly of the class I/beta(2)-microglobulin (beta(2)m) peptide complex. Free class I heavy chains are associated in the ER with the chaperone calnexin(6,7). In human B-cell lines, however, class I/beta(2)m dimers in the ER are physically associated with TAP molecules rather than calnexin. Our results suggest that calnexin mediates class I/beta(2)m dimerization, and subsequent binding of the dimers to TAP molecules facilitates their association with TAP-transported peptides.			ORTMANN, B (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,310 CEDAR ST,NEW HAVEN,CT 06520, USA.							ALEXANDER J, 1989, IMMUNOGENETICS, V29, P380, DOI 10.1007/BF00375866; ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ANDERSON KS, 1993, J IMMUNOL, V151, P3407; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ANDROLEWICZ MJ, IN PRESS IMMUNITY; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOENIG S, 1990, J IMMUNOL, V145, P127; LUTZ PM, 1987, IMMUNOGENETICS, V25, P228, DOI 10.1007/BF00404692; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; ROTHBARD JB, 1988, CELL, V52, P515, DOI 10.1016/0092-8674(88)90464-3; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SHIMIZU Y, 1989, J IMMUNOL, V142, P3320; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	28	351	355	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					864	867		10.1038/368864a0	http://dx.doi.org/10.1038/368864a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159247				2022-12-01	WOS:A1994NH71700074
J	DRAPKIN, R; REARDON, JT; ANSARI, A; HUANG, JC; ZAWEL, L; AHN, KJ; SANCAR, A; REINBERG, D				DRAPKIN, R; REARDON, JT; ANSARI, A; HUANG, JC; ZAWEL, L; AHN, KJ; SANCAR, A; REINBERG, D			DUAL ROLE OF TFIIH IN DNA EXCISION-REPAIR AND IN TRANSCRIPTION BY RNA-POLYMERASE-II	NATURE			English	Article							XERODERMA-PIGMENTOSUM; SUBUNIT; CLONING; MOTIFS	THE RNA polymerase II general transcription factor TFIIH is composed of several polypeptides. The observation that the largest subunit of TFIIH is the excision-repair protein XPB/ERCC3 (ref. 1), a helicase implicated in the human DNA-repair disorders xeroderma pigmentosum (XP) and Cockayne's syndrome(2,3), suggests a functional link between transcription and DNA repair(4,5). To understand the connection between these two cellular processes, we have extensively purified and functionally analysed TFIIH. We find that TFIIH has a dual role, being required for basal transcription of class II genes and for participation in DNA-excision repair. TFIIH is shown to complement three different cell extracts deficient in excision repair: XPB/ERCC3, XPC and XPD/ERCC2. The complementation of XPB and XPD is a consequence of ERCC3 and ERCC2 being integral subunits of TFIIH, whereas complementation of XPC is due to an association of this polypeptide with TFIIH. We found that the general transcription factor IIE negatively modulates the helicase activity of TFIIH through a direct interaction between TFIIE and the ERCC3 subunit of TFIIH.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Reinberg, Danny/0000-0003-4288-2016				Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FISHER L, 1992, SCIENCE, V257, P1392; FLORES O, 1992, J BIOL CHEM, V267, P2786; FRIEDBERG EC, 1992, CELL, V71, P887, DOI 10.1016/0092-8674(92)90384-O; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; LI L, 1993, NAT GENET, V5, P413, DOI 10.1038/ng1293-413; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; Qui H., 1993, GENE DEV, V7, P2161; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; ZAWEL L, 1993, COLD SPRING HARB SYM, V58, P187, DOI 10.1101/SQB.1993.058.01.023	28	418	422	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					769	772		10.1038/368769a0	http://dx.doi.org/10.1038/368769a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152490				2022-12-01	WOS:A1994NG55300066
J	KAMB, A; GRUIS, NA; WEAVERFELDHAUS, J; LIU, QY; HARSHMAN, K; TAVTIGIAN, SV; STOCKERT, E; DAY, RS; JOHNSON, BE; SKOLNICK, MH				KAMB, A; GRUIS, NA; WEAVERFELDHAUS, J; LIU, QY; HARSHMAN, K; TAVTIGIAN, SV; STOCKERT, E; DAY, RS; JOHNSON, BE; SKOLNICK, MH			A CELL-CYCLE REGULATOR POTENTIALLY INVOLVED IN GENESIS OF MANY TUMOR TYPES	SCIENCE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ALPHA-INTERFERON; DELETIONS; ONCOGENE; CARCINOMAS; BCL-1	A putative tumor suppressor locus on the short arm of human chromosome 9 has been localized to a region of less than 40 kilobases by means of homozygous deletions in melanoma cell lines. This region contained a gene, Multiple Tumor Suppressor 1 (MTS1), that encodes a previously identified inhibitor (pl 6) of cyclin-dependent kinase 4. MTS1 was homozygously deleted at high frequency in cell lines derived from tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary, and lymphocyte. Melanoma cell lines that carried at least one copy of MTS1 frequently carried nonsense, missense, or frameshift mutations in the gene. These findings suggest that MTS1 mutations are involved in tumor formation in a wide range of tissues.	NCI,LUNG CANC BIOL SECT,BETHESDA,MD 20889; MYRIAD GENET INC,SALT LAKE CITY,UT 84108; MEM SLOAN KETTERING CANC CTR,LUDWIG INST CANC RES,NEW YORK,NY 10021; CROSS CANC INST,DEPT MED,EDMONTON T6G 1Z2,ALBERTA,CANADA; UNIV UTAH,MED CTR,DEPT MED INFORMAT,SALT LAKE CITY,UT 84112	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Myriad Genetics, Inc; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center; University of Alberta; Utah System of Higher Education; University of Utah	KAMB, A (corresponding author), MYRIAD GENET INC,SALT LAKE CITY,UT 84108, USA.		Yang, Chen/G-1379-2010	Gruis, Nelleke/0000-0002-5210-9150	NCI NIH HHS [CA-48711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA048711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON JA, 1992, J OTOLARYNGOL, V21, P321; CHENG JQ, 1993, CANCER RES, V53, P4761; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GRUIS NA, UNPUB; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; JAMES CD, 1993, CANCER RES, V53, P3674; KAMB A, UNPUB; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; LAMMIE GA, 1991, ONCOGENE, V6, P439; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; MERLO A, 1994, CANCER RES, V54, P640; MIDDLETON PG, 1991, LEUKEMIA, V5, P680; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; Sambrook J., 1989, MOL CLONING LAB MANU; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; VANDERRIET P, 1994, CANCER RES, V54, P1156; WEAVERFELDHAUS J, IN PRESS P NATL ACAD; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	28	2710	2999	0	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					436	440		10.1126/science.8153634	http://dx.doi.org/10.1126/science.8153634			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153634	Green Submitted			2022-12-01	WOS:A1994NG19400044
J	KLEMM, JD; ROULD, MA; AURORA, R; HERR, W; PABO, CO				KLEMM, JD; ROULD, MA; AURORA, R; HERR, W; PABO, CO			CRYSTAL-STRUCTURE OF THE OCT-1 POU DOMAIN BOUND TO AN OCTAMER SITE - DNA RECOGNITION WITH TETHERED DNA-BINDING MODULES	CELL			English	Article							HEAVY-CHAIN PROMOTER; TRANSCRIPTION FACTOR; OPERATOR COMPLEX; NUCLEIC-ACIDS; AMINO-ACID; I-POU; HOMEODOMAIN; PROTEIN; SPECIFICITY; RESOLUTION	The structure of an Oct-1 POU domain-octamer DNA complex has been solved at 3.0 Angstrom resolution. The POU-specific domain contacts the 5' half of this site (ATG- CAAAT), and as predicted from nuclear magnetic resonance studies, the structure, docking, and contacts are remarkably similar to those of the lambda and 434 repressors. The POU homeodomain contacts the 3' half of this site (ATGCAAAT), and the docking is similar to that of the engrailed, MAT alpha 2, and Antennapedia homeodomains. The linker region is not visible and there are no protein-protein contacts between the domains, but overlapping phosphate contacts near the center of the octamer site may favor cooperative binding. This novel arrangement raises important questions about cooperativity in protein-DNA recognition.	MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Cold Spring Harbor Laboratory	KLEMM, JD (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.		Herr, Winship/E-6491-2012	Herr, Winship/0000-0002-3606-4546; Aurora, Rajeev/0000-0002-6609-6055	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031471] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13106] Funding Source: Medline; NIGMS NIH HHS [GM-31471] Funding Source: Medline; PHS HHS [5-T32-6MO7287-18] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BOTFIELD MC, 1992, BIOCHEMISTRY-US, V31, P5841, DOI 10.1021/bi00140a020; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR MANUAL VERSION; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HERR W, 1992, TRANSCRIPTIONAL REGU, P1103; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PABO CO, 1990, SCIENCE, V247, P1210, DOI 10.1126/science.2315694; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; QIAN YQ, 1993, J AM CHEM SOC, V115, P1189, DOI 10.1021/ja00056a077; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROULD MA, 1992, ACTA CRYSTALLOGR A, V48, P751, DOI 10.1107/S0108767392003404; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TREISMAN J, 1989, CELL, V59, P553; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	57	446	458	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	1994	77	1					21	32		10.1016/0092-8674(94)90231-3	http://dx.doi.org/10.1016/0092-8674(94)90231-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156594				2022-12-01	WOS:A1994NF21100006
J	RAAD, II; LUNA, M; KHALIL, SAM; COSTERTON, JW; LAM, C; BODEY, GP				RAAD, II; LUNA, M; KHALIL, SAM; COSTERTON, JW; LAM, C; BODEY, GP			THE RELATIONSHIP BETWEEN THE THROMBOTIC AND INFECTIOUS COMPLICATIONS OF CENTRAL VENOUS CATHETERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SEPTIC THROMBOPHLEBITIS; FIBRONECTIN; FIBRINOGEN; ADHERENCE	Objective.-To assess the frequency of thrombotic and infectious complications of long-term use of vascular catheters in cancer patients and to determine whether the two types of complication are related. Design.-Case series. Setting.-A 500-bed tertiary cancer center. Patients.-Seventy-two cancer patients. Interventions.-During a 16-month Period, postmortem examinations of catheterized veins and contralateral uncatheterized veins were done on all patients with indwelling central venous catheters who met study criteria. Main Outcome Measures.-Catheter-related septicemia determined by clinical and microbiological data as well as postmortem pathology; venous pathological changes such as mural hemorrhage, thrombosis, calcification, ulceration, and inflammation. Results.-Premortem clinical and microbiological data were obtained retrospectively on all patients. Pathological changes were noted in 35 catheterized veins (49%) compared with five contralateral control veins (9.2%) (P<.001). Mural thrombi were noted in 27 catheterized veins (38%) compared with only one contralateral control vein (1.4%) (P<.001). Other pathological changes consisted of four central venous catheter-related mural thrombi (5.6%) in the right atrium and four instances (5.6%) of nonbacterial thrombotic endocarditis, three involving the tricuspid and one the mitral valves. Seven patients had catheter-related septicemia. Of the 31 patients with mural thrombosis of the catheterized vein or right atrium, seven developed catheter-related septicemia, whereas none of the 41 patients with normal catheterized veins and atria developed catheter-related septicemia (P<.01). Conclusions.-Thrombotic complications are common in catheterized veins and are often associated with catheter sepsis.	UNIV CALGARY, DEPT BIOL SCI, CALGARY T2N 1N4, ALBERTA, CANADA; AL-AZHAR UNIV, NASR CITY FAC MED, DEPT PUBL HLTH & EPIDEMIOL, CAIRO, EGYPT; UNIV TEXAS, HLTH SCI CTR, SCH MED, HOUSTON, TX 77225 USA	University of Calgary; Egyptian Knowledge Bank (EKB); Al Azhar University; University of Texas System; University of Texas Health Science Center Houston	RAAD, II (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MED SPECIAL, INFECT DIS SECT, HOUSTON, TX 77030 USA.							FRASCHINI G, 1991, MAY P ANN M AM SOC C; GARRISON RN, 1982, SOUTHERN MED J, V75, P917, DOI 10.1097/00007611-198208000-00004; HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; ONEILL JA, 1968, J TRAUM, V8, P256, DOI 10.1097/00005373-196803000-00012; PETERS WR, 1973, SURG GYNECOL OBSTET, V137, P43; PRUITT BA, 1980, ANN SURG, V191, P546, DOI 10.1097/00000658-198005000-00005; RAAD II, 1992, EUR J CLIN MICROBIOL, V11, P1; RADD I, 1993, J INFECT DIS, V168, P400, DOI 10.1093/infdis/168.2.400; SCHUMAN ES, 1987, INFECT SURG      FEB, P103; SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76, DOI 10.1128/JCM.28.1.76-82.1990; STRINDEN WD, 1985, ANN SURG, V202, P653, DOI 10.1097/00000658-198511000-00019; TENNEY JH, 1986, ARCH INTERN MED, V146, P1949, DOI 10.1001/archinte.146.10.1949; VAUDAUX P, 1989, J INFECT DIS, V160, P865, DOI 10.1093/infdis/160.5.865; VERGHESE A, 1985, MEDICINE, V64, P394, DOI 10.1097/00005792-198511000-00004	15	339	353	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	1994	271	13					1014	1016		10.1001/jama.271.13.1014	http://dx.doi.org/10.1001/jama.271.13.1014			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND949	8139059				2022-12-01	WOS:A1994ND94900032
J	SHAW, LJ; MILLER, D; ROMEIS, JC; KARGL, D; YOUNIS, LT; CHAITMAN, BR				SHAW, LJ; MILLER, D; ROMEIS, JC; KARGL, D; YOUNIS, LT; CHAITMAN, BR			GENDER DIFFERENCES IN THE NONINVASIVE EVALUATION AND MANAGEMENT OF PATIENTS WITH SUSPECTED CORONARY-ARTERY DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; SEX FACTORS; EXERCISE TEST; RADIONUCLIDE ANGIOGRAPHY; MYOCARDIAL REVASCULARIZATION	MULTIVARIABLE MATHEMATICAL-METHODS; MYOCARDIAL-INFARCTION; PREDICTING SURVIVAL; PROGNOSTIC VARIABLES; ELDERLY PATIENTS; BYPASS-SURGERY; HEART-DISEASE; WOMEN; BIAS; MEN	Objective: To determine if gender-based differences exist in the post-test management and clinical outcome of patients with clinically suspected coronary artery disease who have stress electrocardiographic or myocardial perfusion imaging evaluation. Design: Retrospective cohort study. Setting: University medical center. Patients: From a cohort of 3975 middle-aged patients referred for outpatient stress testing, 840 (47% women) were evaluated noninvasively for clinically suspected coronary artery disease. Measurements: The rates of subsequent diagnostic procedures and the incidence of subsequent coronary revascularization, myocardial infarction, or cardiac death were determined for women and men. Results: Pretest cardiac risk profiles were similar, except hypertension and hypercholesterolemia were more frequent in women. Atypical angina was more common in women than in men (57.5% compared with 44.5%, respectively; P < 0.001). Rates of initial test positivity (defined as exercise-induced horizontal or downsloping ST-segment depression greater than or equal to 1.0 mm or greater than or equal to 1 reversible thallium-201 defect) were similar in women and men. Compared with men, most women with an initial positive test result had no additional coronary artery disease evaluation (62.3% compared with 38.0%; P = 0.002). Coronary revascularization procedures were done more frequently in men (4.9% [22 of 449] compared with 2.0% [8 of 391]; P = 0.03). Cardiac death or myocardial infarction occurred more often in women during 2 years of follow-up (6.9% [27 of 391] compared with 2.4% [11 of 449]; P = 0.002). Conclusions: Women with suspected coronary artery disease have fewer additional diagnostic tests than men after an initial abnormal noninvasive stress test result, even though the incidence of typical angina, cardiac risk factors, and initial diagnostic test positivity rates are similar.	ST LOUIS UNIV, MED CTR, SCH MED, DIV CARDIOL, ST LOUIS, MO 63110 USA; ST LOUIS UNIV, SCH MED, ST LOUIS, MO 63104 USA; HLTH SERV RES & DEV PROGRAM, DURHAM, NC USA	Saint Louis University; Saint Louis University								ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BASS EB, 1989, J CLIN EPIDEMIOL, V42, P385, DOI 10.1016/0895-4356(89)90126-1; BELLER GA, 1991, CIRCULATION, V84, pI1; BENEDETTI J, 1990, LIFE TABLES SURVIVOR, V2, P941; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; BRUCE RA, 1971, ANN CLIN RES, V3, P323; CALLAHAM PR, 1989, J AM COLL CARDIOL, V14, P1175, DOI 10.1016/0735-1097(89)90413-0; Cook R.D., 1982, RESIDUALS INFLUENCE; CUNNINGHAM MA, 1989, J GEN INTERN MED, V4, P392, DOI 10.1007/BF02599688; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; Draper NR, 1981, APPL REGRESSION ANAL, DOI DOI 10.1002/9781118625590; ENGELMAN L, 1990, STEPWISE LOGISTIC RE, P1017; EYSMANN SB, 1992, JAMA-J AM MED ASSOC, V268, P1903, DOI 10.1001/jama.268.14.1903; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P339, DOI 10.1016/0895-4356(90)90120-E; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; ISKANDRIAN AS, 1988, AM J CARDIOL, V61, P269, DOI 10.1016/0002-9149(88)90929-0; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; POLISSAR L, 1982, MED CARE, V20, P959, DOI 10.1097/00005650-198209000-00008; RALEVIC V, 1991, CIRCULATION, V84, P1, DOI 10.1161/01.CIR.84.1.1; SHAW L, 1992, J AM COLL CARDIOL, V19, P1390, DOI 10.1016/0735-1097(92)90592-B; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TIERNEY WM, 1985, CRIT CARE MED, V13, P526, DOI 10.1097/00003246-198507000-00002; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; WALTER SD, 1990, J CLIN EPIDEMIOL, V43, P349, DOI 10.1016/0895-4356(90)90121-5; WEISBERG S, 1980, APPLIED LINEAR REGRE; WELLS CK, 1990, J CLIN EPIDEMIOL, V43, P361, DOI 10.1016/0895-4356(90)90122-6; YOUNIS LT, 1989, J AM COLL CARDIOL, V14, P1635, DOI 10.1016/0735-1097(89)90008-9; YOUNIS LT, 1989, AM J CARDIOL, V64, P161, DOI 10.1016/0002-9149(89)90450-5; 1990, DHHS HRSA HRSPDV901; 1990, BMDP STATISTICAL SOF, V1, P269	35	282	284	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					559	566		10.7326/0003-4819-120-7-199404010-00005	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116993				2022-12-01	WOS:A1994NC76400005
J	MASLOV, DA; AVILA, HA; LAKE, JA; SIMPSON, L				MASLOV, DA; AVILA, HA; LAKE, JA; SIMPSON, L			EVOLUTION OF RNA EDITING IN KINETOPLASTID PROTOZOA	NATURE			English	Article							TRYPANOSOMA-BRUCEI; GUIDE RNAS; CRITHIDIA-FASCICULATA; SUBUNIT; GENE; MITOCHONDRIA; TRANSCRIPT; DOMAINS; REGION; DNA	THE editing of RNA in trypanosomatid mitochondria involves the insertion and occasional deletion of uridine residues within coding regions of maxicircle messenger RNA transcripts. The extent to which the transcripts of homologous genes undergo editing differs in different species. In some, entire genes are edited (pan-editing), whereas in others, editing is limited to the 5' termini of editing domains (5' editing)(1,2). Here we investigate which type of editing is ancestral and which is derived, by analysing RNA editing in the different lineages, using a kinetoplastid phylogeny reconstructed from nuclear small subunit ribosomal RNA sequences. We conclude that the ancestral cryptogenes were pan-edited, and we hypothesize that the 5'-edited homologues were generated by several independent events from partially edited RNAs, in which case editing may be a more primitive mechanism than previously thought.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles								BARROIS M, 1981, P NATL ACAD SCI-BIOL, V78, P3323, DOI 10.1073/pnas.78.6.3323; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BRIONES MRS, 1992, MOL BIOCHEM PARASIT, V53, P121, DOI 10.1016/0166-6851(92)90014-B; CORELL RA, 1993, NUCLEIC ACIDS RES, V21, P4313, DOI 10.1093/nar/21.18.4313; COVELLO PS, 1993, TRENDS GENET, V9, P265, DOI 10.1016/0168-9525(93)90011-6; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DERR LK, 1993, NATURE, V361, P170, DOI 10.1038/361170a0; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; Felsenstein J, 1991, PHYLIP PHYLOGENY INF; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FRASCH ACC, 1980, BIOCHIM BIOPHYS ACTA, V607, P397, DOI 10.1016/0005-2787(80)90150-1; HERNANDEZ R, 1990, MOL BIOCHEM PARASIT, V41, P207, DOI 10.1016/0166-6851(90)90183-M; Hoare C, 1972, TRYPANOSOMES MAMMALS; KIVIC PA, 1984, ORIGINS LIFE EVOL B, V13, P269, DOI 10.1007/BF00927177; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; LAKE JA, 1988, P NATL ACAD SCI USA, V85, P4779, DOI 10.1073/pnas.85.13.4779; LAKE JA, 1994, P NATL ACAD SCI USA, V91, P1455, DOI 10.1073/pnas.91.4.1455; LANDWEBER LF, 1993, NATURE, V363, P179, DOI 10.1038/363179a0; LANDWEBER LF, 1992, BIOSYSTEMS, V28, P41, DOI 10.1016/0303-2647(92)90006-K; LEE ST, 1993, MOL BIOCHEM PARASIT, V58, P187, DOI 10.1016/0166-6851(93)90041-U; LIM J, 1976, BIOL KINETIPLASTIDA, P267; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; OLSEN GJ, 1992, NUCLEIC ACIDS RES, V20, P2199, DOI 10.1093/nar/20.suppl.2199; OLSEN GJ, 1990, SEQUENCE EDITOR ANAL; PECKOVA H, 1990, PARASITOL RES, V76, P553, DOI 10.1007/BF00932559; SCHNARE MN, 1986, CURR GENET, V10, P405, DOI 10.1007/BF00418414; Simpson L, 1993, RNA EDITING ALTERATI, P53; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; STUART K, 1993, RNA EDITING ALTERATI, P25; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; STURM NR, 1991, NUCLEIC ACIDS RES, V19, P6277, DOI 10.1093/nar/19.22.6277; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x; Vickerman K., 1976, P1	36	129	132	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					345	348		10.1038/368345a0	http://dx.doi.org/10.1038/368345a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127370				2022-12-01	WOS:A1994NB98500049
J	BARON, JF; MUNDLER, O; BERTRAND, M; VICAUT, E; BARRE, E; GODET, G; SAMAMA, CM; CORIAT, P; KIEFFER, E; VIARS, P				BARON, JF; MUNDLER, O; BERTRAND, M; VICAUT, E; BARRE, E; GODET, G; SAMAMA, CM; CORIAT, P; KIEFFER, E; VIARS, P			DIPYRIDAMOLE-THALLIUM SCINTIGRAPHY AND GATED RADIONUCLIDE ANGIOGRAPHY TO ASSESS CARDIAC RISK BEFORE ABDOMINAL AORTIC-SURGERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERIPHERAL VASCULAR-SURGERY; POSTOPERATIVE MYOCARDIAL-ISCHEMIA; CORONARY-ARTERY DISEASE; REGIONAL WALL MOTION; NONCARDIAC SURGERY; EJECTION FRACTION; SURGICAL-MANAGEMENT; MORTALITY; MORBIDITY; INDEX	Background. Because many patients with atherosclerotic disease of the abdominal aorta also have coronary artery disease, assessment of cardiac risk before abdominal aortic surgery has received much attention. Our prospective study was designed to identify predictors of cardiac risk in consecutive patients evaluated preoperatively with dipyridamole-thallium single-photon-emission computed tomography (SPECT) to assess myocardial perfusion and radionuclide angiography to measure left ventricular ejection fraction. Methods. Clinical and scintigraphic data were collected prospectively during hospitalization in 457 consecutive patients undergoing elective abdominal aortic surgery. Adverse cardiac outcomes were predicted with multivariate analyses. Results. Eighty-six patients (19 percent) had one or more of the following postoperative complications: prolonged myocardial ischemia (61 patients), myocardial infarction (22), congestive heart failure (20), and severe ventricular tachyarrhythmia (2). Twenty patients died postoperatively (4.4 percent), half of them from cardiac causes. Information about myocardial perfusion obtained from dipyridamole-thallium SPECT did not accurately predict adverse cardiac outcomes. The best correlates of cardiac complications were definite clinical evidence of coronary artery disease (odds ratio, 2.6; 95 percent confidence interval, 1.6 to 4.3) and age greater than 65 years (odds ratio, 2.3; 95 percent confidence interval, 1.4 to 3.6). Measurement of the ejection fraction was useful only in the prediction of left ventricular failure. Age greater than 65 years was the only predictor of death (odds ratio, 26.4; 95 percent confidence interval, 3.5 to 200.0). Conclusions. The presence of definite clinical evidence of coronary artery disease and older age were the most important preoperative predictors of an adverse cardiac outcome after abdominal aortic surgery; These results suggest that the routine use of dipyridamole-thallium SPECT and radionuclide angiography for screening before abdominal aortic surgery may not be justified.	HOP LA PITIE SALPETRIERE,DEPT ANESTHESIOL,PARIS,FRANCE; HOP LA PITIE SALPETRIERE,DEPT VASC SURG,PARIS,FRANCE; HOP LARIBOISIERE,NUCL MED LAB,PARIS,FRANCE; HOP FERNAND WIDAL,BIOPHYS LAB,PARIS,FRANCE; HOP FERNAND WIDAL,INSERM,U141,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite								ACINAPURA AJ, 1987, J CARDIOVASC SURG, V28, P552; BARON JF, 1991, ANESTHESIOLOGY, V75, P611, DOI 10.1097/00000542-199110000-00010; BERNARD M, 1989, CLIN CHEM ENZYM COMM, V2, P35; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; CARLINER NH, 1985, AM J CARDIOL, V56, P51, DOI 10.1016/0002-9149(85)90565-X; COOPERMAN M, 1978, SURGERY, V84, P505; CRAWFORD ES, 1981, SURGERY, V90, P1055; CUTLER BS, 1987, J VASC SURG, V5, P91; DEBAKEY ME, 1984, J VASC SURG, V1, P605, DOI 10.1067/mva.1984.avs0010605; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; DILSIZIAN V, 1990, NEW ENGL J MED, V323, P141, DOI 10.1056/NEJM199007193230301; DIXON WJ, 1985, BMDP STATISTICAL SOF; DRAPER N, 1967, REGRESSION ANAL; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; EAGLE KA, 1987, JAMA-J AM MED ASSOC, V257, P2185, DOI 10.1001/jama.257.16.2185; EISNER RL, 1986, J NUCL MED, V27, P1717; FISER WP, 1983, SURGERY, V94, P736; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GOULD KL, 1982, CIRCULATION, V66, P1141, DOI 10.1161/01.CIR.66.6.1141; Gouny P, 1989, Ann Vasc Surg, V3, P328, DOI 10.1016/S0890-5096(06)60155-6; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; HOLLENBERG M, 1992, JAMA-J AM MED ASSOC, V268, P205, DOI 10.1001/jama.268.2.205; JAMIESON WRE, 1982, CIRCULATION, V66, P92; KAZMERS A, 1988, J VASC SURG, V8, P307, DOI 10.1067/mva.1988.avs0080307; KAZMERS A, 1988, J VASC SURG, V8, P128, DOI 10.1067/mva.1988.avs0080128; LEPPO J, 1979, CIRCULATION, V59, P714, DOI 10.1161/01.CIR.59.4.714; LEPPO J, 1982, CIRCULATION, V66, P649, DOI 10.1161/01.CIR.66.3.649; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1991, CIRCULATION, V84, P493, DOI 10.1161/01.CIR.84.2.493; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARSHALL RC, 1977, CIRCULATION, V56, P820, DOI 10.1161/01.CIR.56.5.820; PASTERNACK PF, 1984, J VASC SURG, V1, P320; RABY KE, 1992, JAMA-J AM MED ASSOC, V268, P222, DOI 10.1001/jama.268.2.222; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; THOMPSON JE, 1975, ANN SURG, V181, P654, DOI 10.1097/00000658-197505000-00020	37	250	254	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 10	1994	330	10					663	669		10.1056/NEJM199403103301002	http://dx.doi.org/10.1056/NEJM199403103301002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY575	8107716				2022-12-01	WOS:A1994MY57500002
J	CALAKOS, N; BENNETT, MK; PETERSON, KE; SCHELLER, RH				CALAKOS, N; BENNETT, MK; PETERSON, KE; SCHELLER, RH			PROTEIN-PROTEIN INTERACTIONS CONTRIBUTING TO THE SPECIFICITY OF INTRACELLULAR VESICULAR TRAFFICKING	SCIENCE			English	Article							BIOSPECIFIC INTERACTION ANALYSIS; INTEGRAL MEMBRANE-PROTEIN; SURFACE-PLASMON RESONANCE; SYNAPTIC VESICLES; RAT-BRAIN; PURIFICATION; EXPRESSION; TRANSPORT; COMPLEX; CLONING	Intracellular vesicles destined to fuse with the plasma membrane and secrete their contents must have a mechanism for specifically interacting with the appropriate target membrane. Such a mechanism is now suggested by the demonstration of specific interaction between vesicular proteins and plasma membrane proteins. The vesicle-associated membrane proteins (VAMPs) 1 and 2 specifically bind the acceptor membrane proteins syntaxin 1A and 4 but not syntaxin 2 or 3. The binding site is within amino acids 194 to 267 of syntaxin 1A, and the approximate equilibrium dissociation constant is 4.7 x 10(-6) molar. These data suggest a physical basis for the specificity of intracellular vesicular transport.			CALAKOS, N (corresponding author), STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305, USA.							AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENNETT MK, 1993, J NEUROSCI, V13, P1701; BENNETT MK, 1991, SCIENCE, V252, P1162; CALAKOS N, UNPUB; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FERSHT A, 1985, ENZYME STRUCTURE MEC, P150; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HUTTNER WB, 1993, NATURE, V365, P104, DOI 10.1038/365104a0; INOUE A, 1992, J BIOL CHEM, V267, P10613; JAHN R, 1993, J NEUROCHEM, V61, P12, DOI 10.1111/j.1471-4159.1993.tb03533.x; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPRING J, 1993, TRENDS BIOCHEM SCI, V18, P124, DOI 10.1016/0968-0004(93)90018-I; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	38	376	379	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1146	1149		10.1126/science.8108733	http://dx.doi.org/10.1126/science.8108733			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108733				2022-12-01	WOS:A1994MX75900035
J	DEDHAR, S; RENNIE, PS; SHAGO, M; HAGESTEIJN, CYL; YANG, HL; FILMUS, J; HAWLEY, RG; BRUCHOVSKY, N; CHENG, H; MATUSIK, RJ; GIGUERE, V				DEDHAR, S; RENNIE, PS; SHAGO, M; HAGESTEIJN, CYL; YANG, HL; FILMUS, J; HAWLEY, RG; BRUCHOVSKY, N; CHENG, H; MATUSIK, RJ; GIGUERE, V			INHIBITION OF NUCLEAR HORMONE-RECEPTOR ACTIVITY BY CALRETICULIN	NATURE			English	Article							EMBRYONAL CARCINOMA-CELLS; RO/SS-A AUTOANTIGEN; GLUCOCORTICOID RECEPTOR; MOLECULAR-CLONING; BINDING PROTEIN; BETA-TUBULIN; EXPRESSION; INDUCTION; ANTIGEN; DOMAIN	WE have shown that a polypeptide of M(r) 60,000 (60K) that shares N-terminal homology with a calcium-binding protein, calreticulin, can bind to an amino-acid sequence motif, KXGFFKR, found in the cytoplasmic domains of all integrin alpha-subunits1. The homologous amino-acid sequence, KXFFKR (where X is either G, A or V), is also present in the DNA-binding domain of all known members of the steroid hormone receptor family2; amino acids in this sequence make direct contact with nucleotides in their DNA-responsive elements and are crucial for DNA binding3. Here we show that both the 60K protein (p60), purified on a KLGFFKR-Sepharose affinity matrix, and recombinant calreticulin can inhibit the binding of androgen receptor to its hormone-responsive DNA element in a KXFFKR-sequence-specific manner. Calreticulin can also inhibit androgen receptor and retinoic acid receptor transcriptional activities in vivo, as well as retinoic acid-induced neuronal differentiation. Our results indicate that calreticulin can act as an important modulator of the regulation of gene transcription by nuclear hormone receptors.	UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DEPT MED BIOPHYS,TORONTO M4N 3M5,ON,CANADA; BRITISH CANC CANC AGCY,DEPT CANC ENDOCRINOL,VANCOUVER V5Z 4E6,BC,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,DIV ENDOCRINE RES,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,DEPT MOLEC & MED GENET,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV MANITOBA,DEPT PHYSIOL,WINNIPEG R3E 0W3,MANITOBA,CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Manitoba	DEDHAR, S (corresponding author), UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DIV CANC RES,REICHMANN RES BLDG,2075 BAYVIEW AVE,TORONTO M4N 3M5,ON,CANADA.			Hawley, Robert/0000-0003-3512-5818; Giguere, Vincent/0000-0001-9567-3694; Dedhar, Shoukat/0000-0003-4355-1657; Matusik, Robert/0000-0003-2057-9892				ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; DEDHAR S, 1991, J BIOL CHEM, V266, P21846; DETHE H, 1990, NATURE, V343, P1771; FILMUS J, 1992, NUCLEIC ACIDS RES, V20, P2755, DOI 10.1093/nar/20.11.2755; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCCAULIFFE DP, 1990, J CLIN INVEST, V86, P332, DOI 10.1172/JCI114704; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295	25	329	335	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					480	483		10.1038/367480a0	http://dx.doi.org/10.1038/367480a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107809				2022-12-01	WOS:A1994MU67900060
J	STUART, GJ; SAKMANN, B				STUART, GJ; SAKMANN, B			ACTIVE PROPAGATION OF SOMATIC ACTION-POTENTIALS INTO NEOCORTICAL PYRAMIDAL CELL DENDRITES	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL-NEURONS; RAT HIPPOCAMPUS; VISUAL-CORTEX; THRESHOLDS; INITIATION; INDUCTION; CHANNELS; SYNAPSES; SLICES	THE dendrites of neurons in the mammalian central nervous system have been considered as electrically passive structures which funnel synaptic potentials to the soma and axon initial segment, the site of action potential initiation1,2.More recent studies, however, have shown that the dendrites of many neurons are not passive, but contain active conductances3,4. The role of these dendritic voltage-activated channels in the initiation of action potentials in neurons is largely unknown. To assess this directly, patch-clamp recordings were made from the dendrites of neocortical pyramidal cells in brain slices. Voltage-activated sodium currents were observed in dendritic outside-out patches, while action potentials could be evoked by depolarizing current pulses or by synaptic stimulation during dendritic whole-cell recordings. To determine the site of initiation of these action potentials, simultaneous whole-cell recordings were made from the soma and the apical dendrite or axon of the same cell. These experiments showed that action potentials are initiated first in the axon and then actively propagate back into the dendritic tree.			STUART, GJ (corresponding author), MAX PLANCK INST MED RES,ZELLPHYSIOL ABT,POSTFACH 103820,D-69028 HEIDELBERG,GERMANY.		stuart, greg j/F-7328-2011	stuart, greg/0000-0001-9395-2219				Adams Paul R., 1992, Current Biology, V2, P625, DOI 10.1016/0960-9822(92)90093-P; AMITAI Y, 1993, CEREB CORTEX, V3, P26, DOI 10.1093/cercor/3.1.26; ANDERSEN P, 1987, J PHYSIOL-LONDON, V383, P509; ANDERSEN P, 1966, EXP BRAIN RES, V2, P247; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BENARDO LS, 1982, J NEUROSCI, V2, P1614; DESCHENES M, 1981, EXP BRAIN RES, V43, P304; DODT HU, 1990, BRAIN RES, V537, P333, DOI 10.1016/0006-8993(90)90380-T; Eccles, 2013, PHYSL SYNAPSES; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HERRERAS O, 1990, J NEUROPHYSIOL, V64, P1429, DOI 10.1152/jn.1990.64.5.1429; HUGUENARD JR, 1989, P NATL ACAD SCI USA, V86, P2473, DOI 10.1073/pnas.86.7.2473; JAFFE D, 1990, J NEUROPHYSIOL, V64, P948, DOI 10.1152/jn.1990.64.3.948; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; KOMATSU Y, 1992, J NEUROPHYSIOL, V67, P401, DOI 10.1152/jn.1992.67.2.401; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; MIYAKAWA H, 1986, BRAIN RES, V399, P303, DOI 10.1016/0006-8993(86)91520-9; MOORE JW, 1983, J PHYSIOL-LONDON, V336, P301, DOI 10.1113/jphysiol.1983.sp014582; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; POCKBERGER H, 1991, BRAIN RES, V539, P181, DOI 10.1016/0006-8993(91)91619-C; Purpura DP., 1967, NEUROSCIENCES A STUD, P372; Rall W., 1977, HDB PHYSL          1, P39; REGEHR W, 1993, NEURON, V11, P145, DOI 10.1016/0896-6273(93)90278-Y; Sakmann B, 1983, SINGLE CHANNEL RECOR, P37; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; STRICHARTZ GR, 1973, J GEN PHYSIOL, V62, P37, DOI 10.1085/jgp.62.1.37; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TURNER RW, 1989, J NEUROPHYSIOL, V62, P1375, DOI 10.1152/jn.1989.62.6.1375; TURNER RW, 1991, J NEUROSCI, V11, P2270; WONG RKS, 1979, P NATL ACAD SCI USA, V76, P986, DOI 10.1073/pnas.76.2.986	30	952	971	0	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					69	72		10.1038/367069a0	http://dx.doi.org/10.1038/367069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107777				2022-12-01	WOS:A1994MP86500061
J	SATO, TT				SATO, TT			FRENZIED CALM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Sato, Thomas/0000-0001-6547-6403					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	1993	270	23					2794	2794		10.1001/jama.270.23.2794	http://dx.doi.org/10.1001/jama.270.23.2794			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK941	8133605				2022-12-01	WOS:A1993MK94100008
J	BOLINDER, J; UNGERSTEDT, U; ARNER, P				BOLINDER, J; UNGERSTEDT, U; ARNER, P			LONG-TERM CONTINUOUS GLUCOSE MONITORING WITH MICRODIALYSIS IN AMBULATORY INSULIN-DEPENDENT DIABETIC-PATIENTS	LANCET			English	Article							BLOOD-GLUCOSE; SUBCUTANEOUS TISSUE; ADIPOSE-TISSUE; INSTABILITY; GLYCEMIA; INVIVO	The glucose concentration in the extracellular space of subcutaneous adipose tissue closely mirrors the blood glucose concentration. With a microdialysis technique, we undertook continuous ambulatory monitoring of adipose tissue glucose in 17 insulin-dependent diabetic patients with labile glycaemic control. The aims of the study were to investigate performance of the microdialysis device and to evaluate whether consecutive 24 h glucose profiles could be used to adjust insulin therapy. A microdialysis probe was implanted subcutaneously, perfused by a portable microinfusion pump, and dialysate fractions were collected every 1 or 2 h for 75 h. The mean (SE) tissue dialysate glucose concentration was 93 (3)% of the concentration in venous plasma, and variations in adipose tissue glucose closely paralleled changes in plasma glucose. Mean 24 h tissue glucose concentration correlated significantly with glycosylated haemoglobin (HbA1c; r=0.62, p < 0.01). Most patients had a reproducible daily pattern of glucose swings, and in more than half the patients consecutive ambulatory glucose profiles were almost superimposed. When patients' insulin therapy was adjusted on the basis of ambulatory glucose monitoring, HbA1c decreased by almost 2% (p < 0.01), and this decrease lasted for at least 9 months. Microdialysis of adipose tissue can be used for continuous long-term monitoring of glucose concentrations in diabetic patients during ordinary daily life. Daily glucose profiles are often reproducible and the recordings may thus be used for individual tailoring of insulin therapy to improve glycaemic control.	HUDDINGE UNIV HOSP,DEPT MED,S-14186 HUDDINGE,SWEDEN; HUDDINGE UNIV HOSP,RES CTR,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,DEPT PHARMACOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet				Bolinder, Jan/0000-0003-0035-0142				ALBISSER AM, 1990, DIABETES CARE, V13, P393, DOI 10.2337/diacare.13.4.393; ARNER P, 1991, J INTERN MED, V230, P381, DOI 10.1111/j.1365-2796.1991.tb00461.x; BOLINDER J, 1992, DIABETOLOGIA, V35, P1177, DOI 10.1007/BF00401374; FISCHER U, 1987, DIABETOLOGIA, V30, P940, DOI 10.1007/BF00295878; JANSSON PA, 1988, AM J PHYSIOL, V255, pE218, DOI 10.1152/ajpendo.1988.255.2.E218; KADDISH AH, 1968, CLIN CHEM, V14, P116; LONNROTH P, 1987, AM J PHYSIOL, V253, pE3228; MAZZE RS, 1987, DIABETES CARE, V10, P111, DOI 10.2337/diacare.10.1.111; MEYERHOFF C, 1992, DIABETOLOGIA, V35, P1087, DOI 10.1007/BF02221686; MOATTISIRAT D, 1992, DIABETOLOGIA, V35, P224, DOI 10.1007/BF00400921; MOLNAR GD, 1972, DIABETOLOGIA, V8, P342, DOI 10.1007/BF01218495; PERNICK NL, 1986, DIABETES CARE, V9, P61, DOI 10.2337/diacare.9.1.61; PICKUP JC, 1985, LANCET, V2, P817; SCHIFFRIN A, 1982, DIABETES CARE, V5, P479, DOI 10.2337/diacare.5.5.479; SCHLICHTKRULL J, 1965, ACTA MED SCAND, V177, P95; SERVICE FJ, 1970, DIABETES, V19, P644, DOI 10.2337/diab.19.9.644; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V128, P9, DOI 10.1111/j.1748-1716.1986.tb07943.x; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; WATFORD M, 1991, TRENDS BIOCHEM SCI, V16, P201, DOI 10.1016/0968-0004(91)90082-7; WILSON DE, 1983, DIABETES CARE, V6, P604, DOI 10.2337/diacare.6.6.604; WORTH R, 1982, BRIT MED J, V285, P1233, DOI 10.1136/bmj.285.6350.1233; 1992, LANCET, V339, P1326	22	103	104	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1080	1085		10.1016/0140-6736(93)92063-Y	http://dx.doi.org/10.1016/0140-6736(93)92063-Y			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105311				2022-12-01	WOS:A1993ME82200009
J	MURGATROYD, F				MURGATROYD, F			MALIGNANT ARRHYTHMIAS - TRIBULATIONS POST ESVEM	LANCET			English	Editorial Material							SURVIVAL				MURGATROYD, F (corresponding author), ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON,ENGLAND.							[Anonymous], 1989, CIRCULATION, V79, P1354; GRABOYS TB, 1982, AM J CARDIOL, V50, P437, DOI 10.1016/0002-9149(82)90307-1; MASON JW, 1993, NEW ENGL J MED, V329, P452, DOI 10.1056/NEJM199308123290702; MASON JW, 1993, NEW ENGL J MED, V329, P445, DOI 10.1056/NEJM199308123290701; SHENASA M, 1993, LANCET, V341, P1512, DOI 10.1016/0140-6736(93)90642-T; SWERDLOW CD, 1983, NEW ENGL J MED, V308, P1436, DOI 10.1056/NEJM198306163082402; WARD DE, 1993, NEW ENGL J MED, V329, P498, DOI 10.1056/NEJM199308123290710	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					569	569		10.1016/0140-6736(93)91405-B	http://dx.doi.org/10.1016/0140-6736(93)91405-B			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102715				2022-12-01	WOS:A1993LV96300005
J	TOMOTSUNE, D; SHOJI, H; WAKAMATSU, Y; KONDOH, H; TAKAHASHI, N				TOMOTSUNE, D; SHOJI, H; WAKAMATSU, Y; KONDOH, H; TAKAHASHI, N			A MOUSE HOMOLOG OF THE DROSOPHILA TUMOR-SUPPRESSOR GENE L(2)GL CONTROLLED BY HOX-C8 IN-VIVO	NATURE			English	Article							HOMEOTIC GENES; EXPRESSION; PROTEIN; ULTRABITHORAX; ORGANIZATION; MELANOGASTER; CAPACITIES; DISRUPTION; POLYMERASE; SEQUENCE	THE homeobox is a 183-base-pair DNA sequence originally found in Drosophila segmentation and homeotic genes1,2. In Drosophila, homeotic genes are clustered in the Antennapedia and Bithorax complexes, collectively called the homeotic gene complex (HOM-C)3. In the mouse genome, about 40 homeobox genes (Hox) are clustered in four chromosomal regions (Hox A to D). The Hox genes are arranged in the same order and have the same antero-posterior pattern of expression as their structural homologue in the HOM-C4,5, suggesting that they control mouse pattern formation in the same way that HOM-C members do in Drosophila. Homeobox gene products are believed to be transcription factors that regulate expression of target genes. A few candidate target genes have been identified in Drosophila by various approaches6 but the Hox gene targets are poorly understood, mostly because of limitations in the available approaches. Here we identify several candidate Hox gene targets, including a mouse homologue of the Drosophila tumour-suppressor gene l(2)gl, by immunopurification of DNA sequences bound to a Hox protein in native chromatin.	NAGOYA UNIV,SCH SCI,DEPT MOLEC BIOL,NAGOYA,AICHI 464,JAPAN	Nagoya University								AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ANDREW DJ, 1992, NEW BIOL, V4, P5; ARCIONI L, 1992, EMBO J, V11, P265, DOI 10.1002/j.1460-2075.1992.tb05049.x; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; GATEFF E, 1974, ROUX ARCH DEV BIOL, V176, P23, DOI 10.1007/BF00577830; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; GRABA Y, 1992, EMBO J, V11, P3375, DOI 10.1002/j.1460-2075.1992.tb05416.x; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; JACKSON V, 1974, BIOCHEMISTRY-US, V19, P3952; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; KENNISON JA, 1992, NEW BIOL, V4, P91; KLAMBT C, 1989, DEV BIOL, V133, P425, DOI 10.1016/0012-1606(89)90046-8; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; WAKAMATSU Y, 1990, ACTA HISTOCHEM CYTOC, V23, P367, DOI 10.1267/ahc.23.367; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x	29	104	107	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					69	72		10.1038/365069a0	http://dx.doi.org/10.1038/365069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8103190				2022-12-01	WOS:A1993LV64600056
J	DUBOW, MS				DUBOW, MS			ANTITUBERCULOSIS DRUG SCREENING	LANCET			English	Editorial Material											DUBOW, MS (corresponding author), MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL H3A 2T5,QUEBEC,CANADA.							GUZZO J, 1992, TOXICOL LETT, V64-5, P687, DOI 10.1016/0378-4274(92)90248-I; JACOBS WR, 1993, SCIENCE, V260, P819, DOI 10.1126/science.8484123; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; RAMSAY S, 1993, LANCET, V341, P1340, DOI 10.1016/0140-6736(93)90843-6; STEWART GSA, 1909, ASM NEWS, V59, P241; ULITZUR S, 1987, BIOLUMINESCENCE CHEM, P463	7	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					448	449		10.1016/0140-6736(93)91586-B	http://dx.doi.org/10.1016/0140-6736(93)91586-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102422				2022-12-01	WOS:A1993LU07500003
J	KOCOVA, M; SIEGEL, SF; WENGER, SL; LEE, PA; TRUCCO, M				KOCOVA, M; SIEGEL, SF; WENGER, SL; LEE, PA; TRUCCO, M			DETECTION OF Y-CHROMOSOME SEQUENCES IN TURNERS-SYNDROME BY SOUTHERN BLOT ANALYSIS OF AMPLIFIED DNA	LANCET			English	Article							MARKER CHROMOSOMES; MOSAICISM; GONADOBLASTOMA; GROWTH	Only about half of all patients with Turner's syndrome are monosomy 45,X on karyotyping and there are grounds for supposing that cryptic mosaicism for at least part of the Y chromosome may be present in some patients. If so this would be clinically important because of the risk to patients of gonadal neoplasms and virilisation. We have used a very sensitive method to detect Y chromosomal segments in eighteen patients with Turner's syndrome, none of whom had evidence of Y chromosomal material by cytogenetic analysis. In DNA from peripheral blood lymphocytes and/or fibroblasts we looked for specific nucleotide sequences from the sex-determining region of the Y chromosome (SRY gene) and repetitive sequences located at the centromeric region (DYZ3). By polymerase chain amplification (PCR) one patient had a definite positive signal and two patients had faintly positive signals for the SRY gene. Southern blot analysis of PCR material with a SRY-specific probe confirmed that these patients were positive for SRY and revealed another three. No patient was positive for DYZ3, suggesting that only a small portion of Y was present. These results suggest that ''pure'' 45,X monosomy is less frequent than previously supposed. Long-term follow-up of patients with Y sequences is needed to determine their risk for subsequent gonadal neoplasms and virilisation.	UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT,PITTSBURGH,PA 15213; UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURG,RANGOES RES CTR,DIV ENDOCRINOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURGH,RANGOES CTR,DIV MED GENET,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ARANOFF GS, 1988, J ADOLESCENT HEALTH, V9, P501, DOI 10.1016/S0197-0070(88)80011-1; BONAKDAR MI, 1980, OBSTET GYNECOL, V56, P748; BOSZE P, 1989, GYNECOL OBSTET INVES, V28, P113, DOI 10.1159/000293544; DEARCE MA, 1992, CLIN GENET, V41, P28; DOMINGUEZ CJ, 1962, AM J OBSTET GYNECOL, V83, P674, DOI 10.1016/S0002-9378(16)35898-7; GEMMILL RM, 1987, AM J HUM GENET, V41, P157; HASSOLD T, 1988, AM J HUM GENET, V42, P534; HELD KR, 1992, HUM GENET, V88, P288; HOOK EB, 1983, HUM GENET, V64, P24, DOI 10.1007/BF00289473; JACOBS PA, 1990, ANN HUM GENET, V54, P209, DOI 10.1111/j.1469-1809.1990.tb00379.x; LIN CC, 1990, AM J MED GENET, V37, P71, DOI 10.1002/ajmg.1320370117; LINDSAY AN, 1981, AM J MED GENET, V10, P21, DOI 10.1002/ajmg.1320100104; MAGENIS RE, 1984, J PEDIATR-US, V105, P916, DOI 10.1016/S0022-3476(84)80077-3; MAGENIS RE, 1980, AM J HUM GENET, V32, pA79; MEDLEJ R, 1922, J CLIN ENDOCR METAB, V75, P1289; MULLER U, 1987, HUM GENET, V75, P109, DOI 10.1007/BF00591069; NAKAGOME Y, 1991, AM J MED GENET, V41, P112, DOI 10.1002/ajmg.1320410127; PAGE DC, 1987, DEVELOPMENT, V101, P151; PARK E, 1983, PEDIATR RES, V17, P1; RANKE MB, 1983, EUR J PEDIATR, V141, P81, DOI 10.1007/BF00496795; ROSEN GF, 1988, OBSTET GYNECOL, V71, P677; SHAH KD, 1988, AM J CLIN PATHOL, V90, P622, DOI 10.1093/ajcp/90.5.622; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SINISI AA, 1988, CLIN ENDOCRINOL, V28, P187, DOI 10.1111/j.1365-2265.1988.tb03655.x; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; WARBURTON PE, 1991, GENOMICS, V11, P325	26	53	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					140	143		10.1016/0140-6736(93)91345-M	http://dx.doi.org/10.1016/0140-6736(93)91345-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101256				2022-12-01	WOS:A1993LN04200011
J	OSULLIVAN, C; LEWIS, CE; HARRIS, AL; MCGEE, JO				OSULLIVAN, C; LEWIS, CE; HARRIS, AL; MCGEE, JO			SECRETION OF EPIDERMAL GROWTH-FACTOR BY MACROPHAGES ASSOCIATED WITH BREAST-CARCINOMA	LANCET			English	Note							CANCER; CELLS	By means of a cytokine release assay we have shown that in cell populations derived from primary breast carcinoma, epidermal growth factor (EGF) is secreted by cells with the characteristic morphological and immunophenotypic profile of activated macrophages (positive for CD68, CD16, CD25). EGF secretion was observed in 11 (31%) of 35 primary tumours. Secretion of EGF by normal or malignant epithelial cells was not observed. We found no association between EGF secretion by the primary tumour and recognised clinical indices of prognosis.	JOHN RADCLIFFE HOSP,INST MOLEC MED,ICRF,CLIN ONCOL UNIT,OXFORD OX3 9DU,ENGLAND	University of Oxford	OSULLIVAN, C (corresponding author), JOHN RADCLIFFE HOSP,DEPT PATHOL & BACTERIOL,LEVEL 4,OXFORD OX3 9DU,ENGLAND.		Sroka, Isis C/A-2949-2009; Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BURGESS AW, 1989, BRIT MED BULL, V45, P401, DOI 10.1093/oxfordjournals.bmb.a072331; DOTZLAW H, 1990, CANCER RES, V50, P4204; Harris A L, 1989, Recent Results Cancer Res, V113, P70; LEWIS CE, 1990, J IMMUNOL METHODS, V127, P51, DOI 10.1016/0022-1759(90)90340-2; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; MIZUKAMI Y, 1991, ANTICANCER RES, V11, P1485; WHALEN GF, 1990, LANCET, V336, P1489, DOI 10.1016/0140-6736(90)93188-U	8	116	119	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					148	149		10.1016/0140-6736(93)91348-P	http://dx.doi.org/10.1016/0140-6736(93)91348-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101258				2022-12-01	WOS:A1993LN04200014
J	KIKUCHI, Y; OKABE, S; TAMURA, G; HIDA, W; HOMMA, M; SHIRATO, K; TAKISHIMA, T				KIKUCHI, Y; OKABE, S; TAMURA, G; HIDA, W; HOMMA, M; SHIRATO, K; TAKISHIMA, T			CHEMOSENSITIVITY AND PERCEPTION OF DYSPNEA IN PATIENTS WITH A HISTORY OF NEAR-FATAL ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENIOGLOSSAL ELECTROMYOGRAM RESPONSES; VENTILATORY RESPONSE; CONSCIOUS MAN; HYPERCAPNIA; HYPOXIA; SENSATION; OCCLUSION; PRESSURE; AIRWAY; HUMANS	Background. Many deaths from attacks of asthma may be preventable. However, the difficulty in preventing fatal attacks is that not all the pathophysiologic risk factors have been identified. Methods. To examine whether dyspnea and chemosensitivity to hypoxia and hypercapnia are factors in fatal asthma attacks, we studied 11 patients with asthma who had had near-fatal attacks, 11 patients with asthma who had not had near-fatal attacks, and 16 normal subjects. Their respiratory responses to hypoxia and hypercapnia, determined by the standard rebreathing technique while the patients were in remission, were assessed in terms of the slopes of ventilation and airway occlusion pressure as a function of the percentage of arterial oxygen saturation and end-tidal carbon dioxide tension, respectively. The perception of dyspnea was scored on the Borg scale during breathing through inspiratory resistances ranging from 0 to 30.9 cm of water per liter per second. Results. The mean (+/-SD) hypoxic ventilatory response (0.14+/-0.12 liter per minute per percent of arterial oxygen saturation) and airway occlusion pressure (0.05+/-0.05 cm of water per percent of arterial oxygen saturation) were significantly lower in the patients with near-fatal asthma than in the normal subjects (0.60+/-0.35, P<0.001, and 0.16+/-0.08, P<0.001, respectively) and the patients with asthma who had not had near-fatal attacks (0.46+/-0.29, P = 0.003, and 0.15+/-0.09, P = 0.004). The Borg score was also significantly lower in the patients with near-fatal asthma than in the normal subjects, and their lower hypoxic response was coupled with a blunted perception of dyspnea. Conclusions. Reduced chemosensitivity to hypoxia and blunted perception of dyspnea may predispose patients to fatal asthma attacks.	TOHOKU UNIV, SCH MED, DEPT INTERNAL MED 1, AOBA KU, SENDAI, MIYAGI 980, JAPAN	Tohoku University				Kikuchi, Yoshihiro/0000-0002-3262-3881				ALTOSE MD, 1976, J APPL PHYSIOL, V40, P338, DOI 10.1152/jappl.1976.40.3.338; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BARNES PJ, 1992, THORAX, V47, P408, DOI 10.1136/thx.47.6.408; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; British Thoracic Association, 1982, BR MED J CLIN RES ED, V285, P1251; CHANG KC, 1978, CHEST, V73, P667, DOI 10.1378/chest.73.5.667; CHONAN T, 1990, J APPL PHYSIOL, V69, P1290, DOI 10.1152/jappl.1990.69.4.1290; COLLINS DD, 1978, J CLIN INVEST, V62, P105, DOI 10.1172/JCI109093; DRAZEN JM, 1987, J ALLERGY CLIN IMMUN, V80, P428, DOI 10.1016/0091-6749(87)90069-8; ELMANSHAWI A, 1986, J APPL PHYSIOL, V61, P896, DOI 10.1152/jappl.1986.61.3.896; ES JE, 1979, LUNG FUNCTION ASSESS, P365; HIDA W, 1987, B EUR PHYSIOPATH RES, V23, P227; HUDGEL DW, 1974, ANN INTERN MED, V80, P622, DOI 10.7326/0003-4819-80-5-622; HUDGEL DW, 1975, CHEST, V68, P493, DOI 10.1378/chest.68.4.493; HUDGEL DW, 1985, BRONCHIAL ASTHMA MEC, P193; KAWAKAMI Y, 1982, J APPL PHYSIOL, V52, P537; KELSEN SG, 1979, AM REV RESPIR DIS, V120, P517; LAKSHMINARAYAN S, 1975, AM REV RESPIR DIS, V111, P869; MCFADDEN ER, 1991, NEW ENGL J MED, V324, P409, DOI 10.1056/NEJM199102073240609; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; MOORE GC, 1976, NEW ENGL J MED, V295, P861, DOI 10.1056/NEJM197610142951604; NAKAYAMA K, 1963, J INT COLL SURG, V39, P374; OKABE S, 1993, AM REV RESPIR DIS, V147, P190, DOI 10.1164/ajrccm/147.1.190; ONAL E, 1981, AM REV RESPIR DIS, V124, P215; ONAL E, 1981, J APPL PHYSIOL, V50, P1052, DOI 10.1152/jappl.1981.50.5.1052; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; READ DJC, 1967, AUSTRALAS ANN MED, V16, P20; REBUCK AS, 1974, AM REV RESPIR DIS, V109, P345; RUBINFELD AR, 1976, LANCET, V1, P882; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P477, DOI 10.1016/0091-6749(87)90079-0; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; TAGUCHI O, 1991, J APPL PHYSIOL, V71, P2183, DOI 10.1152/jappl.1991.71.6.2183; TAKISHIMA T, 1981, CHEST, V80, P600, DOI 10.1378/chest.80.5.600; WEST JB, 1985, RESPIRATORY PHYSL ES, P113; WHITELAW WA, 1975, RESP PHYSIOL, V23, P181, DOI 10.1016/0034-5687(75)90059-6; 1991, J ALLERGY CLIN IMM S, V88, P427	36	365	370	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 12	1994	330	19					1329	1334		10.1056/NEJM199405123301901	http://dx.doi.org/10.1056/NEJM199405123301901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK753	8152444	Bronze			2022-12-01	WOS:A1994NK75300001
J	BROWN, KE; HIBBS, JR; GALLINELLA, G; ANDERSON, SM; LEHMAN, ED; MCCARTHY, P; YOUNG, NS				BROWN, KE; HIBBS, JR; GALLINELLA, G; ANDERSON, SM; LEHMAN, ED; MCCARTHY, P; YOUNG, NS			RESISTANCE TO PARVOVIRUS B19 INFECTION DUE TO LACK OF VIRUS RECEPTOR (ERYTHROCYTE P-ANTIGEN)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOCLONAL-ANTIBODIES; INVITRO; DISEASE; ANEMIA; CELLS; SERUM; LIVER	Background. The presence of aspecific cellular receptor is thought to be necessary for susceptibility to viral infection. The erythrocyte P antigen is the cellular receptor for parvovirus B19. We hypothesized that the rare persons with the p phenotype, whose erythrocytes do not have this receptor, would be naturally resistant to B19 infection, which causes erythema infectiosum. Methods. Blood samples were collected from two populations in cross-sectional studies. We determined the P antigen phenotype of the red cells and tested plasma for anti-B19-specific antibodies. Bone marrow from donors of known P antigen phenotype was inoculated with parvovirus B19. Infectivity was measured by assays of erythroid progenitor cells, dot blot analysis, and in situ hybridization for B19 DNA, and an immunofluorescence assay for viral-capsid proteins. Results. Of the 17 subjects with the p red-cell phenotype, who did not have P antigen on their erythrocytes, none (0 of 11 and 0 of 6) had serologic evidence of previous parvovirus B19 infection. In contrast, the seropositivity rates in the two control groups were 71 percent (53 of 75, P<0.001) and 47 percent (32 of 68, P = 0.03). In vitro, bone marrow from donors with the p phenotype maintained normal erythropoiesis despite very high concentrations of virus, with no evidence of infection of erythroid progenitor cells by parvovirus B19. Conclusions. People who do not have P antigen, which is the cellular receptor for parvovirus B19, are naturally resistant to infection with this pathogen.	MT EATON CLIN,MT EATON,OH; AMER RED CROSS,CLEVELAND,OH	American Red Cross	BROWN, KE (corresponding author), NHLBI,HEMATOL BRANCH,BLDG 10,RM 7C218,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Gallinella, Giorgio/H-6864-2017	Gallinella, Giorgio/0000-0003-1118-6341; Brown, Kevin/0000-0002-1568-683X				AGRE PC, 1992, PROTEIN BLOOD GROUP, pR11; ANDERSON LJ, 1987, PEDIATR INFECT DIS J, V6, P711, DOI 10.1097/00006454-198708000-00003; ANDERSON MJ, 1983, LANCET, V1, P1378; BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; BROWN KE, 1989, BRIT J OBSTET GYNAEC, V96, P764, DOI 10.1111/j.1471-0528.1989.tb03313.x; BROWN KE, 1991, J GEN VIROL, V72, P741, DOI 10.1099/0022-1317-72-3-741; COHEN BJ, 1983, J HYG-CAMBRIDGE, V91, P113, DOI 10.1017/S0022172400060095; EDEN CS, 1982, INFECTION, V10, P327, DOI 10.1007/BF01640890; FRICKHOFEN N, 1990, ANN INTERN MED, V113, P926, DOI 10.7326/0003-4819-113-12-926; GENTILOMI G, 1993, MOL CELL PROBE, V7, P19, DOI 10.1006/mcpr.1993.1003; HADLEY TJ, 1992, PROTEIN BLOOD GROUP, P228; KURTZMAN GJ, 1988, LANCET, V2, P1159; Landsteiner K, 1927, P SOC EXP BIOL MED, V24, P941; LEVINE P, 1951, P SOC EXP BIOL MED, V77, P403; LIU JM, 1992, J VIROL, V66, P4686, DOI 10.1128/JVI.66.8.4686-4692.1992; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; MOREY AL, 1992, J CLIN PATHOL, V45, P673, DOI 10.1136/jcp.45.8.673; MORTIMER PP, 1983, NATURE, V302, P426, DOI 10.1038/302426a0; OBREGON E, 1980, TRANSFUSION, V20, P621; OZAWA K, 1986, SCIENCE, V233, P883, DOI 10.1126/science.3738514; RACE RR, 1975, BLOOD GROUPS MAN, P139; ROUGER P, 1987, REV FR TRANSFUS IMMU, V30, P699, DOI 10.1016/S0338-4535(87)80138-1; SANGER R, 1955, NATURE, V176, P1163, DOI 10.1038/1761163a0; SHADE RO, 1986, J VIROL, V58, P921, DOI 10.1128/JVI.58.3.921-936.1986; SRIVASTAVA A, 1990, BLOOD, V76, P1997; VONDEMBORNE AEGK, 1986, BRIT J HAEMATOL, V63, P35; WILLIAMS RK, 1990, J VIROL, V64, P3817, DOI 10.1128/JVI.64.8.3817-3823.1990; WILLIAMS RK, 1990, ADV EXP MED BIOL, V276, P45; YOUNG N, 1988, SEMIN HEMATOL, V25, P159	29	214	229	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 28	1994	330	17					1192	1196		10.1056/NEJM199404283301704	http://dx.doi.org/10.1056/NEJM199404283301704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG586	8139629	Bronze			2022-12-01	WOS:A1994NG58600004
J	GAILLARD, C; STRAUSS, F				GAILLARD, C; STRAUSS, F			ASSOCIATION OF POLY(CA)CENTER-DOT-POLY(TG) DNA FRAGMENTS INTO 4-STRANDED COMPLEXES BOUND BY HMG-1 AND HMG-2	SCIENCE			English	Article							HANDED Z-DNA; HOMOLOGOUS RECOMBINATION; EUKARYOTIC GENOMES; CIRCULAR-DICHROISM; HOT SPOT; Z-FORM; PROTEIN; SEQUENCES; GENE; BINDING	The tandemly repeated DNA sequence poly(CA).poly(TG) is found in tracts up to 60 base pairs long, dispersed at thousands of sites throughout the genomes of eukaryotes. Double-stranded DNA fragments containing such sequences associated spontaneously with each other in vitro, in the absence of protein, forming stable four-stranded structures that were detected by gel electrophoresis and electron microscopy. These structures were recognized specifically by the nuclear nonhistone high mobility group (HMG) proteins 1 and 2 as evidenced by gel retardation. Such sequence-specific complexes might be involved in vivo in recombination or other processes requiring specific association of two double-stranded DNA molecules.	INST JACQUES MONOD, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE	UDICE-French Research Universities; Universite Paris Cite				Strauss, Francois/0000-0003-4327-6827				ANTAO VP, 1990, NUCLEIC ACIDS RES, V18, P4111, DOI 10.1093/nar/18.14.4111; BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BLAHO JA, 1989, PROG NUCLEIC ACID RE, V37, P107; BULLOCK P, 1986, MOL CELL BIOL, V6, P3948, DOI 10.1128/MCB.6.11.3948; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CASTLEMAN H, 1984, J BIOMOL STRUCT DYN, V2, P271, DOI 10.1080/07391102.1984.10507566; DIETRICH W, 1992, GENETICS, V131, P423; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GAILLARD C, UNPUB; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GOODWIN GH, 1977, METHOD CELL BIOL, V16, pCH15; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; HANIFORD DB, 1983, J BIOMOL STRUCT DYN, V1, P593, DOI 10.1080/07391102.1983.10507467; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; Johns EW, 1982, HMG CHROMOSOMAL PROT; KASHI Y, 1990, NUCLEIC ACIDS RES, V18, P1129, DOI 10.1093/nar/18.5.1129; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; LILLEY DMJ, 1993, ANNU REV BIOPH BIOM, V22, P299, DOI 10.1146/annurev.bb.22.060193.001503; LITT M, 1989, AM J HUM GENET, V44, P397; MCGAVIN S, 1971, J MOL BIOL, V55, P293, DOI 10.1016/0022-2836(71)90201-4; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MURPHY KE, 1986, NUCLEIC ACIDS RES, V14, P7325, DOI 10.1093/nar/14.18.7325; NORDHEIM A, 1983, P NATL ACAD SCI-BIOL, V80, P1821, DOI 10.1073/pnas.80.7.1821; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; RIAZANCE JH, 1987, NUCLEIC ACIDS RES, V15, P7627, DOI 10.1093/nar/15.18.7627; RIDOUX JP, 1987, NUCLEIC ACIDS RES, V15, P5813, DOI 10.1093/nar/15.14.5813; STALLINGS RL, 1991, GENOMICS, V10, P807, DOI 10.1016/0888-7543(91)90467-S; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STRINGER JR, 1985, MOL CELL BIOL, V5, P1247, DOI 10.1128/MCB.5.6.1247; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; TIMSIT Y, 1991, J MOL BIOL, V221, P919, DOI 10.1016/0022-2836(91)80184-V; TRECO D, 1986, MOL CELL BIOL, V6, P3934, DOI 10.1128/MCB.6.11.3934; TRECO D, 1985, MOL CELL BIOL, V5, P2029, DOI 10.1128/MCB.5.8.2029; VORLICKOVA M, 1982, NUCLEIC ACIDS RES, V10, P1071, DOI 10.1093/nar/10.3.1071; WAHLS WP, 1990, MOL CELL BIOL, V10, P785, DOI 10.1128/MCB.10.2.785; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WILSON JH, 1979, P NATL ACAD SCI USA, V76, P3641, DOI 10.1073/pnas.76.8.3641; WOISARD A, 1986, BIOCHEMISTRY-US, V25, P2672, DOI 10.1021/bi00357a057; WRIGHT JM, 1988, BIOCHEMISTRY-US, V27, P576, DOI 10.1021/bi00402a012; ZIMMER C, 1982, NUCLEIC ACIDS RES, V10, P1081, DOI 10.1093/nar/10.3.1081	46	96	97	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	1994	264	5157					433	436		10.1126/science.8153633	http://dx.doi.org/10.1126/science.8153633			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153633				2022-12-01	WOS:A1994NG19400043
J	STEPHENS, L; SMRCKA, A; COOKE, FT; JACKSON, TR; STERNWEIS, PC; HAWKINS, PT				STEPHENS, L; SMRCKA, A; COOKE, FT; JACKSON, TR; STERNWEIS, PC; HAWKINS, PT			A NOVEL PHOSPHOINOSITIDE-3 KINASE-ACTIVITY IN MYELOID-DERIVED CELLS IS ACTIVATED BY G-PROTEIN BETA-GAMMA-SUBUNITS	CELL			English	Article							RECEPTOR TYROSINE KINASES; I PHOSPHATIDYLINOSITOL KINASE; BINDING REGULATORY PROTEINS; PHOSPHOLIPASE-C; BOVINE BRAIN; SIGNAL TRANSDUCTION; ADENYLYL CYCLASE; CDNA CLONING; 3-KINASE; EXPRESSION	Phosphoinositide 3 kinase (PI3K) is a key signaling enzyme implicated in receptor-stimulated mitogenesis, oxidative bursting in neutrophils, membrane ruffling, and glucose uptake. A PI3K has already been purified, cloned, and shown to be regulated by receptors that act via tyrosine kinase-dependent regulatory mechanisms. We report that an immunologically, pharmacologically, and chromatographically distinct form of PI3K activity present in neutrophils and U937 cells is specifically activated by G protein py subunits. This data suggests PI3Ks conform to the paradigm set by receptor regulation of phosphoinositidase Cs: different receptor transduction systems specifically regulate dedicated isoforms of effector protein.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	STEPHENS, L (corresponding author), AFRC, BABRAHAM INST, BABRAHAM HALL, CAMBRIDGE, ENGLAND.			Hawkins, Phillip/0000-0002-6979-0464; stephens, len/0000-0002-2771-3487				ARCARO A, 1994, IN PRESS BIOCH J; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; FRY MJ, 1992, BIOCHEM J, V288, P383, DOI 10.1042/bj2880383; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PANG IH, 1990, J BIOL CHEM, V265, P18707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RUIZLARREA F, 1993, BIOCHEM J, V290, P609, DOI 10.1042/bj2900609; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; VALIRI C, 1993, J BIOL CHEM, V73, P321; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WENNSTROM S, 1994, IN PRESS ONCOGENE; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	75	551	560	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	1994	77	1					83	93		10.1016/0092-8674(94)90237-2	http://dx.doi.org/10.1016/0092-8674(94)90237-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156600				2022-12-01	WOS:A1994NF21100012
J	KADOWAKI, T; KADOWAKI, H; MORI, Y; TOBE, K; SAKUTA, R; SUZUKI, Y; TANABE, Y; SAKURA, H; AWATA, T; GOTO, Y; HAYAKAWA, T; MATSUOKA, K; KAWAMORI, R; KAMADA, T; HORAI, S; NONAKA, I; HAGURA, R; AKANUMA, Y; YAZAKI, Y				KADOWAKI, T; KADOWAKI, H; MORI, Y; TOBE, K; SAKUTA, R; SUZUKI, Y; TANABE, Y; SAKURA, H; AWATA, T; GOTO, Y; HAYAKAWA, T; MATSUOKA, K; KAWAMORI, R; KAMADA, T; HORAI, S; NONAKA, I; HAGURA, R; AKANUMA, Y; YAZAKI, Y			A SUBTYPE OF DIABETES-MELLITUS ASSOCIATED WITH A MUTATION OF MITOCHONDRIAL-DNA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSULIN-RECEPTOR GENE; RESISTANCE; DEAFNESS	Background. Several families have been described in which a mutation of mitochondrial DNA, the substitution of guanine for adenine (A --> G) at position 3243 of leucine transfer RNA, is associated with diabetes mellitus and deafness. The prevalence, clinical features, and pathophysiology of diabetes with this mutation are largely undefined. Methods. We studied 55 patients with insulin-dependent diabetes mellitus (IDDM) and a family history of diabetes (group 1), 85 patients with IDDM and no family history of diabetes (group 2), 100 patients with non-insulin-dependent diabetes mellitus (NIDDM) and a family history of diabetes (group 3), and 5 patients with diabetes and deafness (group 4) for the mutation. We also studied the prevalence and characteristics of diabetes in 39 patients with a syndrome consisting of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes who were known to have the mutation and 127 of their relatives (group 5). Results. We identified 16 unrelated patients with diabetes associated with the A --> G mutation: 3 patients from group 1 (6 percent), 2 patients from group 3 (2 percent), 3 patients from group 4 (60 percent), and 8 patients from group 5 (21 percent). We also identified 16 additional subjects who had diabetes and the mutation among 42 relatives of the patients with diabetes and the mutation in groups 1, 2, 3, and 4 and 20 affected subjects among the 127 relatives of the patients in group 5. Diabetes cosegregated with the mutation in a fashion consistent with maternal transmission, was frequently (in 61 percent of cases) associated with sensory hearing loss, and was generally accompanied by impaired insulin secretion. Conclusions. Diabetes mellitus associated with the A --> G mutation at position 3243 of mitochondrial leucine transfer RNA represents a subtype of diabetes found in both patients with IDDM and patients with NIDDM in Japan.	ASAHI LIFE FDN,INST DIABET CARE & RES,TOKYO,JAPAN; NATL INST NEUROSCI,DIV ULTRASTRUCT RES,KODAIRA,JAPAN; CHIBA CHILDRENS HOSP,CHIBA,JAPAN; JICHI MED SCH,DEPT ENDOCRINOL & METAB,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; SAISEIKAI CENT HOSP,TOKYO,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED 1,OSAKA,JAPAN; NATL INST GENET,MISHIMA,JAPAN	Asahi Life Foundation; National Center for Neurology & Psychiatry - Japan; Chiba Children's Hospital; Jichi Medical University; Tokyo Saiseikai Central Hospital; Osaka University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	KADOWAKI, T (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.			Awata, Takuya/0000-0003-2622-8129				[Anonymous], 1985, WHO TECH REP SER, V727, P1; ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; ETO K, 1993, DIABETES, V42, P1133, DOI 10.2337/diabetes.42.8.1133; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1992, NATURE, V357, P607, DOI 10.1038/357607c0; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; KADOWAKI H, 1993, LANCET, V341, P893, DOI 10.1016/0140-6736(93)93101-6; KADOWAKI T, 1984, DIABETOLOGIA, V26, P44, DOI 10.1007/BF00252262; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KAWAMORI R, 1991, J NUTR SCI VITAMINOL, V37, pS35, DOI 10.3177/jnsv.37.Supplement_S35; KOBAYASHI T, 1987, DIABETES, V36, P510, DOI 10.2337/diabetes.36.4.510; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953	21	486	496	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	1994	330	14					962	968		10.1056/NEJM199404073301403	http://dx.doi.org/10.1056/NEJM199404073301403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND793	8121460	Bronze			2022-12-01	WOS:A1994ND79300003
J	TORRES, CF; REBSAMEN, S; SILBER, JH; SUTTON, LN; BILANIUK, LT; ZIMMERMAN, RA; GOLDWEIN, JW; PHILLIPS, PC; LANGE, BJ				TORRES, CF; REBSAMEN, S; SILBER, JH; SUTTON, LN; BILANIUK, LT; ZIMMERMAN, RA; GOLDWEIN, JW; PHILLIPS, PC; LANGE, BJ			SURVEILLANCE SCANNING OF CHILDREN WITH MEDULLOBLASTOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDHOOD BRAIN-TUMORS; RECURRENT MEDULLOBLASTOMA; NEUROECTODERMAL TUMORS; ADJUVANT CHEMOTHERAPY; VINCRISTINE; MYELOGRAPHY; EFFICACY; DISEASE; THERAPY; CCNU	Background. The standard follow-up care for children with medulloblastoma includes regular clinical evaluations and surveillance scanning of the central nervous system with computed tomography or magnetic resonance imaging. The evaluations and scanning assess the response of the tumor to treatment, detect any recurrence of disease, and monitor any complications of treatment. We compared the effectiveness of a periodic history taking and physical examination with that of surveillance scanning in detecting recurrent tumors. Methods. We reviewed the medical records, including 794 scanning reports or scans, of 86 children with posterior fossa medulloblastoma who were followed regularly between 1980 and 1991. Recurrent tumors were classified as symptomatic if neuroimaging studies had been prompted by clinical symptoms or signs and as radiographic if the tumor had been detected by imaging in an asymptomatic patient. Results. Twenty-three of the 86 children (27 percent) had a recurrence of tumor. Four recurrences (17 percent) were detected on scanning only, and 19 (83 percent) were associated with symptoms arising a median of four months after the previous scan. The median and range of survival after a recurrence of the tumor were 5 months and <1 to 38 months, respectively, for a symptomatic recurrence and 20 months and 10 to 32 months, respectively, for a radiographic recurrence (P = 0.03). No patient survived after a recurrence. The longer survival of patients with recurrent tumors detected by scanning most likely reflects the small number of patients and lead-time and length biases associated with screening. Conclusions. Among children with medulloblastoma, surveillance scanning is of little clinical value. Scanning detected a minority of recurrences, and no patient who had a recurrence survived.	UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT PEDIAT,DIV ONCOL,PHILADELPHIA,PA 19104; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT NEUROL,PHILADELPHIA,PA; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT NEUROSURG,PHILADELPHIA,PA; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT RADIOL,PHILADELPHIA,PA; HOSP UNIV PENN,SCH MED,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA; HOSP UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA; HOSP UNIV PENN,SCH MED,DEPT RADIAT THERAPY,PHILADELPHIA,PA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine					NATIONAL CANCER INSTITUTE [K04CA001480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031102] Funding Source: NIH RePORTER; NCI NIH HHS [KO4 CA01480] Funding Source: Medline; NINDS NIH HHS [NS31102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHMSON TG, 1992, MED PEDIATR ONCOL, V20, P381; ALLEN JC, 1987, J CLIN ONCOL, V5, P459, DOI 10.1200/JCO.1987.5.3.459; ALLEN JC, 1982, J NEUROSURG, V57, P446, DOI 10.3171/jns.1982.57.4.0446; BAILAR JC, 1976, ANN INTERN MED, V84, P77, DOI 10.7326/0003-4819-84-1-77; CAIRNCROSS JG, 1985, ANN NEUROL, V17, P570; COHEN BH, 1989, NEUROLOGY, V39, P1178, DOI 10.1212/WNL.39.9.1178; Conover W. J., 1980, PRACTICAL NONPARAMET, P278; CRAFTS DC, 1978, J NEUROSURG, V49, P589, DOI 10.3171/jns.1978.49.4.0589; DEUTSCH M, 1985, CANCER, V56, P1763, DOI 10.1002/1097-0142(19851001)56:7+<1763::AID-CNCR2820561306>3.0.CO;2-6; Elterman R. D., 1993, Pediatric Neurosurgery, V19, P322; EVANS AE, 1990, J NEUROSURG, V72, P572, DOI 10.3171/jns.1990.72.4.0572; FRIEDMAN HS, 1986, NEUROSURGERY, V18, P335, DOI 10.1227/00006123-198603000-00014; FRIEDMAN HS, 1987, J NEURO-ONCOL, V5, P217, DOI 10.1007/BF00151225; GEYER JR, 1988, J CLIN ONCOL, V6, P996, DOI 10.1200/JCO.1988.6.6.996; GOLDWEIN JW, 1993, CANCER, V71, P2647, DOI 10.1002/1097-0142(19930415)71:8<2647::AID-CNCR2820710833>3.0.CO;2-S; KRAMER ED, 1991, NEUROLOGY, V41, P46, DOI 10.1212/WNL.41.1.46; KUN LE, 1985, CANCER-AM CANCER SOC, V56, P1818, DOI 10.1002/1097-0142(19851001)56:7+<1818::AID-CNCR2820561320>3.0.CO;2-9; LEFKOWITZ IB, 1990, CANCER-AM CANCER SOC, V65, P412, DOI 10.1002/1097-0142(19900201)65:3<412::AID-CNCR2820650306>3.0.CO;2-4; MISER J, 1989, P AN M AM SOC CLIN, V8, P84; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; PACKER RJ, 1991, J NEUROSURG, V74, P433, DOI 10.3171/jns.1991.74.3.0433; PACKER RJ, 1988, ANN NEUROL, V24, P503, DOI 10.1002/ana.410240405; ROGERS PCJ, 1984, LANCET, V1, P1320; RORKE LB, 1985, CANCER-AM CANCER SOC, V56, P1869, DOI 10.1002/1097-0142(19851001)56:7+<1869::AID-CNCR2820561330>3.0.CO;2-0; SNEDECOR GW, 1980, STATISTICAL METHODS, P96; VANEYS J, 1988, J PEDIATR-US, V113, P601, DOI 10.1016/S0022-3476(88)80662-0; YACHNIS AT, 1992, AM J SURG PATHOL, V16, P998, DOI 10.1097/00000478-199210000-00011; ZELEN M, 1969, BIOMETRIKA, V56, P601, DOI 10.2307/2334668; ZIMMERMAN RA, 1987, PROG EXP TUMOR RES, V30, P61	29	147	147	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	1994	330	13					892	895		10.1056/NEJM199403313301303	http://dx.doi.org/10.1056/NEJM199403313301303			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC608	8114859				2022-12-01	WOS:A1994NC60800003
J	NOUEIRY, AO; LUCAS, WJ; GILBERTSON, RL				NOUEIRY, AO; LUCAS, WJ; GILBERTSON, RL			2 PROTEINS OF A PLANT DNA VIRUS COORDINATE NUCLEAR AND PLASMODESMAL TRANSPORT	CELL			English	Article							GOLDEN MOSAIC-VIRUS; BEAN-INFECTING GEMINIVIRUSES; NICOTIANA-BENTHAMIANA; SYSTEMIC INFECTION; MOVEMENT PROTEIN; COAT PROTEIN; RIBONUCLEOPROTEINS; EXPORT	Plant viruses establish a systemic infection by moving through plasmodesmata, but little is known of the mechanism(s) involved. The roles of two movement-associated proteins of a single-stranded DNA virus were investigated in vivo, using functional proteins expressed in E. coli and microinjection into plant cells. We report here that the all protein of bean dwarf mosaic geminivirus moves extensively from cell to cell, increases mesophyll plasmodesmal size exclusion limit, and potentiates the movement of double-stranded DNA from cell to cell. Movement of single and double-stranded DNA out of the nucleus is mediated by the BR1 protein. These results provide direct experimental evidence for intercellular macromolecular transport in plants, and suggest that the BR1 and BL1 proteins coordinate the movement of viral DNA across both nuclear and plasmodesmal boundaries.	UNIV CALIF DAVIS,DIV BIOL SCI,PLANT BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis	NOUEIRY, AO (corresponding author), UNIV CALIF DAVIS,DEPT PLANT PATHOL,DAVIS,CA 95616, USA.							AMABILECUEVAS CF, 1993, AM SCI, V81, P332; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BROUGH CL, 1988, J GEN VIROL, V69, P503, DOI 10.1099/0022-1317-69-3-503; DEOM CM, 1992, CELL, V69, P221, DOI 10.1016/0092-8674(92)90403-Y; ELMER S, 1990, NUCLEIC ACIDS RES, V18, P2001, DOI 10.1093/nar/18.8.2001; ETESSAMI P, 1988, NUCLEIC ACIDS RES, V16, P4811, DOI 10.1093/nar/16.11.4811; ETESSAMI P, 1989, J GEN VIROL, V70, P277, DOI 10.1099/0022-1317-70-2-277; GARDINER WE, 1988, EMBO J, V7, P899, DOI 10.1002/j.1460-2075.1988.tb02894.x; GILBERTSON RL, 1991, PLANT DIS, V75, P336, DOI 10.1094/PD-75-0336; GILBERTSON RL, 1993, J GEN VIROL, V74, P23, DOI 10.1099/0022-1317-74-1-23; GILBERTSON RL, 1991, PHYTOPATHOLOGY, V81, P980, DOI 10.1094/Phyto-81-980; GLAZER AN, 1992, NATURE, V359, P859, DOI 10.1038/359859a0; HARRISON BD, 1985, ANNU REV PHYTOPATHOL, V23, P55, DOI 10.1146/annurev.py.23.090185.000415; HIDAYAT SH, 1993, PHYTOPATHOLOGY, V83, P181, DOI 10.1094/Phyto-83-181; HULL R, 1989, ANNU REV PHYTOPATHOL, V27, P213; LAZAROWITZ SG, 1992, CRIT REV PLANT SCI, V11, P327, DOI 10.1080/07352689209382350; Lucas William J., 1993, Trends in Cell Biology, V3, P308, DOI 10.1016/0962-8924(93)90013-Q; MALYSHENKO SI, 1993, J GEN VIROL, V74, P1149, DOI 10.1099/0022-1317-74-6-1149; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; MORALES F, 1990, PHYTOPATHOLOGY, V80, P96, DOI 10.1094/Phyto-80-96; Oparka K J, 1993, Semin Cell Biol, V4, P131, DOI 10.1006/scel.1993.1016; PASCAL E, 1993, PLANT CELL, V5, P795, DOI 10.1105/tpc.5.7.795; PATEL VP, 1993, NUCLEIC ACIDS RES, V21, P1325, DOI 10.1093/nar/21.5.1325; REY O, 1992, J VIROL, V66, P5815, DOI 10.1128/JVI.66.10.5815-5824.1992; ROBARDS AW, 1990, ANNU REV PLANT PHYS, V41, P369, DOI 10.1146/annurev.pp.41.060190.002101; Stanley J., 1991, Seminars in Virology, V2, P139; VANLENT J, 1991, J GEN VIROL, V72, P2615, DOI 10.1099/0022-1317-72-11-2615; VONARNIM A, 1993, VIROLOGY, V192, P264, DOI 10.1006/viro.1993.1029; VONARNIM A, 1992, VIROLOGY, V187, P555, DOI 10.1016/0042-6822(92)90458-2; WICK RA, 1989, BIOTECHNIQUES, V7, P262; WOLF S, 1989, SCIENCE, V246, P377, DOI 10.1126/science.246.4928.377; XIONG Z, 1993, VIROLOGY, V193, P213, DOI 10.1006/viro.1993.1117	32	310	327	1	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					925	932		10.1016/0092-8674(94)90366-2	http://dx.doi.org/10.1016/0092-8674(94)90366-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124726				2022-12-01	WOS:A1994NA89000017
J	SANSONETTI, PJ; MOUNIER, J; PREVOST, MC; MEGE, RM				SANSONETTI, PJ; MOUNIER, J; PREVOST, MC; MEGE, RM			CADHERIN EXPRESSION IS REQUIRED FOR THE SPREAD OF SHIGELLA-FLEXNERI BETWEEN EPITHELIAL-CELLS	CELL			English	Article							ADHESION MOLECULES; LISTERIA-MONOCYTOGENES; INTERCELLULAR SPREAD; ACTIN-FILAMENTS; HELA-CELLS; F-ACTIN; MOVEMENT; POLYMERIZATION; PROTEIN; CACO-2	Shigella flexneri, a gram-negative pathogen, invades the human colonic epithelium. After entering epithelial cells, bacteria escape into the cytoplasm, move intracellularly, and pass from cell to cell. The bacterium diverts actin and associated actin-binding proteins to generate a cytoskeleton-based motor that pushes forward the bacterium. As the moving bacterium reaches the inner face of the host-cell cytoplasmic membrane, a protrusion forms that allows passage of this bacterium into a neighboring cell. We show here that components of the intermediate junction are used by the bacterium to allow this passage. Using S180, a mouse fibroblastic sarcoma cell line that does not produce cell adhesion molecules (CAM), and S180L and S180cadN, the same cell line transfected with L-CAM and N-cadherin cDNA, respectively, we demonstrate that expression of a cadherin is required for cell-to-cell spread to occur.	INST PASTEUR,CENT MICROSCOPIE ELECTR STN,F-75724 PARIS 15,FRANCE; INSERM,U153,F-75005 PARIS,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	SANSONETTI, PJ (corresponding author), INST PASTEUR,INSERM,U389,UNITE PATHOGENIE MICROBIENNE MOLEC,28 RUE DR ROUX,PARIS,FRANCE.		Mege, Rene Marc/M-9569-2013	Mege, Rene-Marc/0000-0001-8128-5543				ALLAOUI A, 1992, MOL MICROBIOL, V6, P1605, DOI 10.1111/j.1365-2958.1992.tb00885.x; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; BOLLER K, 1985, J CELL BIOL, V100, P327, DOI 10.1083/jcb.100.1.327; BOYER B, 1989, J MEMBRANE BIOL, V112, P97, DOI 10.1007/BF01871271; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; DHAUTEVILLE H, 1992, MOL MICROBIOL, V6, P833, DOI 10.1111/j.1365-2958.1992.tb01534.x; DOMMAN E, 1992, EMBO J, V11, P1981; DUNHAM LJ, 1953, JNCI-J NATL CANCER I, V13, P1299; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; GALLIN WJ, 1983, P NATL ACAD SCI-BIOL, V80, P1038, DOI 10.1073/pnas.80.4.1038; GEIGER B, 1991, Current Biology, V1, P237, DOI 10.1016/0960-9822(91)90068-8; GOLDBERG M, 1993, IN PRESS J BACTERIOL; HALE TL, 1979, INFECT IMMUN, V24, P879, DOI 10.1128/IAI.24.3.879-886.1979; HALE TL, 1979, INFECT IMMUN, V24, P887, DOI 10.1128/IAI.24.3.887-894.1979; HATTA K, 1987, DEV BIOL, V120, P215, DOI 10.1016/0012-1606(87)90119-9; KADURUGAMUWA JL, 1991, INFECT IMMUN, V59, P3663; KEMLER R, 1989, BIOESSAYS, V11, P88, DOI 10.1002/bies.950110403; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; LABREC EH, 1964, J BACTERIOL, V88, P1503, DOI 10.1128/JB.88.5.1503-1518.1964; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MOUNIER J, 1990, INFECT IMMUN, V58, P1048, DOI 10.1128/IAI.58.4.1048-1058.1990; MOUNIER J, 1992, INFECT IMMUN, V60, P237, DOI 10.1128/IAI.60.1.237-248.1992; OAKS EV, 1985, INFECT IMMUN, V48, P124, DOI 10.1128/IAI.48.1.124-129.1985; OGAWA H, 1968, JPN J MED SCI BIOL, V21, P259, DOI 10.7883/yoken1952.21.259; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PAL T, 1989, INFECT IMMUN, V57, P477; PREVOST MC, 1992, INFECT IMMUN, V60, P4088; SANGER JM, 1992, INFECT IMMUN, V60, P3509; SANSONETTI PJ, 1991, VACCINE, V9, P416, DOI 10.1016/0264-410X(91)90128-S; SANSONETTI PJ, 1986, INFECT IMMUN, V51, P461, DOI 10.1128/IAI.51.2.461-469.1986; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Theriot Julie A., 1992, Current Biology, V2, P649, DOI 10.1016/0960-9822(92)90115-Q; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; VASSELON T, 1992, INFECT IMMUN, V60, P1031, DOI 10.1128/IAI.60.3.1031-1040.1992; VASSELON T, 1991, INFECT IMMUN, V59, P1723, DOI 10.1128/IAI.59.5.1723-1732.1991; VOLK T, 1986, J CELL BIOL, V103, P1441, DOI 10.1083/jcb.103.4.1441	42	129	130	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					829	839		10.1016/0092-8674(94)90358-1	http://dx.doi.org/10.1016/0092-8674(94)90358-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124719				2022-12-01	WOS:A1994NA89000009
J	DACEY, DM; LEE, BB				DACEY, DM; LEE, BB			THE BLUE-ON OPPONENT PATHWAY IN PRIMATE RETINA ORIGINATES FROM A DISTINCT BISTRATIFIED GANGLION-CELL TYPE	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; MACAQUE RETINA; BIPOLAR CELLS; MONKEY RETINA; RHESUS-MONKEY; COLOR-VISION; CONE INPUTS; SENSITIVITY; MORPHOLOGY; NEURONS	COLOUR vision in humans and Old World monkeys begins with the differential activation of three types of cone photoreceptor which are maximally sensitive to short (S), medium (M) and long (L) wavelengths. Signals from the three cone types are relayed to the retinal ganglion cells via cone-specific bipolar cell types1-4. Colour-coding ganglion cells fall into two major physiological classes: the red-green opponent cells, which receive antagonistic input from M- and L-sensitive cones, and the blue-yellow opponent cells, which receive input from S-sensitive cones, opposed by combined M- and L-cone input. The neural mechanisms producing colour opponency are not understood. It has been assumed that both kinds of opponent signals are transmitted to the lateral geniculate nucleus by one type of ganglion cell, the midget cell5,6. We now report that a distinct non-midget ganglion cell type, the small bistratified cell, corresponds to the physiological type that receives excitatory input from S cones, the 'blue-on' cell. Our results thus demonstrate an anatomically distinct pathway that conveys S-cone signals to the brain. The morphology of the blue-on cell also suggest a novel hypothesis for the retinal circuitry underlying the blue-yellow opponent response.	MAX PLANCK INST BIOPHYS CHEM, D-37077 GOTTINGEN, GERMANY	Max Planck Society	DACEY, DM (corresponding author), UNIV WASHINGTON, DEPT BIOL STRUCT, SEATTLE, WA 98195 USA.			Dacey, Dennis/0000-0001-8476-5585				BOYCOTT BB, 1991, EUR J NEUROSCI, V3, P1069, DOI 10.1111/j.1460-9568.1991.tb00043.x; DACEY DM, 1988, SCIENCE, V240, P1196, DOI 10.1126/science.3375811; DACEY DM, 1993, VISUAL NEUROSCI, V10, P1081, DOI 10.1017/S0952523800010191; DACEY DM, 1992, VISUAL NEUROSCI, V9, P279, DOI 10.1017/S0952523800010695; DACEY DM, 1993, J NEUROSCI, V13, P5334, DOI 10.1523/JNEUROSCI.13-12-05334.1993; DACHEUX RF, 1990, PROC R SOC SER B-BIO, V239, P213, DOI 10.1098/rspb.1990.0014; DEMONASTERIO FM, 1979, BRAIN RES, V166, P39, DOI 10.1016/0006-8993(79)90647-4; DEMONASTERIO FM, 1975, J PHYSIOL-LONDON, V251, P167, DOI 10.1113/jphysiol.1975.sp011086; FAMIGLIETTI EV, 1976, SCIENCE, V194, P193, DOI 10.1126/science.959847; KOUYAMA N, 1992, J NEUROSCI, V12, P1233; LEE BB, 1988, J PHYSIOL-LONDON, V404, P323, DOI 10.1113/jphysiol.1988.sp017292; LEVENTHAL AG, 1981, SCIENCE, V213, P1139, DOI 10.1126/science.7268423; MARIANI AP, 1984, NATURE, V308, P184, DOI 10.1038/308184a0; Mollon J.D., 1990, P119; MOLLON JD, 1989, J EXP BIOL, V146, P21; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; PERRY VH, 1984, NEUROSCIENCE, V12, P1101, DOI 10.1016/0306-4522(84)90006-X; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; RODIECK RW, 1991, NATO ADV SCI I A-LIF, V203, P83; SCHILLER PH, 1978, J NEUROPHYSIOL, V41, P788, DOI 10.1152/jn.1978.41.3.788; SMITH VC, 1975, VISION RES, V15, P161, DOI 10.1016/0042-6989(75)90203-5; SWANSON WH, 1987, J OPT SOC AM A, V4, P1992, DOI 10.1364/JOSAA.4.001992; TSO DY, 1988, J NEUROSCI, V8, P1712; VALBERG A, 1986, VISION RES, V26, P1061, DOI 10.1016/0042-6989(86)90040-4; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115; Wyszecki Gunter, 1982, COLOR SCI, V8; ZRENNER E, 1981, VISION RES, V21, P1605, DOI 10.1016/0042-6989(81)90042-0; ZRENNER E, 1983, BRAIN RES, V262, P181, DOI 10.1016/0006-8993(83)91007-7	28	516	530	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					731	735		10.1038/367731a0	http://dx.doi.org/10.1038/367731a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107868				2022-12-01	WOS:A1994MX63100057
J	RODRIGUEZ, LAG; JICK, H				RODRIGUEZ, LAG; JICK, H			RISK OF GYNECOMASTIA ASSOCIATED WITH CIMETIDINE, OMEPRAZOLE, AND OTHER ANTIULCER	BRITISH MEDICAL JOURNAL			English	Article							GYNECOMASTIA; THERAPY	Objective-To study the risk of gynaecomastia associated with cimetidine, misoprostol, omeprazole and ranitidine. Design-Open cohort study with nested case-control analysis. Setting-General practices in United Kingdom that had computerised offices, 1989-92. Subjects-81 535 men aged 25-84 years who received at least one prescription for cimetidine, misoprostol, omeprazole, or ranitidine during the study period. Main outcome measures-New occurrences of idiopathic gynaecomastia diagnosed by general practitioner. Results-The relative risk of gynaecomastia for current users of cimetidine compared with non-users was 7.2 (95% confidence interval 1.5 to 11.3). Relative risks for misoprostol, omeprazole, and ranitidine were 2.0 (0.1 to 10.7), 0.6 (0.1 to 3.3), and 1.5 (0.8 to 2.6), respectively. Current users of cimetidine on a daily dose greater than or equal to 1000 mg had more than 40 times the risk of developing gynaecomastia than non-users. The period of highest risk was seven to 12 months after starting cimetidine treatment. Spironolactone (relative risk 9.3 (3.3 to 26.1)) and verapamil (9.7 (2.6 to 36.0)) were associated with a relative risk of gynaecomastia comparable to one for cimetidine. Conclusions-Use of cimetidine, but not the three other antiulcer drugs, is associated with a substantially greater risk of gynaecomastia in men. A strong dose-response relation was present among cimetidine users.			RODRIGUEZ, LAG (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,LEXINGTON,MA 02173, USA.		rodriguez, luis a garcia/B-1980-2010	Jick, Hershel/0000-0003-4270-5992				BRAUNSTEIN GD, 1993, NEW ENGL J MED, V328, P490; CARLSON HE, 1980, NEW ENGL J MED, V303, P795, DOI 10.1056/NEJM198010023031405; CONVENS C, 1991, LANCET, V338, P1153, DOI 10.1016/0140-6736(91)92018-W; DELLEFAVE GF, 1977, LANCET, V1, P1319; GALBRAITH RA, 1989, NEW ENGL J MED, V321, P269, DOI 10.1056/NEJM198908033210501; GALBRAITH RA, 1993, PHARMACOLOGY, V47, P8, DOI 10.1159/000139072; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; JENSEN RT, 1983, NEW ENGL J MED, V308, P883, DOI 10.1056/NEJM198304143081508; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; LINDQUIST M, 1992, BRIT MED J, V305, P451, DOI 10.1136/bmj.305.6851.451; MIGNON M, 1982, LANCET, V2, P499; NUTTALL FQ, 1979, J CLIN ENDOCR METAB, V48, P338, DOI 10.1210/jcem-48-2-338; PAYNE CD, 1986, GENERALIZED LINEAR I; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P311; SANTUCCI L, 1991, NEW ENGL J MED, V324, P635; SPENCE RW, 1979, GUT, V20, P154, DOI 10.1136/gut.20.2.154; TOSTI S, 1982, LANCET, V2, P160; Walker AM, 1991, OBSERVATION INFERENC	19	57	58	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 19	1994	308	6927					503	506		10.1136/bmj.308.6927.503	http://dx.doi.org/10.1136/bmj.308.6927.503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX814	8136667	Green Published			2022-12-01	WOS:A1994MX81400020
J	HALLAM, L				HALLAM, L			PRIMARY MEDICAL-CARE OUTSIDE NORMAL WORKING HOURS - REVIEW OF PUBLISHED WORK	BRITISH MEDICAL JOURNAL			English	Review							GENERAL-PRACTICE; HOURS CALLS; DEPUTIZING SERVICES; EMERGENCY DEPARTMENTS; TELEPHONE ADVICE; MENTAL-HEALTH; 24-HOUR CARE; INNER CITIES; JOB STRESS; EAST-END	Fundamental changes in the delivery of primary medical care outside normal surgery hours are under consideration in Great Britain. Published research into the provision and utilisation of out of hours services shows long term trends towards decreasing personal committment among general practitioners and rising demand from patients for primary and hospital accident and emergency department care. Wide variations exist regionally, locally, and between practices. Previous studies, however, have been limited in scope and provide an inadequate basis for assessing the potential impact of change. The overall demand for care across all sources of provision cannot be measured: there is a lack of data on costs, and evaluative studies comparing alternative patterns of service delivery have rarely been undertaken. A period of experimentation and evaluation of a range of options should precede the wider adoption of any particular models.			HALLAM, L (corresponding author), UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,CTR PRIMARY CARE,MANCHESTER M14 5NP,ENGLAND.							BAIN DJG, 1984, BRIT MED J, V289, P471, DOI 10.1136/bmj.289.6443.471; BARLEY SL, 1979, J R COLL GEN PRACT, V29, P752; BLAIR JSG, 1986, J ROY COLL GEN PRACT, V36, P359; BOLLAM MJ, 1988, BRIT MED J, V296, P829, DOI 10.1136/bmj.296.6625.829; BOWLING A, 1987, FAM PRACT, V4, P85, DOI 10.1093/fampra/4.2.85; BRACKENBURY PH, 1985, HLTH TRENDS, V17, P31; BUXTON MJ, 1977, BRIT MED J, V1, P827, DOI 10.1136/bmj.1.6064.827; CALNAN M, 1982, J SOC POLICY, V11, P483, DOI 10.1017/S0047279400022546; CALNAN M, 1984, Journal of Emergency Medicine, V2, P57, DOI 10.1016/0736-4679(84)90049-0; CALNAN M, 1985, SOCIAL HLTH ILLNESS, V5, P149; CARLISLE RD, 1993, BRIT MED J, V306, P1383, DOI 10.1136/bmj.306.6889.1383; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; CAVANAGH AUJM, 1978, BRIT MED J, V2, P34; COHEN J, 1987, FAM PRACT, V4, P81, DOI 10.1093/fampra/4.2.81; COOPER CL, 1989, BRIT MED J, V298, P366, DOI 10.1136/bmj.298.6670.366; CREIGHTON PA, 1982, BRIT MED J, V284, P1090, DOI 10.1136/bmj.284.6322.1090; CROWE MGF, 1976, BRIT MED J, V1, P1582, DOI 10.1136/bmj.1.6025.1582; CUBITT T, 1983, BRIT MED J, V287, P28, DOI 10.1136/bmj.287.6384.28; Cunningham R J, 1980, J R Coll Gen Pract, V30, P745; DAVIES T, 1986, BRIT MED J, V292, P241, DOI 10.1136/bmj.292.6515.241; DAVISON AG, 1983, J ROY SOC MED, V76, P37, DOI 10.1177/014107688307600109; DEER B, 1983, SUNDAY TIMES, V8; DIXON RA, 1988, BRIT MED J, V297, P1519, DOI 10.1136/bmj.297.6662.1519; DIXON RA, 1977, BRIT MED J, V1, P560, DOI 10.1136/bmj.1.6060.560; DRISCOLL PA, 1987, ARCH EMERG MED, V4, P77; FARMER RDT, 1982, RELATIONSHIP USES AC; FEARN R, 1987, SOC SCI MED, V24, P263, DOI 10.1016/0277-9536(87)90053-0; FEGER H, 1992, PULSE           0516, P3; FEGER H, 1992, PULSE           0704, P1; FOROUGHI D, 1989, PRACTITIONER, V233, P657; Fry J, 1984, NHS DATA BOOK; Gabriel R, 1976, J R Coll Gen Pract, V26, P74; GADSBY R, 1987, J ROY COLL GEN PRACT, V37, P462; GILBERT JR, 1978, PRACTITIONER, V220, P21; GRANT JA, 1984, BMJ-BRIT MED J, V288, P1366, DOI 10.1136/bmj.288.6427.1366; GRAVELLE HSE, 1980, DEPUTISING SERVICES; GREEN J, 1992, SOC SCI MED, V35, P987, DOI 10.1016/0277-9536(92)90238-L; Green J, 1991, Health Serv J, V101, P25; HALLAM L, 1992, OUT HOURS CARE GENER; HARRIS A, 1969, BRIT MED J, V298, P63; HOBBS FDR, 1991, BRIT MED J, V302, P329, DOI 10.1136/bmj.302.6772.329; HOBDAY PJ, 1984, BRIT MED J, V289, P663, DOI 10.1136/bmj.289.6446.663; HOBDAY PJ, 1988, J ROY COLL GEN PRACT, V38, P35; Jackson J, 1980, J R Coll Gen Pract, V30, P520; Jeffery R, 1979, Sociol Health Illn, V1, P90, DOI 10.1111/1467-9566.ep11006793; JONES H, 1992, PULSE           0704, P7; KNOX JDE, 1989, PRACTICAL GUIDES GEN, P9; LEWIS B, HLTH SOC SERVICES J, P1139; LINDEN M, 1993, PULSE           0925, P3; LIVINGSTONE AE, 1989, BRIT MED J, V299, P368, DOI 10.1136/bmj.299.6695.368; Lockstone D R, 1976, J R Coll Gen Pract, V26, P68; MAIN JA, 1989, BRIT MED J, V299, P627, DOI 10.1136/bmj.299.6699.627-b; MARSH GN, 1987, J ROY COLL GEN PRACT, V37, P301; MARSH GN, 1987, ARCH DIS CHILD, V62, P392, DOI 10.1136/adc.62.4.392; MAWHINNEY B, 1993, PULSE           1127, P15; MCCARTHY M, 1990, BRIT J GEN PRACT, V40, P19; MILNER PC, 1988, J EPIDEMIOL COMMUN H, V42, P274, DOI 10.1136/jech.42.3.274; MORRISON JM, 1991, BRIT MED J, V303, P1111, DOI 10.1136/bmj.303.6810.1111; MORRISON WG, 1991, BRIT J CLIN PRACT, V45, P95; MORTON DJ, 1979, J R COLL GEN PRACT, V29, P205; MUCKLE DS, 1973, BRIT MED J, V3, P699, DOI 10.1136/bmj.3.5882.699-c; Murray T S, 1977, J R Coll Gen Pract, V27, P209; MYERS P, 1982, J ROY SOC MED, V75, P879; MYERSON S, 1990, FAM PRACT, V7, P91, DOI 10.1093/fampra/7.2.91; MYERSON S, 1991, Medical Science Research, V19, P267; Naidoo A S, 1982, J R Coll Gen Pract, V32, P564; NGUYENVANTAM JS, 1992, BRIT MED J, V305, P157, DOI 10.1136/bmj.305.6846.157; ODWYER F, 1991, ARCH EMERG MED, V8, P196; OLIVER DJ, 1982, BRIT MED J, V284, P1195, DOI 10.1136/bmj.284.6323.1195; PEPIATT R, 1980, PRACTITIONER, V224, P11; PERRY JR, 1990, BRIT J GEN PRACT, V40, P190; PITTS J, 1988, J ROY COLL GEN PRACT, V38, P2; PITTS J, 1990, BRIT MED J, V300, P113; PRINCE A, J PUBLIC HLTH MED, V14, P177; PRUDHOE RH, 1984, BRIT MED J, V288, P718, DOI 10.1136/bmj.288.6418.718-a; Reilly P M, 1981, J R Coll Gen Pract, V31, P223; RIDDELL JA, 1980, BRIT MED J, V280, P1518, DOI 10.1136/bmj.280.6230.1518; RIDSDILLSMITH RM, 1983, UPDATE, V26, P274; ROLAND M, 1984, BRIT MED J, V289, P451, DOI 10.1136/bmj.289.6443.451; ROTH JA, 1972, AM J SOCIOL, V77, P839, DOI 10.1086/225227; SAWYER L, 1982, BRIT MED J, V284, P1531, DOI 10.1136/bmj.284.6328.1531; SHELDON MG, 1984, BRIT MED J, V289, P474, DOI 10.1136/bmj.289.6443.474; SIMPSON R, 1979, 6 ROYAL COMM NAT HLT; SINGH S, 1988, BRIT MED J, V297, P1179, DOI 10.1136/bmj.297.6657.1179; STEVENSON JSK, 1982, BRIT MED J, V284, P947, DOI 10.1136/bmj.284.6320.947; STYLES WM, 1983, J ROY COLL GEN PRACT, V33, P395; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545; TULLOCH AJ, 1984, PRACTITIONER, V228, P663; USHERWOOD TP, 1985, J ROY COLL GEN PRACT, V35, P395; WAKEFORD R, 1984, WORLD MED       0307, P17; WARRY R, 1993, GENERAL PRACTIT 1001, P11; WHITBY M, 1989, PRACTITIONER, V223, P493; WILKIN D, 1987, ANATOMY URGAN GENERA; WILLIAMS BT, 1985, BRIT MED J, V291, P1689, DOI 10.1136/bmj.291.6510.1689; WILLIAMS DJ, 1988, BRIT MED J, V296, P1197, DOI 10.1136/bmj.296.6630.1197; WOOD TCA, 1986, PUBLIC HEALTH, V100, P15; YATES DW, 1987, J ROYAL SOC HLTH, V4, P153; 1992, YOUR CHOICES SPECIAL; 1989, GENERAL PRACTICE NAT; 1976, J R COLL GEN PRACT, V26, P3; 1991, GENERAL MED PRACTITI; 1987, GENERAL MED PRACTITI; 1990, COMMUNITY HOSPITALS; 1993, SOCIAL TRENDS, V23; 1991, HLTH PERSONAL SOCIAL; HLTH CIRCULAR, V84; 1992, BR J GEN PRACT, V42, P90; 1992, PULSE           0404, P1; 1993, GENERAL PRACTIT 0730, P32; 1992, YOUR CHOICES FUTURE; 1984, BRIT MED J, V288, P1627; 1989, JR COLL GEN PRACT, V34, P362; 1984, OUT HOURS PATIENT CA	113	102	102	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 22	1994	308	6923					249	253		10.1136/bmj.308.6923.249	http://dx.doi.org/10.1136/bmj.308.6923.249			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT539	8111262	Green Published			2022-12-01	WOS:A1994MT53900024
J	LOPEZ, GA; JAN, YN; JAN, LY				LOPEZ, GA; JAN, YN; JAN, LY			EVIDENCE THAT THE S6 SEGMENT OF THE SHAKER VOLTAGE-GATED K+ CHANNEL COMPRISES PART OF THE PORE	NATURE			English	Article							POTASSIUM CHANNELS; SODIUM-CHANNELS; GIANT-AXONS; BARIUM IONS; INACTIVATION; BLOCK; DROSOPHILA; MUTATIONS; RECEPTOR; REGION	POTASSIUM channels are highly selective and allow the rapid flux of potassium ions through their pore1. Several studies have implicated the H5 (P or SS1-SS2) segment2,3 as part of the pore in voltage-gated ion channels4-10. The proposal that H5 spans at least 80% of the electric potential drop across the K+ channel pore5,11 is based on altered internal tetraethylammonium sensitivity arising from mutations of H5 residues that are 100% conserved among K+ channels having differing sensitivity to tetraethylammonium5-7,12,13. Here we report that the S6 segment is also involved in K+ ion permeation and in governing the sensitivity to internal tetraethylammonium and barium. Transplanting the S6 segment of NGK2 into Shaker causes this S6 chimaera to adopt the single-channel conductance and sensitivity to internal tetraethylammonium and barium ions from the NGK2 channel. The differences between NGK2 and Shaker in external tetraethylammonium sensitivity, but not single-channel conductance, can be attributed to the differences in their H5 sequences. Three non-conserved S6 residues have been found to affect either single-channel conductance or internal tetraethylammonium sensitivity.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	LOPEZ, GA (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,PARNASSUS & 3RD AVE,U-426,SAN FRANCISCO,CA 94143, USA.		lopez, george/W-4435-2019	Jan, Lily/0000-0003-3938-8498				ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1980, BIOPHYS J, V30, P473, DOI 10.1016/S0006-3495(80)85108-3; ARMSTRONG CM, 1982, J GEN PHYSIOL, V80, P663, DOI 10.1085/jgp.80.5.663; ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; ARMSTRONG CM, 1972, J GEN PHYSIOL, V59, P388, DOI 10.1085/jgp.59.4.388; BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; CHOI KL, 1993, NEURON, V10, P553; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1991, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; KIRSCH GE, 1991, AM J PHYSIOL, V261, pC583, DOI 10.1152/ajpcell.1991.261.4.C583; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; TAGLIALATELA M, 1991, MOL PHARMACOL, V40, P299; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	30	162	163	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 13	1994	367	6459					179	182		10.1038/367179a0	http://dx.doi.org/10.1038/367179a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114915				2022-12-01	WOS:A1994MQ78000063
J	GENEWEIN, A; TELENTI, A; BERNASCONI, C; MORDASINI, C; WEISS, S; MAURER, AM; RIEDER, HL; SCHOPFER, K; BODMER, T				GENEWEIN, A; TELENTI, A; BERNASCONI, C; MORDASINI, C; WEISS, S; MAURER, AM; RIEDER, HL; SCHOPFER, K; BODMER, T			MOLECULAR APPROACH TO IDENTIFYING ROUTE OF TRANSMISSION OF TUBERCULOSIS IN THE COMMUNITY	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MYCOBACTERIUM-TUBERCULOSIS; EPIDEMIOLOGY; OUTBREAK; TOOL; ELEMENT; POLYMORPHISMS; INFECTION; COMPLEX; STRAINS	There is growing concern that tuberculosis is spread in Europe in the way that it is in the USA. We have used DNA ''fingerprinting'' in a systematic evaluation of tuberculosis cases notified in our community to uncover foci of transmission. An IS6110 probe was used to test all isolates from culture-confirmed tuberculosis cases (163 patients) notified in 1991-92 in the Canton of Berne. In total, 45 patients (27.6%), potentially linked on the basis of restriction fragment length polymorphism, were investigated edepidemiologically. The largest group (n = 22) included members of a defined social group (drug addicts, homeless persons, alcoholics), from whom tuberculosis spread to the general population. A key patient developed multidrug-resistant tuberculosis during the surveillance period. This population study showed that (i) extensive transmission of Mycobacterium tuberculosis is now taking place in Europe in the same social setting as in the USA; (ii) there is definite ''spillover'' to the general population; (iii) the dimensions of the problem cannot be recognised easily by routine public health service activities because of the complexity of the transmission network; and (iv) multidrug-resistant tuberculosis develops in this setting.	UNIV BERN,INST MED MICROBIOL,FRIEDBUEHLSTR 51,CH-3010 BERN,SWITZERLAND; TIEFENAU HOSP,BERN,SWITZERLAND; CANTONAL LEAGUE AGAINST TB & LUNG DIS,BERN,SWITZERLAND; CANTONAL OFF PUBL HLTH,BERN,SWITZERLAND; FED OFF PUBL HLTH,LIEBEFELD,SWITZERLAND	University of Bern			Telenti, Amalio/AAY-1674-2021					ANNAS GJ, 1993, NEW ENGL J MED, V328, P585, DOI 10.1056/NEJM199302253280825; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; ISERMAN MD, 1993, NEW ENGL J MED, V328, P576; LAGUNA F, 1991, J INFECTION, V23, P139, DOI 10.1016/0163-4453(91)92016-X; MCADAM RA, 1990, MOL MICROBIOL, V4, P1607, DOI 10.1111/j.1365-2958.1990.tb02073.x; MULLER M, 1992, ZWANGSMASSNAHMEN INS; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; REVES R, 1981, AM J EPIDEMIOL, V113, P423, DOI 10.1093/oxfordjournals.aje.a113110; RIEDER HL, 1992, TUBERCLE LUNG DIS, V73, P181, DOI 10.1016/0962-8479(92)90082-U; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; THIERRY D, 1990, NUCLEIC ACIDS RES, V18, P188, DOI 10.1093/nar/18.1.188; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; VANSOOLINGEN D, 1992, RFLP ANAL MYCOBACTER; ZHANG YS, 1992, J CLIN MICROBIOL, V30, P1551, DOI 10.1128/JCM.30.6.1551-1556.1992; 1992, MMWR, V41, P1; 1991, MMWR, V40, P585; 1991, MMWR, V40, P869; 1991, B OFF FED SANTE PUBL, V35, P546	27	203	207	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					841	844		10.1016/0140-6736(93)92698-S	http://dx.doi.org/10.1016/0140-6736(93)92698-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104275				2022-12-01	WOS:A1993MA02500012
J	HERMANN, E; YU, DTY; ZUMBUSCHENFELDE, KHM; FLEISCHER, B				HERMANN, E; YU, DTY; ZUMBUSCHENFELDE, KHM; FLEISCHER, B			HLA-B27-RESTRICTED CD8 T-CELLS DERIVED FROM SYNOVIAL-FLUIDS OF PATIENTS WITH REACTIVE ARTHRITIS AND ANKYLOSING-SPONDYLITIS	LANCET			English	Article							REITERS-SYNDROME; CLONES; HLA-B27; LYMPHOCYTES; DISEASE; SELF	Ankylosing spondylitis and seronegative spondylarthropathies such as Reiter's syndrome and reactive arthritis are strongly associated with HLA-B27. However, the mechanisms by which HLA-B27 is involved in disease susceptibility and pathogenesis are unknown. If the disease association is a consequence of HLA-B27's physiological function in antigen presentation, the disease should be mediated by cytotoxic T lymphocytes (CTLs) that recognise bacterial or self peptides presented by HLA-B27. Proof of this arthritogenic peptide model requires isolation of B27-restricted CD8 T cells from arthritic joints of patients with spondylarthropathies. An important question is whether ''arthritogenic'' bacteria such as yersinia or salmonella can generate HLA-B27-restricted bacteria-specific CTLs. We describe such HLA-B27-restricted CTLs. We tested a panel of 354 alphabeta-TCR CD8 T lymphocyte clones (TLCs) that had been derived from the synovial fluid of 4 patients with reactive arthritis and 2 patients with ankylosing spondylitis. In 1 patient with yersinia-induced arthritis, 2 TLCs were identified that killed specifically yersinia-infected B27 target cells. In another patient with salmonella-induced arthritis, 1 B27-restricted CD8 TLC that recognised both salmonella and yersinia was identified. In 5 of the 6 patients autoreactive CTLs were found, 5 of which showed B27-restricted killing of uninfected cell lines. B27-restricted CTLs with specificity for arthritogenic bacteria or autoantigens provide a missing link in the pathogenesis of the HLA-B27-associated spondylarthropathies.	UNIV CALIF LOS ANGELES,DEPT MED,DIV RHEUMATOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	HERMANN, E (corresponding author), JOHANNES GUTENBERG UNIV,DEPT MED 1,LANGENBECKSTR 1,D-55101 MAINZ,GERMANY.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR040919] Funding Source: NIH RePORTER; NIAMS NIH HHS [NIAMS P01 AR40919] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahvonen P, 1969, Acta Rheumatol Scand, V15, P232; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BENJAMIN R, 1992, RHEUM DIS CLIN N AM, V18, P11; BIJLSMA JWJ, 1988, ANN RHEUM DIS, V47, P350, DOI 10.1136/ard.47.4.350-b; BRANCATO L, 1989, RHEUMATOL INT, V9, P137; BUCHMEIER NA, 1990, SCIENCE, V248, P730, DOI 10.1126/science.1970672; EDWARDS PAW, 1982, EUR J IMMUNOL, V12, P641, DOI 10.1002/eji.1830120804; GAMMON G, 1991, IMMUNOL TODAY, V12, P193, DOI 10.1016/0167-5699(91)90052-U; GUMPEL JM, 1981, ANN RHEUM DIS, V40, P64, DOI 10.1136/ard.40.1.64; HASSELL AB, 1992, CLIN EXP IMMUNOL, V88, P442; HERMANN E, 1992, CLIN EXP IMMUNOL, V89, P427; HERMANN E, 1992, J RHEUMATOL, V19, P1243; HERMANN E, 1990, SCAND J RHEUMATOL, V19, P350, DOI 10.3109/03009749009096790; HERMANN E, 1992, CELL IMMUNOL, V143, P253, DOI 10.1016/0008-8749(92)90023-I; HERMANN E, 1989, CLIN EXP IMMUNOL, V75, P365; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAPASI K, 1992, J IMMUNOL, V148, P3554; KEAT A, 1983, NEW ENGL J MED, V309, P1606, DOI 10.1056/NEJM198312293092604; KINGSLEY G, 1992, RHEUM DIS CLIN N AM, V18, P49; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; SCHLAAK J, 1992, EUR J IMMUNOL, V22, P2771, DOI 10.1002/eji.1830221103; VARTIAINEN J, 1964, ACTA MED SCAND, V175, P771; VINER NJ, 1991, ARTHRITIS RHEUM, V34, P1151, DOI 10.1002/art.1780340911	24	304	309	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					646	650		10.1016/0140-6736(93)91760-J	http://dx.doi.org/10.1016/0140-6736(93)91760-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103147				2022-12-01	WOS:A1993LX27200011
J	MCGRATH, R				MCGRATH, R			TRADING IN DEATH - ANTI-PERSONNEL MINES	LANCET			English	Editorial Material											MCGRATH, R (corresponding author), MINES ADVISORY GRP,COCKERMOUTH,CUMBRIA,ENGLAND.								0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					628	629		10.1016/0140-6736(93)91751-7	http://dx.doi.org/10.1016/0140-6736(93)91751-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103138				2022-12-01	WOS:A1993LX27200002
J	HARRIS, DN; BAILEY, SM; SMITH, PLC; TAYLOR, KM; OATRIDGE, A; BYDDER, GM				HARRIS, DN; BAILEY, SM; SMITH, PLC; TAYLOR, KM; OATRIDGE, A; BYDDER, GM			BRAIN-SWELLING IN 1ST HOUR AFTER CORONARY-ARTERY BYPASS-SURGERY	LANCET			English	Note							RESONANCE	Six patients undergoing routine coronary artery bypass surgery were examined by magnetic resonance imaging of the brain before surgery, immediately afterwards, and 6-18 days later. Brain swelling was visible in all six patients on the immediate postoperative scan. In five patients who had later scans the swelling had subsided. No major neurological deficits were seen, and the patients were extubated successfully within 3 h of the operation. The mechanism of the cerebral swelling is uncertain, but it may provide insight into the cause of neurophysiological deficits seen after coronary artery surgery.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CARDIAC SURG,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT DIAGNOST RADIOL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London	HARRIS, DN (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT ANAESTHESIA,LONDON W12 0NN,ENGLAND.							BLAUTH CI, 1988, J THORAC CARDIOV SUR, V95, P668; DECOENE B, 1992, AM J NEURORADIOL, V13, P1555; HIS JH, 1991, AJR, V157, P1291; MOODY DM, 1990, ANN NEUROL, V28, P477, DOI 10.1002/ana.410280403; SCHMIDT R, 1993, NEUROLOGY, V43, P775, DOI 10.1212/WNL.43.4.775; SELLMAN M, 1992, ANN THORAC SURG, V53, P807, DOI 10.1016/0003-4975(92)91441-B; SHAW PJ, 1987, Q J MED, V62, P259; SMITH PLC, 1986, LANCET, V1, P823; VIK A, 1991, NEURORADIOLOGY, V33, P396, DOI 10.1007/BF00598610; WHITFIELD A, 1989, BRIT J ANAESTH, V62, P694, DOI 10.1093/bja/62.6.694	10	194	197	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					586	587		10.1016/0140-6736(93)91412-F	http://dx.doi.org/10.1016/0140-6736(93)91412-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102722				2022-12-01	WOS:A1993LV96300012
J	AOKI, TT; BENBARKA, MM; OKIMURA, MC; ARCANGELI, MA; WALTER, RM; WILSON, LD; TRUONG, MP; BARBER, AR; KUMAGAI, LF				AOKI, TT; BENBARKA, MM; OKIMURA, MC; ARCANGELI, MA; WALTER, RM; WILSON, LD; TRUONG, MP; BARBER, AR; KUMAGAI, LF			LONG-TERM INTERMITTENT INTRAVENOUS INSULIN THERAPY AND TYPE-1 DIABETES-MELLITUS	LANCET			English	Article							CARBOHYDRATE EXCHANGE; GLUCOSE-HOMEOSTASIS; GLYCEMIC INDEX; RESTORATION; INFUSION; MUSCLE; FOODS	An important defect in insulin-dependent diabetes mellitus (IDDM) is that the liver does not meet its full fuel-processing function, because many of the enzymes involved depend on high insulin concentrations in the portal vein. We tried to reactivate the liver by long-term treatment of IDDM patients with intravenous insulin in pulses, with the aim of achieving high portal-vein concentrations during and after a glucose meal. We studied 20 IDDM patients with brittle disease; despite use of a four-injection regimen with manipulation of insulin doses, diet, and physical activity, and frequent clinic visits for at least a year, these patients still had wide swings in blood glucose and frequent hypoglycaemic reactions. The intermittent therapy consisted of 7-10 pulses of intravenous insulin, infused while the patient was ingesting carbohydrate, primarily glucose, during the first hour of a 3 h treatment; three treatments were given in a day. After 2 consecutive days' treatment, patients were treated for 1 day per week. No patient was withdrawn from the study. At the time of this analysis the duration of intermittent treatment ranged from 7 to 71 months (mean 41 [SE 5] months). Haemoglobin A1C concentrations declined from 8.5 (0.4)% at the end of the stabilisation phase to 7.0 (0.2)% at the analysis point (p = 0.0003). During the same time the frequencies of major and minor hypoglycaemic events also fell significantly (major 3.0 [1.1] to 0.1 [0], minor 13.0 [2.6] to 2.4 [0.8] per month; both p < 0.0001). Because the use of saline rather than insulin pulses would have led to unacceptable hyperglycaemia we opted for a historical control design. The absence of a true control group limits the interpretation of these preliminary results, but we believe further studies of hepatic and muscle metabolism before and after long-term intermittent intravenous insulin therapy would be worth while.			AOKI, TT (corresponding author), UNIV CALIF DAVIS,SACRAMENTO MED CTR,DEPT INTERNAL MED,DIV ENDOCRINOL,4301 X ST,BLDG FOLB II-C,SACRAMENTO,CA 95817, USA.							AOKI TT, 1983, J CLIN INVEST, V71, P837, DOI 10.1172/JCI110837; BERGER W, 1973, HORM METAB RES, V5, P4, DOI 10.1055/s-0028-1093991; CAHILL GF, 1959, AM J MED, V26, P264, DOI 10.1016/0002-9343(59)90316-X; FOSS MC, 1982, DIABETES, V31, P46, DOI 10.2337/diabetes.31.1.46; HEINEMANN L, 1989, J INTERN MED, V226, P325, DOI 10.1111/j.1365-2796.1989.tb01403.x; HERS HG, 1982, BIOCHEM J, V206, P2; ISHIDA T, 1984, DIABETES, V33, P984, DOI 10.2337/diabetes.33.10.984; JENKINS DJA, 1983, DIABETOLOGIA, V24, P257, DOI 10.1007/BF00282710; JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362; KARAM JH, 1991, BASIC CLIN ENDOCRINO, P592; KELLEY D, 1988, J CLIN INVEST, V81, P1563, DOI 10.1172/JCI113489; MEISTAS MT, 1985, DIABETES, V34, P960, DOI 10.2337/diabetes.34.10.960; PILKIS SJ, 1968, P SOC EXP BIOL MED, V129, P681; RUDERMAN NB, 1968, DIABETES, V17, P611, DOI 10.2337/diab.17.10.611; STORER AC, 1976, BIOCHEM J, V159, P7, DOI 10.1042/bj1590007; WALDHAUSL W, 1982, DIABETOLOGIA, V23, P6, DOI 10.1007/BF00257722; Weinhouse S, 1976, CURRENT TOPICS CELLU, P1; WESSON DE, 1988, JPEN-PARENTER ENTER, V12, P237, DOI 10.1177/0148607188012003237	18	18	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					515	518		10.1016/0140-6736(93)91645-3	http://dx.doi.org/10.1016/0140-6736(93)91645-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102666				2022-12-01	WOS:A1993LU58200008
J	GRINDON, AJ				GRINDON, AJ			BLOOD DONATION FROM PATIENTS WITH HEMOCHROMATOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GRINDON, AJ (corresponding author), AMER RED CROSS,BLOOD SERV,ATLANTA,GA, USA.							ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691	1	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					880	880						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8133632				2022-12-01	WOS:A1993LR61200042
J	MUKADI, Y; PERRIENS, JH; STLOUIS, ME; BROWN, C; PRIGNOT, J; WILLAME, JC; POUTHIER, F; KABOTO, M; RYDER, RW; PORTAELS, F; PIOT, P				MUKADI, Y; PERRIENS, JH; STLOUIS, ME; BROWN, C; PRIGNOT, J; WILLAME, JC; POUTHIER, F; KABOTO, M; RYDER, RW; PORTAELS, F; PIOT, P			SPECTRUM OF IMMUNODEFICIENCY IN HIV-1-INFECTED PATIENTS WITH PULMONARY TUBERCULOSIS IN ZAIRE	LANCET			English	Article							CLINICAL CASE-DEFINITION; VIRUS-INFECTION; IMMUNE-DEFICIENCY; HIV-INFECTION; AIDS; COHORT; RISK; DISEASE	Tuberculosis (TB) is the most common opportunistic infection in African patients who die from AIDS, yet the stage of immunodeficiency at which TB develops is uncertain. We studied the immune status of HIV-infected outpatients with pulmonary TB in relation to their clinical presentation in a cross-sectional study of 216 HIV-seropositive and 146 HIV-seronegative ambulatory incident cases of smear-positive and culture-positive pulmonary TB in Kinshasa, Zaire. HIV-seropositive and seronegative patients had median CD4 lymphocyte counts of 316.5/muL and 830.5/muL, respectively. Of the HIV-seropositive patients, 32 9% had less than 200 CD4 lymphocytes/muL, 37% between 200 and 499, and 30.1% 500 or more. Clinical AIDS, as defined by the WHO clinical case-definition ora modified version, was of similar limited use as a predictor of immunodeficiency. Among HIV-seropositive patients, oral candidosis, lymphopenia, a negative tuberculin purified protein derivative test, and cutaneous anergy were strongly associated with CD4 counts of less than 200/muL, and seemed to be better markers of immune dysfunction. We conclude that pulmonary TB develops across a broad spectrum of HIV-induced immunodeficiency and that a diagnosis of pulmonary TB is of limited use as a marker of stage of HIV disease in African HIV-infected outpatients.	PROJET SIDA, KINSHASA, DEM REP CONGO; BELGIAN ADM DEV & COOPERAT, BRUSSELS, BELGIUM; UNIV CATHOLIQUE LOUVAIN, MT GODINNE, BELGIUM; BUR NATL TB, KINSHASA, DEM REP CONGO; INST TROP MED PRINCE LEOPOLD, B-2000 ANTWERP, BELGIUM; CDC, NCID, DIV HIV AIDS, ATLANTA, GA USA; CTR DEPISTAGE TB, KINSHASA, DEM REP CONGO	Universite Catholique Louvain; Institute of Tropical Medicine (ITM); Centers for Disease Control & Prevention - USA								[Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BATUNGWANAGO J, 1990, 5TH INT C AIDS AFR K; BRAUN MM, 1991, AM REV RESPIR DIS, V143, P501, DOI 10.1164/ajrccm/143.3.501; BURCHAM J, 1991, AIDS, V5, P365, DOI 10.1097/00002030-199104000-00002; COLEBUNDERS R, 1987, LANCET, V1, P492; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; JORDAN TJ, 1987, CHEST, V92, P234, DOI 10.1378/chest.92.2.234; KASLOW RA, 1987, ANN INTERN MED, V107, P474, DOI 10.7326/0003-4819-107-4-474; KLEIN NC, 1989, CHEST, V95, P1190, DOI 10.1378/chest.95.6.1190; KLEIN RS, 1984, NEW ENGL J MED, V311, P354, DOI 10.1056/NEJM198408093110602; MODILEVSKY T, 1989, ARCH INTERN MED, V149, P2201, DOI 10.1001/archinte.149.10.2201; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; OKONDA L, 1991, 7 INT C AIDS FLOR; PAPE JW, 1992, 8 INT C AIDS 3 STD W; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; ROYCE RA, 1991, AIDS, V5, P355, DOI 10.1097/00002030-199104000-00001; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; WADHAWAN D, 1992, 8 INT C AIDS 3 STD W; WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43; WIDYWIRSKI R, 1988, JAMA-J AM MED ASSOC, V260, P3286, DOI 10.1001/jama.260.22.3286; 1963, WHO TB TECH GUIDE, V3; 1986, WKLY EPIDEMIOL REC, V61, P69; 1991, MMWR, V40, P27	27	118	121	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1993	342	8864					143	146		10.1016/0140-6736(93)91346-N	http://dx.doi.org/10.1016/0140-6736(93)91346-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101257				2022-12-01	WOS:A1993LN04200012
J	NOBORI, T; MIURA, K; WU, DJ; LOIS, A; TAKABAYASHI, K; CARSON, DA				NOBORI, T; MIURA, K; WU, DJ; LOIS, A; TAKABAYASHI, K; CARSON, DA			DELETIONS OF THE CYCLIN-DEPENDENT KINASE-4 INHIBITOR GENE IN MULTIPLE HUMAN CANCERS	NATURE			English	Article							HUMAN GLIOMAS; SHORT ARM; CHROMOSOME-9; MELANOMA	CYTOGENETIC abnormalities of chromosome 9p21 are characteristic of malignant melanomas(1,2), gliomas(3), lung cancers(4) and leukaemias(5). From a panel of 46 human malignant cell lines, we localized by positional cloning the most frequently deleted region on 9p21. Sequence analysis of the isolated fragment reveals two open reading frames identical to the recently described complementary DNA for the inhibitor of cyclin-dependent kinase 4 (CDK4)(6). Polymerase chain reaction and Southern blot analysis confirmed the frequent deletion or rearrangement of the CDK4-inhibitor gene in melanomas, gliomas, lung cancers and leukaemias, and the absence of detectable gene transcripts. One carcinoma had a deletion entirety within the CDK4-inhibitor gene. The CDK4-inhibitor gene from a patient with dysplastic nevus syndrome had a germ-line nonsense mutation. The CDK4 inhibitor is thought to be a physiological suppressor of proliferation. Cells unable to produce the inhibitor may be prone to neoplastic transformation.	CIBA GEIGY AG,DIV PHARMACEUT,CH-4002 BASEL,SWITZERLAND	Novartis	NOBORI, T (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HARPER JW, 1993, CELL, V75, P805; MARX J, 1994, SCIENCE, V263, P319, DOI 10.1126/science.8278804; NOBORI T, 1991, CANCER RES, V51, P3193; NOBORI T, 1993, CANCER RES, V53, P1098; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; PETTY EM, 1993, AM J HUM GENET, V53, P96; PIERCE JC, 1992, METHOD ENZYMOL, V216, P549; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	13	1720	1855	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					753	756		10.1038/368753a0	http://dx.doi.org/10.1038/368753a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152487				2022-12-01	WOS:A1994NG55300062
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW FOOD CODE PUBLISHED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1994, JAMA-J AM MED ASSOC, V271, P812	1	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1067	1067		10.1001/jama.271.14.1067	http://dx.doi.org/10.1001/jama.271.14.1067			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151837				2022-12-01	WOS:A1994NE22800006
J	STERN, Y; GURLAND, B; TATEMICHI, TK; TANG, MX; WILDER, D; MAYEUX, R				STERN, Y; GURLAND, B; TATEMICHI, TK; TANG, MX; WILDER, D; MAYEUX, R			INFLUENCE OF EDUCATION AND OCCUPATION ON THE INCIDENCE OF ALZHEIMERS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARIETOTEMPORAL PERFUSION; DEMENTIA; PREVALENCE; AGE; POPULATION; DIAGNOSIS; MEMORY	Objective.-Several cross-sectional studies have found an association between Alzheimer's disease (AD) and limited education experience. It has been difficult to establish whether educational experience is a risk factor for AD because educational attainment can influence performance on diagnostic tests. This study was designed to determine whether limited educational level and oocupational attainment are risk factors for incident dementia. Design.-Cohort incidence study. Setting.-General community. Participants.-A total of 593 nondemented individuals aged 60 years or older who were listed in a registry of individuals at risk for dementia in North Manhattan, NY, were identified and followed up. Interventions.-We reexamined subjects 1 to 4 years later with the identical standardized neurological and neuropsychological measures. Main Outcome Measure.-Incident dementia. Results.-We used Cox proportional hazards models, adjusting for age and gender, to estimate the relative risk (RR) of incident dementia associated with low educational and occupational attainment. Of the 593 subjects, 106 became demented; all but five of these met research criteria for AD. The risk of dementia was increased in subjects with either low education (RR, 2.02; 95% confidence interval [CI], 1.33 to 3.06) or low lifetime occupational attainment (RR, 2.25; 95% CI, 1.32 to 3.84). Risk was greatest for subjects with both low education and low lifetime occupational attainment (RR, 2.87; 95% CI, 1.32 to 3.84). Conclusions.-The data suggest that increased educational and occupational attainment may reduce the risk of incident AD, either by decreasing ease of clinical detection of AD or by imparting a reserve that delays the onset of clinical manifestations.	CTR GERIATR & GERONTOL, NEW YORK, NY USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT NEUROL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PSYCHIAT, NEW YORK, NY 10032 USA	Columbia University; Columbia University	STERN, Y (corresponding author), GERTRUDE H SERGIEVSKY CTR, 630 W 168TH ST, NEW YORK, NY 10032 USA.			Stern, Yaakov/0000-0001-7542-3241	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007370, P01AG007232] Funding Source: NIH RePORTER; NIA NIH HHS [AG07232, AG07370] Funding Source: Medline; NINDS NIH HHS [NS26179] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARONSON MK, 1990, NEUROLOGY, V40, P1102, DOI 10.1212/WNL.40.7.1102; BEARD CM, 1992, NEUROLOGY, V42, P2063, DOI 10.1212/WNL.42.11.2063; BENTON AL, 1955, VISUAL RETENTION; BENTON AL, 1975, MULTILINGUAL APHASIA; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; BONAIUTO S, 1990, NEUROLOGY S1, V40, P346; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CHAPMAN J, 1991, NEUROEPIDEMIOLOGY, V10, P228, DOI 10.1159/000110276; DARTIGUES JF, 1991, REV NEUROL-FRANCE, V147, P225; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; FRIEDLAND RP, 1985, LANCET, V1, P228; FRIEDLAND RP, 1993, NEUROLOGY, V43, P246, DOI 10.1212/WNL.43.2.246; Goodglass H., 1983, ASSESSMENT APHASIA R; Gurland B. J., 1981, AGING-US, V15, P61; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Kaplan E, 1983, BOSTON NAMING TEST; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; KITTNER SJ, 1986, J CHRON DIS, V39, P163, DOI 10.1016/0021-9681(86)90019-6; LAWLESS JF, 1982, STATISTICAL MODELS M; MATTIS S, 1976, GERIATRIC PSYCHIATRY; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mortimer J. A., 1988, ETIOLOGY DEMENTIA AL, P39; Risberg J., 1988, HDB REGIONAL CEREBRA, P219; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P311; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schwab R.S., 1969, 3 S PARKINSONS DIS, P152; SPITZER RL, 1986, STRUCTURED CLIN INTE; STERN Y, 1992, ANN NEUROL, V32, P371, DOI 10.1002/ana.410320311; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; STERN Y, 1992, ANN NEUROL, V32, P270; SULKAVA R, 1985, NEUROLOGY, V35, P1025, DOI 10.1212/WNL.35.7.1025; Wechsler D, 1981, ADULT INTELLIGENCE S; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412; ZIMETBAUM P, 1991, ARCH INTERN MED, V151, P240, DOI 10.1001/archinte.151.2.240; 1987, DIAGNOSTIC STATISTIC; 1981, ROSEN DRAWING TEST	40	1051	1064	3	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	1994	271	13					1004	1010		10.1001/jama.1994.03510370056032	http://dx.doi.org/10.1001/jama.1994.03510370056032			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND949	8139057	Green Submitted			2022-12-01	WOS:A1994ND94900030
J	BASSON, CT; COWLEY, GS; SOLOMON, SD; WEISSMAN, B; POZNANSKI, AK; TRAILL, TA; SEIDMAN, JG; SEIDMAN, CE				BASSON, CT; COWLEY, GS; SOLOMON, SD; WEISSMAN, B; POZNANSKI, AK; TRAILL, TA; SEIDMAN, JG; SEIDMAN, CE			THE CLINICAL AND GENETIC SPECTRUM OF THE HOLT-ORAM SYNDROME (HEART-HAND SYNDROME)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. The Holt-Gram syndrome is an autosomal dominant condition characterized by skeletal abnormalities that are frequently accompanied by congenital cardiac defects. The cause of these disparate clinical features is unknown. To identify the chromosomal location of the Holt-Gram syndrome gene, we performed clinical and genetic studies. Methods. Two large families with the Holt-Gram syndrome were evaluated by radiography of the hands, electrocardiography, and transthoracic echocardiography. Genetic-linkage analyses were performed with polymorphic DNA loci dispersed throughout the genome to identify a locus that was inherited with the Holt-Gram syndrome in family members. Results. A total of 19 members of Family A had Holt-Oram syndrome with mild-to-moderate skeletal deformities, including triphalangeal thumbs and carpal-bone dysmorphism. All affected members of Family A had moderate-to-severe congenital cardiac abnormalities, such as ventricular or atrial septal defects or atrioventricular-canal defects. Eighteen members of a second kindred (Family B) had Holt-Gram syndrome with moderate-to-severe skeletal deformities, including phocomelia. Twelve of the affected members had no cardiac defects; six had only atrial septal defects. Genetic analyses demonstrated linkage of the disease in each family to polymorphic loci on the long arm of chromosome 12 (combined multipoint lod score, 16.8). These data suggest odds greater than 10(16):1 that the genetic defect for Holt-Gram syndrome is present on the long arm of chromosome 12 (12q2). Conclusions. Mutations in a gene on chromosome 12q2 can produce a wide range of disease phenotypes characteristic of the Holt-Gram syndrome. This gene has an important role in both skeletal and cardiac development.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; CHILDRENS MEM HOSP,DEPT RADIOL,CHICAGO,IL 60614; JOHNS HOPKINS UNIV HOSP,DEPT MED,DIV CARDIOVASC,BALTIMORE,MD	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Ann & Robert H. Lurie Children's Hospital of Chicago; Johns Hopkins University; Johns Hopkins Medicine			Solomon, Scott/I-5789-2013					CHANTHOMAS PS, 1993, J CELL BIOCHEM     S, V17, P209; CHOU YHW, 1992, NAT GENET, V1, P295, DOI 10.1038/ng0792-295; Csaba E, 1991, ORVOSI HETILAP, V132, P73; FUKUI K, 1992, J BIOL CHEM, V267, P18631; GALL JC, 1966, AM J HUM GENET, V18, P187; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HOLT M, 1960, BRIT HEART J, V22, P236; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MATTEI MG, 1991, GENOMICS, V10, P1061, DOI 10.1016/0888-7543(91)90199-O; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCKUSICK VA, 1992, MENDELIAN INHERITANC, V1, P542; MENDELSOHN C, 1992, DEV BIOL, V152, P50, DOI 10.1016/0012-1606(92)90155-A; POZNANSK AK, 1970, RADIOLOGY, V94, P45, DOI 10.1148/94.1.45; SMITH AT, 1979, J PEDIATR-US, V95, P538, DOI 10.1016/S0022-3476(79)80758-1; TURLEAU C, 1984, ANN GENET-PARIS, V27, P237; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; YANG S, 1990, PEDIATR RES, V27, pA137	17	234	240	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	1994	330	13					885	891		10.1056/NEJM199403313301302	http://dx.doi.org/10.1056/NEJM199403313301302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC608	8114858				2022-12-01	WOS:A1994NC60800002
J	ROBERTSON, DE; FARID, RS; MOSER, CC; URBAUER, JL; MULHOLLAND, SE; PIDIKITI, R; LEAR, JD; WAND, AJ; DEGRADO, WF; DUTTON, PL				ROBERTSON, DE; FARID, RS; MOSER, CC; URBAUER, JL; MULHOLLAND, SE; PIDIKITI, R; LEAR, JD; WAND, AJ; DEGRADO, WF; DUTTON, PL			DESIGN AND SYNTHESIS OF MULTI-HEME PROTEINS	NATURE			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; BLODGETT MONOLAYER FILMS; VIRIDIS REACTION CENTER; CYTOCHROME-C; RHODOPSEUDOMONAS-VIRIDIS; RHODOBACTER-SPHAEROIDES; DESULFOVIBRIO-VULGARIS; TRANSFER MECHANISMS; REDOX; COMPLEX	A water-soluble, 62-residue, di-alpha-helical peptide has been synthesized which accommodates two bis-histidyl haem groups. The peptide assembles into a four-helix dimer with 2-fold symmetry and four parallel haems that closely resemble native haems in their spectral and electro-chemical properties, including haem-haem redox interaction. This protein is an essential intermediate in the synthesis of molecular 'maquettes', a novel class of simplified versions of the metalloproteins involved in redox catalysis and in energy conversion in respiratory and photosynthetic electron transfer.	UNIV ILLINOIS,SCH CHEM SCI,DEPT BIOCHEM,URBANA,IL 61801; DUPONT CO INC,DEPT CENT RES & DEV,WILMINGTON,DE 19880	University of Illinois System; University of Illinois Urbana-Champaign; DuPont	ROBERTSON, DE (corresponding author), UNIV PENN,DEPT BIOCHEM & BIOPHYS,JOHNSON RES FDN,PHILADELPHIA,PA 19104, USA.		Moser, Christopher C/O-6559-2014	Moser, Christopher C/0000-0003-4814-8568				ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P258, DOI 10.1016/S0005-2728(05)80108-2; ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P239, DOI 10.1016/S0005-2728(05)80107-0; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; BROWN S, 1993, FEBS LETT, V316, P216, DOI 10.1016/0014-5793(93)81296-C; CHOMA CT, 1994, J AM CHEM SOC, V118, P856; CHURG AK, 1986, BIOCHEMISTRY-US, V25, P1675, DOI 10.1021/bi00355a035; Cramer W., 1987, STRUCTURE FUNCTION P; CROFTS A, 1992, BIOCHIM BIOPHYS ACTA, V1101, P162, DOI 10.1016/0005-2728(92)90202-D; DAVIES AM, 1993, BIOCHEMISTRY-US, V32, P5431, DOI 10.1021/bi00071a019; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; DeGrado WF, 1991, CURR OPIN STRUC BIOL, V1, P984, DOI 10.1016/0959-440X(91)90095-B; Dutton P L, 1978, Methods Enzymol, V54, P411; DUTTON PL, 1972, EUR J BIOCHEM, V30, P495, DOI 10.1111/j.1432-1033.1972.tb02121.x; Ernster, 1987, CYTOCHROME SYSTEMS M, P617; FAN K, 1990, BIOCHEMISTRY-US, V29, P2257, DOI 10.1021/bi00461a008; FIELDS GB, 1989, INT J PEPT PROT RES, V33, P1; GLASER EG, 1984, BIOCHIM BIOPHYS ACTA, V766, P322, DOI 10.1016/0005-2728(84)90248-2; GUNNER MR, 1991, P NATL ACAD SCI USA, V88, P9151, DOI 10.1073/pnas.88.20.9151; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HARBURY HA, 1965, P NATL ACAD SCI USA, V54, P1658, DOI 10.1073/pnas.54.6.1658; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; HOWELL N, 1993, BIOCHEMISTRY-US, V32, P1310; HOWELL N, 1987, CYTOCHROME SYSTEMS M, P79; LEITCH FA, 1985, BIOCHIM BIOPHYS ACTA, V808, P213, DOI 10.1016/0005-2728(85)90001-5; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MOORE GR, 1983, FEBS LETT, V161, P171, DOI 10.1016/0014-5793(83)81001-1; MOSER CC, 1992, BIOCHIM BIOPHYS ACTA, V1101, P171, DOI 10.1016/S0005-2728(05)80012-X; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; MOURA JJG, 1982, EUR J BIOCHEM, V127, P151, DOI 10.1111/j.1432-1033.1982.tb06849.x; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V357, P462, DOI 10.1016/0005-2728(74)90038-3; ORMEJOHNSON NR, 1974, J BIOL CHEM, V249, P1928; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PALMER G, 1985, BIOCHEM SOC T, V13, P548, DOI 10.1042/bst0130548; ROBERTSON DE, 1988, BIOCHIM BIOPHYS ACTA, V935, P273, DOI 10.1016/0005-2728(88)90223-X; SALERNO JC, 1984, J BIOL CHEM, V259, P2331; SANTOS H, 1984, EUR J BIOCHEM, V141, P283, DOI 10.1111/j.1432-1033.1984.tb08190.x; SARASTE M, 1984, FEBS LETT, V166, P367, DOI 10.1016/0014-5793(84)80114-3; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038; WEST IC, 1988, BIOCHIM BIOPHYS ACTA, V933, P35, DOI 10.1016/0005-2728(88)90053-9; WIKSTROM MKF, 1976, FEBS LETT, V65, P259, DOI 10.1016/0014-5793(76)80127-5; WILLIE A, 1992, BIOCHEMISTRY-US, V31, P7237, DOI 10.1021/bi00147a005; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007; YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017	49	463	468	1	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 31	1994	368	6470					425	431		10.1038/368425a0	http://dx.doi.org/10.1038/368425a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133888				2022-12-01	WOS:A1994ND12000053
J	DULIC, V; KAUFMANN, WK; WILSON, SJ; TLSTY, TD; LEES, E; HARPER, JW; ELLEDGE, SJ; REED, SI				DULIC, V; KAUFMANN, WK; WILSON, SJ; TLSTY, TD; LEES, E; HARPER, JW; ELLEDGE, SJ; REED, SI			P53-DEPENDENT INHIBITION OF CYCLIN-DEPENDENT KINASE-ACTIVITIES IN HUMAN FIBROBLASTS DURING RADIATION-INDUCED G1 ARREST	CELL			English	Article							WILD-TYPE P53; RETINOBLASTOMA GENE-PRODUCT; HUMAN CELL-CYCLE; ATAXIA-TELANGIECTASIA; PROTEIN-KINASE; FISSION YEAST; S-PHASE; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION	Gamma-irradiation of human diploid fibroblasts in the G1 interval caused arrest of the cell cycle prior to S phase. This cell cycle block was correlated with a lack of activation of both cyclin E-Cyclin-dependent kinase 2 (Cdk2) and cyclin A-Cdk2 kinases and depended on wild-type p53. Although the accumulation of cyclin A was strongly inhibited in gamma-irradiated cells, cyclin E accumulated and bound Cdk2 at normal levels but remained in an inactive state. We found that both whole-cell lysates and inactive cyclin E-Cdk2 complexes prepared from irradiated cells contained an activity capable of inactivating cyclin E-Cdk2 complexes. The protein responsible for this activity was shown to be p21CIP1/WAF1, recently described as a p53-inducible Cdk inhibitor. Our data suggest a model in which ionizing radiation confers G1 arrest via the p53-mediated induction of a Cdk inhibitor protein.	SCRIPPS RES INST, DEPT MOLEC BIOL MB7, LA JOLLA, CA 92037 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; MASSACHUSETTS GEN HOSP, CTR CANC, MOLEC ONCOL LAB, BOSTON, MA 02129 USA; BAYLOR COLL MED, INST MOLEC GENET, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Scripps Research Institute; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Massachusetts General Hospital; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Harper, Jeffrey/0000-0002-6944-7236; Dulic, Vjekoslav/0000-0003-1201-3901	NATIONAL CANCER INSTITUTE [P01CA042765, R01CA055339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM046006] Funding Source: NIH RePORTER; NCI NIH HHS [CA55339, CA42765] Funding Source: Medline; NIGMS NIH HHS [GM46006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HENGST L, 1994, IN PRESS P NATL ACAD; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAUFMANN WK, 1990, MUTAT RES, V236, P107, DOI 10.1016/0921-8777(90)90038-7; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOCK RB, 1990, CANCER RES, V50, P3761; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHAY JW, 1993, ONCOGENE, V8, P1407; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLINGERLAND JM, 1994, IN PRESS MOL CELL BI; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; STUDIER FW, 1990, GENE EXPRESSION TECH, V185, P60; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WHITE S, 1994, IN PRESS GENES DEV; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	81	1457	1491	2	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	1994	76	6					1013	1023		10.1016/0092-8674(94)90379-4	http://dx.doi.org/10.1016/0092-8674(94)90379-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137420				2022-12-01	WOS:A1994ND24600008
J	VANADELSBERG, J; EDWARDS, JC; TAKITO, J; KISS, B; ALAWQATI, Q				VANADELSBERG, J; EDWARDS, JC; TAKITO, J; KISS, B; ALAWQATI, Q			AN INDUCED EXTRACELLULAR-MATRIX PROTEIN REVERSES THE POLARITY OF BAND-3 IN INTERCALATED EPITHELIAL-CELLS	CELL			English	Article							MEMBRANE CYTOSKELETAL COMPLEX; MDCK CELLS; CYTOPLASMIC DOMAIN; BASEMENT-MEMBRANE; KIDNEY; ANKYRIN; SURFACE; FODRIN; IDENTIFICATION; BIOGENESIS	The intercalated epithelial cell exists in two interconvertible forms in vivo, one where band 3 protein is apical and the other where it is basolateral. We seeded an immortalized clone of these cells at low density and found that band 3 was apical at confluence. There was little or no apical endocytosis. But when the cells were plated at high density, band 3 was basolateral, and there was vigorous apical endocytosis. Extracellular matrix produced by high density cells was able to retarget band 3 in low density cells and to induce apical endocytosis, as did a 230 kd protein partially purified from this matrix. Therefore, polarized targeting of some proteins is determined by external cues that might determine their polarity by reorganizing the cytoplasm.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032	Columbia University	VANADELSBERG, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032, USA.		Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK020999, R01DK020999] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20999] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1992, RENAL PHYSL, V1, P323; BARTLES JR, 1984, ANAL BIOCHEM, V140, P284, DOI 10.1016/0003-2697(84)90166-0; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BROWN D, 1987, J CELL BIOL, V105, P1637, DOI 10.1083/jcb.105.4.1637; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DAVIS J, 1989, J BIOL CHEM, V264, P6417; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; EDWARDS JC, 1992, AM J PHYSIOL, V263, pC521, DOI 10.1152/ajpcell.1992.263.2.C521; GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395; GUNDERSEN D, 1993, J CELL BIOL, V121, P335, DOI 10.1083/jcb.121.2.335; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HARLOW E, 1988, ANTIBODIES LABORATOR; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Kopito R R, 1988, Soc Gen Physiol Ser, V43, P151; LEHIR M, 1982, AM J PHYSIOL, V242, pC117, DOI 10.1152/ajpcell.1982.242.1.C117; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISAWNTI M, 1990, TRENDS BIOCHEM SCI, V15, P133; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; OSTEDGAARD LS, 1991, P NATL ACAD SCI USA, V88, P981, DOI 10.1073/pnas.88.3.981; PATHAK RK, 1990, J CELL BIOL, V112, P863; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SAMBUY Y, 1988, P NATL ACAD SCI USA, V85, P1529, DOI 10.1073/pnas.85.5.1529; SCHUSTER VL, 1993, ANNU REV PHYSIOL, V55, P267, DOI 10.1146/annurev.ph.55.030193.001411; SCHWARTZ GJ, 1985, NATURE, V318, P368, DOI 10.1038/318368a0; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; STEULI CH, 1990, J CELL BIOL, V110, P1405; STOW JL, 1987, J CELL BIOL, V105, P529, DOI 10.1083/jcb.105.1.529; STOW JL, 1989, AM J PATHOL, V135, P637; THORENS B, 1990, AM J PHYSIOL, V259, pC286; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANADELSBERG J, 1989, AM J PHYSIOL, V256, pC1004, DOI 10.1152/ajpcell.1989.256.5.C1004; VANADELSBERG JS, 1993, J BIOL CHEM, V268, P11283; ZURZOLO C, 1993, SCIENCE, V260, P550, DOI 10.1126/science.8386394; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	39	83	83	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1053	1061		10.1016/0092-8674(94)90382-4	http://dx.doi.org/10.1016/0092-8674(94)90382-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137422				2022-12-01	WOS:A1994ND24600011
J	TANEV, PT; CHIBWE, M; PINNAVAIA, TJ				TANEV, PT; CHIBWE, M; PINNAVAIA, TJ			TITANIUM-CONTAINING MESOPOROUS MOLECULAR-SIEVES FOR CATALYTIC-OXIDATION OF AROMATIC-COMPOUNDS	NATURE			English	Article							SILICALITE	TITANIUM silicalite is an effective molecular-sieve catalyst for the selective oxidation of alkanes, the hydroxylation of phenol and the epoxidation of alkenes in the presence of H2O2 (refs 1-3). The range of organic compounds that can be oxidized is greatly limited, however, by the relatively small pore size (about 0.6 nm) of the host framework(4). Large-pore (mesoporous) silica-based molecular sieves have been prepared recently by Kresge et al.(5-7) and Kuroda et al.(8); the former used a templating approach in which the formation of an inorganic mesoporous structure is assisted by self-organization of surfactants, and the latter involved topochemical rearrangement of a layered silica precursor. Here we describe the use of the templating approach to synthesize mesoporous silica-based molecular sieves partly substituted with titanium-large-pore analogues of titanium silicalite. We find that these materials show selective catalytic activity towards the oxidation of 2,6-di-tert-butyl phenol to the corresponding quinone and the conversion of benzene to phenol.	MICHIGAN STATE UNIV, DEPT CHEM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, CTR FUNDAMENTAL MAT RES, E LANSING, MI 48824 USA	Michigan State University; Michigan State University								BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020; FLANIGEN EM, 1978, NATURE, V271, P512, DOI 10.1038/271512a0; HORVATH G, 1983, J CHEM ENG JPN, V16, P470, DOI 10.1252/jcej.16.470; HUYBRECHTS DRC, 1990, NATURE, V345, P240, DOI 10.1038/345240a0; INAGAKI S, 1993, J CHEM SOC CHEM COMM, P680, DOI 10.1039/c39930000680; Kresge C.T., 1992, U.S. Patent, Patent No. [5098684, 5,098,684]; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; NEUMANN R, 1993, J CHEM SOC CHEM COMM, P1685, DOI 10.1039/c39930001685; NOTARI B, 1991, STUD SURF SCI CATAL, V67, P243, DOI 10.1016/S0167-2991(08)61943-6; SHELDON RA, 1990, STUD SURF SCI CATAL, V55, P1; SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603; TANGARAJ A, 1991, J CATAL, V130, P1; Taramasso M., 1983, US Patent, Patent No. [US4410501, 4410501]	14	1602	1716	11	487	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					321	323		10.1038/368321a0	http://dx.doi.org/10.1038/368321a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127366				2022-12-01	WOS:A1994NB98500041
J	CHUNG, H; CAFFREY, M				CHUNG, H; CAFFREY, M			THE CURVATURE ELASTIC-ENERGY FUNCTION OF THE LIPID-WATER CUBIC MESOPHASE	NATURE			English	Article							X-RAY-DIFFRACTION; MEMBRANE-LIPIDS; PHASES; LAMELLAR; TRANSITIONS; SYSTEMS; CRYSTALS; SURFACE	CELL and lipid membranes are able to bend, as manifested during membrane fusion and the formation of non-lamellar lyotropic mesophases in water. But there is an energy cost to bending of lipid layers, called the curvature elastic energy. Although the functional form of this energy is known(1), a complete quantitative knowledge of the curvature elastic energy, which is central to predicting the relative stability of the large number of phases that lipid membranes can adopt, has been lacking. Here we use X-ray synchrotron diffraction measurements of the variation of lattice parameter with pressure and temperature for the periodic Ia3d (Q(230)) cubic phase of hydrated monoolein to calculate the complete curvature elastic-energy function for the lipid cubic mesophase. This allows us to predict the stabilities of different cubic and lamellar phases for this system as a function of composition.			CHUNG, H (corresponding author), OHIO STATE UNIV,DEPT CHEM,COLUMBUS,OH 43210, USA.							ANDERSON DM, 1988, P NATL ACAD SCI USA, V85, P5364, DOI 10.1073/pnas.85.15.5364; ANDERSSON S, 1988, CHEM REV, V88, P221, DOI 10.1021/cr00083a011; CAFFREY M, 1987, BIOCHEMISTRY-US, V26, P6349, DOI 10.1021/bi00394a008; CHUNG H, IN PRESS BIOPHYS J; CHUNG HS, 1992, BIOPHYS J, V63, P438, DOI 10.1016/S0006-3495(92)81621-1; GRUNER SM, 1989, J PHYS CHEM-US, V93, P7562, DOI 10.1021/j100359a011; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; HYDE ST, 1984, Z KRISTALLOGR, V168, P213, DOI 10.1524/zkri.1984.168.1-4.213; KIRK GL, 1984, BIOCHEMISTRY-US, V23, P1093, DOI 10.1021/bi00301a009; KOZLOV MM, 1991, J PHYS II, V1, P1077, DOI 10.1051/jp2:1991201; LARSSON K, 1983, NATURE, V304, P664, DOI 10.1038/304664c0; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; LINDBLOM G, 1979, J AM CHEM SOC, V101, P5465, DOI 10.1021/ja00513a002; LONGLEY W, 1983, NATURE, V303, P612, DOI 10.1038/303612a0; MARIANI P, 1988, J MOL BIOL, V204, P165, DOI 10.1016/0022-2836(88)90607-9; MICHEL BE, 1973, PLANT PHYSIOL, V51, P914, DOI 10.1104/pp.51.5.914; NANAVATI C, 1992, BIOPHYS J, V63, P1118, DOI 10.1016/S0006-3495(92)81679-X; PARSEGIAN VA, 1986, METHOD ENZYMOL, V127, P400; RAND RP, 1990, BIOCHEMISTRY-US, V29, P76, DOI 10.1021/bi00453a010; SCRIVEN LE, 1976, NATURE, V263, P123, DOI 10.1038/263123a0; SEDDON JM, 1990, BIOCHIM BIOPHYS ACTA, V1031, P1, DOI 10.1016/0304-4157(90)90002-T; TATE MW, 1991, CHEM PHYS LIPIDS, V57, P147, DOI 10.1016/0009-3084(91)90073-K; TEMPLER RH, IN PRESS BIOPHYSICAL; TURNER DC, 1992, J PHYS II, V2, P2039, DOI 10.1051/jp2:1992250	24	107	108	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					224	226		10.1038/368224a0	http://dx.doi.org/10.1038/368224a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145820				2022-12-01	WOS:A1994NA87000048
J	FINER, JT; SIMMONS, RM; SPUDICH, JA				FINER, JT; SIMMONS, RM; SPUDICH, JA			SINGLE MYOSIN MOLECULE MECHANICS - PICONEWTON FORCES AND NANOMETER STEPS	NATURE			English	Article							RABBIT PSOAS MUSCLE; KINESIN MOLECULES; SLIDING DISTANCE; SKELETAL-MUSCLE; ACTIN FILAMENT; MOVEMENT; INVITRO; FIBERS; CONTRACTION; ATP	A new in vitro assay using a feedback enhanced laser trap system allows direct measurement of force and displacement that results from the interaction of a single myosin molecule with a single suspended actin filament. Discrete stepwise movements averaging ai nm were seen under conditions of low load, and single force transients averaging 3-4 pN were measured under isometric conditions. The magnitudes of the single forces and displacements are consistent with predictions of the conventional swinging-crossbridge model of muscle contraction.	STANFORD UNIV,SCH MED,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,SCH MED,BECKMAN CTR,DEPT BIOL,STANFORD,CA 94305; KINGS COLL LONDON,RANDALL INST,MRC MUSCLE & CELL MOTIL UNIT,LONDON WC2B 5RL,ENGLAND	Stanford University; Stanford University; University of London; King's College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAGSHAW CR, 1993, MUSCLE CONTRACTION, P98; BERGER CL, 1993, BIOCHEMISTRY-US, V32, P3812, DOI 10.1021/bi00065a038; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BRENNER B, 1991, J PHYSIOL-LONDON, V441, P703, DOI 10.1113/jphysiol.1991.sp018774; BRENNER B, 1991, P NATL ACAD SCI USA, V88, P10490, DOI 10.1073/pnas.88.23.10490; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; FAJER PG, 1990, P NATL ACAD SCI USA, V87, P5538, DOI 10.1073/pnas.87.14.5538; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; FORD LE, 1981, J PHYSIOL-LONDON, V311, P219, DOI 10.1113/jphysiol.1981.sp013582; GOLDMAN YE, 1977, J PHYSIOL-LONDON, V269, pP55; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P577, DOI 10.1113/jphysiol.1984.sp015394; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1988, CELL MOTIL CYTOSKEL, V10, P71, DOI 10.1002/cm.970100112; HASELGROVE JC, 1973, J MOL BIOL, V77, P549, DOI 10.1016/0022-2836(73)90222-2; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY AF, 1957, PROG BIOPHYS BIOPHYS, V7, P225; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; SELLERS JR, 1990, SCIENCE, V249, P406, DOI 10.1126/science.2377894; SIMMONS RM, 1993, MECHANISM MYOFILAMEN; SIMMONS RM, UNPUB BIOPHYS J; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, IN PRESS REV BIOPHYS; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WARRICK HM, 1993, METHOD CELL BIOL, P1; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WOLEDGE RC, 1985, ENERGETIC ASPECTS MU, P103; YAMADA A, 1990, J BIOCHEM-TOKYO, V108, P341, DOI 10.1093/oxfordjournals.jbchem.a123203; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YOSHINO S, 1978, BIOPHYS CHEM, V8, P317, DOI 10.1016/0301-4622(78)80014-3	45	1514	1542	5	209	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					113	119		10.1038/368113a0	http://dx.doi.org/10.1038/368113a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139653				2022-12-01	WOS:A1994NA03000055
J	TSUKIYAMA, T; BECKER, PB; WU, C				TSUKIYAMA, T; BECKER, PB; WU, C			ATP-DEPENDENT NUCLEOSOME DISRUPTION AT A HEAT-SHOCK PROMOTER MEDIATED BY BINDING OF GAGA TRANSCRIPTION FACTOR	NATURE			English	Article							TUMOR VIRUS PROMOTER; DROSOPHILA-MELANOGASTER; CHROMATIN STRUCTURE; GENE; PROTEINS; DNA; COMPLEX; ACTIVATION; ENCODES; EXTRACTS	Genetic control elements are usually situated in local regions of chromatin that are hypersensitive to structural probes such as DNase I. We have reconstructed the chromatin structure of the hsp70 promoter using an in vitro nucleosome assembly system. Binding of the GAGA transcription factor on existing nucleosomes leads to nucleosome disruption, DNase I hypersensitivity at the TATA box and heat-shock elements, and rearrangement of adjacent nucleosomes. ATP hydrolysis facilitates this process, suggesting that an energy-dependent pathway is involved in chromatin remodelling.	NCI,BIOCHEM LAB,BLDG 37,ROOM 4C-09,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Becker, Peter/0000-0001-7186-0372				ALMOUZNI G, 1993, EXP CELL RES, V205, P1, DOI 10.1006/excr.1993.1051; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ASHBURNER M, 1972, DEV STUDIES GIANT CH; AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BLACKMAN RK, 1986, J MOL BIOL, V188, P499, DOI 10.1016/S0022-2836(86)80001-8; BROWN JL, 1993, DEVELOPMENT, V117, P45; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; Croston G.E., 1991, Protein Expression and Purification, V2, P162, DOI 10.1016/1046-5928(91)90066-R; DEVLIN C, 1991, MOL CELL BIOL, V11, P3642, DOI 10.1128/MCB.11.7.3642; DIBELLO PR, 1991, GENETICS, V129, P385; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELGIN SCR, 1973, BIOCHEMISTRY-US, V12, P4984, DOI 10.1021/bi00748a026; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HAYES JJ, 1992, BIOESSAYS, V14, P597, DOI 10.1002/bies.950140905; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P291, DOI 10.1016/0968-0004(93)90037-N; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; LUE Q, 1993, MOL CELL BIOL, V13, P2802; MASON PJ, 1982, J MOL BIOL, V156, P21, DOI 10.1016/0022-2836(82)90456-9; MORROW BE, 1993, MOL CELL BIOL, V13, P1173, DOI 10.1128/MCB.13.2.1173; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PURNELL BA, 1993, MOL CELL BIOL, V13, P2593, DOI 10.1128/MCB.13.4.2593; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SCHMID A, 1992, CELL, V71, P1; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; van Holde K.E., 1989, CHROMATIN, P16; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	51	569	573	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					525	532		10.1038/367525a0	http://dx.doi.org/10.1038/367525a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	8107823	Green Submitted			2022-12-01	WOS:A1994MV86300049
J	LAGNADO, L; BAYLOR, DA				LAGNADO, L; BAYLOR, DA			CALCIUM CONTROLS LIGHT-TRIGGERED FORMATION OF CATALYTICALLY ACTIVE RHODOPSIN	NATURE			English	Article							ROD OUTER SEGMENTS; RETINAL RODS; GUANYLATE-CYCLASE; SALAMANDER RODS; TOAD RODS; PHOTORECEPTORS; SENSITIVITY; ACTIVATION; PROTEIN; PHOTOTRANSDUCTION	BACKGROUND light reduces the gain of phototransduction in retinal rods so that the ability to register changes in light intensity is not prevented by saturation of the cell's response1,2. The gain is reduced by a light-induced fall in the intracellular calcium concentration which results from blockage of Ca2+ entry through the channels closed by light and continued Ca2+ extrusion by the Na:Ca,K exchanger3-7. Calcium seems to exert several coordinated effects on the cyclic GMP cascade: a fall in [Ca2+] stimulates cGMP synthesis8,9, increases the affinity of the cGMP-gated channel for cGMP10 and accelerates rhodopsin deactivation by phosphorylation11. We now report that lowering intracellular [Ca2+] reduces the catalytic rhodopsin activity produced by light. The effect is operationally equivalent to a fourfold reduction in the number of rhodopsin molecules available for activation. The reduction in gain is cooperative and half-maximal at about 35 nM Ca2+, suggesting that it is mediated by a specific Ca2+-binding protein. Reduced rhodopsin activity in low Ca2+ should contribute to adaptation in background light.	STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University								BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BAYLOR DA, 1974, J PHYSIOL-LONDON, V242, P729, DOI 10.1113/jphysiol.1974.sp010732; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FAIN GL, 1976, J PHYSIOL-LONDON, V261, P71, DOI 10.1113/jphysiol.1976.sp011549; GORDON SE, 1992, NEURON, V9, P739, DOI 10.1016/0896-6273(92)90036-D; HODGKIN AL, 1986, J PHYSIOL-LONDON, V372, pP54; HODGKIN AL, 1985, J PHYSIOL-LONDON, V358, P447, DOI 10.1113/jphysiol.1985.sp015561; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOCH KW, 1990, J BIOL CHEM, V265, P9659; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; LAGNADO L, 1992, J PHYSIOL-LONDON, V455, P111, DOI 10.1113/jphysiol.1992.sp019293; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMB TD, 1981, J PHYSIOL-LONDON, V319, P463, DOI 10.1113/jphysiol.1981.sp013921; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; LAMB TD, 1986, J PHYSIOL-LONDON, V372, P315, DOI 10.1113/jphysiol.1986.sp016011; LOLLEY RN, 1982, VISION RES, V22, P1481, DOI 10.1016/0042-6989(82)90213-9; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCCARTHY ST, 1993, THESIS U CALIFORNIA; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P731, DOI 10.1113/jphysiol.1988.sp016943; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; YOUNGER JP, 1992, INVEST OPHTH VIS SCI, V33, P1104	29	117	118	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					273	277		10.1038/367273a0	http://dx.doi.org/10.1038/367273a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121492				2022-12-01	WOS:A1994MR49400057
J	WORONICZ, JD; CALNAN, B; NGO, V; WINOTO, A				WORONICZ, JD; CALNAN, B; NGO, V; WINOTO, A			REQUIREMENT FOR THE ORPHAN STEROID-RECEPTOR NUR77 IN APOPTOSIS OF T-CELL HYBRIDOMAS	NATURE			English	Article							GROWTH-FACTORS ENCODES; FACTOR-INDUCIBLE GENE; DNA-BINDING; EXPRESSION VECTORS; NGFI-B; DEATH; PROTEIN; SUPERFAMILY; INDUCTION; MEMBER	APOPTOSIS is a phenomenon observed during development of many cell types in many organisms. It is an internal, programmed cell death characterized by DNA fragmentation into nucleosome-size pieces1-3. Anti-CD3-induced apoptosis in T-cell hybridomas and immature thymocytes requires new gene transcription and may be related to negative selection during T-cell development4-6. Using subtractive hybridization, we isolated a complementary DNA clone encoding the orphan steroid receptor Nur77 (refs 7-9). It shows different patterns of messenger RNA induction between apoptotic and stimulated T cells. We report here the use of gel shift analysis to demonstrate that the Nur77 protein is present at high levels in apoptotic T-cell hybridomas and apoptotic thymocytes, but not in growing T cells or stimulated splenocytes. A Nur77 dominant negative protected T-cell hybridomas from activation-induced apoptosis. Hence Nur77 is necessary for induced apoptosis in T-cell hybridomas.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley				Ngo, Vu/0000-0002-9501-6990				CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARINE J, 1991, P NATL ACAD SCI USA, V88, P7284, DOI 10.1073/pnas.88.16.7284; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MERCEP M, 1989, J IMMUNOL, V142, P4085; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHASTRI N, 1986, J EXP MED, V164, P882, DOI 10.1084/jem.164.3.882; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1990, J IMMUNOL, V144, P3326; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	31	507	519	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					277	281		10.1038/367277a0	http://dx.doi.org/10.1038/367277a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121493				2022-12-01	WOS:A1994MR49400058
J	PSATY, BM; SAVAGE, PJ; TELL, GS; POLAK, JF; HIRSCH, CH; GARDIN, JM; MCDONALD, RH				PSATY, BM; SAVAGE, PJ; TELL, GS; POLAK, JF; HIRSCH, CH; GARDIN, JM; MCDONALD, RH			TEMPORAL PATTERNS OF ANTIHYPERTENSIVE MEDICATION USE AMONG ELDERLY PATIENTS - THE CARDIOVASCULAR HEALTH STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; HYPERTENSION; EXPERIENCE; GLUCOSE; THERAPY; TRIAL	Objectives.-To estimate the incidence of newly treated hypertension and to describe the patterns of antihypertensive medication use among those aged 65 years and older. Design.-Medicare eligibility lists from four US communities (Forsyth County, North Carolina; Washington County, Maryland; Sacramento County, California; and Pittsburgh, Pa) were used to obtain a representative sample of 5201 community-dwelling elderly for the Cardiovascular Health Study, a prospective cohort study of risk factors for coronary heart disease and stroke. Participants were examined at baseline and again 1 year later. The two examinations included standardized questionnaires, blood pressure measurements, and the assessment of medication use by medication inventory. In this cohort analysis, we excluded 231 subjects (4.4%) who did not return for follow-up, 69 (1.3%) who had missing data for medications, and another 495 (9.5%) who were taking ''antihypertensive'' medications for an indication other than high blood pressure. Interventions.-None. Results.-Among the 4406 participants, 1613 used antihypertensive medications at both visits. Between the two visits, 144 started and 115 stopped antihypertensive therapy. Among nonusers at baseline, the annual incidence of newly treated hypertension was 5.2% in women and 5.6% in men. Due to the number of participants who stopped therapy, the overall prevalence of antihypertensive treatment increased only slightly, from 40.7% to 41.1% in women and from 37.1% to 38.2% in men, during 1 year of follow-up. After adjustment for age, systolic blood pressure, number of antihypertensive drugs, diabetes, and cardiovascular disease, the newly treated hypertensives were about half as likely as the previously treated hypertensives to receive diuretics (odds ratio [OR], 0.59; P=.008) or beta-blockers (OR, 0.52; P=.01); and they were about twice as likely to receive calcium channel blockers (OR, 1.88; P<.004) or angiotensin converting enzyme inhibitors (OR, 2.40; P<.001). A similar pattern of within-person changes over time was apparent among the continuous users. Conclusions.-Between June 1990 and June 1991, physicians were increasingly prescribing angiotensin converting enzyme inhibitors and calcium channel blockers in place of diuretics and beta-blockers for the treatment of hypertension in elderly patients, especially for those just starting therapy.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV PITTSBURGH, DEPT EPIDEMIOL, PITTSBURGH, PA 15260 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, EPIDEMIOL & BIOMETRY PROGRAM, BETHESDA, MD 20892 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27103 USA; BRIGHAM & WOMENS HOSP, DEPT RADIOL, BOSTON, MA 02115 USA; UNIV CALIF DAVIS, SACRAMENTO MED CTR, DEPT MED, SACRAMENTO, CA 95817 USA; UNIV CALIF IRVINE, DEPT MED, IRVINE, CA 92717 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University; Wake Forest Baptist Medical Center; Harvard University; Brigham & Women's Hospital; University of California System; University of California Davis; University of California System; University of California Irvine	PSATY, BM (corresponding author), CARDIOVASC HLTH STUDY, CTR COORDINATING, CENTURY SQ, SUITE 2025, 1501 4TH AVE, SEATTLE, WA 98101 USA.		Tell, Grethe/G-5639-2015	Tell, Grethe/0000-0003-1386-1638	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085086, N01HC085079] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043201] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-85079, HL-43201, N01-HC-85086] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; APPLEGATE WB, 1989, ANN INTERN MED, V110, P901, DOI 10.7326/0003-4819-110-11-901; AVANZINI F, 1989, CLIN CARDIOL, V12, P283; Cochran W.G, 1957, STAT METHODS, V6th ed; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DANNENBERG AL, 1988, AM J PUBLIC HEALTH, V78, P676, DOI 10.2105/AJPH.78.6.676; DANNENBERG AL, 1987, JAMA-J AM MED ASSOC, V257, P1477, DOI 10.1001/jama.257.11.1477; DAVIDSON RA, 1989, J AM GERIATR SOC, V37, P861, DOI 10.1111/j.1532-5415.1989.tb02267.x; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; HARRIS MI, 1985, DIABETES CARE, V8, P562, DOI 10.2337/diacare.8.6.562; MCCLOSKEY LW, 1992, ARCH INTERN MED, V152, P513, DOI 10.1001/archinte.152.3.513; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MITTELMARK MB, 1993, AM J EPIDEMIOL, V137, P311, DOI 10.1093/oxfordjournals.aje.a116678; MOSER M, 1993, ARCH INTERN MED, V153, P1843, DOI 10.1001/archinte.153.15.1843; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; PSATY BM, 1992, JAMA-J AM MED ASSOC, V268, P1287, DOI 10.1001/jama.268.10.1287; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; PSATY BM, IN PRESS PRIMER HYPE; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; WEBER MA, 1993, ARCH INTERN MED, V153, P149, DOI 10.1001/archinte.153.2.149; WEISSFELD JL, 1985, J CHRON DIS, V38, P915, DOI 10.1016/0021-9681(85)90127-4; 1993, ARCH INTERN MED, V153, P1023	28	61	61	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1837	1841		10.1001/jama.270.15.1837	http://dx.doi.org/10.1001/jama.270.15.1837			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8105112				2022-12-01	WOS:A1993MB46400027
J	AKAHANE, Y; KOJIMA, M; SUGAI, Y; SAKAMOTO, M; MIYAZAKI, Y; TANAKA, T; TSUDA, F; MISHIRO, S; OKAMOTO, H; MIYAKAWA, Y; MAYUMI, M				AKAHANE, Y; KOJIMA, M; SUGAI, Y; SAKAMOTO, M; MIYAZAKI, Y; TANAKA, T; TSUDA, F; MISHIRO, S; OKAMOTO, H; MIYAKAWA, Y; MAYUMI, M			HEPATITIS-C VIRUS-INFECTION IN SPOUSES OF PATIENTS WITH TYPE-C CHRONIC LIVER-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C; HEPATITIS C VIRUSES; MARRIAGE; LIVER DISEASES; SEXUALLY TRANSMITTED DISEASES	NON-B-HEPATITIS; POLYMERASE CHAIN-REACTION; NON-A; HETEROSEXUAL TRANSMISSION; RISK-FACTORS; ANTIBODIES; DIAGNOSIS; GENOTYPES; PARTNERS; DISTINCT	Objective: Survey for markers of hepatitis C virus (HCV) infection in spouses of patients with HCV-related chronic liver disease. Design: Cross-sectional clinical, serologic, and molecular biological study of spouses of patients with HCV viremia and chronic liver disease. Setting: University and city hospitals. Participants: Spouses (52 men and 102 women; mean age, 56 +/- 11 years) of 154 patients with HCV viremia (102 men and 52 women; mean age, 58 +/- 10 years), of whom 66 had chronic hepatitis, 49 had liver cirrhosis, and 39 had primary hepatocellular carcinoma. Methods: Tests for HCV-associated antibodies were done using a second-generation enzyme immunoassay and immunoassays with synthetic oligopeptides deduced from the HCV core gene. Hepatitis C virus RNA was detected by polymerase chain reaction with primers deduced from the 5'-noncoding region and HCV genotypes by reaction with type-specific primers deduced from the HCV core gene. Results: Hepatitis C virus-associated antibodies were detected in 42 (27%) spouses, of whom 25 were also positive for HCV RNA. Of 112 (73%) spouses without detectable antibodies, 2 had chronic liver disease. The development of markers of HCV infection in spouses increased with the duration of marriage, ranging from 1 to 60 years (30 +/- 11 years). Conclusions: Spouses of patients with HCV viremia and chronic liver disease have an increased risk for acquiring HCV, which is proportional to the duration of marriage. They should be followed routinely for markers of HCV infection and liver disease.	JICHI MED SCH, DIV IMMUNOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; KOJIMA CLIN, GIFU, JAPAN; IWAKI KYORITSU GEN HOSP, FUKUSHIMA, JAPAN; YAMANASHI MED COLL, YAMANASHI, JAPAN; VIRAL HEPATITIS RES FDN JAPAN, TOKYO, JAPAN; INST IMMUNOL, TOKYO, JAPAN; MITA INST, TOKYO, JAPAN	Jichi Medical University; University of Yamanashi			Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964; Mishiro, Shunji/0000-0001-9618-6468				AKAHANE Y, 1992, LANCET, V339, P1059, DOI 10.1016/0140-6736(92)90585-Q; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; BRETTLER DB, 1992, BLOOD, V80, P540; CHA TA, 1992, P NATL ACAD SCI USA, V89, P7144, DOI 10.1073/pnas.89.15.7144; CHAN SW, 1992, J GEN VIROL, V73, P1131, DOI 10.1099/0022-1317-73-5-1131; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.1093/biomet/26.4.404; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; GORDON SC, 1992, AM J GASTROENTEROL, V87, P1849; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; KAO JH, 1992, J INFECT DIS, V166, P900, DOI 10.1093/infdis/166.4.900; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; MORI S, 1992, BIOCHEM BIOPH RES CO, V183, P334, DOI 10.1016/0006-291X(92)91648-A; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; OKAMOTO H, 1992, HEPATOLOGY, V15, P180, DOI 10.1002/hep.1840150203; OKAMOTO H, 1990, JPN J EXP MED, V60, P223; OSHITA M, 1993, J MED VIROL, V41, P251, DOI 10.1002/jmv.1890410314; OSMOND DH, 1993, JAMA-J AM MED ASSOC, V269, P361, DOI 10.1001/jama.269.3.361; OSMOND DH, 1993, J INFECT DIS, V167, P66, DOI 10.1093/infdis/167.1.66; PEANO GM, 1992, BRIT MED J, V305, P1473, DOI 10.1136/bmj.305.6867.1473; REINUS JF, 1992, ANN INTERN MED, V117, P881, DOI 10.7326/0003-4819-117-11-881; SHEV S, 1991, SCAND J INFECT DIS, V23, P407, DOI 10.3109/00365549109075087; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; WATANABE J, 1993, VOX SANG, V65, P199, DOI 10.1111/j.1423-0410.1993.tb02148.x; WEINSTOCK HS, 1993, JAMA-J AM MED ASSOC, V269, P392; Wejstal R, 1992, ANN INTERN MED, V117, P887, DOI 10.7326/0003-4819-117-11-887	32	163	167	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					748	752		10.7326/0003-4819-120-9-199405010-00005	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147548				2022-12-01	WOS:A1994NH25100005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC HEARING ON PROPOSED SWITCH OF ACYCLOVIR FROM PRESCRIPTION TO OVER-THE-COUNTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V59, P10650	1	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1067	1067		10.1001/jama.271.14.1067	http://dx.doi.org/10.1001/jama.271.14.1067			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151837				2022-12-01	WOS:A1994NE22800005
J	CARMELIET, P; SCHOONJANS, L; KIECKENS, L; REAM, B; DEGEN, J; BRONSON, R; DEVOS, R; VANDENOORD, JJ; COLLEN, D; MULLIGAN, RC				CARMELIET, P; SCHOONJANS, L; KIECKENS, L; REAM, B; DEGEN, J; BRONSON, R; DEVOS, R; VANDENOORD, JJ; COLLEN, D; MULLIGAN, RC			PHYSIOLOGICAL CONSEQUENCES OF LOSS OF PLASMINOGEN-ACTIVATOR GENE-FUNCTION IN MICE	NATURE			English	Article							UROKINASE-TYPE; MESSENGER-RNA; TISSUE; MOUSE; LOCALIZATION; INHIBITOR; FIBRINOLYSIS; DEGRADATION; TROPHOBLAST; MECHANISMS	Indirect evidence suggests a crucial role for the fibrinolytic system and its physiological triggers, tissue-type (t-PA) and urokinase-type (u-PA) plasminogen activator, in many proteolytic processes. Inactivation of the t-PA gene impairs clot lysis and inactivation of the u-PA gene results in occasional fibrin deposition. Mice with combined t-PA and u-PA deficiency suffer extensive spontaneous fibrin deposition, with its associated effects on growth, fertility and survival.	CATHOLIC UNIV LEUVEN, CTR MOLEC & VASC BIOL, B-3000 LOUVAIN, BELGIUM; MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; UNIV CINCINNATI, CHILDRENS HOSP RES FDN, CINCINNATI, OH 45229 USA; TUFTS UNIV, SCH VET MED, BOSTON, MA 02111 USA; CATHOLIC UNIV LEUVEN, HISTO & CYTOCHEM LAB, B-3000 LOUVAIN, BELGIUM	KU Leuven; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Tufts University; KU Leuven			Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821; Neugeboren, Beverly/0000-0003-3127-9369				ASTRUP T, 1952, ARCH BIOCHEM BIOPHYS, V40, P346, DOI 10.1016/0003-9861(52)90121-5; ASTRUP T, 1987, PROGR CHEM FIBRINOLY, V3, P1; BAKER MS, 1990, CANCER RES, V50, P4676; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BUSSO N, 1989, J BIOL CHEM, V264, P7455; CANIPARI R, 1987, J CELL BIOL, V105, P977, DOI 10.1083/jcb.105.2.977; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; COLLEN D, 1991, BLOOD, V78, P3114; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P8270, DOI 10.1021/bi00399a038; Denker H W, 1977, Adv Anat Embryol Cell Biol, V53, P3; FREYRIA AM, 1991, COMP BIOCHEM PHYS A, V99, P517, DOI 10.1016/0300-9629(91)90125-V; GRANELLIPIPERNO A, 1977, J EXP MED, V146, P1693, DOI 10.1084/jem.146.6.1693; HUARTE J, 1985, CELL, V43, P551, DOI 10.1016/0092-8674(85)90184-9; HUARTE J, 1987, J CELL BIOL, V104, P1281, DOI 10.1083/jcb.104.5.1281; IDELL S, 1989, J CLIN INVEST, V84, P695, DOI 10.1172/JCI114217; Juhan-Vague I, 1992, Ann Epidemiol, V2, P427; KLUFT C, 1988, TISSUE TYPE PLASMINO, V1, P47; LALA PK, 1990, CANCER METAST REV, V9, P369, DOI 10.1007/BF00049525; MENOUD PA, 1989, ROUX ARCH DEV BIOL, V198, P219, DOI 10.1007/BF00375908; MORIOKA S, 1987, J INVEST DERMATOL, V88, P418, DOI 10.1111/1523-1747.ep12469754; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NILSSON IM, 1985, BRIT MED J, V290, P1453, DOI 10.1136/bmj.290.6480.1453; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; PENG F, 1990, J BIOL CHEM, V265, P2022; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; STASSEN JM, 1990, FIBRINOLYSIS, V4, P15, DOI 10.1016/0268-9499(90)90349-O; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; TOMOOKA S, 1992, KIDNEY INT, V42, P1462, DOI 10.1038/ki.1992.442; TSAFRIRI A, 1989, ENDOCRINOLOGY, V124, P415, DOI 10.1210/endo-124-1-415; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UNKELESS JC, 1974, J EXP MED, V139, P834, DOI 10.1084/jem.139.4.834; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; VERHEIJEN JH, 1984, THROMB HAEMOSTASIS, V51, P392; WAGNER EF, 1990, EMBO J, V9, P3025, DOI 10.1002/j.1460-2075.1990.tb07498.x	38	914	939	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	1994	368	6470					419	424		10.1038/368419a0	http://dx.doi.org/10.1038/368419a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133887				2022-12-01	WOS:A1994ND12000052
J	USHEVA, A; SHENK, T				USHEVA, A; SHENK, T			TATA-BINDING PROTEIN-INDEPENDENT INITIATION - YY1, TFIIB, AND RNA POLYMERASE-II DIRECT BASAL TRANSCRIPTION ON SUPERCOILED TEMPLATE DNA	CELL			English	Article							PREINITIATION COMPLEX; MONOCLONAL-ANTIBODY; LESS PROMOTER; PURIFICATION; COMPONENTS; ACTIVATOR; INVITRO; REGION; DELTA	YY1 is a zinc finger transcription factor whose DNA-binding motif exhibits the properties of an initiator element. Only three factors were required to direct specific basal transcription on a supercoiled template DNA carrying the YY1 initiator: YY1, general transcription factor IIB, and RNA polymerase II. This minimal in vitro reaction did not require the TATA-binding protein (TBP). We propose that, under appropriate conditions, YY1 can function like TBP, as a factor that binds to the core promoter and recruits the polymerase to the initiation complex.			USHEVA, A (corresponding author), PRINCETON UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.				NATIONAL CANCER INSTITUTE [R01CA038965, R37CA038965] Funding Source: NIH RePORTER; NCI NIH HHS [CA38965] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CHRISTMANN JL, 1981, J BIOL CHEM, V256, P1798; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LUSBY EW, 1982, J VIROL, V41, P518, DOI 10.1128/JVI.41.2.518-526.1982; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; Weinmann Roberto, 1992, Gene Expression, V2, P81; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; ZAWAL L, 1993, PROG NUCLEIC ACID RE, V44, P67; ZAWAL L, 1992, CURR OPIN CELL BIOL, V4, P488; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	41	246	254	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1115	1121		10.1016/0092-8674(94)90387-5	http://dx.doi.org/10.1016/0092-8674(94)90387-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137426				2022-12-01	WOS:A1994ND24600016
J	GOOPTU, C; MULLEY, GP				GOOPTU, C; MULLEY, GP			SURVEY OF ELDERLY PEOPLE WHO GET STUCK IN THE BATH	BRITISH MEDICAL JOURNAL			English	Article									ST JAMES UNIV HOSP,DEPT MED ELDERLY,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND	Saint James's University Hospital								Clarke M, 1984, Health Trends, V16, P3; PENN ND, 1989, BRIT MED J, V298, P1158, DOI 10.1136/bmj.298.6681.1158-a; 1990, OLD CLEAN REPORT BAT	3	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					762	762		10.1136/bmj.308.6931.762	http://dx.doi.org/10.1136/bmj.308.6931.762			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142833	Green Published			2022-12-01	WOS:A1994NC34800023
J	KOHTZ, JD; JAMISON, SF; WILL, CL; ZUO, P; LUHRMANN, R; GARCIABLANCO, MA; MANLEY, JL				KOHTZ, JD; JAMISON, SF; WILL, CL; ZUO, P; LUHRMANN, R; GARCIABLANCO, MA; MANLEY, JL			PROTEIN-PROTEIN INTERACTIONS AND 5'-SPLICE-SITE RECOGNITION IN MAMMALIAN MESSENGER-RNA PRECURSORS	NATURE			English	Article							PRE-MESSENGER-RNA; 5' SPLICE SITE; SMALL NUCLEAR RIBONUCLEOPROTEIN; U1 SNRNA; ASSEMBLY PATHWAY; BINDING PROTEINS; FACTOR SC35; COMPLEX; INVITRO; PURIFICATION	Exactly how specific splice sites are recognized during the processing of complex precursor messenger RNAs is not clear. Small nuclear ribonucleoprotein particles (snRNPs) are involved, but are not sufficient by themselves to define splice sites. Now a human protein essential for splicing in vitro, called alternative splicing factor/splicing factor 2, is shown to cooperate with the U1 snRNP particle in binding pre-mRNA. This cooperation is probably achieved by specific interactions between the arginine/serine-rich domain of the splicing factor and a similar region in a U1 snRNP-specific protein.	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University; Duke University; Duke University	KOHTZ, JD (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Manley, James/0000-0002-8341-1459				AYANE M, 1991, NUCLEIC ACIDS RES, V19, P1273, DOI 10.1093/nar/19.6.1273; BACH M, 1990, METHOD ENZYMOL, V181, P232; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; CHABOT B, 1987, MOL CELL BIOL, V7, P698, DOI 10.1128/MCB.7.2.698; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; FU XD, 1992, P NATN ACAD SCI US, V89; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1992, GENE DEV, V6, P2569, DOI 10.1101/gad.6.12b.2569; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH V, 1991, EMBO J, V10, P2627, DOI 10.1002/j.1460-2075.1991.tb07805.x; SMTH CWJ, 1989, A REV GENET, V3, P527; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TATEI K, 1987, J BIOL CHEM, V262, P11667; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x; ZUO P, IN PRESS P NATN ACAD	50	547	553	2	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					119	124		10.1038/368119a0	http://dx.doi.org/10.1038/368119a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139654				2022-12-01	WOS:A1994NA03000056
J	ULLRICH, O; HORIUCHI, H; BUCCI, C; ZERIAL, M				ULLRICH, O; HORIUCHI, H; BUCCI, C; ZERIAL, M			MEMBRANE ASSOCIATION OF RAB5 MEDIATED BY GDP-DISSOCIATION INHIBITOR AND ACCOMPANIED BY GDP/GTP EXCHANGE	NATURE			English	Article							GTP-BINDING PROTEIN; REGULATORY PROTEIN; SMG P25A	THE Rab GTPases function as specific regulators of membrane transport(1-4) The GTP/GDP cycle is believed to control shuttling of Rab proteins between the cytosol and organelle membranes. In vitro, Rab proteins are removed from membranes by a protein that inhibits GDP dissociation (rabGDI)(5), which leads to formation of a cytosolic complex of Rab with the inhibitor protein(6-8). Here we use a purified Rab5-rabGDI complex in a permeabilized cell system to investigate how the cytosolic complexed form of Rab reassociates with the membrane. We find that exogenous Rab5 is correctly targeted and induces the formation of enlarged early endosomes, demonstrating that it is functionally active. Binding of Rab5 to the acceptor membrane is accompanied by release of the rabGDI protein into the cytosol. A transient GDP-Rab5 intermediate was detected which was subsequently converted into the GTP-bound form. Our results indicate that there is a multistep mechanism for the insertion of Rab5 into the membrane which is mediated by a guanine-nucleotide-exchange factor.	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Bucci, Cecilia/F-6699-2012	Bucci, Cecilia/0000-0002-6232-6183				ARAKI S, 1990, J BIOL CHEM, V265, P13007; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; KOBAYASHI T, 1992, FEBS LETT, V300, P227, DOI 10.1016/0014-5793(92)80851-7; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STENMARK H, IN PRESS EMBO J; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	17	268	269	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					157	160		10.1038/368157a0	http://dx.doi.org/10.1038/368157a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139660				2022-12-01	WOS:A1994NA03000069
J	COOK, DG; WHINCUP, PH; JARVIS, MJ; STRACHAN, DP; PAPACOSTA, O; BRYANT, A				COOK, DG; WHINCUP, PH; JARVIS, MJ; STRACHAN, DP; PAPACOSTA, O; BRYANT, A			PASSIVE EXPOSURE TO TOBACCO-SMOKE IN CHILDREN AGED 5-7 YEARS - INDIVIDUAL, FAMILY, AND COMMUNITY FACTORS	BRITISH MEDICAL JOURNAL			English	Article							COTININE CONCENTRATIONS; SALIVARY COTININE; NICOTINE; MARKERS	Objective-To examine the importance of parental smoking on passive exposure to tobacco smoke in children and the social and geographical patterns of exposure. Design-Cross sectional study. Setting-Schools in 10 towns in England and Wales; five towns with high adult cardiovascular mortality and five with low rates. Subjects-4043 children aged 5-7 years of European origin. Main outcome measures-Salivary cotinine concentration and parents self reported smoking habits. Results-1061 (53.0%) children were exposed to cigarette smoke at home or by an outside carer. Geometric mean cotinine rose from 0.29 (95% confidence interval 0.28 to 0.31) ng/ml in children with no identified exposure to 4.05 (3.71 to 4.42) ng/ml in households where both parents smoked and 9.03 (6.73 to 12.10) ng/ml if both parents smoked more than 20 cigarettes a day. The effect of mothers' smoking was greater than that of fathers', especially at high levels of consumption. After adjustment for known exposures geometric mean cotinine concentrations rose from 0.52 ng/ml in social class I to 1.36 ng/ml in social class V (P<0.0001); and were doubled in high mortality towns compared with the low mortality towns (P=0.002). In children with no identified exposure similar trends by social class and town were observed and the cotinine concentrations correlated with the prevalence of parental smoking, both between towns (r=0.69, P=0.02) and between schools within towns (r=0.50, P<0.001). Conclusions-Mothers' smoking is more important that fathers' despite the lower levels of smoking by mothers. Children not exposed at home had low cotinine concentration, the level depending on the prevalence of smoking in the community.	ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,LONDON,ENGLAND; INST PSYCHIAT,IMPERIAL CANC RES FUND,HLTH BEHAV UNIT,LONDON SE5 8AF,ENGLAND; NEW CROSS HOSP,NATL POISONS UNIT,LONDON SE14 5ER,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Cancer Research UK; University of London; King's College London; New Cross Hospital	COOK, DG (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Jarvis, Martin J/B-1034-2008	Jarvis, Martin J/0000-0001-9238-8038; Whincup, Peter/0000-0002-5589-4107; Cook, Derek/0000-0002-9723-5759; Papacosta, Olia/0000-0001-8781-6747	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; COOK DG, 1993, THORAX, V48, P14, DOI 10.1136/thx.48.1.14; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; IDLE JR, 1990, J CLIN EPIDEMIOL, V43, P313, DOI 10.1016/0895-4356(90)90117-8; JARVIS M, 1984, J EPIDEMIOL COMMUN H, V38, P335, DOI 10.1136/jech.38.4.335; JARVIS MJ, 1991, INT J EPIDEMIOL, V20, P126, DOI 10.1093/ije/20.1.126; JARVIS MJ, 1992, AM J PUBLIC HEALTH, V82, P1225, DOI 10.2105/AJPH.82.9.1225; JARVIS MJ, 1989, MUTAT RES, V222, P101, DOI 10.1016/0165-1218(89)90023-2; MCNEILL AD, 1987, BRIT J ADDICT, V82, P1355; STRACHAN DP, 1990, AM REV RESPIR DIS, V142, P147, DOI 10.1164/ajrccm/142.1.147; STRACHAN DP, 1989, BRIT MED J, V298, P1549, DOI 10.1136/bmj.298.6687.1549; WHINCUP PH, 1993, ARCH DIS CHILD, V68, P729, DOI 10.1136/adc.68.6.729; WHINCUP PH, 1992, J EPIDEMIOL COMMUN H, V46, P396, DOI 10.1136/jech.46.4.396; WHINCUP PH, 1991, THESIS U LONDON LOND, P222; 1988, OCCUPATIONAL MORTALI; 1985, SAS USERS GUIDE BASI; 1992, SMOKING YOUNG	17	108	110	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 5	1994	308	6925					384	389						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MV862	8124146	Green Published			2022-12-01	WOS:A1994MV86200021
J	VELDMAN, PHJM; REYNEN, HM; ARNTZ, IE; GORIS, RJA				VELDMAN, PHJM; REYNEN, HM; ARNTZ, IE; GORIS, RJA			SIGNS AND SYMPTOMS OF REFLEX SYMPATHETIC DYSTROPHY - PROSPECTIVE-STUDY OF 829 PATIENTS	LANCET			English	Article							CORTICOSTEROIDS; CAUSALGIA; TRIAL	The pathogenesis of reflex sympathetic dystrophy-variously known as Sudeck's atrophy, causalgia, algodystrophy, and peripheral trophoneurosis-is not yet understood, and diagnosing and treating patients is difficult. We have prospectively studied 829 patients, paying particular attention to early signs and symptoms. In its early phase, reflex sympathetic dystrophy is characterised by regional inflammation, which increases after muscular exercise. Pain was present in 93% of patients, and hypoaesthesia and hyperpathy were present in 69% and 75% respectively. With time, tissue atrophy may occur as well as involuntary movements, muscle spasms, or pseudoparalysis. Tremor was found in 49% and muscular incoordination in 54% of patients. Sympathetic signs such as hyperhidrosis are infrequent and therefore have no diagnostic value. We found no evidence consistent with the presence of three consecutive phases of the disease. Early symptoms are those of an inflammatory reaction and not of a disturbance of the sympathetic nervous system. These data support the concept of an exaggerated regional inflammatory response to injury or operation in reflex sympathetic dystrophy.			VELDMAN, PHJM (corresponding author), UNIV HOSP NIJMEGEN,DEPT SURG,6500 HB NIJMEGEN,NETHERLANDS.							ACQUAVIVA P, 1982, REV RHUM, V49, P761; ADLER E., 1959, PSYCHIAT ET NEUROL, V138, P256; ATKINS RM, 1990, J BONE JOINT SURG BR, V72, P105, DOI 10.1302/0301-620X.72B1.2298766; BABINSKY J, 1917, HYSTERIE PITHIATISME; Bohm E., 1985, HEFTE UNFALLHEILKD, V174, P241; BONNET J, 1953, THESIS LEIDEN; CHRISTENSEN K, 1982, ACTA CHIR SCAND, V148, P653; EVANS JA, 1947, ANN INTERN MED, V26, P417, DOI 10.7326/0003-4819-26-3-417; GORIS RJA, 1990, LETSELS ENKEL VOET E, P435; Goris RJA, 1991, TISSUE OXYGEN UTILIZ, P350; HADDOX JD, 1990, PAIN SYMPATHETIC NER, P207; HANNA MH, 1989, PAIN, V38, P145, DOI 10.1016/0304-3959(89)90232-7; HEERSCHAP A, 1993, MUSCLE NERVE, V16, P367, DOI 10.1002/mus.880160405; HOLDER LE, 1984, RADIOLOGY, V152, P517, DOI 10.1148/radiology.152.2.6739825; Johnson AC, 1943, ANN INTERN MED, V19, P433, DOI 10.7326/0003-4819-19-3-433; Kleinert H E, 1973, Orthop Clin North Am, V4, P917; KOZIN F, 1976, AM J MED, V60, P321, DOI 10.1016/0002-9343(76)90747-6; KOZIN F, 1981, RADIOLOGY, V138, P437, DOI 10.1148/radiology.138.2.7455127; MARSDEN CD, 1984, BRIT MED J, V288, P173, DOI 10.1136/bmj.288.6412.173; MAURER G, 1940, ERG CHIR, V33, P476; MILLER DS, 1942, SURG GYNECOL OBSTET, V75, P558; Mitchell SW, 1864, GUNSHOT WOUNDS OTHER; MOESKER A, 1985, PAIN CLINIC, V1, P171; Omer G, 1971, Tex Med, V67, P93; OYEN WJG, 1993, IN PRESS PAIN; Pak T J, 1970, Minn Med, V53, P507; PLEWES LW, 1956, J BONE JOINT SURG BR, V38, P195, DOI 10.1302/0301-620X.38B1.195; PROUGH DS, 1985, ANESTHESIOLOGY, V62, P796, DOI 10.1097/00000542-198506000-00017; ROSEN P S, 1957, Can Med Assoc J, V77, P86; ROUMEN RMH, 1991, J BONE JOINT SURG BR, V73, P307, DOI 10.1302/0301-620X.73B2.2005162; SAUNDERS PR, 1988, BRIT MED J, V297, P1635, DOI 10.1136/bmj.297.6664.1635-b; SCHUTZER SF, 1984, J BONE JOINT SURG AM, V66A, P625, DOI 10.2106/00004623-198466040-00025; SHAW RS, 1964, NEW ENGL J MED, V271, P22, DOI 10.1056/NEJM196407022710104; SHUMACKER HB, 1948, SURG GYNECOL OBSTET, V86, P452; STEINBROCKER O, 1947, AM J MED, V3, P402, DOI 10.1016/0002-9343(47)90170-8; Subarrao J, 1981, ARCH PHYS MED REHAB, V62, P549; Sudeck P, 1942, CHIRURG, V15, P449; SUDECK P, 1900, ARCH KLIN CHIR, V62, P147; TAHMOUSH AJ, 1983, NEUROLOGY, V33, P1483, DOI 10.1212/WNL.33.11.1483; TILMAN P B J, 1990, Micron and Microscopica Acta, V21, P271, DOI 10.1016/0739-6260(90)90143-4; WILDER RT, 1992, J BONE JOINT SURG AM, V74A, P910, DOI 10.2106/00004623-199274060-00013	41	800	818	0	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1012	1016		10.1016/0140-6736(93)92877-V	http://dx.doi.org/10.1016/0140-6736(93)92877-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105263				2022-12-01	WOS:A1993MD06600008
J	BLAU, JN				BLAU, JN			BEHAVIOR DURING A CLUSTER HEADACHE	LANCET			English	Article								Because cluster headache is short-lasting and tends to occur during the early morning hours, physicians rarely witness an attack. Accurate diagnosis is important because effective treatments are available. The diagnosis is made from the history of temporal pattern, reddening and tearing of the affected eye, and ipsilateral nasal congestion. An additional diagnostic aid is to invite patients to demonstrate how they respond to attacks. The pain, one of the worst known, causes extreme restlessness. 50 patients showed how they walk around, sit (or kneel) and rock, and clutch the affected side of the head. Diagnostic value apart, the patient will often be relieved to learn that bizarre behavioural responses are not a mark of insanity.			BLAU, JN (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							EKBOM K, 1970, ACTA NEUROL SCAND, V46, P1; EKBOM K, 1968, BRAIN MIND PROBLEMS, P482; HORTON BT, 1956, JAMA-J AM MED ASSOC, V160, P468, DOI 10.1001/jama.1956.02960410044011; KUDROW L, 1980, CLUSTER HEADACHE, P35; LANCE JW, NEUROL SCI, V13, P401; LEVI P, 1986, MOMENTS REPRIEVE, P100; MCKINNEY AS, 1983, HEADACHE, V23, P305, DOI 10.1111/j.1526-4610.1983.hed2306305.x; NAPPI G, 1992, CEPHALALGIA, V12, P165, DOI 10.1046/j.1468-2982.1992.1203165.x; SAKAI F, 1990, HEADACHE Q-CURR TREA, V1, P71; SJAASTAD O, 1992, CLUSTER HEADACHE SYN, P206; SOLZHENITSYN A, 1969, CANCER WARD, P454	11	31	34	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					723	725		10.1016/0140-6736(93)91713-V	http://dx.doi.org/10.1016/0140-6736(93)91713-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103827				2022-12-01	WOS:A1993LX46900014
J	ECKMAN, MH; LEVINE, HJ; PAUKER, SG				ECKMAN, MH; LEVINE, HJ; PAUKER, SG			EFFECT OF LABORATORY VARIATION IN THE PROTHROMBIN-TIME RATIO ON THE RESULTS OF ORAL ANTICOAGULANT-THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-VALVE REPLACEMENT; ARTERIAL THROMBOEMBOLIC COMPLICATIONS; JUDE MEDICAL VALVE; QUALITY-OF-LIFE; BJORK-SHILEY; MEDTRONIC-HALL; CARDIAC-VALVE; DIFFERENT INTENSITIES; PERSONAL-COMPUTER; DECISION-ANALYSIS	Background. Patients receiving long-term anticoagulant therapy may be subject to unnecessary risks of bleeding or thromboembolism because of variability in the commercial thromboplastins used to determine prothrombin time and consequent uncertainty about the actual intensity of anticoagulation. Methods. We explored the effect of this uncertainty on the benefits and risks of anticoagulation in patients with prosthetic heart valves, using models of thromboembolic and hemorrhagic complications as a function of the intensity of anticoagulation, with quality-adjusted life expectancy and average variable costs used to describe outcomes. Results. Anticoagulation provides a striking benefit for patients whose treatment is conducted within the recommended range of the international normalized ratio (INR) - i.e., 2.5 to 3.5 - but if uncertainty about the laboratory results causes the intensity of anticoagulation to fall outside this range, the gain becomes smaller. Uncertainty about the true intensity of anticoagulation may reduce the potential gain in life expectancy, adjusted for quality of life, by more than half and may increase the ratio of costs to effectiveness to almost five times the optimal value. Variability in the intensity of anticoagulation is even greater if older recommendations advocating a higher level of anticoagulation are followed. Conclusions. Uncertainty about the sensitivities of the commercially available thromboplastins used in the United States can have important clinical and economic effects. This problem could be eliminated if clinical laboratories uniformly reported the intensity of anticoagulation as the INR, by adjusting prothrombin-time ratios for variability in thromboplastins.	TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, DIV CARDIOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University	ECKMAN, MH (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, DIV CLIN DECIS MAKING, BOX 302, 750 WASHINGTON ST, BOSTON, MA 02111 USA.			Eckman, Mark/0000-0001-8253-269X	AHRQ HHS [HS-06503] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AKBARIAN M, 1968, CIRCULATION, V37, P826, DOI 10.1161/01.CIR.37.5.826; ALTMAN R, 1976, J THORAC CARDIOV SUR, V72, P127; ALTMAN R, 1991, J THORAC CARDIOV SUR, V101, P427; ANSELL JE, 1992, AM J CLIN PATHOL, V98, P237, DOI 10.1093/ajcp/98.2.237; BAUDET EM, 1985, J THORAC CARDIOV SUR, V90, P137; BEAUDET RL, 1986, ANN THORAC SURG, V42, P644, DOI 10.1016/S0003-4975(10)64598-5; BJORK VO, 1979, J THORAC CARDIOV SUR, V78, P331; BJORK VO, 1975, SCAND J THORAC CARD, V9, P183, DOI 10.3109/14017437509138637; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278, DOI 10.1001/archinte.152.2.278; CHESEBRO JH, 1983, AM J CARDIOL, V51, P1537, DOI 10.1016/0002-9149(83)90673-2; COPELAND JG, 1977, J THORAC CARDIOV SUR, V74, P875; CORTINA JM, 1986, J THORAC CARDIOV SUR, V91, P174; CZER LSC, 1990, J THORAC CARDIOV SUR, V100, P44; DALE J, 1977, AM HEART J, V93, P715, DOI 10.1016/S0002-8703(77)80066-5; DALE J, 1977, AM HEART J, V94, P101, DOI 10.1016/S0002-8703(77)80351-7; DALE J, 1976, AM HEART J, V91, P653, DOI 10.1016/S0002-8703(76)80152-4; DESESA VJ, 1989, ANN THORAC SURG, V48, P280; DUVOISIN GE, 1967, CIRCULATION       S1, V35, P70; EBERLEIN U, 1990, EUR J CARDIO-THORAC, V4, P605, DOI 10.1016/1010-7940(90)90020-Z; ECKMAN MH, 1992, CHEST, V102, pS538, DOI 10.1378/chest.102.4_Supplement.538S; EDMUNDS LH, 1982, ANN THORAC SURG, V34, P96, DOI 10.1016/S0003-4975(10)60862-4; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; HIRSCH J, 1992, ARCH INTERN MED, V152, P959; HIRSH J, 1992, ARCH INTERN MED, V152, P257, DOI 10.1001/archinte.152.2.257; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; HIRSH J, 1992, CHEST, V102, pS312, DOI 10.1378/chest.102.4.312S; HIRSH J, 1991, ARCH INTERN MED, V151, P1921, DOI 10.1001/archinte.151.10.1921; Hirsh J, 1989, CHEST, V96, P962; HORSTKOTTE D, 1983, CIRCULATION S2, V68, P75; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; KOPF GS, 1987, CIRCULATION, V76, P132; LANCASTER TR, 1991, ARCH INTERN MED, V151, P1944, DOI 10.1001/archinte.151.10.1944; LANCASTER TR, 1992, ARCH INTERN MED, V152, P825; LANDEFELD CS, 1989, AM J MED, V87, P153; LARSEN GL, 1977, ANN THORAC SURG, V23, P323, DOI 10.1016/S0003-4975(10)64133-1; LAU J, 1983, MED DECIS MAKING, V3, P39, DOI 10.1177/0272989X8300300110; MOGGIO RA, 1978, J THORAC CARDIOV SUR, V75, P296; PAUKER SG, 1981, ARCH INTERN MED, V141, P1831, DOI 10.1001/archinte.141.13.1831; Poller L., 1987, HEMATOLOGY REV, V1, P225; Quick AJ, 1935, AM J MED SCI, V190, P501, DOI 10.1097/00000441-193510000-00009; RACKLEY CE, 1986, HEART, P754; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P338; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; SETHIA B, 1986, J THORAC CARDIOV SUR, V91, P350; SINGER RB, 1976, MED RISKS PATTERNS M, P3; SONNENBERG FA, 1986, P MEDINFO 86, P1152; STEIN DW, 1976, J THORAC CARDIOV SUR, V71, P680; STEIN PD, 1992, CHEST, V102, pS445, DOI 10.1378/chest.102.4_Supplement.445S; SULLIVAN JM, 1971, NEW ENGL J MED, V284, P1391, DOI 10.1056/NEJM197106242842501; SULLIVAN JM, 1969, CIRCULATION       S1, V39, P149; TURPIE A G G, 1992, Journal of the American College of Cardiology, V19, p103A; TURPIE AGG, 1988, LANCET, V1, P1242; VALLEJO JL, 1990, ANN THORAC SURG, V50, P429, DOI 10.1016/0003-4975(90)90489-S; VIDNE B, 1974, ISRAEL J MED SCI, V10, P586; VOGT S, 1990, EUR HEART J, V11, P583, DOI 10.1093/oxfordjournals.eurheartj.a059763; 1987, DHSS PHS901101 PUBL; 1982, LANCET, V1, P64; 1990, SAS PROCEDURES GUIDE, P210; 1991, CGD2 COLL AM PATH CO	59	70	72	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1993	329	10					696	702		10.1056/NEJM199309023291005	http://dx.doi.org/10.1056/NEJM199309023291005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU583	8135917				2022-12-01	WOS:A1993LU58300005
J	KOGAN, MD; ALEXANDER, GR; KOTELCHUCK, M; NAGEY, DA				KOGAN, MD; ALEXANDER, GR; KOTELCHUCK, M; NAGEY, DA			RELATION OF THE CONTENT OF PRENATAL-CARE TO THE RISK OF LOW-BIRTH-WEIGHT - MATERNAL REPORTS OF HEALTH BEHAVIOR ADVICE AND INITIAL PRENATAL-CARE PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPACT; POPULATION; PROGRAMS; OUTCOMES; WOMEN	Objective.-Numerous studies have found a relationship between the quantity of prenatal care received and birth outcomes. Few studies have had the opportunity to examine the content of prenatal care. This study examined the relationship between two components of the content of prenatal care: maternal reports of health behavior advice received and initial prenatal care procedures performed during the first two visits and low birth weight in a national sample of women. Advice and initial procedures were categorized based on the recommendations of the US Public Health Service Expert Panel on the Content of Prenatal Care. Design.-Interview survey of a nationally representative sample of women who had live births in 1988. Participants.-A total of 9394 women, with data from the National Maternal and Infant Health Survey. Main Outcome Measure.-Low birth weight (<2500 g) as reported on the birth certificate. Results.-After controlling for other sociodemographic, utilization, medical, and behavioral factors, women who reported not receiving all the types of advice recommended by the Expert Panel on the Content of Prenatal Care were more likely to have a low-birth-weight infant compared with women who reported receiving the optimal level of advice (odds ratio=1.38; 95% confidence interval, 1.18 to 1.60). There were no differences between women who reported receiving all the recommended initial prenatal care procedures and those who reported not receiving all recommended prenatal care (odds ratio=1.00; 95% confidence interval, 0.87 to 1.14). Conclusion.-These data suggest that women who report receiving sufficient health behavior advice as part of their prenatal care are at lower risk of delivering a low-birth-weight infant.	UNIV MINNESOTA,DEPT MATERNAL & CHILD HLTH,MINNEAPOLIS,MN 55455; UNIV N CAROLINA,DEPT MATERNAL & CHILD HLTH,CHAPEL HILL,NC; UNIV MARYLAND,SCH MED,DEPT OBSTET & GYNECOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PREVENT MED,BALTIMORE,MD 21201	University of Minnesota System; University of Minnesota Twin Cities; University of North Carolina; University of North Carolina Chapel Hill; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	KOGAN, MD (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,6525 BELCREST RD,ROOM 840,HYATTSVILLE,MD 20782, USA.							ALEXANDER GR, 1987, AM J PREV MED, V3, P243; DAVIDSON EC, 1992, NEW ENGL J MED, V327, P1022, DOI 10.1056/NEJM199210013271409; FINK A, 1992, OBSTET GYNECOL, V80, P867; FISHER ES, 1985, AM J PUBLIC HEALTH, V75, P866, DOI 10.2105/AJPH.75.8.866; GORTMAKER SL, 1979, AM J PUBLIC HEALTH, V69, P653, DOI 10.2105/AJPH.69.7.653; GREENBERG RS, 1983, AM J OBSTET GYNECOL, V145, P797, DOI 10.1016/0002-9378(83)90681-6; HEMMINKI E, 1988, MED CARE, V26, P199, DOI 10.1097/00005650-198802000-00010; KESSEL SS, 1988, CLIN PERINATOL, V15, P745, DOI 10.1016/S0095-5108(18)30671-7; Kessner DM, 1973, CONTRASTS HLTH STATU; KOGAN MD, 1994, AM J PUBLIC HEALTH, V84, P82, DOI 10.2105/AJPH.84.1.82; Koonin L M, 1991, MMWR CDC Surveill Summ, V40, P1; KOTELCHUCK M, IN PRESS AM J PUBLIC; LIBBUS MK, 1991, BIRTH-ISS PERINAT C, V18, P78, DOI 10.1111/j.1523-536X.1991.tb00064.x; LIEBERMAN E, 1987, NEW ENGL J MED, V317, P743, DOI 10.1056/NEJM198709173171206; MCLAUGHLIN FJ, 1992, PEDIATRICS, V89, P128; MOORE TR, 1986, AM J OBSTET GYNECOL, V154, P29, DOI 10.1016/0002-9378(86)90387-X; NAGEY DA, 1989, OBSTET GYNECOL, V74, P516; PEOPLES MD, 1983, MED CARE, V21, P586, DOI 10.1097/00005650-198306000-00002; PEOPLESSHEPS MD, 1991, AM J OBSTET GYNECOL, V164, P514, DOI 10.1016/S0002-9378(11)80011-6; PEOPLESSHEPS MD, 1988, HEALTH SERV RES, V23, P359; PETTITI DB, 1991, BIRTH-ISS PERINAT C, V18, P21; POLAND ML, 1991, J PERINAT MED, V19, P427, DOI 10.1515/jpme.1991.19.6.427; QUICK JD, 1981, AM J PUBLIC HEALTH, V71, P381, DOI 10.2105/AJPH.71.4.381; SANDERSON M, 1991, BIRTH-ISS PERINAT C, V18, P26, DOI 10.1111/j.1523-536X.1991.tb00050.x; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P48, DOI 10.1001/jama.255.1.48; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; SOKOL RJ, 1980, OBSTET GYNECOL, V56, P150; 1993, SURVEY DATA ANAL VER; 1989, CARING OUR FUTURE CO	29	153	156	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	1994	271	17					1340	1345		10.1001/jama.271.17.1340	http://dx.doi.org/10.1001/jama.271.17.1340			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NH487	8158819				2022-12-01	WOS:A1994NH48700026
J	BECKER, TM; WHEELER, CM; MCGOUGH, NS; PARMENTER, CA; JORDAN, SW; STIDLEY, CA; MCPHERSON, RS; DORIN, MH				BECKER, TM; WHEELER, CM; MCGOUGH, NS; PARMENTER, CA; JORDAN, SW; STIDLEY, CA; MCPHERSON, RS; DORIN, MH			SEXUALLY-TRANSMITTED DISEASES AND OTHER RISK-FACTORS FOR CERVICAL DYSPLASIA AMONG SOUTHWESTERN HISPANIC AND NON-HISPANIC WHITE WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN PAPILLOMAVIRUS INFECTION; HERPES-SIMPLEX INFECTIONS; GENITAL INFECTIONS; CANCER; NEOPLASIA; GLYCOPROTEIN; POPULATION; DIAGNOSIS	Objective.-To assess risk factors for high-grade cervical dysplasia among southwestern Hispanic and non-Hispanic white women. Design.-Clinic-based case-control study. Setting.-University-affiliated gynecology clinics. Subjects.-Cases were Hispanic and non-Hispanic white women with biopsy proven high-grade cervical dysplasia (n=201). Controls were Hispanic and non-Hispanic white women from the same clinics with normal cervical epithelium (n=337). Methods.-Study design included interviews focused on histories of sexually transmitted diseases, sexual behavior, reproductive histories, hygienic practices, contraceptive use, cigarette smoking, and diet. Laboratory studies included bacterial and protozoal cultures of the cervix; hybridization tests to identify human papillomavirus (HPV) genome with commercial (ViraPap and ViraType) and polymerase chain reaction-based assays; and serum antibody tests for herpes simplex virus, Chlamydia trachomatis, syphilis, hepatitis B, and hepatitis C. Results.-For both ethnic groups combined, after adjustment for ethnicity, age, and sexual behavior, the strongest risks for cervical dysplasia were associated with cervical HPV infection as identified by ViraPap (odds ratio [OR], 12.8; 95% confidence interval [CI], 8.2 to 20.0) or with polymerase chain reaction (OR, 20.8; 95% CI, 10.8 to 40.2). Other factors associated with dysplasia included cigarette smoking at the time of diagnosis (OR, 1.8; 95% CI, 1.2 to 2.8); low income (OR, 2.2; 95% CI, 1.2 to 4.0); low educational level (OR, 6.2; 95% CI, 3.4 to 11.1); history of any sexually transmitted disease (OR, 1.9; 95% CI, 1.3 to 2.7); and seroprevalence of antibodies to hepatitis B (OR, 1.8; 95% CI, 0.9 to 3.5). For Hispanic women, HPV 16/18 identified by ViraType was strongly associated with cervical dysplasia (OR, 171.0; 95% CI, 22.8 to 1280.5). Antibodies to herpes simplex virus type 2 were not associated with dysplasia in Hispanic women but were significantly associated with dysplasia among non-Hispanic whites. Risks associated with cigarette smoking also varied by ethnic group. Conclusions.-The strongest risk factor associated With high-grade cervical dysplasia among clinic attendees was HPV infection. Although most of the risk factors we examined showed similar associations for dysplasia for both ethnic groups, our data suggest that several different risk factors may be relevant to the development of cervical dysplasia in Hispanics compared with non-Hispanic whites who attend the same clinics.	UNIV TEXAS, SCH PUBL HLTH, HOUSTON, TX 77025 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	BECKER, TM (corresponding author), UNIV NEW MEXICO, SCH MED, CTR CANC, NEW MEXICO TUMOR REGISTRY, ALBUQUERQUE, NM 87131 USA.				NCI NIH HHS [CA-48003] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA048003] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BECKER TM, 1992, WESTERN J MED, V156, P376; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; BRINTON LA, 1992, EPIDEMIOLOGY CERVICA; COSSMAN J, 1991, J NATL CANCER I, V83, P980, DOI 10.1093/jnci/83.14.980; ESCHENBACH DA, 1988, AM J OBSTET GYNECOL, V158, P819, DOI 10.1016/0002-9378(88)90078-6; Franco E L, 1991, Epidemiology, V2, P98, DOI 10.1097/00001648-199103000-00003; HERRERO R, 1990, CANCER-AM CANCER SOC, V65, P380, DOI 10.1002/1097-0142(19900115)65:2<380::AID-CNCR2820650234>3.0.CO;2-9; JORDAN SW, 1981, CANCER, V47, P2523, DOI 10.1002/1097-0142(19810515)47:10<2523::AID-CNCR2820471036>3.0.CO;2-T; KJAER SK, 1991, INT J CANCER, V48, P39; KLITZ W, 1992, NATURE, V356, P17, DOI 10.1038/356017a0; LEE FK, 1986, J VIROL METHODS, V14, P111, DOI 10.1016/0166-0934(86)90041-8; LEE FK, 1985, J CLIN MICROBIOL, V22, P641, DOI 10.1128/JCM.22.4.641-644.1985; Linstead D., 1989, TRICHOMONADS PARASIT, P91; MANOS MM, 1989, CANCER CEL, V7, P209; MANOS MM, 1991, JUL PAP WORKSH SEATT; MORRISON EAB, 1991, INT J CANCER, V49, P6, DOI 10.1002/ijc.2910490103; MUNOZ N, 1992, EPIDEMIOLOGY CERVICA, P251; NETTLEMAN MD, 1988, JAMA-J AM MED ASSOC, V260, P207, DOI 10.1001/jama.260.2.207; OBERLE MW, 1989, AM J TROP MED HYG, V41, P224, DOI 10.4269/ajtmh.1989.41.224; Odds FC, 1979, CANDIDA CANDIDOSIS; Paavonen J, 1990, SEXUALLY TRANSMITTED, V2, P561; PETERS RK, 1986, JNCI-J NATL CANCER I, V77, P1063; REEVES WC, 1989, NEW ENGL J MED, V320, P1437, DOI 10.1056/NEJM198906013202201; Sampson L., 1985, CLIN NUTR, V4, P171; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SCHMAUZ R, 1989, INT J CANCER, V43, P805, DOI 10.1002/ijc.2910430511; SCHNEIDER A, 1992, OBSTET GYNECOL, V79, P683; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V268, P1702, DOI 10.1001/jama.268.13.1702; SLATTERY ML, 1989, AM J EPIDEMIOL, V130, P248, DOI 10.1093/oxfordjournals.aje.a115331; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; STAMM WE, 1986, DIAGN MICROBIOL, V4, P935; THAYER JD, 1966, HLTH LAB REP, V81, P559; WANK R, 1991, NATURE, V352, P723, DOI 10.1038/352723a0; WILLETT WC, 1987, J AM DIET ASSOC, V87, P43; ZUNZUNEGUI MV, 1986, AM J EPIDEMIOL, V123, P302, DOI 10.1093/oxfordjournals.aje.a114238; 1989, SAS STAT USERS GUIDE; 1969, MANUAL TESTS SYPHILI	38	84	85	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1181	1188						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	8151876				2022-12-01	WOS:A1994NF20700027
J	ASHBY, J				ASHBY, J			CHANGE THE RULES FOR FOOD-ADDITIVES	NATURE			English	Editorial Material							CARCINOGENS				ASHBY, J (corresponding author), ZENECA CENT TOXICOL LAB,MACCLESFIELD SK10 4TJ,CHESHIRE,ENGLAND.							AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; ASHBY J, 1993, MUTAGENESIS, V8, P489, DOI 10.1093/mutage/8.6.489; ASHBY J, 1991, NATURE, V352, P185, DOI 10.1038/352185a0; ASHBY J, 1994, MUTAT RES, V306, P107, DOI 10.1016/0027-5107(94)90173-2; HILDEBRAND B, 1991, MUTAT RES, V248, P211; JUKES TH, 1972, PREV MED, V2, P133; SWENBERG JA, 1993, ENVIRON HEALTH PERSP, V101, P39, DOI 10.1289/ehp.93101s639; SWENBERG JA, 1993, ENV HLTH PERSPECT S, V5; 1993, NATURE, V363, P287; 1993, NTP431 TECHN REP; 1986, NTP250 TECHN REP	11	4	4	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					582	582		10.1038/368582a0	http://dx.doi.org/10.1038/368582a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145840	Bronze			2022-12-01	WOS:A1994NF39200026
J	FERRIS, PJ; GOODENOUGH, UW				FERRIS, PJ; GOODENOUGH, UW			THE MATING-TYPE LOCUS OF CHLAMYDOMONAS-REINHARDTII CONTAINS HIGHLY REARRANGED DNA-SEQUENCES	CELL			English	Article							A-ALPHA; SCHIZOPHYLLUM-COMMUNE; FUNCTIONAL-ANALYSIS; CHLOROPLAST GENES; NEUROSPORA-CRASSA; LINKED MUTATIONS; MUTANTS; YEAST; RECOMBINATION; PROTEINS	The mating-type locus of Chlamydomonas reinhardtii exists as two apparent alleles (mt+ and mt-) that control mating in haploid gametes and sporulation and meiosis in diploid mt+/mt- zygotes. Twelve genes, seven unrelated to life cycle transitions, are tightly linked to mt, suggesting that the locus exerts recombinational suppression. A 1.1 Mb chromosome walk from a gene linked to mt demonstrates that the mt+ and mt- loci carry four intrachromosomal translocations, two inversions, and large deletions and duplications within a 190 kb sector, presumably accounting for the recombinational suppression that extends through 640 kb of flanking homologous DNA. The rearranged domain also carries blocks of mt+- and mt--specific sequences, at least one of which includes a mt+-specific gene. The locus has the properties of an incipient sex chromosome.			FERRIS, PJ (corresponding author), WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130, USA.							ADAMS GMW, 1982, GENETICS, V100, P579; Allen CE, 1932, AM NAT, V66, P97, DOI 10.1086/280416; Allen CE, 1935, BOT REV, V1, P269; [Anonymous], 1966, GENETICS SEXUALITY H; ARMBRUST EV, 1993, CELL, V74, P801, DOI 10.1016/0092-8674(93)90460-8; ARNAISE S, 1993, P NATL ACAD SCI USA, V90, P6616, DOI 10.1073/pnas.90.14.6616; ASTELL CR, 1981, CELL, V27, P15, DOI 10.1016/0092-8674(81)90356-1; BAKKEREN G, 1993, PLANT CELL, V5, P2323; BELL G, 1989, SEX DEATH PROTOZOA; Bull J.J., 1983, EVOLUTION SEX DETERM; BURGOYNE PS, 1992, CELL, V71, P391, DOI 10.1016/0092-8674(92)90509-B; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; DEBUCHY R, 1992, MOL GEN GENET, V233, P113, DOI 10.1007/BF00587568; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; Dee J., 1982, CELL BIOL PHYSARUM D, P211; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; DUTCHER SK, 1992, GENETICS, V131, P593; DZELZKALNS VA, 1992, DEV BIOL, V153, P70, DOI 10.1016/0012-1606(92)90092-U; EBERSOLD WT, 1967, SCIENCE, V157, P447, DOI 10.1126/science.157.3787.447; FERRIS PJ, 1989, GENETICS, V122, P363; FERRIS PJ, 1987, MOL CELL BIOL, V7, P2360, DOI 10.1128/MCB.7.7.2360; GALLOWAY RE, 1985, GENETICS, V111, P447; GILLHAM NW, 1969, AM NAT, V103, P355, DOI 10.1086/282608; GILLHAM NW, 1987, GENETICS, V115, P677; GILLHAM NW, 1978, ORGANELLE HEREDITY; GILLISSEN B, 1992, CELL, V68, P647, DOI 10.1016/0092-8674(92)90141-X; GLASS NL, 1990, P NATL ACAD SCI USA, V87, P4912, DOI 10.1073/pnas.87.13.4912; Goodenough U.W., 1991, MICROBIAL CELL CELL, P71; GOODENOUGH UW, 1982, J CELL BIOL, V92, P378, DOI 10.1083/jcb.92.2.378; GOODENOUGH UW, 1987, GENETIC REGULATION D, P171; GORING DR, 1993, PLANT CELL, V5, P531, DOI 10.1105/tpc.5.5.531; HABER JE, 1991, P NATL ACAD SCI USA, V88, P1120, DOI 10.1073/pnas.88.4.1120; HAMMER MF, 1991, GENETICS, V128, P799; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HICKEY DA, 1982, GENETICS, V101, P519; Hickey DA, 1988, EVOLUTION SEX, P161; HIMMELBAUER H, 1993, GENOMICS, V17, P110, DOI 10.1006/geno.1993.1291; HURST LD, 1991, GENETICS, V128, P841; HURST LD, 1992, P ROY SOC B-BIOL SCI, V247, P189, DOI 10.1098/rspb.1992.0027; HURST LD, 1992, P ROY SOC B-BIOL SCI, V248, P135, DOI 10.1098/rspb.1992.0053; HWANG CJ, 1981, GENETICS, V99, P41; KAISER K, 1985, DNA CLONING PRACTICA, V1, P1; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KUES U, 1992, GENE DEV, V6, P568, DOI 10.1101/gad.6.4.568; LEWIN RA, 1983, EXPERIENTIA, V39, P1397, DOI 10.1007/BF01990124; LOPPES R, 1986, ARCH MICROBIOL, V143, P348, DOI 10.1007/BF00412801; LORENTZ A, 1992, MOL GEN GENET, V233, P436, DOI 10.1007/BF00265441; LYTTLE TW, 1993, TRENDS GENET, V9, P205, DOI 10.1016/0168-9525(93)90120-7; Maniatis T., 1982, MOL CLONING; MATSUDA Y, 1988, CURR GENET, V14, P53, DOI 10.1007/BF00405854; Michod R, 1988, EVOLUTION SEX EXAMIN; MOORE TDE, 1993, MOL CELL BIOL, V13, P1962, DOI 10.1128/MCB.13.3.1962; Roberts PA, 1976, GENETICS BIOL DROS A, P68; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; SAGER R, 1954, P NATL ACAD SCI USA, V40, P356, DOI 10.1073/pnas.40.5.356; SCHMITT R, 1992, INT REV CYTOL, V139, P189, DOI 10.1016/S0074-7696(08)61413-8; SEGAL RA, 1984, J CELL BIOL, V98, P2026, DOI 10.1083/jcb.98.6.2026; SELANDER RK, 1991, EVOLUTON MOL LEVEL; SILVER LM, 1993, TRENDS GENET, V9, P250, DOI 10.1016/0168-9525(93)90090-5; SILVER LM, 1985, ANNU REV GENET, V19, P179, DOI 10.1146/annurev.ge.19.120185.001143; SMYTH RD, 1975, J BACTERIOL, V124, P1615, DOI 10.1128/JB.124.3.1615-1617.1975; SPECHT CA, 1992, P NATL ACAD SCI USA, V89, P7174, DOI 10.1073/pnas.89.15.7174; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; STANKIS MM, 1992, P NATL ACAD SCI USA, V89, P7169, DOI 10.1073/pnas.89.15.7169; TANTIKANJANA T, 1993, PLANT CELL, V5, P657, DOI 10.1105/tpc.5.6.657; THON G, 1993, GENETICS, V134, P1045; TURGEON BG, 1993, MOL GEN GENET, V238, P270; TURMEL M, 1993, J MOL BIOL, V232, P446, DOI 10.1006/jmbi.1993.1402; TYMON AM, 1992, EMBO J, V11, P1805, DOI 10.1002/j.1460-2075.1992.tb05232.x; WESTERGAARD M, 1958, ADV GENET, V9, P217, DOI 10.1016/S0065-2660(08)60163-7; WU CI, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P177	72	115	117	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1135	1145		10.1016/0092-8674(94)90389-1	http://dx.doi.org/10.1016/0092-8674(94)90389-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137428				2022-12-01	WOS:A1994ND24600018
J	XIE, T; FINELLI, AL; PADGETT, RW				XIE, T; FINELLI, AL; PADGETT, RW			THE DROSOPHILA SAXOPHONE GENE - A SERINE-THREONINE KINASE RECEPTOR OF THE TGF-BETA SUPERFAMILY	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; DECAPENTAPLEGIC GENE; EXPRESSION CLONING; CELL-PROLIFERATION; CATALYTIC SUBUNIT; PATTERN-FORMATION; MELANOGASTER; COMPLEX; FAMILY; INHIBITION	The Drosophila decapentaplegic (dpp) gene encodes a transforming growth factor-beta (TGF-beta)-like protein that plays a key role in several aspects of development. Transduction of the DPP signal was investigated by cloning of serine-threonine kinase transmembrane receptors from Drosophila because this type of receptor is specific for the TGF-beta-like ligands. Here evidence is provided demonstrating that the Drosophila saxophone (sax) gene, a previously identified female sterile locus, encodes a TGF-beta-like type I receptor. Embryos from sax mothers and dpp embryos exhibit similar mutant phenotypes during early gastrulation, and these two loci exhibit genetic interactions, which suggest that they are utilized in the same pathway. These data suggest that sax encodes a receptor for dpp.	RUTGERS STATE UNIV,WAKSMAN INST,PISCATAWAY,NJ 08855; RUTGERS STATE UNIV,DEPT MOLEC BIOL & BIOCHEM,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick								ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FINELLI AL, IN PRESS DEVELOPMENT; FRANZEN P, 1993, CELL, V75, P69; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PADGETT RW, UNPUB; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SCHUPBACH T, 1989, GENETICS, V121, P101; SEGAL D, 1985, GENETICS, V109, P119; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WEISER R, 1993, MOL CELL BIOL, V13, P7239; WHARTON KA, 1993, DEVELOPMENT, V117, P807; Wieschaus E., 1986, P199; Xie T., UNPUB	43	122	127	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1756	1759		10.1126/science.8134837	http://dx.doi.org/10.1126/science.8134837			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	8134837				2022-12-01	WOS:A1994NC04000034
J	KOPF, M; BAUMANN, H; FREER, G; FREUDENBERG, M; LAMERS, M; KISHIMOTO, T; ZINKERNAGEL, R; BLUETHMANN, H; KOHLER, G				KOPF, M; BAUMANN, H; FREER, G; FREUDENBERG, M; LAMERS, M; KISHIMOTO, T; ZINKERNAGEL, R; BLUETHMANN, H; KOHLER, G			IMPAIRED IMMUNE AND ACUTE-PHASE RESPONSES IN INTERLEUKIN-6-DEFICIENT MICE	NATURE			English	Article							VACCINIA VIRUS; GROWTH-FACTOR; CYTOKINES; RECEPTOR; CD8+	INTERLEUKIN-6 (IL-6) is a multifunctional cytokine that regulates various aspects of the immune response, acute-phase reaction and haematopoiesis (for reviews see refs 1, 2). In vitro, leukaemia inhibitory factor, oncostatin M, ciliary neurotrophic factor and interleukin-ll display overlapping activities with IL-6. This functional redundancy may be explained by the interactions of specific binding receptors with a common signal-transducing receptor (gp130) (for reviews see refs 3, 4). To elucidate the unique function of IL-6 in vivo, we have disrupted the IL-6 gene by homologous recombination. IL-6-deficient mice develop normally. They fail to control efficiently vaccinia virus and infection with Listeria mono-cytogenes, a facultative intracellular bacterium. The T-cell-dependent antibody response against vesicular stomatitis virus is impaired. Further, the inflammatory acute-phase response after tissue damage or infection is severely compromised, whereas it is only moderately affected after challenge with lipopolysaccharide. We conclude that IL-6 production induced by injury or infection is an important in vivo SOS signal which coordinates activities of liver cells, macrophages and lymphocytes.	ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA; UNIV ZURICH, INST EXPTL IMMUNOL, ZURICH, SWITZERLAND; HOFFMANN LA ROCHE AG, DEPT BIOL, CH-4002 BASEL, SWITZERLAND; OSAKA UNIV, SCH MED, DEPT MED 3, OSAKA, OSAKA 565, JAPAN	Roswell Park Cancer Institute; University of Zurich; Roche Holding; Osaka University	KOPF, M (corresponding author), MAX PLANCK INST IMMUNBIOL, STUBEWEG 51, D-79108 FREIBURG, GERMANY.		freer, giulia/H-4609-2012; Kopf, Manfred/B-6907-2009; Kishimoto, Tadamitsu/C-8470-2009	Kopf, Manfred/0000-0002-0628-7140; Freudenberg, Marina Alexandra/0000-0001-5894-1805				BAUMANN H, 1988, METHOD ENZYMOL, V163, P566; BAUMANN H, 1986, ARCH BIOCHEM BIOPHYS, V246, P488, DOI 10.1016/0003-9861(86)90495-9; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BINDER D, 1991, J IMMUNOL, V146, P4301; Blanden R V, 1972, Scand J Immunol, V1, P379, DOI 10.1111/j.1365-3083.1972.tb03304.x; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DING AH, 1988, J IMMUNOL, V141, P2407; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; GREGORY SH, 1993, J IMMUNOL, V150, P2901; GUPTA SC, 1986, P NATL ACAD SCI USA, V83, P2604, DOI 10.1073/pnas.83.8.2604; HAVELL EA, 1992, J IMMUNOL, V148, P1486; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KOJ A, 1985, INJURY INFECTION, P145; LEIST TP, 1989, SCAND J IMMUNOL, V30, P679, DOI 10.1111/j.1365-3083.1989.tb02476.x; LIEW FY, 1991, IMMUNOPARASITOL TOD, pA17, DOI 10.1016/S0167-5699(05)80006-4; LOTZ M, 1988, J EXP MED, V167, P1253, DOI 10.1084/jem.167.3.1253; NORTH RJ, 1978, J IMMUNOL, V121, P806; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RAMSAY AJ, 1993, IMMUNOL TODAY, V14, P155, DOI 10.1016/0167-5699(93)90277-R; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHSTEIN JL, 1992, GENE DEV, V6, P1190, DOI 10.1101/gad.6.7.1190; SPRIGGS MK, 1992, P NATL ACAD SCI USA, V89, P6070, DOI 10.1073/pnas.89.13.6070; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; UYTTENHOVE C, 1988, J EXP MED, V167, P1417, DOI 10.1084/jem.167.4.1417; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.iy.08.040190.001345	30	1488	1530	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	1994	368	6469					339	342		10.1038/368339a0	http://dx.doi.org/10.1038/368339a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127368				2022-12-01	WOS:A1994NB98500047
J	HILGEMANN, DW				HILGEMANN, DW			CHANNEL-LIKE FUNCTION OF THE NA,K PUMP PROBED AT MICROSECOND RESOLUTION IN GIANT MEMBRANE PATCHES	SCIENCE			English	Article							TRANSLOCATION; EXCHANGE; SODIUM; CURRENTS; K+	Ion transporters can be thought of as ion channels that open and close only at one end at a time. As in real channels, ions may cross through an electrical field as they diffuse into and bind within the transporter pore, thereby generating electrical current. Extracellular sodium binding by the sodium potassium (Na,K) pump is associated with ultrafast charge movements in giant cardiac membrane patches. The charge movements are complete within 4 microseconds. They occur only when binding sites are open to the extracellular side, and they are abolished by ouabain and by the removal of extracellular sodium. Fast extracellular ion binding may be the exclusive source of Na,K pump electrogenicity.			HILGEMANN, DW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							ALTHOFF G, 1989, J MEMBRANE BIOL, V108, P263, DOI 10.1007/BF01871741; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; FENDLER K, 1987, FEBS LETT, V224, P83, DOI 10.1016/0014-5793(87)80427-1; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; HEYSE S, IN PRESS J GEN PHYSL; HILGEMANN D W, 1992, Biophysical Journal, V61, pA390; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; LAGNADO L, 1988, P NATL ACAD SCI USA, V85, P4548, DOI 10.1073/pnas.85.12.4548; Lauger P., 1991, ELECTROGENIC ION PUM; LEE KH, 1980, NATURE, V285, P338, DOI 10.1038/285338a0; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Mitchell P., 1974, BIOCHEM SOC SPEC PUB, V4, P91, DOI DOI 10.1042/BST0020463; NAKAO M, 1986, NATURE, V323, P628, DOI 10.1038/323628a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; RAKAWSKI RF, 1989, J GEN PHYSIOL, V93, P903; RAKOWSKI RF, 1991, J MEMBRANE BIOL, V121, P177, DOI 10.1007/BF01870531; RAKOWSKI RF, 1993, J GEN PHYSIOL, V101, P117, DOI 10.1085/jgp.101.1.117; STURMER W, 1991, J MEMBRANE BIOL, V121, P163, DOI 10.1007/BF01870530; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; VASILETS LA, 1990, J MEMBRANE BIOL, V91, P43	23	167	170	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1429	1432		10.1126/science.8128223	http://dx.doi.org/10.1126/science.8128223			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128223				2022-12-01	WOS:A1994MZ92700029
J	WARD, Y; GUPTA, S; JENSEN, P; WARTMANN, M; DAVIS, RJ; KELLY, K				WARD, Y; GUPTA, S; JENSEN, P; WARTMANN, M; DAVIS, RJ; KELLY, K			CONTROL OF MAP KINASE ACTIVATION BY THE MITOGEN-INDUCED THREONINE/TYROSINE PHOSPHATASE PAC1	NATURE			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE; ENCODED PROTEIN; PHOSPHORYLATION; SEQUENCE; GENE	INTRACELLULAR Signalling following mitogenic stimulation of quiescent cells involves the initiation of a phosphorylation cascade that leads to the rapid and reversible activation of the mitogen-activated protein (MAP) kinases ERK1 and ERK2 (refs 1, 2). MAP kinase activation is mediated by dual phosphorylation within the motif Thr-Glu-Tyr by MAP kinase kinase (MEK)(3). Following activation, the MAP kinases translocate into the nucleus where they phosphorylate several transduction targets, including transcription factors(4-7). We have previously identified PAC1 as an immediate-early mitogen-inducible tyrosine phosphatase in nuclei of T cells(8). Here we present several lines of evidence indicating that PAC1 is a physiologically relevant MAP kinase phosphatase. Recombinant PAC1 in vitro is a dual-specific Thr/Tyr phosphatase with stringent substrate specificity for MAP kinase. Constitutive expression of PAC1 in vivo leads to inhibition of MAP kinase activity normally stimulated by epidermal growth factor, phorbol myristyl acetate, or T-cell receptor crosslinking. The inactivation of MAP kinase by PAC1 results in inhibition of MAP kinase-regulated reporter gene expression.	NCI,PATHOL LAB,BETHESDA,MD 20892; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1993, ONCOGENE, V8, P2015; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; Harlow E., 1988, ANTIBODIES LABORATOR, P1; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SETH A, 1992, J BIOL CHEM, V267, P24796; SIEGEL JN, 1991, CURRENT PROTOCOLS IM; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	25	318	329	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 17	1994	367	6464					651	654		10.1038/367651a0	http://dx.doi.org/10.1038/367651a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107850	Green Published			2022-12-01	WOS:A1994MW68800056
J	SCHLUTER, H; OFFERS, E; BRUGGEMANN, G; VANDERGIET, M; TEPEL, M; NORDHOFF, E; KARAS, M; SPIEKER, C; WITZEL, H; ZIDEK, W				SCHLUTER, H; OFFERS, E; BRUGGEMANN, G; VANDERGIET, M; TEPEL, M; NORDHOFF, E; KARAS, M; SPIEKER, C; WITZEL, H; ZIDEK, W			DIADENOSINE PHOSPHATES AND THE PHYSIOLOGICAL CONTROL OF BLOOD-PRESSURE	NATURE			English	Article							BOVINE ADRENAL-MEDULLA; ESSENTIAL HYPERTENSIVES; CHROMAFFIN CELLS; INDUCED RELEASE; AP4A; POLYPHOSPHATES; TETRAPHOSPHATE; CHROMATOGRAPHY; ENDOTHELIUM; NUCLEOTIDES	OUR understanding of the regulation of vascular tone has been extended since the identification of vasoactive agents such as the atrial natriuretic peptides1, endothelial-derived relaxing factor2 and endothelin3. Unidentified vasopressive agents have been found in platelets4. Here we isolate these vasopressors and identify them as diadenosine pentaphosphate (AP5A) and diadenosine hexaphosphate (AP6A) by chromatography, mass spectrometry, ultraviolet spectroscopy and enzymatic cleavage. In the vasculature of isolated perfused rat kidney, both diadenosine phosphates were active at a concentration of 10(-9) M; in aortic rings, contractions were elicited at 10(-8) M. Intra-aortic injection in the rat caused a prolonged increase in blood pressure. We conclude that AP5A and AP6A may play a part in local vasoregulation and possibly in the regulation of blood pressure.	UNIV MUNSTER,INST BIOCHEM,MED POLIKLIN,D-48129 MUNSTER,GERMANY	University of Munster	SCHLUTER, H (corresponding author), UNIV MUNSTER,INST MED PHYS,MED POLIKLIN,ALBERT SCHWEITZER STR 33,D-48129 MUNSTER,GERMANY.		Tepel, Martin/GRS-9581-2022; Schluter, Hartmut/D-1371-2015	Schluter, Hartmut/0000-0002-9358-7036; Tepel, Martin/0000-0002-0086-0997				AGHA A, 1992, J VASC RES, V29, P281, DOI 10.1159/000158943; ALLY A, 1992, J CHROMATOGR-BIOMED, V575, P19, DOI 10.1016/0378-4347(92)80499-G; BARIL EF, 1985, CANCER INVEST, V3, P465, DOI 10.3109/07357908509039808; BUSSE R, 1988, AM J PHYSIOL, V254, pH828, DOI 10.1152/ajpheart.1988.254.5.H828; DELCASTILLO AR, 1988, J NEUROCHEM, V51, P1696, DOI 10.1111/j.1471-4159.1988.tb01147.x; FLYNN TG, 1983, BIOCHEM BIOPH RES CO, V117, P859, DOI 10.1016/0006-291X(83)91675-3; FRENZ J, 1985, J CHROMATOGR, V330, P1, DOI 10.1016/S0021-9673(01)81958-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARRISON MJ, 1975, FEBS LETT, V54, P57, DOI 10.1016/0014-5793(75)81067-2; MORII H, 1992, EUR J BIOCHEM, V205, P979, DOI 10.1111/j.1432-1033.1992.tb16864.x; NEES S, 1989, EUR HEART J, V10, P28, DOI 10.1093/eurheartj/10.suppl_F.28; NEUSSER M, 1993, J VASC RES, V30, P116, DOI 10.1159/000158983; NORDHOFF E, 1992, RAPID COMMUN MASS SP, V6, P771, DOI 10.1002/rcm.1290061212; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PINTOR J, 1992, ANAL BIOCHEM, V200, P296, DOI 10.1016/0003-2697(92)90469-N; PINTOR J, 1991, LIFE SCI, V48, P2317, DOI 10.1016/0024-3205(91)90268-G; POHL U, 1991, AM J PHYSIOL, V260, pH1692, DOI 10.1152/ajpheart.1991.260.5.H1692; SULKOWSKI E, 1971, BIOCHIM BIOPHYS ACTA, V240, P443, DOI 10.1016/0005-2787(71)90538-7; WEINMANNDORSCH C, 1984, EUR J BIOCHEM, V138, P179, DOI 10.1111/j.1432-1033.1984.tb07897.x; YAMAGUCHI N, 1985, GASTROENTEROLOGY, V89, P723, DOI 10.1016/0016-5085(85)90565-7; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZAMECNIK PC, 1966, BIOCHEM BIOPH RES CO, V24, P91, DOI 10.1016/0006-291X(66)90415-3; ZIDEK W, 1990, CLIN EXP HYPERTENS A, V12, P365, DOI 10.3109/10641969009074740	23	203	208	2	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 13	1994	367	6459					186	188		10.1038/367186a0	http://dx.doi.org/10.1038/367186a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114917				2022-12-01	WOS:A1994MQ78000065
J	SEE, WA; COOPER, CS; FISHER, RJ				SEE, WA; COOPER, CS; FISHER, RJ			PREDICTORS OF LAPAROSCOPIC COMPLICATIONS AFTER FORMAL TRAINING IN LAPAROSCOPIC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To evaluate the relationship between laparoscopic complication rates and surgeon-dependent variables following a laparoscopic training course. Design.-Participants were surveyed regarding their interval laparoscopic experience 3 months and 12 months after the course. Participants.-Course participants/survey respondents represented a cross section of urologic surgeons in the United States. A total of 181 individuals (61% of 297 participants) completed and returned the 3-month questionnaire. A total of 128 surgeons responded to the 12-month questionnaire (78.5% of 163 participants). Main Outcome Measure.-Logistic regression analysis tested the relationship between surgeons' complication rates and study variables. Results.-At 3 months, surgeons who performed clinical procedures without additional training were 3.39 times more likely to have at least one complication compared with surgeons who sought additional training (P=.03). At 12 months, surgeons who had attended the training course alone, were in solo practice, or performed laparoscopic surgery with a variable assistant were 4.85, 7.74, and 4.80 times more likely, respectively, to have had a complication than their counterparts who attended the course with a partner, were in group practice, or operated with the same assistant (P=.004, P=.0008, and P=.0015, respectively). At both 3 and 12 months, laparoscopic complication rates of individual surgeons demonstrated a significant inverse correlation with the number of laparoscopic procedures performed. Conclusions.-The rate of complications associated with the clinical learning curve can be decreased by additional education following an initial course in laparoscopy. An ongoing clinical association with surgeons performing similar procedures decreases long-term complication rates.			SEE, WA (corresponding author), UNIV IOWA HOSP & CLIN,DEPT UROL,IOWA CITY,IA 52242, USA.			Cooper, Christopher/0000-0002-4169-2088				Airan M C, 1990, Am J Surg, V159, P619, DOI 10.1016/S0002-9610(06)80082-6; ALTMAN LK, 1992, NY TIMES C      0623, P3; ALTMAN LK, 1992, NY TIMES        0726, P1; DENT TL, 1991, AM J SURG, V161, P399, DOI 10.1016/0002-9610(91)90607-F; FISCHER WA, 1993, J UROLOGY, V149, P1054; GREEN FL, 1991, SURG ENDOSC, V6, P271; LICHT J, 1992, WASHINGTON PO Z 0616, P9; WINFIELD HN, 1991, J UROLOGY, V146, P941, DOI 10.1016/S0022-5347(17)37970-3; 1992, NEW YORK STATE DEPT, V9220; 1991, AM J SURG, V161, P324	10	154	164	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2689	2692		10.1001/jama.270.22.2689	http://dx.doi.org/10.1001/jama.270.22.2689			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133586				2022-12-01	WOS:A1993MJ82100027
J	COX, TM				COX, TM			GAUCHERS-DISEASE - A BRAND LEADER	LANCET			English	Editorial Material							GLUCOCEREBROSIDASE				COX, TM (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND.							ACHORD DT, 1978, CELL, V15, P269, DOI 10.1016/0092-8674(78)90102-2; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; DEDUVE C, 1964, FED PROC, V23, P1045; FRATANTONI JC, 1968, SCIENCE, V163, P570; MISTRY PK, 1992, Q J MED, V84, P541; MOULLIER P, 1993, NAT GENET, V4, P154, DOI 10.1038/ng0693-154; OHASHI T, 1992, P NATL ACAD SCI USA, V89, P11332, DOI 10.1073/pnas.89.23.11332; SATO Y, 1993, J CLIN INVEST, V91, P1909, DOI 10.1172/JCI116409; ZIMRAN A, 1993, BLOOD, V82, P1107	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					694	695		10.1016/0140-6736(93)91703-O	http://dx.doi.org/10.1016/0140-6736(93)91703-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103817				2022-12-01	WOS:A1993LX46900004
J	HORWICH, AL; LOW, KB; FENTON, WA; HIRSHFIELD, IN; FURTAK, K				HORWICH, AL; LOW, KB; FENTON, WA; HIRSHFIELD, IN; FURTAK, K			FOLDING IN-VIVO OF BACTERIAL CYTOPLASMIC PROTEINS - ROLE OF GROEL	CELL			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI K-12; HEAT-SHOCK PROTEINS; ORNITHINE TRANSCARBAMYLASE; MOLECULAR CHAPERONE; YEAST MITOCHONDRIA; HSP60; GENE; DNAK; MUTAGENESIS	A general role for chaperonin ring structures in mediating folding of newly translated proteins has been suggested. Here we have directly examined the role of the E. coli chaperonin GroEL in the bacterial cytoplasm by production of temperature-sensitive lethal mutations in this essential gene. After shift to nonpermissive temperature, the rate of general translation in the mutant cells was reduced, but, more specifically, a defined group of cytoplasmic proteins - including citrate synthase, ketoglutarate dehydrogenase, and polynucleotide phosphorylase - were translated but failed to reach native form. Similarly, a monomeric test protein, maltose-binding protein, devoid of its signal domain, was translated but failed to fold to its native conformation. We conclude that GroEL indeed is a machine at the distal end of the pathway of transfer of genetic information, assisting a large and specific set of newly translated cytoplasmic proteins to reach their native tertiary structures.	YALE UNIV, SCH MED, DEPT THERAPEUT RADIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; ST JOHNS UNIV, DEPT BIOL SCI, JAMAICA, NY 11439 USA	Yale University; Howard Hughes Medical Institute; Yale University; Saint John's University	HORWICH, AL (corresponding author), YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA.							Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BUSBY S, 1982, J MOL BIOL, V154, P197, DOI 10.1016/0022-2836(82)90060-2; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; DONNELLY CE, 1992, J BACTERIOL, V174, P3133, DOI 10.1128/jb.174.10.3133-3139.1992; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.biochem.60.1.321; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS C P, 1974, Journal of Supramolecular Structure, V2, P349, DOI 10.1002/jss.400020224; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.biophys.21.1.293; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOOGENRAAD NJ, 1980, ANAL BIOCHEM, V101, P97, DOI 10.1016/0003-2697(80)90045-7; HORWICH A, 1980, J VIROL, V36, P125, DOI 10.1128/JVI.36.1.125-132.1980; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; KALOUSEK F, 1978, J BIOL CHEM, V253, P3939; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEE SC, 1992, J BIOL CHEM, V267, P2849; LOW B, 1971, J BACTERIOL, V108, P742, DOI 10.1128/JB.108.2.742-750.1971; LOW B, 1973, J BACTERIOL, V113, P798, DOI 10.1128/JB.113.2.798-812.1973; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; SCHELLHORN HE, 1991, J BACTERIOL, V173, P6192, DOI 10.1128/jb.173.19.6192-6198.1991; STERNBERG N, 1973, J MOL BIOL, V76, P45; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VANBOGELEN RA, 1992, ELECTROPHORESIS, V13, P1014, DOI 10.1002/elps.11501301203; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; WANG Z, 1992, PROTEIN SCI, V1, P522; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; WYNN RM, 1992, J BIOL CHEM, V267, P12400; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	56	298	303	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 10	1993	74	5					909	917		10.1016/0092-8674(93)90470-B	http://dx.doi.org/10.1016/0092-8674(93)90470-B			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8104102				2022-12-01	WOS:A1993LX29200016
J	WEISSKOPF, MG; ZALUTSKY, RA; NICOLL, RA				WEISSKOPF, MG; ZALUTSKY, RA; NICOLL, RA			THE OPIOID PEPTIDE DYNORPHIN MEDIATES HETEROSYNAPTIC DEPRESSION OF HIPPOCAMPAL MOSSY FIBER SYNAPSES AND MODULATES LONG-TERM POTENTIATION (VOL 362, PG 423, 1993)	NATURE			English	Correction, Addition																		DERRICK BE, 1991, BRAIN RES BULL, V27, P219, DOI 10.1016/0361-9230(91)90071-Q; KUPFERMANN I, 1991, PHYSIOL REV, V71, P683, DOI 10.1152/physrev.1991.71.3.683; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0	3	35	35	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					188	188		10.1038/365188a0	http://dx.doi.org/10.1038/365188a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8103916	Bronze			2022-12-01	WOS:A1993LW44200056
J	PRAYITNO, SW; ADDY, M; WADE, WG				PRAYITNO, SW; ADDY, M; WADE, WG			DOES GINGIVITIS LEAD TO PERIODONTITIS IN YOUNG-ADULTS	LANCET			English	Note								It has been assumed that poor oral hygiene predisposes to gingivitis with progression to periodontitis and tooth loss. However, a high prevalence of gingivitis occurs in some populations in which severe periodontitis is rare. To assess whether gingivitis is a reliable predictor of periodontitis, we compared the periodontal health of tea pickers and university students aged between 18 and 30 in Indonesia. Oral hygiene and gingival health was significantly better in students than in tea pickers. However, the prevalence and the severity of chronic periodontitis were similar in the two groups. Our findings suggest that gingivitis is a poor predictor of periodontitis in subjects younger than 30 years. Attempts to prevent periodontitis in young adults through antigingivitis measures. such as plaque control may be unsuccessful.	DENT SCH, DEPT PERIODONTOL, JAKARTA, INDONESIA; UNIV WALES COLL MED, SCH DENT, DEPT PERIODONTOL, CARDIFF CF4 4XY, WALES	Cardiff University				Wade, William/0000-0003-2685-826X				Addy M, 1988, Community Dent Health, V5, P345; BAELUM V, 1986, J PERIODONTAL RES, V21, P221, DOI 10.1111/j.1600-0765.1986.tb01454.x; CUTRESS TW, 1982, COMMUNITY DENT ORAL, V10, P193, DOI 10.1111/j.1600-0528.1982.tb00378.x; LOE H, 1965, J PERIODONTOL, V36, P177, DOI 10.1902/jop.1965.36.3.177; LOVDAL A., 1958, JOUR AMER DENTAL ASSOC, V56, P21; MARSHALLDAY CD, 1955, J PERIODONTOL, V26, P185; PAPAPANOU PN, 1988, J CLIN PERIODONTOL, V15, P469, DOI 10.1111/j.1600-051X.1988.tb01602.x; PRAYITNO SW, 1990, THESIS U WALES CARDI; Sheiham A, 1969, Dent Pract Dent Rec, V19, P232; SILNESS J, 1964, Acta Odontol Scand, V22, P121, DOI 10.3109/00016356408993968	10	20	20	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	1993	342	8869					471	472		10.1016/0140-6736(93)91596-E	http://dx.doi.org/10.1016/0140-6736(93)91596-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102432				2022-12-01	WOS:A1993LU07500013
J	COLDITZ, GA; WILLETT, WC; HUNTER, DJ; STAMPFER, MJ; MANSON, JE; HENNEKENS, CH; ROSNER, BA; SPEIZER, FE				COLDITZ, GA; WILLETT, WC; HUNTER, DJ; STAMPFER, MJ; MANSON, JE; HENNEKENS, CH; ROSNER, BA; SPEIZER, FE			FAMILY HISTORY, AGE, AND RISK OF BREAST-CANCER - PROSPECTIVE DATA FROM THE NURSES HEALTH STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; INDICATOR; ONSET	Objective.-To examine prospectively the risk of breast cancer as influenced by a maternal history of breast cancer, the mother's age at diagnosis, or a sister's history of breast cancer. Design.-Prospective cohort study with biennial follow-up. Setting/Participants.-117 988 women in the Nurses' Health Study aged 30 to 55 years in 1976, followed up through 1988 (1.3 million person-years of follow-up). Results.-We identified 2389 incident Gases of invasive breast cancer. Compared with women without a maternal history of breast cancer, the age-adjusted relative risk (RR) of breast cancer was highest among women whose mother was diagnosed before the age of 40 years (RR, 2.1 [95% confidence interval, 1.6 to 2.8]). The RR decreased with advancing maternal age at time of diagnosis to 1.5 (95% confidence interval, 1.1 to 2.2) for maternal diagnosis after the age of 70 years. Having a sister with a history of breast cancer also was related to increased risk; for women with one sister with breast cancer compared with those with one sister without such a history, the age-adjusted RR was 2.3 (95% confidence interval, 1.6 to 3.4). Women whose mother and sister both had a history of breast cancer had an RR of 2.5 (95% confidence interval, 1.5 to 4.2) compared with those without a family history. These associations did not differ appreciably when stratified by age; menopausal status; history of benign breast disease; body mass index; age at menarche; or parity or age at first birth of the women at risk. The results remained unchanged when we controlled for these risk factors in multivariate models. Despite slightly greater mammography surveillance and earlier detection of tumors among women with a family history of breast cancer, detection bias is unlikely to account for more than a small part of the observed association. Conclusions.-Risk of breast cancer is approximately doubled among women whose mother had breast cancer diagnosed before the age of 40 years or who have a sister with breast cancer, and remains elevated even for those whose mothers were diagnosed with breast cancer at the age of 70 years or older. However, the risk associated with a mother or sister history of breast cancer is smaller than suggested by earlier retrospective studies. Overall, within this population of middle-aged women, only 2.5% of breast cancer cases are attributable to a positive family history.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	COLDITZ, GA (corresponding author), BRIGHAM & WOMENS HOSP, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA40356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1981, CANCER, V48, P1688, DOI 10.1002/1097-0142(19811001)48:7<1688::AID-CNCR2820480736>3.0.CO;2-W; AMOS CI, 1991, CANCER RES, V51, P1793; ANDERSON DE, 1971, CANCER, V28, P1500, DOI 10.1002/1097-0142(197112)28:6<1500::AID-CNCR2820280623>3.0.CO;2-D; ANDERSON DE, 1974, CANCER, V34, P1090, DOI 10.1002/1097-0142(197410)34:4<1090::AID-CNCR2820340419>3.0.CO;2-J; ANDERSON DE, 1985, CANCER, V56, P3830; BAIN C, 1980, AM J EPIDEMIOL, V111, P301, DOI 10.1093/oxfordjournals.aje.a112901; BRINTON LA, 1982, J NATL CANCER I, V69, P817; BURNS PE, 1981, CAN MED ASSOC J, V124, P1451; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COX DR, 1972, J R STAT SOC B, V34, P187; Floderus B, 1990, Epidemiology, V1, P318, DOI 10.1097/00001648-199007000-00011; HOULSTON RS, 1992, J MED GENET, V29, P154, DOI 10.1136/jmg.29.3.154; ISELIUS L, 1991, ANN HUM GENET, V55, P154; KHOURY MJ, 1987, AM J EPIDEMIOL, V126, P561, DOI 10.1093/oxfordjournals.aje.a114695; KING MC, 1993, JAMA-J AM MED ASSOC, V269, P1975, DOI 10.1001/jama.269.15.1975; LONDON S J, 1989, Journal of the American Medical Association, V262, P2853, DOI 10.1001/jama.262.20.2853; LOVE RR, 1985, J CHRON DIS, V38, P289, DOI 10.1016/0021-9681(85)90074-8; LYNCH HT, 1990, ARCH SURG-CHICAGO, V125, P151; METTLIN C, 1990, AM J EPIDEMIOL, V131, P973, DOI 10.1093/oxfordjournals.aje.a115617; OTTMAN R, 1986, AM J EPIDEMIOL, V123, P15, DOI 10.1093/oxfordjournals.aje.a114209; PAPADIAMANTIS Y, 1990, CANCER J, V3, P244; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; ROSEMAN DL, 1990, ARCH INTERN MED, V150, P191, DOI 10.1001/archinte.150.1.191; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; SCHNEIDER NR, 1983, AM J HUM GENET, V35, P454; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SMITHERS DW, 1948, BRIT J CANCER, V2, P163, DOI 10.1038/bjc.1948.24; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Wells HG, 1923, J AMER MED ASSOC, V81, P1017, DOI 10.1001/jama.1923.26510120005012; WILLETT WC, 1992, JAMA-J AM MED ASSOC, V268, P2037, DOI 10.1001/jama.268.15.2037	32	263	268	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1993	270	3					338	343		10.1001/jama.270.3.338	http://dx.doi.org/10.1001/jama.270.3.338			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM435	8123079				2022-12-01	WOS:A1993LM43500028
J	BOTKER, HE; MOLLER, N; OVESEN, P; MENGEL, A; SCHMITZ, O; ORSKOV, H; BAGGER, JP				BOTKER, HE; MOLLER, N; OVESEN, P; MENGEL, A; SCHMITZ, O; ORSKOV, H; BAGGER, JP			INSULIN-RESISTANCE IN MICROVASCULAR ANGINA (SYNDROME-X)	LANCET			English	Article							NORMAL CORONARY-ARTERIES; ESSENTIAL-HYPERTENSION; MUSCLE; DISEASE; DISORDER; OBESITY; NIDDM	Patients with microvascular angina (syndrome X) may be insulin resistant. We designed a study to establish whether this is the case. 11 patients with microvascular angina were compared with 9 matched subjects with noncardiac chest pain. Patients and controls were evaluated by coronary sinus catheterisation, and by isotopic measurement of glucose turnover, indirect calorimetry, and forearm technique during a 3 h baseline period after overnight fast and during a 2 h hyperinsulinaemic euglycaemic clamp. Pace-induced increase in coronary sinus blood flow was less in patients than in controls, whereas forearm blood flow did not differ between groups. Baseline measures of glucose metabolism were normal. During the clamp, glucose production and lipolysis were equally suppressed in both groups. Mean (SE) total insulin-induced glucose uptake was significantly impaired in patients compared with controls (3.9 [0.7] vs 6.4 [0.7] mg/kg per min; p < 0.01), and insulin-stimulated glucose uptake in the forearm was significantly reduced in patients (0.88 [0-101 vs 1.6 [0.301 mmol/L; p < 0.001). Reduced oxidative and nonoxidative metabolism accounted for the defect in overall glucose uptake in patients. No correlation between changes in coronary sinus blood flow and total body glucose uptake was seen. We found that microvascular angina was associated with substantial insulin resistance. Whether this relation is causal or coincidental is as yet unsettled.	AARHUS UNIV,INST EXPTL CLIN RES,DK-8000 AARHUS,DENMARK; AARHUS UNIV HOSP,AARHUS KOMMUNEHOSP,DEPT MED ENDOCRINOL & DIABET M,DK-8000 AARHUS,DENMARK	Aarhus University; Aarhus University	BOTKER, HE (corresponding author), UNIV HOSP AARHUS,SKEJBY HOSP,DEPT CARDIOL,DK-8200 AARHUS N,DENMARK.		Moller, Niels/E-5091-2011	Moller, Niels/0000-0001-5627-7322; Botker, Hans Erik/0000-0001-6358-8962				BAGGER JP, 1985, CARDIOVASC RES, V19, P27, DOI 10.1093/cvr/19.1.27; BARON AD, 1990, J CLIN ENDOCR METAB, V70, P1525, DOI 10.1210/jcem-70-6-1525; BRESSLER P, 1992, DIABETES S1, V41, pA24; CANNON RO, 1990, AM J MED, V88, P217, DOI 10.1016/0002-9343(90)90145-4; CANNON RO, 1992, CIRCULATION, V85, P883, DOI 10.1161/01.CIR.85.3.883; CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; CANNON RO, 1990, CIRCULATION, V82, P2011, DOI 10.1161/01.CIR.82.6.2011; DEAN JD, 1991, LANCET, V337, P456; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DETEJADA IS, 1989, NEW ENGL J MED, V320, P1025, DOI 10.1056/NEJM198904203201601; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FISHER BM, 1986, DIABETOLOGIA, V29, P706, DOI 10.1007/BF00870280; HOTHERNIELSEN O, 1987, DIABETOLOGIA, V30, P834; KEMP HG, 1973, AM J CARDIOL, V32, P375, DOI 10.1016/S0002-9149(73)80150-X; KOIVISTO V A, 1986, Diabetes Metabolism Reviews, V1, P445; LILLIOJA S, 1987, J CLIN INVEST, V80, P415, DOI 10.1172/JCI113088; MOLLER N, 1990, J CLIN ENDOCR METAB, V70, P1179, DOI 10.1210/jcem-70-4-1179; OPERK D, 1989, CIRCULATION, V80, P1610; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RICHARDSON PJ, 1974, LANCET, V2, P677; SAX FL, 1987, NEW ENGL J MED, V317, P1366, DOI 10.1056/NEJM198711263172202; STALDER M, 1982, DIABETOLOGIA, V21, P544; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x	26	88	92	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					136	140						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101255				2022-12-01	WOS:A1993LN04200010
J	CLARK, SG; CHISHOLM, AD; HORVITZ, HR				CLARK, SG; CHISHOLM, AD; HORVITZ, HR			CONTROL OF CELL FATES IN THE CENTRAL BODY REGION OF C-ELEGANS BY THE HOMEOBOX GENE LIN-39	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; POST-EMBRYONIC DEVELOPMENT; PATTERN-FORMATION; DROSOPHILA; EXPRESSION; SEQUENCES; SYSTEM; SPECIFICATION; LINEAGES; CLUSTER	Cells in the mid-body region of the nematode C. elegans develop differently from their anterior or posterior homologs. The gene lin-39 is required for mid-body region-specific development. In lin-39 mutants, midbody cells express fates characteristic of more anterior or posterior homologs, and the migration of a neuroblast through the mid-body is defective. lin-39 acts cell autonomously in these mid-body cells and in the migrating neuroblast. lin-39 encodes a protein with an Antennapedia class homeodomain, most similar to those of the Drosophila homeotic genes Deformed and Sex combs reduced, and is located in a homeotic gene cluster with two other regional homeotic genes, mab-5 and egl-5. lin-39 and mab-5 function combinatorially in 2 ectodermal cells and have redundant functions in gonad development.	MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)				Chisholm, Andrew/0000-0001-5091-0537	NIGMS NIH HHS [GM24943, GM24663] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024663, R01GM024663, R01GM024943] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROIAN RV, 1993, MOL CELL BIOL, V13, P626, DOI 10.1128/MCB.13.1.626; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; BURGLIN TR, 1993, IN PRESS GUIDEBOOK H; CHALFIE M, 1983, SCIENCE, V221, P61, DOI 10.1126/science.6857263; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLARK SG, 1992, THESIS MIT CAMBRIDGE; COSTA M, 1988, CELL, V55, P747, DOI 10.1016/0092-8674(88)90131-6; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; ELLIS H, 1985, THESIS MIT CAMBRIDGE; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FIXSEN W, 1985, COLD SPRING HARB SYM, V50, P99, DOI 10.1101/SQB.1985.050.01.014; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HIRSH D, 1976, DEV BIOL, V49, P200, DOI 10.1016/0012-1606(76)90267-0; HODGKIN J, 1979, GENETICS, V91, P67; HODGKIN J, 1988, NEMATODE CAENORHABDI, P491; Innis MA, 1990, PCR PROTOCOLS GUIDE; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KENYON C, 1991, SCIENCE, V253, P516, DOI 10.1126/science.1677487; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEMOTTE PK, 1989, EMBO J, V8, P219, DOI 10.1002/j.1460-2075.1989.tb03367.x; LI C, 1990, NEURON, V4, P681, DOI 10.1016/0896-6273(90)90195-L; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; ROSENBLUTH RE, 1985, GENETICS, V109, P493; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SCHALLER D, 1990, NUCLEIC ACIDS RES, V18, P2033, DOI 10.1093/nar/18.8.2033; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STROEHER VL, 1986, MOL CELL BIOL, V6, P4667, DOI 10.1128/MCB.6.12.4667; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; White J., 1988, NEMATODE CAENORHABDI, V17, P81; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	50	216	232	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					43	55		10.1016/0092-8674(93)90293-Y	http://dx.doi.org/10.1016/0092-8674(93)90293-Y			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8101475				2022-12-01	WOS:A1993LN62500006
J	KREMER, B; GOLDBERG, P; ANDREW, SE; THEILMANN, J; TELENIUS, H; ZEISLER, J; SQUITIERI, F; LIN, BY; BASSETT, A; ALMQVIST, E; BIRD, TD; HAYDEN, MR				KREMER, B; GOLDBERG, P; ANDREW, SE; THEILMANN, J; TELENIUS, H; ZEISLER, J; SQUITIERI, F; LIN, BY; BASSETT, A; ALMQVIST, E; BIRD, TD; HAYDEN, MR			A WORLDWIDE STUDY OF THE HUNTINGTONS-DISEASE MUTATION - THE SENSITIVITY AND SPECIFICITY OF MEASURING CAG REPEATS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED DNA MARKERS; MYOTONIC-DYSTROPHY; REGION; GENE	Background. Huntington's disease is associated with an expanded sequence of CAG repeats in a gene on chromosome 4p16.3. However, neither the sensitivity of expanded CAG repeats in affected persons of different ethnic origins nor the specificity of such repeats for Huntington's disease as compared with other neuropsychiatric disorders has been determined. Methods. We studied 1007 patients with diagnosed Huntington's disease from 565 families and 43 national and ethnic groups. In addition, the length of the CAG repeat was determined in 113 control subjects with a family history of Alzheimer's disease (44 patients), schizophrenia (39), major depression (16), senile chorea (5), benign heriditary chorea (5), neuroacanthocytosis (2), and dentatorubropallidoluysian atrophy (2). The number of CAG repeats was also assessed in 1595 control chromosomes, with the size of adjacent polymorphic CCG trinucleotide repeats taken into account. Results. Of 1007 patients with signs and symptoms compatible with a diagnosis of Huntington's disease, 995 had an expanded CAG repeat that included from 36 to 121 repeats (median, 44) (sensitivity, 98.8 percent; 95 percent confidence interval, 97.7 to 99.4 percent). There were no significant differences among national and ethnic groups in the number of repeats. No CAG expansion was found in the 113 control subjects with other neuropsychiatric disorders (specificity, 100 percent; 95 percent confidence interval, 95.2 to 100 percent). In 1581 of the 1595 control chromosomes (99.1 percent), the number of CAG repeats ranged from 10 to 29 (median, 18). In 12 control chromosomes (0.75 percent), intermediate-sized CAG sequences with 30 to 35 repeats were found, and 2 normal chromosomes unexpectedly had expanded CAG sequences, of 39 and 37 repeats. Conclusions. CAG trinucleotide expansion is the molecular basis of Huntington's disease worldwide and is a highly sensitive and specific marker for inheritance of the disease mutation.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1Z4,BC,CANADA; UNIV TORONTO,CLARKE INST PSYCHIAT,TORONTO,ON,CANADA; KAROLINSKA HOSP,S-10401 STOCKHOLM,SWEDEN; VET AFFAIRS MED CTR,SEATTLE,WA 98108; UNIV WASHINGTON,DEPT MED,SEATTLE,WA	University of British Columbia; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Karolinska Institutet; Karolinska University Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle			Squitieri, Ferdinando/N-1852-2019; Hayden, Michael R/D-8581-2011	Squitieri, Ferdinando/0000-0002-7397-1727; Hayden, Michael R/0000-0001-5159-1419	NATIONAL INSTITUTE ON AGING [P50AG005136] Funding Source: NIH RePORTER; NIA NIH HHS [AGO 5136] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREW SE, 1994, HUM MOL GENET, V3, P65, DOI 10.1093/hmg/3.1.65; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; ANDREW SE, 1994, AM J HUM GENET, V54, P852; BABUL R, 1993, JAMA-J AM MED ASSOC, V270, P2321, DOI 10.1001/jama.270.19.2321; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GOLDBERG YP, 1993, HUM MOL GENET, V2, P635, DOI 10.1093/hmg/2.6.635; GOLDBERG YP, 1993, NAT GENET, V5, P174, DOI 10.1038/ng1093-174; Griner P F, 1981, Ann Intern Med, V94, P557; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARPER PS, 1991, MAJOR PROBLEMS NEURO, V22; HAYDEN MR, 1988, AM J HUM GENET, V43, P689; Hayden MR, 1981, HUNTINGTONS CHOREA; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LI SH, 1993, NEURON, V11, P985, DOI 10.1016/0896-6273(93)90127-D; LIN BY, 1993, HUM MOL GENET, V2, P1541, DOI 10.1093/hmg/2.10.1541; MACMILLAN JC, 1993, LANCET, V342, P954, DOI 10.1016/0140-6736(93)92002-B; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MYERS RH, 1993, NAT GENET, V5, P168, DOI 10.1038/ng1093-168; MYERS RH, 1989, AM J HUM GENET, V45, P615; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; RIESS O, 1993, HUM MOL GENET, V2, P637, DOI 10.1093/hmg/2.6.637; RUBENSZTEIN DC, 1993, HUM MOL GENET, V2, P1713; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; STRONG TV, 1993, NAT GENET, V5, P259, DOI 10.1038/ng1193-259; VALDES JM, 1993, HUM MOL GENET, V2, P633, DOI 10.1093/hmg/2.6.633; VOGEL F, 1986, HUMAN GENETICS; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001; World Federation of Neurology, 1989, J NEUROL SCI, V94, P327; 1993, CELL, V72, P971	36	412	433	0	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	1994	330	20					1401	1406		10.1056/NEJM199405193302001	http://dx.doi.org/10.1056/NEJM199405193302001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK972	8159192				2022-12-01	WOS:A1994NK97200001
J	RAMSAY, AJ; HUSBAND, AJ; RAMSHAW, IA; BAO, SS; MATTHAEI, KI; KOEHLER, G; KOPF, M				RAMSAY, AJ; HUSBAND, AJ; RAMSHAW, IA; BAO, SS; MATTHAEI, KI; KOEHLER, G; KOPF, M			THE ROLE OF INTERLEUKIN-6 IN MUCOSAL IGA ANTIBODY-RESPONSES IN-VIVO	SCIENCE			English	Article							B-CELL DIFFERENTIATION; RECOMBINANT VACCINIA VIRUS; GROWTH-FACTOR-BETA; PEYERS PATCH; IMMUNOGLOBULIN-A; T-CELLS; IFN-GAMMA; TERMINAL DIFFERENTIATION; EXPRESSION; TISSUES	In mice with targeted disruption of the gene that encodes interleukin-6 (IL-6), greatly reduced numbers of immunoglobulin A (IgA)-producing cells were observed at mucosae and grossly deficient local antibody responses were recorded after mucosal challenge with either ovalbumin or vaccinia virus. The IgA response in the lungs was completely restored after intranasal infection with recombinant vaccinia viruses engineered to express IL-6. These findings demonstrate a critical role for IL-6 in vivo in the development of local IgA antibody responses and illustrate the effectiveness of vector-directed cytokine gene therapy.	UNIV SYDNEY, DEPT VET PATHOL, SYDNEY, NSW 2006, AUSTRALIA; MAX PLANCK INST IMMUNBIOL, D-79108 FREIBURG, GERMANY	University of Sydney; Max Planck Society	RAMSAY, AJ (corresponding author), AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, CANBERRA, ACT 0200, AUSTRALIA.		Bao, Shisan/C-6072-2014; Kopf, Manfred/B-6907-2009; Klaus, Matthaei/D-8691-2011; Bao, Shisan/AAF-6464-2020	Kopf, Manfred/0000-0002-0628-7140; Bao, Shisan/0000-0002-6687-3846				ADA G, 1993, NATURE, V364, P489, DOI 10.1038/364489a0; ANDREW ME, 1986, MICROB PATHOGENESIS, V1, P443, DOI 10.1016/0882-4010(86)90006-9; BAO S, 1993, IMMUNOLOGY, V80, P666; BEAGLEY KW, 1989, J EXP MED, V169, P2133, DOI 10.1084/jem.169.6.2133; BEAGLEY KW, 1991, CYTOKINE, V3, P107, DOI 10.1016/1043-4666(91)90030-H; BOYLE DB, 1985, GENE, V35, P169, DOI 10.1016/0378-1119(85)90169-6; BRANDTZAEG P, 1989, CURR TOP MICROBIOL, V146, P13; BUTLER JL, 1984, P NATL ACAD SCI-BIOL, V81, P2475, DOI 10.1073/pnas.81.8.2475; CHIU CP, 1988, P NATL ACAD SCI USA, V85, P7099, DOI 10.1073/pnas.85.19.7099; COHEN J, 1993, SCIENCE, V260, P1254, DOI 10.1126/science.8493564; COUPAR BEH, 1987, J GEN VIROL, V68, P2299, DOI 10.1099/0022-1317-68-9-2299; CRAIG SW, 1971, J EXP MED, V134, P188, DOI 10.1084/jem.134.1.188; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; DUNKLEY ML, 1990, IMMUNOLOGY, V71, P16; DUNKLEY ML, 1990, IMMUNOL LETT, V26, P165, DOI 10.1016/0165-2478(90)90140-L; DUNKLEY ML, 1991, REG IMMUNOL, V3, P336; FUJIHASHI K, 1991, J CLIN INVEST, V88, P248, DOI 10.1172/JCI115284; HARRIMAN GR, 1988, J IMMUNOL, V140, P3033; HAYNES BF, 1993, SCIENCE, V260, P1279, DOI 10.1126/science.8493572; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; HUSBAND AJ, 1978, J EXP MED, V148, P1146, DOI 10.1084/jem.148.5.1146; HUSBAND AJ, UNPUB; KARUPIAH G, 1990, J IMMUNOL, V144, P290; KAWANISHI H, 1983, J EXP MED, V158, P649, DOI 10.1084/jem.158.3.649; KELLY EAB, 1991, J IMMUNOL, V147, P306; KIYONO H, 1982, J EXP MED, V156, P1115, DOI 10.1084/jem.156.4.1115; KIYONO H, 1984, J EXP MED, V159, P798, DOI 10.1084/jem.159.3.798; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kroese FGM, 1989, INT IMMUNOL, V1, P75, DOI 10.1093/intimm/1.1.75; LEBMAN DA, 1990, J IMMUNOL, V144, P952; MEGA J, 1992, J IMMUNOL, V148, P2030; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MILLER CJ, 1993, LAB INVEST, V68, P129; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; MURRAY PD, 1987, J IMMUNOL, V139, P2669; OKADA M, 1983, J EXP MED, V157, P583, DOI 10.1084/jem.157.2.583; RAMSAY AJ, 1993, EUR J IMMUNOL, V23, P3141, DOI 10.1002/eji.1830231215; RAMSAY AJ, 1993, IMMUNOL TODAY, V14, P155, DOI 10.1016/0167-5699(93)90277-R; RAMSHAW I, 1992, IMMUNOL REV, V127, P157, DOI 10.1111/j.1600-065X.1992.tb01413.x; RUDZIK R, 1975, J IMMUNOL, V114, P1599; TAGUCHI T, 1990, J IMMUNOL, V145, P68; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; XUAMANO JC, 1993, J EXP MED, V178, P1309, DOI 10.1084/jem.178.4.1309; [No title captured]	45	390	404	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 22	1994	264	5158					561	563		10.1126/science.8160012	http://dx.doi.org/10.1126/science.8160012			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	8160012				2022-12-01	WOS:A1994NH01000034
J	CORNELIUSSEN, B; HOLM, M; WALTERSSON, Y; ONIONS, J; HALLBERG, B; THORNELL, A; GRUNDSTROM, T				CORNELIUSSEN, B; HOLM, M; WALTERSSON, Y; ONIONS, J; HALLBERG, B; THORNELL, A; GRUNDSTROM, T			CALCIUM/CALMODULIN INHIBITION OF BASIC-HELIX-LOOP-HELIX TRANSCRIPTION FACTOR DOMAINS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CALMODULIN-BINDING PROTEINS; MOUSE RETROVIRUS SL3-3; DNA-BINDING; SEQUENCE; ENHANCER; MYOD; ACTIVATION; CELLS; GENE	THE ubiquitous Ca2+-binding protein calmodulin (CaM) is a key protein in Ca2+ homeostasis and activation of eukaryotic cells. CaM is the molecular link between free Ca2+ in the cell and the inhibition, or activation, of numerous enzymes. Many nuclear functions are under Ca2+/CaM control, and some transcriptional activators are known to be Ca2+ modulated indirectly through Ca2+/CaM-dependent protein kinases(1-4). But Ca2+/CaM has not yet been found to directly modulate any transcription factor or other DNA-binding protein. Transcription factors of the basic-helix-loop-helix (bHLK) group are important regulators in numerous systems(5-11). Here we report that binding of Ca2+-loaded CaM to the bHLH domains of several bHLH proteins directly inhibits their DNA binding. Other bHLH proteins are either less sensitive or resistant. Ca2+ ionophore selectively inhibits transcriptional activation by Ca2+/CaM-sensitive bHLH proteins in vivo, implying that Ca2+ can directly influence transcription through differential CaM inhibition of bHLH domains.	UMEA UNIV,DEPT APPL CELL & MOLEC BIOL,S-90187 UMEA,SWEDEN	Umea University			Holm, Magnus/B-8932-2008					BACHS O, 1987, J BIOL CHEM, V262, P10786; BRODIN P, 1989, PROTEIN ENG, V2, P353, DOI 10.1093/protein/2.5.353; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; HALLBERG B, 1988, NUCLEIC ACIDS RES, V16, P5927, DOI 10.1093/nar/16.13.5927; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; LARS N, 1993, INT IMMUNOL, V5, P271, DOI 10.1093/intimm/5.3.271; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PUJOL MJ, 1989, J BIOL CHEM, V264, P18863; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; THORNELL A, 1993, J BIOL CHEM, V268, P21946; VENDRELL M, 1991, J NEUROCHEM, V57, P622, DOI 10.1111/j.1471-4159.1991.tb03793.x; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WALTERSSON Y, 1993, BIOCHEMISTRY-US, V32, P7866, DOI 10.1021/bi00082a005; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	30	144	147	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					760	764		10.1038/368760a0	http://dx.doi.org/10.1038/368760a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152489				2022-12-01	WOS:A1994NG55300064
J	WANG, XD; SATO, R; BROWN, MS; HUA, XX; GOLDSTEIN, JL				WANG, XD; SATO, R; BROWN, MS; HUA, XX; GOLDSTEIN, JL			SREBP-1, A MEMBRANE-BOUND TRANSCRIPTION FACTOR RELEASED BY STEROL-REGULATED PROTEOLYSIS	CELL			English	Article							PROTEIN; CHOLESTEROL; RECEPTOR; REPRESSION; INHIBITORS; SEQUENCES; PROMOTER; SYNTHASE; PATHWAY; BINDING	Sterol regulatory element-binding protein 1 (SREBP-1), a member of the basic-helix-loop-helix-leucine zipper (bHLH-ZIP) family of transcription factors, is synthesized as a 125 kd precursor that is attached to the nuclear envelope and endoplasmic reticulum. In sterol-depleted cells, the membrane-bound precursor is cleaved to generate a soluble NH2-terminal fragment (apparent molecular mass, 68 kd) that translocates to the nucleus. This fragment, which includes the bHLH-ZIP domain, activates transcription of the genes for the LDL receptor and HMG coA synthase. Sterols inhibit the cleavage of SREBP-1, and the 68 kd nuclear form is rapidly catabolized, thereby reducing transcription. ALLN, an inhibitor of neutral cysteine proteases, blocks the breakdown of the 68 kd form and superinduces sterol-regulated genes. Sterol-regulated proteolysis of a membrane-bound transcription factor provides a novel mechanism by which transcription can be regulated by membrane lipids.			WANG, XD (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Wang, Xiaodong/0000-0001-9885-356X	FIC NIH HHS [FO5 TWO4571] Funding Source: Medline; NHLBI NIH HHS [HL-20948] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004571] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHEN IT, 1986, P NATL ACAD SCI USA, V83, P6907, DOI 10.1073/pnas.83.18.6907; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GIL G, 1987, P NATL ACAD SCI USA, V84, P1863, DOI 10.1073/pnas.84.7.1863; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; INOUE S, 1991, J BIOL CHEM, V266, P13311; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE Y, 1992, J LIPID RES, V33, P315; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Murre  C., 1992, TRANSCRIPTIONAL REGU, P861; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH JR, 1988, J BIOL CHEM, V263, P18480; URBANI L, 1990, J BIOL CHEM, V265, P1919; WANG XD, 1993, J BIOL CHEM, V268, P14497; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	25	824	854	2	62	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					53	62		10.1016/0092-8674(94)90234-8	http://dx.doi.org/10.1016/0092-8674(94)90234-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156598				2022-12-01	WOS:A1994NF21100009
J	FEI, YJ; KANAI, Y; NUSSBERGER, S; GANAPATHY, V; LEIBACH, FH; ROMERO, MF; SINGH, SK; BORON, WF; HEDIGER, MA				FEI, YJ; KANAI, Y; NUSSBERGER, S; GANAPATHY, V; LEIBACH, FH; ROMERO, MF; SINGH, SK; BORON, WF; HEDIGER, MA			EXPRESSION CLONING OF A MAMMALIAN PROTON-COUPLED OLIGOPEPTIDE TRANSPORTER	NATURE			English	Article							NA+ GLUCOSE COTRANSPORTER; BORDER MEMBRANE-VESICLES; BETA-LACTAM ANTIBIOTICS; GLYCYL-L-PROLINE; SMALL-INTESTINE; RABBIT; PH; SPECIFICITY; ABSORPTION; CDNA	IN mammals, active transport of organic solutes across plasma membranes was thought to be primarily driven by the Na+ gradient1-3. Here we report the cloning and functional characterization of a H+-coupled transporter of oligopeptides and peptide-derived antibiotics from rabbit small intestine. This new protein, named PepT1, displays an unusually broad substrate specificity. PepT1-mediated uptake is electrogenic, independent of extracellular Na+, K+ and Cl-, and of membrane potential. PepT1 messenger RNA was found in intestine, kidney and liver and in small amounts in brain. In the intestine, the PepT1 pathway constitutes a major mechanism for absorption of the products of protein digestion. To our knowledge, the PepT1 primary structure is the first reported for a proton-coupled organic solute transporter in vertebrates and represents an interesting evolutionary link between prokaryotic H+-coupled and vertebrate Na+-coupled transporters of organic solutes.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; MED COLL GEORGIA,DEPT BIOCHEM & MOLEC BIOL,AUGUSTA,GA 30912; YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University System of Georgia; Augusta University; Yale University			Boron, Walter/ABI-1564-2020	Boron, Walter/0000-0003-4741-7287; Hediger, Matthias/0000-0003-1946-027X; Nussberger, Stephan/0000-0003-3619-4452; Romero, Michael F/0000-0002-1555-7835	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009342] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK009342, F32 DK009342-02, F32 DK009342-01, F32 DK009342-03] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE M, 1987, J PHYSIOL-LONDON, V394, P481, DOI 10.1113/jphysiol.1987.sp016882; ADEDOYIN A, 1993, DRUG METAB DISPOS, V21, P184; ADIBI SA, 1973, J CLIN INVEST, V52, P1586, DOI 10.1172/JCI107335; CRANE RK, 1961, MEMBRANE TRANSPORT M, P439; DANIEL H, 1993, J CLIN INVEST, V92, P2215, DOI 10.1172/JCI116824; DAVIS BA, 1992, AM J PHYSIOL, V263, pC246, DOI 10.1152/ajpcell.1992.263.1.C246; DYER J, 1990, BIOCHEM J, V269, P565, DOI 10.1042/bj2690565; GANAPATHY V, 1983, J BIOL CHEM, V258, P4189; GANAPATHY V, 1985, BIOCHIM BIOPHYS ACTA, V816, P234, DOI 10.1016/0005-2736(85)90490-0; Ganapathy Vadivel, 1994, P1773; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; KABACK HR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P210, DOI 10.1016/0005-2728(92)90227-S; KANAI Y, 1993, FASEB J, V7, P1450, DOI 10.1096/fasebj.7.15.7903261; KANAI Y, 1994, J CLIN INVEST, V93, P397, DOI 10.1172/JCI116972; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KRAMER W, 1992, EUR J BIOCHEM, V204, P923, DOI 10.1111/j.1432-1033.1992.tb16713.x; LOMBARDO YB, 1988, J BIOL CHEM, V263, P12920; LUCAS M, 1983, GUT, V24, P734, DOI 10.1136/gut.24.8.734; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PERRY JR, 1994, MOL CELL BIOL, V14, P104, DOI 10.1128/MCB.14.1.104; SIEBENS AW, 1987, J GEN PHYSIOL, V90, P799, DOI 10.1085/jgp.90.6.799; SINKO PJ, 1989, J PHARM SCI, V78, P723, DOI 10.1002/jps.2600780904; THWAITES DT, 1993, J BIOL CHEM, V268, P7340; TRUPPATHI C, 1990, J BIOL CHEM, V265, P14870; TSAY YF, 1993, CELL, V72, P705, DOI 10.1016/0092-8674(93)90399-B; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WRIGHT E M, 1992, Current Opinion in Cell Biology, V4, P696, DOI 10.1016/0955-0674(92)90091-P; YOU GF, 1993, NATURE, V365, P844, DOI 10.1038/365844a0	30	739	778	3	51	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					563	566		10.1038/368563a0	http://dx.doi.org/10.1038/368563a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139693				2022-12-01	WOS:A1994NE33500060
J	FREEMAN, WT				FREEMAN, WT			THE GENERIC VIEWPOINT ASSUMPTION IN A FRAMEWORK FOR VISUAL-PERCEPTION	NATURE			English	Article							REGULARIZATION; VISION	A VISUAL system makes assumptions in order to interpret visual data. The assumption of 'generic view'1-4 states that the observer is not in a special position relative to the scene. Researchers commonly use a binary decision of generic or accidental view to disqualify scene interpretations that assume accidental viewpoints5-10. Here we show how to use the generic view assumption, and others like it, to quantify the likelihood of a view, adding a new term to the probability of a given image interpretation. The resulting framework better models the visual world and reduces the reliance on other prior assumptions. It may lead to computer vision algorithms of greater power and accuracy, or to better models of human vision. We show applications to the problems of inferring shape, surface reflectance properties, and motion from images.			FREEMAN, WT (corresponding author), MITSUBISHI ELECT RES LABS, 201 BROADWAY, CAMBRIDGE, MA 02139 USA.							Berger J. O., 1985, STAT DECISION THEORY, V2nd; Bichsel M., 1992, Proceedings. 1992 IEEE Computer Society Conference on Computer Vision and Pattern Recognition (Cat. No.92CH3168-2), P459, DOI 10.1109/CVPR.1992.223150; BIEDERMAN I, 1985, COMPUT VISION GRAPH, V32, P29, DOI 10.1016/0734-189X(85)90002-7; BINFORD TO, 1981, ARTIF INTELL, V17, P205, DOI 10.1016/0004-3702(81)90025-4; COOK RL, 1981, SIGGRAPH 81; Freeman W. T., 1993, [1993] Proceedings Fourth International Conference on Computer Vision, P347, DOI 10.1109/ICCV.1993.378193; FREEMAN WT, IN PRESS INT J COMP; HORN BKP, 1981, ARTIF INTELL, V17, P185, DOI 10.1016/0004-3702(81)90024-2; JEPSON AD, 1992, SPATIAL VISION HUMAN; KOENDERINK JJ, 1979, BIOL CYBERN, V32, P211, DOI 10.1007/BF00337644; Leclerc Y. G., 1991, Proceedings 1991 IEEE Computer Society Conference on Computer Vision and Pattern Recognition (91CH2983-5), P552, DOI 10.1109/CVPR.1991.139752; LOWE DG, 1985, IEEE T PATTERN ANAL, V7, P320, DOI 10.1109/TPAMI.1985.4767660; MACKAY DJC, 1992, NEURAL COMPUT, V4, P415, DOI [10.1162/neco.1992.4.3.415, 10.1162/neco.1992.4.3.448]; MALIK J, 1987, INT J COMPUT VISION, V1, P73, DOI 10.1007/BF00128527; Marr D., 1982, VISION; NAKAYAMA K, 1992, SCIENCE, V257, P1357, DOI 10.1126/science.1529336; NAKAYAMA K, 1988, VISION RES, V28, P739, DOI 10.1016/0042-6989(88)90052-1; PENTLAND AP, 1990, INT J COMPUT VISION, V4, P153, DOI 10.1007/BF00127815; POGGIO T, 1985, NATURE, V317, P314, DOI 10.1038/317314a0; RICHARDS WA, 1987, J OPT SOC AM A, V4, P1168, DOI 10.1364/JOSAA.4.001168; SZELISKI R, 1989, BAYESIAN MODELING UN; TERZOPOULOS D, 1986, IEEE T PATTERN ANAL, V8, P413, DOI 10.1109/TPAMI.1986.4767807; Tikhonov A., 1977, SIAM REV, DOI DOI 10.1137/1021044; WEINSHALL D, 1994, 3RD P EUR C COMP VIS	24	139	139	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	1994	368	6471					542	545		10.1038/368542a0	http://dx.doi.org/10.1038/368542a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139687				2022-12-01	WOS:A1994NE33500053
J	DANIS, M; GARRETT, J; HARRIS, R; PATRICK, DL				DANIS, M; GARRETT, J; HARRIS, R; PATRICK, DL			STABILITY OF CHOICES ABOUT LIFE-SUSTAINING TREATMENTS	ANNALS OF INTERNAL MEDICINE			English	Article						LIFE SUPPORT CARE; PATIENT PARTICIPATION; DECISION MAKING; LIVING WILLS; TREATMENT REFUSAL	ADVANCE DIRECTIVES; HEALTH; CARE	Objective: To examine the stability of patients' choices for life-sustaining treatments. Design: A longitudinal cohort study. Setting: Primary care practices in central North Carolina. Patients: Medicare recipients (n = 2536). Intervention: Participants were asked about demographic characteristics, health status, well-being, depression, social support, use of a living will, and desire for life-sustaining treatments if they were to become terminally ill. These questions were repeated 2 years later (n = 2073, 82% follow-up). Results: The population tended to choose to forego one more treatment at follow-up than they did at baseline. A choice to forego treatment was twice as stable as a choice to receive treatment. Patients with a living will were less likely to change their wishes (14%) than those without a living will (41%). Persons were more likely to want increased treatment at a later time if they had been hospitalized (23% compared with 18%), had had an accident (29% compared with 19%), had become more immobile (23% compared with 19%), had become more depressed (25% compared with 15%), or had less social support (25% compared with 14%). Conclusions: Most patients (85%) who had chosen to forego life-sustaining treatments did not change their choices. Nonetheless, these data suggest that it is important to review patients' preferences for life-sustaining treatments rather than to assume the stability of their choices.	UNIV N CAROLINA, SHEPS CTR HLTH SERV, CHAPEL HILL, NC 27599 USA; UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT HLTH SERV, SEATTLE, WA 98195 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle	DANIS, M (corresponding author), UNIV N CAROLINA, DEPT MED, DIV GEN MED, CB 7110, 5025A OLD CLIN BLDG, CHAPEL HILL, NC 27599 USA.		Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492				DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; EVERHART MA, 1990, CHEST, V97, P159, DOI 10.1378/chest.97.1.159; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; GARRETT JM, 1993, J GEN INTERN MED, V8, P361, DOI 10.1007/BF02600073; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; Kaplan R., 1990, QUALITY LIFE ASSESSM, P131; KAPLAN RM, 1976, HEALTH SERV RES, V11, P478; MENIKOFF JA, 1992, NEW ENGL J MED, V327, P1165, DOI 10.1056/NEJM199210153271612; MOSSEY JM, 1982, AM J PUBLIC HEALTH, V72, P800, DOI 10.2105/AJPH.72.8.800; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PATRICK DL, 1973, J HEALTH SOC BEHAV, V14, P6, DOI 10.2307/2136932; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SILVERSTEIN MD, 1991, MAYO CLIN PROC, V66, P906, DOI 10.1016/S0025-6196(12)61577-8; 1987, GUIDELINES TERMINATI	16	193	193	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					567	573		10.7326/0003-4819-120-7-199404010-00006	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8116994				2022-12-01	WOS:A1994NC76400006
J	GAFFNEY, G; SELLERS, S; FLAVELL, V; SQUIER, M; JOHNSON, A				GAFFNEY, G; SELLERS, S; FLAVELL, V; SQUIER, M; JOHNSON, A			CASE-CONTROL STUDY OF INTRAPARTUM CARE, CEREBRAL-PALSY, AND PERINATAL DEATH	BRITISH MEDICAL JOURNAL			English	Article							ASPHYXIA	Objective-To investigate the relation between suboptimal intrapartum obstetric care and cerebral palsy or death. Design-Case-control study. Setting-Oxford Regional Health Authority. Subjects-141 babies who subsequently developed cerebral palsy and 62 who died intrapartum or neonatally, 1984-7. All subjects were born at term of singleton pregnancies and had no congenital anomaly. Two controls, matched for place and time of birth, were selected for each index case. Main outcome measures-Adverse antenatal factors and suboptimal intrapartum care (by using predefined criteria). Results-Failure to respond to signs of severe fetal distress was more common in cases of cerebral palsy (odds ratio 4.5; 95% confidence interval 2.4 to 8.4) and in cases of death (26.1; 6.2 to 109.7) than among controls. This association persisted even after adjustment for increased incidence of a complicated obstetric history in cases of cerebral palsy. Neonatal encephalopathy is regarded as the best clinical indicator of birth asphyxia; only two thirds (23/33) of the children with cerebral palsy in whom there had been a suboptimal response to fetal distress, however, had evidence of neonatal encephalopathy; these 23 formed 6.8% of all children with cerebral palsy born to residents of the region in the four years studied. Conclusion-There is an association between quality of intrapartum care and death. The findings also suggest an association between suboptimal care and cerebral palsy, but this seems to have a role in only a small proportion of all cases of cerebral palsy. The contribution of adverse antenatal factors in the origin of cerebral palsy needs further study.	RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,OXON,ENGLAND; JOHN RADCLIFFE MATERN HOSP,OXFORD OX3 9DU,OXON,ENGLAND; RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,OXON,ENGLAND	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary			Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Johnson, Anne/0000-0003-1330-7100				BLAIR E, 1988, J PEDIATR-US, V112, P515, DOI 10.1016/S0022-3476(88)80161-6; BLAIR E, 1990, AM J OBSTET GYNECOL, V162, P229, DOI 10.1016/0002-9378(90)90856-3; BRESLOW NE, 1980, INT AGENCY RES CANCE, V32; BRYCE R, 1989, EFFECTIVE CARE PREGN, P1313; FREEMAN JM, 1988, PEDIATRICS, V82, P240; Gilles FH, 1983, DEV HUMAN BRAIN GROW, P227; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; JOHNSON A, 1989, COMMUNITY MED, V11, P352; MACDONALD D, 1985, AM J OBSTET GYNECOL, V152, P524, DOI 10.1016/0002-9378(85)90619-2; MYERS RE, 1972, AM J OBSTET GYNECOL, V112, P246, DOI 10.1016/0002-9378(72)90124-X; NAEYE RL, 1989, AM J DIS CHILD, V143, P1154, DOI 10.1001/archpedi.1989.02150220044018; NELSON KB, 1988, J PEDIATR-US, V112, P572, DOI 10.1016/S0022-3476(88)80169-0; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; NELSON KB, 1989, CLIN PERINATOL, V16, P995, DOI 10.1016/S0095-5108(18)30617-1; NISWANDER K, 1984, LANCET, V2, P827; PANETH N, 1983, OBSTET GYNECOL, V61, P547; RICHMOND S, IN PRESS OBSTET GYNE; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SIMS ME, 1985, AM J OBSTET GYNECOL, V151, P721, DOI 10.1016/0002-9378(85)90503-4; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; TORFS CP, 1990, J PEDIATR-US, V116, P615, DOI 10.1016/S0022-3476(05)81615-4; 1989, WORKING PARTY RESUSC; 1989, EGRET EPIDEMIOLOGICA; 1988, OPCS MONITOR, pDH3	25	128	129	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					743	750		10.1136/bmj.308.6931.743	http://dx.doi.org/10.1136/bmj.308.6931.743			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142827	Green Published			2022-12-01	WOS:A1994NC34800016
J	KAS, J; STREY, H; SACKMANN, E				KAS, J; STREY, H; SACKMANN, E			DIRECT IMAGING OF REPTATION FOR SEMIFLEXIBLE ACTIN-FILAMENTS	NATURE			English	Article							F-ACTIN; DYNAMICS; CHAIN; MOTION	ACCORDING to the reptation model of polymer diffusion(1), a polymer chain exhibits snake-like motion through the entangled mesh of surrounding molecules, in which the undulations of the chain are restricted to a tubelike region(2). The reptation model can account for many of the dynamic properties of entangled polymer solutions and melts, and has received support from observations of block copolymer diffusion across an interface(3); but reptative motion has not previously been imaged directly(4,5). Here we report such a direct observation of reptation, obtained by video microscopy of fluorescently labelled single, semiflexible filaments of actin in a solution of unlabelled actin filaments. From the restricted thermal undulations of these filaments we can measure the diameter of the confining tube, and we also observe the characteristic thermally excited sliding of the filament out of the end of the tube. We find that the chain self-diffusion coefficient decreases approximately linearly as the filament length increases, in agreement with the reptation model.	TECH UNIV MUNICH, DEPT PHYS, BIOPHYS GRP, D-85748 GARCHING, GERMANY	Technical University of Munich	KAS, J (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV EXPTL MED, BOSTON, MA 02115 USA.		Strey, Helmut/B-5456-2009	Strey, Helmut/0000-0002-6554-5322; Kas, Josef A./0000-0003-3158-2480				Alberts B., 1989, MOL BIOL CELL; DEGENNES PG, 1971, J CHEM PHYS, V55, P572, DOI 10.1063/1.1675789; DEGENNES PG, 1976, J PHYS-PARIS, V37, P1461, DOI 10.1051/jphys:0197600370120146100; Doi M., 1988, INT SERIES MONOGRAPH; EDWARDS SF, 1967, P PHYS SOC LOND, V92, P9, DOI 10.1088/0370-1328/92/1/303; GRAESSLEY WW, 1980, J POLYM SCI, V13, P17; HIGGINS J, 1993, NATURE, V365, P205, DOI 10.1038/365205a0; HONDA H, 1986, J MOL BIOL, V191, P131, DOI 10.1016/0022-2836(86)90428-6; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; KAS J, 1993, EUROPHYS LETT, V21, P865, DOI 10.1209/0295-5075/21/8/012; KAUFMANN S, 1992, FEBS LETT, V314, P203, DOI 10.1016/0014-5793(92)80975-M; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; Landau L. D., 1980, STAT PHYS, P544; LODGE TP, 1990, ADV CHEM PHYS, V79, P1; RUSSELL TP, 1993, NATURE, V365, P235, DOI 10.1038/365235a0; SACKMANN E, 1994, MACROMOL CHEM PHYSIC, V195, P7, DOI 10.1002/macp.1994.021950103; SCHMIDT CF, 1989, MACROMOLECULES, V22, P3638, DOI 10.1021/ma00199a023; SEMENOV AN, 1986, J CHEM SOC FARAD T 2, V82, P317, DOI 10.1039/f29868200317; WENDEL H, 1982, MACROMOLECULES, V15, P1318, DOI 10.1021/ma00233a020; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0	20	211	211	1	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 17	1994	368	6468					226	229		10.1038/368226a0	http://dx.doi.org/10.1038/368226a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145821				2022-12-01	WOS:A1994NA87000049
J	ARPAIA, E; SHAHAR, M; DADI, H; COHEN, A; ROIFMAN, CM				ARPAIA, E; SHAHAR, M; DADI, H; COHEN, A; ROIFMAN, CM			DEFECTIVE T-CELL RECEPTOR SIGNALING AND CD8(+) THYMIC SELECTION IN HUMANS LACKING ZAP-70 KINASE	CELL			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; POSITIVE SELECTION; MICE LACKING; ZETA-CHAIN; PHOSPHORYLATION; ACTIVATION; TRANSDUCTION; CD4	We have previously described a type of selective T cell deficiency (STD) characterized by persistent infections reminiscent of severe combined immunodeficiency. We show here that STD patients carry a mutation of zap-70, resulting in loss of the activity of this kinase. The thymi of zap-70(-/-) patients show the presence of CD4(+)CD8(+) cells in the cortex; however, only CD4, not CD8, single-positive cells are present in the medulla. Peripheral CD4(+) T cells from the zap 70(-/-) patients exhibit markedly reduced tyrosine phosphorylation, fail to produce interleukin-2, and do not proliferate in response to T cell receptor stimulation by mitogens or antigens. Thus, Zap-70 kinase appears to be indispensable for the development of CD8 single-positive T cells as well as for signal transduction and function of single-positive CD4 T cells.	HOSP SICK CHILDREN, DIV IMMUNNOL & ALLERGY, TORONTO M5G 1X8, ON, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BILL J, 1989, NATURE, V341, P649, DOI 10.1038/341649a0; BOSMA GC, 1988, J EXP MED, V167, P1016, DOI 10.1084/jem.167.3.1016; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN IT, 1993, SCIENCE, V261, P1581, DOI 10.1126/science.8372352; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DOHERTY PJ, 1991, MOL IMMUNOL, V28, P607, DOI 10.1016/0161-5890(91)90129-8; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GILLILAND LK, 1991, J IMMUNOL, V146, P1759; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GREENE WC, 1986, ANNU REV IMMUNOL, V4, P69, DOI 10.1146/annurev.iy.04.040186.000441; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; MARUSICGALESIC S, 1988, NATURE, V333, P180, DOI 10.1038/333180a0; MILLS GB, 1986, INTERLEUKIN, V2, P113; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MONAFO WJ, 1992, CLIN EXP IMMUNOL, V90, P390; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; ROIFMAN CM, 1986, CLIN EXP IMMUNOL, V66, P139; ROIFMAN CM, 1992, J IMMUNOL, V148, P1136; ROIFMAN CM, 1989, J EXP MED, V170, P2177, DOI 10.1084/jem.170.6.2177; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKAHAMA Y, 1992, SCIENCE, V258, P1456, DOI 10.1126/science.1439838; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VONBOEHMER H, 1989, IMMUNOL TODAY, V10, P57, DOI 10.1016/0167-5699(89)90307-1; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	52	472	479	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 11	1994	76	5					947	958		10.1016/0092-8674(94)90368-9	http://dx.doi.org/10.1016/0092-8674(94)90368-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124727				2022-12-01	WOS:A1994NA89000019
J	GREENE, AE; ALLISON, RF				GREENE, AE; ALLISON, RF			RECOMBINATION BETWEEN VIRAL-RNA AND TRANSGENIC PLANT TRANSCRIPTS	SCIENCE			English	Article							BROME MOSAIC-VIRUS; DEFECTIVE INTERFERING RNA; GENETIC-RECOMBINATION; SEQUENCE; GENOME; COMPONENTS; RESISTANCE; INFECTION	Transformed plants expressing the 3' two-thirds of the cowpea chlorotic mottle virus (CCMV) capsid gene were inoculated with a CCMV deletion mutant lacking the 3' one-third of the capsid gene. Although the deletion inoculum replicates in inoculated cells, systemic infections occur only if recombination restores a functional capsid gene. Four of 125 inoculated transgenic plants, representing three different transgenic lines, became systemically infected. Analysis of viral RNA confirmed that RNA recombination had united the transgenic messenger RNA and the challenging virus through aberrant homologous recombination.	MICHIGAN STATE UNIV,DEPT BOT & PLANT PATHOL,E LANSING,MI 48824	Michigan State University								ALLISON R, 1990, P NATL ACAD SCI USA, V87, P1820, DOI 10.1073/pnas.87.5.1820; ALLISON RF, 1988, J VIROL, V62, P3581, DOI 10.1128/JVI.62.10.3581-3588.1988; ALLISON RF, 1989, VIROLOGY, V172, P321, DOI 10.1016/0042-6822(89)90134-7; AN G, 1988, PLANT MOL BIOL MAN A, V3, P1; ANGENENT GC, 1989, VIROLOGY, V171, P271, DOI 10.1016/0042-6822(89)90537-0; BEACHY RN, 1990, ANNU REV PHYTOPATHOL, V28, P451, DOI 10.1146/annurev.py.28.090190.002315; BUJARSKI JJ, 1986, NATURE, V321, P528, DOI 10.1038/321528a0; BURGYAN J, 1989, J GEN VIROL, V70, P235, DOI 10.1099/0022-1317-70-1-235; CASCONE PJ, 1993, SCIENCE, V260, P801, DOI 10.1126/science.8484119; DAWSON WO, 1992, ANNU REV PLANT PHYS, V43, P527, DOI 10.1146/annurev.pp.43.060192.002523; DEZOETEN GA, 1991, PHYTOPATHOLOGY, V81, P585; GRUMET R, 1990, HORTSCIENCE, V25, P508, DOI 10.21273/HORTSCI.25.5.508; HILLMAN BI, 1987, CELL, V51, P427, DOI 10.1016/0092-8674(87)90638-6; KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8; LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992; Lommel S.A., 1991, J CELL BIOCHEM, V15, P151; MATTHEWS REF, 1991, PLANT VIROLOGY, P376; MAYO MA, 1991, J GEN VIROL, V72, P2591, DOI 10.1099/0022-1317-72-10-2591; MILLER WA, 1986, J MOL BIOL, V187, P537, DOI 10.1016/0022-2836(86)90332-3; NAGY PD, 1993, P NATL ACAD SCI USA, V90, P6390, DOI 10.1073/pnas.90.14.6390; NAGY PD, 1992, J VIROL, V66, P6824, DOI 10.1128/JVI.66.11.6824-6828.1992; RAO ALN, 1993, J VIROL, V67, P969, DOI 10.1128/JVI.67.2.969-979.1993; RAO ALN, 1990, J GEN VIROL, V71, P1403, DOI 10.1099/0022-1317-71-6-1403; ROBINSON DJ, 1987, J GEN VIROL, V68, P2551, DOI 10.1099/0022-1317-68-10-2551	24	140	161	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1423	1425		10.1126/science.8128222	http://dx.doi.org/10.1126/science.8128222			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128222				2022-12-01	WOS:A1994MZ92700027
J	DOHMEN, RJ; WU, PP; VARSHAVSKY, A				DOHMEN, RJ; WU, PP; VARSHAVSKY, A			HEAT-INDUCIBLE DEGRON - A METHOD FOR CONSTRUCTING TEMPERATURE-SENSITIVE MUTANTS	SCIENCE			English	Article							N-END RULE; CEREVISIAE CHROMOSOME-I; SACCHAROMYCES-CEREVISIAE; LETHAL MUTATIONS; ESCHERICHIA-COLI; DIHYDROFOLATE-REDUCTASE; CONDITIONAL MUTATIONS; DEGRADATION SIGNAL; CRYSTAL-STRUCTURE; GENE-EXPRESSION	A temperature-sensitive (ts) mutant retains the function of a gene at a low (permissive) temperature but not at a high (nonpermissive) temperature. Arg-DHFR, a dihydrofolate reductase bearing an amino-terminal (N-terminal) arginine, is long-lived in the yeast Saccharomyces cerevisiae, even though arginine is a destabilizing residue in the N-end rule of protein degradation. A ts derivative of Arg-DHFR was identified that is long-lived at 23 degrees C but rapidly degraded by the N-end rule pathway at 37 degrees C. Fusions of ts Arg-DHFR to either Ura3 or Cdc28 of S. cerevisiae confer ts phenotypes specific for these gene products. Thus, Arg-DHFR(ts) is a heat-inducible degradation signal that can be used to produce ts mutants without a search for ts mutations.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology			Dohmen, R. Jürgen/AAD-6649-2022	Dohmen, R. Jürgen/0000-0002-5756-6780				ALANI E, 1987, GENETICS, V117, P5; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; BALAKRISHNAN R, 1988, GENE, V67, P97, DOI 10.1016/0378-1119(88)90012-1; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BARTEL B, 1988, CELL, V52, P935, DOI 10.1016/0092-8674(88)90435-7; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BUSBY S, 1982, J MOL BIOL, V154, P197, DOI 10.1016/0022-2836(82)90060-2; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHOW WY, 1988, P NATL ACAD SCI USA, V85, P6468, DOI 10.1073/pnas.85.17.6468; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; Futcher A B, 1991, Semin Cell Biol, V2, P205; HARRIS SD, 1992, J MOL BIOL, V225, P53, DOI 10.1016/0022-2836(92)91025-K; HARRIS SD, 1991, GENETICS, V127, P279; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILL A, 1987, MOL CELL BIOL, V7, P2397, DOI 10.1128/MCB.7.7.2397; HILL CP, 1993, P NATL ACAD SCI USA, V90, P4136, DOI 10.1073/pnas.90.9.4136; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HOROWITZ NH, 1950, ADV GENET, V3, P33, DOI 10.1016/S0065-2660(08)60082-6; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; Johnston J. C., UNPUB; KABACK DB, 1984, GENETICS, V108, P67; MADURA K, 1993, J BIOL CHEM, V268, P12046; MOIR D, 1982, GENETICS, V100, P565; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NASMYTH K, 1991, COLD SPRING HARB SYM, V56, P9; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OEFNER C, 1988, EUR J BIOCHEM, V174, P377, DOI 10.1111/j.1432-1033.1988.tb14108.x; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; Pringle J R, 1975, Methods Cell Biol, V12, P233; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RILES L, 1988, GENETICS, V118, P601; ROSE M, 1984, GENE, V29, P113, DOI 10.1016/0378-1119(84)90172-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SIKORSKI RS, 1989, GENETICS, V122, P19; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VOLZ KW, 1982, J BIOL CHEM, V257, P2528; YOSHIMATSU T, 1989, SCIENCE, V244, P1346, DOI 10.1126/science.2544026; ZHANG YF, 1991, P NATL ACAD SCI USA, V88, P1511, DOI 10.1073/pnas.88.4.1511	48	297	318	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 4	1994	263	5151					1273	1276		10.1126/science.8122109	http://dx.doi.org/10.1126/science.8122109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122109				2022-12-01	WOS:A1994MY57000034
J	RIDDIHOUGH, G				RIDDIHOUGH, G			FEELING THE GROOVE	NATURE			English	Editorial Material							PROTEINS											BROWN BM, 1994, NAT STRUCT BIOL, V1, P164, DOI 10.1038/nsb0394-164; CARTER CW, 1974, P NATL ACAD SCI USA, V71, P283, DOI 10.1073/pnas.71.2.283; CHOU PY, 1975, J MOL BIOL, V96, P29, DOI 10.1016/0022-2836(75)90180-1; CHURCH GM, 1977, P NATL ACAD SCI USA, V74, P1458, DOI 10.1073/pnas.74.4.1458; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804	10	2	2	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					82	82		10.1038/368082a0	http://dx.doi.org/10.1038/368082a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	8107890				2022-12-01	WOS:A1994MY56900059
J	BELL, TW; JOUSSELIN, H				BELL, TW; JOUSSELIN, H			SELF-ASSEMBLY OF A DOUBLE-HELICAL COMPLEX OF SODIUM	NATURE			English	Article							X-RAY CRYSTAL; MOLECULAR-STRUCTURE; METAL-COMPLEXES; LIGANDS; PREFERENCE; CHEMISTRY	SPONTANEOUS self-organization of helical and multiple-helical molecular structures occurs on several levels in living organisms. Key examples are alpha-helical polypeptides, double-helical nucleic acids and helical protein structures, including F-actin, microtubules and the protein sheath of the tobacco mosaic virus1. Although the self-assembly of double-helical transition-metal complexes1-15 bears some resemblance to the molecular organization of double-stranded DNA, selection between monohelical, double-helical and triple-helical structures is determined largely by the size and geometrical preference of the tightly bound metal14. Here we present an example of double-helical assembly induced by the weaker and non-directional interactions of an alkali-metal ion with an organic ligand that is pre-organized into a coil. We have characterized the resulting complex by two-dimensional NMR and fast-atom-bombardment mass spectrometry. These results provide a step toward the creation of molecular tubes or ion channels consisting of intertwined coils.			BELL, TW (corresponding author), SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794, USA.							BELL TW, 1993, PURE APPL CHEM, V65, P361, DOI 10.1351/pac199365030361; BELL TW, 1991, J AM CHEM SOC, V113, P6283, DOI 10.1021/ja00016a062; BELL TW, 1992, ANGEW CHEM INT EDIT, V31, P345, DOI 10.1002/anie.199203451; BELL TW, 1992, ANGEW CHEM INT EDIT, V31, P348, DOI 10.1002/anie.199203481; BELL TW, 1992, CROWN COMPOUNDS FUTU, P303; BERNARDINELLI G, 1992, ANGEW CHEM INT EDIT, V31, P1622; BRADLEY D, 1993, SCIENCE, V259, P890, DOI 10.1126/science.259.5097.890; CONSTABLE EC, 1992, ANGEW CHEM INT EDIT, V31, P230, DOI 10.1002/anie.199202301; CONSTABLE EC, 1990, NATURE, V346, P314, DOI 10.1038/346314a0; CONSTABLE EC, 1992, POLYHEDRON, V11, P2967, DOI 10.1016/S0277-5387(00)83604-9; CONSTABLE EC, 1992, TETRAHEDRON, V48, P10013, DOI 10.1016/S0040-4020(01)89035-9; CONSTABLE EC, 1987, J CHEM SOC CHEM COMM, P1600, DOI 10.1039/c39870001600; CONSTABLE EC, 1993, NATURE, V362, P412, DOI 10.1038/362412a0; CONSTABLE EC, 1991, ANGEW CHEM INT EDIT, V30, P1450, DOI 10.1002/anie.199114501; DIETRICHBUCHECKER CO, 1990, ANGEW CHEM INT EDIT, V29, P1154, DOI 10.1002/anie.199011541; HUANG CY, 1992, ANGEW CHEM INT EDIT, V31, P1244, DOI 10.1002/anie.199212441; KOERT U, 1990, NATURE, V346, P339, DOI 10.1038/346339a0; Lehn J. M., 1992, PERSPECTIVES COORDIN, P447; LEHN JM, 1987, P NATL ACAD SCI USA, V84, P2565, DOI 10.1073/pnas.84.9.2565; LEHN JM, 1983, NOUV J CHIM, V7, P413; LINDSEY JS, 1991, NEW J CHEM, V15, P153; LORENZI GP, 1991, CHIRALITY, V3, P315, DOI 10.1002/chir.530030416; PFIEL A, 1992, J CHEM SOC CHEM COMM, P838; PIGUET C, 1992, J AM CHEM SOC, V114, P7440, DOI 10.1021/ja00045a016; STUCKMEIER G, 1976, J AM CHEM SOC, V98, P278; THUMMEL RP, 1991, TETRAHEDRON, V47, P6851, DOI 10.1016/S0040-4020(01)96143-5; TOMASIK P, 1985, Z PYRIDINE METAL COM, pCH1; VANSTEIN GC, 1984, J AM CHEM SOC, V106, P4486, DOI 10.1021/ja00328a031; WESTER D, 1975, J CHEM SOC CHEM COMM, P74, DOI 10.1039/c39750000074; WILLIAMS AF, 1991, ANGEW CHEM INT EDIT, V30, P1490, DOI 10.1002/anie.199114901	30	100	100	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					441	444		10.1038/367441a0	http://dx.doi.org/10.1038/367441a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107802				2022-12-01	WOS:A1994MU67900048
J	TOGGAS, SM; MASLIAH, E; ROCKENSTEIN, EM; RALL, GF; ABRAHAM, CR; MUCKE, L				TOGGAS, SM; MASLIAH, E; ROCKENSTEIN, EM; RALL, GF; ABRAHAM, CR; MUCKE, L			CENTRAL-NERVOUS-SYSTEM DAMAGE PRODUCED BY EXPRESSION OF THE HIV-1 COAT PROTEIN GP120 IN TRANSGENIC MICE	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ASTROCYTE-SPECIFIC EXPRESSION; NEOCORTICAL DAMAGE; ACTIVATION; CLEAVAGE; INJURY; RAT	MANY people infected with human immunodeficiency virus type 1 (HIV-1) develop neurological complications that can culminate in dementia and paralysis1. The discrepancy between the severity of impairment and the paucity of detectable HIV-1 within neurons has led to an intense search for diffusible virus- and host-derived factors that might be neurotoxic (see ref. 2 for review). The HIV-1 envelope glycoprotein gp120 is an extracellular protein that is shed from infected cells3 and so has the potential to diffuse and interact with distant uninfected brain cells. Studies on cultured immature cells suggest that gp120 induces neurotoxicity (reviewed in refs 2, 4), and systemic injection of gp120 in neonatal rats5 and intracerebroventricular injection in adult rats results in deleterious effects on the brain6,7. To assess the pathogenic potential of gp120 in the intact brain, we have now produced gp120 in the brains of transgenic mice and found a spectrum of neuronal and glial changes resembling abnormalities in brains of HIV-1-infected humans. The severity of damage correlated positively with the brain level of gp120 expression. These results provide in vivo evidence that gp120 plays a key part in HIV-1-associated nervous system impairment. This model should facilitate the evaluation and development of therapeutic strategies aimed at HIV-brain interactions.	Scripps Res Inst, DEPT NEUROPHARMACOL, DIV VIROL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; BOSTON UNIV, SCH MED, DEPT MED, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA	Scripps Research Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Boston University; Boston University				Mucke, Lennart/0000-0001-6256-9559; Abraham, Carmela/0000-0002-6649-1960				ABRAHAM CR, 1993, BRAIN RES, V621, P222, DOI 10.1016/0006-8993(93)90110-9; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; Budka H, 1991, BRAIN PATHOL, V1, P163, DOI 10.1111/j.1750-3639.1991.tb00656.x; CAMPBELL I, 1993, SOC NEUR ABSTR, V19; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; EPSTEIN J, 1993, J GEN VIROL, V33, P429; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; GIULIAN D, 1993, P NATL ACAD SCI USA, V90, P2769, DOI 10.1073/pnas.90.7.2769; GLOWA JR, 1992, BRAIN RES, V570, P49, DOI 10.1016/0006-8993(92)90562-N; HAASS C, 1991, J NEUROSCI, V11, P3783; HILL JM, 1993, BRAIN RES, V603, P222, DOI 10.1016/0006-8993(93)91241-J; JANSSEN RS, 1991, NEUROLOGY, V41, P778; KIMES AS, 1991, EXP NEUROL, V112, P224, DOI 10.1016/0014-4886(91)90073-L; LIPTON SA, 1992, NEUROREPORT, V3, P913, DOI 10.1097/00001756-199210000-00023; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MASLIAH E, 1992, ANN NEUROL, V32, P321, DOI 10.1002/ana.410320304; MASLIAH E, 1992, LAB INVEST, V66, P285; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MIURA M, 1990, J NEUROCHEM, V55, P1180, DOI 10.1111/j.1471-4159.1990.tb03123.x; MUCKE L, 1991, NEW BIOL, V3, P465; MUCKE L, 1993, FASEB J, V7, P1226, DOI 10.1096/fasebj.7.13.8405808; MUCKE L, 1992, Neurobiology of Aging, V13, pS101; MUCKE L, 1993, TRANSGENE, V1, P3; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; SCHNEIDER J, 1986, J GEN VIROL, V67, P2533, DOI 10.1099/0022-1317-67-11-2533; SPENCER DC, 1992, ANNU REV MICROBIOL, V46, P655; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613; WILSON MC, 1989, NEUROMETHODS, V16, P239	31	598	610	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 13	1994	367	6459					188	193		10.1038/367188a0	http://dx.doi.org/10.1038/367188a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114918				2022-12-01	WOS:A1994MQ78000066
J	ANDERSON, EL; BECHERER, PR; BELSHE, RB				ANDERSON, EL; BECHERER, PR; BELSHE, RB			REVACCINATION WITH PNEUMOCOCCAL AND HEPATITIS-B VACCINES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											ANDERSON, EL (corresponding author), ST LOUIS UNIV,ST LOUIS,MO 63103, USA.							1990, GUIDE ADULT IMMUNIZA, P16; 1991, MMWR MORB MORTAL WKL, V40, P42	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2735	2736						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133596				2022-12-01	WOS:A1993MJ82100038
J	MASKELL, K; MINTZER, IM; CALLANDER, BA				MASKELL, K; MINTZER, IM; CALLANDER, BA			BASIC SCIENCE OF CLIMATE-CHANGE	LANCET			English	Article									UNIV MARYLAND,STOCKHOLM ENVIRONM INST,COLL PK,MD 20742; UNIV MARYLAND,CTR GLOBAL CHANGE,COLL PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	MASKELL, K (corresponding author), METEOROL OFF,HADLEY CTR,INTERGOVT PANEL CLIMATE CHANGE TECH SUPPORT UNIT,BRACKNELL RG12 2SY,ENGLAND.							DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Houghton J.T., 1992, CLIMATE CHANGE 1992; Intergovernmental Panel on Climate Change, 1990, IPCC 1 ASS REP POL S, P63; MURPHY JM, 1992, 32 HADL CTR CLIM RES; WJMcG Tegart, 1990, CLIMATE CHANGE IPCC, DOI Australian Government Publishing Service	5	16	19	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1027	1031		10.1016/0140-6736(93)92883-U	http://dx.doi.org/10.1016/0140-6736(93)92883-U			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105268				2022-12-01	WOS:A1993MD06600014
J	MERTENS, TE				MERTENS, TE			ESTIMATING THE EFFECTS OF MISCLASSIFICATION	LANCET			English	Article							RELATIVE RISK; CORRELATED EXPOSURES; BIAS		WHO,GLOBAL PROGRAMME AIDS,CH-1211 GENEVA 27,SWITZERLAND	World Health Organization				Mertens, Thierry Eric/0000-0002-1593-6608				[Anonymous], 1988, BMJ, V297, P319; BENNETT KJ, 1987, JAMA-J AM MED ASSOC, V257, P2451, DOI 10.1001/jama.257.18.2451; COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488, DOI 10.1093/oxfordjournals.aje.a112408; CURTIS V, 1993, B WORLD HEALTH ORGAN, V71, P20; DEKLERK NH, 1989, INT J EPIDEMIOL, V18, P705, DOI 10.1093/ije/18.3.705; DUFFY SW, 1989, STAT MED, V8, P1529, DOI 10.1002/sim.4780081213; FINK AJ, 1989, J ROY SOC MED, V82, P695, DOI 10.1177/014107688908201132; FULLER WA, 1978, J AM STAT ASSOC, V73, P99, DOI 10.2307/2286529; GREENLAND S, 1985, AM J EPIDEMIOL, V122, P495, DOI 10.1093/oxfordjournals.aje.a114131; LILIENFELD AM, 1958, J NATL CANCER I, V27, P713; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MERTENS TE, 1990, TROP MED PARASITOL, V41, P79; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; SILVERMAN WA, 1985, HUMAN EXPT GUIDED ST; SMITH GD, 1992, LANCET, V340, P709; SURICK I, 1989, 5 INT C AIDS MONTR; TZONOU A, 1986, REV EPIDEMIOL SANTE, V34, P10	18	62	63	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					418	421		10.1016/0140-6736(93)92820-J	http://dx.doi.org/10.1016/0140-6736(93)92820-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101908				2022-12-01	WOS:A1993LR90000016
J	ROSENMUND, C; CARR, DW; BERGESON, SE; NILAVER, G; SCOTT, JD; WESTBROOK, GL				ROSENMUND, C; CARR, DW; BERGESON, SE; NILAVER, G; SCOTT, JD; WESTBROOK, GL			ANCHORING OF PROTEIN-KINASE-A IS REQUIRED FOR MODULATION OF AMPA/KAINATE RECEPTORS ON HIPPOCAMPAL-NEURONS	NATURE			English	Article							METHYL-D-ASPARTATE; REGULATORY SUBUNIT; ION CHANNELS; CAMP; CLONING; KAINATE; RII; LOCALIZATION; ACCUMULATION; EXPRESSION	PHOSPHORYLATION of molecules involved in synaptic transmission by multifunctional protein kinases modulates both pre- and postsynaptic events in the central nervous system(1,2). The positioning of kinases near their substrates may be an important part of the regulatory mechanism. The A-kinase-anchoring proteins (AKAPs; ref. 3) are known to bind the regulatory subunit of cyclic AMP-dependent protein kinase A with nanomolar affinity. Here we show that anchoring of protein kinase A by AKAPs is required for the modulation of alpha-amino-3-hydroxy-5'methyl-4-isoxazole-propionic acid (AMPA)/kainate channels(4,5). Intracellular perfusion of cultured hippocampal neurons with peptides derived from the conserved kinase binding region of AKAPs prevented the protein kinase A-mediated regulation of AMPA/kainate currents as well as fast excitatory synaptic currents. This effect could be overcome by adding the purified catalytic subunit of protein kinase. A control peptide lacking kinase-binding activity had no effect. To our knowledge, these results provide the first evidence that anchoring of protein kinase A is crucial in the regulation of synaptic function.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University			Rosenmund, Christian/AAC-3596-2020	Rosenmund, Christian/0000-0002-3905-2444				BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHAVEZNORIEGA LE, 1992, BRAIN RES, V574, P85, DOI 10.1016/0006-8993(92)90803-H; CORBIN JD, 1975, J BIOL CHEM, V250, P218; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GASIC GP, 1992, REV PHYSL, V54, P507; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KELLER BU, 1992, EMBO J, V11, P891, DOI 10.1002/j.1460-2075.1992.tb05127.x; LEGENDRE P, 1990, J PHYSIOL-LONDON, V429, P429, DOI 10.1113/jphysiol.1990.sp018266; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROSENMUND C, 1993, J PHYSIOL-LONDON, V470, P705, DOI 10.1113/jphysiol.1993.sp019884; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; THREURFAUF W, 1982, J BIOL CHEM, V357, P3284; UHLER MD, 1986, J BIOL CHEM, V261, P5360; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455	29	317	327	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					853	856		10.1038/368853a0	http://dx.doi.org/10.1038/368853a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159245				2022-12-01	WOS:A1994NH71700071
J	SENGPIEL, F; BLAKEMORE, C				SENGPIEL, F; BLAKEMORE, C			INTEROCULAR CONTROL OF NEURONAL RESPONSIVENESS IN CAT VISUAL-CORTEX	NATURE			English	Article							CROSS-ORIENTATION INHIBITION; BINOCULAR-RIVALRY; STRIATE CORTEX; CELLS; ADAPTATION; ORGANIZATION; MODEL	NEURONS in the cat primary visual cortex are selective for particular contour orientations' but their responsiveness can vary under certain conditions. After prolonged stimulation (adaptation), the contrast sensitivity of cortical cells is reduced(2-5) and the 'gain' (the strength of response as a function of contrast) falls(5-6). The response to an optimal contour is also reduced when,a different stimulus is superimposed on the receptive field in the same eye(7-9). Here we report that the sudden appearance of an inappropriate stimulus in one eye can interocularly suppress the activity of cortical neurons if they are already responding to an optimally oriented stimulus in the other eye. In strabismic cats, whose cortical neurons lack binocular facilitation, even contours of similar orientation shown to the two eyes trigger such suppression. This interocular control of cortical responsiveness could serve to veto signals from one eye under conditions that would otherwise cause double vision and perceptual confusion.			SENGPIEL, F (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.		Sengpiel, Frank/A-4682-2010	Sengpiel, Frank/0000-0002-7060-1851; Blakemore, Colin/0000-0003-2659-7899				ALBRECHT DG, 1984, J PHYSIOL-LONDON, V347, P713, DOI 10.1113/jphysiol.1984.sp015092; BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; BLAKE R, 1989, PSYCHOL REV, V96, P145, DOI 10.1037/0033-295X.96.1.145; BLAKEMORE C, 1972, J PHYSIOL-LONDON, V226, P725, DOI 10.1113/jphysiol.1972.sp010006; BLAKEMORE C, 1987, J PHYSIOL-LONDON, V384, P263, DOI 10.1113/jphysiol.1987.sp016454; BONDS AB, 1989, VISUAL NEUROSCI, V2, P41, DOI 10.1017/S0952523800004314; DEANGELIS GC, 1992, NEUROPHYSIOL, V68, P144; Douglas RJ, 1989, NEURAL COMPUT, V1, P480, DOI 10.1162/neco.1989.1.4.480; FREEMAN RD, 1990, VISION RES, V30, P1661, DOI 10.1016/0042-6989(90)90151-A; FREEMAN RD, 1987, J PHYSIOL-LONDON, V396, pP69; HOLOPIGIAN K, 1988, INVEST OPHTH VIS SCI, V29, P444; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KISVARDAY ZF, 1993, EUR J NEUROSCI, V6, P14; LEHKY SR, 1988, PERCEPTION, V17, P215, DOI 10.1068/p170215; MAFFEI L, 1973, SCIENCE, V182, P1036, DOI 10.1126/science.182.4116.1036; MATSUOKA K, 1984, BIOL CYBERN, V49, P201, DOI 10.1007/BF00334466; MORRONE MC, 1982, PROC R SOC SER B-BIO, V216, P335, DOI 10.1098/rspb.1982.0078; MORRONE MC, 1987, EXP BRAIN RES, V67, P635; MOVSHON JA, 1979, NATURE, V278, P850, DOI 10.1038/278850a0; OHZAWA I, 1985, J NEUROPHYSIOL, V54, P651, DOI 10.1152/jn.1985.54.3.651; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; SCHWARZ C, 1991, J NEUROSCI, V11, P2995; Sengpeil Frank, 1992, Society for Neuroscience Abstracts, V18, P295; SOMOGYI P, 1983, NEUROSCIENCE, V10, P261, DOI 10.1016/0306-4522(83)90133-1; TONG L, 1992, VISUAL NEUROSCI, V8, P557, DOI 10.1017/S0952523800005654; TSO DY, 1986, J NEUROSCI, V6, P1160; VARELA FJ, 1987, EXP BRAIN RES, V66, P10; VAUTIN RG, 1977, J NEUROPHYSIOL, V40, P1051, DOI 10.1152/jn.1977.40.5.1051; XUE J-T, 1987, Investigative Ophthalmology and Visual Science, V28, P102	30	89	89	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					847	850		10.1038/368847a0	http://dx.doi.org/10.1038/368847a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159244				2022-12-01	WOS:A1994NH71700069
J	MADDOX, J				MADDOX, J			STUDY CONFIRMS AZTS LACK OF PROPHYLACTIC EFFECT	NATURE			English	Editorial Material																		1994, LANCET, V343, P871; 1993, LANCET, V341, P889	2	0	0	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					577	577		10.1038/368577b0	http://dx.doi.org/10.1038/368577b0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145833	Bronze			2022-12-01	WOS:A1994NF39200012
J	SCHLIEWEN, UK; TAUTZ, D; PAABO, S				SCHLIEWEN, UK; TAUTZ, D; PAABO, S			SYMPATRIC SPECIATION SUGGESTED BY MONOPHYLY OF CRATER LAKE CICHLIDS	NATURE			English	Article							MITOCHONDRIAL-DNA SEQUENCES; REPRODUCTIVE ISOLATION; EVOLUTION; FISHES; MALAWI; ANIMALS; AFRICA; PISCES	THE existence of sympatric speciation-that populations diverge into species in the absence of physical or ecological barriers-is controversial1-6. The East African Great Lakes harbour hundreds of cichlid species representing only a few monophyletic lineages7,8, although palaeolimnological evidence9-11 and local restrictions on species distribution12 suggest that speciation in these lakes could have been allopatric13,14. The case for sympatry in restricted areas of Lakes Malawi and Tanganyika is stronger15-17 but not unassailable. A better case might be made for cichlid species flocks in small, ecologically monotonous crater lakes. Here we present a mitochondrial DNA analysis of cichlid species flocks endemic to two such lakes in Cameroon. The results suggest that the flocks in each lake are monophyletic: the implication being that each lake was colonized once only, the size and shape of each lake being such that subsequent diversification would have been sympatric.	MAX PLANCK INST VERHALTENSPHYSIOL,D-82319 SEEWIESEN,GERMANY	Max Planck Society	SCHLIEWEN, UK (corresponding author), INST ZOOL,POSTFACH 202136,D-80021 MUNICH,GERMANY.		Villsen, Kurt/C-7965-2015; Langerhans, R. Brian/A-7205-2009; Tautz, Diethard/D-4304-2011; Tautz, Diethard/H-8436-2014	Tautz, Diethard/0000-0002-0460-5344				BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; DOMINEY WJ, 1988, ENVIRON BIOL FISH, V22, P155, DOI 10.1007/BF00001545; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FELSENSTEIN J, 1981, EVOLUTION, V35, P124, DOI 10.1111/j.1558-5646.1981.tb04864.x; FELSENSTEIN JP, 1990, VERSION 3 3; FUTUYMA DJ, 1980, SYST ZOOL, V29, P254, DOI 10.2307/2412661; Grant P.R., 1989, P433; GREENWOOD PH, 1987, B BRIT MUS NAT HIST, V83, P139; HASSERT K, 1912, Z GES ERDK BERL, P135; HASSERT K, 1912, Z GES ERDK BERL, P7; HASSERT K, 1912, Z GES ERDK BERL, P203; KING GW, 1987, THESIS DUKE U PRINCE; KLING GW, 1988, LIMNOL OCEANOGR, V33, P27, DOI 10.4319/lo.1988.33.1.0027; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KONDRASHOV AS, 1986, BIOL J LINN SOC, V27, P201, DOI 10.1111/j.1095-8312.1986.tb01734.x; LIVINGSTONE DA, 1975, ANNU REV ECOL SYST, V6, P249, DOI 10.1146/annurev.es.06.110175.001341; Mayr E., 1984, EVOLUTION FISH SPECI, P3; MCKAYE ER, 1982, ZOOL J LINN SOC-LOND, V76, P91, DOI 10.1111/j.1096-3642.1982.tb01956.x; MCKAYE KR, 1984, EVOLUTION, V38, P215, DOI 10.1111/j.1558-5646.1984.tb00273.x; MCKAYE KR, 1980, ENVIRON BIOL FISH, V5, P75, DOI 10.1007/BF00000953; MEYER A, 1990, BIOL J LINN SOC, V39, P279, DOI 10.1111/j.1095-8312.1990.tb00517.x; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; NISHIDA M, 1991, EXPERIENTIA, V47, P974, DOI 10.1007/BF01929896; Otte D., 1989, SPECIATION ITS CONSE; OWEN RB, 1990, PROC R SOC SER B-BIO, V240, P519, DOI 10.1098/rspb.1990.0052; PAABO S, 1988, NUCLEIC ACIDS RES, V16, P9775, DOI 10.1093/nar/16.20.9775; PIMM SL, 1979, BIOL J LINN SOC, V11, P131, DOI 10.1111/j.1095-8312.1979.tb00030.x; RIBBINK AJ, 1983, AFR J ZOOL, V18, P1; Rice WR, 1987, EVOL ECOL, V1, P301, DOI 10.1007/BF02071555; RICE WR, 1990, EVOLUTION, V44, P1140, DOI 10.1111/j.1558-5646.1990.tb05221.x; Seger J., 1985, P43; SMITH JM, 1966, AM NAT, V100, P637, DOI 10.1086/282457; Stiassny M.L.J., 1992, Ichthyological Exploration of Freshwaters, V3, P311; STURMBAUER C, 1992, NATURE, V358, P578, DOI 10.1038/358578a0; TEUGELS GG, 1992, ANN SCI ZOOLOGIQUES, V266, P1; THOMAS RH, 1989, NATURE, V340, P465, DOI 10.1038/340465a0; Tiercelin J.-J., 1991, LAKE TANGANYIKA ITS, P7; TREWAVAS E, 1972, J ZOOL, V167, P41; TREWAVAS E, 1984, B BRIT MUS NAT HIST, V26, P331; UDOVIC D, 1980, AM NAT, V116, P621, DOI 10.1086/283654; VANDENAUDENAERD.DF, 1970, REV ZOOL BOT AFR, V82, P285	42	344	348	0	105	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					629	632		10.1038/368629a0	http://dx.doi.org/10.1038/368629a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145848				2022-12-01	WOS:A1994NF39200059
J	BURNS, R				BURNS, R			FROZEN IN TIME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	1994	271	13					965	965		10.1001/jama.271.13.965	http://dx.doi.org/10.1001/jama.271.13.965			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND949	8139066				2022-12-01	WOS:A1994ND94900002
J	SHAKKED, Z; GUZIKEVICHGUERSTEIN, G; FROLOW, F; RABINOVICH, D; JOACHIMIAK, A; SIGLER, PB				SHAKKED, Z; GUZIKEVICHGUERSTEIN, G; FROLOW, F; RABINOVICH, D; JOACHIMIAK, A; SIGLER, PB			DETERMINANTS OF REPRESSOR-OPERATOR RECOGNITION FROM THE STRUCTURE OF THE TRP OPERATOR BINDING-SITE	NATURE			English	Article							DNA DOUBLE HELIX; T-C-G; B-DNA; RESOLUTION; CRYSTAL; COMPLEX	ON the basis of the crystal structure of the trp repressor/operator complex1, it has been proposed that the specificity of the interaction can be explained not only by direct hydrogen bonding and non-polar contacts between the protein and the bases of its target DNA, but also by indirect structural effects and water-mediated interactions. To understand the contribution of DNA structure and hydration in this context, the structure of the free DNA must be compared with its structure when complexed with the protein. Here we present the high-resolution crystal structure of the trp operator region that is most important in the recognition process. By comparing the free and bound states of the DNA regulatory sequence, we show that the structure and hydration of the DNA target are important elements in its recognition by the repressor protein.	YALE UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University	SHAKKED, Z (corresponding author), WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL.		Frolow, Felix/A-1760-2013					BAIKALOV I, 1993, J MOL BIOL, V231, P768, DOI 10.1006/jmbi.1993.1325; Brunger AT, 1992, X PLOR VERSION 3 0 S; Chandrasekaran R., 1989, LANDOLTBORNSTEIN B, V1/II, P31; Dickerson RE, 1989, EMBO J, V8, P1; GRZESKOWIAK K, 1991, J BIOL CHEM, V266, P8861; HEINEMANN U, 1989, J MOL BIOL, V210, P369, DOI 10.1016/0022-2836(89)90337-9; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; LIPANOV A, 1993, BIOCHEMISTRY-US, V32, P1373, DOI 10.1021/bi00056a024; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PRIVE GG, 1991, J MOL BIOL, V217, P177, DOI 10.1016/0022-2836(91)90619-H; QUINTANA J, 1991, J MOL BIOL, V225, P379; RABINOVICH D, 1984, ACTA CRYSTALLOGR A, V40, P195, DOI 10.1107/S010876738400043X; SCHNEIDER B, 1992, BIOPOLYMERS, V32, P725, DOI 10.1002/bip.360320703; SHAKKED Z, 1989, NATURE, V342, P456, DOI 10.1038/342456a0; SHAKKED Z, 1986, PROG BIOPHYS MOL BIO, V47, P159, DOI 10.1016/0079-6107(86)90013-1; Shakked Z, 1991, CURR OPIN STRUC BIOL, V1, P446, DOI 10.1016/0959-440X(91)90046-V; SIGLER PB, 1992, TRANSCRIPTIONAL REGU, V1, P475; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; YUAN H, 1992, BIOCHEMISTRY-US, V31, P8009, DOI 10.1021/bi00149a035	22	165	169	2	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 31	1994	368	6470					469	473		10.1038/368469a0	http://dx.doi.org/10.1038/368469a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133895				2022-12-01	WOS:A1994ND12000068
J	VONMUTIUS, E; MARTINEZ, FD; FRITZSCH, C; NICOLAI, T; REITMEIR, P; THIEMANN, H				VONMUTIUS, E; MARTINEZ, FD; FRITZSCH, C; NICOLAI, T; REITMEIR, P; THIEMANN, H			SKIN-TEST REACTIVITY AND NUMBER OF SIBLINGS	BRITISH MEDICAL JOURNAL			English	Article							HAY-FEVER; HUMAN TH1; PREVALENCE; ASTHMA; CLONES; GAMMA; IL-4	Objective-To investigate the relation between skin test reactivity in children and number of siblings. Design-Cross sectional survey among school-children aged 9-11 years. Skin prick tests in the children and self completion of written questionnaire by their parents. Subjects-5030 children in Munich and 2623 children in Leipzig and Halle, Germany. Main outcome measures-Atopic status assessed by skin prick tests. Results-After possible confounders were controlled for, the prevalence of atopic sensitisation decreased linearly with increasing number of siblings (odds ratio=0.96 for one sibling, 0.67 for five or more siblings; P=0.005). In atopic children the severity of the skin test reaction as assessed by the weal size was not associated with the number of siblings. Conclusions-Factors directly or indirectly related to the number of siblings may decrease the susceptibility of children to become atopic. Thus, declining family size may in part contribute to the increased prevalence of atopic diseases reported in Western countries over the past few decades.	UNIV ARIZONA,CTR RESP SCI,DEPT PEDIAT,TUCSON,AZ; UNIV LEIPZIG,CHILDRENS HOSP,O-7010 LEIPZIG,GERMANY; MEDIS INST,ENVIRONM & HUMAN HLTH RES CTR,MUNICH,GERMANY; MARTIN LUTHER UNIV HALLE WITTENBERG,CHILDRENS HOSP,HALLE,GERMANY	University of Arizona; Leipzig University; Martin Luther University Halle Wittenberg	VONMUTIUS, E (corresponding author), UNIV MUNICH,CHILDRENS HOSP,LINDWURMSTR 4,W-8000 MUNICH 2,GERMANY.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERBIG B, 1991, ALLERGOLOGIE, V14, P51; BRESLOW NE, 1980, IARC SCI PUBL, V32, P192; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; KOMLOS L, 1992, BIOL NEONATE, V62, P379; MAGGI E, 1992, J IMMUNOL, V148, P2142; MARTINEZ FD, 1992, AM J EPIDEMIOL, V136, P1258, DOI 10.1093/oxfordjournals.aje.a116434; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; PARRONCHI P, 1992, J IMMUNOL, V149, P2977; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P327; SHEARER WT, 1977, J IMMUNOL, V119, P614; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; VERONIER HS, 1984, HELV PAEDIATR ACTA, V39, P129; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; VONMUTIUS E, IN PRESS AM REV RESP; WUTHRICH B, 1986, SCHWEIZ MED WSCHR, V116, P909; [No title captured]; 1991, SPSS STATISTICAL ALG	19	368	372	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					692	695		10.1136/bmj.308.6930.692	http://dx.doi.org/10.1136/bmj.308.6930.692			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142793	Green Published			2022-12-01	WOS:A1994NA86900020
J	SINGH, BM; PRESCOTT, JJW; GUY, R; WALFORD, S; MURPHY, M; WISE, PH				SINGH, BM; PRESCOTT, JJW; GUY, R; WALFORD, S; MURPHY, M; WISE, PH			EFFECT OF ADVERTISING ON AWARENESS OF SYMPTOMS OF DIABETES AMONG THE GENERAL PUBLIC - THE BRITISH-DIABETIC-ASSOCIATION STUDY	BRITISH MEDICAL JOURNAL			English	Article							MELLITUS; DIAGNOSIS	Objective-To determine the impact of posters advertising symptoms of diabetes on public knowledge of these symptoms. Design-Structured street interviews of members of the general public before, at the end of, and 10 weeks after a campaign advertising the main symptoms of diabetes. Setting-Basingstoke and Wolverhampton. Subjects-Three samples of 1000 members of the general public were interviewed. Samples were selected randomly but stratified to match the local population's age (20-75), sex, social class, and racial characteristics. Main outcome measures-Knowledge of symptoms of diabetes; perceived seriousness of diabetes; and induction of anxiety about symptoms in the target population. Results-Advertising significantly raised knowledge (without prompting) of symptoms: thirst, 245 before v 411 at end of campaign (P<0.0001) v 341 after (P=0.0012 v before); polyuria, 72 v 101 (P=0.0211) v 92 (P=0.5169); lethargy,; 180 v 373 (P<0.0001) v 298 (P<0.0001); knowledge of weight loss and visual disturbance was unaffected. The number of subjects lacking knowledge of any symptoms was reduced from 550 to 388 (P<0.0001). The perceived seriousness of diabetes was unaffected (mean 7.6 in each phase on a scale of 1 (not) to 10 (very). Before advertising, 449 (45%) claimed to have one or more symptoms of diabetes, but this number fell at the end of the campaign (403; P=0.0419) and 10 weeks afterwards (278; P<0.0001). Conclusions-An advertising campaign raised public knowledge of diabetes symptoms without inducing fear of diabetes or anxiety about symptoms. Its potential for achieving earlier detection of noninsulin dependent diabetes should be evaluated.	KILMARTIN BAKER LTD,LONDON WC2E 9OS,ENGLAND; BASINGSTOKE DIST GEN HOSP,BASINGSTOKE RG24 9NA,HANTS,ENGLAND; NEW CROSS HOSP,WOLVERHAMPTON WV10 0QP,W MIDLANDS,ENGLAND; BRITISH DIABET ASSOC,LONDON W1M 0BD,ENGLAND	New Cross Hospital	SINGH, BM (corresponding author), CHARING CROSS HOSP,DEPT ENDOCRINOL,LONDON W6 8RF,ENGLAND.							FORREST RD, 1987, DIABETIC MED, V4, P254, DOI 10.1111/j.1464-5491.1987.tb00875.x; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; Hillson R M, 1985, Diabet Med, V2, P383; JACKSON DMA, 1991, DIABETIC MED, V8, P971, DOI 10.1111/j.1464-5491.1991.tb01540.x; MINCU I, 1970, MED INTERNAT, V304, P1331; SINGH BM, 1992, BRIT MED J, V304, P1154, DOI 10.1136/bmj.304.6835.1154; SOLER NG, 1969, BMJ-BRIT MED J, V3, P567, DOI 10.1136/bmj.3.5670.567; 1991, ADVERTISING WORKS	8	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1994	308	6929					632	636		10.1136/bmj.308.6929.632	http://dx.doi.org/10.1136/bmj.308.6929.632			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148713	Green Published			2022-12-01	WOS:A1994MZ69800024
J	PICOT, D; LOLL, PJ; GARAVITO, RM				PICOT, D; LOLL, PJ; GARAVITO, RM			THE X-RAY CRYSTAL-STRUCTURE OF THE MEMBRANE-PROTEIN PROSTAGLANDIN-H(2) SYNTHASE-1	NATURE			English	Article							HIGHER OXIDATION-STATES; CYTOCHROME-C PEROXIDASE; ENDOPEROXIDE SYNTHASE; H SYNTHASE; COMPLEMENTARY-DNA; CYCLOOXYGENASE; ENZYME; SPECTROSCOPY; RESOLUTION; CATALYSIS	The three-dimensional structure of prostaglandin H-2 synthase-1, an integral membrane Protein, has been determined at 3.5 angstrom resolution by X-ray crystallography. This bifunctional enzyme comprises three independent folding units: an epidermal growth factor domain, a membrane-binding motif and an enzymatic domain. Two adjacent but spatially distinct active sites were found for its haem-dependent peroxidase and cyclooxygenase activities. The cyclooxygenase active site is created by a long, hydrophobic channel that is the site of non-steroidal anti-inflammatory drug binding. The conformation of the membrane-binding motif strongly suggests that the enzyme integrates into only one leaflet of the lipid bilayer and is thus a monotopic membrane protein.	UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, 920 E 58TH ST, CHICAGO, IL 60637 USA	University of Chicago				Picot, Daniel/0000-0002-1375-1490				ABRAMSON S, 1991, Current Opinion in Rheumatology, V3, P336, DOI 10.1097/00002281-199106000-00002; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; ERMAN JE, 1992, J AM CHEM SOC, V114, P6592, DOI 10.1021/ja00042a068; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; GARAVITO R M, 1990, Methods (Orlando), V1, P57, DOI 10.1016/S1046-2023(05)80147-1; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAISER ET, 1987, ANNU REV BIOPHYS BIO, V16, P561; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LANDS WEM, 1984, FREE RADICAL BIO MED, V6, P34; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MAKHEJA AN, 1992, MOL CELL BIOCHEM, V111, P137; MARNETT L J, 1990, Environmental Health Perspectives, V88, P5, DOI 10.2307/3431044; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OTTO JC, 1993, J BIOL CHEM, V268, P18234; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PASCHER I, 1987, BIOCHIM BIOPHYS ACTA, V896, P77, DOI 10.1016/0005-2736(87)90358-0; PICOT D, 1989, CYTOCHROME P, V450, P29; POULOS TL, 1993, J BIOL CHEM, V268, P4429; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; Smith W.L.B.P., 1991, BIOCH LIPIDS LIPOPRO, P297, DOI [10.1016/S0167-7306(08)60338-5, DOI 10.1016/S0167-7306(08)60338-5]; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TOH H, 1989, FEBS LETT, V258, P317, DOI 10.1016/0014-5793(89)81683-7; VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928; WILLARD JE, 1992, NEW ENGL J MED, V327, P175; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	49	1114	1139	0	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	1994	367	6460					243	249		10.1038/367243a0	http://dx.doi.org/10.1038/367243a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121489				2022-12-01	WOS:A1994MR49400046
J	HEDRICK, MH; JENNINGS, RW; MACGILLIVRAY, TE; RICE, HE; FLAKE, AW; ADZICK, NS; HARRISON, MR				HEDRICK, MH; JENNINGS, RW; MACGILLIVRAY, TE; RICE, HE; FLAKE, AW; ADZICK, NS; HARRISON, MR			CHRONIC FETAL VASCULAR ACCESS	LANCET			English	Note							DIAPHRAGMATIC-HERNIA; MANAGEMENT	Intensive management of the fetus is limited by our inability to achieve access to the fetal circulation. Using laparoscopic surgery, we can maintain long-term access to the fetal circulation by extra-amniotic catheterisation of chorionic vessels in third-trimester monkeys and early-gestation sheep. We can sample fetal blood, continuously measure blood pressure, and infuse drugs without complications. Safe vascular access will permit assessment of fetal status during fetal surgical procedures and improve postoperative monitoring.			HEDRICK, MH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT SURG,CTR FETAL TREATMENT,ROOM 1601-HSW,BOX 0570,SAN FRANCISCO,CA 94143, USA.		Harrison, Michael/GYD-8608-2022					HARRISON MR, 1982, J PEDIATR SURG, V17, P115, DOI 10.1016/S0022-3468(82)80193-0; HARRISON MR, 1990, NEW ENGL J MED, V322, P1582, DOI 10.1056/NEJM199005313222207; HARRISON MR, 1980, SURGERY, V88, P174; HARRISON MR, 1982, J PEDIATR SURG, V17, P728, DOI 10.1016/S0022-3468(82)80437-5; HARRISON MR, 1990, LANCET, V336, P965, DOI 10.1016/0140-6736(90)92420-M; HEDRICK MH, 1993, TRANSPLANT SCI, V3, P23; HEDRICK MH, 1992, SURG FORUM, P504; JENNINGS R W, 1991, Surgical Forum (Chicago), V42, P575; RICE HE, IN PRESS SURG FORUM	9	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1086	1087		10.1016/0140-6736(93)92065-2	http://dx.doi.org/10.1016/0140-6736(93)92065-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105313				2022-12-01	WOS:A1993ME82200011
J	MEADE, TW; RUDDOCK, V; STIRLING, Y; CHAKRABARTI, R; MILLER, GJ				MEADE, TW; RUDDOCK, V; STIRLING, Y; CHAKRABARTI, R; MILLER, GJ			FIBRINOLYTIC-ACTIVITY, CLOTTING FACTORS, AND LONG-TERM INCIDENCE OF ISCHEMIC-HEART-DISEASE IN THE NORTHWICK-PARK-HEART-STUDY	LANCET			English	Article							MYOCARDIAL-INFARCTION; HEMOSTATIC FUNCTION; IMPAIRED FIBRINOLYSIS; PLASMINOGEN-ACTIVATOR; CORRELATED EXPOSURES; RISK FACTOR; PLASMA; FIBRINOGEN; DEATH	Fibrinolytic activity (FA) was measured by dilute blood clot lysis time at entry to the Northwick Park Heart Study in 1382 white men aged 40-64, of whom 179 subsequently experienced episodes of ischaemic heart disease during a mean follow-up period of 16.1 years. There was a significant interaction between age and low FA (p = 0.02) with respect to ischaemic heart disease: a difference of one standard deviation in FA was associated with a difference of about 40% in ischaemic heart disease risk (p = 0.002) in those aged 40-54 at entry. The FA association remained after adjusting for plasma fibrinogen. High fibrinogen concentrations themselves were also associated with ischaemic heart disease, as was high factor VII activity with fatal events. Low FA in younger men may exert a long-term influence by impairing the removal of fibrin deposits that contribute to atherogenesis. Low FA appears to be a leading determinant of ischaemic heart disease in younger men and methods of enhancing fibrinolytic activity, whether by life-style changes or pharmacologically, should be considered.			MEADE, TW (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,MRC,EPIDEMIOL & MED CARE UNIT,LONDON EC1M 6BQ,ENGLAND.							ASHFORD TP, 1968, AM J PATHOL, V53, P599; CHAKRABARTI R, 1968, LANCET, V1, P987; CHAKRABARTI R, 1978, THROMB HAEMOSTASIS, V39, P450; CHAKRABARTI R, 1962, J CLIN PATHOL, V15, P228, DOI 10.1136/jcp.15.3.228; FOLSOM AR, 1993, ARTERIOSCLER THROMB, V13, P162, DOI 10.1161/01.ATV.13.2.162; FRANCIS RB, 1988, AM HEART J, V115, P776, DOI 10.1016/0002-8703(88)90878-2; HAMSTEN A, 1986, BRIT HEART J, V55, P58; HAMSTEN A, 1987, LANCET, V2, P3; HEINRICH J, IN PRESS ARTERIOSCLE; HICKMAN JA, 1973, J CLIN PATHOL, V26, P189, DOI 10.1136/jcp.26.3.189; JANSSON JH, 1991, EUR HEART J, V12, P157, DOI 10.1093/oxfordjournals.eurheartj.a059862; MEADE TW, 1987, LANCET, V2, P986; MEADE TW, 1977, BRIT MED BULL, V33, P283, DOI 10.1093/oxfordjournals.bmb.a071448; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1980, LANCET, V1, P1050; MILLER GJ, 1991, LANCET, V338, P1079, DOI 10.1016/0140-6736(91)91936-O; MILLER GJ, IN PRESS THROMB HAEM; MUSSONI L, 1992, ARTERIOSCLER THROMB, V12, P19, DOI 10.1161/01.ATV.12.1.19; PEDERSEN OD, 1993, EUR HEART J, V14, P785, DOI 10.1093/eurheartj/14.6.785; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; PRINS MH, 1991, AM HEART J, V122, P545, DOI 10.1016/0002-8703(91)91014-E; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; SMITH EB, 1987, FIBRINOGEN, V2, P115; TORBJORN K, 1987, THROMB RES, V48, P621; WALMSLEY D, 1991, DIABETIC MED, V8, P954, DOI 10.1111/j.1464-5491.1991.tb01536.x; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; 1976, WHO5 REG OFF EUR	30	704	714	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1076	1079		10.1016/0140-6736(93)92062-X	http://dx.doi.org/10.1016/0140-6736(93)92062-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105310				2022-12-01	WOS:A1993ME82200008
J	CARPENTER, RHS				CARPENTER, RHS			BEYOND THE DARROW-YANNET DIAGRAM - AN ENHANCED PLOT FOR BODY-FLUID SPACES AND OSMOLALITY	LANCET			English	Article								The C-plot is a new method of plotting the volumes and osmolality of extracellular and intracellular body fluids, which in many circumstances is an improvement on the classical Darrow-Yannet diagram. The C-plot allows natural perturbations to be seen easily, and enables the relation between threats to fluid homoeostasis and the physiological mechanisms that counter those threats to be appreciated. The course of such events can also be shown in a single diagram.			CARPENTER, RHS (corresponding author), UNIV CAMBRIDGE,PHYSIOL LAB,CAMBRIDGE CB2 3EG,ENGLAND.			Carpenter, Roger/0000-0003-2572-1448				Darrow DC, 1935, J CLIN INVEST, V14, P266, DOI 10.1172/JCI100674; Kindig N B, 1983, Physiologist, V26, P304; SIGAARDANDERSEN O, 1971, SCAND J LAB INVEST, V27, P239	3	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					968	970		10.1016/0140-6736(93)92007-G	http://dx.doi.org/10.1016/0140-6736(93)92007-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105219				2022-12-01	WOS:A1993MC00500014
J	BENSON, JR; BAUM, M				BENSON, JR; BAUM, M			BREAST-CANCER, DESMOID TUMORS, AND FAMILIAL ADENOMATOUS POLYPOSIS - A UNIFYING HYPOTHESIS	LANCET			English	Article							GROWTH; FIBROBLASTS; FETAL; CARCINOMA; INVITRO; INVIVO; CELLS; BETA	There is widespread agreement that epithelial tumours develop as a consequence of primary events within epithelial cells. According to the monoclonal theory, a tumour is caused by genetic change within a single cell, which imparts a selective growth advantage. This simple theory fails to take into account two important concepts. First, tumour generation is likely to involve multiple genetic events, some of which initiate a tumour, and others promote its growth.1 Second, tumours are usually composed of several tissue components, although they are known by the dominant proliferative cell type. This convention has tended to obscure the importance of ''secondary'' tissue components in carcinogenesis, despite evidence for the involvement of mesenchymal elements both in the induction and maintenance of transformation. To shift emphasis from the monoclonal theory, we propose a unifying hypothesis accounting for the effect of adjuvant tamoxifen in early breast cancer and the association between gastrointestinal polyps and desmoid tumours.	ROYAL MARSDEN HOSP,LONDON SW3 1JJ,ENGLAND	Royal Marsden NHS Foundation Trust	BENSON, JR (corresponding author), INST CANC RES,ACAD SECT SURG,HARTWELL LAB,FULHAM RD,LONDON SW3 1JJ,ENGLAND.							ADAMS EF, 1988, BREAST CANCER RES TR, V11, P165, DOI 10.1007/BF01805840; BAUM M, 1991, BRIT J CANCER, V64, P205, DOI 10.1038/bjc.1991.276; BROOKS MD, 1992, EUR J CANCER, V28A, P1014, DOI 10.1016/0959-8049(92)90445-8; BULOW S, 1987, SEMIN SURG ONCOL, V3, P84, DOI 10.1002/ssu.2980030207; BUTTA A, 1992, CANCER RES, V52, P4261; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; COOPER M, 1977, CANCER RES, V37, P2544; Cunha G R, 1987, Prog Clin Biol Res, V239, P251; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; GORSCH SM, 1992, CANCER RES, V52, P6949; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; HAGGIE JA, 1987, LANCET, V1, P1455; HERRERA L, 1986, AM J MED GENET, V25, P269; HORGAN K, 1987, BRIT J SURG, V74, P227, DOI 10.1002/bjs.1800740326; HUYNH HT, 1993, CANCER RES, V53, P1727; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIVINGSTONE DM, 1992 WINT M BACR ABP; LONGAKER MT, 1991, PLAST RECONSTR SURG, V87, P788, DOI 10.1097/00006534-199104000-00032; MANNING AM, 1991, ONCOGENE, V6, P1471; NAYLOR EW, 1979, ARCH SURG-CHICAGO, V114, P1181; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; PFEFFER L, 1976, J CELL PHYSIOL, V89, P29, DOI 10.1002/jcp.1040890104; RICHMAN PI, 1988, J PATHOL, V156, P197, DOI 10.1002/path.1711560305; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; WILLIAMS AC, 1990, CANCER RES, V50, P4724; 1992, LANCET, V339, P11; 1992, LANCET, V339, P71	29	34	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 2	1993	342	8875					848	850		10.1016/0140-6736(93)92700-4	http://dx.doi.org/10.1016/0140-6736(93)92700-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA025	8104277				2022-12-01	WOS:A1993MA02500014
J	DEDERA, DA; WALLER, EK; LEBRUN, DP; SENMAJUMDAR, A; STEVENS, ME; BARSH, GS; CLEARY, ML				DEDERA, DA; WALLER, EK; LEBRUN, DP; SENMAJUMDAR, A; STEVENS, ME; BARSH, GS; CLEARY, ML			CHIMERIC HOMEOBOX GENE E2A-PBX1 INDUCES PROLIFERATION, APOPTOSIS, AND MALIGNANT-LYMPHOMAS IN TRANSGENIC MICE	CELL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; C-MYC EXPRESSION; PRE-B; CELL-DEATH; TRANSCRIPTION FACTORS; NEGATIVE SELECTION; ENHANCER BINDING; DNA-BINDING; N-MYC; BCL-2	Expression of the homeobox fusion gene E2A-PBX1 under control of the immunoglobulin heavy chain enhancer efficiently induced malignancies in transgenic mice. All animals died before 5 months of age with lymphomas that demonstrated phenotypes consistent with transitional intermediate thymocytes (CD4+/CD8+/CD3med). E2A-PBX1 also markedly altered lymphoid development in pretumorous animals, reducing the number of thymocytes and bone marrow B lineage progenitors to 20% of normal levels. In spite of the observed reductions in lymphoid cells, premalignant animals contained significantly increased numbers of cycling thymocytes, but a higher proportion was also undergoing apoptosis, suggesting that increased cell death resulted in the marked lymphopenias. These data indicate that the chimeric homeodomain protein E2A-PBX1 paradoxically induces both proliferation and apoptosis in lymphoid cells, suggesting an in vivo association between nuclear oncogene-induced cell cycle progression and programed cell death.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT RADIAT ONCOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	DEDERA, DA (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305, USA.		Waller, Edmund K/AAP-3055-2020		NCI NIH HHS [CA42971] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042971, R01CA042971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ASKEW DS, 1991, ONCOGENE, V6, P1915; BINDL JM, 1986, AM J CLIN PATHOL, V85, P490, DOI 10.1093/ajcp/85.4.490; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLANKENSTEIN T, 1988, NUCLEIC ACIDS RES, V16, P10939, DOI 10.1093/nar/16.22.10939; BOROWITZ MJ, 1993, BLOOD, V82, P1086; CARROLL AJ, 1984, BLOOD, V63, P721; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FISCH P, 1992, ONCOGENE, V7, P2389; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GROSSCHEDL R, 1984, CELL, V38, P647, DOI 10.1016/0092-8674(84)90259-9; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Hogan B., 1986, MANIPULATING MOUSE E; HOLLANDER Z, 1988, CYTOMETRY, V9, P485, DOI 10.1002/cyto.990090513; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MELLENTIN JD, 1990, GENE CHROMOSOME CANC, V2, P239, DOI 10.1002/gcc.2870020313; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PRIVITERA E, 1992, BLOOD, V79, P1781; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SENMAJUMDAR A, 1990, J IMMUNOL, V144, P111; SENMAJUMDAR A, 1992, J EXP MED, V176, P543, DOI 10.1084/jem.176.2.543; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251	52	184	188	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					833	843		10.1016/0092-8674(93)90463-Z	http://dx.doi.org/10.1016/0092-8674(93)90463-Z			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8104101				2022-12-01	WOS:A1993LX29200009
J	HUSSELL, T; ISAACSON, PG; CRABTREE, JE; SPENCER, J				HUSSELL, T; ISAACSON, PG; CRABTREE, JE; SPENCER, J			THE RESPONSE OF CELLS FROM LOW-GRADE B-CELL GASTRIC LYMPHOMAS OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE TO HELICOBACTER-PYLORI	LANCET			English	Article							PROLIFERATION; ANTIGEN; MICE	An association has been shown between colonisation of gastric mucosa by Helicobacter pylori, acquisition of mucosa-associated lymphoid tissue (MALT), and occurrence of primary B-cell gastric MALT lymphoma. We investigated the immunological response of cells from 3 low-grade primary B-cell gastric MALT lymphomas to H pylori type NCTC 11637 and 12 isolates of H pylori from patients without lymphomas. After co-culture of tumour cells with bacteria, cells were examined for phenotypic evidence of activation and proliferation, and supernatant assayed to detect tumour-derived immunoglobulin and interleukin-2 (IL-2). Neoplastic B cells and non-neoplastic T cells proliferated, and IL-2-receptor expression by most cells in the cultures was increased with stimulating strains of H pylori. There were also increases in tumour immunoglobulin and IL-2 release when activation and proliferation were seen in response to stimulating bacteria. Removal of T cells from the tumour cell suspension reduced proliferation and IL-2-receptor expression. In comparison, no responses were seen in cells from high-grade gastric MALT lymphomas or low-grade B-cell MALT lymphomas of other sites. The response of low-grade B-cell gastric MALT lymphomas to stimulating strains of H pylori is dependent on H-pylori-specific T cells and their products, rather than the bacteria themselves.	UCL,SCH MED,DEPT HISTOPATHOL,UNIV ST,LONDON WC1E 6JJ,ENGLAND; ST JAMES HOSP,DEPT CLIN MED,LEEDS,ENGLAND	University of London; University College London; UCL Medical School; Saint James's University Hospital			Hussell, Tracy/O-4630-2014; Crabtree, Jean E/A-3549-2010	Hussell, Tracy/0000-0001-7186-6141; Spencer, Jo/0000-0002-7202-2431				AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P6221, DOI 10.1093/nar/20.23.6221; BEVERLEY PCL, 1981, EUR J IMMUNOL, V126, P2117; CARACCI A, 1993, P NATL ACAD SCI USA, V90, P5791; COGLIATTI SB, 1991, GASTROENTEROLOGY, V101, P1159, DOI 10.1016/0016-5085(91)90063-Q; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; GERDES J, 1984, J IMMUNOL, V133, P1710; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HUSSELL T, 1993, AM J PATHOL, V142, P285; HUSSELL T, 1993, J PATHOL, V169, P221, DOI 10.1002/path.1711690208; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; MASON DY, 1990, AM J PATHOL, V136, P1215; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SMITH KA, 1988, SCIENCE, V240, P1164; SPENCER J, 1990, J PATHOL, V160, P231, DOI 10.1002/path.1711600309; THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L; UMETSU DT, 1990, J IMMUNOL, V144, P2550; VERONESE ML, 1992, J EXP MED, V176, P1763, DOI 10.1084/jem.176.6.1763; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z	20	719	745	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					571	574		10.1016/0140-6736(93)91408-E	http://dx.doi.org/10.1016/0140-6736(93)91408-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102718				2022-12-01	WOS:A1993LV96300008
J	SCHMIDT, E; SCHIMMEL, P				SCHMIDT, E; SCHIMMEL, P			MUTATIONAL ISOLATION OF A SIEVE FOR EDITING IN A TRANSFER-RNA SYNTHETASE	SCIENCE			English	Article							RIBONUCLEIC-ACID SYNTHETASE; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; ISOLEUCINE; VALINE; DISCRIMINATION; RECOGNITION; DEACYLATION; MECHANISMS; RESOLUTION	Editing reactions are essential for the high fidelity of information transfer in processes such as replication, RNA splicing, and protein synthesis. The accuracy of interpretation of the genetic code is enhanced by the editing reactions of aminoacyl transfer RNA (tRNA) synthetases, whereby amino acids are prevented from being attached to the wrong tRNAs. Amino acid discrimination is achieved through sieves that may overlap with or coincide with the amino acid binding site. With the class I Escherichia coli isoleucine tRNA synthetase, which activates isoleucine and occasionally misactivates valine, as an example, a rationally chosen mutant enzyme was constructed that lacks entirely its normally strong ability to distinguish valine from isoleucine by the initial amino acid recognition sieve. The misactivated valine, however, is still eliminated by hydrolytic editing reactions. These data suggest that there is a distinct sieve for editing that is functionally independent of the amino acid binding site.			SCHMIDT, E (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NIGMS NIH HHS [GM 15539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015539, R37GM015539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BERGMANN F, 1961, J BIOL CHEM, V236, P1735; BRICK P, 1988, J MOL BIOL, V208, P83; BRUNIE S, 1987, J MOL GRAPHICS, V5, P18, DOI 10.1016/0263-7855(87)80039-5; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; BURBAUM JJ, 1992, PROTEIN SCI, V1, P574; BURGESS SM, 1993, TRENDS BIOCHEM SCI, V18, P381, DOI 10.1016/0968-0004(93)90094-4; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH U, 1985, ANGEW CHEM INT EDIT, V224, P1015; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FREIST W, 1985, BIOCHEMISTRY-US, V24, P7014, DOI 10.1021/bi00345a040; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; GHOSH G, 1991, BIOCHEMISTRY-US, V30, P9569, DOI 10.1021/bi00104a002; GIEGE R, 1974, EUR J BIOCHEM, V45, P351, DOI 10.1111/j.1432-1033.1974.tb03560.x; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; IACCARINO M, 1971, J BACTERIOL, V105, P527, DOI 10.1128/JB.105.2.527-537.1971; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NORRIS AT, 1964, P NATL ACAD SCI USA, V52, P3300; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SCHMIDT E, 1993, P NATL ACAD SCI USA, V90, P6919, DOI 10.1073/pnas.90.15.6919; SCHMIDT EG, UNPUB; SCHREIER AA, 1972, BIOCHEMISTRY-US, V11, P1582, DOI 10.1021/bi00759a006; SHEPARD A, 1992, P NATL ACAD SCI USA, V89, P9964, DOI 10.1073/pnas.89.20.9964; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; TREIBER G, 1971, J BACTERIOL, V107, P828, DOI 10.1128/JB.107.3.828-832.1971; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679	36	141	143	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					265	267		10.1126/science.8146659	http://dx.doi.org/10.1126/science.8146659			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146659				2022-12-01	WOS:A1994NE41000038
J	BARTLEY, TD; HUNT, RW; WELCHER, AA; BOYLE, WJ; PARKER, VP; LINDBERG, RA; LU, HS; COLOMBERO, AM; ELLIOTT, RL; GUTHRIE, BA; HOLST, PL; SKRINE, JD; TOSO, RJ; ZHANG, M; FERNANDEZ, E; TRAIL, G; VARNUM, B; YARDEN, Y; HUNTER, T; FOX, GM				BARTLEY, TD; HUNT, RW; WELCHER, AA; BOYLE, WJ; PARKER, VP; LINDBERG, RA; LU, HS; COLOMBERO, AM; ELLIOTT, RL; GUTHRIE, BA; HOLST, PL; SKRINE, JD; TOSO, RJ; ZHANG, M; FERNANDEZ, E; TRAIL, G; VARNUM, B; YARDEN, Y; HUNTER, T; FOX, GM			B61 IS A LIGAND FOR THE ECK RECEPTOR PROTEIN-TYROSINE KINASE	NATURE			English	Article							CELL	A PROTEIN ligand for the ECK1 receptor protein-tyrosine kinase has been isolated by using the extracellular domain (ECK-X) of the receptor as an affinity reagent. Initially, concentrated cell culture supernatants were screened for receptor binding activity using immobilized ECK-X in a surface plasmon resonance detection system2,3. Subsequently, supernatants from selected cell lines were fractionated directly by receptor affinity chromatography, resulting in the single-step purification of B61, a protein previously identified as the product of an early response gene induced by tumour necrosis factor-alpha4. We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK. ECK is a member of a large orphan receptor protein-tyrosine kinase family headed by EPH5, and we suggest that ligands for other members of this family will be related to B61, and can be isolated in the same way.	WEIZMANN INST SCI, DEPT CLIN IMMUNOL, IL-76100 REHOVOT, ISRAEL; SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, SAN DIEGO, CA 92186 USA	Weizmann Institute of Science; Salk Institute	BARTLEY, TD (corresponding author), AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA.		YARDEN, YOSEF/K-1467-2012					BOYD AW, 1992, J BIOL CHEM, V267, P3262; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; FAUSSET PR, 1991, ELECTROPHORESIS, V12, P22, DOI 10.1002/elps.1150120106; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Merril C.R., 1990, METHOD ENZYMOL, V182, P477; NIETO MA, 1992, DEVELOPMENT, V116, P1137; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WHITEHEAD RH, 1992, IMMUNOL CELL BIOL, V70, P227, DOI 10.1038/icb.1992.30; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020	17	223	242	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	1994	368	6471					558	560		10.1038/368558a0	http://dx.doi.org/10.1038/368558a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139691				2022-12-01	WOS:A1994NE33500058
J	WITTUNG, P; NIELSEN, PE; BUCHARDT, O; EGHOLM, M; NORDEN, B				WITTUNG, P; NIELSEN, PE; BUCHARDT, O; EGHOLM, M; NORDEN, B			DNA-LIKE DOUBLE HELIX FORMED BY PEPTIDE NUCLEIC-ACID	NATURE			English	Article							RECOGNITION; THYMINE	ALTHOUGH the importance of the nucleobases in the DNA double helix is well understood, the evolutionary significance of the deoxyribose phosphate backbone and the contribution of this chemical entity to the overall helical structure and stability of the double helix is not so clear. Peptide nucleic acid (PNA)1-7 is a DNA analogue with a backbone consisting of N-(2-aminoethyl)glycine units (Fig. 1) which has been shown to mimic DNA in forming Watson-Crick complementary duplexes with normal DNA7. Using circular dichroism spectroscopy we show here that two complementary PNA strands can hybridize to one another to form a helical duplex. There is a seeding of preferred chirality which is induced by the presence of an L- (or D-) lysine residue attached at the carboxy terminus of the PNA strand. These results indicate that a (deoxy)ribose phosphate backbone is not an essential requirement for the formation of double helical DNA-like structures in solution.	PANUM INST,DEPT BIOCHEM B,MED BIOTECHNOL RES CTR,BLEGDAMSVEJ 3C,DK-2200 N COPENHAGEN,DENMARK; CHALMERS UNIV TECHNOL,DEPT PHYS CHEM,S-41296 GOTHENBURG,SWEDEN; HC ORSTED INST,DEPT ORGAN CHEM,DK-2100 COPENHAGEN 0,DENMARK	Chalmers University of Technology; University of Copenhagen			Norden, Bengt/ABE-3675-2020; wittung-stafshede, pernilla/AAV-4392-2021	Norden, Bengt/0000-0002-7946-200X; wittung-stafshede, pernilla/0000-0003-1058-1964; /0000-0001-8771-330X				CHERNY DY, 1993, P NATL ACAD SCI USA, V90, P1667, DOI 10.1073/pnas.90.5.1667; EGHOLM M, 1993, J CHEM SOC CHEM COMM, P800, DOI 10.1039/c39930000800; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P9677, DOI 10.1021/ja00050a068; ESCHENMOSER A, 1992, CHEM SOC REV, V21, P1, DOI 10.1039/cs9922100001; KIM SK, 1993, J AM CHEM SOC, V115, P6477, DOI 10.1021/ja00068a001; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1993, ORIGINS LIFE EVOL B, V23, P323, DOI 10.1007/BF01582083; NRODEN B, 1992, REV BIOPHYS, V25, P51; Schimmel P. R., 1980, BIOPHYSICAL CHEM; TIBANYENDA N, 1984, EUR J BIOCHEM, V139, P19, DOI 10.1111/j.1432-1033.1984.tb07970.x	12	427	473	1	76	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					561	563		10.1038/368561a0	http://dx.doi.org/10.1038/368561a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139692				2022-12-01	WOS:A1994NE33500059
J	DAVIES, JF; ALMASSY, RJ; HOSTOMSKA, Z; FERRE, RA; HOSTOMSKY, Z				DAVIES, JF; ALMASSY, RJ; HOSTOMSKA, Z; FERRE, RA; HOSTOMSKY, Z			2.3-ANGSTROM CRYSTAL-STRUCTURE OF THE CATALYTIC DOMAIN OF DNA POLYMERASE-BETA	CELL			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; IDENTIFICATION; RESIDUES; REPAIR; REPLICATION; REFINEMENT; EXPRESSION; RESOLUTION; FRAGMENT	The crystal structure of the catalytic domain of rat DNA polymerase beta (pol beta) has been determined at 2.3 angstrom resolution and refined to an R factor of 0.22. The mixed alpha/beta protein has three subdomains arranged in an overall U shape reminiscent of other polymerase structures. The folding topology of pol beta, however, is unique. Two divalent metals bind near three aspartic acid residues implicated in the catalytic activity. In the presence of Mn2+ and dTTP, interpretable electron density is seen for two metals and the triphosphate, but not the deoxythymidine moiety. The principal interaction of the triphosphate moiety is with the bound divalent metals.			DAVIES, JF (corresponding author), AGOURON PHARMACEUT INC,3565 GEN ATOM COURT,SAN DIEGO,CA 92121, USA.							BAKER H, 1879, J CHEM SOC, V35, P7860; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARMICHAEL J, 1991, INT J RADIAT ONCOL, V20, P197, DOI 10.1016/0360-3016(91)90089-M; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; GILSON MK, 1987, J COMPUT CHEM, V9, P327; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; HIROSE F, 1989, EXP CELL RES, V181, P169, DOI 10.1016/0014-4827(89)90191-2; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JAYARAM B, 1989, BIOPOLYMERS, V28, P975, DOI 10.1002/bip.360280506; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; JOHNSON CK, 1965, OAK RIDGE THERMAL EL; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; LINSKENS MHK, 1990, CELL, V62, P845, DOI 10.1016/0092-8674(90)90258-G; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; NOWAK R, 1990, EXP CELL RES, V191, P51, DOI 10.1016/0014-4827(90)90034-8; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P900, DOI 10.1107/S0108767390005529; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199	41	162	163	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1123	1133		10.1016/0092-8674(94)90388-3	http://dx.doi.org/10.1016/0092-8674(94)90388-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137427				2022-12-01	WOS:A1994ND24600017
J	VERSELIS, VK; GINTER, CS; BARGIELLO, TA				VERSELIS, VK; GINTER, CS; BARGIELLO, TA			OPPOSITE VOLTAGE GATING POLARITIES OF 2 CLOSELY-RELATED CONNEXINS	NATURE			English	Article							DEPENDENT JUNCTIONAL CONDUCTANCE; GAP JUNCTION; MOLECULAR-CLONING; XENOPUS OOCYTES; CELL CHANNELS; EXPRESSION; MEMBRANE	THE molecular mechanisms underlying the voltage dependence of intercellular channels formed by the family of vertebrate gap junction proteins (connexins) are unknown. All vertebrate gap junctions are sensitive to the voltage difference between the cells, defined as the transjunctional voltage, V-j (refs 1, 2), and most appear to gate by the separate actions of their component hemichannels(3-8). The heterotypic Cx32/Cx26 junction displays an unpredicted rectification that was reported to represent a novel V-j dependence created by hemichannel interactions, mediated in part by the first extracellular loop E1 (ref. 9). Here we show that aspects of the rectification of Cx32/Cx26 junctions are explained by opposite gating polarities of the component hemichannels, and that the opposite gating polarity of Cx32 and Cx26 results from a charge difference in a single amino-acid residue located at the second position in the N terminus. We also shea that charge substitutions at the border of the first transmembrane (M1) and E1 domains can reverse gating polarity and suppress the effects of a charge substitution at the N terminus. We conclude that the combined actions of residues at the N terminus and M1/E1 border form a charge complex that is probably an integral part of tbe connexin voltage sensor. A consistent correlation between charge substitution and gating polarity indicates that Cx26 and Cx32 voltage sensors are oppositely charged and that both move towards the cytoplasm upon hemichannel closure.			VERSELIS, VK (corresponding author), ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,1300 MORRIS PK AVE,BRONX,NY 10461, USA.							BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; Bennett M V, 1992, Semin Cell Biol, V3, P29; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BENNETT MVL, 1988, GAP JUNCTIONS, P287; BRUZZONE R, 1993, MOL BIOL CELL, V4, P7, DOI 10.1091/mbc.4.1.7; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HARRIS AL, 1981, J GEN PHYSIOL, V77, P95, DOI 10.1085/jgp.77.1.95; HENNEMANN H, 1992, J CELL BIOL, V117, P1299, DOI 10.1083/jcb.117.6.1299; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; OBAID AL, 1983, J MEMBRANE BIOL, V73, P69, DOI 10.1007/BF01870342; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; RUBIN JB, 1992, P NATL ACAD SCI USA, V89, P3820, DOI 10.1073/pnas.89.9.3820; RUBIN JB, 1992, THESIS A EINSTEIN CO; RUBIN JB, 1992, BIOPHYS J, V62, P197; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; SUCHYNA TM, 1993, NATURE, V365, P847, DOI 10.1038/365847a0; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; THOMAS L, 1993, P NATL ACAD SCI USA, V90, P5446, DOI 10.1073/pnas.90.12.5446; VERSELIS VK, 1991, BIOPHYS J, V59, P114, DOI 10.1016/S0006-3495(91)82204-4; WERNER R, 1991, P ROY SOC B-BIOL SCI, V243, P5, DOI 10.1098/rspb.1991.0002; WILDERS R, 1992, BIOPHYS J, V63, P942, DOI 10.1016/S0006-3495(92)81664-8	27	298	304	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					348	351		10.1038/368348a0	http://dx.doi.org/10.1038/368348a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127371				2022-12-01	WOS:A1994NB98500050
J	XIE, X; HARRISON, DH; SCHLICHTLING, I; SWEET, RM; KALABOKIS, VN; SZENTGYORGYI, AG; COHEN, C				XIE, X; HARRISON, DH; SCHLICHTLING, I; SWEET, RM; KALABOKIS, VN; SZENTGYORGYI, AG; COHEN, C			STRUCTURE OF THE REGULATORY DOMAIN OF SCALLOP MYOSIN AT 2.8 ANGSTROM RESOLUTION	NATURE			English	Article							LIGHT-CHAINS; CALCIUM-BINDING; PEPTIDE COMPLEX; CALMODULIN; PROTEIN; DISSOCIATION; ACTIN	The regulatory domain of scallop myosin is a three-chain protein complex that switches on this major in response to Ca2+ binding. This domain has been crystallized and the structure solved to 2.8 Angstrom resolution. Side-chain interactions link the two light chains in tandem to adjacent segments of the heavy chain bearing the IQ-sequence motif. The Ca2+-binding site is a novel EF-hand motif on the essential light chain and is stabilized by linkages involving the heavy chain and both light chains, accounting for the requirement of all three chains for Ca2+ binding and regulation in the intact myosin molecule.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; MAX PLANCK INST MED RES,W-6900 HEIDELBERG,GERMANY; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University; Max Planck Society; United States Department of Energy (DOE); Brookhaven National Laboratory; Brandeis University			Schlichting, Ilme/I-1339-2013					BENNETT AJ, 1986, BIOCHEM J, V233, P173, DOI 10.1042/bj2330173; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BRUNGER AT, 1992, X PLOR V 3 0 MANUAL; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; DASILVA ACR, 1991, TRENDS BIOCHEM SCI, V16, P53, DOI 10.1016/0968-0004(91)90024-P; FROMHERZ S, 1993, BIOPHYS J A, V64, P7; FUNK MO, 1979, INT J PEPT PROT RES, V13, P296; HARDWICKE PMD, 1983, NATURE, V301, P478, DOI 10.1038/301478a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KENDRICK-JONES J, 1970, Journal of Molecular Biology, V54, P313, DOI 10.1016/0022-2836(70)90432-8; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KWON H, 1990, P NATL ACAD SCI USA, V87, P4771, DOI 10.1073/pnas.87.12.4771; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROWE T, 1992, EMBO J, V11, P4715, DOI 10.1002/j.1460-2075.1992.tb05576.x; SEKHARUDU CY, 1993, PROTEIN SCI, V2, P620; SELLERS JR, 1980, J MOL BIOL, V144, P223, DOI 10.1016/0022-2836(80)90088-1; STAFFORD WF, 1979, BIOCHEMISTRY-US, V24, P5273; Strynadka NCJ, 1991, CURR OPIN STRUC BIOL, V1, P905, DOI 10.1016/0959-440X(91)90085-8; SZENTGYO.AG, 1973, J MOL BIOL, V74, P179, DOI 10.1016/0022-2836(73)90106-X; SZENTGYORGYI AG, 1994, MYOLOGY, V2, P506; SZENTKIRALYI EM, 1984, J MUSCLE RES CELL M, V5, P147, DOI 10.1007/BF00712153; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WELLS C, 1985, NATURE, V313, P696, DOI 10.1038/313696a0; WELLS JA, 1982, METHOD ENZYMOL, V85, P93; WILLIAMANN T, 1981, BIOCHEMISTRY-US, V20, P1176	37	285	294	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					306	312		10.1038/368306a0	http://dx.doi.org/10.1038/368306a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127365				2022-12-01	WOS:A1994NB98500037
J	STERN, LJ; BROWN, JH; JARDETZKY, TS; GORGA, JC; URBAN, RG; STROMINGER, JL; WILEY, DC				STERN, LJ; BROWN, JH; JARDETZKY, TS; GORGA, JC; URBAN, RG; STROMINGER, JL; WILEY, DC			CRYSTAL-STRUCTURE OF THE HUMAN CLASS-II MHC PROTEIN HLA-DR1 COMPLEXED WITH AN INFLUENZA-VIRUS PEPTIDE	NATURE			English	Article							BINDING; MOLECULES; MOTIFS; IDENTIFICATION; RECOGNITION; EPITOPES; ANTIGEN; HLA-B27; MODELS	An influenza virus peptide binds to HLA-DR1 in an extended conformation with a pronounced twist. Thirty-five per cent of the peptide surface is accessible to solvent and potentially available for interaction with the antigen receptor on T cells. pockets in the peptide-binding site accommodate five of the thirteen side chains of the bound peptide, and explain the peptide specificity of HLA-DR1. Twelve hydrogen bonds between conserved HLA-DR1 residues and the main chain of the peptide provide a universal mode of peptide binding, distinct from the strategy used by class I histocompatibility proteins.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; BRANDEIS UNIV,ROSENSTIEL RES CTR,WALTHAM,MA 02254; CHILDRENS HOSP PITTSBURGH,RANGOS RES CTR,PITTSBURGH,PA 15213; UNIV PITTSBURGH,MED CTR,PITTSBURGH,PA 15213	Harvard University; Howard Hughes Medical Institute; Harvard University; Brandeis University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ALEXANDER J, 1993, J IMMUNOL, V150, P1; BERMAIN RN, 1993, A REV IMMUN, V11, P403; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOEHNCKE WH, 1993, J IMMUNOL, V150, P331; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BUSCH R, 1991, J IMMUNOL, V147, P1292; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COPPIN HL, 1993, EUR J IMMUNOL, V23, P343, DOI 10.1002/eji.1830230207; DEMOTZ S, 1993, EUR J IMMUNOL, V23, P425, DOI 10.1002/eji.1830230219; DRISCOLL PC, 1993, J MOL BIOL, V232, P342, DOI 10.1006/jmbi.1993.1394; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GELUK A, 1992, J IMMUNOL, V149, P2864; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREIGER JI, 1991, J IMMUNOL, V146, P2331; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEQUESTEL JY, 1993, J MOL BIOL, V231, P888, DOI 10.1006/jmbi.1993.1335; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MADDEN DR, 1992, CURR OPIN STRUC BIOL, V2, P300; MALCHEREK G, 1993, INT IMMUNOL, V5, P1229, DOI 10.1093/intimm/5.10.1229; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; NEWTONNASH DK, 1993, J IMMUNOL, V150, P1813; OLSEN AC, IN PRESS EUR J IMMUN; ONG B, 1991, P NATL ACAD SCI USA, V88, P7343, DOI 10.1073/pnas.88.16.7343; OSULLIVAN D, 1991, J IMMUNOL, V146, P1240; OSULLIVAN D, 1991, J IMMUNOL, V147, P2663; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; RUDENSKY AY, 1992, NATURE, V359, P429, DOI 10.1038/359429a0; SETTE A, 1993, J IMMUNOL, V151, P3163; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; STEM LJ, 1992, CELL, V68, P465; VERRECK FAW, 1993, EUR J IMMUNOL, V23, P1346, DOI 10.1002/eji.1830230624; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	51	1420	1467	0	137	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					215	221		10.1038/368215a0	http://dx.doi.org/10.1038/368215a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145819				2022-12-01	WOS:A1994NA87000046
J	TORNALETTI, S; PFEIFER, GP				TORNALETTI, S; PFEIFER, GP			SLOW REPAIR OF PYRIMIDINE DIMERS AT P53 MUTATION HOTSPOTS IN SKIN-CANCER	SCIENCE			English	Article							TUMOR SUPPRESSOR GENE; LIGATION MEDIATED PCR; UV-INDUCED MUTATIONS; ESCHERICHIA-COLI; TRANSCRIBED STRAND; CELL CARCINOMAS; MAMMALIAN-CELLS; DHFR GENE; PHOTOPRODUCTS; MUTAGENESIS	Ultraviolet light has been linked with the development of human skin cancers. Such cancers often exhibit mutations in the p53 tumor suppressor gene. Ligation-mediated polymerase chain reaction was used to analyze at nucleotide resolution the repair of cyclobutane pyrimidine dimers along the p53 gene in ultraviolet-irradiated human fibroblasts. Repair rates at individual nucleotides were highly variable and sequence-dependent. Slow repair was seen at seven of eight positions frequently mutated in skin cancer, suggesting that repair efficiency may strongly contribute to the mutation spectrum in a cancer-associated gene.	BECKMAN RES INST CITY HOPE,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NIEHS NIH HHS [ES06070] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES006070, R01ES006070] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; BRASH E, 1991, P NATL ACAD SCI USA, V88, P1014; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; EVANS MK, 1993, CANCER RES, V53, P5377; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; HSIA HC, 1989, J MOL BIOL, V205, P103, DOI 10.1016/0022-2836(89)90368-9; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MOLES JP, 1993, ONCOGENE, V8, P583; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; PFEIFER GP, 1993, METHOD ENZYMOL, V225, P567; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; RADY P, 1992, CANCER RES, V52, P3804; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; THOMAS DC, 1988, P NATL ACAD SCI USA, V85, P3723, DOI 10.1073/pnas.85.11.3723; TORNALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, UNPUB; URBACH F, 1989, PHOTOCHEM PHOTOBIOL, V50, P507, DOI 10.1111/j.1751-1097.1989.tb05556.x; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	30	268	272	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1436	1438		10.1126/science.8128225	http://dx.doi.org/10.1126/science.8128225			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128225				2022-12-01	WOS:A1994MZ92700031
J	GILSON, MK; STRAATSMA, TP; MCCAMMON, JA; RIPOLL, DR; FAERMAN, CH; AXELSEN, PH; SILMAN, I; SUSSMAN, JL				GILSON, MK; STRAATSMA, TP; MCCAMMON, JA; RIPOLL, DR; FAERMAN, CH; AXELSEN, PH; SILMAN, I; SUSSMAN, JL			OPEN BACK DOOR IN A MOLECULAR-DYNAMICS SIMULATION OF ACETYLCHOLINESTERASE	SCIENCE			English	Article							TORPEDO-CALIFORNICA; PROTEIN; PROGRAM	The enzyme acetylcholinesterase generates a strong electrostatic field that can attract the cationic substrate acetylcholine to the active site. However, the long and narrow active site gorge seems inconsistent with the enzyme's high catalytic rate. A molecular dynamics simulation of acetylcholinesterase in water reveals the transient opening of a short channel, large enough to pass a water molecule, through a thin wall of the active site near tryptophan-84. This simulation suggests that substrate, products, or solvent could move through this ''back door,'' in addition to the entrance revealed by the crystallographic structure. Electrostatic calculations show a strong field at the back door, oriented to attract the substrate and the reaction product choline and to repel the other reaction product, acetate. Analysis of the open back door conformation suggests a mutation that could seal the back door and thus test the hypothesis that thermal motion of this enzyme may open multiple routes of access to its active site.	CORNELL UNIV,CORNELL THEORY CTR,ITHACA,NY 14853; CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL	Cornell University; Cornell University; University of Pennsylvania; Weizmann Institute of Science; Weizmann Institute of Science	GILSON, MK (corresponding author), UNIV HOUSTON,DEPT CHEM,HOUSTON,TX 77204, USA.		McCammon, J. Andrew/AAG-1832-2021	Sussman, Joel/0000-0003-0306-3878				AXELSEN PH, IN PRESS PROTEIN SCI; BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; CYGLER M, 1993, PROTEIN SCI, V2, P366; DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2; DEMCHENKO AP, 1986, ESSAYS BIOCHEM, V22, P120; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; NICHOLLS A, GRASP VERS 1 04; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; STRAATSMA TP, 1990, J COMPUT CHEM, V11, P943, DOI 10.1002/jcc.540110806; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAN RC, 1993, BIOCHEMISTRY-US, V32, P401, DOI 10.1021/bi00053a003; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VIGNY M, 1978, EUR J BIOCHEM, V85, P317, DOI 10.1111/j.1432-1033.1978.tb12241.x; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x	23	241	244	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1276	1278		10.1126/science.8122110	http://dx.doi.org/10.1126/science.8122110			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122110				2022-12-01	WOS:A1994MY57000035
J	BARONDES, SH				BARONDES, SH			THINKING ABOUT PROZAC	SCIENCE			English	Editorial Material											BARONDES, SH (corresponding author), UNIV CALIF SAN FRANCISCO,CTR NEUROBIOL & PSYCHIAT,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143, USA.							BARONDES SH, 1993, MOL MENTAL ILLNESS, P3; Deniker P., 1970, DISCOVERIES BIOL PSY, P155; KLEIN DF, 1964, PSYCHOPHARMACOLOGIA, V5, P397, DOI 10.1007/BF02193476; Kramer P. D., 1989, MOMENTS ENGAGEMENT I; Kramer PD, 1993, LISTENING PROZAC PSY; Kuhn R, 1970, DISCOVERIES BIOL PSY, P205; MONSMA FJ, 1993, MOL PHARMACOL, V43, P320; Rapoport J.L., 1989, BOY WHO COULDNT STOP; SHEN Y, 1993, J BIOL CHEM, V268, P18200; STARK P, 1985, J CLIN PSYCHIAT, V46, P58; Tecott L H, 1993, Curr Opin Neurobiol, V3, P310, DOI 10.1016/0959-4388(93)90122-F	11	23	23	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1102	1103		10.1126/science.8108727	http://dx.doi.org/10.1126/science.8108727			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	8108727				2022-12-01	WOS:A1994MX75900020
J	TOVO, PA				TOVO, PA			CESAREAN-SECTION AND PERINATAL HIV TRANSMISSION - WHAT NEXT	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; INFECTION				TOVO, PA (corresponding author), UNIV TURIN,DEPT PAEDIAT,I-10124 TURIN,ITALY.			Tovo, Pier Angelo/0000-0002-0192-3240				BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; GABIANO C, 1992, PEDIATRICS, V90, P362; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; KIND C, 1992, EUR J PEDIATR, V151, P442, DOI 10.1007/BF01959360; LINDGREN S, 1991, AIDS, V5, P1111, DOI 10.1097/00002030-199109000-00009; NAIR P, 1993, J ACQ IMMUN DEF SYND, V6, P298; VILLARI P, 1993, ONLINE J CURR C 0708; 1992, LANCET, V339, P1007	9	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 11	1993	342	8872					630	630		10.1016/0140-6736(93)91753-9	http://dx.doi.org/10.1016/0140-6736(93)91753-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX272	8103140				2022-12-01	WOS:A1993LX27200004
J	ELTUMI, M; TRIVEDI, P; HOBBS, JR; PORTMANN, B; CHEESEMAN, P; DOWNIE, C; RISTELI, J; RISTELI, L; MOWAT, AP				ELTUMI, M; TRIVEDI, P; HOBBS, JR; PORTMANN, B; CHEESEMAN, P; DOWNIE, C; RISTELI, J; RISTELI, L; MOWAT, AP			MONITORING OF VENOOCCLUSIVE DISEASE AFTER BONE-MARROW TRANSPLANTATION BY SERUM AMINOPROPEPTIDE OF TYPE-III PROCOLLAGEN	LANCET			English	Article							AMINO-TERMINAL PROPEPTIDE; LIVER; CHILDREN; MARKERS	Differential diagnosis of hepatic complications after bone marrow transplantation (BMT) is often difficult. To assess whether serum concentrations of the aminopropeptide of type III procollagen (PIIINP) could facilitate diagnosis,we measured serum PIIINP, corrected for age by conversion to standard deviation scores (SDS), serially after BMT in 27 children. A preliminary study of 11 patients showed that a PNIIINP-SDS cutoff of 8.0 was an optimum for diagnosis of veno-occlusive disease (VOD). PIIINP-SDS was increased above cut-off 1-25 days before the onset of clinical signs in the 12 patients (4 from the preliminary group, the others from a group of 16 studied prospectively) who developed VOD, with subsequent changes in PIIINP-SDS mirroring the course of VOD. By contrast, PIIINP-SDS remained below cut-off in all other patients, including 7 with liver graft-versus-host disease and 3 with drug hepatotoxicity. PIIINP-SDS values greater than 8.0 predict, diagnose, and monitor VOD after BMT.	WESTMINSTER MED SCH & HOSP,BONE MARROW TRANSPLANT UNIT,LONDON,ENGLAND; UNIV LONDON KINGS COLL HOSP,INST LIVER STUDIES,LONDON SE5 8RX,ENGLAND; UNIV OULU,DEPT CLIN CHEM,SF-90100 OULU 10,FINLAND; UNIV OULU,DEPT MED BIOCHEM,SF-90100 OULU 10,FINLAND; UNIV LONDON KINGS COLL HOSP,DEPT CHILD HLTH,LONDON SE5 8RX,ENGLAND	Imperial College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Oulu; University of Oulu; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London				Risteli, Leila/0000-0002-5532-5895				EL-TUMI M, 1990, Bone Marrow Transplantation, V5, P116; HERSHKO C, 1980, BIOL BONE MARROW TRA, P56; HOBBS JR, 1986, BONE MARROW TRANSPL, V1, P201; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MCDONALD GB, 1984, HEPATOLOGY, V4, P116, DOI 10.1002/hep.1840040121; MCDONALD GB, 1987, SEMIN LIVER DIS, V7, P210, DOI 10.1055/s-2008-1040578; PLEBANI M, 1991, CLIN BIOCHEM, V24, P219, DOI 10.1016/0009-9120(91)80013-S; RISTELI J, 1988, CLIN CHEM, V34, P715; SHULMAN HM, 1992, BONE MARROW TRANSPL, V10, P197; SMEDSROD B, 1988, COLLAGEN REL RES, V8, P375; TRIVEDI P, 1985, EUR J CLIN INVEST, V15, P69, DOI 10.1111/j.1365-2362.1985.tb00147.x; TRIVEDI P, 1987, HEPATOLOGY, V7, P1249, DOI 10.1002/hep.1840070612; TRIVEDI P, 1989, J PEDIATR-US, V114, P225, DOI 10.1016/S0022-3476(89)80787-5	13	39	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					518	521		10.1016/0140-6736(93)91646-4	http://dx.doi.org/10.1016/0140-6736(93)91646-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102667				2022-12-01	WOS:A1993LU58200009
J	OU, WJ; CAMERON, PH; THOMAS, DY; BERGERON, JJM				OU, WJ; CAMERON, PH; THOMAS, DY; BERGERON, JJM			ASSOCIATION OF FOLDING INTERMEDIATES OF GLYCOPROTEINS WITH CALNEXIN DURING PROTEIN MATURATION	NATURE			English	Article							ROUGH ENDOPLASMIC-RETICULUM; NEWLY SYNTHESIZED PROTEINS; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; LINKED OLIGOSACCHARIDES; MOLECULAR CHAPERONE; ALPHA-SUBUNIT; COMPLEX; GLYCOSYLATION; SECRETION	Calnexin, an endoplasmic reticulum transmembrane protein, represents a new type of molecular chaperone that selectively associates in a transient fashion with newly synthesized monomeric glycoproteins in HepG2 cells. Calnexin only recognizes glycoproteins when they are incompletely folded. Dissociation of glycoproteins from calnexin occurs at different rates and is related to the time taken for their folding, which may then initiate their differential transport rates from the endoplasmic reticulum.	MCGILL UNIV,DEPT BIOL,MONTREAL H3A 2B2,QUEBEC,CANADA; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,EUKARYOT GENET GRP,MONTREAL H4P 2R2,PQ,CANADA	McGill University; National Research Council Canada	OU, WJ (corresponding author), MCGILL UNIV,DEPT ANAT & CELL BIOL,MONTREAL H3A 2B2,QUEBEC,CANADA.		Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; CALLEA F, 1992, LIVER, V12, P357; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LAW SW, 1981, NATURE, V291, P201, DOI 10.1038/291201a0; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; REDMAN CM, 1972, J CELL BIOL, V52, P231, DOI 10.1083/jcb.52.2.231; WADA I, 1991, J BIOL CHEM, V266, P19599; WEITZ G, 1992, J BIOL CHEM, V267, P10039	35	520	531	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					771	776		10.1038/364771a0	http://dx.doi.org/10.1038/364771a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8102790				2022-12-01	WOS:A1993LU58100046
J	VANMEERWIJK, JPM; GERMAIN, RN				VANMEERWIJK, JPM; GERMAIN, RN			DEVELOPMENT OF MATURE CD8+ THYMOCYTES - SELECTION RATHER THAN INSTRUCTION	SCIENCE			English	Article							T-CELL RECEPTOR; THYMIC SELECTION; SEQUENTIAL APPEARANCE; SUBLETHAL IRRADIATION; NEGATIVE SELECTION; PRECURSOR CELLS; LYMPHOCYTES-T; MOUSE THYMUS; STEM-CELLS; CD4	The role of major histocompatibility complex (MHC) molecules in T cell differentiation was investigated by comparison of thymocyte subpopulations in wild-type mice and beta2-microglobulin (beta2M) mutant mice deficient in MHC class I expression and mature CD8+ cells. On the basis of surface markers, glucocorticoid resistance, in vitro differentiation capacity, and absence in beta2M-/- mice, CD4(intermediate)CD8hi cells with high expression of alphabeta T cell receptor (TCRalphabeta) were identified as having been positively selected by MHC class I for development into mature CD8+ T cells. Activated CD4(int)CD8hi cells bearing intermediate rather than high amounts of TCR were present in both wild-type and beta2M-/- animals. These data suggest that recognition of MHC class I molecules is required for full maturation to CD8+ T cells, but not for receptor-initiated commitment to the CD8+ lineage, consistent with a stochastic (selection) model of thymocyte development.	NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Germain, Ronald N./Z-1945-2019; van Meerwijk, Joost P.M./K-1345-2014; Germain, Ronald/ABE-7090-2020	van Meerwijk, Joost P.M./0000-0001-8231-1897; 				ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRISPE IN, 1987, NATURE, V329, P336, DOI 10.1038/329336a0; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; ECKHARDT LA, 1980, IMMUNOGENETICS, V11, P275, DOI 10.1007/BF01567794; FOWLKES BJ, 1985, J EXP MED, V162, P802, DOI 10.1084/jem.162.3.802; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; HAYAKAWA K, 1992, J EXP MED, V176, P269, DOI 10.1084/jem.176.1.269; HUGO P, 1991, INT IMMUNOL, V3, P265, DOI 10.1093/intimm/3.3.265; HUGO P, 1991, EUR J IMMUNOL, V21, P2655, DOI 10.1002/eji.1830211103; HUGO P, 1990, INT IMMUNOL, V2, P209, DOI 10.1093/intimm/2.3.209; HUISKAMP R, 1985, J IMMUNOL, V134, P2161; KADISH JL, 1975, J IMMUNOL, V114, P452; KARIV I, 1993, J EXP MED, V177, P1429, DOI 10.1084/jem.177.5.1429; KISIELOW P, 1991, IMMUNOL REV, V122, P69, DOI 10.1111/j.1600-065X.1991.tb00597.x; KISIELOW P, 1984, J IMMUNOL, V133, P1117; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MARUSICGALESIC S, 1988, NATURE, V333, P180, DOI 10.1038/333180a0; NIKOLICZUGIC J, 1991, IMMUNOL TODAY, V12, P65, DOI 10.1016/0167-5699(91)90160-U; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; RAMSDELL F, 1991, J IMMUNOL, V147, P1779; Robey E A, 1990, Semin Immunol, V2, P25; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SCOLLAY R, 1985, J IMMUNOL, V134, P3632; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; TAKAHAMA Y, 1992, SCIENCE, V258, P653, DOI 10.1126/science.1357752; TAKAHAMA Y, 1991, J IMMUNOL, V146, P1134; TOMOOKA S, 1987, J IMMUNOL, V139, P3986; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VONBOEHMER H, 1986, IMMUNOL TODAY, V7, P333; VONBOEHMER H, 1992, IMMUNOL TODAY, V13, P454, DOI 10.1016/0167-5699(92)90075-I; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUNIGAPFLUCKER JC, 1990, J IMMUNOL, V144, P3736; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085	47	99	99	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					911	915		10.1126/science.8102208	http://dx.doi.org/10.1126/science.8102208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8102208				2022-12-01	WOS:A1993LR89700038
J	BLACK, J				BLACK, J			DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM	LANCET			English	Editorial Material																		BERGQVIST D, 1986, BRIT MED J, V292, P658, DOI 10.1136/bmj.292.6521.658-a; JULIAN DG, 1989, DISEASES HEART, P515; OGSTRON D, 1987, VENOUS THROMBOSIS CA, P52; SASAHARA AA, 1987, VENOUS THROMBOSIS PU, P128	4	20	20	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					352	353		10.1016/0140-6736(93)91480-A	http://dx.doi.org/10.1016/0140-6736(93)91480-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	8101590				2022-12-01	WOS:A1993LQ86800018
J	BERKELMAN, RL; BRYAN, RT; OSTERHOLM, MT; LEDUC, JW; HUGHES, JM				BERKELMAN, RL; BRYAN, RT; OSTERHOLM, MT; LEDUC, JW; HUGHES, JM			INFECTIOUS-DISEASE SURVEILLANCE - A CRUMBLING FOUNDATION	SCIENCE			English	Editorial Material									MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,MINNEAPOLIS,MN 55440; WHO,DIV COMMUNICABLE DIS,MICROBIOL & IMMUNOL SUPPORT SERV,CH-1211 GENEVA 27,SWITZERLAND	Minnesota Department of Health (MHD); World Health Organization	BERKELMAN, RL (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA 30333, USA.							BELL B, 1993, 33RD INT C ANT AG CH; BERKELMAN RL, 1993, ANN INTERN MED, V119, P426, DOI 10.7326/0003-4819-119-5-199309010-00014; BROWN RE, 1993, ESTIMATE IDENTIFIABL; BRYAN RT, IN PRESS DISEASE EVO; BUEHLER JW, 1989, JAMA-J AM MED ASSOC, V262, P2896; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CIESLAK P, COMMUNICATION; DAVIS JE, UNPUB; DOWDLE WR, 1993, ANNU REV PUBL HEALTH, V14, P649; HEDBERG CW, IN PRESS CLIN INFECT; LEDUC J, UNPUB; NEAL JJ, 1993, 8TH INT S VIR HEP LI; OSTERHOLM MT, UNPUB; OSTERHOLM MT, IN PRESS PRINCIPLES; SLATER PE, 1989, INT J EPIDEMIOL, V18, P693, DOI 10.1093/ije/18.3.693; 1992, EMERGING INFECTIONS; 1993, 1993 WORLD BANK REP; 1993, MORB MORTAL WKLY REP, V42, P258	18	142	146	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					368	370		10.1126/science.8153621	http://dx.doi.org/10.1126/science.8153621			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153621				2022-12-01	WOS:A1994NG19400024
J	LAUNER, LJ; HARRIS, T; RUMPEL, C; MADANS, J				LAUNER, LJ; HARRIS, T; RUMPEL, C; MADANS, J			BODY-MASS INDEX, WEIGHT CHANGE, AND RISK OF MOBILITY DISABILITY IN MIDDLE-AGED AND OLDER WOMEN - THE EPIDEMIOLOGIC FOLLOW-UP-STUDY OF NHANES-I	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR-DISEASE; MUSCLE LOSS; OVERWEIGHT; POPULATION; STRATEGIES; ARTHRITIS; MORTALITY; STRENGTH; OBESITY; ADULTS	Objective.-As disability is highly prevalent among older women, is costly, and affects the quality of life, preventable causes of disability must be identified. In this study, we investigated the relationship between the body mass index (BMI), weight change, and the onset of disability in older women. Design.-Prospective cohort study. Setting.-The nationally representative US epidemiologic follow-up study of the National Health and Nutrition Examination Survey (NHANES) I (1971 through 1987). Patients.-White women classified as young-old (mean age 60 years at baseline, mean age 65 years at follow-up) and old-old (mean age 76 years at baseline, mean age 80 years at follow-up). Main Outcome Measures.-The relative odds for the onset of mobility disability associated with tertiles of past BMI (measured 8 to 16 years prior to disability ascertainment) and current BMI (measured 2 to 5 years prior to disability ascertainment) and with weight change between the two weight measurements. Results.-In both cohorts, women in the high past BMI group (>27 in the young-old and >28.1 in the old-old cohort) had a twofold increase in the risk for disability compared with women in the low past BMI group. High current BMI was as strongly related as past-BMI to risk of disability in the young-old women; it was not as strong a predictor in old-old women. In the old-old group only, women who experienced a weight loss of more than 5% had a twofold increase in risk of disability compared with weight-stable women. These results were adjusted for age, smoking, education, and study time and were not importantly modified with the addition into the models of single or multiple health conditions. Conclusions.-These prospective data suggest that high BMI is a strong predictor of long-term risk for mobility disability in older women and that this risk persists even to very old age. However, the paradoxical increase in risk associated with weight loss in the old-old women requires further study. Programs to prevent over weight may have potential for decreasing disability in women.	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS; NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,BETHESDA,MD 20892; NATL CTR HLTH STAT,HYATTSVILLE,MD 20782	Erasmus University Rotterdam; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	LAUNER, LJ (corresponding author), FREE UNIV AMSTERDAM,DEPT PSYCHIAT,1007 MC AMSTERDAM,NETHERLANDS.							ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; Buchner D M, 1992, Clin Geriatr Med, V8, P1; COOK NR, 1989, AM J EPIDEMIOL, V130, P66, DOI 10.1093/oxfordjournals.aje.a115324; CRIMMINS EM, 1993, J ING HLTH, V0005; FLEG JL, 1988, J APPL PHYSIOL, V65, P1147, DOI 10.1152/jappl.1988.65.3.1147; Grunfeld C, 1992, AIDS Clin Rev, P191; GURALNIK JM, 1993, AM J EPIDEMIL, V137, P858; HARRIS T, 1989, AM J PUBLIC HEALTH, V79, P698, DOI 10.2105/AJPH.79.6.698; HELLERSTEIN MK, 1990, SEMIN ONCOL, V17, P17; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KALLMAN DA, 1990, J GERONTOL, V45, pM82, DOI 10.1093/geronj/45.3.M82; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KUCZMARSKI RJ, 1989, AM J CLIN NUTR, V50, P1150, DOI 10.1093/ajcn/50.5.1150; Lawrence RC, 1990, HLTH STATUS WELL BEI, P136; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; PAMUK ER, 1992, AM J EPIDEMIOL, V136, P686, DOI 10.1093/oxfordjournals.aje.a116548; PINSKY JL, 1985, AM J EPIDEMIOL, V122, P644, DOI 10.1093/oxfordjournals.aje.a114144; POPE AM, 1991, DISABILITY AM, P41; RABKIN SW, 1977, AM J CARDIOL, V39, P452, DOI 10.1016/S0002-9149(77)80104-5; REED RL, 1991, J AM GERIATR SOC, V39, P555, DOI 10.1111/j.1532-5415.1991.tb03592.x; RISSANEN A, 1990, BRIT MED J, V301, P835, DOI 10.1136/bmj.301.6756.835; RISSANEN AM, 1991, EUR J CLIN NUTR, V45, P419; ROUBENOFF R, 1991, NUTR REV, V49, P163, DOI 10.1111/j.1753-4887.1991.tb03013.x; VERBRUGGE LM, 1989, MILBANK Q, V67, P450, DOI 10.2307/3350223; VERBRUGGE LM, 1991, J CLIN EPIDEMIOL, V44, P167, DOI 10.1016/0895-4356(91)90264-A; WADDEN TA, 1992, MAR METH VOL WEIGHT; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; WILMORE DW, 1991, NEW ENGL J MED, V325, P695, DOI 10.1056/NEJM199109053251005; 1992, VITAL HLTH STAT 1, V27; 1987, VITAL HLTH STAT 1, V25; 1977, VITAL HLTH STAT 1 B, V10; 1987, VITAL HLTH STAT 1, V22	33	360	369	1	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1093	1098		10.1001/jama.271.14.1093	http://dx.doi.org/10.1001/jama.271.14.1093			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151851				2022-12-01	WOS:A1994NE22800031
J	GONZALEZCRESPO, S; LEVINE, M				GONZALEZCRESPO, S; LEVINE, M			RELATED TARGET ENHANCERS FOR DORSAL AND NF-KAPPA-B SIGNALING PATHWAYS	SCIENCE			English	Article							ACHAETE-SCUTE COMPLEX; DNA-BINDING PROTEIN; DROSOPHILA EMBRYO; DORSOVENTRAL PATTERN; SEX DETERMINATION; REL ONCOGENE; GENE-COMPLEX; EXPRESSION; SEQUENCE; MORPHOGEN	Drosophila dorsoventral (DV) patterning and mammalian hematopoiesis are regulated by related signaling pathways (Toll, interleukin-1) and transcription factors (dorsal, nuclear factor-kappaB). These factors interact with related enhancers, such as the rhomboid NEE and kappa light chain enhancer, that contain similar arrangements of activator and repressor binding sites. It is shown that the kappa enhancer can generate lateral stripes of gene expression in transgenic Drosophila embryos in a pattern similar to that directed by the rhomboid NEE. Drosophila DV determinants direct these stripes through the corresponding mammalian cis regulatory elements in the kappa enhancer, including the kappaB site and kappaE boxes. These results suggest that enhancers can couple conserved signaling pathways to divergent gene functions.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego				Levine, Michael/0000-0001-7629-0081	NIGMS NIH HHS [GM 46638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046638, R37GM046638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEL T, 1992, GENE DEV, V6, P466, DOI 10.1101/gad.6.3.466; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; CRONMILLER C, 1993, MECH DEVELOP, V42, P159, DOI 10.1016/0925-4773(93)90005-I; DESAIYAJNIK V, 1993, MOL CELL BIOL, V13, P5057, DOI 10.1128/MCB.13.8.5057; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GONZALEZCRESPO S, 1993, GENE DEV, V7, P1703, DOI 10.1101/gad.7.9.1703; GONZALEZCRESPO S, UNPUB; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1991, CELL, V64, P439; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NIETO MA, 1992, DEVELOPMENT, V116, P227; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; ROMANI S, 1987, EMBO J, V6, P2085, DOI 10.1002/j.1460-2075.1987.tb02474.x; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; SMITH DE, 1992, DEVELOPMENT, V116, P1033; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P	48	29	31	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					255	258		10.1126/science.8146656	http://dx.doi.org/10.1126/science.8146656			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146656				2022-12-01	WOS:A1994NE41000035
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW SEAFOOD SAFETY INITIATIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					812	812						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114223				2022-12-01	WOS:A1994MZ49800040
J	IRVING, WL; NEAL, KR; UNDERWOOD, JCE; SIMMONDS, PN; JONES, DA; NUTTALL, P; DAY, S; BENNETT, D; EGLIN, RP; FINCH, RG; READ, R; MCKENDRICK, M; TRIGER, RD; WILLIAMS, D; SCOTT, BB; NICHOLSON, KG; WISELKA, M; FREEMAN, J; ROSE, K				IRVING, WL; NEAL, KR; UNDERWOOD, JCE; SIMMONDS, PN; JONES, DA; NUTTALL, P; DAY, S; BENNETT, D; EGLIN, RP; FINCH, RG; READ, R; MCKENDRICK, M; TRIGER, RD; WILLIAMS, D; SCOTT, BB; NICHOLSON, KG; WISELKA, M; FREEMAN, J; ROSE, K			CHRONIC HEPATITIS IN UNITED-KINGDOM BLOOD-DONORS INFECTED WITH HEPATITIS-C VIRUS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL HALLAMSHIRE HOSP,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; UNIV EDINBURGH,SCH MED,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; TRENT REG BLOOD TRANSFUS CTR,SHEFFIELD S5 7JN,S YORKSHIRE,ENGLAND; LEEDS PUBL HLTH LAB,LEEDS,W YORKSHIRE,ENGLAND; CITY HOSP NOTTINGHAM,NOTTINGHAM,ENGLAND; LINCOLN CTY HOSP,LINCOLN,ENGLAND; LEICESTER ROYAL INFIRM,LEICESTER,ENGLAND; DERBYSHIRE ROYAL INFIRM,DERBY DE1 2QY,ENGLAND; UNIV EDINBURGH,DEPT MICROBIOL,EDINBURGH,SCOTLAND	University of Sheffield; University of Edinburgh; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Leicester; University of Edinburgh	IRVING, WL (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND.			Simmonds, Peter/0000-0002-7964-4700; Irving, William/0000-0002-7268-3168				ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; GARSON JA, 1991, LANCET, V338, P1466, DOI 10.1016/0140-6736(91)92775-W; IRVING WL, 1993, VOX SANG, V65, P38, DOI 10.1111/j.1423-0410.1993.tb04522.x; MAKRIS M, 1991, BLOOD, V78, P1672; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993	5	42	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					695	696		10.1136/bmj.308.6930.695	http://dx.doi.org/10.1136/bmj.308.6930.695			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142794	Green Submitted, Green Published			2022-12-01	WOS:A1994NA86900021
J	BALCH, WE; MCCAFFERY, JM; PLUTNER, H; FARQUHAR, MG				BALCH, WE; MCCAFFERY, JM; PLUTNER, H; FARQUHAR, MG			VESICULAR STOMATITIS-VIRUS GLYCOPROTEIN IS SORTED AND CONCENTRATED DURING EXPORT FROM THE ENDOPLASMIC-RETICULUM	CELL			English	Article							PLASMA-MEMBRANE PROTEINS; GOLGI-COMPLEX; INTERMEDIATE COMPARTMENT; INTRACELLULAR MEMBRANES; CELL-SURFACE; TRANSPORT; ER; CLATHRIN; DENSITY	Newly synthesized proteins are believed to move from the endoplasmic reticulum (ER) to the Golgi by bulk flow, and sorting is assumed to occur exclusively in the trans-Golgi network (TGN). Using quantitative immunoelectron microscopy, we demonstrate that vesicular stomatitis virus glycoprotein (VSV-G) is sorted from resident ER proteins and concentrated 5- to 10-fold in 40-80 nm vesicles during vesicle budding from the ER. Accumulation of VSV-G in pre-Golgi vesicular carriers is the only detectable concentration step in its transport to the TGN. From these results, it is apparent that export from the ER is not exclusively mediated by bulk flow. The ER exerts an unanticipated level of control to insure selective and efficient entry of mature protein into the secretory pathway.	UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	BALCH, WE (corresponding author), SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [P01CA058689, P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58689, CA46128] Funding Source: Medline; NIGMS NIH HHS [GM42336] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH W E, 1992, Current Biology, V2, P157, DOI 10.1016/0960-9822(92)90276-G; BERGMANN JE, 1981, P NATL ACAD SCI-BIOL, V78, P1746, DOI 10.1073/pnas.78.3.1746; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FITTING T, 1982, J BIOL CHEM, V257, P4011; GRIFFITHS G, 1984, J CELL BIOL, V98, P2133, DOI 10.1083/jcb.98.6.2133; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JAMIESON JD, 1967, J CELL BIOL, V34, P577, DOI 10.1083/jcb.34.2.577; KUGE O, 1994, IN PRESS J CELL BIOL; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; Nguyen Van PPF, 1989, J BIOL CHEM, V264, P17494; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PETER F, 1992, J BIOL CHEM, V267, P10631; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PIND S, 1994, IN PRESS J CELL BIOL, V125; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; ROMISCH K, 1992, P NATL ACAD SCI USA, V89, P7227, DOI 10.1073/pnas.89.15.7227; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SARASTE J, 1991, J CELL SCI, V100, P415; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	40	342	346	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 11	1994	76	5					841	852		10.1016/0092-8674(94)90359-X	http://dx.doi.org/10.1016/0092-8674(94)90359-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124720				2022-12-01	WOS:A1994NA89000010
J	MATSUMURA, Y; HANBURY, D; SMITH, J; TARIN, D				MATSUMURA, Y; HANBURY, D; SMITH, J; TARIN, D			NONINVASIVE DETECTION OF MALIGNANCY BY IDENTIFICATION OF UNUSUAL CD44 GENE ACTIVITY IN EXFOLIATED CANCER-CELLS	BRITISH MEDICAL JOURNAL			English	Article							BLADDER-CANCER; URINE; MUTATIONS; CYTOLOGY; VARIANTS; TUMORS	Objective-To investigate non-invasive detection of cancer by testing for unusual CD44 gene activity in a clinical sample as an indicator of exfoliated tumour cells. Design-Case-control study. Subjects-44 unselected, consecutive patients with bladder cancer and 46 people with no evidence of neoplasia. Main outcome measure-Presence or absence of large CD44 gene products containing exon 6 derivatives in urine samples. Results-Novel abnormalities in the pattern of expression of this gene, seen specifically in tumour tissue, led to cloning of a newly recognised coding region in it (exon 6). This was tested as a probe for detection of exfoliated malignant cells in naturally voided urine. CD44 gene products extracted from the urine and amplified with polymerase chain reaction contained predicted electrophoretic band of 735 base pairs in 40 of the 44 patients with bladder cancer (sensitivity 91%). Products from 38 of the 46 people with no evidence of neoplasia showed no such band (specificity 83%). Conclusions-Unusual activity of the CD44 locus in neoplasia and malignancy is confirmed, and techniques for the analysis of such activity can enable non-invasive investigation of patients for primary or recurrent bladder cancer or for other tumours that shed neoplastic cells into body fluids.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL,OXFORD OX3 9DU,ENGLAND; CHURCHILL HOSP,DEPT UROL,OXFORD OX3 8LJ,ENGLAND	University of Oxford; University of Oxford			Matsumura, Yasuhiro/N-4472-2016					BRITTON JP, 1992, J UROLOGY, V148, P788, DOI 10.1016/S0022-5347(17)36720-4; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; FINN L, 1993, LAB INVEST, V68, pA49; HALIASSOS A, 1992, INT J ONCOL, V1, P731; HEDIN A, 1983, P NATL ACAD SCI-BIOL, V80, P3470, DOI 10.1073/pnas.80.11.3470; HEIDER KH, 1993, CANCER RES, V53, P4197; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1991, CANCER RES, V51, P5292; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; Kantoff P W, 1990, Curr Probl Cancer, V14, P233; KERN WH, 1984, CANCER, V53, P1185, DOI 10.1002/1097-0142(19840301)53:5<1185::AID-CNCR2820530526>3.0.CO;2-R; KOSS LG, 1985, ACTA CYTOL, V29, P810; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MATSUMURA Y, 1993, J PATHOL, V171, P249; MATZKIN H, 1992, UROLOGY, V39, P201, DOI 10.1016/0090-4295(92)90288-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TARIN D, 1981, CANCER RES, V41, P3604; WIELENGA VJM, 1993, CANCER RES, V53, P4754; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243	23	88	96	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1994	308	6929					619	624		10.1136/bmj.308.6929.619	http://dx.doi.org/10.1136/bmj.308.6929.619			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ698	8148709	Green Published			2022-12-01	WOS:A1994MZ69800019
J	BARRETTCONNOR, E; PALINKAS, LA				BARRETTCONNOR, E; PALINKAS, LA			LOW BLOOD-PRESSURE AND DEPRESSION IN OLDER MEN - A POPULATION-BASED STUDY	BRITISH MEDICAL JOURNAL			English	Article							SYMPTOMS; MOOD	Objective-To determine if an association exists between low blood pressure and depressive symptoms in older men living in the community. Design-Cross sectional, population based study. Setting-Town of Rancho Bernardo, California, United States. Subjects-846 men aged 60-89 years. Comparisons between hypotensive, normotensive, and hypertensive groups were limited to 594 men not taking drugs for hypertension. Main outcome measures-Mean scores on Beck depression inventory and prevalence of scores greater than or equal to 13. n Results-Men with diastolic blood pressure <75 mm Hg had significantly higher depression scores (mean scores 6.35 v 4.96; P < 0.001) and more categorical depression (7.6% v 1.8% with scores greater than or equal to 13; P < 0.01) than men with diastolic blood pressure levels between 75 and 85 mm Hg. Men with diastolic blood pressure levels > 85 mm Hg had higher depression scores than men with intermediate blood pressure levels (mean scores 5.85 v 4.96; P < 0.05). Men with diastolic hypotension scored significantly higher on both affective and somatic item subscales of the Beck depression inventory and on individual measures of fatigue, pessimism, sadness, loss of appetite, weight loss, and preoccupation with health. Low diastolic blood pressure was a significant predictor of both mean depression score and prevalence of categorical depression, independent of age and change in weight since the baseline visit. The presence of several chronic diseases was associated with depressed mood and higher blood pressure but not with low blood pressure. Conclusion-The association of relatively low diastolic blood pressure with higher depressive symptom scores and rates of categorical depression was independent of age or weight loss. Since fatigue is a prominent symptom of depression, any association of low blood pressure with fatigue could reflect depressive disorders or clinically important depression.			BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.				NIA NIH HHS [R37 AG07181-05] Funding Source: Medline; NIDDK NIH HHS [R01-DK31801] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007181] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1976, Prev Med, V5, P207; Beck A. T., 1960, ARCH GEN PSYCHIAT, V4, P53, DOI DOI 10.1001/ARCHPSYC.1961.01710120031004; Bengtsson C, 1987, Scand J Prim Health Care, V5, P155, DOI 10.3109/02813438709013997; DIMSDALE JE, 1992, ARCH INTERN MED, V152, P35, DOI 10.1001/archinte.152.1.35; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; GOLDBERG EL, 1980, PSYCHOL MED, V10, P243, DOI 10.1017/S0033291700044007; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; MANTEL N, 1959, J NATL CANCER I, V22, P719; NAKAGAWARA M, 1987, PSYCHIAT RES, V21, P85, DOI 10.1016/0165-1781(87)90065-5; NIELSEN AC, 1980, ARCH GEN PSYCHIAT, V37, P999; PEMBERTON J, 1989, BRIT MED J, V298, P660, DOI 10.1136/bmj.298.6674.660; PILGRIM JA, 1993, BRIT MED J, V306, P655, DOI 10.1136/bmj.306.6878.655-a; PILGRIM JA, 1992, BRIT MED J, V304, P75, DOI 10.1136/bmj.304.6819.75; PLUMB MM, 1977, PSYCHOSOM MED, V39, P264, DOI 10.1097/00006842-197707000-00007; ROBBINS JM, 1982, SOC SCI MED, V16, P27, DOI 10.1016/0277-9536(82)90420-8; SHROUT PE, 1989, J CLIN EPIDEMIOL, V42, P69, DOI 10.1016/0895-4356(89)90027-9; WESSELY S, 1990, BRIT MED J, V301, P362, DOI 10.1136/bmj.301.6748.362	17	103	105	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	1994	308	6926					446	449		10.1136/bmj.308.6926.446	http://dx.doi.org/10.1136/bmj.308.6926.446			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MW976	8124175	Green Published			2022-12-01	WOS:A1994MW97600022
J	BURNS, K; DUGGAN, B; ATKINSON, EA; FAMULSKI, KS; NEMER, M; BLEACKLEY, RC; MICHALAK, M				BURNS, K; DUGGAN, B; ATKINSON, EA; FAMULSKI, KS; NEMER, M; BLEACKLEY, RC; MICHALAK, M			MODULATION OF GENE-EXPRESSION BY CALRETICULIN BINDING TO THE GLUCOCORTICOID RECEPTOR	NATURE			English	Article							MESSENGER-RNA; PROTEIN; CELLS; DNA	CALRETICULIN is a multifunctional protein that acts as a major Ca2+-binding (storage) protein in the lumen of the endoplasmic reticulum1. It is also found in the nucleus2, suggesting that it may have a role in transcription regulation. Calreticulin has been reported to bind to the synthetic peptide KLGFFKR3, which is almost identical to an amino-acid sequence in the DNA-binding domain of the superfamily of nuclear receptors4-6. Could calreticulin interact with the DNA-binding domain of these receptors and affect their function? Here we report that the amino terminus of calreticulin interacts with the DNA-binding domain of the glucocorticoid receptor and prevents the receptor from binding to its specific glucocorticoid response element. Overexpression of calreticulin in mouse L fibroblasts inhibits glucocorticoid-response-mediated transcriptional activation of a glucocorticoid-sensitive reporter gene and of the endogenous, glucocorticoid-sensitive gene encoding cytochrome P450. Together these results indicate that calreticulin may be important in gene transcription, regulating the glucocorticoid receptor and perhaps other members of the superfamily of nuclear receptors.	UNIV ALBERTA, CARDIOVASC DIS RES GRP, EDMONTON T6G 2S2, AB, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2S2, AB, CANADA; CLIN RES INST MONTREAL, MONTREAL H2W 1R7, QUEBEC, CANADA	University of Alberta; University of Alberta; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Famulski, Konrad/J-8685-2012					ARGENTIN S, 1991, J BIOL CHEM, V266, P23315; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BURNS K, 1992, J BIOL CHEM, V267, P19039; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; EDWARDS RJ, 1991, METHOD ENZYMOL, V206, P220; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; HARDWICK JP, 1983, J BIOL CHEM, V258, P182; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1991, J BIOL CHEM, V266, P7155; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008	19	343	354	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 3	1994	367	6462					476	480		10.1038/367476a0	http://dx.doi.org/10.1038/367476a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107808				2022-12-01	WOS:A1994MU67900059
J	MANSER, E; LEUNG, T; SALIHUDDIN, H; ZHAO, ZS; LIM, L				MANSER, E; LEUNG, T; SALIHUDDIN, H; ZHAO, ZS; LIM, L			A BRAIN SERINE THREONINE PROTEIN-KINASE ACTIVATED BY CDC42 AND RAC1	NATURE			English	Article							GTP-BINDING-PROTEIN; GDP DISSOCIATION INHIBITOR; FOCAL ADHESIONS; RAS PROTEINS; R-RAS; RHO; IDENTIFICATION; EXPRESSION; HOMOLOG; PHOSPHORYLATION	A new brain serine/threonine protein kinase may be a target for the p21ras-related proteins Cdc42 and Rac1. The kinase sequence is related to that of the yeast protein STE20, implicated in pheromone-response pathways. The kinase complexes specifically with activated (GTP-bound) p21, inhibiting p21 GTPase activity and leading to kinase autophosphorylation and activation. Autophosphorylated kinase has a decreased affinity for Cdc42/Rac, freeing the p21 for further stimulatory activities or downregulation by GTPase-activating proteins. This bimolecular interaction provides a model for studying p21 regulation of mammalian phosphorylation signalling pathways.	INST NEUROL,LONDON WC1N 1PJ,ENGLAND	University of London; University College London	MANSER, E (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,GLAXO IMCB GRP,KENT RIDGE,SINGAPORE 0511,SINGAPORE.		Manser, Edward/ABD-2301-2020					Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Barbacid M., 1987, REV BIOCH, V56, P779; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOUCET JP, 1992, J BIOL CHEM, V267, P16503; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEUNG T, 1993, J BIOL CHEM, V268, P3813; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MARSH L, 1991, REV CELL BIOL, V7, P699; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MENARD L, 1992, EUR J BIOCHEM, V206, P537, DOI 10.1111/j.1432-1033.1992.tb16957.x; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SELF AJ, 1993, ONCOGENE, V8, P655; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SLUIJS P, 1992, CELL, V70, P729; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG J, 1992, MOL CELL BIOL, V12, P4937, DOI 10.1128/MCB.12.11.4937; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	49	1319	1361	2	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					40	46		10.1038/367040a0	http://dx.doi.org/10.1038/367040a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107774				2022-12-01	WOS:A1994MP86500051
J	SMIT, JJM; SCHINKEL, AH; ELFERINK, RPJO; GROEN, AK; WAGENAAR, E; VANDEEMTER, L; MOL, CAAM; OTTENHOFF, R; VANDERLUGT, NMT; VANROON, MA; VANDERVALK, MA; OFFERHAUS, GJA; BERNS, AJM; BORST, P				SMIT, JJM; SCHINKEL, AH; ELFERINK, RPJO; GROEN, AK; WAGENAAR, E; VANDEEMTER, L; MOL, CAAM; OTTENHOFF, R; VANDERLUGT, NMT; VANROON, MA; VANDERVALK, MA; OFFERHAUS, GJA; BERNS, AJM; BORST, P			HOMOZYGOUS DISRUPTION OF THE MURINE MDR2 P-GLYCOPROTEIN GENE LEADS TO A COMPLETE ABSENCE OF PHOSPHOLIPID FROM BILE AND TO LIVER-DISEASE	CELL			English	Article							MULTIDRUG-RESISTANCE GENE; BETA-INTERFERON GENE; EMBRYONIC STEM-CELLS; MOUSE PGK-1 GENE; HEPATOBILIARY TRANSPORT; MONOCLONAL-ANTIBODIES; COMPLEMENTARY-DNA; BILIARY-EXCRETION; LIPID ASYMMETRY; RAT-LIVER	Two types of P-glycoprotein have been found in mammals: the drug-transporting P-glycoproteins and a second type, unable to transport hydrophobic anticancer drugs. The latter is encoded by the human MDR3 (also called MDR2) and the mouse mdr2 genes, and its tissue distribution (bile canalicular membrane of hepatocytes, B cells, heart, and muscle) suggests a specialized metabolic function. We have generated mice homozygous for a disruption of the mdr2 gene. These mice develop a liver disease that appears to be caused by the complete inability of the liver to secrete phospholipid into the bile. Mice heterozygous for the disrupted allele had no detectable liver pathology, but half the level of phospholipid in bile. We conclude that the mdr2 P-glycoprotein has an essential role in the secretion of phosphatidylcholine into bile and hypothesize that it may be a phospholipid transport protein or phospholipid flippase.	NETHERLANDS CANC INST, DIV MOLEC GENET, 1066 CX AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT PATHOL, 1105 AZ AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	SMIT, JJM (corresponding author), NETHERLANDS CANC INST, DIV MOLEC BIOL, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS.							ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ALPINI G, 1988, J CLIN INVEST, V81, P569, DOI 10.1172/JCI113355; BAAS F, 1990, CANCER RES, V50, P5392; BARINAGA M, 1992, SCIENCE, V256, P444, DOI 10.1126/science.1373905; BERR F, 1993, J BIOL CHEM, V268, P3976; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BRADLEY G, 1992, CANCER RES, V52, P5154; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; CHIN JE, 1989, MOL CELL BIOL, V9, P3808, DOI 10.1128/MCB.9.9.3808; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DE, 1990, J LIPID RES, V31, P55; COLEMAN R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P113, DOI 10.1016/0005-2760(92)90036-U; COLEMAN R, 1987, BIOCHEM J, V244, P249, DOI 10.1042/bj2440249; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVAUX PF, 1992, ANNU REV BIOPH BIOM, V21, P417, DOI 10.1146/annurev.bb.21.060192.002221; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; ELFERINK RPJ, 1989, J CLIN INVEST, V84, P476, DOI 10.1172/JCI114189; Endicott J A, 1991, DNA Seq, V2, P89, DOI 10.3109/10425179109039677; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2849, DOI 10.1021/bi00333a006; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Fromm H, 1992, Gastroenterology, V103, P343; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1993, CANCER RES, V53, P747; GROS P, 1991, CANCER INVEST, V9, P563, DOI 10.3109/07357909109018954; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; GURANTZ D, 1981, J LIPID RES, V22, P373; HARRISON PTC, 1984, LAB ANIM, V18, P325, DOI 10.1258/002367784780865324; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JANSEN PLM, 1987, HEPATOLOGY, V7, P71, DOI 10.1002/hep.1840070116; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KAPLAN MM, 1993, GASTROENTEROLOGY, V104, P651, DOI 10.1016/0016-5085(93)90440-N; KATAGIRI K, 1992, GASTROENTEROLOGY, V102, P1660, DOI 10.1016/0016-5085(92)91727-L; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KUO MT, 1992, CELL GROWTH DIFFER, V3, P531; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LINCKE CR, 1990, CANCER RES, V50, P1779; LOWE PJ, 1984, BIOCHEM J, V222, P631, DOI 10.1042/bj2220631; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARZOLO MP, 1990, HEPATOLOGY, V12, pS134; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MORI N, 1986, GENE, V45, P275; NOOTER K, 1991, BRIT J CANCER, V63, P663, DOI 10.1038/bjc.1991.152; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.me.42.020191.001425; PHILLIPS MJ, 1986, LAB INVEST, V54, P593; RATHJEN PD, 1990, GENE DEV, V4, P2308, DOI 10.1101/gad.4.12b.2308; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; RONINSON IB, 1992, MUTAT RES, V276, P151, DOI 10.1016/0165-1110(92)90005-T; Sambrook J., 1989, MOL CLONING LAB MANU; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SCHINKELAH, 1991, SEMIN CANCER BIOL, V2, P213; SCHRIER SL, 1992, BLOOD, V79, P782; SONNEVELD P, 1992, BLOOD, V79, P1496, DOI 10.1182/blood.V79.6.1496.bloodjournal7961496; SPIVAK W, 1985, BIOCHEM J, V225, P787, DOI 10.1042/bj2250787; STEIN AF, 1988, TOXICOL APPL PHARM, V93, P351, DOI 10.1016/0041-008X(88)90037-3; STRICKER BHC, 1992, DRUG INDUCED DISORDE, V5, P71; SUCHY FJ, 1986, AM J PHYSIOL, V251, pG655, DOI 10.1152/ajpgi.1986.251.5.G665; Szasz G., 1974, METHOD ENZYMAT AN, P715; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; TEETER LD, 1991, MOL CARCINOGEN, V4, P358, DOI 10.1002/mc.2940040506; TENASBROEK ALM, 1993, IN PRESS MOL BIOCH P; THORGEIRSSON SS, 1991, PHARMACOL THERAPEUT, V49, P283, DOI 10.1016/0163-7258(91)90059-U; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TURLEY SD, 1978, J LIPID RES, V19, P924; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDERBLIEK AM, 1987, EMBO J, V6, P3325, DOI 10.1002/j.1460-2075.1987.tb02653.x; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERBLIEK AM, 1988, CANCER RES, V48, P5927; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; VANDERVALK P, 1990, ANN ONCOL, V1, P56; WHEELER HO, 1972, J CLIN INVEST, V51, P1337, DOI 10.1172/JCI106930; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	88	1257	1283	1	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 5	1993	75	3					451	462		10.1016/0092-8674(93)90380-9	http://dx.doi.org/10.1016/0092-8674(93)90380-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	8106172				2022-12-01	WOS:A1993MF83000008
J	MANSFIELD, S; SINGH, S				MANSFIELD, S; SINGH, S			WHO SHOULD FILL THE CARE GAP IN HIV DISEASE	LANCET			English	Editorial Material							GENERAL-PRACTITIONER; INFECTION; AIDS; ATTITUDES		ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND; WESTMINSTER MED SCH & HOSP,LONDON SW1P 2AP,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Imperial College London								ANDERSON P, 1988, BRIT MED J, V296, P535, DOI 10.1136/bmj.296.6621.535; BARTON S, 1992, BRIT MED J, V305, P902, DOI 10.1136/bmj.305.6859.902; BOYTON R, 1988, BRIT MED J, V296, P538, DOI 10.1136/bmj.296.6621.538; HASLAR J, 1984, CONTINUING CARE MANA; HIGGINSON I, 1991, HLTH TRENDS, V23, P59; KING E, 1992, HIV PREVENTION GAY M; KING MB, 1988, BRIT MED J, V297, P182, DOI 10.1136/bmj.297.6642.182; LANDE R, 1989, ROLE GP CARE PEOPLE; MANSFIELD S, 1992, INT J STD AIDS, V3, P248, DOI 10.1177/095646249200300403; MANSFIELD SJ, 1989, J ROY COLL GEN PRACT, V39, P104; MILNE RIG, 1988, BMJ, V296, P280; PINCHING AJ, 1989, AIDS S1, V3, P209; SHAPIRO J, 1991, BR J GEN PRACT, V41, P401; Singh S, 1991, Health Trends, V23, P55; SINGH S, 1990, IN PRESS BR J GEN PR; SMITS A, 1990, BRIT MED J, V300, P241, DOI 10.1136/bmj.300.6719.241; STRANG J, 1992, BMJ, V304, P1129; WADSWORTH E, 1992, BRIT J GEN PRACT, V42, P107; 1992 REPORT MINISTER; 1992, C REPORT ROLE GENERA	20	16	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					726	728						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103828				2022-12-01	WOS:A1993LX46900015
J	MICHAEL, AE; GREGORY, L; WALKER, SM; ANTONIW, JW; SHAW, RW; EDWARDS, CRW; COOKE, BA				MICHAEL, AE; GREGORY, L; WALKER, SM; ANTONIW, JW; SHAW, RW; EDWARDS, CRW; COOKE, BA			OVARIAN 11-BETA-HYDROXYSTEROID DEHYDROGENASE - POTENTIAL PREDICTOR OF CONCEPTION BY IN-VITRO FERTILIZATION AND EMBRYO-TRANSFER	LANCET			English	Note							FLUID	Cortisol is converted to the inactive glucocorticoid, cortisone, in several tissues by 11beta-hydroxysteroid dehydrogenase (11betaHSD). We have recently measured 11betaHSD activity in cultured human granulosa-lutein cells recovered from patients undergoing in-vitro fertilisation and embryo transfer (IVF-ET). We now report an association between the outcome of IVF-ET and 11betaHSD activity in these cells. Of the 64 patients studied, 32 had detectable 11betaHSD activity and none became pregnant; whereas 76% of the remaining ''11betaHSD-negative'' patients achieved pregnancies. Hence 11betaHSD activity may predict the outcome of IVF-ET.	ROYAL FREE HOSP,SCH MED,DEPT BIOCHEM,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND; UNIV HOSP WALES,ACAD DEPT OBSTET & GYNAECOL,FERTIL UNIT,CARDIFF,WALES; UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Cardiff University; University of Edinburgh								ANDERSEN CY, 1990, J CLIN ENDOCR METAB, V71, P1375, DOI 10.1210/jcem-71-5-1375; BENEDIKTSSON R, 1992, J ENDOCRINOL, V135, P53, DOI 10.1677/joe.0.1350053; FATEH M, 1989, FERTIL STERIL, V51, P538; LAKSHMI V, 1985, ENDOCRINOLOGY, V116, P552, DOI 10.1210/endo-116-2-552; MICHAEL AE, 1993, CLIN ENDOCRINOL, V38, P641, DOI 10.1111/j.1365-2265.1993.tb02147.x; MURPHY BEP, 1981, J STEROID BIOCHEM, V14, P811; TANNIN GM, 1991, J BIOL CHEM, V266, P16653	7	63	65	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					711	712		10.1016/0140-6736(93)91710-4	http://dx.doi.org/10.1016/0140-6736(93)91710-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103824				2022-12-01	WOS:A1993LX46900011
J	ANNAS, GJ				ANNAS, GJ			DETENTION OF HIV-POSITIVE HAITIANS AT GUANTANAMO - HUMAN-RIGHTS AND MEDICAL-CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AIDS							Annas, George/0000-0001-5836-7831				ANNAS GJ, 1993, NEW ENGL J MED, V328, P585, DOI 10.1056/NEJM199302253280825; BAYER R, 1989, NEW ENGL J MED, V320, P1022, DOI 10.1056/NEJM198904133201529; BAYER R, 1993, WASHINGTON POST 0112, pA17; DUBLER NN, 1989, MILBANK Q, V67, P171, DOI 10.2307/3350137; Eide Asbjorn, 1992, UNIVERSAL DECLARATIO; Friedman Thomas L., 1993, NY TIMES        0610, pA12; GOSTIN LO, 1990, NEW ENGL J MED, V322, P1743, DOI 10.1056/NEJM199006143222411; GRODIN MA, 1993, HASTINGS CTR REP, V23, P4; Rohter L., 1993, NY TIMES, pA20; SCIOLINO E, 1993, NY TIMES        1016, P1; Strossen Nadine, 1992, U TOL L REV, V24, P203	11	17	17	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1993	329	8					589	592		10.1056/NEJM199308193290826	http://dx.doi.org/10.1056/NEJM199308193290826			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR892	8123086				2022-12-01	WOS:A1993LR89200028
J	KELLER, M; BLOCHL, E; WACHTERSHAUSER, G; STETTER, KO				KELLER, M; BLOCHL, E; WACHTERSHAUSER, G; STETTER, KO			FORMATION OF AMIDE BONDS WITHOUT A CONDENSATION AGENT AND IMPLICATIONS FOR ORIGIN OF LIFE	NATURE			English	Article							PYRITE FORMATION; EVOLUTION; BIOCHEMISTRY; WORLD	AMIDE bonds are of central importance for biochemistry; in the guise of peptide bonds, they form the backbone of proteins. The formation of amide bonds without the assistance of enzymes poses a major challenge for theories of the orgin of life. Enzyme-free formation of amide bonds between amino acids has been demonstrated in the presence of condensing agents such as cyanamide(1-4) Here we report the formation of amide bonds in aqueous solution in the absence of any condensing agent. We find that the formation of pyrite (FeS2) from FeS and H2S can provide the driving force for reductive acetylation of amino acids,vith mercaptoacetic acid (HSCH2COOH). The redox energy of pyrite formation permits the activation of the carboxylic acid group, which is converted to a species that reacts readily with amines. This process provides support for the chemo-autotrophic theory(5-8) for the origin of life, in which pyrite formation supplies the energy source for the first autocatalytic reproduction cycle.	LEHRSTUHL MIKROBIOL,D-93040 REGENSBURG,GERMANY				Keller, Martin/C-4416-2012					BLOCHL E, 1992, P NATL ACAD SCI USA, V89, P8117, DOI 10.1073/pnas.89.17.8117; BRACK A, 1993, PURE APPL CHEM, V65, P1143, DOI 10.1351/pac199365061143; de Duve, 1991, BLUEPRINT CELL; DROBNER E, 1990, NATURE, V346, P742, DOI 10.1038/346742a0; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; HAWKER JR, 1981, ORIGINS LIFE, P225; HULSHOF J, 1976, ORIGINS LIFE EVOL B, V7, P197, DOI 10.1007/BF00926938; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; ORO J, 1963, ANN NY ACAD SCI, V108, P464, DOI 10.1111/j.1749-6632.1963.tb13402.x; STREHLER BL, 1982, J MOL EVOL, V19, P1, DOI 10.1007/BF02100218; WACHTERSHAUSER G, 1990, P NATL ACAD SCI USA, V87, P200, DOI 10.1073/pnas.87.1.200; WACHTERSHAUSER G, 1988, SYST APPL MICROBIOL, V10, P207; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; WEBER AL, 1984, ORIGINS LIFE EVOL B, V15, P17, DOI 10.1007/BF01809390	15	54	56	0	51	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					836	838		10.1038/368836a0	http://dx.doi.org/10.1038/368836a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159243				2022-12-01	WOS:A1994NH71700065
J	CONSTANT, P; DAVODEAU, F; PEYRAT, MA; POQUET, Y; PUZO, G; BONNEVILLE, M; FOURNIE, JJ				CONSTANT, P; DAVODEAU, F; PEYRAT, MA; POQUET, Y; PUZO, G; BONNEVILLE, M; FOURNIE, JJ			STIMULATION OF HUMAN GAMMA-DELTA T-CELLS BY NONPEPTIDIC MYCOBACTERIAL LIGANDS	SCIENCE			English	Article							HEAT-SHOCK PROTEIN; LYMPHOCYTES; RECEPTOR; TUBERCULOSIS; RECOGNITION; ANTIGEN; RESPONSES; SUBSET	Most human peripheral blood gammadelta T lymphocytes respond to hitherto unidentified mycobacterial antigens. Four ligands from Mycobacterium tuberculosis strain H37Rv that stimulated proliferation of a major human gammadelta T cell subset were isolated and partially characterized. One of these ligands, TUBag4, is a 5' triphosphorylated thymidine-containing compound, to which the three other stimulatory molecules are structurally related. These findings support the hypothesis that some gammadelta T cells recognize nonpeptidic ligands.	CNRS,PHARMACOL & TOXICOL FONDAMENTALES LAB,DEPT 3,118 RTE NARBONNE,F-31062 TOULOUSE,FRANCE; INST BIOL,INSERM,U211,F-44035 NANTES,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			François, Davodeau/GLU-4061-2022; Davodeau, Francois/M-1888-2015; Fournie, Jean-Jacques/J-7805-2013	François, Davodeau/0000-0001-8181-0192; Fournie, Jean-Jacques/0000-0001-6542-6908				AUGUSTIN A, 1989, NATURE, V340, P239, DOI 10.1038/340239a0; BORN W, 1990, IMMUNOL TODAY, V11, P40; BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; BREITMAIER E, 1987, CARBON 13 NMR SPECTR, P401; CONSTANT P, UNPUB; DAVODEAU F, 1993, J IMMUNOL, V151, P1214; DAVODEAU F, 1993, J BIOL CHEM, V268, P15455; DAVODEAU F, UNPUB; FISCH P, 1990, SCIENCE, V250, P1269, DOI 10.1126/science.1978758; FISCH P, 1992, J IMMUNOL, V148, P2315; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.iy.11.040193.003225; HAPP MP, 1989, NATURE, V342, P696, DOI 10.1038/342696a0; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; HOLOSHITZ J, 1989, NATURE, V339, P226, DOI 10.1038/339226a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; JANIS EM, 1989, SCIENCE, V244, P713, DOI 10.1126/science.2524098; KABELITZ D, 1990, J EXP MED, V171, P667, DOI 10.1084/jem.171.3.667; KABELITZ D, 1991, J EXP MED, V173, P1331, DOI 10.1084/jem.173.6.1331; KAUR I, 1993, J IMMUNOL, V150, P2046; MCCLOSKEY JA, 1974, BASIC PRINCIPLES NUC, V1, pCH3; MODLIN RL, 1989, NATURE, V339, P544, DOI 10.1038/339544a0; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; PFEFFER K, 1992, J IMMUNOL, V148, P575; PFEFFER K, 1990, EUR J IMMUNOL, V20, P1175, DOI 10.1002/eji.1830200534; RAJAGOPALAN S, 1990, P NATL ACAD SCI USA, V87, P7020, DOI 10.1073/pnas.87.18.7020; RAULET DH, 1989, NATURE, V339, P342, DOI 10.1038/339342a0; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7	27	639	656	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					267	270		10.1126/science.8146660	http://dx.doi.org/10.1126/science.8146660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146660				2022-12-01	WOS:A1994NE41000039
J	ENGELS, WR; PRESTON, CR; JOHNSONSCHLITZ, DM				ENGELS, WR; PRESTON, CR; JOHNSONSCHLITZ, DM			LONG-RANGE CIS PREFERENCE IN DNA HOMOLOGY SEARCH OVER THE LENGTH OF A DROSOPHILA CHROMOSOME	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; GENE CONVERSION; ESCHERICHIA-COLI; MAMMALIAN-CELLS; RECOMBINATION; REQUIREMENTS; MELANOGASTER; REPLACEMENT; SEQUENCES; RATES	P element-induced chromosome breakage on the X chromosome of Drosophila melanogaster was repaired six times more frequently when a homologous template was located anywhere on the X chromosome rather than on an autosome. Cis-trans comparisons confirmed that recombinational repair was more frequent when the interacting sequences were physically connected. These results suggest that the search for homology between the broken ends and a matching template sequence occurs preferentially in the cis configuration. This cis advantage operates over more than 15 megabases of DNA.			ENGELS, WR (corresponding author), UNIV WISCONSIN, DEPT GENET, MADISON, WI 53706 USA.				NIGMS NIH HHS [GM30948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030948, R56GM030948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1988, MOL CELL BIOL, V8, P2442, DOI 10.1128/MCB.8.6.2442; BAKER BS, 1983, ANNU REV GENET, V17, P345, DOI 10.1146/annurev.ge.17.120183.002021; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; ENGELS WR, 1979, ENVIRON MUTAGEN, V1, P37, DOI 10.1002/em.2860010110; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; ENGELS WR, 1986, FOCUS, V8, P6; Erlich H.A., 1989, PCR TECHNOLOGY; GLOOR GB, 1991, SCIENCE, V253, P1110, DOI 10.1126/science.1653452; GLOOR GB, 1993, GENETICS, V135, P81; JEONGYU S, 1992, MOL CELL BIOL, V12, P5426, DOI 10.1128/MCB.12.12.5426; JOHNSONSCHLITZ DM, 1993, MOL CELL BIOL, V13, P7006, DOI 10.1128/MCB.13.11.7006; KUPIEC M, 1988, MOL CELL BIOL, V8, P2942, DOI 10.1128/MCB.8.7.2942; LICHTEN M, 1989, GENETICS, V123, P261; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LISKAY RM, 1987, GENETICS, V115, P161; MEZARD C, 1992, CELL, V70, P659, DOI 10.1016/0092-8674(92)90434-E; NASSIF N, 1993, P NATL ACAD SCI USA, V90, P1262, DOI 10.1073/pnas.90.4.1262; RAO BJ, 1993, P NATL ACAD SCI USA, V90, P6646, DOI 10.1073/pnas.90.14.6646; ROBERTSON HM, 1988, GENETICS, V118, P461; ROEDER GS, 1984, MOL CELL BIOL, V4, P703, DOI 10.1128/MCB.4.4.703; RUBIN GM, 1982, CELL, V29, P987, DOI 10.1016/0092-8674(82)90462-7; RUBNITZ J, 1984, MOL CELL BIOL, V4, P2253, DOI 10.1128/MCB.4.11.2253; SHEN P, 1986, GENETICS, V112, P441; SINGER BS, 1982, CELL, V31, P25, DOI 10.1016/0092-8674(82)90401-9; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; THOMAS KR, 1992, MOL CELL BIOL, V12, P2919, DOI 10.1128/MCB.12.7.2919; WALDMAN AS, 1987, P NATL ACAD SCI USA, V84, P5340, DOI 10.1073/pnas.84.15.5340; WATT VM, 1985, P NATL ACAD SCI USA, V82, P4768, DOI 10.1073/pnas.82.14.4768	29	54	56	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 18	1994	263	5153					1623	1625		10.1126/science.8128250	http://dx.doi.org/10.1126/science.8128250			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128250				2022-12-01	WOS:A1994NB67300035
J	SEHGAL, A; PRICE, JL; MAN, B; YOUNG, MW				SEHGAL, A; PRICE, JL; MAN, B; YOUNG, MW			LOSS OF CIRCADIAN BEHAVIORAL RHYTHMS AND PER RNA OSCILLATIONS IN THE DROSOPHILA MUTANT TIMELESS	SCIENCE			English	Article							PERIOD GENE-PRODUCT; VISUAL-SYSTEM; NUCLEAR-PROTEIN; CLOCK MUTANTS; AH-RECEPTOR; MELANOGASTER; EXPRESSION; IDENTIFICATION; ENCODES; CLONING	Eclosion, or emergence of adult flies from the pupa, and locomotor activity of adults occur rhythmically in Drosophila melanogaster, with a circadian period of about 24 hours. Here, a clock mutation, timeless (tim), is described that produces arrhythmia for both behaviors. The effects of tim on behavioral rhythms are likely to involve products of the X chromesome-linked clock gene period (per), because tim alters circadian oscillations of per RNA. Genetic mapping places tim on the left arm of the second chromosome between dumpy (dp) and decapentaplegic (dpp).	ROCKEFELLER UNIV,NATL SCI FDN SCI & TECHNOL CTR BIOL TIMING,HOWARD HUGHES MED INST,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; National Science Foundation (NSF); Rockefeller University; Rockefeller University			Jansen, Heiko T./A-5770-2008; , 机智的马小跳和机智的羊不愁/ABC-5169-2020	Jansen, Heiko T./0000-0003-0178-396X; 				BAYLIES MK, 1993, MOL GENETICS BIOL RH, P123; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DANIELS SB, 1993, GENETICS, V133, P623; DOWSE HB, 1987, BEHAV GENET, V17, P19, DOI 10.1007/BF01066008; DUSHAY MS, 1989, J BIOL RHYTHM, V4, P1, DOI 10.1177/074873048900400101; DUSHAY MS, 1990, GENETICS, V125, P557; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HELFRICH C, 1987, Z NATURFORSCH C, V42, P1335; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Jackson FR, 1983, J NEUROGENET, V1, P3, DOI 10.3109/01677068309107068; JACKSON FR, 1993, MOL GENETICS BIOL RH, P91; JAMES AA, 1986, EMBO J, V5, P2313, DOI 10.1002/j.1460-2075.1986.tb04499.x; KIDWELL MG, 1986, DROSOPHILA PRACTICAL, pCH3; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KONOPKA RJ, 1991, J NEUROGENET, V7, P103, DOI 10.3109/01677069109066214; LIU X, 1992, J NEUROSCI, V12, P2735; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; PITTENDRIGH CS, 1974, NEUROSCIENCES 3RD ST, pCH38; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ROBERTSON HM, 1988, GENETICS, V118, P461; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; SAEZ L, 1988, MOL CELL BIOL, V8, P5378, DOI 10.1128/MCB.8.12.5378; SEHGAL A, 1992, P NATL ACAD SCI USA, V89, P1423, DOI 10.1073/pnas.89.4.1423; SEHGAL A, UNPUB; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	39	475	495	4	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 18	1994	263	5153					1603	1606		10.1126/science.8128246	http://dx.doi.org/10.1126/science.8128246			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128246				2022-12-01	WOS:A1994NB67300029
J	BRONNER, CE; BAKER, SM; MORRISON, PT; WARREN, G; SMITH, LG; LESCOE, MK; KANE, M; EARABINO, C; LIPFORD, J; LINDBLOM, A; TANNERGARD, P; BOLLAG, RJ; GODWIN, AR; WARD, DC; NORDENSKJOLD, M; FISHEL, R; KOLODNER, R; LISKAY, RM				BRONNER, CE; BAKER, SM; MORRISON, PT; WARREN, G; SMITH, LG; LESCOE, MK; KANE, M; EARABINO, C; LIPFORD, J; LINDBLOM, A; TANNERGARD, P; BOLLAG, RJ; GODWIN, AR; WARD, DC; NORDENSKJOLD, M; FISHEL, R; KOLODNER, R; LISKAY, RM			MUTATION IN THE DNA MISMATCH REPAIR GENE HOMOLOG HMLH1 IS ASSOCIATED WITH HEREDITARY NONPOLYPOSIS COLON-CANCER	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; STREPTOCOCCUS-PNEUMONIAE; SALMONELLA-TYPHIMURIUM; INSITU HYBRIDIZATION; PMS1; MUTL; HEXB	THE human DNA mismatch repair gene homologue, hMSH2, on chromosome 2p is involved in hereditary non-polyposis colon cancer (HNPCC)(1,2). On the basis of linkage data, a second HNPCC locus was assigned to chromosome 3p21-23 (ref. 3). Here we report that a human gene encoding a protein, hMLH1 (human MutL homologue), homologous to the bacterial DNA mismatch repair protein MutL, is located on human chromosome 3p21.3-23. We propose that hMLH1 is the HNPCC gene located on 3p because of the similarity of the hMLH1 gene product to the yeast DNA mismatch repair protein, MLH1(4,5), the coincident location of the hMLH1 gene and the HNPCC locus on chromosome 3, and hMLH1 missense mutations in affected individuals from a chromosome 3-linked HNPCC family.	OREGON HLTH SCI UNIV,DEPT MOLEC & MED GENET,PORTLAND,OR 97201; DANA FARBER CANC INST,MOLEC BIOL CORE FACIL,BOSTON,MA 02115; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; UNIV VERMONT,MARKEY CTR MOLEC GENET,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; KAROLINSKA HOSP,DEPT MOLEC MED,S-17176 STOCKHOLM,SWEDEN	Oregon Health & Science University; Harvard University; Dana-Farber Cancer Institute; Yale University; Yale University; University of Vermont; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Karolinska Institutet; Karolinska University Hospital				Smith, Leslie/0000-0001-6452-6624				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; BISHOP DT, 1990, CANCER SURV, V9, P585; BOYLE AL, 1992, GENOMICS, V12, P106, DOI 10.1016/0888-7543(92)90412-L; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HAN HJ, 1993, CANCER RES, V53, P5087; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LATIF F, 1992, CANCER RES, V52, P1451; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Lyon M. F., 1993, Mouse Genome, V91, P40; MANKOVICH JA, 1989, J BACTERIOL, V171, P5325, DOI 10.1128/jb.171.10.5325-5331.1989; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; PRUDHOMME M, 1989, J BACTERIOL, V171, P5332, DOI 10.1128/jb.171.10.5332-5338.1989; REENAN RAG, 1992, GENETICS, V132, P963; REENAN RAG, 1992, GENETICS, V132, P975; RISINGER JI, 1993, CANCER RES, V53, P5100; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WILLIAMSON MS, 1985, GENETICS, V110, P609; WU DY, 1989, DNA-J MOLEC CELL BIO, V8, P135, DOI 10.1089/dna.1.1989.8.135	30	1838	1911	0	110	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					258	261		10.1038/368258a0	http://dx.doi.org/10.1038/368258a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145827				2022-12-01	WOS:A1994NA87000060
J	STAPLETON, FB; LINSHAW, MA				STAPLETON, FB; LINSHAW, MA			URIC-ACID CRYSTALS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts University	STAPLETON, FB (corresponding author), SUNY BUFFALO, BUFFALO, NY USA.								0	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					762	762						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	8107742				2022-12-01	WOS:A1994NA74200006
J	BROWN, CJ; WILLARD, HF				BROWN, CJ; WILLARD, HF			THE HUMAN X-INACTIVATION CENTER IS NOT REQUIRED FOR MAINTENANCE OF X-CHROMOSOME INACTIVATION	NATURE			English	Article							XIST GENE; LOCALIZATION; EXPRESSION; NUCLEUS; REGION; LOCUS; CELLS	X-CHROMOSOME inactivation occurs early in mammalian female development to achieve dosage compensation with males(1). Although it is widely accepted that this inactivation requires the presence in cis of the X-inactivation centre (XIC)(2-5), it is not known whether the XIC is required for the initiation, promulgation or maintenance of X inactivation(6,7). The XIST gene, which is localized within the XIC interval on both the human and mouse X chromosomes, is constitutively expressed from inactive X chromosomes(8-10), suggesting a possible role in the maintenance of X inactivation. To address whether the presence of the XIC, including the XIST gene, is continuously required for the maintenance of X-chromosome inactivation, we have analysed the transcriptional activity of a number of X-linked genes in mouse/human somatic cell hybrids retaining an intact human inactive X chromosome or derivatives of the inactive X chromosome lacking the XIC. Genes subject to X inactivation remain transcriptionally silent despite the loss of the XIC, demonstrating that the presence of the XIC is not required for the maintenance of X inactivation in somatic cells.			BROWN, CJ (corresponding author), CASE WESTERN RESERVE UNIV,CTR HUMAN GENET,DEPT GENET,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.		Brown, Carolyn J/A-5159-2014	Brown, Carolyn J/0000-0002-8959-0101				[Anonymous], ADV DEV BIO; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1989, AM J HUM GENET, V45, P592; BROWN CJ, 1990, NUCLEIC ACIDS RES, V18, P4191, DOI 10.1093/nar/18.14.4191; BROWN CJ, 1989, CYTOGENET CELL GENET, V51, P970; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BROWN RM, 1989, GENOMICS, V4, P174, DOI 10.1016/0888-7543(89)90297-8; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; GARTLER SM, 1992, MOL GENETIC MED, P121; GILES RE, 1979, GENETICS, V93, P975; GOODFELLOW P, 1984, AM J HUM GENET, V36, P777; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; LAFRENIERE RG, 1991, GENOMICS, V11, P352, DOI 10.1016/0888-7543(91)90143-3; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; LYON MF, 1963, 2ND INT C CONG MALF, P67; LYON MFA, 1992, REV GENET, V26, P17; MATTEI MG, 1981, HUM GENET, V56, P401, DOI 10.1007/BF00274702; MCCARREY JR, 1992, NAT GENET, V2, P200, DOI 10.1038/ng1192-200; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; RICHLER C, 1992, NAT GENET, V2, P192, DOI 10.1038/ng1192-192; RIGGS AD, 1990, AUST J ZOOL, V37, P419, DOI 10.1071/ZO9890419; RUSSELL LB, 1963, SCIENCE, V140, P976, DOI 10.1126/science.140.3570.976; SALIDO EC, 1992, NAT GENET, V2, P196, DOI 10.1038/ng1192-196	26	237	244	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					154	156		10.1038/368154a0	http://dx.doi.org/10.1038/368154a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139659				2022-12-01	WOS:A1994NA03000068
J	DOXSEY, SJ; STEIN, P; EVANS, L; CALARCO, PD; KIRSCHNER, M				DOXSEY, SJ; STEIN, P; EVANS, L; CALARCO, PD; KIRSCHNER, M			PERICENTRIN, A HIGHLY CONSERVED CENTROSOME PROTEIN INVOLVED IN MICROTUBULE ORGANIZATION	CELL			English	Article							COIL RELATED PROTEIN; CELL-CYCLE; PROTOFILAMENT NUMBER; ORGANIZING CENTERS; GAMMA-TUBULIN; MOUSE OOCYTES; SITES; SEQUENCE; GENE; IDENTIFICATION	Antisera from scleroderma patients that react widely with centrosomes in plants and animals were used to isolate cDNAs encoding a novel centrosomal protein. The nucleotide sequence is consistent with a 7 kb mRNA and contains an open reading frame encoding a protein with a putative large coiled-coil domain flanked by noncoiled ends. Antisera recognize a 220 kd protein and stain centrosomes and acentriolar microtubule-organizing centers, where the protein is localized to the pericentriolar material (hence, the name pericentrin). Anti-pericentrin antibodies disrupt mitotic and meiotic divisions in vivo and block microtubule aster formation in Xenopus extracts, but do not block gamma-tubulin assembly or microtubule nucleation from mature centrosomes. These results suggest that pericentrin is a conserved integral component of the filamentous matrix of the centrosome involved in the initial establishment of organized microtubule arrays.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco								AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BARON AT, 1988, J CELL BIOL, V107, P2669, DOI 10.1083/jcb.107.6.2669; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BORNENS M, 1987, CELL MOTIL CYTOSKEL, V8, P238, DOI 10.1002/cm.970080305; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; BUENDIA B, 1992, J CELL BIOL, V117, P1055; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CALARCO PD, 1983, J CELL BIOL, V101, P319; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CLAYTON L, 1985, CELL, V35, P621; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COHEN C, 1987, BIOSCIENCE REP, V7, P11, DOI 10.1007/BF01122722; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GARD DL, 1987, J CELL BIOL, V105, P2191, DOI 10.1083/jcb.105.5.2191; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOULD RR, 1977, J CELL BIOL, V73, P601, DOI 10.1083/jcb.73.3.601; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; HARLOW E, 1988, ANTIBODIES LABORATOR; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KRSTIC K, 1976, ULTRASTRUCTURE MAMMA; Kuriyama Ryoko, 1992, P131; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MANDELKOW EM, 1986, J CELL BIOL, V102, P1067, DOI 10.1083/jcb.102.3.1067; MIRZAYAN C, 1992, J CELL BIOL, V116, P1319, DOI 10.1083/jcb.116.6.1319; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; OAKLEY BR, 1990, NATURE, V338, P662; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON JB, 1976, J CELL SCI, V22, P219; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIMERLY C, 1990, J CELL BIOL, V111, P1491, DOI 10.1083/jcb.111.4.1491; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNYDER M, 1988, CELL, V54, P743, DOI 10.1016/S0092-8674(88)90977-4; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; SZOLLOSI D, 1972, J CELL SCI, V11, P521; TUCKER JB, 1986, EUR J CELL BIOL, V41, P279; TUFFANELLI DL, 1983, ARCH DERMATOL, V119, P560, DOI 10.1001/archderm.119.7.560; VALE RD, 1993, GUIDEBOOK CYTOSKELET; VIDAIR CA, 1993, J CELL PHYSIOL, V154, P443, DOI 10.1002/jcp.1041540302; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WHEATLEY DN, 1982, CENTRIOLE CENTRAL EN; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303	55	493	498	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					639	650		10.1016/0092-8674(94)90504-5	http://dx.doi.org/10.1016/0092-8674(94)90504-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124707				2022-12-01	WOS:A1994MZ28500007
J	LAW, MR; WALD, NJ; WU, T; HACKSHAW, A; BAILEY, A				LAW, MR; WALD, NJ; WU, T; HACKSHAW, A; BAILEY, A			SYSTEMATIC UNDERESTIMATION OF ASSOCIATION BETWEEN SERUM-CHOLESTEROL CONCENTRATION AND ISCHEMIC-HEART-DISEASE IN OBSERVATIONAL STUDIES - DATA FROM THE BUPA STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; RESEARCH-CLINICS PREVALENCE; PLASMA; RISK; TRIGLYCERIDE; VARIABILITY	Objective-To estimate the size of the association between serum concentration of low density lipoprotein cholesterol and mortality from ischaemic heart disease. Design-Prospective study of total serum cholesterol concentration and mortality from ischaemic heart disease in 21 515 men (538 deaths) and study of total cholesterol concentration measured on two occasions an average of three years apart in 5696 men in whom low density lipoprotein cholesterol concentration was also measured on the second occasion. Subjects-Men who attended the medical centre of the British United Provident Association (BUPA) in London between 1975 and 1982. Main outcome measure-The difference in mortality from ischaemic heart disease for a 0.6 mmol/l difference in concentration of low density lipoprotein cholesterol after adjustment for, firstly, regression dilution bias, which arises from the random fluctuation of serum cholesterol concentration in people over time, and, secondly, the surrogate dilution effect, which arises because differences in total cholesterol concentration between people reflect smaller differences in low density lipoprotein cholesterol concentration. Results-The observed difference in mortality from ischaemic heart disease associated with a difference of 0.6 mmol/l in total serum cholesterol concentration was 17% but increased to 24% after correction for the regression dilution bias and to 27% (95% confidence interval 21% to 33%) after adjustment for both sources of underestimation, which provides an estimate of the difference in mortality for a true difference of 0.6 mmol/l in low density lipoprotein cholesterol concentration. The association was greater at younger ages. The estimated decrease in mortality from all causes was 6% before and 10% (1% to 17%) after adjustment for the two sources of underestimation. There was no excess mortality from any cause associated with low cholesterol concentration. Conclusions-The association between serum cholesterol concentration and ischaemic heart disease is materially stronger than directly inferred from prospective studies. This has important implications for the health benefit of achieving low cholesterol concentrations.	ST BARTHOLOMEWS HOSP, COLL MED,WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED,BUPA, LONDON EC1M 6BQ, ENGLAND	University of London; Queen Mary University London			Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CREMER P, 1988, KLIN WOCHENSCHR, V66, P42; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; DELONG DM, 1986, JAMA-J AM MED ASSOC, V256, P2372, DOI 10.1001/jama.256.17.2372; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2351, DOI 10.1001/jama.256.17.2351; HARLAN WR, 1967, ANN INTERN MED, V66, P540, DOI 10.7326/0003-4819-66-3-540; JACOBS DR, 1982, AM J EPIDEMIOL, V116, P878, DOI 10.1093/oxfordjournals.aje.a113490; LENTNER C, 1984, GEIGY SCI TABLES, V3; RAO A, 1988, CLIN CHEM, V34, P2532; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; THOMPSON SG, 1990, J CLIN EPIDEMIOL, V43, P783, DOI 10.1016/0895-4356(90)90238-K; TORNBERG SA, 1988, INT J EPIDEMIOL, V17, P797, DOI 10.1093/ije/17.4.797; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; WALD NJ, 1989, BRIT J CANCER, V59, P936, DOI 10.1038/bjc.1989.198; WILLIAMS GZ, 1978, CLIN CHEM, V24, P313; 1968, CIRCULATION S, V37, P428; 1979, PREV MED, V8, P625	21	260	266	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 5	1994	308	6925					363	366		10.1136/bmj.308.6925.363	http://dx.doi.org/10.1136/bmj.308.6925.363			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV862	8124143	Green Published			2022-12-01	WOS:A1994MV86200017
J	HAY, PE; LAMONT, RF; TAYLORROBINSON, D; MORGAN, DJ; ISON, C; PEARSON, J				HAY, PE; LAMONT, RF; TAYLORROBINSON, D; MORGAN, DJ; ISON, C; PEARSON, J			ABNORMAL BACTERIAL-COLONIZATION OF THE GENITAL-TRACT AND SUBSEQUENT PRETERM DELIVERY AND LATE MISCARRIAGE	BRITISH MEDICAL JOURNAL			English	Article							PLACEBO-CONTROLLED TRIAL; ERYTHROMYCIN TREATMENT; VAGINAL FLORA; DOUBLE-BLIND; GRAM STAIN; LABOR; PREGNANCY; VAGINOSIS; INFECTION; DIAGNOSIS	Objective-To find out whether women with bacterial vaginosis detected early in pregnancy are at increased risk of preterm delivery. Design-Prospective description cohort study. Setting-Antenatal clinic in a district general hospital. Subjects-783 women examined during their first antenatal clinic visit and screened for recognised risk factors for preterm delivery and the presence of bacterial vaginosis or intermediate abnormal flora detected by examination of a vaginal smear stained by Gram's method. Main outcome measures-Gestational age at delivery classified as late miscarriage (16-24 weeks' gestation), preterm delivery (24-37 weeks' gestation), term delivery (greater-than-or-equal-to 37 weeks' gestation). Results-Multiple logistic analysis showed that there was an increased incidence of preterm delivery in women with a previous preterm delivery (9/24; odds ratio 25; 95% confidence interval 9 to 70; P < 0.001) and bacterial vaginosis (9/115; 2.8; 1.1 to 7.4; P = 0.04). A further logistic analysis of data from women recruited before 16 weeks' gestation showed that preterm deliveries or late miscarriages occurred more often in women with bacterial vaginosis (12/7; 5.5; 2.3 to 13.3; P < 0.001). Conclusions-Late miscarriage and preterm delivery are associated with the presence of bacterial vaginosis in early pregnancy. This is independent of recognised risk factors such as previous preterm delivery.	NORTHWICK PK HOSP & CLIN RES CTR,DEPT OBSTET & GYNAECOL,HARROW HA1 3UJ,MIDDX,ENGLAND; CLIN RES CTR,DIV SEXUALLY TRANSMITTED DIS,HARROW HA1 3UJ,MIDDX,ENGLAND; ST MARYS HOSP,SCH MED,DEPT MED MICROBIOL,LONDON W2 1PG,ENGLAND; CLIN RES CTR,DEPT MED STAT,HARROW HA1 3UJ,MIDDX,ENGLAND	Imperial College London; Imperial College London								GIBBS RS, 1992, AM J OBSTET GYNECOL, V166, P1515, DOI 10.1016/0002-9378(92)91628-N; GRAVETT MG, 1986, JAMA-J AM MED ASSOC, V256, P1899; HAY PE, 1992, BRIT J OBSTET GYNAEC, V99, P63, DOI 10.1111/j.1471-0528.1992.tb14395.x; HEMMINKI E, 1978, BRIT J OBSTET GYNAEC, V85, P411, DOI 10.1111/j.1471-0528.1978.tb14906.x; HILLIER SL, 1992, AM J OBSTET GYNECOL, V166, P938, DOI 10.1016/0002-9378(92)91368-K; HOSMER DW, 1989, APPL LOGISTIC REGRES, P80; KURKI T, 1992, OBSTET GYNECOL, V80, P173; Lamont RFFN, 1993, PROGR OBSTETRICS GYN, V10, P135; LEVENO KJ, 1992, NEW ENGL J MED, V327, P349, DOI 10.1056/NEJM199207303270510; LOCKWOOD CJ, 1991, NEW ENGL J MED, V325, P669, DOI 10.1056/NEJM199109053251001; MCGREGOR JA, 1991, AM J OBSTET GYNECOL, V165, P867, DOI 10.1016/0002-9378(91)90430-Y; MCGREGOR JA, 1986, AM J OBSTET GYNECOL, V154, P98, DOI 10.1016/0002-9378(86)90401-1; MCGREGOR JA, 1990, AM J OBSTET GYNECOL, V163, P1580, DOI 10.1016/0002-9378(90)90632-H; MCGREGOR JA, 1988, AM J REPROD IMMUNOL, V16, P123; MIETTINEN OS, 1976, AM J EPIDEMIOL, V104, P609, DOI 10.1093/oxfordjournals.aje.a112339; MINKOFF H, 1984, AM J OBSTET GYNECOL, V150, P965, DOI 10.1016/0002-9378(84)90392-2; NEWCOMBE RG, 1981, PRETERM LABOUR, P47; ROMERO R, 1988, SEMIN PERINATOL, V12, P262; SPIEGEL CA, 1983, J CLIN MICROBIOL, V18, P170, DOI 10.1128/JCM.18.1.170-177.1983; 1992, NEW ENGL J MED, V327, P308	20	480	504	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 29	1994	308	6924					295	298		10.1136/bmj.308.6924.295	http://dx.doi.org/10.1136/bmj.308.6924.295			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU492	8124116	Green Published			2022-12-01	WOS:A1994MU49200018
J	ARTALEJO, CR; ADAMS, ME; FOX, AP				ARTALEJO, CR; ADAMS, ME; FOX, AP			3 TYPES OF CA2+ CHANNEL TRIGGER SECRETION WITH DIFFERENT EFFICACIES IN CHROMAFFIN CELLS	NATURE			English	Article							CALCIUM CHANNELS; CAPACITANCE MEASUREMENTS; OMEGA-CONOTOXIN; FACILITATION	To determine whether the different types of Ca2+ channels present in the same secretory cell contribute equally to secretion, we used chromaffin cells to analyse the coupling between three distinct types of Ca2+ channel1 and exocytosis2,3. These are omega-conotoxin-GVIA-sensitive4,5 N-type channels, omega-agatoxin-IVA-sensitive P-type Ca2+ channels6 and dihydropyridine-sensitive facilitation Ca2+ channels, which are normally quiescent but are activated by depolarizing pre-pulses, repetitive depolarizations to physiological potentials7,8, or agents that raise cyclic AMP9. We have simultaneously monitored changes in capacitance as an assay of catecholamine secretion10, and Ca2+ currents. Although all three types of Ca2+ channel trigger secretion individually, facilitation channels produce much greater secretion for a given size of Ca2+ current, indicating that they are coupled more efficiently to exocytosis. These results indicate that facilitation Ca2+ channels may be physically nearer vesicle release sites. They also show that low efficiency P- and N-type channels could trigger mild release and that high-efficiency facilitation channels may underlie the massive catecholamine release that occurs during the 'fight or flight' response.	UNIV AUTONOMA MADRID,FAC MED,DEPT FARMACOL,E-28029 MADRID,SPAIN; UNIV CALIF RIVERSIDE,DEPT ENTOMOL & NEUROSCI,RIVERSIDE,CA 92521; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637	Autonomous University of Madrid; University of California System; University of California Riverside; University of Chicago	ARTALEJO, CR (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,2153 N CAMPUS DR,EVANSTON,IL 60208, USA.							AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; ARTALEJO CR, 1991, J PHYSIOL-LONDON, V432, P681, DOI 10.1113/jphysiol.1991.sp018406; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; ARTALEJO CR, 1992, NEURON, V8, P85, DOI 10.1016/0896-6273(92)90110-Y; ARTALEJO CR, 1991, J PHYSIOL-LONDON, V444, P213, DOI 10.1113/jphysiol.1991.sp018874; ARTALEJO CR, 1992, NATURE, V358, P63, DOI 10.1038/358063a0; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; COUPLAND RE, 1968, NATURE, V217, P384, DOI 10.1038/217384a0; FIDLER N, 1989, BIOPHYS J, V56, P1153, DOI 10.1016/S0006-3495(89)82762-6; HANS M, 1990, NEUROSCI LETT, V114, P63, DOI 10.1016/0304-3940(90)90429-D; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORGAN A, 1993, EMBO J, V12, P3747, DOI 10.1002/j.1460-2075.1993.tb06052.x; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; NOWYCKY MC, 1993, BIOPHYS J, V64, P77, DOI 10.1016/S0006-3495(93)81342-0; NOWYCKY MC, 1992, BIOPHYS J, V64, pA230; PUMPLIN DW, 1981, P NATL ACAD SCI-BIOL, V78, P7210, DOI 10.1073/pnas.78.11.7210	22	250	251	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					72	76		10.1038/367072a0	http://dx.doi.org/10.1038/367072a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107778				2022-12-01	WOS:A1994MP86500062
J	HUGHES, KA; CHARLESWORTH, B				HUGHES, KA; CHARLESWORTH, B			A GENETIC-ANALYSIS OF SENESCENCE IN DROSOPHILA	NATURE			English	Article							MELANOGASTER; SELECTION; COMPONENT; VARIANCE	Two attractive theories for the evolution of senescence are based on the principle that the force of natural selection decreases with age1-5. The theories differ in the type of age-specific gene action that they assume. Antagonistic pleiotropy2-5 postulates that pleiotropic genes with positive effects early in life and negative effects of comparable magnitude late in life are favoured by selection, whereas genes with the reverse pattern of action are selected against. Mutation accumulation1,3-5 assumes that deleterious mutant alleles with age-specific effects will equilibrate at a lower frequency if their effects are expressed early rather than late in life. Explicit models demonstrate that both mechanisms can lead to the evolution of senescent life histories under reasonable conditions3-5. Antagonistic pleiotropy has gained considerable empirical support4-6, but the evidence in support of mutation accumulation is more sparse4,5,7. Here we report that the genetic variability of mortality in male Drosophila melanogaster increases greatly at very late ages, as predicted by the mutation accumulation hypothesis3-5. The rate of increase in mortality with age exhibits substantial genetic and environmental variability. This result provides a possible explanation for recent observations of non-increasing mortality rates in very old flies8,9.	UNIV CHICAGO, COMM EVOLUT BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT ECOL & EVOLUT, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago								CAREY JR, 1992, SCIENCE, V258, P457, DOI 10.1126/science.1411540; CHARLESWORTH B, 1990, EVOLUTION, V44, P520, DOI 10.1111/j.1558-5646.1990.tb05936.x; CHARLESWORTH B, 1985, HEREDITY, V54, P71, DOI 10.1038/hdy.1985.10; Charlesworth B., 1994, EVOLUTION AGE STRUCT; Charlesworth B, 1987, SEXUAL SELECTION TES, P21; COMSTOCK RE, 1952, HETEROSIS; CURTSINGER JW, 1992, SCIENCE, V258, P461, DOI 10.1126/science.1411541; Engels WR, 1989, MOBILE DNA; Falconer D. S., 1989, Introduction to quantitative genetics.; FINCH CE, 1990, SCIENCE, V249, P902, DOI 10.1126/science.2392680; Finch CE., 1990, LONGEVITY SENESCENCE; HARTLEY HO, 1967, BIOMETRICS, V23, P105, DOI 10.2307/2528284; HOULE D, 1992, GENETICS, V130, P195; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Medawar P., 1952, UNSOLVED PROBLEM BIO; MUKAI T, 1974, GENETICS, V78, P1195; PARTRIDGE L, 1993, NATURE, V362, P305, DOI 10.1038/362305a0; ROPER C, 1993, EVOLUTION, V47, P445, DOI 10.1111/j.1558-5646.1993.tb02105.x; ROSE MR, 1981, GENETICS, V97, P172; ROSE MR, 1984, EVOLUTION, V38, P516, DOI 10.1111/j.1558-5646.1984.tb00317.x; Rose MR, 1991, EVOLUTIONARY BIOL AG; SEARLE SR, 1971, BIOMETRICS, V27, P1, DOI 10.2307/2528928; SERVICE PM, 1993, EVOLUTION, V47, P387, DOI 10.1111/j.1558-5646.1993.tb02101.x; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Wright S., 1977, EVOLUTION GENETICS P, V3	25	142	144	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	1994	367	6458					64	66		10.1038/367064a0	http://dx.doi.org/10.1038/367064a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107775				2022-12-01	WOS:A1994MP86500059
J	NITTI, VW				NITTI, VW			ICE-WATER TEST IN URODYNAMIC ASSESSMENT	LANCET			English	Editorial Material							BLADDER				NITTI, VW (corresponding author), SUNY HLTH SCI CTR,DEPT UROL,BROOKLYN,NY 11203, USA.			Nitti, Victor/0000-0002-1390-7053				BALMASEDA MT, 1988, AM J PHYS MED REHAB, V67, P225, DOI 10.1097/00002060-198810000-00008; BORS EH, 1957, ARCH NEURO PSYCHIATR, V78, P339, DOI 10.1001/archneurpsyc.1957.02330400013002; FALL M, 1989, BRIT J UROL, V64, P368, DOI 10.1111/j.1464-410X.1989.tb06045.x; GEIRSSON G, 1993, BRIT J UROL, V71, P681, DOI 10.1111/j.1464-410X.1993.tb16065.x; GEIRSSON G, 1993, J UROLOGY, V150, P427, DOI 10.1016/S0022-5347(17)35501-5; HELLSTROM PA, 1991, BRIT J UROL, V67, P275, DOI 10.1111/j.1464-410X.1991.tb15134.x; LINDSTROM S, 1990, NEUROUROL URODYNAM, V9, P365; RAZ S, 1973, J UROLOGY, V109, P603, DOI 10.1016/S0022-5347(17)60491-9; SUSSET JG, 1985, NEUROUROL URODYNAM, V4, P157, DOI 10.1002/nau.1930040303	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1066	1067		10.1016/0140-6736(93)92057-Z	http://dx.doi.org/10.1016/0140-6736(93)92057-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105305				2022-12-01	WOS:A1993ME82200003
J	SMITH, GCM; KENNA, JG; HARRISON, DJ; TEW, D; WOLF, CR				SMITH, GCM; KENNA, JG; HARRISON, DJ; TEW, D; WOLF, CR			AUTOANTIBODIES TO HEPATIC-MICROSOMAL CARBOXYLESTERASE IN HALOTHANE HEPATITIS	LANCET			English	Note							ANTIBODIES; LIVER; SERA; NEOANTIGENS	Halothane hepatitis can be life-threatening, and this severe adverse reaction may arise via an immune process. We have detected autoantibodies to purified human liver microsomal carboxylesterase in sera of 17 out of 20 patients with halothane hepatitis (85%) but not in 9 halothane-exposed controls and in only 2 (at low levels) of 33 patients with liver disease due to other causes. Immunohistochemical studies localised the carboxylesterase predominantly to the centrilobular region of liver sections, which is consistent with the area affected by halothane hepatitis. Human hepatic microsomal carboxylesterase is a target antigen in halothane hepatitis, and an immune response to this protein may be involved in the liver damage observed.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,BIOMED RES CTR,IMPERIAL CANC RES UNIT,MOLEC PHARMACOL UNIT,DUNDEE DD1 9SY,SCOTLAND; IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT PHARMACOL & TOXICOL,LONDON W2,ENGLAND; UNIV EDINBURGH,SCH MED,DEPT PATHOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; SMITHKLINE BEECHAM RES,WELWYN GARDEN CIT,ENGLAND	University of Dundee; Imperial College London; University of Edinburgh; GlaxoSmithKline			Kenna, J Gerry/H-9929-2012	Wolf, Charles Roland/0000-0002-6969-0113; Smith, Gillian/0000-0001-9288-7566				CHRIST DD, 1988, ANESTHESIOLOGY, V69, P833, DOI 10.1097/00000542-198812000-00006; HARRISON DJ, 1989, J CLIN PATHOL, V42, P624, DOI 10.1136/jcp.42.6.624; KENNA JG, 1988, J PHARMACOL EXP THER, V245, P1103; KENNA JG, 1988, HEPATOLOGY, V8, P1635, DOI 10.1002/hep.1840080627; KENNA JG, 1993, ANN NY ACAD SCI, V685, P646, DOI 10.1111/j.1749-6632.1993.tb35930.x; KENNA JG, 1984, J IMMUNOL METHODS, V75, P3, DOI 10.1016/0022-1759(84)90219-9; RAY DC, 1991, BRIT J ANAESTH, V67, P84, DOI 10.1093/bja/67.1.84; SATOH H, 1985, J PHARMACOL EXP THER, V233, P857; SATOH H, 1989, P NATL ACAD SCI USA, V86, P322, DOI 10.1073/pnas.86.1.322	9	41	41	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					963	964		10.1016/0140-6736(93)92005-E	http://dx.doi.org/10.1016/0140-6736(93)92005-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105217				2022-12-01	WOS:A1993MC00500012
J	SMIRNOVA, T; LAROCHE, S; ERRINGTON, ML; HICKS, AA; BLISS, TVP; MALLET, J				SMIRNOVA, T; LAROCHE, S; ERRINGTON, ML; HICKS, AA; BLISS, TVP; MALLET, J			TRANSSYNAPTIC EXPRESSION OF A PRESYNAPTIC GLUTAMATE-RECEPTOR DURING HIPPOCAMPAL LONG-TERM POTENTIATION	SCIENCE			English	Article							DENTATE GYRUS; NMDA RECEPTORS; AMINO-ACIDS; RAT; INDUCTION; RELEASE	Repetitive activation of excitatory synapses in the hippocampus produces a persistent enhancement of synaptic efficiency known as long-term potentiation (LTP). In anesthetized and in freely moving rats, the induction of LTP in the perforant path led to a transient increase in the amount of messenger RNA (mRNA) coding for a presynaptic glutamate receptor (GR33) in dentate granule cells. The amount of GR33 mRNA was increased for at least 5 hours after the induction of LTP but was indistinguishable from control values 1 day after induction. The N-methyl-D-aspartate receptor antagonist 2-aminophosphonovalerate prevented the induction of both LTP and the increase in GR33 mRNA. The amount of GR33 protein was increased in the mossy fiber terminal zone of dentate granule cells 5 hours after the induction of LTP. These results suggest that the induction of LTP in synapses at one stage in a neural network may lead to modification in synaptic function at the next stage in the network.	LAB GENET MOLEC & NEUROTRANSMISS & PROC, NEURODEGENERAT, CNRS, C9923, F-91198 GIF SUR YVETTE, FRANCE; NATL INST MED RES, DIV NEUROPHYSIOL & NEUROPHARMACOL, LONDON NW7 1AA, ENGLAND; UNIV PARIS 11, NEUROBIOL APPRENTISSAGE & MEMOIRE LAB, CNRS, URA 1491, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; MRC National Institute for Medical Research; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Hicks, Andrew Anthony/E-9518-2017	Hicks, Andrew Anthony/0000-0001-6320-0411				ALZHEIMER C, 1991, BRAIN RES, V543, P163, DOI 10.1016/0006-8993(91)91061-5; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CLAIBORNE BJ, 1986, J COMP NEUROL, V246, P435, DOI 10.1002/cne.902460403; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; DOYERE V, 1992, HIPPOCAMPUS, V2, P39, DOI 10.1002/hipo.450020106; GANNON RL, 1991, NEUROSCIENCE, V41, P401, DOI 10.1016/0306-4522(91)90336-M; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; JAFFE D, 1990, J NEUROPHYSIOL, V64, P948, DOI 10.1152/jn.1990.64.3.948; LAROCHE S, 1989, NEUROSCIENCE, V28, P375, DOI 10.1016/0306-4522(89)90184-X; LOVINGER DM, 1986, BRAIN RES, V399, P205, DOI 10.1016/0006-8993(86)91510-6; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MORRIS RGM, 1990, PHILOS T ROY SOC B, V329, P187, DOI 10.1098/rstb.1990.0164; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; SMIRNOVA T, 1993, SCIENCE, V262, P430, DOI 10.1126/science.8105537; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	18	55	61	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					433	436		10.1126/science.8105538	http://dx.doi.org/10.1126/science.8105538			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	8105538				2022-12-01	WOS:A1993MB85900062
J	LITTLETON, JT; STERN, M; SCHULZE, K; PERIN, M; BELLEN, HJ				LITTLETON, JT; STERN, M; SCHULZE, K; PERIN, M; BELLEN, HJ			MUTATIONAL ANALYSIS OF DROSOPHILA SYNAPTOTAGMIN DEMONSTRATES ITS ESSENTIAL ROLE IN CA(2+)-ACTIVATED NEUROTRANSMITTER RELEASE	CELL			English	Article							SYNAPTIC TRANSMITTER RELEASE; ALPHA-LATROTOXIN RECEPTOR; PROTEIN KINASE-C; NEUROMUSCULAR-JUNCTION; VESICLE EXOCYTOSIS; NERVE TERMINALS; ACTIVE ZONES; CALCIUM-IONS; BINDING; MELANOGASTER	Synaptotagmin (syt), a synaptic vesicle-specific protein known to bind Call in the presence of phospholipids, has been proposed to mediate Ca2+-dependent neurotransmitter release. We have addressed the role of syt in neurotransmitter release in vivo by generating mutations in synaptotagmin (syt) in the fruitfly and assaying the subsequent effects on neurotransmission. Most embryos that lack syt fall to hatch and exhibit very reduced, uncoordinated muscle contractions. Larvae with partial lack-of-function mutations show almost no evoked excitatory junctional potentials (EJPs) in 0.4 mM Ca2+ and a 15-fold reduction in EJP amplitude in 1.0 mM Ca2+ when compared with heterozygous controls. In contrast, we observe an increase in the frequency of spontaneous miniature EJPs in the mutants. These results provide in vivo evidence that syt plays a key role in Ca2+ activation of neurotransmitter release and indicate the existence of separate pathways for evoked and spontaneous neurotransmitter release.	BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA; RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Rice University	LITTLETON, JT (corresponding author), BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA.			Littleton, J. Troy/0000-0001-5576-2887; Bellen, Hugo/0000-0001-5992-5989				AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROADIE KS, 1993, J NEUROSCI, V13, P144; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CECCARELLI B, 1980, PHYSIOL REV, V60, P396, DOI 10.1152/physrev.1980.60.2.396; COHEN MW, 1991, J NEUROSCI, V11, P1032; COPE TC, 1982, J NEUROPHYSIOL, V47, P469, DOI 10.1152/jn.1982.47.3.469; DELCASTILLO J, 1956, PROG BIOPHYS MOL BIO, V6, P122, DOI 10.1016/S0096-4174(18)30106-9; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; GANETZKY B, 1982, J NEUROPHYSIOL, V47, P501, DOI 10.1152/jn.1982.47.3.501; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; JAN YN, 1978, P NATL ACAD SCI USA, V75, P515, DOI 10.1073/pnas.75.1.515; KAISER K, 1990, P NATL ACAD SCI USA, V87, P1686, DOI 10.1073/pnas.87.5.1686; KATZ B, 1967, PROC R SOC SER B-BIO, V167, P23, DOI 10.1098/rspb.1967.0011; KUFFLER SW, 1984, NEURON BRAIN; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; Lewis E., 1968, DROSOPHILA INFO SERV, V43, P193; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; LLINAS R, 1981, BIOPHYS J, V33, P289, DOI 10.1016/S0006-3495(81)84898-9; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MATTEOLI M, 1988, P NATL ACAD SCI USA, V85, P7366, DOI 10.1073/pnas.85.19.7366; MILEDI R, 1973, PROC R SOC SER B-BIO, V183, P421, DOI 10.1098/rspb.1973.0026; MULKEY RM, 1991, NATURE, V350, P153, DOI 10.1038/350153a0; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; POPOV SV, 1993, CELL, V73, P1247, DOI 10.1016/0092-8674(93)90352-Q; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STERN M, 1989, J NEUROGENET, V5, P215, DOI 10.3109/01677068909066209; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOWER J, 1993, GENETICS, V133, P347; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; Walch-Solimena C, 1993, Curr Opin Neurobiol, V3, P329, DOI 10.1016/0959-4388(93)90125-I; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0	52	384	390	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					1125	1134		10.1016/0092-8674(93)90733-7	http://dx.doi.org/10.1016/0092-8674(93)90733-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8104705				2022-12-01	WOS:A1993LY49300018
J	FELDMAN, RD; BIERBRIER, GS				FELDMAN, RD; BIERBRIER, GS			INSULIN-MEDIATED VASODILATION - IMPAIRMENT WITH INCREASED BLOOD-PRESSURE AND BODY-MASS	LANCET			English	Article							LOW-SODIUM DIET; BETA-ADRENERGIC RESPONSE; ESSENTIAL-HYPERTENSION; SKELETAL-MUSCLE; RESISTANCE; CORRECTS; RESPONSIVENESS; PATHOGENESIS; DISORDERS; HUMANS	Insulin resistance is associated with hypertension although it is not known if this relationship is casual. Studies have shown that insulin increases skeletal-muscle blood flow despite also increasing sympathetic activity. To determine whether insulin may act as a direct vasodilator and whether insulin-mediated vascular effects are altered in hypertension, we studied insulin-mediated alterations in dorsal-hand-vein compliance in normotensive and mild and borderline hypertensive subjects. In phenylephrine pre-constricted vessels, insulin caused a dose-dependent increase in venous distensibility. Insulin-mediated venodilation was significantly impaired in hypertensive subjects. The vasodilator potency of insulin was significantly correlated with both blood pressure and body mass index. Insulin may be an endogenous vasodilator. Further, in hypertensive and obese subjects, impairment of insulin-mediated vasodilation may contribute to the increase in peripheral resistance characteristic of hypertension.	UNIV WESTERN ONTARIO,DEPT MED,LONDON N6A 3K7,ONTARIO,CANADA; UNIV WESTERN ONTARIO,DEPT PHARMACOL & TOXICOL,LONDON N6A 3K7,ONTARIO,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario)			Feldman, Ross/G-3293-2011					AELLIG WH, 1981, BRIT J CLIN PHARMACO, V11, P237, DOI 10.1111/j.1365-2125.1981.tb00527.x; ANDERSON EA, 1993, HYPERTENSION, V21, P136, DOI 10.1161/01.HYP.21.2.136; ANDERSON EA, 1992, HYPERTENSION, V19, P621, DOI 10.1161/01.HYP.19.6.621; ANDERSON EA, 1991, J CLIN INVEST, V87, P2246, DOI 10.1172/JCI115260; CAPALDO B, 1991, METABOLISM, V40, P1320, DOI 10.1016/0026-0495(91)90036-V; CREAGER MA, 1985, J PHARMACOL EXP THER, V235, P709; FELDMAN RD, 1992, CIRCULATION, V85, P612, DOI 10.1161/01.CIR.85.2.612; FELDMAN RD, 1987, J CLIN INVEST, V79, P290, DOI 10.1172/JCI112797; FELDMAN RD, 1990, J CLIN INVEST, V85, P647, DOI 10.1172/JCI114487; FERRANNINI E, 1991, AM HEART J, V121, P1274, DOI 10.1016/0002-8703(91)90433-I; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; KORNER PI, 1984, CLIN EXP HYPERTENS A, V6, P565, DOI 10.3109/10641968409062584; KUZYA H, 1977, DIABETES, V26, P22; LAAKSO M, 1990, J CLIN INVEST, V85, P1844, DOI 10.1172/JCI114644; LEE A, 1992, DIABETES, V41, P759; NASLUND T, 1990, CLIN PHARMACOL THER, V48, P87, DOI 10.1038/clpt.1990.121; NATALI A, 1991, HYPERTENSION, V17, P170, DOI 10.1161/01.HYP.17.2.170; PAN HYM, 1986, J PHARMACOL EXP THER, V239, P802; STROZZI C, 1979, GERONTOLOGY, V25, P24, DOI 10.1159/000212317; THORBURN AW, 1986, BRIT MED J, V292, P1697, DOI 10.1136/bmj.292.6537.1697; VANBRUMMELEN P, 1981, CLIN SCI, V60, P571, DOI 10.1042/cs0600571; WEBB RC, 1981, AM HEART J, V102, P251	22	133	133	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					707	709		10.1016/0140-6736(93)91708-T	http://dx.doi.org/10.1016/0140-6736(93)91708-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103822				2022-12-01	WOS:A1993LX46900009
J	MOERTEL, CG; FLEMING, TR; MACDONALD, JS; HALLER, DG; LAURIE, JA; TANGEN, C				MOERTEL, CG; FLEMING, TR; MACDONALD, JS; HALLER, DG; LAURIE, JA; TANGEN, C			AN EVALUATION OF THE CARCINOEMBRYONIC ANTIGEN (CEA) TEST FOR MONITORING PATIENTS WITH RESECTED COLON-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLORECTAL-CANCER; CARCINOMA; THERAPY	Objective.-To determine the effectiveness of carcinoembryonic antigen (CEA) monitoring in detecting surgically curable recurrence of colon cancer. Design.-Clinical data were collected from a national surgical adjuvant trial in which CEA monitoring was elective. Setting.-Cancer centers, universities, and community clinics. Patients.-A total of 1216 patients with resected colon cancer, 1017 (84%) of whom had CEA monitoring. Main Outcome Measures.-Sensitivity and specificity of CEA testing for cancer recurrence and CEA-motivated diagnostic and surgical interventions and their end results. Results.-Among 417 monitored patients with recurrence, 59% had a preceding elevation of CEA concentration. Sixteen percent of 600 patients without recurrence showed a false-positive test result. Carcinoembryonic antigen testing was most sensitive for hepatic or retroperitoneal metastasis and relatively insensitive for local, pulmonary, or peritoneal involvement. Surgical explorations were performed in 115 patients with CEA elevations, and 47 recurrences, usually hepatic, were resected with curative intent. On the other hand, 38 patients with normal CEA concentrations and 23 patients not monitored also underwent such resections-usually for pulmonary or local recurrence. Of all CEA-monitored patients, 2.3% are alive and disease free more than 1 year after salvage surgery (2.9% of those with CEA elevations and 1.9% of those with no elevations). Of patients with no CEA monitoring, 2.0% are also alive and disease free more than 1 year after salvage surgery. Conclusions.-Cancer cures attributable to CEA monitoring are, at best, infrequent. It is questionable whether this small gain justifies the substantial cost in dollars and physical and emotional stress that this intervention may cause for patients.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, PHILADELPHIA, PA 19140 USA; UNIV PENN, CTR CANC, PHILADELPHIA, PA 19104 USA; GRAND FORKS CLIN LTD, GRAND FORKS, ND USA	Fred Hutchinson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	MOERTEL, CG (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.				NCI NIH HHS [CA-21115, CA-25224, CA-37404] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA037404, U10CA025224, U10CA021115] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGUST DA, 1984, CANCER METAST REV, V3, P303, DOI 10.1007/BF00051457; Beatty J D, 1982, Prog Clin Cancer, V8, P9; BOEY J, 1984, WORLD J SURG, V8, P279, DOI 10.1007/BF01655052; DENTSMAN F, 1986, CANCER, V58, P2089; FLETCHER RH, 1986, ANN INTERN MED, V104, P66, DOI 10.7326/0003-4819-104-1-66; FUCINI C, 1983, TUMORI, V69, P359, DOI 10.1177/030089168306900415; GOLD P, 1965, J EXP MED, V121, P439, DOI 10.1084/jem.121.3.439; KOCH M, 1982, J NATL CANCER I, V69, P813; MARTIN EW, 1980, J SURG RES, V28, P389, DOI 10.1016/0022-4804(80)90100-6; MINTON JP, 1985, CANCER, V55, P1284, DOI 10.1002/1097-0142(19850315)55:6<1284::AID-CNCR2820550622>3.0.CO;2-B; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; NORTHOVER J, 1986, GUT, V27, P117, DOI 10.1136/gut.27.2.117; STEELE G, 1982, ANN SURG, V196, P162, DOI 10.1097/00000658-198208000-00008; WANEBO HJ, 1989, SURG GYNECOL OBSTET, V169, P479; WOLMARK N, 1984, ANN SURG, V199, P375, DOI 10.1097/00000658-198404000-00001; 1981, BMJ, V282, P373	16	403	415	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1993	270	8					943	947		10.1001/jama.270.8.943	http://dx.doi.org/10.1001/jama.270.8.943			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LT567	8141873				2022-12-01	WOS:A1993LT56700024
J	SCHLAGGAR, BL; FOX, K; OLEARY, DDM				SCHLAGGAR, BL; FOX, K; OLEARY, DDM			POSTSYNAPTIC CONTROL OF PLASTICITY IN DEVELOPING SOMATOSENSORY CORTEX	NATURE			English	Article							RECEPTOR ANTAGONISTS DISRUPT; STRIATE CORTEX; BLOCKADE PREVENTS; CORTICAL ACTIVITY; NMDA RECEPTORS; VISUAL-CORTEX; RAT; ACETYLCHOLINESTERASE; PERIOD; AXONS	THE rearrangement of synaptic connections during normal and deprived development is thought to be controlled by correlations in afferent impulse activity1. A favoured model is based on postsynaptic detection of synchronously active afferents; synapses are stabilized when pre- and postsynaptic activity is correlated and weakened or eliminated when their activity is uncorrelated2,3. Most evidence for this model comes from demonstrations that correlated afferent input is necessary for the segregation of eye-dominant inputs in the developing vertebrate visual system1,4,5 and that critical period plasticity of ocular dominance columns in cat visual cortex is disrupted by blockade of postsynaptic transmission6-8. We tested whether the developmental plasticity of somatosensory columns, known as 'barrels', in rodent primary somatosensory cortex (S1)9-13 is similar to that of ocular dominance columns. We report here that the selective disruption of postsynaptic activation in rat S1 by application of a glutamate receptor antagonist inhibits rearrangements in the somatotopic patterning of thalamocortical afferents induced by manipulations of the sensory periphery during the critical period. These findings show that postsynaptic activation has a prominent role in critical period plasticity in S1 cortex.	SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037; UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455	Salk Institute; University of Minnesota System; University of Minnesota Twin Cities			Fox, Kevin/E-8836-2010; Schlaggar, Bradley/AAZ-4153-2020	Fox, Kevin/0000-0002-2563-112X				AGMON A, 1992, J NEUROPHYSIOL, V68, P345, DOI 10.1152/jn.1992.68.1.345; BEAR MF, 1985, J COMP NEUROL, V234, P411, DOI 10.1002/cne.902340402; BEAR MF, 1990, J NEUROSCI, V10, P909; BELFORD GR, 1980, J COMP NEUROL, V193, P335, DOI 10.1002/cne.901930203; CHIAIA NL, 1992, DEV BRAIN RES, V66, P244, DOI 10.1016/0165-3806(92)90086-C; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CONSTAINTINEPAT.M, 1991, A REV NEUROSCI, V13, P129; ERZURUMLU RS, 1990, DEV BRAIN RES, V56, P229; FOX K, 1992, J NEUROSCI, V12, P1826; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HEBB DO, 1949, ORG BEHAVIOR; HENDERSON TA, 1992, DEV BRAIN RES, V66, P146, DOI 10.1016/0165-3806(92)90152-M; HONORE T, 1988, SCIENCE, V214, P1701; KILLACKEY HP, 1975, BRAIN RES, V86, P469, DOI 10.1016/0006-8993(75)90897-5; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; LEVAY S, 1980, J COMP NEUROL, V91, P1; MCCASLAND JS, 1992, P NATL ACAD SCI USA, V89, P1832, DOI 10.1073/pnas.89.5.1832; REITER HO, 1986, EXP BRAIN RES, V65, P182; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; ROBERTSON RT, 1987, NEUROSCI LETT, V75, P259, DOI 10.1016/0304-3940(87)90531-3; Schlaggar B L, 1993, Perspect Dev Neurobiol, V1, P81; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1029, DOI 10.1152/jn.1965.28.6.1029; WOOLSEY TA, 1976, J COMP NEUROL, V170, P53, DOI 10.1002/cne.901700105; WOOLSEY TA, 1970, BRAIN RES, V1, P205	30	279	280	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					623	626		10.1038/364623a0	http://dx.doi.org/10.1038/364623a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8102476				2022-12-01	WOS:A1993LR77100052
J	STODDARD, JJ; STPETER, RF; NEWACHECK, PW				STODDARD, JJ; STPETER, RF; NEWACHECK, PW			HEALTH-INSURANCE STATUS AND AMBULATORY CARE FOR CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							A STREPTOCOCCAL INFECTIONS; ACUTE RHEUMATIC-FEVER; UNITED-STATES; MEDICAL-CARE; OTITIS-MEDIA; ACCESS; SERVICES; DIAGNOSIS; LANGUAGE; DECADE	Background. Many children in the United States lack health insurance. We tested the hypothesis that these children are less likely than children with insurance to visit a physician when they have specific conditions for which care is considered to be indicated. Methods. We examined the association between whether children were covered by health insurance and whether they received medical attention from a physician for pharyngitis, acute earache, recurrent ear infections, or asthma. Data were obtained on the subsample of 7578 children and adolescents 1 through 17 years of age who were included in the 1987 National Medical Expenditures Survey, a national probability sample of the civilian, noninstitutionalized population. Results. Uninsured children were more likely than children with health insurance to receive no care from a physician for all four conditions (unadjusted odds ratios, 2.38 for pharyngitis; 2.04 for acute earache; 2.84 for recurrent ear infections; and 1.87 for asthma). Multiple logistic-regression analysis was subsequently used to control for age, sex, family size, race or ethnic group, region of the country, place of residence (rural vs. urban), and household income. After adjustment for these factors, uninsured children remained significantly more likely than insured children to go without a visit to a physician for pharyngitis (adjusted odds ratio, 1.72; 95 percent confidence interval, 1.11 to 2.68), acute earache (1..85; 95 percent confidence interval, 1.15 to 2.99), recurrent ear infections (2.12; 95 percent confidence interval, 1.28 to 3.51), and asthma (1.72; 95 percent confidence interval, 1.05 to 2.83). Conclusions. As compared with children with health insurance, children who lack health insurance are less likely to receive medical care from a physician when it seems reasonably indicated and are therefore at risk for substantial avoidable morbidity.	US DEPT HHS,OFF DIS PREVENT & HLTH PROMOT,WASHINGTON,DC; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	STODDARD, JJ (corresponding author), UNIV WISCONSIN,SCH MED,DEPT PEDIAT,DIV GEN PEDIAT & ADOLESCENT MED,H6-4 CLIN SCI CTR,MADISON,WI 53792, USA.							BAKER RB, 1992, PEDIATRICS, V90, P1006; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; BUTLER JA, 1985, PEDIATRICS, V76, P495; CUNNINGHAM PJ, 1990, HEALTH AFFAIR, V9, P76, DOI 10.1377/hlthaff.9.4.76; DAJANI AS, 1991, PEDIATR INFECT DIS J, V10, pS25, DOI 10.1097/00006454-199110001-00006; HARDY AM, 1991, DEP HLTH HUMAN SE 10, V180; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P434, DOI 10.2105/AJPH.81.4.434; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P838; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; KASPER JD, 1987, MED CARE, V25, P386, DOI 10.1097/00005650-198705000-00003; KLEIN JO, 1991, PEDIATR INFECT DIS J, V10, pS3, DOI 10.1097/00006454-199110001-00001; LEIBOWITZ A, 1985, PEDIATRICS, V75, P942; LEVEY LA, 1986, AM J PUBLIC HEALTH, V76, P1000, DOI 10.2105/AJPH.76.8.1000; Lohr K N, 1986, Med Care, V24, pS1; MYER CM, 1991, PEDIATR ANN, V20, P622, DOI 10.3928/0090-4481-19911101-10; NEWACHECK PW, 1986, PEDIATRICS, V78, P813; PARADISE JL, 1978, NEW ENGL J MED, V298, P409, DOI 10.1056/NEJM197802232980801; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549, DOI 10.1164/ajrccm/142.3.549; ROSENBACH ML, 1989, AM J PUBLIC HEALTH, V79, P1220, DOI 10.2105/AJPH.79.9.1220; SHAH BV, 1984, RTILOGIT PROCEDURE L; TEELE DW, 1990, J INFECT DIS, V162, P685, DOI 10.1093/infdis/162.3.685; WALLACE MR, 1989, JAMA-J AM MED ASSOC, V262, P2557, DOI 10.1001/jama.262.18.2557; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WOOD DL, 1990, PEDIATRICS, V86, P666; WRIGHT PF, 1991, PEDIATR ANN, V20, P617, DOI 10.3928/0090-4481-19911101-09; 1993, PRESIDENTS HLTH SECU; [No title captured]; 1991, PB91190165	29	134	134	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	1994	330	20					1421	1425		10.1056/NEJM199405193302006	http://dx.doi.org/10.1056/NEJM199405193302006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NK972	8159197				2022-12-01	WOS:A1994NK97200006
J	BUHL, EH; HALASY, K; SOMOGYI, P				BUHL, EH; HALASY, K; SOMOGYI, P			DIVERSE SOURCES OF HIPPOCAMPAL UNITARY INHIBITORY POSTSYNAPTIC POTENTIALS AND THE NUMBER OF SYNAPTIC RELEASE SITES	NATURE			English	Article							GUINEA-PIG HIPPOCAMPUS; CA1 PYRAMIDAL CELLS; GRANULE CELLS; DENTATE GYRUS; GABA-A; NEURONS; INTERNEURONS; SLICES; RAT; CONNECTIONS	Dual intracellular recordings from microscopically identified neurons in the hippocampus reveal that the synaptic terminals of three morphologically distinct types of interneuron act through GABA(A) receptors. Each type of interneuron forms up to 12 synaptic contacts with a postsynaptic principal neuron, but each interneuron innervates a different domain of the surface of the postsynaptic neuron. Different kinetics of the postsynaptic effects, together with the strategic placement of synapses, indicate that these GABAergic interneurons serve distinct functions in the cortical network.	ATTILA JOZSEF UNIV,DEPT ZOOL,H-6701 SZEGED,HUNGARY	Szeged University	BUHL, EH (corresponding author), UNIV OXFORD,MRC,ANAT NEUROPHARMACOL UNIT,MANSFIELD RD,OXFORD OX1 3TH,OXON,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALGER BE, 1979, NATURE, V281, P315, DOI 10.1038/281315a0; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P608, DOI 10.1152/jn.1964.27.4.608; ANDERSEN P, 1963, NATURE, V198, P540, DOI 10.1038/198540a0; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P592, DOI 10.1152/jn.1964.27.4.592; BUHL EH, IN PRESS J NEUROPHYS; CADDICK SJ, IN PRESS J PHYSL LON; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DAVIES CH, 1993, NEUROPHARMACOLOGY, V32, P1071, DOI 10.1016/0028-3908(93)90073-C; de No RL, 1934, J PSYCHOL NEUROL, V46, P113; Douglas RJ, 1990, NEURAL COMPUT, V2, P283, DOI 10.1162/neco.1990.2.3.283; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FROESTL W, 1992, PHARM COMMUN, V2, P52; GULYAS AI, 1993, EUR J NEUROSCI, V5, P1729, DOI 10.1111/j.1460-9568.1993.tb00240.x; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; HALASY K, 1993, EUR J NEUROSCI, V5, P411, DOI 10.1111/j.1460-9568.1993.tb00508.x; HAN ZS, 1993, EUR J NEUROSCI, V5, P395, DOI 10.1111/j.1460-9568.1993.tb00507.x; HODGSON AJ, 1985, J HISTOCHEM CYTOCHEM, V33, P229, DOI 10.1177/33.3.3973378; KANDEL ER, 1961, J NEUROPHYSIOL, V24, P225, DOI 10.1152/jn.1961.24.3.225; KAWAGUCHI Y, 1988, EXP BRAIN RES, V72, P494; KNOWLES WD, 1981, J NEUROSCI, V1, P318; LACAILLE JC, 1988, J NEUROSCI, V8, P1411; LACAILLE JC, 1987, J NEUROSCI, V7, P1979; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MILES R, 1984, J PHYSIOL-LONDON, V356, P97, DOI 10.1113/jphysiol.1984.sp015455; MILES R, 1990, J PHYSIOL-LONDON, V431, P659, DOI 10.1113/jphysiol.1990.sp018353; MILES R, 1987, J PHYSIOL-LONDON, V388, P611, DOI 10.1113/jphysiol.1987.sp016634; MILES R, 1986, J PHYSIOL-LONDON, V373, P397, DOI 10.1113/jphysiol.1986.sp016055; MISGELD U, 1986, SCIENCE, V232, P1413, DOI 10.1126/science.2424084; MULLER W, 1990, J NEUROPHYSIOL, V64, P46, DOI 10.1152/jn.1990.64.1.46; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; OTIS TS, 1993, J PHYSIOL-LONDON, V463, P391, DOI 10.1113/jphysiol.1993.sp019600; OTIS TS, 1992, J NEUROPHYSIOL, V67, P227, DOI 10.1152/jn.1992.67.1.227; PEARCE RA, 1993, NEURON, V10, P189, DOI 10.1016/0896-6273(93)90310-N; RIBAK CE, 1978, BRAIN RES, V140, P315, DOI 10.1016/0006-8993(78)90463-8; SCHARFMAN HE, 1990, NEUROSCIENCE, V37, P693, DOI 10.1016/0306-4522(90)90100-I; SEGAL M, 1990, BRAIN RES, V511, P163, DOI 10.1016/0006-8993(90)90236-5; SOLTESZ I, 1993, NEUROSCIENCE, V57, P555, DOI 10.1016/0306-4522(93)90005-Z; SOMOGYI P, 1983, BRAIN RES, V259, P137, DOI 10.1016/0006-8993(83)91076-4; SOMOGYI P, 1982, NEUROSCIENCE, V7, P2577, DOI 10.1016/0306-4522(82)90086-0; SOMOGYI P, 1985, BRAIN RES, V332, P143, DOI 10.1016/0006-8993(85)90397-X; STALEY KJ, 1992, J NEUROPHYSIOL, V68, P197, DOI 10.1152/jn.1992.68.1.197; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; Szentagothai J, 1974, Neurosci Res Program Bull, V12, P305; THOMSON AM, 1991, EUR J NEUROSCI, V3, P587, DOI 10.1111/j.1460-9568.1991.tb00845.x; VU ET, 1992, SCIENCE, V255, P1710, DOI 10.1126/science.1553559	45	611	613	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					823	828		10.1038/368823a0	http://dx.doi.org/10.1038/368823a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	8159242				2022-12-01	WOS:A1994NH71700061
J	TOMASZ, A				TOMASZ, A			MULTIPLE-ANTIBIOTIC-RESISTANT PATHOGENIC BACTERIA - A REPORT ON THE ROCKEFELLER-UNIVERSITY WORKSHOP	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							STREPTOCOCCUS-PNEUMONIAE; METHICILLIN-RESISTANT; PENICILLIN-RESISTANT; STAPHYLOCOCCUS-AUREUS; PNEUMOCOCCI; MENINGITIS; ENTEROCOCCUS; INFECTIONS; MORTALITY; FAILURE				TOMASZ, A (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.			Tomasz, Alexander/0000-0003-1520-1983				AUSTRIAN R, 1981, REV INFECT DIS, V3, pS1; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRADLEY JS, 1991, PEDIATR INFECT DIS J, V10, P871; CASSELL GH, 1994, ASM NEWS, V60, P90; COL NF, 1987, REV INFECT DIS, V9, pS232; COLEMAN DC, 1992, METHICILLIN RESISTAN, P37; DUPONT HL, 1987, REV INFECT DIS, V9, P447; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; FRIEDLAND IR, 1991, PEDIATR INFECT DIS J, V10, P705, DOI 10.1097/00006454-199109000-00018; HANDWERGER S, 1993, CLIN INFECT DIS, V16, P750, DOI 10.1093/clind/16.6.750; HANSMAN D, 1974, MED J AUSTRALIA, V2, P353, DOI 10.5694/j.1326-5377.1974.tb70836.x; HERSHOW RC, 1992, INFECT CONT HOSP EP, V13, P587, DOI 10.2307/30148461; JABES D, 1989, J INFECT DIS, V159, P16, DOI 10.1093/infdis/159.1.16; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; KARANFIL LV, 1992, INFECT CONT HOSP EP, V13, P195, DOI 10.1086/646509; KRISTINSSON KG, 1992, LANCET, V339, P1606, DOI 10.1016/0140-6736(92)91868-9; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; Lederberg J., 1992, EMERGING INFECT MICR; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; MCGOWAN JE, 1991, REV MED MICROBIOL, V2, P161; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; MUNOZ R, 1992, CLIN INFECT DIS, V15, P112, DOI 10.1093/clinids/15.1.112; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; PHELPS CE, 1989, MED CARE, V27, P194, DOI 10.1097/00005650-198902000-00009; Shlaes D, 1991, ASM NEWS, V57, P455; SLOAS MM, 1992, PEDIATR INFECT DIS J, V11, P662; SOARES S, 1993, J INFECT DIS, V168, P158, DOI 10.1093/infdis/168.1.158; TENOVER FC, 1991, AM J MED, V91, pS76, DOI 10.1016/0002-9343(91)90347-Z; URBAN C, 1993, J INFECT DIS, V167, P448, DOI 10.1093/infdis/167.2.448; WENZEL RP, 1988, INT J EPIDEMIOL, V17, P225, DOI 10.1093/ije/17.1.225; WENZEL RP, 1991, AM J MED, V91, pS221, DOI 10.1016/0002-9343(91)90372-5; 1992, SCIENCE, V257, P1016; 1992, MMWR MORB MORTAL WKL, V41, P783; 1993, US NEWS WORLD R 0719, P16	35	354	360	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 28	1994	330	17					1247	1251		10.1056/NEJM199404283301725	http://dx.doi.org/10.1056/NEJM199404283301725			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG586	8139650				2022-12-01	WOS:A1994NG58600036
J	CRONAN, JJ				CRONAN, JJ			OPERATIVE CHOLANGIOGRAPHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											CRONAN, JJ (corresponding author), BROWN UNIV,RHODE ISL HOSP,SCH MED,PROVIDENCE,RI 02903, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1210	1210		10.1001/jama.1994.03510390082037	http://dx.doi.org/10.1001/jama.1994.03510390082037			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	8151881				2022-12-01	WOS:A1994NF20700034
J	FLORIN, EL; MOY, VT; GAUB, HE				FLORIN, EL; MOY, VT; GAUB, HE			ADHESION FORCES BETWEEN INDIVIDUAL LIGAND-RECEPTOR PAIRS	SCIENCE			English	Article							MICROSCOPE; CELLS; MOLECULES; CRYSTALS	The adhesion force between the tip of an atomic force microscope cantilever derivatized with avidin and agarose beads functionalized with biotin, desthiobiotin, or iminobiotin was measured. Under conditions that allowed only a limited number of molecular pairs to interact, the force required to separate tip and bead was found to be quantized in integer multiples of 160 +/- 20 piconewtons for biotin and 85 +/- 15 piconewtons for iminobiotin. The measured force quanta are interpreted as the unbinding forces of individual molecular pairs.	TECH UNIV MUNICH,DEPT PHYS,D-85748 GARCHING,GERMANY	Technical University of Munich								ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; DARST SA, 1991, BIOPHYS J, V59, P387, DOI 10.1016/S0006-3495(91)82232-9; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; EGGER M, 1992, BIOCHIM BIOPHYS ACTA, V1104, P45, DOI 10.1016/0005-2736(92)90130-E; EVANS E, 1991, BIOPHYS J, V59, P838, DOI 10.1016/S0006-3495(91)82296-2; EVANS EH, IN PRESS; FLORIN EL, 1994, REV SCI INSTRUM, V65, P639, DOI 10.1063/1.1145130; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HELM CA, 1991, P NATL ACAD SCI USA, V88, P8169, DOI 10.1073/pnas.88.18.8169; Israelachvili J., 1992, INTERMOLECULAR SURFA; KARRASCH S, 1993, BIOPHYS J, V65, P2437, DOI 10.1016/S0006-3495(93)81327-4; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; MARCHAND P, 1983, REV SCI INSTRUM, V54, P1034, DOI 10.1063/1.1137498; MOY VT, UNPUB; PETHICA JB, 1987, PHYS SCRIPTA, VT19A, P61, DOI 10.1088/0031-8949/1987/T19A/010; Pierce M., UNPUB; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161	24	1662	1717	9	287	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					415	417		10.1126/science.8153628	http://dx.doi.org/10.1126/science.8153628			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153628				2022-12-01	WOS:A1994NG19400037
J	STORM, EE; HUYNH, TV; COPELAND, NG; JENKINS, NA; KINGSLEY, DM; LEE, SJ				STORM, EE; HUYNH, TV; COPELAND, NG; JENKINS, NA; KINGSLEY, DM; LEE, SJ			LIMB ALTERATIONS IN BRACHYPODISM MICE DUE TO MUTATIONS IN A NEW MEMBER OF THE TGF-BETA-SUPERFAMILY	NATURE			English	Article							MOUSE; BONE; MORPHOGENESIS; PROTEIN; LINKAGE; FAMILY; LOCUS	THE mutation brachypodism (bp) alters the length and number of bones in the limbs of mice but spares the axial skeleton1,2. It illustrates the importance of specific genes in controlling the morphogenesis of individual skeletal elements in the tetrapod limb3,4. We now report the isolation of three new members of the transforming growth factor-beta (TGF-beta) superfamily5 (growth/differentiation factors (GDF) 5, 6 and 7) and show by mapping, expression patterns and sequencing that mutations in Gdf5 are responsible for skeletal alterations in bp mice. GDF5 and the closely related GDF6 and GDF7 define a new subgroup of factors related to known bone- and cartilage-inducing molecules, the bone morphogenetic proteins (BMPs)6. Studies of Bmp5 mutations in short ear mice have shown that at least one other BMP gene is also required for normal skeletal development7. The highly specific skeletal alterations in bp and short ear mice suggest that different members of the BMP family control the formation of different morphological features in the mammalian skeleton.	STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,BECKMAN CTR B300,STANFORD,CA 94305; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Stanford University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								AHMAD M, 1990, AM J MED GENET, V36, P292, DOI 10.1002/ajmg.1320360309; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DICKINSON ME, 1990, GENOMICS, V6, P505, DOI 10.1016/0888-7543(90)90480-I; ELMER WA, 1975, J EMBRYOL EXP MORPH, V33, P371; GREEN MARGARET C., 1952, OHIO JOUR SCI, V52, P31; GRUNEBERG H, 1973, J EMBRYOL EXP MORPH, V30, P119; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; JONES CM, 1991, DEVELOPMENT, V111, P531; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; LANDAUER W, 1952, J HERED, V43, P293, DOI 10.1093/oxfordjournals.jhered.a106335; LANE PW, 1993, LIST MUTATIONS MUTAN; MALININA N A, 1984, Ontogenez, V15, P514; Massague J., 1990, REV CELL BIOL, V6, P597; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; OSEBOLD WR, 1985, AM J MED GENET, V22, P791, DOI 10.1002/ajmg.1320220414; OWENS EM, 1982, DEV BIOL, V91, P376, DOI 10.1016/0012-1606(82)90043-4; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; SIRACUSA LD, 1989, GENETICS, V122, P669; SIRACUSA LD, 1990, GENOMICS, V6, P491, DOI 10.1016/0888-7543(90)90479-E; SIRACUSA LD, 1993, MAMM GENOME, V4, pS31, DOI 10.1007/BF00360828; TEMTAMY SA, 1978, GENETICS HAND MALFOR, P1; [No title captured]	26	722	767	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					639	643		10.1038/368639a0	http://dx.doi.org/10.1038/368639a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145850				2022-12-01	WOS:A1994NF39200062
J	WACKETT, LP; SADOWSKY, MJ; NEWMAN, LM; HUR, HG; LI, SY				WACKETT, LP; SADOWSKY, MJ; NEWMAN, LM; HUR, HG; LI, SY			METABOLISM OF POLYHALOGENATED COMPOUNDS BY A GENETICALLY-ENGINEERED BACTERIUM	NATURE			English	Article							TOLUENE DIOXYGENASE; TRICHLOROETHYLENE; OXIDATION; BIOSYNTHESIS; DEGRADATION; PSEUDOMONAS	THE decomposition of organic compounds by bacteria has been studied for almost a century1, during which time selective enrichment culture has generated microoganisms capable of metabolizing thousands of organic compounds. But attempts to obtain pure cultures of bacteria that can metabolize highly halogenated compounds2, a large and important class of pollutants 3,4, have been largely unsuccessful. Polyhalogenated compounds are most frequently metabolized by anaerobic bacteria as a result of reductive dehalogenation reactions5, the products of which are typically substrates for bacterial oxygenases6. Complete metabolism of polyhalogenated compounds therefore necessitates the sequential use of anaerobic and aerobic bacteria7. Here we combine seven genes encoding two multi-component oxygenases in a single strain of Pseudomonas which as a result metabolizes polyhalogenated compounds by means of sequential reductive and oxidative reactions to yield non-toxic products. Cytochrome P450(cam) monooxygenase reduces polyhalogenated compounds8, which are bound at the camphor-binding site9,10, under subatmospheric oxygen tensions9. We find that these reduction products are oxidizable substrates for toluene dioxygenase. Perhalogenated chlorofluorocarbons also act as substrates for the genetically engineered strain.	UNIV MINNESOTA,DEPT MICROBIOL,ST PAUL,MN 55108; UNIV MINNESOTA,GORTNER LAB,INST ADV STUDIES BIOL PROC TECHNOL,ST PAUL,MN 55108; UNIV MINNESOTA,DEPT SOIL SCI,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	WACKETT, LP (corresponding author), UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108, USA.		Sadowsky, Michael/J-2507-2016	Sadowsky, Michael/0000-0001-8779-2781				ABRAMOWICZ DA, 1990, CRIT REV BIOTECHNOL, V10, P241, DOI 10.3109/07388559009038210; Anders M. W., 1985, BIOACTIVATION FOREIG, P284; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BAGDASARIAN M, 1981, GENE, V16, P237, DOI 10.1016/0378-1119(81)90080-9; BAGDASARIAN MM, 1983, GENE, V26, P273, DOI 10.1016/0378-1119(83)90197-X; BRADSHAW WH, 1959, J AM CHEM SOC, V81, P5507, DOI 10.1021/ja01529a060; CASTRO CE, 1985, BIOCHEMISTRY-US, V24, P204, DOI 10.1021/bi00322a029; ENSLEY BD, 1983, SCIENCE, V222, P167, DOI 10.1126/science.6353574; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; GIBSON DT, 1990, PSEUDOMONAS : BIOTRANSFORMATIONS, PATHOGENESIS, AND EVOLVING BIOTECHNOLOGY, P121; LEONG SA, 1982, J BIOL CHEM, V257, P8724; LI SY, 1993, BIOCHEMISTRY-US, V32, P9355, DOI 10.1021/bi00087a014; LI SY, 1992, BIOCHEM BIOPH RES CO, V185, P443, DOI 10.1016/S0006-291X(05)81005-8; Logan Michael S. P., 1993, Biodegradation, V4, P39, DOI 10.1007/BF00701453; ORNSTEIN RL, 1991, P HAZMACON, P470; PAULSEN MD, 1993, PROTEIN SCI, V2, P357; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; QUENSEN JF, 1988, SCIENCE, V242, P752, DOI 10.1126/science.242.4879.752; REINEKE W, 1984, MICROBIAL DEGRADATIO, P319; Stanier R., 1976, MICROBIAL WORLD; Wackett Lawrence P., 1992, Biodegradation, V3, P19, DOI 10.1007/BF00189633; WACKETT LP, 1989, APPL ENVIRON MICROB, V55, P2960, DOI 10.1128/AEM.55.11.2960-2964.1989; WACKETT LP, 1988, APPL ENVIRON MICROB, V54, P1703, DOI 10.1128/AEM.54.7.1703-1708.1988; Zylstra G J, 1991, Genet Eng (N Y), V13, P183	24	69	80	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					627	629		10.1038/368627a0	http://dx.doi.org/10.1038/368627a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145847				2022-12-01	WOS:A1994NF39200058
J	TABONY, J				TABONY, J			MORPHOLOGICAL BIFURCATIONS INVOLVING REACTION-DIFFUSION PROCESSES DURING MICROTUBULE FORMATION	SCIENCE			English	Article							ORGANIZATION; PATTERN; MODELS	Nonlinear chemically dissipative mechanisms have been proposed as providing a possible underlying process for some aspects of biological self-organization, pattern formation, and morphogenesis. Nonlinearities during the formation of microtubular solutions result in a chemical instability and bifurcation between pathways leading to macroscopically self-organized states of different morphology. The self-organizing process, which contains reactive and diffusive contributions, involves chemical waves and differences in microtubule concentration in the sample. Patterns of similar appearance are observed at different distance scales. This behavior is in agreement with theories of chemically dissipative systems.			TABONY, J (corresponding author), CEN,DEPT BIOL MOLEC & STRUCT,RESONANCE MAGNET BIOL & MED LAB,85X,F-38041 GRENOBLE,FRANCE.							ABRTAHAM R, 1988, DYNAMICS 4; Alberts B., 2012, MOL BIOL CELL CLASSI; BABYLOYANTZ A, 1986, DYNAMICS LIFE; BUXBAUM RE, 1987, SCIENCE, V235, P1511, DOI 10.1126/science.2881354; CASTETS V, 1990, PHYS REV LETT, V64, P2953, DOI 10.1103/PhysRevLett.64.2953; DETRICH HW, 1985, J BIOL CHEM, V260, P9479; GRAY P, 1990, CHEM OSCILLATIONS IN, pCH10; HALL SS, 1992, SCIENCE, V257, P344, DOI 10.1126/science.1631556; HARRISON LG, 1987, J THEOR BIOL, V125, P369, DOI 10.1016/S0022-5193(87)80208-4; HITT AL, 1990, J BIOL CHEM, V265, P1639; IBEL K, 1976, J APPL CRYSTALLOGR, V9, P296, DOI 10.1107/S0021889876011394; JACROT B, 1976, REP PROG PHYS, V39, P911, DOI 10.1088/0034-4885/39/10/001; JOB D, 1985, J CELL BIOL, V101, P1680, DOI 10.1083/jcb.101.5.1680; JOHNSON K, 1977, J MOL BIOL, V117, P31; MACNEAL RK, 1977, BIOCHEM BIOPH RES CO, V74, P440, DOI 10.1016/0006-291X(77)90323-0; MANDELKOW E, 1989, SCIENCE, V246, P1291, DOI 10.1126/science.2588005; MANDELKOW EM, 1980, NATURE, V287, P595, DOI 10.1038/287595a0; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MURRAY JD, 1984, J MATH BIOL, V19, P265, DOI 10.1007/BF00277099; Nicolis G., 1977, SELF ORG NONEQUILIBR; Nicolis G., 1989, EXPLORING COMPLEXITY; PATZELT W, 1974, POLARISING MICROSCOP; PEACOCKE AR, 1983, PHYSICAL CHEM BIOL O; PURICH DL, 1984, ADV PROTEIN CHEM, V36, P133, DOI 10.1016/S0065-3233(08)60297-1; ROBERT C, 1990, BIOL CELL, V68, P177, DOI 10.1016/0248-4900(90)90306-N; SOMERS M, 1990, EUR BIOPHYS J, V18, P239, DOI 10.1007/BF00183377; TABONY J, 1990, NATURE, V346, P448, DOI 10.1038/346448a0; TABONY J, 1992, P NATL ACAD SCI USA, V89, P6948, DOI 10.1073/pnas.89.15.6948; Tabony J, 1992, NANOBIOLOGY, V1, P131; Thompson J.M.T., 1982, INSTABILITIES CATAST; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012	32	84	85	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 8	1994	264	5156					245	248		10.1126/science.8146654	http://dx.doi.org/10.1126/science.8146654			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE410	8146654				2022-12-01	WOS:A1994NE41000032
J	RIDDIHOUGH, G				RIDDIHOUGH, G			SHAPE-SHIFTING SERPINS	NATURE			English	Editorial Material																		Bode W, 1991, CURR OPIN STRUC BIOL, V1, P45, DOI 10.1016/0959-440X(91)90010-Q; CARELL RW, 1992, CURR OPIN STRUCT BIO, V2, P438; CARRELL RW, IN PRESS STRUCTURE; Engh R A, 1993, Behring Inst Mitt, P41; FLETTERICK RJ, 1994, NAT STRUCT BIOL, V1, P201, DOI 10.1038/nsb0494-201; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; WEI A, 1994, NAT STRUCT BIOL, V1, P250	7	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					570	570		10.1038/368570a0	http://dx.doi.org/10.1038/368570a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	8139695	Bronze			2022-12-01	WOS:A1994NE33500063
J	LANG, CA; RANSOHOFF, DF				LANG, CA; RANSOHOFF, DF			FECAL OCCULT BLOOD SCREENING FOR COLORECTAL-CANCER - IS MORTALITY REDUCED BY CHANCE SELECTION FOR SCREENING COLONOSCOPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED TRIAL; SIGMOIDOSCOPY	Annual fecal occult blood test (FOBT) screening using rehydrated Hemoccult slides has been reported in the Minnesota Colon Cancer Control Study to reduce colorectal cancer mortality by about 33%. However, some of the benefit of FOBT screening may come from ''chance'' selection of persons for colonoscopic examination because of the high positivity rate of FOBT (about 1 0%) that may occur for reasons other than a bleeding cancer or polyp. To determine how much this mechanism could account for the benefit of FOBT screening, we used a simple mathematical model to simulate the course of a cohort of screened persons, incorporating published data including those f rom the Minnesota study. The results suggest that one third to one half of the mortality reduction observed from FOBT screening in the Minnesota study may be attributable to chance selection for colonoscopy. We conclude that annual FOBT screening with rehydration is a haphazard method for selecting persons for colonoscopy.	UNIV N CAROLINA, CB 7105, 5034 OLD CLIN BLDG, CHAPEL HILL, NC 27599 USA; UNIV COLORADO, COLORADO PERMANENTE MED GRP, DENVER, CO 80202 USA; UNIV COLORADO, DEPT MED, DENVER, CO 80202 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; BOLAND CR, 1993, MAY AM GASTR ASS M B; CLAYMAN CB, 1989, JAMA-J AM MED ASSOC, V261, P609, DOI 10.1001/jama.261.4.609; HARDCASTLE JD, 1989, LANCET, V1, P1160; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; KNIGHT KK, 1989, JAMA-J AM MED ASSOC, V261, P587; KRONBORG O, 1987, SCAND J GASTROENTERO, V22, P677, DOI 10.3109/00365528709011142; LEVIN B, 1992, CA-CANCER J CLIN, V42, P296, DOI 10.3322/canjclin.42.5.296; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MILLER BA, 1992, 922789 NAT I HLTH PU; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; RANSOHOFF DF, 1993, JAMA-J AM MED ASSOC, V269, P1278, DOI 10.1001/jama.269.10.1278; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SMART CR, 1990, MAYO CLIN PROC, V65, P892, DOI 10.1016/S0025-6196(12)62581-6; WINAWER SJ, 1993, J NATL CANCER I, V85, P1311, DOI 10.1093/jnci/85.16.1311; WINAWER SJ, 1993, NEW ENGL J MED, V328, P1416, DOI 10.1056/NEJM199305133281909; 1993, NY TIMES        0521, pA26; 1989, SUMMARY CURRENT GUID; 1992, VITAL STATISTICS US, V11; 1990, SCREENING COLORECTAL; 1987, WORKING GUIDELINES E	24	122	125	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	1994	271	13					1011	1013		10.1001/jama.271.13.1011	http://dx.doi.org/10.1001/jama.271.13.1011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND949	8139058				2022-12-01	WOS:A1994ND94900031
J	MOHER, M; MOHER, D; HAVELOCK, P				MOHER, M; MOHER, D; HAVELOCK, P			SURVEY OF WHETHER GENERAL-PRACTITIONERS CARRY ASPIRIN IN THEIR DOCTORS BAG	BMJ-BRITISH MEDICAL JOURNAL			English	Article									LOEB MED RES INST, CLIN EPIDEMIOL UNIT, OTTAWA K1Y 4E9, ON, CANADA; POUND HOUSE SURG, WOOBURN GREEN HP10 0EE, BUCKS, ENGLAND	University of Ottawa; Ottawa Hospital Research Institute	MOHER, M (corresponding author), SOUTHMEAD SURG, FARNHAM SL2 3ER, BUCKS, ENGLAND.			Moher, David/0000-0003-2434-4206				[Anonymous], 1988, LANCET, V2, P349; DEAN AG, 1990, EPIINFO VERSION 5 WO; JULIAN DG, 1989, BMJ-BRIT MED J, V299, P555; MOHER M, 1994, BMJ-BRIT MED J, V308, P760, DOI 10.1136/bmj.308.6931.760	4	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	1994	308	6931					761	762		10.1136/bmj.308.6931.761	http://dx.doi.org/10.1136/bmj.308.6931.761			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142832	Green Published			2022-12-01	WOS:A1994NC34800022
J	ARONSON, BD; JOHNSON, KA; LOROS, JJ; DUNLAP, JC				ARONSON, BD; JOHNSON, KA; LOROS, JJ; DUNLAP, JC			NEGATIVE FEEDBACK DEFINING A CIRCADIAN CLOCK - AUTOREGULATION OF THE CLOCK GENE-FREQUENCY	SCIENCE			English	Article							MESSENGER-RNA LEVELS; NEUROSPORA-CRASSA; PERIOD GENE; PROTEIN-SYNTHESIS; DROSOPHILA-MELANOGASTER; VISUAL-SYSTEM; PHASE; RHYTHMS; PRODUCT; TRANSCRIPTION	The frequency(frq) locus of Neurospora crassa was originally identified in searches for loci encoding components of the circadian clock. The frq gene is now shown to encode a central component in a molecular feedback loop in which the product of frq negatively regulated its own transcript, which resulted in a daily oscillation in the amount of frq transcript. Rhythmic messenger RNA expression was essential for overt rhythmicity in the organism and no amount of constitutive expression rescued normal rhythmicity in frq loss-of-function mutants. Step reductions in the amount of FRQ-encoding transcript set the clock to a specific and predicted phase. These results establish frq as encoding a central component in a circadian oscillator.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Dartmouth College; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Rice University			Loros, Jennifer/B-6293-2014; Dunlap, Jay/L-6232-2013	Dunlap, Jay/0000-0003-1577-0457; Johnson, Keith/0000-0001-6404-4780	NIGMS NIH HHS [GM14465, GM 34985] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014465, R37GM034985, R01GM034985] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON BD, 1994, IN PRESS P NATL ACAD; ARONSON BD, IN PRESS MOL GEN GEN; ARPAIA G, 1993, PLANT PHYSIOL, V102, P1299, DOI 10.1104/pp.102.4.1299; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BELLPEDERSEN D, 1992, GENE DEV, V6, P2382, DOI 10.1101/gad.6.12a.2382; BELLPEDERSEN D, UNPUB; CHADWICK DJ, IN PRESS CIBA F S, V183; CHALEFF RS, 1974, J GEN MICROBIOL, V81, P357, DOI 10.1099/00221287-81-2-357; CHARY P, 1990, J BIOL CHEM, V265, P18961; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; DHARMANANDA S, 1979, PLANT PHYSIOL, V63, P1049, DOI 10.1104/pp.63.6.1049; DUNLAP JC, 1988, P NATL ACAD SCI USA, V85, P1096, DOI 10.1073/pnas.85.4.1096; DUNLAP JC, 1980, J COMP PHYSIOL, V138, P1, DOI 10.1007/BF00688728; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; DUNLAP JC, 1990, TRENDS GENET, V6, P159, DOI 10.1016/0168-9525(90)90151-U; DUNLAP JL, UNPUB; EBBOLE D, 1990, FUNGAL GENET NEWSL, V37, P15; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; EDERY I, IN PRESS P NAT ACAD; Edmunds L.N., 1988, CELLULAR MOL BASES B; EWER J, 1988, NATURE, V333, P82, DOI 10.1038/333082a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FELDMAN J F, 1973, Genetics, V75, P605; FRISCH B, 1994, IN PRESS NEURON; GILES NH, 1985, MICROBIOL REV, V49, P338, DOI 10.1128/MMBR.49.3.338-358.1985; Goodwin B., 1963, TEMPORAL ORG CELLS; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HASTINGS JW, 1959, ANNU REV MICROBIOL, V13, P297, DOI 10.1146/annurev.mi.13.100159.001501; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JACKLET JW, 1977, SCIENCE, V198, P69, DOI 10.1126/science.897685; KHALSA SBS, 1992, P NATL ACAD SCI USA, V89, P10862, DOI 10.1073/pnas.89.22.10862; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LAKINTHOMAS PL, 1990, CRIT REV MICROBIOL, V17, P365, DOI 10.3109/10408419009114762; LAUTER FR, 1992, GENE DEV, V6, P2373, DOI 10.1101/gad.6.12a.2373; LAUTER FR, 1993, P NATL ACAD SCI USA, V90, P8249, DOI 10.1073/pnas.90.17.8249; LINDGREN K, UNPUB; LIU X, 1991, NEURON, V6, P753, DOI 10.1016/0896-6273(91)90172-V; Loros J J, 1986, J Biol Rhythms, V1, P187, DOI 10.1177/074873048600100302; LOROS JJ, 1986, GENETICS, V114, P1095; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; LOROS JJ, 1991, MOL CELL BIOL, V11, P558, DOI 10.1128/MCB.11.1.558; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; MERROW M, IN PRESS EMBO J; MICHEL S, 1993, SCIENCE, V259, P239, DOI 10.1126/science.8421785; MILLAR AJ, 1991, PLANT CELL, V3, P541, DOI 10.1105/tpc.3.5.541; Moore-Ede MC., 1982, CLOCKS TIME US; NAKASHIMA H, 1981, AM J PHYSIOL, V241, pR31, DOI 10.1152/ajpregu.1981.241.1.R31; NAKASHIMA H, 1981, PLANT CELL PHYSIOL, V22, P231; PAVLIDIS T, 1969, ARCH BIOCHEM BIOPHYS, V132, P338, DOI 10.1016/0003-9861(69)90371-3; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; SMITH RF, 1982, MOL GEN GENET, V185, P30, DOI 10.1007/BF00333786; TAKAHASHI JS, 1993, CURR OPIN GENET DEV, V3, P301, DOI 10.1016/0959-437X(93)90038-Q; TYSON J, 1976, MOL BASIS CIRCADIAN, P85; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4869, DOI 10.1073/pnas.83.13.4869; YEUNG SJ, 1988, J BIOL RHYTHM, V3, P225, DOI 10.1177/074873048800300301; ZATZ M, 1992, DISCUSS NEUROSCI, V8, P67; ZERR DM, 1990, J NEUROSCI, V10, P2749	58	504	513	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 18	1994	263	5153					1578	1584		10.1126/science.8128244	http://dx.doi.org/10.1126/science.8128244			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128244				2022-12-01	WOS:A1994NB67300021
J	GREF, R; MINAMITAKE, Y; PERACCHIA, MT; TRUBETSKOY, V; TORCHILIN, V; LANGER, R				GREF, R; MINAMITAKE, Y; PERACCHIA, MT; TRUBETSKOY, V; TORCHILIN, V; LANGER, R			BIODEGRADABLE LONG-CIRCULATING POLYMERIC NANOSPHERES	SCIENCE			English	Article							PARTICLES; LIPOSOMES	Injectable nanoparticulate carriers have important potential applications such as site-specific drug delivery or medical imaging. Conventional carriers, however, cannot generally be used because they are eliminated by the reticulo-endothelial system within seconds or minutes after intravenous injection. To address these limitations, monodisperse biodegradable nanospheres were developed from amphiphilic copolymers composed of two biocompatible blocks. The nanospheres exhibited dramatically increased blood circulation times and reduced liver accumulation in mice. Furthermore, they entrapped up to 45 percent by weight of the drug in the dense core in a one-step procedure and could be freeze-dried and easily redispersed without additives in aqueous solutions.	MIT,HARVARD MIT DIV HLTH SCI,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; MASSACHUSETTS GEN HOSP E,DEPT RADIOL,BOSTON,MA 02129; MIT,WHITAKER COLL HLTH SCI,CAMBRIDGE,MA 02139; CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115	Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital			Gref, Ruxandra/F-1487-2011	Gref, Ruxandra/0000-0002-7869-0908	NATIONAL CANCER INSTITUTE [U01CA052857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026698] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA52857] Funding Source: Medline; NIGMS NIH HHS [GM 26698] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1068, P133, DOI 10.1016/0005-2736(91)90201-I; BAZILE D, 1993, YANUZAIGAKU, V53, P10; BECK LR, 1986, ADV CONTRACEP DELIVE, V1, P79; BLUME G, 1993, BIOCHIM BIOPHYS ACTA, V1149, P180, DOI 10.1016/0005-2736(93)90039-3; DONBROW M, 1992, MICROCAPSULES NANOPA; GOTTLIEB S, 1990, J AM SOC ECHO, V3, P238; GREF R, UNPUB; HOLLAND S J, 1986, Journal of Controlled Release, V4, P155, DOI 10.1016/0168-3659(86)90001-5; ILLUM L, 1987, BIOMATERIALS, V8, P113, DOI 10.1016/0142-9612(87)90099-8; KELLY RJ, 1970, REV SURG, V2, P142; KIM SW, 1992, POLYM DRUG DELIVERY, P193; Kimmel G., 1977, CONTEMP TOP POLYM S, P251; LASIC DD, 1991, BIOCHIM BIOPHYS ACTA, V1070, P187, DOI 10.1016/0005-2736(91)90162-2; LEE J, 1989, J COLLOID INTERF SCI, V131, P252, DOI 10.1016/0021-9797(89)90166-5; Muller B., 1993, PHARM PHARM LETT, V3, P67; MULLER RH, 1992, J CONTROL RELEASE, V20, P237, DOI 10.1016/0168-3659(92)90126-C; Saphiro J., 1990, J AM COLL CARDIOL, V16, P1603; SUGIBAYASHI K, 1977, CHEM PHARM BULL, V25, P3433; TORCHILIN VP, 1992, FASEB J, V6, P2716, DOI 10.1096/fasebj.6.9.1612296; VERRECCHIA T, 1993, 8 JORUN SCI GROUP TH; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410	21	2435	2618	16	800	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 18	1994	263	5153					1600	1603		10.1126/science.8128245	http://dx.doi.org/10.1126/science.8128245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128245				2022-12-01	WOS:A1994NB67300028
J	KLEIN, R; SILOSSANTIAGO, I; SMEYNE, RJ; LIRA, SA; BRAMBILLA, R; BRYANT, S; ZHANG, L; SNIDER, WD; BARBACID, M				KLEIN, R; SILOSSANTIAGO, I; SMEYNE, RJ; LIRA, SA; BRAMBILLA, R; BRYANT, S; ZHANG, L; SNIDER, WD; BARBACID, M			DISRUPTION OF THE NEURATROPHIN-3 RECEPTOR GENE TRKC ELIMINATES LA MUSCLE AFFERENTS AND RESULTS IN ABNORMAL MOVEMENTS	NATURE			English	Article							MOTOR NEURONS; STEM-CELLS; RNA	THE trkC gene(1,2) is expressed throughout the mammalian nervous system(3-5) and encodes a series of tyrosine protein kinase isoforms that serve as receptors for neurotrophin-3 (NT3), a member of the nerve growth factor (NGF) family of neurotrophic factors(2,6-8). One of these isoforms, gp145(trkC)/TrkC K1, mediates the trophic properties of NT3 in cultured Cells(2,6-8). Here we show that homozygous mice defective for TrkC tyrosine protein kinase receptors lack Ia muscle afferent projections to spinal motor neurons and have fewer large myelinated axons in the dorsal root and posterior columns of the spinal cord. These mice display abnormal movements and postures, indicating that NT3/TrkC-dependent sensory neurons may play a primary role in proprioception, the sense of position and movement of the limbs.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY; WASHINGTON UNIV,SCH MED,DEPT NEUROL & NEUROL SURG,ST LOUIS,MO 63110	European Molecular Biology Laboratory (EMBL); Washington University (WUSTL)	KLEIN, R (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543, USA.		Klein, Ruediger/C-6147-2008; Brambilla, Riccardo/A-6082-2010	Klein, Ruediger/0000-0002-3109-0163; Brambilla, Riccardo/0000-0003-3569-5706; Smeyne, Richard/0000-0002-8459-5472				Barbacid Mariano, 1993, P123; CARROLL SL, 1992, NEURON, V9, P779, DOI 10.1016/0896-6273(92)90040-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; GRIFFIN JW, 1990, ANN NEUROL, V27, P304, DOI 10.1002/ana.410270313; Jessell T., 1991, PRINCIPLES NEURAL SC; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1994, J NEUROSCI, V14, P14; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARZIALI G, 1993, DEV BIOL, V157, P182, DOI 10.1006/dbio.1993.1122; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MU XJ, 1993, J NEUROSCI, V13, P4029; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SMITH BE, 1992, NEUROL CLIN, V10, P735, DOI 10.1016/S0733-8619(18)30206-8; SNIDER WD, 1992, J NEUROSCI, V12, P3494; TESSAROLLO L, 1993, DEVELOPMENT, V118, P463; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; Willis WD, 1991, SENSORY MECH SPINAL	24	535	552	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					249	251		10.1038/368249a0	http://dx.doi.org/10.1038/368249a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145824				2022-12-01	WOS:A1994NA87000057
J	MOORE, RD; STANTON, D; GOPALAN, R; CHAISSON, RE				MOORE, RD; STANTON, D; GOPALAN, R; CHAISSON, RE			RACIAL-DIFFERENCES IN THE USE OF DRUG-THERAPY FOR HIV DISEASE IN AN URBAN-COMMUNITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; PNEUMOCYSTIS-CARINII PNEUMONIA; PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; DOUBLE-BLIND; AZIDOTHYMIDINE AZT; ZIDOVUDINE AZT; SAN-FRANCISCO; PROPHYLAXIS; EFFICACY	Background. Guidelines for drug therapy in human immunodeficiency virus (HIV) disease are based primarily on the stage of the disease. To determine whether sociodemographic characteristics of patients influence drug therapy in practice, we analyzed the use of antiretroviral therapy and prophylactic therapy for Pneumocystis carinii pneumonia (PCP) in an urban population infected with HIV. Methods. All patients presenting for the first time to our HIV clinic from March 1990 through December 1992 were enrolled. Data on sociodemographic and clinical variables and on drug use were collected at the time of presentation and after six months. We asked whether patients with CD4+ cell counts of 500 or less per cubic millimeter were receiving antiretroviral therapy at the time of presentation, and whether patients with CD4+ cell counts of 200 or less per cubic millimeter were receiving PCP prophylaxis. Results. Among the 838 patients enrolled, 656 (79 percent) were blacks, 167 (20 percent) were non-Hispanic whites, and 15 (2 percent) were Asian or Hispanic or were not racially classified. There were no racial differences in the stage of HIV disease at the time of presentation. However, there were racial disparities in the receipt of antiretroviral therapy: 63 percent of eligible whites but only 48 percent of eligible blacks received such therapy (P = 0.003). PCP prophylaxis was received by 82 percent of eligible whites but only 58 percent of eligible blacks (P<0.001). There were no significant differences in the receipt of drug therapy with respect to age, sex, mode of HIV transmission, type of insurance, income, education, or place of residence. In a logistic-regression analysis, race was the feature most strongly associated with the receipt of drug therapy. When blacks were compared with whites, the adjusted relative odds were 0.59 (95 percent confidence interval, 0.38 to 0.93) for the receipt of an antiretroviral agent and 0.27 (95 percent confidence interval, 0.13 to 0.56) for the receipt of PCP prophylaxis. Conclusions. Among patients infected with HIV, blacks were significantly less likely than whites to have received antiretroviral therapy or PCP prophylaxis when they were first referred to an HIV clinic. This disparity suggests a need for culturally specific interventions to ensure uniform access to care, including drug therapy, and uniform standards of care.			MOORE, RD (corresponding author), JOHNS HOPKINS UNIV,SCH MED,1830 E MONUMENT ST,RM 8059,BALTIMORE,MD 21205, USA.				AHRQ HHS [R01-HS07809-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; BLUM RN, 1992, J ACQ IMMUN DEF SYND, V5, P341; BONE LR, 1989, AM J EMERG MED, V7, P16, DOI 10.1016/0735-6757(89)90077-6; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; CHAISSON RE, 1993, AIDS, V7, P857, DOI 10.1097/00002030-199306000-00015; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; DIEHR P, 1989, MED CARE, V27, P942, DOI 10.1097/00005650-198910000-00005; EASTERBROOK PJ, 1991, JAMA-J AM MED ASSOC, V266, P2713, DOI 10.1001/jama.266.19.2713; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FOLSOM AR, 1988, AM J PREV MED, V4, P121, DOI 10.1016/S0749-3797(18)31183-8; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P737; Guinan M E, 1993, Ann Epidemiol, V3, P193; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KAHN HA, 1989, STATISTICAL METHODS; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KEMPER CA, 1992, ANN INTERN MED, V116, P466, DOI 10.7326/0003-4819-116-6-466; LAGAKOS S, 1991, JAMA-J AM MED ASSOC, V266, P2709, DOI 10.1001/jama.266.19.2709; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; Levine David M., 1992, Ethnicity and Disease, V2, P296; LEVINE DM, 1990, J HUM HYPERTENS, V4, P317; LEVINE DM, 1992, AM J PREV MED, V8, P319, DOI 10.1016/S0749-3797(18)30799-2; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MINDEL A, 1988, LANCET, V1, P926; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; PERUGA A, 1992, AIDS EDUC PREV, V4, P52; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PIETTE JD, 1993, AM J PUBLIC HEALTH, V83, P510, DOI 10.2105/AJPH.83.4.510; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; Singer M, 1991, AIDS Educ Prev, V3, P258; SKOWRON G, 1993, ANN INTERN MED, V118, P321, DOI 10.7326/0003-4819-118-5-199303010-00001; SMITH MD, 1991, JAMA-J AM MED ASSOC, V266, P2750, DOI 10.1001/jama.266.19.2750; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; VOLBERDING PA, 1985, ANN INTERN MED, V103, P729, DOI 10.7326/0003-4819-103-5-729; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1981, CA-CANCER J CLIN, V31, P212; 1991, MMWR MORB MORTAL WKL, V40, P358; 1985, REPORT SECRETARYS TA, V1; 1993, HIV AIDS SURVEILLANC, P1; 1990, JAMA-J AM MED ASSOC, V263, P1606; 1992, NEW ENGL J MED, V326, P213	49	268	269	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					763	768		10.1056/NEJM199403173301107	http://dx.doi.org/10.1056/NEJM199403173301107			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	8107743	Bronze			2022-12-01	WOS:A1994NA74200007
J	SMEYNE, RJ; KLEIN, R; SCHNAPP, A; LONG, LK; BRYANT, S; LEWIN, A; LIRA, SA; BARBACID, M				SMEYNE, RJ; KLEIN, R; SCHNAPP, A; LONG, LK; BRYANT, S; LEWIN, A; LIRA, SA; BARBACID, M			SEVERE SENSORY AND SYMPATHETIC NEUROPATHIES IN MICE CARRYING A DISRUPTED TRK/NGF RECEPTOR GENE	NATURE			English	Article							NERVE GROWTH-FACTOR; ROOT GANGLION NEURONS; PROTO-ONCOGENE; EXPRESSION; NGF	NERVE growth factor (NGF) induces neurite outgrowth and promotes survival of embryonic sensory and sympathetic neurons in culture(1,2). In vivo, NGF decreases the extent of naturally occurring cell death in developing sympathetic ganglia and protects cholinergic neurons of the basal forebrain and caudatoputamen(1-3). NGF interacts with the low-affinity p75 receptor and with Trk, a receptor tyrosine kinase encoded by the trk proto-oncogene(4,5). To study the role of Trk in vivo, we have ablated the gene in embryonic stem cells by homologous recombination. Mice lacking Trk have severe sensory and sympathetic neuropathies and most die within one month of birth. They have extensive neuronal cell loss in trigeminal, sympathetic and dorsal root ganglia, as well as a decrease in the cholinergic basal forebrain projections to the hippocampus and cortex. These findings demonstrate that Trk is the primary mediator of the trophic actions of NGF in vivo and that this signalling pathway plays a crucial role in the development of both the peripheral and the central nervous systems.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	SMEYNE, RJ (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543, USA.		Klein, Ruediger/C-6147-2008	Klein, Ruediger/0000-0002-3109-0163; Smeyne, Richard/0000-0002-8459-5472				BARBACID M, 1993, ONCOGENE, V8, P2033; BRADSHAW RA, 1993, TRENDS BIOCHEM SCI, V18, P48, DOI 10.1016/0968-0004(93)90052-O; BUTCHER LL, 1984, HDB CHEM NEUROANATOM, V2; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DREYFUS CF, 1989, TRENDS PHARMACOL SCI, V10, P145, DOI 10.1016/0165-6147(89)90166-1; HOLTZMAN DM, 1992, NEURON, V9, P465, DOI 10.1016/0896-6273(92)90184-F; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MU XJ, 1993, J NEUROSCI, V13, P4029; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; STEININGER TL, 1993, BRAIN RES, V612, P330, DOI 10.1016/0006-8993(93)91681-H; TESSAROLLO L, 1993, DEVELOPMENT, V118, P463	20	807	825	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					246	249		10.1038/368246a0	http://dx.doi.org/10.1038/368246a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145823				2022-12-01	WOS:A1994NA87000056
J	SCHWARZ, DF; GRISSO, JA; MILES, CG; HOLMES, JH; WISHNER, AR; SUTTON, RL				SCHWARZ, DF; GRISSO, JA; MILES, CG; HOLMES, JH; WISHNER, AR; SUTTON, RL			A LONGITUDINAL-STUDY OF INJURY MORBIDITY IN AN AFRICAN-AMERICAN POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NORTHEASTERN OHIO TRAUMA; CHILDHOOD; MASSACHUSETTS; ADOLESCENTS; COMMUNITY; CHILDREN; DEATHS; RATES	Objective.-To improve understanding of the patterns of injury morbidity and mortality in an urban African-American population. Design.-Prospective survey of emergency department records for a geographically defined population from 1987 through 1990. Setting.-Eleven hospital emergency departments in Philadelphia, Pa. Participants.-The approximately 68 000 people living in 17 census tracts in western Philadelphia. Results.-A total of 46260 injury events were identified in the survey (168.8 events per 1000 population annually). Half of the population made an emergency department visit for one or more injuries during the 4 years of study. There were 2796 hospital admissions (10.2/1000 population) and 403 deaths (1.5/1000 population) as a result of these injuries. Although in 1987 falls were the most frequent type of injury resulting in an emergency department visit, by 1989 the number of interpersonal intentional injury events exceeded the number of falls. Interpersonal intentional injuries accounted for 31.2% of hospital admissions and 42.7% of deaths. Of men 20 through 29 years old, 94.3% visited an emergency department at least once in the 4 years because of an injury, and 40.9% of men in this age group sought treatment for one or more interpersonal intentional injuries. The likelihood of future interpersonal intentional injury-related visits increased with the number of previous injuries of this type. Conclusions.-lnterpersonal intentional injury occurs frequently in this population. More attention needs to be paid to prevention and intervention to reduce the toll of this violence. The high prevalence of injury in certain age strata may make general, population-based efforts for injury prevention more efficient than efforts targeted to subgroups.	UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,CLIN EPIDEMIOL UNIT,PHILADELPHIA,PA 19104; PHILADELPHIA DEPT PUBL HLTH,PHILADELPHIA,PA	University of Pennsylvania; Childrens Hospital of Philadelphia	SCHWARZ, DF (corresponding author), UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT PEDIAT,DIV GEN PEDIAT,PHILADELPHIA,PA 19104, USA.				PHS HHS [U50/CCU300738-03, R49/CCR303282-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS PF, 1991, VITAL HLTH STAT, V181, P1; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BARANCIK JI, 1983, AM J PUBLIC HEALTH, V73, P746, DOI 10.2105/AJPH.73.7.746; Davidson L L, 1992, Paediatr Perinat Epidemiol, V6, P153, DOI 10.1111/j.1365-3016.1992.tb00757.x; FIFE D, 1984, AM J PUBLIC HEALTH, V74, P473, DOI 10.2105/AJPH.74.5.473; FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3054, DOI 10.1001/jama.267.22.3054; GALLAGHER SS, 1984, AM J PUBLIC HEALTH, V74, P1340, DOI 10.2105/AJPH.74.12.1340; GOLDBERG WG, 1984, JAMA-J AM MED ASSOC, V251, P8263; GRISSO JA, 1990, J AM GERIATR SOC, V38, P1326, DOI 10.1111/j.1532-5415.1990.tb03456.x; GRISSO JA, 1991, AM J EPIDEMIOL, V134, P59, DOI 10.1093/oxfordjournals.aje.a115993; GUYER B, 1989, NEW ENGL J MED, V321, P1584, DOI 10.1056/NEJM198912073212306; HODGES K, 1984, MAY ANN POP ASS AM M; HOLMES JH, 1990, MMWR-MORBID MORTAL W, V39, P1; Langan P., 1986, PREVENTING DOMESTIC; MANHEIMER DI, 1986, PUBLIC HLTH REP, V81, P519; MITCHELL MA, 1992, CHILDREN VIOLENCE; PROTHROWSTITH D, 1991, DEADLY CONSEQUENCES; RICE DP, 1992, MMWR MORB MORTAL WKL, V41, P10; RIVARA FP, 1989, AM J PUBLIC HEALTH, V79, P990, DOI 10.2105/AJPH.79.8.990; RUNYAN CW, 1985, AM J PUBLIC HEALTH, V75, P1429, DOI 10.2105/AJPH.75.12.1429; STARK E, 1981, MONOGRAPH OFFICE DOM, V7; TIRET L, 1989, AM J PUBLIC HEALTH, V79, P316, DOI 10.2105/AJPH.79.3.316; WISHNER AR, 1991, AM J PUBLIC HEALTH, V81, P1474, DOI 10.2105/AJPH.81.11.1474; 1992, MMWR MORB MORTAL WKL, V41, P313; 1980, INT CLASSIFICATION D; 1985, INJURY AM; 1988, MMWR MORB MORTAL WKL, V37, P27; 1991, FATAL ACCIDENT REPOR; 1992, PREVENTION YOUTH VIO; 1993, VITAL STATISTICS U A, V2	30	60	61	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					755	760		10.1001/jama.271.10.755	http://dx.doi.org/10.1001/jama.271.10.755			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MY288	8114212				2022-12-01	WOS:A1994MY28800029
J	MORISATO, D; ANDERSON, KV				MORISATO, D; ANDERSON, KV			THE SPATZLE GENE ENCODES A COMPONENT OF THE EXTRACELLULAR SIGNALING PATHWAY ESTABLISHING THE DORSAL-VENTRAL PATTERN OF THE DROSOPHILA EMBRYO	CELL			English	Article							SERINE PROTEASE; TOLL GENE; TRANSMEMBRANE PROTEIN; POLARITY; MORPHOGEN; PRODUCT; EASTER; TWIST; LOCALIZATION; MELANOGASTER	spatzle is a maternal effect gene required in the signal transduction pathway that establishes the dorsal-ventral pattern of the Drosophila embryo. spatzle acts immediately upstream of the membrane protein Toll in the genetic pathway, suggesting that spatzle could encode the ventrally localized ligand that activates the receptor activity of Toll. The spatzle gene encodes a novel secreted protein that appears to require activation by a proteolytic processing reaction, which is controlled by the genes that act upstream of spatzle in the genetic pathway. We propose that proteolytic processing of the spatzle protein is confined to the ventral side of the embryo and that the localization of processed spatzle determines where the receptor, Toll, is active.			MORISATO, D (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA.				NIGMS NIH HHS [GM 35437] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035437] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, PATTERN FORMATION, P269; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HECHT PM, 1993, GENETICS, V135, P405; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; IP YT, 1991, CELL, V64, P439; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JIN YS, 1990, CELL, V60, P873, DOI 10.1016/0092-8674(90)90100-S; LEVIS R, 1982, P NATL ACAD SCI-BIOL, V79, P564, DOI 10.1073/pnas.79.2.564; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; RAY RP, 1991, DEVELOPMENT, V113, P35; ROBERTSON HM, 1988, GENETICS, V118, P461; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; Saiki R. K., 1988, Genome analysis: a practical approach., P141; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SEIFERT E, 1987, ROUX ARCH DEV BIOL, V196, P78, DOI 10.1007/BF00402028; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	42	272	280	0	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					677	688		10.1016/0092-8674(94)90507-X	http://dx.doi.org/10.1016/0092-8674(94)90507-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124709				2022-12-01	WOS:A1994MZ28500010
J	LIMA, CD; WANG, JC; MONDRAGON, A				LIMA, CD; WANG, JC; MONDRAGON, A			3-DIMENSIONAL STRUCTURE OF THE 67K N-TERMINAL FRAGMENT OF ESCHERICHIA-COLI DNA TOPOISOMERASE-I	NATURE			English	Article							RAY-DIFFRACTION DATA; ESCHERICHIA-COLI; MACROMOLECULAR CRYSTALLOGRAPHY; TYPE-1 TOPOISOMERASES; CRYSTAL-STRUCTURES; ACTIVE-SITE; PROTEIN; BINDING; RESOLUTION; IDENTIFICATION	The three-dimensional structure of the 67K amino-terminal fragment of Escherichia coli DNA topoisomerase I has been determined to 2.2 angstrom resolution. The polypeptide folds in an unusual way to give four distinct domains enclosing a hole large enough to accommodate a double-stranded DNA. The active-site tyrosyl residue, which is involved in the transient breakage of a DNA strand and the formation of a covalent enzyme-DNA intermediate, is present at the interface of two domains. The structure suggests a plausible mechanism by which E. coli DNA topoisomerase I and other members of the same DNA topoisomerase subfamily could catalyse the passage of one DNA strand through a transient break in another strand.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138; NORTHWESTERN AVE,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208	Harvard University				Lima, Christopher/0000-0002-9163-6092	NIGMS NIH HHS [R01 GM051350] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051350] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANHOH T, 1993, P INT S DNA TOOISOME; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERANSTEED RK, 1989, PROTEINS, V6, P249, DOI 10.1002/prot.340060307; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BROWN PO, 1981, P NATL ACAD SCI-BIOL, V78, P843, DOI 10.1073/pnas.78.2.843; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; DEAN F, 1983, COLD SPRING HARB SYM, V47, P769; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DOMANICO PL, 1991, J INORG BIOCHEM, V42, P87, DOI 10.1016/0162-0134(91)80035-G; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GILSON MK, 1987, J COMPUT CHEM, V9, P327; GRAU UM, 1981, J MOL BIOL, V151, P289, DOI 10.1016/0022-2836(81)90516-7; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HENDRICKSON WA, 1980, BIOMOLECULAR STRUCTU, V1, P43; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; IVEY DM, 1992, NUCLEIC ACIDS RES, V20, P4928, DOI 10.1093/nar/20.18.4928; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM RA, 1992, J BIOL CHEM, V267, P17178; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; KIRKEGAARD K, 1984, COLD SPRING HARB SYM, V49, P411, DOI 10.1101/SQB.1984.049.01.047; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; LIMA CD, 1993, J MOL BIOL, V232, P1213, DOI 10.1006/jmbi.1993.1474; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SIM GA, 1960, ACTA CRYSTALLOGR, V13, P511, DOI 10.1107/S0365110X60001266; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TSE Y, 1980, CELL, V22, P269, DOI 10.1016/0092-8674(80)90174-9; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1991, J BIOL CHEM, V266, P14217; VANDERLAAN JM, 1989, BIOCHEMISTRY-US, V28, P7199, DOI 10.1021/bi00444a011; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1982, NUCLEASES, P41; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0; 1979, 4 DAR LAB COLL COMP	62	265	269	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 13	1994	367	6459					138	146		10.1038/367138a0	http://dx.doi.org/10.1038/367138a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ780	8114910				2022-12-01	WOS:A1994MQ78000050
J	THOROGOOD, M				THOROGOOD, M			LOSING HEART	LANCET			English	Editorial Material											THOROGOOD, M (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,HLTH PROMOT SCI UNIT,LONDON WC1E 7HT,ENGLAND.							ANDA R, 1993, EPIDEMIOLOGY, V4, P285, DOI 10.1097/00001648-199307000-00003	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					570	570		10.1016/0140-6736(93)91407-D	http://dx.doi.org/10.1016/0140-6736(93)91407-D			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102717				2022-12-01	WOS:A1993LV96300007
J	BRINDLE, P; LINKE, S; MONTMINY, M				BRINDLE, P; LINKE, S; MONTMINY, M			PROTEIN-KINASE-A-DEPENDENT ACTIVATOR IN TRANSCRIPTION FACTOR CREB REVEALS NEW ROLE FOR CREM REPRESSORS	NATURE			English	Article							MAMMALIAN-CELLS; GENE; CAMP; PHOSPHORYLATION; EXPRESSION; PROMOTER	HORMONALLY induced increases in cyclic AMP levels induce phosphorylation of the transcription factor CREB at a serine residue at position 133 by protein kinase A (ref. 1), enhancing its ability to activate transcription without affecting its intracellular location or DNA-binding activity. This effect is dependent on a 60-amino-acid region of CREB that contains Ser 133 and is termed the kinase-inducible domain (KID)2, which also occurs in the CREB-related CREM-alpha and -beta proteins, although these are transcriptional repressors3 . Here we show that the KID domain confers a cAMP-inducible increase on the activity of the Q2 activation domain from CREB and the acidic activation domains from the yeast proteins GAL4 and GCN4. Remarkably, it retains this ability even when attached to a separate polypeptide bound to an adjacent site in the promoter. KID may therefore be the first of a new class of conditional activators that work through other promoter-bound factors to stimulate gene expression in response to hormonal stimuli.			BRINDLE, P (corresponding author), SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037, USA.			Brindle, Paul/0000-0001-7172-8478; Linke, Steven/0000-0001-8584-4947				CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OHLSSON M, 1993, MOL CELL BIOL, V13, P266, DOI 10.1128/MCB.13.1.266; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	16	150	152	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					821	824		10.1038/364821a0	http://dx.doi.org/10.1038/364821a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8102791				2022-12-01	WOS:A1993LU58100061
J	POWELLTUCK, J				POWELLTUCK, J			GLUTAMINE, PARENTERAL-FEEDING, AND INTESTINAL NUTRITION	LANCET			English	Editorial Material							METABOLISM; MUSCLE				POWELLTUCK, J (corresponding author), ROYAL LONDON HOSP,DEPT MED,LONDON,ENGLAND.							ADIBI SA, 1987, DIPEPTIDES NEW SUBST; DEUTZ NEP, 1992, CLIN SCI, V83, P607, DOI 10.1042/cs0830607; HAUSSINGER D, 1993, LANCET, V341, P1330, DOI 10.1016/0140-6736(93)90828-5; HAUSSINGER D, 1989, METABOLISM, V38, P14, DOI 10.1016/0026-0495(89)90133-9; RENNIE MJ, 1986, LANCET, V2, P1008; SOUBA WW, 1985, JPEN-PARENTER ENTER, V9, P608, DOI 10.1177/0148607185009005608; TAMARAPPOO BK, 1990, MINER ELECTROL METAB, V16, P322; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; WINDMUELLER HG, 1980, J BIOL CHEM, V255, P107	9	6	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					451	452		10.1016/0140-6736(93)91589-E	http://dx.doi.org/10.1016/0140-6736(93)91589-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102425				2022-12-01	WOS:A1993LU07500006
J	NICOLAOU, KC; RIEMER, C; KERR, MA; RIDEOUT, D; WRASIDLO, W				NICOLAOU, KC; RIEMER, C; KERR, MA; RIDEOUT, D; WRASIDLO, W			DESIGN, SYNTHESIS AND BIOLOGICAL-ACTIVITY OF PROTAXOLS	NATURE			English	Article							WATER-SOLUBLE PRODRUGS; ANTITUMOR-ACTIVITY; TAXOL; CELLS; MICROTUBULES; AGENTS; ASSAY	TAXOL1-6 is a product isolated from the Pacific yew tree (Taxus brevifolia) and is a potent microtubule-stabilizing agent which has recently been approved for treatment of otherwise intractable ovarian cancer. Despite taxol's therapeutic promise, its aqueous insolubility (<0.004 mg ml-1) hampers its clinical application. Here we report the design, synthesis and biological activity of a series of taxol-releasing compounds (protaxols) with improved pharmacological properties. These prodrugs were designed to increase their aqueous solubility and allow for taxol release under basic or physiological conditions. We demonstrate the stability of these prodrugs at pH less-than-or-equal-to 7 and their ability to release taxol in a basic medium. Taxol-like microtubule-stabilizing activity7-9 appears after the release of taxol. In vitro these prodrugs have cytotoxic properties against tumour cell lines comparable to those of taxol; moreover, human plasma catalyses the release of active taxol. These protaxols have greater potential as anticancer agents than the parent compounds taxol and taxotere (Fig. 1a).	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DRUG DISCOVERY UNIT, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute; Scripps Research Institute	NICOLAOU, KC (corresponding author), SCRIPPS RES INST, DEPT CHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							DEBRABANDER M, 1981, P NATL ACAD SCI-BIOL, V78, P5608; DEUTSCH HM, 1989, J MED CHEM, V32, P788, DOI 10.1021/jm00124a011; KEIZER HG, 1989, J NATL CANCER I, V81, P706, DOI 10.1093/jnci/81.9.706; KINGSTON DGI, 1991, PHARMACOL THERAPEUT, V52, P1, DOI 10.1016/0163-7258(91)90085-Z; LONGNECKER SM, 1987, CANCER TREAT REP, V71, P53; MATHEW AE, 1992, J MED CHEM, V35, P145, DOI 10.1021/jm00079a019; MERLOCK R, IN PRESS ANAL BIOCH; NICOLAOU KC, IN PRESS ANGEW CHEM; POITIER P, 1992, CHEM SOC REV, V21, P113; ROWINSKY EK, 1991, PHARMACOL THERAPEUT, V52, P35, DOI 10.1016/0163-7258(91)90086-2; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SWINDELL CS, 1991, ORG PREP PROCED INT, V23, P465, DOI 10.1080/00304949109458240; SWINDELL CS, 1991, J MED CHEM, V34, P1176, DOI 10.1021/jm00107a042; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; ZHAO ZY, 1991, J NAT PROD, V54, P1607, DOI 10.1021/np50078a018	17	118	157	3	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					464	466		10.1038/364464a0	http://dx.doi.org/10.1038/364464a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	LP640	8101355				2022-12-01	WOS:A1993LP64000061
J	HAEFNER, HK				HAEFNER, HK			ITS A BOY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											HAEFNER, HK (corresponding author), UNIV MICHIGAN, MED CTR, DIV GYNECOL, MED PROFESS BLDG D2202-0718, 1500 E MED CTR DR, ANN ARBOR, MI 48109 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					806	806		10.7326/0003-4819-120-9-199405010-00013	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147554				2022-12-01	WOS:A1994NH25100013
J	LORENZO, A; RAZZABONI, B; WEIR, GC; YANKNER, BA				LORENZO, A; RAZZABONI, B; WEIR, GC; YANKNER, BA			PANCREATIC-ISLET CELL TOXICITY OF AMYLIN ASSOCIATED WITH TYPE-2 DIABETES-MELLITUS	NATURE			English	Article							AMYLOID POLYPEPTIDE; ALZHEIMERS-DISEASE; SKELETAL-MUSCLE; HORMONE; LANGERHANS; SEQUENCE; PEPTIDE; PROTEIN; DEATH	THE 37-amino-acid polypeptide amylin is the principal constituent of the amyloid deposits that form in the islets of Langerhans in patients with type-2 diabetes menitus(1-5), but its role in the pathogenesis of this disease is unresolved(6-8). In view of the fact that the beta-amyloid protein that forms fibrils in Alzheimer's disease is toxic to neurons(9,10), we have investigated whether amylin fibrils could be toxic to pancreatic islet cells. We show here that human amylin is toxic to insulin-producing beta-cells of the adult pancreas of rats and humans. This toxicity is mediated by the fibrillar form of the amylin peptide and requires direct contact of the fibrils with the cell surface. The mechanism of cell death involves RNA and protein synthesis and is characterized by plasma membrane-blebbing, chromatin condensation and DNA fragmentation, indicating that amylin induces islet cell apoptosis. These findings indicate that amylin fibril formation in the pancreas may cause islet cell dysfunction and death in type-2 diabetes mellitus.	HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,BOSTON,MA 02115; JOSLIN DIABET CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School								BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BETSHOLTZ C, 1989, FEBS LETT, V251, P261, DOI 10.1016/0014-5793(89)81467-X; COOPER GJS, 1988, P NATL ACAD SCI USA, V85, P7763, DOI 10.1073/pnas.85.20.7763; COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; JOHNSON KH, 1989, NEW ENGL J MED, V321, P513; LEFFERT JD, 1989, P NATL ACAD SCI USA, V86, P3127, DOI 10.1073/pnas.86.9.3127; LEIGHTON B, 1988, NATURE, V335, P632, DOI 10.1038/335632a0; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MALOY AL, 1981, HUM PATHOL, V12, P917, DOI 10.1016/S0046-8177(81)80197-9; MAY PC, 1993, J NEUROCHEM, V61, P2330, DOI 10.1111/j.1471-4159.1993.tb07480.x; NISHI M, 1989, P NATL ACAD SCI USA, V86, P5738, DOI 10.1073/pnas.86.15.5738; OBRIEN TD, 1993, VET PATHOL, V30, P317, DOI 10.1177/030098589303000401; OPIE EL, 1900, J EXP MED, V5, P397; RICORDI C, 1990, SURGERY, V107, P688; SCHUPPIN GT, 1993, IN VITRO CELL DEV-AN, V29A, P339; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; WESTERMARK P, 1987, AM J PATHOL, V127, P414; WESTERMARK P, 1987, P NATL ACAD SCI USA, V84, P3881, DOI 10.1073/pnas.84.11.3881; WESTERMARK P, 1972, UPSALA J MED SCI, V77, P91, DOI 10.1517/03009734000000014; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; WESTON SA, 1990, J IMMUNOL METHODS, V133, P87, DOI 10.1016/0022-1759(90)90322-M; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849	29	718	741	2	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					756	760		10.1038/368756a0	http://dx.doi.org/10.1038/368756a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152488				2022-12-01	WOS:A1994NG55300063
J	GARG, SK; CHASE, HP; MARSHALL, G; HOOPS, SL; HOLMES, DL; JACKSON, WE				GARG, SK; CHASE, HP; MARSHALL, G; HOOPS, SL; HOLMES, DL; JACKSON, WE			ORAL-CONTRACEPTIVES AND RENAL AND RETINAL COMPLICATIONS IN YOUNG-WOMEN WITH INSULIN-DEPENDENT DIABETES-MELLITUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; RETINOPATHY; RISK; PROGRESSION; PREVALENCE; DIAGNOSIS; INCREASES; ALBUMIN; HEART; AGE	Objective.-To evaluate the effects of oral contraceptives (OCs) as a possible risk factor for early diabetic renal and/or retinal complications. Design.-A retrospective case-control study. Setting.-A university hospital diabetes clinic. Participants.-Forty-three diabetic women who used OCs for 1 year or longer (mean, 3.4 years; range, 1.0 to 7.0 years) were compared with a computer-matched control group of 43 diabetic women who never used OCs. Main Outcome Measures.-Hemoglobin A1c levels, albumin excretion rates, and mean retinopathy scores. Results.-The mean+/-SEM age and duration of diabetes were 22.7+/-0.5 years (range, 17.1 to 30.5 years) and 13.8+/-0.8 years, respectively, for the study group. The mean longitudinal hemoglobin Al, values were similar for study subjects and control subjects. The final mean albumin excretion rates, reflecting diabetic renal damage, and the mean eye grades were not significantly different between the groups. Conclusions.-The use of OCs among young women with insulin-dependent diabetes mellitus does not pose an additional risk for the development of early diabetic retinopathy and/or nephropathy.	UNIV COLORADO, HLTH SCI CTR, DEPT PEDIAT, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT PREVENT MED & BIOSTAT, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT OPHTHALMOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	GARG, SK (corresponding author), UNIV COLORADO, HLTH SCI CTR, BARBARA DAVIS CTR CHILDHOOD DIABET, 4200 E 9TH AVE, BOX B140, DENVER, CO 80262 USA.		Marshall, Guillermo/F-2302-2011		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000069] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00069] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARRETTCONNOR E, 1983, AM J EPIDEMIOL, V118, P489, DOI 10.1093/oxfordjournals.aje.a113654; CHASE HP, 1990, OPHTHALMOLOGY, V97, P155; CHASE HP, 1990, ARCH INTERN MED, V150, P639, DOI 10.1001/archinte.150.3.639; CHASE HP, 1991, JAMA-J AM MED ASSOC, V265, P614, DOI 10.1001/jama.265.5.614; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; CHASE HP, 1991, CLIN CHEM, V37, P2048; CHASE HP, 1990, DIABETIC MED, V7, P299, DOI 10.1111/j.1464-5491.1990.tb01393.x; CRUICKSHANKS KJ, 1985, DIABETES CARE, V8, P118, DOI 10.2337/diacare.8.2.118; GARG SK, 1992, DIABETES NUTR METAB, V5, P205; KALKHOFF RK, 1982, AM J OBSTET GYNECOL, V142, P735; Kirk RE, 1982, EXPT DESIGN PROCEDUR; KLEIN BEK, 1984, OPHTHALMOLOGY, V91, P10; KLEIN BEK, 1990, DIABETES CARE, V13, P34, DOI 10.2337/diacare.13.1.34; KLEIN BEK, 1990, DIABETES CARE, V13, P895, DOI 10.2337/diacare.13.8.895; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; OSBERG I, 1990, CLIN CHEM, V36, P1428; PERLMAN JA, 1985, J CHRON DIS, V38, P857, DOI 10.1016/0021-9681(85)90110-9; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; VOORS AW, 1976, CIRCULATION, V54, P319, DOI 10.1161/01.CIR.54.2.319; WAHL P, 1983, NEW ENGL J MED, V308, P862, DOI 10.1056/NEJM198304143081502; WILSON ESB, 1984, BRIT J OBSTET GYNAEC, V91, P1254, DOI 10.1111/j.1471-0528.1984.tb04747.x; 1981, INVEST OPHTH VIS SCI, V21, P210; 1987, SAS STAT GUIDE PERSO; 1985, 032741987 HLTH CAR F	26	67	68	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1099	1102		10.1001/jama.271.14.1099	http://dx.doi.org/10.1001/jama.271.14.1099			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	8151852				2022-12-01	WOS:A1994NE22800032
J	KOLESKE, AJ; YOUNG, RA				KOLESKE, AJ; YOUNG, RA			AN RNA POLYMERASE-II HOLOENZYME RESPONSIVE TO ACTIVATORS	NATURE			English	Article							TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; TERMINAL DOMAIN; INITIATION; PURIFICATION; PROMOTER; INVITRO; PHOSPHORYLATION; IDENTIFICATION; COMPLEXES	RNA POLYMERASE II requires multiple general transcription factors to initiate site-specific transcription1-3. These proteins can assemble in an ordered fashion onto promoter DNA in vitro2-8, and such ordered assembly may occur in vivo (Fig. 1a). Some general transcription factors can interact with RNA polymerase II in the absence of DNA3,9-15, however, suggesting that RNA polymerase II may also assemble into a multi-component complex containing a subset of initiation factors before binding to promoter DNA (Fig. 1b). Here we present evidence from the yeast Saccharomyces cerevisiae for such an RN.A polymerase II holoenzyme, a multi-subunit complex containing roughly equimolar amounts of RNA polymerase II, a subset of general transcription factors, and SRB regulatory proteins. Transcription by this holoenzyme is stimulated by the activator protein GAL4-VP16, a feature not observed with purified RNA polymerase II and general transcription factors alone. We propose that the holoenzyme is a form of RNA polymerase II readily recruited to promoters in vivo.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	KOLESKE, AJ (corresponding author), WHITEHAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CONAWAY RC, 1993, REV BIOCH, V62, P161; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLANAGAN PM, 1992, P NATL ACAD SCI USA, V89, P7659, DOI 10.1073/pnas.89.16.7659; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; HENRY NL, 1992, J BIOL CHEM, V267, P23388; KITAJIMA S, 1990, NUCLEIC ACIDS RES, V18, P4843, DOI 10.1093/nar/18.16.4843; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SOPTA M, 1985, J BIOL CHEM, V260, P353; THOMPSON CM, 1993, CELL, V73, P1367; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	30	551	560	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 31	1994	368	6470					466	469		10.1038/368466a0	http://dx.doi.org/10.1038/368466a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133894				2022-12-01	WOS:A1994ND12000067
J	DERIJARD, B; HIBI, M; WU, IH; BARRETT, T; SU, B; DENG, TL; KARIN, M; DAVIS, RJ				DERIJARD, B; HIBI, M; WU, IH; BARRETT, T; SU, B; DENG, TL; KARIN, M; DAVIS, RJ			JNK1 - A PROTEIN-KINASE STIMULATED BY UV-LIGHT AND HA-RAS THAT BINDS AND PHOSPHORYLATES THE C-JUN ACTIVATION DOMAIN	CELL			English	Article							DNA-BINDING; MAP KINASE; GENE; SITES; IDENTIFICATION; ONCOPROTEIN; EXPRESSION; CEREVISIAE; SERINE-63; TYROSINE	The ultraviolet (UV) response of mammalian cells is characterized by a rapid and selective increase in gene expression mediated by AP-1 and NF-kappaB. The effect on AP-1 transcriptional activity results, in part, from enhanced phosphorylation of the c-Jun NH2-terminal activation domain. Here, we describe the molecular cloning and characterization of JNK1, a distant relative of the MAP kinase group that is activated by dual phosphorylation at Thr and Tyr during the UV response. Significantly, Ha-Ras partially activates JNK1 and potentiates the activation caused by UV. JNK1 binds to the c-Jun transactivation domain and phosphorylates it on Ser-63 and Ser-73. Thus, JNK1 is a component of a novel signal transduction pathway that is activated by oncoproteins and UV irradiation. These properties indicate that JNK1 activation may play an important role in tumor promotion.	UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LEHRSTUHL BIOMED SCI,LA JOLLA,CA 92093	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California San Diego	DERIJARD, B (corresponding author), UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOWARD HUGHES MED INST,WORCESTER,MA 01605, USA.		Hibi, Masahiko/I-6215-2014	Hibi, Masahiko/0000-0002-9142-4444	NCI NIH HHS [CA58396, CA50528] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396, P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, CELL, V55, P85; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P573; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; HUNTER T, 1992, CELL, V70, P3755; KARIN M, 1989, GENES SIGNAL TRANSDU, P415; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Romerdahl C A, 1989, Cancer Commun, V1, P209; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TRUSH MA, 1991, FREE RADICAL BIO MED, V10, P201, DOI 10.1016/0891-5849(91)90077-G; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WEINSTEIN IB, 1988, CANCER RES, V48, P4136	60	2960	3047	2	85	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1025	1037		10.1016/0092-8674(94)90380-8	http://dx.doi.org/10.1016/0092-8674(94)90380-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137421				2022-12-01	WOS:A1994ND24600009
J	HEUSEL, JW; WESSELSCHMIDT, RL; SHRESTA, S; RUSSELL, JH; LEY, TJ				HEUSEL, JW; WESSELSCHMIDT, RL; SHRESTA, S; RUSSELL, JH; LEY, TJ			CYTOTOXIC LYMPHOCYTES REQUIRE GRANZYME-B FOR THE RAPID INDUCTION OF DNA FRAGMENTATION AND APOPTOSIS IN ALLOGENEIC TARGET-CELLS	CELL			English	Article							CYTO-TOXIC LYMPHOCYTE; SERINE PROTEASE GENES; FUNCTIONAL-CHARACTERIZATION; MOUSE CHROMOSOME-14; GLOBIN GENE; T-CELLS; EXPRESSION; GRANULES; PERFORIN; LYSIS	We have generated H-2b mice with a homozygous null mutation in the granzyme (gzm) B gene. Gzm B is a neutral serine protease with Aspase activity that is found only in the granules of activated cytolytic T cells, natural killer cells, and lymphokine-activated killer cells. Gzm B-/- mice develop normally and have normal hematopoiesis and lymphopoiesis. In vitro, cytotoxic T lymphocytes (CTL) derived from gzm B-/- animals are able to induce Cr-51 release from allotarget cells, but with reduced efficiency. However, gzm B-/- CTL have a profound defect in their ability to induce rapid DNA fragmentation and apoptosis in allogeneic target cells. This defect is kinetic since DNA fragmentation is partially compensated and Cr-51 release is completely rescued with long incubation times. We conclude that gzm B serves a critical and nonredundant role for the rapid induction of target cell DNA fragmentation and apoptosis by alloreactive cytotoxic T lymphocytes.	WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	HEUSEL, JW (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT MED, DIV BONE MARROW TRANSPLANT, ST LOUIS, MO 63110 USA.		Heusel, Jon/AAC-8050-2021	Russell, John/0000-0002-3680-9587	NCI NIH HHS [CA-49712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLEACKLEY RC, 1988, IMMUNOL REV, V103, P5, DOI 10.1111/j.1600-065X.1988.tb00746.x; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; CROSBY JL, 1990, GENOMICS, V6, P252, DOI 10.1016/0888-7543(90)90564-B; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOURMASHKIN RR, 1980, CLIN EXP IMMUNOL, V42, P554; DUKE RC, 1989, J EXP MED, V170, P1451, DOI 10.1084/jem.170.4.1451; EBNET K, 1991, INT IMMUNOL, V3, P9, DOI 10.1093/intimm/3.1.9; EWOLDT GR, 1992, MOL IMMUNOL, V29, P713, DOI 10.1016/0161-5890(92)90181-V; GARCIASANZ JA, 1990, J IMMUNOL, V145, P3111; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; GROSCURTH P, 1989, ANAT EMBRYOL, V180, P109, DOI 10.1007/BF00309762; HADDAD P, 1990, GENE, V87, P265, DOI 10.1016/0378-1119(90)90311-E; HAMPSON IN, 1992, BLOOD, V80, P3097; HANSON RD, 1990, MOL CELL BIOL, V10, P5655, DOI 10.1128/MCB.10.11.5655; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; HANSON RD, 1991, J BIOL CHEM, V266, P24433; HARPER K, 1988, IMMUNOGENETICS, V28, P439, DOI 10.1007/BF00355376; HAYES MP, 1989, J EXP MED, V170, P933, DOI 10.1084/jem.170.3.933; HELD W, 1990, INT IMMUNOL, V2, P57, DOI 10.1093/intimm/2.1.57; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HENKART PA, 1993, CYTOTOXIC CELLS, P153; HEUSEL JW, 1993, BLOOD, V81, P1614; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; HUDIG D, 1991, J IMMUNOL, V147, P1360; HUDIG D, 1993, CURR OPIN IMMUNOL, V5, P90, DOI 10.1016/0952-7915(93)90086-8; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KLEIN JL, 1989, GENOMICS, V5, P110, DOI 10.1016/0888-7543(89)90093-1; KRAHENBUHL O, 1988, J IMMUNOL, V141, P3471; LANIER LL, 1986, IMMUNOL TODAY, V7, P132, DOI 10.1016/0167-5699(86)90076-9; LEY TJ, 1989, J CLIN INVEST, V83, P1032, DOI 10.1172/JCI113944; LIPMAN ML, 1992, TRANSPLANTATION, V53, P73, DOI 10.1097/00007890-199201000-00014; LOBE CG, 1988, BIOCHEMISTRY-US, V27, P6941, DOI 10.1021/bi00418a040; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASSON D, 1985, J BIOL CHEM, V260, P9069; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MILLARD PJ, 1984, J IMMUNOL, V132, P3197; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUELLER C, 1988, J EXP MED, V167, P1124, DOI 10.1084/jem.167.3.1124; Nemeth MJ, 2006, P NATL ACAD SCI USA, V103, P13783, DOI 10.1073/pnas.0604006103; OCONNELL PJ, 1993, J IMMUNOL, V150, P1093; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; PODACK ER, 1984, J EXP MED, V160, P695, DOI 10.1084/jem.160.3.695; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; PODACK ER, 1983, NATURE, V302, P442, DOI 10.1038/302442a0; POE M, 1991, J BIOL CHEM, V266, P98; PRENDERGAST JA, 1992, J BIOL CHEM, V267, P5090; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1983, IMMUNOL REV, V72, P97, DOI 10.1111/j.1600-065X.1983.tb01074.x; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; RUSSELL JH, 1982, J IMMUNOL, V128, P2087; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SITKOVSKY MV, 1993, CYTOTOXIC CELLS; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; WIJNGAARD PLJ, 1993, TRANSPLANTATION, V55, P103, DOI 10.1097/00007890-199301000-00020; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	65	728	744	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	1994	76	6					977	987		10.1016/0092-8674(94)90376-X	http://dx.doi.org/10.1016/0092-8674(94)90376-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	8137431				2022-12-01	WOS:A1994ND24600005
J	WICKMAN, KD; INIGUEZLLUHI, JA; DAVENPORT, PA; TAUSSIG, R; KRAPIVINSKY, GB; LINDER, ME; GILMAN, AG; CLAPHAM, DE				WICKMAN, KD; INIGUEZLLUHI, JA; DAVENPORT, PA; TAUSSIG, R; KRAPIVINSKY, GB; LINDER, ME; GILMAN, AG; CLAPHAM, DE			RECOMBINANT G-PROTEIN BETA-GAMMA-SUBUNITS ACTIVATE THE MUSCARINIC-GATED ATRIAL POTASSIUM CHANNEL	NATURE			English	Article							BINDING REGULATORY PROTEINS; K+ CHANNELS; AFFINITY; PRENYLATION; RECEPTORS; MEMBRANES; CELLS; HEART	ACETYLCHOLINE activates inwardly rectifying potassium channels (I-K.ACh) in the heart(1) through muscarinic receptor binding and activation of pertussis-toxin-sensitive G proteins(2,3). Experiments showing that only the beta gamma-subunit (G beta gamma) activates I-K.ACh (ref. 4) were challenged by reports that only the activated alpha-subunit (G alpha) was effective(5). Here we examine I-K.ACh regulation using purified brain and recombinant G-protein subunits. Six recombinant G beta gamma-subunits activated I-K.ACh with apparent half-maximal activation concentrations of 3-30 nM. Activation of I-K.ACh by recombinant G alpha-GTP gamma S was observed, but this was probably due to release of GTP gamma S from the protein. Importantly, I-K.ACh activity elicited by GTP gamma S was inhibited by purified brain and recombinant G alpha-GDP, suggesting that native G beta gamma plays a major role in this pathway. We conclude that G beta gamma is a primary regulator of I-K.ACh activity.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905; UNIV TEXAS,SW MED CTR,DALLAS,TX 75235	Mayo Clinic; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Linder, Maurine/AAU-9999-2021; Clapham, David/R-5974-2019	Linder, Maurine/0000-0003-2202-9712; Clapham, David/0000-0002-4459-9428; Iniguez-Lluhi, Jorge/0000-0001-7010-089X; Wickman, Kevin/0000-0002-5179-9540				BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MATTERA R, 1989, J BIOL CHEM, V264, P465; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAUSSIG R, 1993, SCIENCE, V268, P9; UEDA N, IN PRESS J BIOL CHEM	17	398	404	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					255	257		10.1038/368255a0	http://dx.doi.org/10.1038/368255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145826				2022-12-01	WOS:A1994NA87000059
J	BENJAMIN, EJ; LEVY, D; VAZIRI, SM; DAGOSTINO, RB; BELANGER, AJ; WOLF, PA				BENJAMIN, EJ; LEVY, D; VAZIRI, SM; DAGOSTINO, RB; BELANGER, AJ; WOLF, PA			INDEPENDENT RISK-FACTORS FOR ATRIAL-FIBRILLATION IN A POPULATION-BASED COHORT - THE FRAMINGHAM HEART-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDEMIOLOGIC FEATURES; PREVENTION; STROKE; MORTALITY; WARFARIN; DISEASE; RHYTHM; TRIALS; TIME	Objective.-To determine the independent risk factors for atrial fibrillation. Design.-Cohort study. Setting.-The Framingham Heart Study. Subjects.-A total of 2090 men and 2641 women members of the original cohort, free of a history of atrial fibrilltation, between the ages of 55 and 94 years. Main Outcome Measures.-Sex-specific multiple logistic regression models to identify independent risk factors for atrial fibrillation, including age, smoking, diabetes, electrocardiographic left ventricular hypertrophy, hypertension, myocardial infarction, congestive heart failure, and valve disease. Results.-During up to 38 years of follow-up, 264 men and 298 women developed atrial fibrillation, After adjusting for age and other risk factors for atrial fibrillation, men had a 1.5 times greater risk of developing atrial fibrillation than women. In the full multivariable model, the odds ratio (OR) of atrial fibrillation for each decade of advancing age was 2.1 for men and 2.2 for women (P<.0001). In addition, after multivariable adjustment, diabetes (OR, 1.4 for men and 1.6 for women), hypertension (OR, 1.5 for men and 1.4 for women), congestive heart failure (OR, 4.5 for men and 5.9 for women), and valve disease (OR, 1.8 for men and 3.4 for women) were significantly associated with risk for atrial fibrillation in both sexes. Myocardial infarction (OR, 1.4) was significantly associated with the development of atrial fibrillation in men. Women were significantly more likely than men to have valvular heart disease as a risk factor for atrial fibrillation. The multivariable models were largely unchanged after eliminating subjects with valvular heart disease. Conclusion.-In addition to intrinsic cardiac causes such as valve disease and congestive heart failure, risk factors for cardiovascular disease also predispose to atrial fibrillation. Modification of risk factors for cardiovascular disease may have the added benefit of diminishing the incidence of atrial fibrillation.	BOSTON UNIV, BOSTON CITY HOSP, SCH MED, CARDIOL SECT, BOSTON, MA 02118 USA; NHLBI, BETHESDA, MD 20892 USA; BOSTON UNIV, DEPT MATH, BOSTON, MA 02215 USA; BOSTON UNIV, SCH MED, DEPT PREVENT MED, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; BETH ISRAEL HOSP, DIV CARDIOL, BOSTON, MA USA; BETH ISRAEL HOSP, DIV CLIN EPIDEMIOL, BOSTON, MA USA	Boston Medical Center; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	BENJAMIN, EJ (corresponding author), FRAMINGHAM HEART DIS EPIDEMIOL STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA.		Levy, Daniel/ABF-6873-2021; Benjamin, Emelia/E-7103-2011	Levy, Daniel/0000-0003-1843-8724; Benjamin, Emelia/0000-0003-4076-2336; Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-R01-NS-17950-11] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABERG H, 1968, ACTA MED SCAND, V184, P425; ALBERS GW, 1991, ANN NEUROL, V30, P511, DOI 10.1002/ana.410300402; CAMERON A, 1988, AM J CARDIOL, V61, P714, DOI 10.1016/0002-9149(88)91053-3; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DAVIDSON E, 1989, ARCH INTERN MED, V149, P457, DOI 10.1001/archinte.149.2.457; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; ETTINGER PO, 1978, AM HEART J, V95, P555, DOI 10.1016/0002-8703(78)90296-X; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; GAJEWSKI J, 1981, JAMA-J AM MED ASSOC, V245, P1540; GODTFREDSEN J, 1982, ATRIAL FIBRILLATION, P134; KANNEL WB, 1983, AM HEART J, V106, P389, DOI 10.1016/0002-8703(83)90208-9; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; McEachern D, 1932, AM J MED SCI, V183, P35, DOI 10.1097/00000441-193201000-00004; ONUNDARSON PT, 1987, EUR HEART J, V8, P521; PETERSEN P, 1989, LANCET, V1, P175; ROBINSON K, 1990, J AM COLL CARDIOL, V15, P1279, DOI 10.1016/S0735-1097(10)80014-2; SAWYER C G, 1958, South Med J, V51, P84; SHERMAN DG, 1984, ARCH NEUROL-CHICAGO, V41, P708, DOI 10.1001/archneur.1984.04050180030011; SHURTLEFF D, 1974, DHEW NIH74599 PUBL; Stroud WD, 1932, AM J MED SCI, V183, P48; VAZIRI SM, 1994, CIRCULATION, V89, P724, DOI 10.1161/01.CIR.89.2.724; WALKER SD, 1976, BIOMETRICS, V32, P829; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; WOOD P, 1954, BRIT MED J, V1, P1063	31	2217	2271	2	64	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					840	844		10.1001/jama.271.11.840	http://dx.doi.org/10.1001/jama.271.11.840			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114238				2022-12-01	WOS:A1994MZ49800030
J	BELRHALI, H; YAREMCHUK, A; TUKALO, M; LARSEN, K; BERTHETCOLOMINAS, C; LEBERMAN, R; BEIJER, B; SPROAT, B; ALSNIELSEN, J; GRUBEL, G; LEGRAND, JF; LEHMANN, M; CUSACK, S				BELRHALI, H; YAREMCHUK, A; TUKALO, M; LARSEN, K; BERTHETCOLOMINAS, C; LEBERMAN, R; BEIJER, B; SPROAT, B; ALSNIELSEN, J; GRUBEL, G; LEGRAND, JF; LEHMANN, M; CUSACK, S			CRYSTAL-STRUCTURES AT 2.5 ANGSTROM RESOLUTION OF SERYL-TRANSFER-RNA SYNTHETASE COMPLEXED 2 ANALOGS OF SERYL ADENYLATE	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; SERINE HYDROXAMATE; SEQUENCE; ATP	Crystal structures of seryl-tRNA synthetase from Thermus thermophilus complexed with two different analogs of seryl adenylate have been determined at 2.5 Angstrom resolution. The first complex is between the enzyme and seryl-hydroxamate-AMP (adenosine monophosphate), produced enzymatically in the crystal from adenosine triphosphate (ATP) and serine hydroxamate, and the second is with a synthetic analog of seryl adenylate (5'-O-[N-(L-seryl)-sulfamoyl]adenosine), which is a strong inhibitor of the enzyme. Both molecules are bound in a similar fashion by a network of hydrogen bond interactions in a deep hydrophilic cleft formed by the antiparallel beta sheet and surrounding loops of the synthetase catalytic domain. Four regions in the primary sequence are involved in the interactions, including the motif 2 and 3 regions of class 2 synthetases. Apart from the specific recognition of the serine side chain, the interactions are likely to be similar in all class 2 synthetases.	ILL GRENOBLE, EMBL, GRENOBLE OUTSTN, F-38042 GRENOBLE 9, FRANCE; EMBL, BIOCHEM INSTRUMENTAT PROGRAMME, D-69012 HEIDELBERG, GERMANY; EUROPEAN SYNCHROTRON RADIAT FACIL, F-38043 GRENOBLE, FRANCE	European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL); European Molecular Biology Laboratory (EMBL); European Synchrotron Radiation Facility (ESRF)				Tukalo, Michael/0000-0002-0982-2372				BEGUM AS, 1988, ACTA CRYSTALLOGR C, V44, P1047; BELRHALI H, UNPUB; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRICK P, 1987, J MOL BIOL, V194, P287, DOI 10.1016/0022-2836(87)90376-7; BRUNGER AT, 1993, X PLOR VERSION 3 1; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CASTROPICHEL J, 1987, TETRAHEDRON, V43, P383, DOI 10.1016/S0040-4020(01)89967-1; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1993, TRANSLATIONAL APPARATUS, P1; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DEPOUPLANA LR, 1993, PROTEIN SCI, V2, P2259; DOUBLIE S, 1993, THESIS U N CAROLINA; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FOURME R, 1992, REV SCI INSTRUM, V63, P982, DOI 10.1063/1.1143716; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; GARBER MB, 1990, J MOL BIOL, V213, P631, DOI 10.1016/S0022-2836(05)80251-7; KAST P, 1991, J MOL BIOL, V222, P99, DOI 10.1016/0022-2836(91)90740-W; LARSEN KJ, UNPUB; LEHMANN MS, 1993, NEWSLETTER PROTEIN C; Leslie A, 1992, NEWSLETTER PROTEIN C; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; TOSA T, 1971, J BACTERIOL, V106, P972, DOI 10.1128/JB.106.3.972-982.1971; TOSA T, 1971, J BACTERIOL, V106, P966, DOI 10.1128/JB.106.3.966-971.1971; UEDA H, 1991, BIOCHIM BIOPHYS ACTA, V1080, P126, DOI 10.1016/0167-4838(91)90138-P	31	156	163	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 11	1994	263	5152					1432	1436		10.1126/science.8128224	http://dx.doi.org/10.1126/science.8128224			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	MZ927	8128224				2022-12-01	WOS:A1994MZ92700030
J	GARCIA, CK; GOLDSTEIN, JL; PATHAK, RK; ANDERSON, RGW; BROWN, MS				GARCIA, CK; GOLDSTEIN, JL; PATHAK, RK; ANDERSON, RGW; BROWN, MS			MOLECULAR CHARACTERIZATION OF A MEMBRANE TRANSPORTER FOR LACTATE, PYRUVATE, AND OTHER MONOCARBOXYLATES - IMPLICATIONS FOR THE CORI CYCLE	CELL			English	Article							ERYTHROCYTE-MEMBRANE; SKELETAL-MUSCLE; RAT; IDENTIFICATION; PURIFICATION; MEVALONATE; INHIBITION; MECHANISM; PROTEIN; CARRIER	Lactate and pyruvate cross cell membranes via a monocarboxylate transporter (MCT) with well-defined properties but undefined molecular structure. We report the cloning of a cDNA encoding MCT1, a monocarboxylate transporter whose properties resemble those of the erythrocyte MCT, including proton symport, trans acceleration, and sensitivity to alpha-cyanocinammates. A Phe to Cys substitution in MCT1 converts it to Mev, a mevalonate transporter. MCT1 is abundant in erythrocytes, cardiac muscle, and basolateral intestinal epithelium. In skeletal muscle it is restricted to mitochondria-rich myocytes. As sperm traverse the epididymis, MCT1 switches from sperm to epithelial cells. MCT1 is present at low levels in liver, suggesting another MCT in this tissue. By exporting lactate from intestine and erythrocytes, MCT1 participates in the Cori cycle. It also participates in novel pathways of monocarboxylate metabolism in muscle and sperm.	UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	GARCIA, CK (corresponding author), UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA.				NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014, GM07062] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN MS, 1978, J BIOL CHEM, V253, P1121; BUCHALTER SE, 1989, DIABETES METAB REV, V5, P379, DOI 10.1002/dmr.5610050405; DEUTICKE B, 1982, BIOCHIM BIOPHYS ACTA, V684, P96, DOI 10.1016/0005-2736(82)90053-0; DRAKE AJ, 1980, CARDIOVASC RES, V14, P65, DOI 10.1093/cvr/14.2.65; DUBINSKY WP, 1978, J MEMBRANE BIOL, V44, P25, DOI 10.1007/BF01940571; Dubowitz V., 1973, MUSCLE BIOPSY MODERN, P34; FAUST J, 1987, J BIOL CHEM, V262, P1996; GLADDEN LB, 1989, EXERCISE SPORT SCI R, V17, P115; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALESTRAP AP, 1974, BIOCHEM J, V138, P313, DOI 10.1042/bj1380313; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; JENNINGS ML, 1982, J BIOL CHEM, V257, P2866; KIM CM, 1992, J BIOL CHEM, V267, P23113; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDERMOTT JC, 1993, MOL CELL BIOCHEM, V122, P113, DOI 10.1007/BF01076095; NAVE JF, 1985, BIOCHEM J, V227, P247, DOI 10.1042/bj2270247; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; POOLE RC, 1992, BIOCHEM J, V283, P855, DOI 10.1042/bj2830855; POOLE RC, 1988, BIOCHEM J, V254, P385, DOI 10.1042/bj2540385; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; POOLE RC, 1990, BIOCHEM J, V269, P827, DOI 10.1042/bj2690827; REICHMANN H, 1982, HISTOCHEMISTRY, V74, P27, DOI 10.1007/BF00495049; ROTH DA, 1990, ARCH BIOCHEM BIOPHYS, V279, P377, DOI 10.1016/0003-9861(90)90505-S; Sambrook J., 1989, MOL CLONING LAB MANU; SPENCER TL, 1976, BIOCHEM J, V154, P405, DOI 10.1042/bj1540405; Stein WD, 1986, TRANSPORT DIFFUSION, P231; VOET D, 1990, BIOCHEMISTRY-US, P568	27	419	435	1	52	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 11	1994	76	5					865	873		10.1016/0092-8674(94)90361-1	http://dx.doi.org/10.1016/0092-8674(94)90361-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124722				2022-12-01	WOS:A1994NA89000012
J	ZHENG, JQ; FELDER, M; CONNOR, JA; POO, MM				ZHENG, JQ; FELDER, M; CONNOR, JA; POO, MM			TURNING OF NERVE GROWTH CONES INDUCED BY NEUROTRANSMITTERS	NATURE			English	Article							PROTEIN KINASE-II; INTRACELLULAR CALCIUM; NEURITE ELONGATION; ACETYLCHOLINE-RECEPTORS; IDENTIFIED NEURONS; GUIDANCE; MOTILITY; SEROTONIN; CULTURE; AXONS	PATHFINDING by growing nerve processes in the developing nervous system depends on the turning response of the growing tip, the growth cone, to extracellular guidance cues(1-4). There is evidence in vivo and in cell culture that some growth cones exhibit chemotropic behaviour(5-12), but the identity of endogenous chemoattractants remains elusive. Neurotransmitters appear early in the developing embryo and may have morphogenic roles in development(13,14). In cell culture a number of neurotransmitters were found to induce growth inhibition or retraction of neurites(15-19). Here we report positive turning responses of the nerve growth cone in a defined extracellular gradient of the neurotransmitter acetylcholine (ACh). The growth cone response depends on the activation of neuronal nicotinic ACh receptors, requires the presence of extracellular Ca2+, and appears to be mediated by Ca2+-calmodulin-dependent protein kinase II. Fluorescence imaging of cytosolic Ca2+ concentration ([Ca2+](i)) at the growth cone showed a small but significant evaluation of [Ca2+](i) within minutes of the onset of ACh application and before the turning of the growth cone. These findings suggest that neurotransmitters may serve as specific chemoattractants for growth cone guidance and that cytosolic Ca2+ may act as a second messenger in the cytoplasm of the growth cone to initiate the turning response.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA; ROCHE RES CTR, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA	Columbia University; Roche Holding								ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; BEDLACK RS, 1992, NEURON, V9, P393, DOI 10.1016/0896-6273(92)90178-G; BIXBY JL, 1984, DEV BIOL, V106, P89, DOI 10.1016/0012-1606(84)90065-4; BRAY D, 1988, ANNU REV CELL BIOL, V4, P43, DOI 10.1146/annurev.cb.04.110188.000355; BUZNIKOV GA, 1968, J EMBRYOL EXP MORPH, V20, P119; COHAN CS, 1987, J NEUROSCI, V7, P3588; Conner J.A., 1982, Lectures on Mathematics in the Life Sciences, V15, P79; CONNOR JA, 1993, CELL CALCIUM, V14, P185, DOI 10.1016/0143-4160(93)90066-F; DAVENPORT RW, 1992, NEURON, V9, P405, DOI 10.1016/0896-6273(92)90179-H; EVERS J, 1989, J NEUROSCI, V9, P1523; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HAYDON PG, 1984, SCIENCE, V226, P561, DOI 10.1126/science.6093252; ITO I, 1991, NEUROSCI LETT, V121, P119, DOI 10.1016/0304-3940(91)90663-E; JEFFNER CD, 1990, SCIENCE, V247, P217; LANDMESSER L, 1986, TRENDS NEUROSCI, V9, P489, DOI 10.1016/0166-2236(86)90156-6; LANKFORD KL, 1988, P NATL ACAD SCI USA, V85, P2839, DOI 10.1073/pnas.85.8.2839; LAUDER JM, 1988, PROG BRAIN RES, V73, P365; LETO, 1985, LETOURNEAU P, P269; LETOURNEAU PC, 1978, DEV BIOL, V66, P183, DOI 10.1016/0012-1606(78)90283-X; LIPTON SA, 1988, SCIENCE, V239, P1293, DOI 10.1126/science.3344435; LOHOF AM, 1992, J NEUROSCI, V12, P1253; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MATTSON MP, 1988, J NEUROSCI, V8, P2087; MATTSON MP, 1987, J NEUROSCI, V7, P4034; MCCOBB DP, 1988, NEURON, V1, P377, DOI 10.1016/0896-6273(88)90187-0; MCCOBB DP, 1988, J NEUROSCI RES, V19, P19, DOI 10.1002/jnr.490190104; MCCRAIG CD, 1986, J PHYSL, V375, P39; Menesini Chen M G, 1978, Arch Ital Biol, V116, P53; PATEL NB, 1984, J NEUROSCI, V4, P2939; PURVES D, 1985, PRINCIPLES NEURAL DE; REHDER V, 1992, J NEUROSCI, V12, P3175, DOI 10.1523/JNEUROSCI.12-08-03175.1992; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; Tabti N., 1991, CULTURING NERVE CELL, P137; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; VERNINO S, 1992, NEURON, V8, P127, DOI 10.1016/0896-6273(92)90114-S; VIJAYARAGHAVAN S, 1992, NEURON, V8, P353, DOI 10.1016/0896-6273(92)90301-S; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YAGINUMA H, 1991, J NEUROSCI, V11, P2598	40	508	517	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 10	1994	368	6467					140	144		10.1038/368140a0	http://dx.doi.org/10.1038/368140a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139655				2022-12-01	WOS:A1994NA03000064
J	EMSLEY, J; WHITE, HE; OHARA, BP; OLIVA, G; SRINIVASAN, N; TICKLE, IJ; BLUNDELL, TL; PEPYS, MB; WOOD, SP				EMSLEY, J; WHITE, HE; OHARA, BP; OLIVA, G; SRINIVASAN, N; TICKLE, IJ; BLUNDELL, TL; PEPYS, MB; WOOD, SP			STRUCTURE OF PENTAMERIC HUMAN SERUM AMYLOID-P COMPONENT	NATURE			English	Article							C-REACTIVE PROTEIN; CYCLIC 4,6-PYRUVATE ACETAL; BINDING-PROTEIN; CONCANAVALIN-A; SENSITIVE SITE; CALCIUM; RESOLUTION; GALACTOSE; SPECIFICITY; REFINEMENT	The three-dimensional structure of pentameric human serum amyloid P component at high resolution, the first reported for a pentraxin, reveals that the tertiary fold is remarkably similar to that of the legume lectins. Carboxylate and phosphate compounds bind directly to two calcium ions; interactions with a carboxyethylidene ring are mediated by Asn 59 and Gln 148 ligands of the calcium ions. These X-ray results indicate the probable modes of binding of the biologically important ligands, DNA and amyloid fibrils.	UNIV LONDON BIRKBECK COLL,MOLEC BIOL LAB,LONDON WC1E 7HX,ENGLAND; UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,ICRF,STRUCT MOLEC BIOL UNIT,LONDON WC1E 7HX,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,IMMUNOL MED UNIT,LONDON W12 0NN,ENGLAND	University of London; Birkbeck University London; University of London; Birkbeck University London; Imperial College London			emsley, jonas/A-8509-2016; Oliva, Glaucius/B-9059-2012; Wood, Stephen P/B-1438-2009	emsley, jonas/0000-0002-8949-8030; Oliva, Glaucius/0000-0003-2719-0302; Tickle, Ian/0000-0003-2977-0650				AGRAWAL A, 1992, J BIOL CHEM, V267, P25352; BREATHNACH SM, 1981, NATURE, V293, P652, DOI 10.1038/293652a0; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BUTLER PJG, 1990, J EXP MED, V172, P13, DOI 10.1084/jem.172.1.13; CARRINGTON DM, 1985, NATURE, V313, P64, DOI 10.1038/313064a0; CORIA F, 1988, LAB INVEST, V58, P454; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; DYCK RF, 1980, J EXP MED, V152, P1162, DOI 10.1084/jem.152.5.1162; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; HANEEF I, 1985, ACTA CRYSTALLOGR A, V41, P426, DOI 10.1107/S0108767385000915; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; HARTSHORN KL, 1993, J CLIN INVEST, V91, P1414, DOI 10.1172/JCI116345; HAWKINS PN, 1991, CLIN EXP IMMUNOL, V84, P308; HAWKINS PN, 1990, NEW ENGL J MED, V323, P508, DOI 10.1056/NEJM199008233230803; HIND CRK, 1984, J EXP MED, V159, P1058, DOI 10.1084/jem.159.4.1058; HIND CRK, 1984, BIOCHIM BIOPHYS ACTA, V802, P148, DOI 10.1016/0304-4165(84)90045-X; HIND CRK, 1984, LANCET, V2, P376; HIND CRK, 1985, BIOCHEM J, V225, P107, DOI 10.1042/bj2250107; HUTCHINSON EG, 1990, PROTEINS, V8, P203, DOI 10.1002/prot.340080303; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P272; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KINOSHITA CM, 1992, PROTEIN SCI, V1, P700, DOI 10.1002/pro.5560010602; KINOSHITA CM, 1989, BIOCHEMISTRY-US, V28, P9840, DOI 10.1021/bi00451a044; LIU TY, 1987, J PROTEIN CHEM, V6, P263; OVERINGTON J, 1990, P ROY SOC B-BIOL SCI, V241, P132, DOI 10.1098/rspb.1990.0077; PEPYS MB, 1977, LANCET, V1, P1029; PEPYS MB, 1979, CLIN EXP IMMUNOL, V38, P284; PEPYS MB, 1987, BIOCHEM BIOPH RES CO, V148, P308, DOI 10.1016/0006-291X(87)91111-9; PEPYS MB, 1978, NATURE, V273, P168, DOI 10.1038/273168a0; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; PEPYS MB, 1993, 41ST P ASMS C MASS S; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; SALI A, 1990, TRENDS BIOCHEM SCI, V15, P235, DOI 10.1016/0968-0004(90)90036-B; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; SWANSON SJ, 1990, MOL IMMUNOL, V27, P679, DOI 10.1016/0161-5890(90)90011-N; TENNENT GA, 1993, EUR J BIOCHEM, V214, P91, DOI 10.1111/j.1432-1033.1993.tb17900.x; TURNELL WG, 1988, FEBS LETT, V232, P263, DOI 10.1016/0014-5793(88)80750-6; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOOD SP, 1988, J MOL BIOL, V202, P169, DOI 10.1016/0022-2836(88)90529-3	42	414	439	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					338	345		10.1038/367338a0	http://dx.doi.org/10.1038/367338a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	8114934				2022-12-01	WOS:A1994MT54000058
J	WALMRATH, D; SCHNEIDER, T; PILCH, J; GRIMMINGER, F; SEEGER, W				WALMRATH, D; SCHNEIDER, T; PILCH, J; GRIMMINGER, F; SEEGER, W			AEROSOLIZED PROSTACYCLIN IN ADULT-RESPIRATORY-DISTRESS-SYNDROME	LANCET			English	Note							INHALED NITRIC-OXIDE; PULMONARY-HYPERTENSION	We studied the effects of aerosolised prostacyclin (PGI2) in three patients with acute severe adult respiratory distress syndrome. 17-50 ng/kg per min, nebulised into the afferent limb of the ventilator circuit, decreased mean pulmonary artery pressure (SEM) from 40.3 (13.5) to 32.0 (3.8) mm Hg (pulmonary vascular resistance fell by 30%); systemic arterial pressure decreased slightly from 76.8 (2.2) to 74.5 (6.1) mm Hg. Concomitantly, the ratio of arterial oxygen partial pressure to the fraction of inspired oxygen increased from 120 (19) to 173 (18), mainly due to redistribution of blood flow from shunt areas to regions of normal ventilation-perfusion. All effects were reversed on drug withdrawal.	UNIV GIESSEN,DEPT INTERNAL MED,KLIN STR 36,W-6300 GIESSEN,GERMANY	Justus Liebig University Giessen				Grimminger, Friedrich/0000-0001-8725-6276; Seeger, Werner/0000-0003-1946-0894				BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; HARDY CC, 1988, J APPL PHYSIOL, V64, P1567, DOI 10.1152/jappl.1988.64.4.1567; HIGENBOTTAM T, 1987, AM REV RESPIR DIS, V136, P782, DOI 10.1164/ajrccm/136.3.782; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; MELOT C, 1989, AM REV RESPIR DIS, V139, P106, DOI 10.1164/ajrccm/139.1.106; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; RADERMACHER P, 1990, INTENS CARE MED, V16, P227, DOI 10.1007/BF01705156; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; WAGNER PD, 1974, J APPL PHYSIOL, V36, P588, DOI 10.1152/jappl.1974.36.5.588	10	232	239	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					961	962		10.1016/0140-6736(93)92004-D	http://dx.doi.org/10.1016/0140-6736(93)92004-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC005	8105216				2022-12-01	WOS:A1993MC00500011
J	CALNE, RY				CALNE, RY			RESECTION OF LARGE LIVER-TUMORS - LESSONS FROM TRANSPLANTATION SURGERY	LANCET			English	Editorial Material											CALNE, RY (corresponding author), UNIV CAMBRIDGE,SCH CLIN,DEPT SURG,CAMBRIDGE,ENGLAND.							FORTNER JG, 1974, ANN SURG, V180, P644; PICHLMAYR R, 1990, BRIT J SURG, V77, P21, DOI 10.1002/bjs.1800770107; YANAGA K, 1993, SURGERY, V113, P637	3	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					386	386						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101898				2022-12-01	WOS:A1993LR90000006
J	ROS, E; NAVARRO, S; BRU, C; GILABERT, R; BIANCHI, L; BRUGUERA, M				ROS, E; NAVARRO, S; BRU, C; GILABERT, R; BIANCHI, L; BRUGUERA, M			URSODEOXYCHOLIC ACID TREATMENT OF PRIMARY HEPATOLITHIASIS IN CAROLIS SYNDROME	LANCET			English	Note							INTRAHEPATIC CHOLESTEROL STONES; DISSOLUTION THERAPY; GALLSTONES; DISEASE	Congenital cystic dilation of the intrahepatic bile ducts (Caroli's syndrome) is a rare cause of chronic cholestasis and hepatolithiasis in young adults. Long-term prognosis is poor even with surgical drainage. We treated twelve patients who had Caroli's syndrome and intrahepatic stones with ursodeoxycholic acid (UDCA), 10-20 mg/kg daily. The duodenal bile of these patients contained cholesterol crystals, which suggests that the stones were cholesterol rich. UDCA led to sustained clinical remission, return to normal liver function, and dissolution of intrahepatic stones on ultrasound in all patients (nine partial, three complete) after 48 (range 12-114) months' follow-up. Litholytic therapy is indicated for intrahepatic stones in Caroli's syndrome.	HOSP CLIN BARCELONA,DEPT RADIOL,E-08036 BARCELONA,SPAIN; HOSP CLIN BARCELONA,LIVER UNIT,E-08036 BARCELONA,SPAIN	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona	ROS, E (corresponding author), HOSP CLIN BARCELONA,GASTROENTEROL SERV,C VILLARROEL 170,E-08036 BARCELONA,SPAIN.		Navarro, Samuel/AAD-2021-2020	Navarro, Samuel/0000-0001-5016-5653; Ros, Emilio/0000-0002-2573-1294				BENHAMOU JP, 1987, DISEASES LIVER, P1461; CAROLI J, 1958, Sem Hop, V34, P488; DAYTON MT, 1983, AM J SURG, V145, P41, DOI 10.1016/0002-9610(83)90164-2; DECAESTECKER JS, 1991, GUT, V32, P1061, DOI 10.1136/gut.32.9.1061; HEUMAN DM, 1991, HEPATOLOGY, V14, P920, DOI 10.1002/hep.1840140527; OKUDA K, 1984, INTRAHEPATIC CALCULI; ROS E, 1986, GASTROENTEROLOGY, V91, P703, DOI 10.1016/0016-5085(86)90642-6; SCHILLIO Y, 1992, DIGEST DIS SCI, V37, P1460, DOI 10.1007/BF01296020; SEDAGHAT A, 1980, NEW ENGL J MED, V302, P1274, DOI 10.1056/NEJM198006053022302; STRICHARTZ SD, 1991, GASTROENTEROLOGY, V100, P228, DOI 10.1016/0016-5085(91)90605-K	10	72	77	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 14	1993	342	8868					404	406		10.1016/0140-6736(93)92817-D	http://dx.doi.org/10.1016/0140-6736(93)92817-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR900	8101905				2022-12-01	WOS:A1993LR90000013
J	VANDERWAALS, FW; MOHRS, J; FOETS, M				VANDERWAALS, FW; MOHRS, J; FOETS, M			SEX-DIFFERENCES AMONG RECIPIENTS OF BENZODIAZEPINES IN DUTCH GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							SEDATIVE DRUG-USE; PREVALENCE; DURATION	Objective-To analyse sex differences among recipients of benzodiazepines in Dutch general practice. Design-Study of consultations and associated interventions as recorded in the Dutch national survey of general practice. Setting-Practices of 45 general practitioners monitored during 1 April to 30 June 1987. Subjects-61249 patients (29035 (47.4%) men in the age groups 19-44, 45-64, and 65 years and over. Main outcome measures-Symptoms among recipients of repeat as well as new benzodiazepine prescriptions stratified by sex and age. Results-Prescriptions for benzodiazepines were found to be significantly more common among women than among men, (a) after correcting for the sex distribution of the total patient population, and (b) in the two oldest age groups after correcting for the number of consultations. Of all prescriptions for benzodiazepines, 89% (6055/6777) were repeats and 70% (4759/6777) requests. Only 9% (439/4759) of these were authorised by the general practitioner, the rest being issued by the general practitioner's assistant after he or she had referred to the diagnosis in the patient's record. In contrast, only three (1%) of the 492 first time recipients of benzodiazepines had requested a prescription and were not seen by the general practitioner. Women (43/96; 45%) aged 45-64 years received their first prescription for benzodiazepines almost twice as often as men (15/63; 24%) without symptoms or a diagnosis being an indication (female to male relative risk 1.88 (95% confidence interval 1.15 to 3.08)). Conclusions-The sex difference among first time recipients of benzodiazepines seems to be due to general practitioners being less stringent when prescribing this drug for women. The difference continues in repeat prescriptions, physicians failing to check adequately the need for these.	NETHERLANDS INST PRIMARY HLTH CARE,3500 BN UTRECHT,NETHERLANDS; UNIV AMSTERDAM,FAC MED,DEPT GEN PRACTICE,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam	VANDERWAALS, FW (corresponding author), UNIV AMSTERDAM,FAC MED,1105 AZ AMSTERDAM,NETHERLANDS.							BALTER MB, 1974, NEW ENGL J MED, V290, P769, DOI 10.1056/NEJM197404042901404; BALTER MB, 1984, CURR MED RES OPIN, V8, P5; Bensing JM, 1991, HUISARTS WETENSCHAP, V34, P51; BLIJENBERGRUIS B, 1986, TIJDSCHRIFT SOCIALE, V64, P491; CATALAN J, 1988, BRIT J PSYCHIAT, V152, P399, DOI 10.1192/bjp.152.3.399; HAAFKENS J, 1992, CONT DRUG PROBLE FAL, P505; HERINGS RMC, 1989, EFFECTEN CHRONISCH G; Lamberts H., 1987, INT CLASSIFICATION P; MELLINGER GD, 1984, CURR MED RES OPIN, V8, P21, DOI 10.1185/03007998409109542; MELLINGER GD, 1984, JAMA-J AM MED ASSOC, V251, P375, DOI 10.1001/jama.251.3.375; MORGAN K, 1988, BRIT MED J, V296, P601, DOI 10.1136/bmj.296.6622.601; NIJLAND A, 1991, THESIS RIJKS U GRONI; NOLAN L, 1988, EUR J CLIN PHARMACOL, V35, P225, DOI 10.1007/BF00558257; POST D, 1988, PHARM WEEKBLAD, V123, P522; RODRIGO EK, 1988, BMJ-BRIT MED J, V296, P603, DOI 10.1136/bmj.296.6622.603; SWINKELS H, 1990, HUISARTS WET, V33, P504; TIMMERMANS AJG, 1983, MED CONTACT, V38, P1331; VANASSELT JW, 1989, SLAAPVERWEKKEND ONDE; VANDENBREKEL EJG, 1987, MAANDBERICHTEN GEZON, V3, P5; VANDERVELDEN J, 1989, INT CLASSIFICATION P; WOODS JH, 1987, PHARMACOL REV, V39, P251; 1993, VADEMECUM GEZONDHEID; 1989, DIAGNOSE INFORMATIE; 1989, VODEMECUM GEZONDHEID	24	80	82	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					363	366		10.1136/bmj.307.6900.363	http://dx.doi.org/10.1136/bmj.307.6900.363			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR768	8104066	Green Published, Bronze			2022-12-01	WOS:A1993LR76800022
J	TYLER, VE				TYLER, VE			REJUVEX FOR POSTMENOPAUSAL SYMPTOMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											TYLER, VE (corresponding author), PURDUE UNIV,W LAFAYETTE,IN 47907, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1210	1210		10.1001/jama.1994.03510390082038	http://dx.doi.org/10.1001/jama.1994.03510390082038			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	8151882				2022-12-01	WOS:A1994NF20700035
J	RAJARATHNAM, K; SYKES, BD; KAY, CM; DEWALD, B; GEISER, T; BAGGIOLINI, M; CLARKLEWIS, I				RAJARATHNAM, K; SYKES, BD; KAY, CM; DEWALD, B; GEISER, T; BAGGIOLINI, M; CLARKLEWIS, I			NEUTROPHIL ACTIVATION BY MONOMERIC INTERLEUKIN-8	SCIENCE			English	Article							PEPTIDE-1 INTERLEUKIN-8; CRYSTAL-STRUCTURE; RECEPTOR-BINDING; CYTOKINE; RESIDUES; PROTEINS; FAMILY; DIMER	Interleukin-8 (IL-8), a pro-inflammatory protein, has been shown by nuclear magnetic resonance (NMR) and x-ray techniques to exist as a homodimer. An IL-8 analog was chemically synthesized, with the amide nitrogen of leucine-25 methylated to selectively block formation of hydrogen bonds between monomers.and thereby prevent dimerization. This analog was shown to be a monomer, as assessed by analytical ultracentrifugation and NMR. Nevertheless, it was equivalent to IL-8 in assays of neutrophil activation, which indicates that the monomer is a functional form of IL-8.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,BIOMED RES CTR,VANCOUVER V6T 1Z3,BC,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA; UNIV BERN,THEODOR KOCHER INST,CH-3000 BERN,SWITZERLAND; UNIV BRITISH COLUMBIA,PENCE,VANCOUVER V6T 1Z3,BC,CANADA; UNIV ALBERTA,PROT ENGN NETWORK CTR EXCELLENCE,EDMONTON T6G 2S2,AB,CANADA	University of British Columbia; University of Alberta; University of Bern; University of British Columbia; University of Alberta								BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; GEISER T, UNPUB; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; IDA N, 1992, J IMMUNOL METHODS, V156, P27, DOI 10.1016/0022-1759(92)90007-G; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P925, DOI 10.1021/bi00218a007; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MOSER B, 1991, J BIOL CHEM, V266, P10666; MOSER B, 1993, J BIOL CHEM, V268, P7125; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; SEITZ M, 1991, J CLIN INVEST, V87, P463, DOI 10.1172/JCI115018; Spatola A. F., 1983, CHEM BIOCH AMINO ACI, V7, P267; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMSON M P, 1990, Biopolymers, V29, P1423, DOI 10.1002/bip.360291009; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K., 1986, NMR PROTEINS NUCL AC	32	278	289	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					90	92		10.1126/science.8140420	http://dx.doi.org/10.1126/science.8140420			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	8140420				2022-12-01	WOS:A1994ND53600036
J	LICHTENSTEIN, M; KEINI, G; CEDAR, H; BERGMAN, Y				LICHTENSTEIN, M; KEINI, G; CEDAR, H; BERGMAN, Y			B-CELL-SPECIFIC DEMETHYLATION - A NOVEL ROLE FOR THE INTRONIC KAPPA-CHAIN ENHANCER SEQUENCE	CELL			English	Article							IMMUNOGLOBULIN GENE-TRANSCRIPTION; DNA METHYLATION; GERM-LINE; STABLE INTEGRATION; CONSERVED SEQUENCE; ACTIN GENE; EXPRESSION; ELEMENTS; RECOMBINATION; REARRANGEMENT	We studied the molecular mechanism of demethylation and its role in kappa chain gene regulation. Following transfection into B cell cultures, this gene undergoes regional demethylation in a process that is developmentally regulated in a lineage- and stage-specific manner. Although a germline V kappa promoter is not required for the demodification activity, a fragment containing the intronic kappa chain transcriptional enhancer and the nearby matrix attachment region is essential. In its natural location downstream to the J kappa 5 sequence, this element induces bidirectional demodification of plasmid constructs in a distance- and orientation-independent manner. When this enhancer is placed in an upstream position, however, the kappa gene remains modified and transcriptionally inactive, demonstrating that demethylation is required for kappa chain activation. These studies suggest that the kappa enhancer plays a dual role in regulating B cell differentiation by inducing demethylation and by promoting tissue-specific transcription.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT CELLULAR BIOCHEM,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	LICHTENSTEIN, M (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,HUBERT H HUMPHREY CTR EXPTL MED & CANC RES,IL-91010 JERUSALEM,ISRAEL.							BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; Blackwell T. K., 1988, Molecular Immunology., P1; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CALAME KL, 1985, ANNU REV IMMUNOL, V3, P159, DOI 10.1146/annurev.iy.03.040185.001111; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANK D, 1990, PHILOS T ROY SOC B, V326, P241, DOI 10.1098/rstb.1990.0008; GREENBERG A, 1987, MOL CELL BIOL, V7, P936, DOI 10.1128/MCB.7.2.936; GROSSVELD FG, 1982, NUCLEIC ACIDS RES, V21, P6725; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KELLEY DE, 1988, MOL CELL BIOL, V8, P930, DOI 10.1128/MCB.8.2.930; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; LECLERCQ L, 1989, NUCLEIC ACIDS RES, V17, P6809, DOI 10.1093/nar/17.17.6809; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; MARTIN DJ, 1990, MOL CELL BIOL, V10, P1950, DOI 10.1128/MCB.10.5.1950; MATHER EL, 1983, P NATL ACAD SCI-BIOL, V80, P4689, DOI 10.1073/pnas.80.15.4689; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; NELSON KJ, 1984, NUCLEIC ACIDS RES, V12, P1911, DOI 10.1093/nar/12.4.1911; OLTZ EM, 1993, MOL CELL BIOL, V13, P6223, DOI 10.1128/MCB.13.10.6223; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; PICARD D, 1985, EMBO J, V4, P2831, DOI 10.1002/j.1460-2075.1985.tb04011.x; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; ROBERTS D, 1985, CELL, V43, P117, DOI 10.1016/0092-8674(85)90017-0; Sambrook J., 1989, MOL CLONING LAB MANU; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; TAKEDA S, 1993, EMBO J, V12, P2329, DOI 10.1002/j.1460-2075.1993.tb05887.x; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; XU M, 1989, J BIOL CHEM, V264, P21190; YISRAELI J, 1986, CELL, V46, P409, DOI 10.1016/0092-8674(86)90661-6; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638; Yisraeli J, 1984, DNA METHYLATION, P352	51	175	176	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					913	923		10.1016/0092-8674(94)90365-4	http://dx.doi.org/10.1016/0092-8674(94)90365-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	8124725				2022-12-01	WOS:A1994NA89000016
J	KAHN, JD; YUN, E; CROTHERS, DM				KAHN, JD; YUN, E; CROTHERS, DM			DETECTION OF LOCALIZED DNA FLEXIBILITY	NATURE			English	Article							ESCHERICHIA-COLI; RING-CLOSURE; GEL-ELECTROPHORESIS; BEND DIRECTION; PROTEIN HU; CYCLIZATION; REPLICATION; SIMULATION; ORIGIN; MODEL	THE bending and flexibility of DNA are important in packaging, recombination and transcription(1-3). Bending decreases electrophoretic mobility in a manner depending on bend position within a fragment (circular permutation(4)) and on the distance between bends (phasing analysis(5,6)). Bending can also affect DNA ring closure (cyclization(7-10)). The lack of a complete theory for the mechanism of gel retardation hampers measurement of bend magnitudes by electrophoresis, whereas cyclization is done entirely in solution and is well understood theoretically(9). Disagreements between bend angles estimated by the two electrophoretic assays have been ascribed to DNA flexibility(11). Here we test this interpretation using an internal loop as a model flexible locus. Whereas the circular permutation and helical phasing experiments are only subtly affected by the loop, DNA cyclization kinetics detects and quantifies substantial increases in torsional and bending flexibility. Furthermore, the results support a functional role for the stress of DNA bending in inducing base-pair opening(12).	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Yale University; Yale University			Kahn, Jason D/B-6361-2009	Kahn, Jason D/0000-0001-5060-4724				Crothers D. M., 1992, TRANSCRIPTIONAL REGU, P501; CROTHERS DM, 1971, BIOPOLYMERS, V10, P1949, DOI 10.1002/bip.360101013; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P1; DRAK J, 1991, P NATL ACAD SCI USA, V88, P3074, DOI 10.1073/pnas.88.8.3074; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HAGERMAN PJ, 1990, J MOL BIOL, V212, P351, DOI 10.1016/0022-2836(90)90130-E; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; HWANG DS, 1992, J BIOL CHEM, V267, P23083; KAHN JD, 1992, P NATL ACAD SCI USA, V89, P6343, DOI 10.1073/pnas.89.14.6343; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOTLARZ D, 1986, EMBO J, V5, P799, DOI 10.1002/j.1460-2075.1986.tb04284.x; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LEVENE SD, 1989, SCIENCE, V245, P396, DOI 10.1126/science.2756426; LEVENE SD, 1986, J MOL BIOL, V189, P61, DOI 10.1016/0022-2836(86)90381-5; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; OLSON WK, 1993, J MOL BIOL, V232, P530, DOI 10.1006/jmbi.1993.1409; RAMSTEIN J, 1988, P NATL ACAD SCI USA, V85, P7231, DOI 10.1073/pnas.85.19.7231; SALVO JJ, 1987, NUCLEIC ACIDS RES, V15, P9771, DOI 10.1093/nar/15.23.9771; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1987, CRIT REV BIOCHEM MOL, V22, P181, DOI 10.3109/10409238709101483; WEREL W, 1991, EMBO J, V10, P2589, DOI 10.1002/j.1460-2075.1991.tb07800.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZHURKIN VB, 1991, P NATL ACAD SCI USA, V88, P7046, DOI 10.1073/pnas.88.16.7046; ZIMM BH, 1993, MACROMOLECULES, V26, P226, DOI 10.1021/ma00053a035; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106	30	177	177	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					163	166		10.1038/368163a0	http://dx.doi.org/10.1038/368163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139661				2022-12-01	WOS:A1994NA03000071
J	PHILLIPS, AO; SNOWDEN, SA; HILLIS, AN; BEWICK, M				PHILLIPS, AO; SNOWDEN, SA; HILLIS, AN; BEWICK, M			RENAL GRAFTS FROM NON-HEART-BEATING DONORS	BRITISH MEDICAL JOURNAL			English	Article									KINGS COLL HOSP DULWICH,RENAL UNIT,LONDON SE22 8PT,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital								CASTELAO AM, 1991, TRANSPLANT P, V23, P2584; DALY LE, 1991, INTERPRETATION USES, P179; GEERLINGS W, 1991, P EUR DIAL TRANSPLAN, V21, P1; GOMEZ M, 1992, BR J SURG S, V79, pS144; KOZAKI M, 1991, TRANSPLANT P, V5, P2575	5	30	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 26	1994	308	6928					575	576		10.1136/bmj.308.6928.575a	http://dx.doi.org/10.1136/bmj.308.6928.575a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY714	8148682	Green Published			2022-12-01	WOS:A1994MY71400023
J	MCINNES, E; POWELL, J				MCINNES, E; POWELL, J			DRUG AND ALCOHOL REFERRALS - ARE ELDERLY SUBSTANCE-ABUSE DIAGNOSES AND REFERRALS BEING MISSED	BRITISH MEDICAL JOURNAL			English	Article							ADMISSION	Objective-To examine the diagnosis of problem substance use in hospital inpatients aged 65 years and over and their referral to drug and alcohol services by medical staff. Design-Questionnaire to registrars or house officers caring for patients 65 years of age and over with problem substance use. Setting-5 hospitals in New South Wales, Australia. Subjects-Medical staff caring for 263 inpatients. Results-Medical staff did not recognise substance misuse in older hospital patients and did not seem to be aware of current recommendations of the National Health and Medical Research Council recommendations for safe use of alcohol and benzodiazepines. Three out of 88 problem users of benzodiazepines, 29 out of 76 smokers, and 33 out of 99 problem drinkers were identified by medical staff. Of those identified with problems, 2 benzodiazepine users, 6 smokers, and 19 drinkers were considered for referral to drug and alcohol services. Conclusions-Greater awareness of recommendations for dealing with problem use of benzodiazepines and alcohol needs to be promoted among medical staff, along with an increased emphasis in medical education on substance use as a potentially important problem for older people. Drug and alcohol services also need to promote a broader role, particularly in regard to early intervention in a hospital setting for older patients.	ROYAL PRINCE ALFRED HOSP,DEPT DRUG & ALCOHOL,SYDNEY,NSW,AUSTRALIA	University of Sydney			McInnes, Liz/R-6374-2019	McInnes, Liz/0000-0002-0567-9679				BIENENFELD D, 1987, CLIN GERONTOLOGIST, V7, P3; BROWN BB, 1982, GERONTOLOGIST, V22, P519, DOI 10.1093/geront/22.6.519; CADIEUX RJ, 1989, POSTGRAD MED, V86, P179; COLT HG, 1989, J AM GERIATR SOC, V37, P323, DOI 10.1111/j.1532-5415.1989.tb05498.x; CURTIS JR, 1989, J AM GERIATR SOC, V37, P310, DOI 10.1111/j.1532-5415.1989.tb05496.x; FOY A, 1986, BRIT MED J, V293, P1072, DOI 10.1136/bmj.293.6554.1072; GLANTZ M, 1981, J PSYCHOACTIVE DRUGS, V13, P117, DOI 10.1080/02791072.1981.10524293; GORBIEN MJ, 1989, GERIATRIC MED TODAY, V8, P115; KREJCIE RV, 1970, EDUC PSYCHOL MEAS, V30, P607, DOI 10.1177/001316447003000308; LEAROYD BM, 1982, MED J AUSTRALIA, V1, P1131; POWELL J, 1993, ALCOHOL MED USE OLDE; SHERIN KM, 1982, J FAM PRACTICE, V15, P1091; TOBIAS CR, 1988, POSTGRAD MED, V83, P313, DOI 10.1080/00325481.1988.11700123; 1991, RECOMMENDATIONS REGA; 1987, DIAGNOSTIC STATISTIC; 1991, TOBACCO ALERT WHO PR; 1987, RECOMMENDATIONS REGA	17	68	69	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	1994	308	6926					444	446		10.1136/bmj.308.6926.444	http://dx.doi.org/10.1136/bmj.308.6926.444			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MW976	8124174	Green Published			2022-12-01	WOS:A1994MW97600021
J	CREMER, H; LANGE, R; CHRISTOPH, A; PLOMANN, M; VOPPER, G; ROES, J; BROWN, R; BALDWIN, S; KRAEMER, P; SCHEFF, S; BARTHELS, D; RAJEWSKY, K; WILLE, W				CREMER, H; LANGE, R; CHRISTOPH, A; PLOMANN, M; VOPPER, G; ROES, J; BROWN, R; BALDWIN, S; KRAEMER, P; SCHEFF, S; BARTHELS, D; RAJEWSKY, K; WILLE, W			INACTIVATION OF THE N-CAM GENE IN MICE RESULTS IN SIZE-REDUCTION OF THE OLFACTORY-BULB AND DEFICITS IN SPATIAL-LEARNING	NATURE			English	Article							CELL-ADHESION MOLECULE; NEURAL DEVELOPMENT; POLYSIALIC ACID; DENTATE GYRUS; MUTANT MICE; ADULT-RAT; NCAM; EXPRESSION; MOUSE; PLASTICITY	NEURAL-CELL adhesion molecules (N-CAMs) are members of the immunoglobulin superfamily mediating homo- and heterophilic cell-cell interactions. N-CAM exists in various isoforms which are generated by alternative splicing1-3. During embryonic development, N-CAMs are expressed in derivatives of all three germ layers, whereas in the adult animal they are predominantly present in neural tissue. Processes like neurulation4, axonal outgrowth5, histogenesis of the retina6,7 and development of the olfactory system8-10 are correlated with the regulated expression of N-CAMs11-14. We show here that N-CAM-deficient mice generated by gene targeting appear healthy and fertile, but adult mutants show a 10% reduction in overall brain weight and a 36% decline in size of the olfactory bulb. N-CAM deficiency coincides with almost total loss of protein-bound alpha-(2,8)-linked polysialic acid, a carbohydrate structure thought to be correlated with neural development and plasticity15,16. The animals showed deficits in spatial learning when tested in the Morris water maze17, whereas activity and motor abilities appeared normal.	UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY; UNIV KENTUCKY,SANDERS BROWN CTR AGING,LEXINGTON,KY 40536	University of Cologne; University of Kentucky	CREMER, H (corresponding author), UNIV COLOGNE,INST GENET,ZULPICHER STR 47,D-50674 COLOGNE,GERMANY.			Cremer, Harold/0000-0002-8673-5176; Roes, Jurgen/0000-0003-3235-2345				BARTHELS D, 1992, EUR J NEUROSCI, V4, P327, DOI 10.1111/j.1460-9568.1992.tb00880.x; BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; Breipohl W., 1986, ONTOGENY OLFACTION, P21; CHUNG WW, 1991, J COMP NEUROL, V314, P290, DOI 10.1002/cne.903140207; CORNWELL CA, 1976, BEHAV BIOL, V17, P131, DOI 10.1016/S0091-6773(76)90377-1; CROSSIN KL, 1990, EXP NEUROL, V109, P6, DOI 10.1016/S0014-4886(05)80004-4; DANILOFF JK, 1986, J CELL BIOL, V103, P929, DOI 10.1083/jcb.103.3.929; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3534; GOLDOWITZ D, 1990, DEV BRAIN RES, V52, P151, DOI 10.1016/0165-3806(90)90230-V; Goridis C, 1992, Semin Cell Biol, V3, P189; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P3037, DOI 10.1073/pnas.83.9.3037; JESSELL TM, 1990, NEURON, V1, P3; KEY B, 1991, NEURON, V6, P381, DOI 10.1016/0896-6273(91)90247-W; KEY B, 1990, J CELL BIOL, V110, P1729, DOI 10.1083/jcb.110.5.1729; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SCHENK F, 1985, EXP BRAIN RES, V58, P11; SCHOLEY AB, 1993, NEUROSCIENCE, V55, P499, DOI 10.1016/0306-4522(93)90519-L; SEKI T, 1991, NEUROSCI RES, V12, P503, DOI 10.1016/S0168-0102(09)80003-5; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVER J, 1984, DEV BIOL, V106, P485, DOI 10.1016/0012-1606(84)90248-3; THEODOSIS DT, 1991, P NATL ACAD SCI USA, V88, P5494, DOI 10.1073/pnas.88.13.5494; THIEL G, 1993, BRAIN PATHOL, V3, P87, DOI 10.1111/j.1750-3639.1993.tb00729.x; THIERY JP, 1977, J BIOL CHEM, V252, P6841; TOSNEY KW, 1986, DEV BIOL, V114, P437, DOI 10.1016/0012-1606(86)90208-3; ZUBER C, 1992, J BIOL CHEM, V267, P9965	30	881	905	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					455	459		10.1038/367455a0	http://dx.doi.org/10.1038/367455a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107803				2022-12-01	WOS:A1994MU67900053
J	KOJIMA, T; SASAI, M; KOBAYASHI, Y				KOJIMA, T; SASAI, M; KOBAYASHI, Y			INCREASED SOLUBLE ICAM-1 IN TRACHEAL ASPIRATES OF INFANTS WITH BRONCHOPULMONARY DYSPLASIA	LANCET			English	Note							ADHESION MOLECULE-1 ICAM-1; CIRCULATING ICAM-1	Raised concentrations of soluble intercellular adhesion molecule 1 (sICAM-1) in tracheal aspirates from premature infants may predict development of bronchopulmonary dysplasia (BPD). We measured sICAM-1 in tracheal aspirates and serum samples from 15 newborn babies (9 with BPD, 6 without BPD) at 2-4, 6-7, and 12-14 days of age. sICAM-1 concentrations in tracheal aspirates were significantly raised at 6-7 and 12-14 days of age in infants who later developed BPD compared with infants who did not develop BPD. Serum samples from the two groups did not differ significantly in sICAM-1. Raised sICAM-1 in tracheal aspirate was a good predictor of lung injury in infants who later developed BPD.			KOJIMA, T (corresponding author), KANSAI MED UNIV,DEPT PAEDIAT,FUMIZONOCHO 1,MORIGUCHI,OSAKA 570,JAPAN.							CLEMENT A, 1988, PEDIATR RES, V23, P470, DOI 10.1203/00006450-198805000-00007; DUSTIN ML, 1986, J IMMUNOL, V137, P245; JACOBSON W, 1992, EUR J PEDIATR, V151, P204, DOI 10.1007/BF01954385; KUSTER H, 1993, LANCET, V341, P506, DOI 10.1016/0140-6736(93)90272-I; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; NORTHWAY WH, 1992, PEDIATRICS, V89, P969; OGDEN BE, 1984, AM REV RESPIR DIS, V130, P817; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851	10	36	36	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1023	1024		10.1016/0140-6736(93)92880-3	http://dx.doi.org/10.1016/0140-6736(93)92880-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105265				2022-12-01	WOS:A1993MD06600011
J	WEINER, TM; LIU, ET; CRAVEN, RJ; CANCE, WG				WEINER, TM; LIU, ET; CRAVEN, RJ; CANCE, WG			EXPRESSION OF FOCAL ADHESION KINASE GENE AND INVASIVE CANCER	LANCET			English	Note							PROTEIN-TYROSINE KINASE; PHOSPHORYLATION; INTEGRINS	The focal adhesion kinase (FAK) gene produces a tyrosine kinase that localises to contact points between cells and extracellular matrix. It is believed to be an important signal molecule in cell adhesion. We have isolated a human homologue of the FAK gene from primary sarcomas and looked for FAK mRNA in 49 human tissue samples, including paired normal and neoplastic samples. We found increased levels of FAK in 1 of 8 adenomatous tissues, in 17 of 20 invasive tumours, and in all 15 metastatic tumours. There was no detectable FAK mRNA in 6 normal tissue samples. These observations suggest that FAK overexpression may accompany changes in signal pathways involved in tumour cell invasion.	UNIV N CAROLINA,SCH MED,DEPT SURG,3010 OLD CLIN BLDG,CB 7210,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Liu, Edison/C-4141-2008		NATIONAL CANCER INSTITUTE [T32CA009688, P50CA058223] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09688, KO8-CA-01635, 1-P50-CA-58223-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; TIERNEY RP, 1990, SURG GYNECOL OBSTET, V171, P81; WEINER TM, IN PRESS ANN SURG ON; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	10	308	321	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1024	1025		10.1016/0140-6736(93)92881-S	http://dx.doi.org/10.1016/0140-6736(93)92881-S			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105266				2022-12-01	WOS:A1993MD06600012
J	BOGREN, HG; BUONOCORE, MH				BOGREN, HG; BUONOCORE, MH			MEASUREMENT OF CORONARY-ARTERY FLOW RESERVE BY MAGNETIC-RESONANCE VELOCITY MAPPING IN THE AORTA	LANCET			English	Note							BLOOD-FLOW	Coronary artery flow occurs predominantly in diastole via retrograde flow in the ascending aorta, some of which supplies the coronary arteries while the remainder recirculates in the ascending aorta. We used magnetic resonance velocity mapping to measure global coronary artery diastolic flow in the ascending aorta. In eight normal subjects and in four patients with possible ischaemic heart disease but with normal perfusion scans, the mean coronary flow reserve (CFR) was 269 ml/min. CFR was zero in seven patients with coronary artery disease. We have shown that CFR can be measured non-invasively with this technique.			BOGREN, HG (corresponding author), UNIV CALIF DAVIS,SACRAMENTO MED CTR,DEPT RADIOL,TICON 11 BLDG,SACRAMENTO,CA 95817, USA.							BOGREN HG, 1989, AM HEART J, V117, P1214, DOI 10.1016/0002-8703(89)90399-2; BUONOCORE MH, 1992, MAGNET RESON MED, V26, P141, DOI 10.1002/mrm.1910260115; GOULD KL, 1988, CIRCULATION, V78, P237, DOI 10.1161/01.CIR.78.2.237; HOFFMAN JIE, 1984, CIRCULATION, V70, P153, DOI 10.1161/01.CIR.70.2.153; LENTNER C, 1990, GEIGY SCI TABLES, V5, P124; VOGEL RA, 1984, ARCH INTERN MED, V144, P1773, DOI 10.1001/archinte.144.9.1773; WILSON RF, 1988, PROG CARDIOVASC DIS, V31, P95, DOI 10.1016/0033-0620(88)90013-8	7	13	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					899	900		10.1016/0140-6736(93)91948-L	http://dx.doi.org/10.1016/0140-6736(93)91948-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105169				2022-12-01	WOS:A1993MA96300012
J	CARSWELL, W				CARSWELL, W			HIV IN SOUTH-AFRICA	LANCET			English	Editorial Material																			0	4	4	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					132	132		10.1016/0140-6736(93)91342-J	http://dx.doi.org/10.1016/0140-6736(93)91342-J			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	8101253				2022-12-01	WOS:A1993LN04200008
J	BORTOLOTTO, ZA; BASHIR, ZI; DAVIES, CH; COLLINGRIDGE, GL				BORTOLOTTO, ZA; BASHIR, ZI; DAVIES, CH; COLLINGRIDGE, GL			A MOLECULAR SWITCH ACTIVATED BY METABOTROPIC GLUTAMATE RECEPTORS REGULATES INDUCTION OF LONG-TERM POTENTIATION	NATURE			English	Article							RAT HIPPOCAMPUS; AREA CA1; STIMULATION; DEPRESSION; NEURONS	PHARMACOLOGICAL studies of long-term potentiation (LTP) in the hippocampus are starting to provide a molecular understanding of synaptic plastic processes which are believed to be important for learning and memory in vertebrates(1). In the CA1 region of the hippocampus, the synaptic activation of glutamate receptors of the N-methyl-D-aspartate (NMDA) subtype is necessary for the induction of LTP under most experimental conditions(2,3). The synaptic activation of metabotropic glutamate receptors (mGluRs) is also needed for the induction of LTP(4,5). We now show that the role of mGluRs in the induction of LTP is fundamentally different from that of NMDA receptors. NMDA receptors initiate a molecular event that needs to be triggered each time a tetanus is delivered to induce LTP. In contrast, mGluRs activate a molecular switch which then negates the need for mGluR stimulation during the induction of LTP. This mGluR-activated switch is input-specific and can be turned off by a train of low-frequency stimulation. The molecular switch is a new feature of LTP which has fundamental consequences for our understanding of synaptic plastic mechanisms.			BORTOLOTTO, ZA (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT PHARMACOL,BIRMINGHAM B15 2TT,ENGLAND.		collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015	Collingridge, Graham L/0000-0002-9572-5359; Bashir, Zafar/0000-0003-3650-2136				BARRIONUEVO G, 1980, LIFE SCI, V27, P2385, DOI 10.1016/0024-3205(80)90509-3; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P266; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BORTOLOTTO ZA, 1993, NEUROPHARMACOLOGY, V32, P1, DOI 10.1016/0028-3908(93)90123-K; BORTOLOTTO ZA, 1993, SOC NEUR ABSTR, V19; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EATON SA, 1993, EUR J PHARM-MOLEC PH, V244, P195, DOI 10.1016/0922-4106(93)90028-8; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; JANE DE, 1993, NEUROPHARMACOLOGY, V32, P725, DOI 10.1016/0028-3908(93)90088-K; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; NICOLETTI F, 1986, J NEUROCHEM, V46, P40, DOI 10.1111/j.1471-4159.1986.tb12922.x; REYMANN KG, 1990, EUR J NEUROSCI, V2, P481, DOI 10.1111/j.1460-9568.1990.tb00439.x; SERGUEEVA OA, 1993, NEUROPHARMACOLOGY, V32, P933, DOI 10.1016/0028-3908(93)90150-2; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0	18	332	349	3	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					740	743		10.1038/368740a0	http://dx.doi.org/10.1038/368740a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152485				2022-12-01	WOS:A1994NG55300058
J	DEBYSER, Z; TABOR, S; RICHARDSON, CC				DEBYSER, Z; TABOR, S; RICHARDSON, CC			COORDINATION OF LEADING AND LAGGING-STRAND DNA-SYNTHESIS AT THE REPLICATION FORK OF BACTERIOPHAGE-T7	CELL			English	Article							POLYMERASE-III HOLOENZYME; NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; RNA PRIMER SYNTHESIS; DEOXYRIBONUCLEIC-ACID; ESCHERICHIA-COLI; GENE-4 PROTEIN; HELICASE ACTIVITY; PRIMASE; INVITRO; THIOREDOXIN	We have used the T7 DNA replication system to examine coordination of leading and lagging strand synthesis at a replication fork. The 63 kd gene 4 protein provides both helicase and primase activities; we demonstrate that primer synthesis inhibits helicase activity on a synthetic replication fork. Lagging strand DNA synthesis by a complex of gene 4 protein and T7 DNA polymerase decreases the rate of leading strand synthesis. Both leading and fagging strand synthesis are resistant to dilution of the replication proteins, and to challenge with heparin. Furthermore, dilution does trot increase the average length of Okazaki fragments. We propose that leading and lagging strand synthesis at a T7 replication fork are coupled and that the replication proteins are recycled.			DEBYSER, Z (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.		debyser, zeger/H-1310-2013	debyser, zeger/0000-0002-3982-1565	NIAID NIH HHS [AI-06045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI006045, R37AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS B, 1975, DNA SYNTHESIS ITS RE, P241; ARAI N, 1981, J BIOL CHEM, V256, P5294; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; HUBER HE, 1988, CANCER CELL, V6, P11; KOLODNER R, 1978, J BIOL CHEM, V253, P574; KORNBERG A, 1991, DNA REPLICATION, P487; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; MAKI H, 1988, J BIOL CHEM, V263, P6570; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1984, PROTEINS INVOLVED DN, P315; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MENDELMAN LV, 1992, J BIOL CHEM, V89, P10638; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; MODRICH P, 1975, J BIOL CHEM, V250, P5515; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9831; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; Sambrook J., 1989, MOL CLONING LAB MANU; SCHERZINGER E, 1979, NUCLEIC ACIDS RES, V4, P4151; SINHA NK, 1980, J BIOL CHEM, V255, P4290; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; WU CA, 1992, J BIOL CHEM, V267, P4064	41	81	81	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 8	1994	77	1					157	166		10.1016/0092-8674(94)90243-7	http://dx.doi.org/10.1016/0092-8674(94)90243-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156591				2022-12-01	WOS:A1994NF21100018
J	KNOBLICH, JA; SAUER, K; JONES, L; RICHARDSON, H; SAINT, R; LEHNER, CF				KNOBLICH, JA; SAUER, K; JONES, L; RICHARDSON, H; SAINT, R; LEHNER, CF			CYCLIN-E CONTROLS S-PHASE PROGRESSION AND ITS DOWN-REGULATION DURING DROSOPHILA EMBRYOGENESIS IS REQUIRED FOR THE ARREST OF CELL-PROLIFERATION	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; CDC2-RELATED KINASE; CATALYTIC SUBUNIT; DNA-REPLICATION; GENETIC-CONTROL; CDC28 MUTATION; CLN FUNCTION	Most cells of the dorsal epidermis exit from the mitotic cycle after division 16 in Drosophila embryogenesis. This exit is dependent on the down-regulation of Drosaphila cyclin E (DmcycE) during the final mitotic cycle. Ectopic expression of DmcycE after the final mitosis induces entry into S phase and reaccumulation of G2 cyclins and results in progression through a complete additional cell cycle. Conversely, analyses in DmcycE mutant embryos indicate that cyclin E is required for progression through S phase of the mitotic cycle. Moreover, endoreplication, which occurs in late wild-type embryos in the same pattern as DmcycE expression, is not observed in the mutant embryos. Therefore, Drosophila cyclin E, which forms a complex with the Dmcdc2c kinase, controls progression through S phase and its down-regulation limits embryonic proliferation.	UNIV ADELAIDE, DEPT BIOCHEM, ADELAIDE, SA 5005, AUSTRALIA	University of Adelaide	KNOBLICH, JA (corresponding author), MAX PLANCK GESELL, FRIEDRICH MIESCHER LAB, SPEMANNSTR 37-39, D-72076 TUBINGEN, GERMANY.		Knoblich, Juergen A/C-2974-2015; Richardson, Helena E/A-8080-2013; Saint, Robert/A-4190-2008	Knoblich, Juergen A/0000-0002-6751-3404; Richardson, Helena E/0000-0003-3852-4953; Saint, Robert/0000-0002-7989-6043				ASHBURNER M, 1990, GENETICS, V126, P679; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GABRIELLI BG, 1992, J BIOL CHEM, V267, P1969; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HARTENSTEIN V, 1990, DEV BIOL, V138, P147, DOI 10.1016/0012-1606(90)90184-K; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KARPEN GH, 1992, GENETICS, V132, P737; KATO J, 1993, GENE DEV, V7, P331; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAHUE EE, 1991, GENE DEV, V5, P2166, DOI 10.1101/gad.5.12a.2166; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1991, COLD SH Q B, V56, P465; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MALDONADOCODINA G, 1993, J CELL SCI, V105, P711; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MICHIELS F, 1987, CHROMOSOMA, V95, P387, DOI 10.1007/BF00333989; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PIROTTA V, 1986, DROSOPHILA PRACTICAL, P83; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMITH AV, 1991, DEVELOPMENT, V112, P997; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; STERN B, 1993, DEVELOPMENT, V117, P219; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	75	479	482	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	1994	77	1					107	120		10.1016/0092-8674(94)90239-9	http://dx.doi.org/10.1016/0092-8674(94)90239-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	8156587				2022-12-01	WOS:A1994NF21100014
J	CHEN, LY; DURLEY, RCE; MATHEWS, FS; DAVIDSON, VL				CHEN, LY; DURLEY, RCE; MATHEWS, FS; DAVIDSON, VL			STRUCTURE OF AN ELECTRON-TRANSFER COMPLEX - METHYLAMINE DEHYDROGENASE, AMICYANIN, AND CYTOCHROME-C(551I)	SCIENCE			English	Article							C-TYPE CYTOCHROMES; PARACOCCUS-DENITRIFICANS; PLASTOCYANIN; COFACTOR; PROTEIN; RESOLUTION; OXIDATION	The crystal structure of a ternary protein complex has been determined at 2.4 angstrom resolution. The complex is composed of three electron transfer proteins from Paracoccus denitrificans, the quinoprotein methylamine dehydrogenase, the blue copper protein amicyanin, and the cytochrome c551i. The central region of the c551i is folded similarly to several small bacterial c-type cytochromes; there is a 45-residue extension at the amino terminus and a 25-residue extension at the carboxyl terminus. The methylamine dehydrogenase-amicyanin interface is largely hydrophobic, whereas the amicyanin-cytochrome interface is more polar, with several charged groups present on each surface. Analysis of the simplest electron transfer pathways between the redox partners points out the importance of other factors such as energetics in determining the electron transfer rates.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216	Washington University (WUSTL); University of Mississippi; University of Mississippi Medical Center				Davidson, Victor/0000-0002-1966-7302	NIGMS NIH HHS [GM41574] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041574, R01GM041574] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKS H, UNPUB; BROOKS HB, 1993, BIOCHEM J, V294, P211, DOI 10.1042/bj2940211; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CANTERS CW, 1992, CURR OPIN STRUC BIOL, V2, P859; CHEN L, 1993, PROTEIN SCI, V2, P47; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; CHEN LY, 1991, FEBS LETT, V287, P163, DOI 10.1016/0014-5793(91)80041-Z; CHEN LY, 1992, PROTEINS, V14, P288, DOI 10.1002/prot.340140214; CHISTOSERDOV AY, 1992, BIOCHEM BIOPH RES CO, V184, P1181, DOI 10.1016/S0006-291X(05)80007-5; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DAVIDSON VL, 1991, ANAL CHIM ACTA, V249, P235, DOI 10.1016/0003-2670(91)87028-6; DAVIDSON VL, 1993, PRINCIPLES APPL QUIN, P73; Denoyelle S., SYNTHESIS SAR STUDY; DURLEY R, 1993, PROTEIN SCI, V2, P739, DOI 10.1002/pro.5560020506; EVENSON JW, 1993, SCIENCE, V262, P1247, DOI 10.1126/science.8235654; GRAY KA, 1986, FEBS LETT, V207, P239, DOI 10.1016/0014-5793(86)81496-X; GUSS JM, 1983, J MOL BIOL, V169, P521; HE S, 1991, EMBO J, V10, P4011, DOI 10.1002/j.1460-2075.1991.tb04976.x; HOFFMAN BM, 1987, J AM CHEM SOC, V109, P6237, DOI 10.1021/ja00255a003; HUIZINGA EG, 1992, BIOCHEMISTRY-US, V31, P9789, DOI 10.1021/bi00155a036; HUSAIN M, 1986, J BIOL CHEM, V261, P8577; HUSAIN M, 1985, J BIOL CHEM, V260, P4626; HUSAIN M, 1986, BIOCHEMISTRY-US, V25, P2431, DOI 10.1021/bi00357a020; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4719, DOI 10.1021/bi00069a005; NORDLING M, 1991, FEBS LETT, V291, P327, DOI 10.1016/0014-5793(91)81313-W; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; PEEREY LM, 1991, BIOCHEMISTRY-US, V30, P9297, DOI 10.1021/bi00102a023; QIN L, 1993, BIOCHEMISTRY-US, V32, P6073, DOI 10.1021/bi00074a019; REGAN J, 1993, PATHWAYS, V2; VANSPANNING RJM, 1990, FEBS LETT, V275, P217, DOI 10.1016/0014-5793(90)81475-4; VELLIEUX FMD, 1990, ACTA CRYSTALLOGR B, V46, P806, DOI 10.1107/S010876819000636X	35	216	222	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					86	90		10.1126/science.8140419	http://dx.doi.org/10.1126/science.8140419			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	8140419				2022-12-01	WOS:A1994ND53600035
J	DEEN, PMT; VERDIJK, MAJ; KNOERS, NVAM; WIERINGA, B; MONNENS, LAH; VANOS, CH; VANOOST, BA				DEEN, PMT; VERDIJK, MAJ; KNOERS, NVAM; WIERINGA, B; MONNENS, LAH; VANOS, CH; VANOOST, BA			REQUIREMENT OF HUMAN RENAL WATER CHANNEL AQUAPORIN-2 FOR VASOPRESSIN-DEPENDENT CONCENTRATION OF URINE	SCIENCE			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; XENOPUS OOCYTES; IDENTIFICATION; RESPONSES; PROTEIN; RNA	Concentration of urine in mammals is regulated by the antidiuretic hormone vasopressin. Binding of vasopressin to its V2 receptor leads to the insertion of water channels in apical membranes of principal cells in collecting ducts. In nephrogenic diabetes insipidus (NDI), the kidney fails to concentrate urine in response to vasopressin. A male patient with an autosomal recessive form of NDI was found to be a compound heterozygote for two mutations in the gene encoding aquaporin-2, a water channel. Functional expression studies in Xenopus oocytes revealed that each mutation resulted in nonfunctional water channel proteins. Thus, aquaporin-2 is essential for vasopressin-dependent concentration of urine.	CATHOLIC UNIV NIJMEGEN, DEPT CELL PHYSIOL, 6500 HB NIJMEGEN, NETHERLANDS; CATHOLIC UNIV NIJMEGEN, DEPT CELLULAR BIOL, 6500 HB NIJMEGEN, NETHERLANDS; UNIV HOSP NIJMEGEN, DEPT HUMAN GENET, 6500 HB NIJMEGEN, NETHERLANDS; UNIV HOSP NIJMEGEN, DEPT PEDIAT, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen			Monnens, L.A.H./L-4526-2015; Wieringa, Berend/A-5346-2011; Deen, P.M.T./H-8023-2014; Deen, Peter MT/B-9854-2013	Wieringa, Berend/0000-0001-9192-8020; Deen, P.M.T./0000-0002-7868-4655; Deen, Peter MT/0000-0002-7868-4655				BICHET DG, 1988, NEW ENGL J MED, V318, P881, DOI 10.1056/NEJM198804073181403; BROWN D, 1989, AM J PHYSIOL, V256, pF1; Deen P P, UNPUB; DEENPMT, 1994, CYTOGENET CELL GENET, V66, P260; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; KNOERS N, 1991, EUR J PEDIATR, V150, P370, DOI 10.1007/BF01955943; KNOERS N, 1990, NEPHRON, V54, P322, DOI 10.1159/000185888; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MOON C, 1993, J BIOL CHEM, V268, P15772; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; PISANO MM, 1991, GENOMICS, V11, P981; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; REEVES WB, 1989, METABOLIC BASIS INHE, P1985; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; VANDENOUWELAND AMW, 1992, NAT GENET, V2, P99, DOI 10.1038/ng1092-99; VERDIJK MAJ, UNPUB; ZHANG R, 1991, AM J PHYSIOL, V260, pC26	22	711	725	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					92	95		10.1126/science.8140421	http://dx.doi.org/10.1126/science.8140421			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	8140421				2022-12-01	WOS:A1994ND53600037
J	STRASSER, A; HARRIS, AW; CORCORAN, LM; CORY, S				STRASSER, A; HARRIS, AW; CORCORAN, LM; CORY, S			BCL-2 EXPRESSION PROMOTES B-LYMPHOID BUT NOT T-LYMPHOID DEVELOPMENT IN SCID MICE	NATURE			English	Article							TRANSGENIC MICE; CELL-RECEPTOR; BONE-MARROW; MOUSE; SURVIVAL; ACTIVATION; APOPTOSIS	EXPRESSION of antigen receptors is vital for the development of B and T lymphocytes. In mice with the scid mutation1,2, which are unable to make productive rearrangements of their immunoglobulin and T-cell receptor (TCR) genes, lymphopoiesis aborts at an early stage. The death of the immature lymphocytes by apoptosis3 is postulated to result from a failure to receive a survival signal induced by receptor engagement4. Consistent with this hypothesis, introduction of immunoglobulin or TCR transgenes into scid mice promoted an increase in B- or T-lymphoid cells, respectively5-7. As the protein encoded by the bcl-2 gene can inhibit cell death8,9, we tested whether lymphopoiesis could be rescued in scid mice by crossing in a bcl-2 transgene. Strikingly, the bcl-2/scid mice accumulated almost normal numbers of B-lymphoid cells which lacked surface immunoglobulin but expressed markers of maturity. T-cell development remained blocked. Introducing a TCR transgene enabled bcl-2/scid mice to develop normal numbers of CD4+8+ thymocytes even in the absence of immunological selection, suggesting that T cells become competent to respond to bcl-2 protein only after the TCR complex is displayed at the cell surface.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Cory, Suzanne/E-1642-2013; Strasser, Andreas/C-7581-2013; Corcoran, Lynn M/C-9316-2013	Cory, Suzanne/0000-0002-6818-3451; Strasser, Andreas/0000-0002-5020-4891; 				ASHWELL JD, 1990, REV IMMUNOL, V8, P531; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; HARDY RR, 1989, CURR TOP MICROBIOL, V152, P19; KINOSHITA T, 1988, J IMMUNOL, V140, P3066; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MELCHERS F, 1993, IMMUNOL TODAY, V14, P60, DOI 10.1016/0167-5699(93)90060-X; MULLERSIEBURG CE, 1986, CELL, V44, P653, DOI 10.1016/0092-8674(86)90274-6; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OSMOND DG, 1992, BLOOD, V79, P1695; PENNYCOOK JL, 1993, J EXP MED, V178, P1007, DOI 10.1084/jem.178.3.1007; REICHMANFRIED M, 1990, P NATL ACAD SCI USA, V87, P2730, DOI 10.1073/pnas.87.7.2730; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.immunol.10.1.97; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, P NATL ACAD SCI USA, V91, P1376, DOI 10.1073/pnas.91.4.1376; TORRES RM, 1992, J IMMUNOL, V149, P2641; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WALDSCHMIDT TJ, 1988, J IMMUNOL, V140, P2148	28	145	146	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	1994	368	6470					457	460		10.1038/368457a0	http://dx.doi.org/10.1038/368457a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	8133891				2022-12-01	WOS:A1994ND12000064
J	OLIVOTTO, IA; BAJDIK, CD; PLENDERLEITH, IH; COPPIN, CM; GELMON, KA; JACKSON, SM; RAGAZ, J; WILSON, KS; WORTH, A				OLIVOTTO, IA; BAJDIK, CD; PLENDERLEITH, IH; COPPIN, CM; GELMON, KA; JACKSON, SM; RAGAZ, J; WILSON, KS; WORTH, A			ADJUVANT SYSTEMIC THERAPY AND SURVIVAL AFTER BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEMOTHERAPY	Background and Methods. We examined the effect of adjuvant systemic therapy on survival after breast cancer among the residents of the Canadian province of British Columbia. Data on survival were collected for all women in whom breast cancer was diagnosed in British Columbia during each of three calendar years chosen to represent different province-wide treatment recommendations: 1974, when no adjuvant systemic therapy was recommended; 1980, when adjuvant chemotherapy was recommended only for premenopausal women with node-positive disease; and 1984, when adjuvant chemotherapy was also recommended for premenopausal women with node-negative disease and lymphatic, vascular, or neural invasion and tamoxifen was recommended for postmenopausal women with involved lymph nodes or lymphatic, vascular, or neural invasion unless their tumors were negative for estrogen receptors. Results. For women less than 50 years of age, disease-specific survival at seven years (i.e., with censoring of data on women who died from causes other than breast cancer) improved from 65.2 to 76.3 percent between 1974 and 1984 (P = 0.008), and overall survival improved from 64.8 to 74.6 percent (P = 0.02). For women from 50 through 89 years of age, disease-specific survival at seven years improved from 62.5 to 70.4 percent between 1980 and 1984 (P = 0.001), and overall survival improved from 53.9 to 58.3 percent (P = 0.05). The timing of the improvements in survival correlated with the introduction of adjuvant systemic therapy in each group. Conclusions. Survival among women with breast cancer improved significantly in a geographically defined population during the period when adjuvant systemic therapy became widely used.	BRITISH COLUMBIA CANC AGCY,DIV EPIDEMIOL,VANCOUVER,BC,CANADA; BRITISH COLUMBIA CANC AGCY,DIV MED ONCOL,VANCOUVER,BC,CANADA; BRITISH COLUMBIA CANC AGCY,DIV LAB MED,VANCOUVER,BC,CANADA; UNIV BRITISH COLUMBIA,VANCOUVER,BC,CANADA	British Columbia Cancer Agency; British Columbia Cancer Agency; British Columbia Cancer Agency; University of British Columbia	OLIVOTTO, IA (corresponding author), BRITISH COLUMBIA CANC AGCY,DIV RADIAT ONCOL,600 W 10TH AVE,VANCOUVER V5Z 4E6,BC,CANADA.							BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BURHENNE LJW, 1992, AM J ROENTGENOL, V158, P45, DOI 10.2214/ajr.158.1.1307850; COPPIN C, 1989, P AM SOC CLIN ONCOL, V8, P20; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; ELWOOD JM, 1980, BRIT J CANCER, V42, P635, DOI 10.1038/bjc.1980.296; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HOWARD J, 1987, CA-CANCER J CLIN, V37, P33, DOI 10.3322/canjclin.37.1.33; JOENSUU H, 1991, BRIT MED J, V303, P155, DOI 10.1136/bmj.303.6795.155; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MCBRIDE ML, 1987, BC MED J, V29, P30; MCGUIRE WL, 1978, CANCER RES, V38, P4289; MILLER BA, 1991, CANCER CAUSE CONTROL, V2, P67, DOI 10.1007/BF00053123; Paterson A H, 1981, Breast Cancer Res Treat, V1, P357, DOI 10.1007/BF01806751; POWLES TJ, 1980, LANCET, V1, P580; RAGAZ J, 1991, 3RD P INT C NEOADJ C, P186; 1976, B C MED J, V18, P288; 1992, CANADIAN CANCER STAT; 1992, 93310 STAT CAN CAT; 1992, LANCET, V339, P71	21	72	72	1	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	1994	330	12					805	810		10.1056/NEJM199403243301201	http://dx.doi.org/10.1056/NEJM199403243301201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB803	8114832				2022-12-01	WOS:A1994NB80300001
J	VIDGREN, J; SVENSSON, LA; LILJAS, A				VIDGREN, J; SVENSSON, LA; LILJAS, A			CRYSTAL-STRUCTURE OF CATECHOL O-METHYLTRANSFERASE	NATURE			English	Article							RAT-LIVER; PARKINSONS-DISEASE; METHYLATION; INHIBITION; BINDING; PURIFICATION; CLONING; OR-462; MODELS; SITE	CATECHOL O-methyltransferase (COMT, EC 2.1.1.6) is important in the central nervous system because it metabolizes catecholamine neurotransmitters such as dopamine. The enzyme catalyses the transfer of the methyl group from S-adenosyl-L-methionine (AdoMet) to one hydroxyl group of catechols(1-4). COMT also inactivates catechol-type compounds such as L-DOPA. With selective inhibitors of COMT in combination with L-DOPA, a new principle has been realized in the therapy of Parkinson's disease(5-9). Here we solve the atomic structure of COMT to 2.0 Angstrom resolution, which provides new insights into the mechanism of the methyl transfer reaction. The co-enzyme-binding domain is strikingly similar to that of an AdoMet-dependent DNA methylase(10), indicating that all AdoMet methylases may have a common structure.	LUND UNIV,CTR CHEM,S-22100 LUND,SWEDEN	Lund University	VIDGREN, J (corresponding author), ORION CORP,ORION FARMOS,POB 65,SF-02101 ESPOO,FINLAND.							AXELROD J, 1958, J BIOL CHEM, V233, P702; BACKSTROM R, 1989, J MED CHEM, V32, P841, DOI 10.1021/jm00124a017; BALL P, 1972, J CLIN ENDOCR METAB, V34, P736, DOI 10.1210/jcem-34-4-736; BERTOCCI B, 1991, BIOCHIM BIOPHYS ACTA, V1080, P103, DOI 10.1016/0167-4838(91)90135-M; BORCHARDT RT, 1980, ENZYMATIC BASIS DETO, P43; BORGULYA J, 1989, HELV CHIM ACTA, V72, P952, DOI 10.1002/hlca.19890720511; Brunger AT, 1992, X PLOR VERSION 3 0 S; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; COWARD JK, 1973, BIOCHEMISTRY-US, V12, P2291, DOI 10.1021/bi00736a017; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; CREVELING CR, 1972, MOL PHARMACOL, V8, P398; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; GOMI T, 1992, INT J BIOCHEM, V24, P1639; GULDBERG HC, 1975, PHARMACOL REV, V27, P135; HOWARD A, 1987, J APPL CRYSTALLOGR, V20, P373; JEFFERY DR, 1987, BIOCHEMISTRY-US, V26, P2955, DOI 10.1021/bi00384a042; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LINDEN IB, 1988, J PHARMACOL EXP THER, V247, P289; LUNDSTROM K, 1991, DNA CELL BIOL, V10, P181, DOI 10.1089/dna.1991.10.181; LUNDSTROM K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P149, DOI 10.1016/0167-4781(92)90479-J; Mannisto P. T., 1992, V39, P291; MANNISTO PT, 1989, TRENDS PHARMACOL SCI, V10, P54, DOI 10.1016/0165-6147(89)90075-8; Piedrafita F J, 1990, J Enzyme Inhib, V4, P43, DOI 10.3109/14756369009030387; SALMINEN M, 1990, GENE, V93, P241, DOI 10.1016/0378-1119(90)90231-F; SCHULTZ E, 1989, BIOCHEM PHARMACOL, V38, P3953, DOI 10.1016/0006-2952(89)90673-4; THAKKER DR, 1986, J BIOL CHEM, V261, P178; VIDGREN J, 1991, PROTEINS, V11, P233, DOI 10.1002/prot.340110309; WOODARD RW, 1980, J BIOL CHEM, V255, P9124; 1979, SERC4 DAR LAB COLL C	29	379	386	3	53	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					354	358		10.1038/368354a0	http://dx.doi.org/10.1038/368354a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127373				2022-12-01	WOS:A1994NB98500052
J	WILLIAMS, JA; PADDOCK, SW; VORWERK, K; CARROLL, SB				WILLIAMS, JA; PADDOCK, SW; VORWERK, K; CARROLL, SB			ORGANIZATION OF WING FORMATION AND INDUCTION OF A WING-PATTERNING GENE AT THE DORSAL/VENTRAL COMPARTMENT BOUNDARY	NATURE			English	Article							DROSOPHILA-MELANOGASTER; IMAGINAL DISKS; DIFFERENTIATION; TRANSCRIPTION; ENCODES; PRODUCT; ELEGANS; FIELDS	The appendages of arthropods and vertebrates possess a third, proximodistal patterning axis that is established after the primary anteroposterior and dorsoventral body axes by mechanisms that are largely unknown. The vestigial gene is required for formation of the entire Drosophila wing, and the dorsal/ventral boundary is shown to organize wing formation and vestigial gene expression. Interactions between dorsal and ventral cells in the growing imaginal disc induce vestigial gene expression through a discrete, extraordinarily conserved imaginal disc-specific enhancer. The link between dorsal/ventral compartmentalization and wing formation distinguishes the development of this sheet-like appendage from that of legs and antennae.	UNIV WISCONSIN, HOWARD HUGHES MED INST, MOLEC BIOL LAB, MADISON, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison								ANDERSON DT, 1963, J EMBRYOL EXP MORPH, V11, P339; BAKER NE, 1988, DEVELOPMENT, V102, P489; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BOWNES M, 1981, DIFFERENTIATION, V18, P89, DOI 10.1111/j.1432-0436.1981.tb01108.x; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHEN SM, IN PRESS DEV DROSOPH; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; KUKALOVAPECK J, 1978, J MORPHOL, V156, P53, DOI 10.1002/jmor.1051560104; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1993, NATURE, V366, P305, DOI 10.1038/366305a0; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; Meinhardt H., 1991, Seminars in Developmental Biology, V2, P129; NELSON HB, 1993, W ROUX ARCH DEV BIOL, V202, P341; PADDOCK SW, 1993, BIOTECHNIQUES, V14, P42; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WIESCHAUS E, 1976, DEV BIOL, V50, P249, DOI 10.1016/0012-1606(76)90150-0; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WILLIAMS JA, 1988, EMBO J, V7, P1355, DOI 10.1002/j.1460-2075.1988.tb02951.x; WILLIAMS JA, 1990, MOL GEN GENET, V221, P8, DOI 10.1007/BF00280361; WILLIAMS JA, 1993, BIOESSAYS, V15, P567, DOI 10.1002/bies.950150902; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; XU T, 1993, DEVELOPMENT, V117, P1223	34	222	223	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	1994	368	6469					299	305		10.1038/368299a0	http://dx.doi.org/10.1038/368299a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127364				2022-12-01	WOS:A1994NB98500036
J	WILSON, A; HICKIE, I; LLOYD, A; HADZIPAVLOVIC, D; BOUGHTON, C; DWYER, J; WAKEFIELD, D				WILSON, A; HICKIE, I; LLOYD, A; HADZIPAVLOVIC, D; BOUGHTON, C; DWYER, J; WAKEFIELD, D			LONGITUDINAL-STUDY OF OUTCOME OF CHRONIC FATIGUE SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							CANCER; BEHAVIOR	Objective-To examine the predictors of long term outcome for patients with the chronic fatigue syndrome. Design-Cohort study. Subjects-139 subjects previously enrolled in two treatment trials; 103 (74%) were reassessed a mean of 3.2 years after start of the trials. Setting-University hospital referral centre. Main outcome measures-Age at onset, duration of illness, psychological and immunological status at initial assessment. Ongoing symptom severity, levels of disability, and immunological function at follow up. Results-65 subjects had improved but only six reported no current symptoms. An alternative medical diagnosis had been made in two and psychiatric illness diagnosed in 20. The assignment of a primary psychiatric diagnosis at follow up and the strength of the belief that a physical disease process explained all symptoms at entry to the trials both predicted poor outcome. Age at onset of illness, duration of illness, neuroticism, premorbid psychiatric diagnoses, and cell mediated immune function did not predict outcome. Conclusion-Though most patients with the chronic fatigue syndrome improve, a substantial proportion remain functionally impaired. Psychological factors such as illness attitudes and coping style seem more important predictors of long term outcome than immunological or demographic variables.	PRINCE HENRY HOSP,DEPT IMMUNOL & INFECT DIS,LITTLE BAY,NSW 2036,AUSTRALIA		WILSON, A (corresponding author), PRINCE HENRY HOSP,DEPT PSYCHIAT,LITTLE BAY,NSW 2036,AUSTRALIA.		Hadzi-Pavlovic, Dusan/ABE-2266-2021; Lloyd, Andrew/E-7334-2017; Lloyd, Andrew/AAF-6071-2022; Hickie, Ian B/K-8975-2015; Lloyd, Andrew/AFJ-8960-2022	Lloyd, Andrew/0000-0001-6277-8887; Hickie, Ian B/0000-0001-8832-9895; Lloyd, Andrew/0000-0001-6277-8887				BUTLER S, 1991, J NEUROL NEUROSUR PS, V54, P153, DOI 10.1136/jnnp.54.2.153; Eysenck HJ, 1964, MANUAL EYSENCK PERSO, DOI DOI 10.1007/SPRINGERREFERENCE_184643; FARAGHER EB, 1990, PSYCHOL MED, V20, P663, DOI 10.1017/S0033291700017189; FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P729; GOLD D, 1990, JAMA-J AM MED ASSOC, V264, P48, DOI 10.1001/jama.264.1.48; GOLDBERG DP, 1979, MANUAL GENERAL HLTH; HICKIE I, 1990, BRIT J PSYCHIAT, V156, P534, DOI 10.1192/bjp.156.4.534; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; KELLNER R, 1988, J PSYCHOSOM RES, V32, P303, DOI 10.1016/0022-3999(88)90072-4; KNIFER W, 1984, ANN ALLERGY, V52, P75; LANDAY AL, 1991, LANCET, V338, P707, DOI 10.1016/0140-6736(91)91440-6; LLOYD A, 1990, AM J MED, V89, P554; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; LLOYD AR, 1988, LANCET, V1, P1286; LLOYD AR, 1993, AM J MED, V94, P197, DOI 10.1016/0002-9343(93)90183-P; Pilowsky I., 1983, MANUAL ILLNESS BEHAV; PILOWSKY I, 1988, HDB SOCIAL PSYCHIATR; SHARPE M, 1992, BRIT MED J, V305, P147, DOI 10.1136/bmj.305.6846.147; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; WATSON M, 1990, PSYCHOL REP, V66, P39, DOI 10.2466/PR0.66.1.39-48; 1987, DIAGNOSTIC STATISTIC	22	208	209	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					756	759		10.1136/bmj.308.6931.756	http://dx.doi.org/10.1136/bmj.308.6931.756			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NC348	8142830	Green Published			2022-12-01	WOS:A1994NC34800019
J	NEUMANN, HPH; BERGER, DP; SIGMUND, G; BLUM, U; SCHMIDT, D; PARMER, RJ; VOLK, B; KIRSTE, G				NEUMANN, HPH; BERGER, DP; SIGMUND, G; BLUM, U; SCHMIDT, D; PARMER, RJ; VOLK, B; KIRSTE, G			PHEOCHROMOCYTOMAS, MULTIPLE ENDOCRINE NEOPLASIA TYPE-2, AND VONHIPPEL-LINDAU DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHROMOGRANIN-A; FAMILIAL PHEOCHROMOCYTOMA; MR; NEUROFIBROMATOSIS; FEATURES; MEMBERS; LESIONS; COMPLEX; TUMOR; CT	Background. Pheochromocytoma is a feature of two disorders with an autosomal dominant pattern of inheritance - multiple endocrine neoplasia type 2 (MEN-2) (with medullary thyroid carcinoma and hyperparathyroidism) and von Hippel-Lindau disease (with angioma of the retina, hemangioblastoma of the central nervous system, renal-cell carcinoma, pancreatic cysts, and epididymal cystadenoma). The frequency of these syndromes in patients with pheochromocytoma is not known. Methods. In an unselected group of patients with pheochromocytoma, we performed pentagastrin tests, parathyroid hormone assays, computed tomography (CT) or magnetic resonance imaging (MRI) of the brain, ophthalmoscopy, CT imaging of the abdomen, and ultrasonography of the testes. We also screened members of families with MEN-2 or von Hippel-Lindau disease for pheochromocytoma by measuring plasma and urine catecholamines and plasma chromogranin A and by performing abdominal ultrasonography, CT and MRI, and metaiodobenzylguanidine scintigraphy. Results. Nineteen of 82 unselected patients with pheochromocytomas (23 percent) were carriers of familial disorders; 19 percent had von Hippel-Lindau disease and 4 percent had MEN-2. Prospectively, in 36 of 79 subjects at risk for pheochromocytoma (46 percent), 42 unsuspected pheochromocytomas were found. Overall, there were 130 patients with 185 pheochromocytomas; 43 had von Hippel-Lindau disease, 24 had MEN-2, and 63 had sporadic tumors. The patients with familial and those with sporadic pheochromocytomas differed in mean age at diagnosis (32 vs. 46 years, P<0.001), multifocal localization (55 vs. 8 percent, P<0.001), and cancer (0 vs. 11 percent, P = 0.005); but not in the frequency of extraadrenal tumors (24 vs. 16 percent). Thirty-eight percent of carriers of von Hippel-Lindau disease and 24 percent of carriers of MEN-2 had pheochromocytoma as the only manifestation of their syndrome. Conclusions. All patients with pheochromocytomas should be screened for MEN-2 and von Hippel-Lindau disease to avert further morbidity and mortality in the patients and their families. All patients in families with MEN-2 or von Hippel-Lindau disease should be screened for pheochromocytoma, even if they are asymptomatic.	UNIV FREIBURG,DEPT RADIOL,W-7800 FREIBURG,GERMANY; UNIV FREIBURG,DEPT OPHTHALMOL,W-7800 FREIBURG,GERMANY; UNIV FREIBURG,DEPT SURG,W-7800 FREIBURG,GERMANY; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103	University of Freiburg; University of Freiburg; University of Freiburg; University of California System; University of California San Diego	NEUMANN, HPH (corresponding author), UNIV FREIBURG,DEPT MED,DIV NEPHROL & HYPERTENS,HUGSTETTERSTR 55,D-79106 FREIBURG,GERMANY.							ATUK NO, 1979, MEDICINE, V58, P209, DOI 10.1097/00005792-197905000-00001; BRAVO EL, 1991, KIDNEY INT, V40, P544, DOI 10.1038/ki.1991.244; CARMAN CT, 1960, NEW ENGL J MED, V263, P419, DOI 10.1056/NEJM196009012630901; CHATAL JF, 1985, J CLIN ENDOCR METAB, V61, P769, DOI 10.1210/jcem-61-4-769; EASTON DF, 1989, AM J HUM GENET, V44, P208; GLOWNIAK JV, 1985, ARCH INTERN MED, V145, P257, DOI 10.1001/archinte.145.2.257; GREEN JS, 1986, CAN MED ASSOC J, V134, P133; GRIFFITHS DFR, 1987, Q J MED, V64, P769; HORTON WA, 1976, ARCH INTERN MED, V136, P769, DOI 10.1001/archinte.136.7.769; HSIAO RJ, 1990, AM J MED, V88, P607, DOI 10.1016/0002-9343(90)90526-J; LAMIELL JM, 1989, MEDICINE, V68, P1; Landsberg L., 1992, WILLIAMS TXB ENDOCRI, P621; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEVINE E, 1982, AM J ROENTGENOL, V139, P505, DOI 10.2214/ajr.139.3.505; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NEUMANN HPH, 1987, VASA-J VASCULAR DIS, V16, P220; NEUMANN HPH, 1992, J NEUROL NEUROSUR PS, V55, P898, DOI 10.1136/jnnp.55.10.898; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; NEUMANN HPH, 1991, GASTROENTEROLOGY, V101, P465, DOI 10.1016/0016-5085(91)90026-H; OCONNOR DT, 1986, NEW ENGL J MED, V314, P1145, DOI 10.1056/NEJM198605013141803; OCONNOR DT, 1989, CLIN CHEM, V35, P1631; QUINT LE, 1987, RADIOLOGY, V165, P89, DOI 10.1148/radiology.165.1.3628794; REINIG JW, 1986, RADIOLOGY, V158, P81, DOI 10.1148/radiology.158.1.3940403; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; SATO Y, 1988, RADIOLOGY, V166, P241, DOI 10.1148/radiology.166.1.3336687; SCHIMKE RN, 1990, AM J MED GENET, V37, P375, DOI 10.1002/ajmg.1320370317; STEIN PP, 1990, MEDICINE, V70, P46; VASEN HFA, 1987, AM J MED, V83, P847, DOI 10.1016/0002-9343(87)90641-3; WILSON RA, 1978, HUM PATHOL, V9, P181, DOI 10.1016/S0046-8177(78)80109-9; YEH HC, 1980, AM J ROENTGENOL, V135, P1167, DOI 10.2214/ajr.135.6.1167	32	356	364	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1993	329	21					1531	1538		10.1056/NEJM199311183292103	http://dx.doi.org/10.1056/NEJM199311183292103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG188	8105382				2022-12-01	WOS:A1993MG18800003
J	HERTOG, MGL; FESKENS, EJM; HOLLMAN, PCH; KATAN, MB; KROMHOUT, D				HERTOG, MGL; FESKENS, EJM; HOLLMAN, PCH; KATAN, MB; KROMHOUT, D			DIETARY ANTIOXIDANT FLAVONOIDS AND RISK OF CORONARY HEART-DISEASE - THE ZUTPHEN ELDERLY STUDY	LANCET			English	Article							DENSITY-LIPOPROTEIN; QUERCETIN; CHOLESTEROL; INHIBITION	Flavonoids are polyphenolic antioxidants naturally present in vegetables, fruits, and beverages such as tea and wine. In vitro, flavonoids inhibit oxidation of low-density lipoprotein and reduce thrombotic tendency, but their effects on atherosclerotic complications in human beings are unknown. We measured the content in various foods of the flavonoids quercetin, kaempferol, myricetin, apigenin, and luteolin. We then assessed the flavonoid intake of 805 men aged 65-84 years in 1985 by a cross-check dietary history; the men were then followed up for 5 years. Mean baseline flavonoid intake was 25.9 mg daily. The major sources of intake were tea (61%), onions (13%), and apples (10%). Between 1985 and 1990, 43 men died of coronary heart disease. Fatal or non-fatal myocardial infarction occurred in 38 of 693 men with no history of myocardial infarction at baseline. Flavonoid intake (analysed in tertiles) was significantly inversely associated with mortality from coronary heart disease (p for trend = 0.015) and showed an inverse relation with incidence of myocardial infarction, which was of borderline significance (p for trend = 0 08). The relative risk of coronary heart disease mortality in the highest versus the lowest tertile of flavonoid intake was 0.42 (95% Cl 0.20-0.88). After adjustment for age, body-mass index, smoking, serum total and high-density-lipoprotein cholesterol, blood pressure, physical activity, coffee consumption, and intake of energy, vitamin C, vitamin E, beta-carotene, and dietary fibre, the risk was still significant (0.32 [0.15-0.71]). Intakes of tea, onions, and apples were also inversely related to coronary heart disease mortality, but these associations were weaker. Flavonoids in regularly consumed foods may reduce the risk of death from coronary heart disease in elderly men.	AGR UNIV WAGENINGEN,6700 HB WAGENINGEN,NETHERLANDS; STATE INST QUAL CONTROL AGR PROD,WAGENINGEN,NETHERLANDS	Wageningen University & Research	HERTOG, MGL (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT CHRON DIS & ENVIRONM EPIDEMIOL,POB 1,3720 BA BILTHOVEN,NETHERLANDS.		Feskens, Edith JM/A-3757-2012; Kromhout, Daan/A-8566-2014; Ibrahim, Essam Hassan/G-1960-2018; Hollman, Peter C.H./I-7446-2013; Feskens, Edith/ABI-1446-2020	Ibrahim, Essam Hassan/0000-0003-0130-2257; Hollman, Peter C.H./0000-0002-7510-6809; Feskens, Edith/0000-0001-5819-2488				BLOEMBERG BPM, 1989, AM J EPIDEMIOL, V130, P1047, DOI 10.1093/oxfordjournals.aje.a115405; CASPERSEN CJ, 1991, AM J EPIDEMIOL, V133, P1078, DOI 10.1093/oxfordjournals.aje.a115821; CONNEY AH, 1992, PREV MED, V21, P361, DOI 10.1016/0091-7435(92)90043-H; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; GUGLER R, 1975, EUR J CLIN PHARMACOL, V9, P229, DOI 10.1007/BF00614022; HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267; HERTOG MGL, 1992, J AGR FOOD CHEM, V40, P1591, DOI 10.1021/jf00021a023; HERTOG MGL, 1992, J AGR FOOD CHEM, V40, P2379, DOI 10.1021/jf00024a011; HERTOG MGL, 1993, J AGR FOOD CHEM, V41, P1242, DOI 10.1021/jf00032a015; HUSAIN SR, 1987, PHYTOCHEMISTRY, V26, P2489, DOI 10.1016/s0031-9422(00)83860-1; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KATIYAR SK, 1992, NUTR CANCER, V18, P73, DOI 10.1080/01635589209514207; KEYS A, 1967, ACTA MED SCAND, P1; KLELIJNEN J, 1992, LANCET, V340, P1136; Kuhnau J, 1976, World Rev Nutr Diet, V24, P117; LAUGHTON MJ, 1991, BIOCHEM PHARMACOL, V42, P1673, DOI 10.1016/0006-2952(91)90501-U; NEGRESALVAYRE A, 1992, FREE RADICAL BIO MED, V12, P101, DOI 10.1016/0891-5849(92)90002-X; Robak J, 1998, BIOCHEM PHARMACOL, V37, P83; Rose G, 1968, CARDIOVASCULAR SURVE; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; SORATA Y, 1984, BIOCHIM BIOPHYS ACTA, V799, P313, DOI 10.1016/0304-4165(84)90276-9; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TAKAHAMA U, 1985, PHYTOCHEMISTRY, V24, P1443, DOI 10.1016/S0031-9422(00)81040-7; UENO I, 1983, JPN J EXP MED, V53, P41; VANBUCHEM FSP, 1967, ACTA MED SCAND  S460, P191; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WILSON PWF, 1989, ARCH INTERN MED, V149, P1169, DOI 10.1001/archinte.149.5.1169; 1985, UCV TABEL UITGEBREID	29	3465	3612	10	512	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1007	1011		10.1016/0140-6736(93)92876-U	http://dx.doi.org/10.1016/0140-6736(93)92876-U			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	8105262				2022-12-01	WOS:A1993MD06600007
J	MITCHISON, TJ				MITCHISON, TJ			LOCALIZATION OF AN EXCHANGEABLE GTP-BINDING SITE AT THE PLUS END OF MICROTUBULES	SCIENCE			English	Article							MECHANISM; DYNAMICS; TUBULINS; INVITRO	Microtubule polarity arises from the head-to-tall orientation of alpha-beta tubulin heterodimers in the microtubule lattice. The identity of the polypeptide at each end of the microtubule is unknown, but structural models predict that the beta-tubulin end contains an exchangeable guanosine triphosphate (GTP) binding site. When GTP-coated fluorescent beads were incubated with microtubules, they bound specifically to plus ends, suggesting that tubulin is oriented in microtubules with beta-tubulin toward the plus end.			MITCHISON, TJ (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039565, R37GM039565] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39565] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS LA, 1974, J CELL SCI, V14, P523; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BERGEN LG, 1980, J CELL BIOL, V84, P151, DOI 10.1083/jcb.84.1.151; BURNS RG, 1991, CELL MOTIL CYTOSKEL, V20, P181, DOI 10.1002/cm.970200302; CAPLOW M, 1990, J BIOL CHEM, V265, P8935; CARLIER MF, 1989, INT REV CYTOL, V115, P139; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1991, J CELL SCI, P125; JACKSON RJ, 1973, BIOCHEM BIOPH RES CO, V51, P428, DOI 10.1016/0006-291X(73)91275-8; Kirschner M W, 1978, Int Rev Cytol, V54, P1, DOI 10.1016/S0074-7696(08)60164-3; MANDELKOW E, 1989, CELL MOVEMENT, V2, P23; MANDELKOW EM, 1985, J MOL BIOL, V181, P123, DOI 10.1016/0022-2836(85)90330-4; NATH JP, 1985, BIOCHEMISTRY-US, V24, P1555, DOI 10.1021/bi00327a040; Oakley B R, 1992, Trends Cell Biol, V2, P1, DOI 10.1016/0962-8924(92)90125-7; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1989, J CELL BIOL, V108, P931, DOI 10.1083/jcb.108.3.931; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043	18	138	141	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	1993	261	5124					1044	1047		10.1126/science.8102497	http://dx.doi.org/10.1126/science.8102497			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8102497				2022-12-01	WOS:A1993LT74700034
J	COLDITZ, GA				COLDITZ, GA			ORAL-CONTRACEPTIVE USE AND MORTALITY DURING 12 YEARS OF FOLLOW-UP - THE NURSES-HEALTH-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						CONTRACEPTIVES, ORAL; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RISK; RISK FACTORS	BREAST-CANCER; PAST USE; RISK; METAANALYSIS; WOMEN	Objective: To examine prospectively the risk for mortality among women who had ever used oral contraceptives compared with those who had never used oral contraceptives. Design: Prospective cohort study. Setting: Nurses' Health Study. Participants: 166 755 women aged 30 to 55 years in 1976, followed through 1988 (1.3 million person-years of follow-up). Results: On the basis of 2879 deaths, we found no overall difference in mortality among women who had ever used oral contraceptives compared with women who had never used oral contraceptives; the relative risk for ever-users, adjusted for age, body mass index, and cigarette smoking was 0.93 (95% CI, 0.85 to 1.01). We observed no trend in risk for total mortality with increasing duration of past use of oral contraceptives. After adjusting for age, body mass index, and cigarette smoking, women who had used oral contraceptives for 10 or more years had a relative risk of 1.06 (CI, 0.83 to 1.35). Conclusion: Use of oral contraceptives is safe; no evidence from this study indicates that long durations of oral contraceptive use adversely affect long-term risk for mortality.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40936] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COLDITZ GA, 1986, AM J EPIDEMIOL, V124, P520; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; GIOVANNUCCI E, 1992, NEW ENGL J MED, V326, P1392, DOI 10.1056/NEJM199205213262104; HANKINSON SE, 1992, OBSTET GYNECOL, V80, P708; HANKINSON SE, 1993, JAMA-J AM MED ASSOC, V270, P2813, DOI 10.1001/jama.270.23.2813; KAY CR, 1984, CLIN OBSTET GYNAECOL, V11, P759; KAY CR, 1981, LANCET, V1, P541; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MILNE R, 1992, J PUBLIC HEALTH MED, V14, P9; ORY HW, 1982, FAM PLANN PERSPECT, V14, P182, DOI 10.2307/2134636; ROMIEU I, 1990, CANCER-AM CANCER SOC, V66, P2253, DOI 10.1002/1097-0142(19901201)66:11<2253::AID-CNCR2820661102>3.0.CO;2-G; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; ROSENBERG L, 1992, AM J EPIDEMIOL, V136, P1437, DOI 10.1093/oxfordjournals.aje.a116464; STAMPFER MJ, 1990, AM J OBSTET GYNECOL, V163, P285, DOI 10.1016/0002-9378(90)90569-S; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1986, AM J EPIDEMIOL, V124, P520; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P1313, DOI 10.1056/NEJM198811173192004; THOMAS DB, 1990, BRIT J CANCER, V61, P110; THOMAS DB, 1993, JNCI-J NATL CANCER I, V85, P359, DOI 10.1093/jnci/85.5.359; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; Tietze C, 1978, Int J Gynaecol Obstet, V16, P456; VESSEY MP, 1989, BMJ-BRIT MED J, V299, P1487, DOI 10.1136/bmj.299.6714.1487; VESSEY MP, 1990, ORAL CONTRACEPTIVES, P1221; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; WINGO PA, 1993, CANCER-AM CANCER SOC, V71, P1506, DOI 10.1002/cncr.2820710416; 1991, ORAL CONTRACEPTIVES, P1	26	89	90	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1994	120	10					821	826		10.7326/0003-4819-120-10-199405150-00002	http://dx.doi.org/10.7326/0003-4819-120-10-199405150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK458	8154642				2022-12-01	WOS:A1994NK45800002
J	LEE, DKP; SWINBURNE, AJ; FEDULLO, AJ; WAHL, GW				LEE, DKP; SWINBURNE, AJ; FEDULLO, AJ; WAHL, GW			WITHDRAWING CARE - EXPERIENCE IN A MEDICAL INTENSIVE-CARE UNIT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIFE-SUPPORT; PATIENT; ILLUSION; FAMILIES; FUTILITY	Objective.-To describe the process and outcomes of withdrawing life-sustaining interventions in a medical intensive care unit (MICU). Design.-Retrospective case series. Setting.-Medical intensive care unit in a community teaching hospital. Patients.-Consecutive series of 28 patients in whom mechanical ventilation, dialysis, and/or vasopressors were withdrawn. We distinguished physiological, neurological, and functional rationales for care withdrawal. Main Outcome Measures.-Duration of discussions, MICU length of stay, and hospital survival. Results.-Mean +/-SD Acute Physiology and Chronic Health Evaluation (APACHE II) score was 27.1 +/- 7.3 on MICU admission, and average +/-SD predicted hospital mortality was 61% +/- 22%. Discussions leading to withdrawal of care occurred over an average +/-SD of 5.2 +/- 5.5 days, with decisions achieved soonest in cases with poor neurological prognosis. Average +/-SD MICU length of stay was 1.4 +/- 1.8 days following a decision to withdraw MICU care, and only four patients received more than 48 hours of additional MICU care. Four patients were discharged alive from the hospital. Conclusions.-Patients and their surrogates willingly considered outcomes in addition to mortality when considering withdrawal of life-sustaining interventions. Finding an accommodation between physician judgments and patient preferences took time and effort but was an effective means of limiting ineffective life-sustaining efforts. Withdrawing futile or unwanted care was not always fatal.	UNIV ROCHESTER,SCH MED & DENT,DEPT DERMATOL,ROCHESTER,NY 14642	University of Rochester	LEE, DKP (corresponding author), ROCHESTER GEN HOSP,PULM UNIT,1425 PORTLAND AVE,ROCHESTER,NY 14621, USA.							[Anonymous], 1991, ANN INTERN MED, V115, P478; [Anonymous], 1990, CRIT CARE MED, V18, P1435; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; CALLAHAN D, 1991, HASTINGS CENT REP, V21, P30, DOI 10.2307/3562999; CHELLURI L, 1993, JAMA-J AM MED ASSOC, V269, P3119, DOI 10.1001/jama.269.24.3119; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; EDWARDS MJ, 1992, ANN INTERN MED, V117, P254, DOI 10.7326/0003-4819-117-3-254; FABERLANGENDOEN K, 1992, CRIT CARE MED, V20, P570, DOI 10.1097/00003246-199205000-00005; FABERLANGENDOEN K, 1991, ARCH INTERN MED, V151, P235, DOI 10.1001/archinte.151.2.235; FEINSTEIN AR, 1986, ANN INTERN MED, V105, P413, DOI 10.7326/0003-4819-105-3-413; GOLDSTEIN RL, 1986, CRIT CARE MED, V14, P783, DOI 10.1097/00003246-198609000-00005; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; JENNETT B, 1975, LANCET, V1, P480; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANTOS JD, 1989, AM J MED, V87, P81; LUCE JM, 1992, CHEST, V101, P1185, DOI 10.1378/chest.101.5.1185; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2101, DOI 10.1001/jama.267.15.2101; PELLEGRINO ED, 1981, B NEW YORK ACAD MED, V57, P70; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SCHNEIDERMAN LJ, 1988, NEW ENGL J MED, V318, P984, DOI 10.1056/NEJM198804143181509; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHNEIDERMAN LJ, 1993, ARCH INTERN MED, V153, P437, DOI 10.1001/archinte.153.4.437; SIEGLER M, 1981, B NEW YORK ACAD MED, V57, P56; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SNIDER GL, 1991, AM REV RESPIR DIS, V143, P665, DOI 10.1164/ajrccm/143.3.665; SPICHER JE, 1987, ARCH INTERN MED, V147, P421, DOI 10.1001/archinte.147.3.421; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; 1987, GUIDELINES TERMINATI; 1991, JAMA-J AM MED ASSOC, V265, P1868	30	67	68	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	1994	271	17					1358	1361		10.1001/jama.271.17.1358	http://dx.doi.org/10.1001/jama.271.17.1358			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH487	8158822				2022-12-01	WOS:A1994NH48700029
J	ZADNIK, K; SATARIANO, WA; MUTTI, DO; SHOLTZ, RI; ADAMS, AJ				ZADNIK, K; SATARIANO, WA; MUTTI, DO; SHOLTZ, RI; ADAMS, AJ			THE EFFECT OF PARENTAL HISTORY OF MYOPIA ON CHILDRENS EYE SIZE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OCULAR COMPONENT DIMENSIONS; TUPAIA-BELANGERI; QUESTIONNAIRE; EMMETROPIZATION; VALIDATION; VISION	Objective.-To evaluate whether eye size and shape are different in children based on their parental history of myopia. Design.-A community-based cohort study of schoolchildren (aged 6 to 14 years), the Orinda (Calif) Longitudinal Study of Myopia. Setting.-Four campuses of the Orinda Union School District, a predominantly white, high socioeconomic status community. Participants.-A cross-sectional volunteer sample of 716 children (662 nonmyopic) in the first, third, and sixth grades in 1989, 1990, and 1991. All children in those grades were eligible for inclusion in the study. Intervention(s).-None. Main Outcome Measures.-Refractive error (measured by autorefraction), corneal curvature (measured by photokeratoscopy), crystalline lens power (measured by video phakometry), and axial ocular dimensions (measured by ultrasonography). Results.-With prevalent cases of myopia excluded and grade in school and ''near work'' controlled for, children with two myopic parents had longer eyes and less hyperopic refractive error (analysis of covariance, P less than or equal to.01) than children with only one myopic parent or no myopic parents. A model incorporating parental history is only improved by the addition of near work for the prediction of refractive error. Conclusions.-Even before the onset of juvenile myopia, children of myopic parents have longer eyes. These results suggest that the premyopic eye in children with a family history of myopia already resembles the elongated eye present in myopia.	UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720	University of California System; University of California Berkeley	ZADNIK, K (corresponding author), UNIV CALIF BERKELEY,SCH OPTOMETRY,BERKELEY,CA 94720, USA.				NEI NIH HHS [R01 EY08893] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008893] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALSBIRK PH, 1979, ACTA OPHTHALMOL, V57, P84; ANGLE J, 1980, AM J EPIDEMIOL, V111, P220, DOI 10.1093/oxfordjournals.aje.a112889; ASHTON GC, 1985, J BIOSOC SCI, V17, P223, DOI 10.1017/S0021932000015686; ASHTON GC, 1985, HUM HERED, V35, P232, DOI 10.1159/000153551; BASU SK, 1983, HUM HERED, V33, P163, DOI 10.1159/000153369; Blum HL, 1959, VISION SCREENING ELE; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; FINEGAN JAK, 1991, ARCH SEX BEHAV, V20, P393, DOI 10.1007/BF01542619; FLEDELIUS HC, 1980, ACTA OPHTHALMOL, V58, P889; FLEDELIUS HC, 1982, ACTA OPHTHALMOL, V60, P393; FLEDELIUS HC, 1982, ACTA OPHTHALMOL, V60, P403; GARNER LF, 1990, OPHTHAL PHYSL OPT, V10, P234, DOI 10.1111/j.1475-1313.1990.tb00857.x; GARNER LF, 1988, AM J OPTOM PHYS OPT, V65, P182; Goldschmidt E., 1968, ACTA OPHTHALMOL, V98, P1; Goss D A, 1988, J Am Optom Assoc, V59, P875; GWIAZDA J, 1993, CLIN VISION SCI, V8, P337; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233, DOI 10.1093/oxfordjournals.aje.a115129; KIMURA T, 1965, NIPPON GANKA GAKKAI, V69, P963; LARSEN JS, 1971, ACTA OPHTHALMOL, V49, P427; LARSEN JS, 1971, ACTA OPHTHALMOL, V49, P239; LARSEN JS, 1971, ACTA OPHTHALMOL, V49, P441; MCBRIEN NA, 1992, VISION RES, V32, P843, DOI 10.1016/0042-6989(92)90027-G; MCBRIEN NA, 1989, OPHTHAL PHYSL OPT, V4, P201; MELTZER JW, 1970, PUBLIC HLTH REP, V85, P1057; MILES FA, 1990, VISION RES, V30, P339, DOI 10.1016/0042-6989(90)90076-W; MINKOVITZ JB, 1993, INVEST OPHTH VIS SCI, V34, P1218; MURPHY JM, 1992, J AM ACAD CHILD PSY, V31, P1105, DOI 10.1097/00004583-199211000-00019; MUTTI DO, 1992, INVEST OPHTH VIS SCI, V33, P1771; NAKAJIMA A, 1968, Japanese Journal of Human Genetics, V13, P20; NORTON TT, 1992, VISION RES, V32, P833, DOI 10.1016/0042-6989(92)90026-F; RABIN J, 1981, INVEST OPHTH VIS SCI, V20, P561; RAVIOLA E, 1985, NEW ENGL J MED, V312, P1609, DOI 10.1056/NEJM198506203122505; RICHLER A, 1980, ACTA OPHTHALMOL, V58, P468; ROSNER M, 1987, ARCH OPHTHALMOL-CHIC, V105, P1508; SORSBY A, 1966, Journal of Medical Genetics, V3, P269, DOI 10.1136/jmg.3.4.269; Sorsby A, 1957, EMMETROPIA ITS ABERR; Sorsby A., 1962, REFRACTION ITS COMPO; SORSBY A, 1961, REFRACTION ITS COMPO; Sorsby A, 1970, LONGITUDINAL STUDY R; SPERDUTO RD, 1983, ARCH OPHTHALMOL-CHIC, V101, P405, DOI 10.1001/archopht.1983.01040010405011; TEIKARI JM, 1991, HUM HERED, V41, P151, DOI 10.1159/000153994; TEIKARI JM, 1992, SCAND J SOC MED, V20, P73; Tokoro T, 1969, JPN J OPHTHALMOL, V13, P27; WALLMAN J, 1987, VISION RES, V27, P1139, DOI 10.1016/0042-6989(87)90027-7; WOLD KC, 1949, ARCH OPHTHALMOL-CHIC, V42, P225; YOUNG FA, 1969, AMER J OPT ARCH AM A, V46, P676; YOUNG FA, 1963, INVEST OPHTH VISUAL, V2, P571; YOUNG FA, 1972, AMER J OPT ARCH AM A, V49, P546; ZADNIK K, 1993, OPTOMETRY VISION SCI, V70, P750, DOI 10.1097/00006324-199309000-00012; 1989, MYOPIA PREVALENCE PR; 1987, VISION RES NATIONAL	51	224	230	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	1994	271	17					1323	1327		10.1001/jama.271.17.1323	http://dx.doi.org/10.1001/jama.271.17.1323			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH487	8158816				2022-12-01	WOS:A1994NH48700023
J	KURIHARA, Y; KURIHARA, H; SUZUKI, H; KODAMA, T; MAEMURA, K; NAGAI, R; ODA, H; KUWAKI, T; CAO, WH; KAMADA, N; JISHAGE, K; OUCHI, Y; AZUMA, S; TOYODA, Y; ISHIKAWA, T; KUMADA, M; YAZAKI, Y				KURIHARA, Y; KURIHARA, H; SUZUKI, H; KODAMA, T; MAEMURA, K; NAGAI, R; ODA, H; KUWAKI, T; CAO, WH; KAMADA, N; JISHAGE, K; OUCHI, Y; AZUMA, S; TOYODA, Y; ISHIKAWA, T; KUMADA, M; YAZAKI, Y			ELEVATED BLOOD-PRESSURE AND CRANIOFACIAL ABNORMALITIES IN MICE DEFICIENT IN ENDOTHELIN-1	NATURE			English	Article							DEVELOPMENTAL DEFECTS; TARGETED DISRUPTION; VENTRAL SURFACE; BINDING-SITES; RAT MEDULLA; GENE; EXPRESSION; PEPTIDE; CELLS; HYPERTENSION	The endothelin-l (ET-1) gene was disrupted in mouse embryonic stem cells by homologous recombination to generate mice deficient in ET-1. These: ET-1(-/-) homozygous mice die of respiratory failure at birth and have morphological abnormalities of the pharyngeal-arch-derived craniofacial tissues and organs. ET-1(+/-) heterozygous mice, which produce lower levels of ET-1 than wild-type mice, develop elevated blood pressure. These results suggest that ET-1 is essential for normal mouse development and may also play a physiological role in cardiovascular homeostasis.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC MED, DEPT PATHOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC MED, DEPT PHYSIOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC MED, DEPT GERIATR, BUNKYO KU, TOKYO 113, JAPAN; CHUGAI PHARMACEUT CO LTD, GOTEMBA, SHIZUOKA 412, JAPAN; UNIV TOKYO, INST MED SCI, DEPT REPROD & DEV BIOL, MINATO KU, TOKYO 108, JAPAN	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of Tokyo								ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AZUMA S, 1991, Japanese Journal of Animal Reproduction, V37, P37; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; CAO WH, 1993, J CARDIOVASC PHARM, V22, pS196, DOI 10.1097/00005344-199322008-00053; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; FUKUDA Y, 1988, BIOCHEM BIOPH RES CO, V155, P167, DOI 10.1016/S0006-291X(88)81064-7; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; INOUE A, 1989, J BIOL CHEM, V264, P14954; JOHNSTON MC, 1991, J CRAN GENET DEV BIO, V11, P227; KAY ED, 1987, TERATOLOGY, V35, P105, DOI 10.1002/tera.1420350114; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KOSEKI C, 1989, NEUROSCI RES, V6, P581, DOI 10.1016/0168-0102(89)90047-3; KRONMILLER JE, 1991, DEV BIOL, V147, P485, DOI 10.1016/0012-1606(91)90307-O; KUMADA M, 1990, PROG NEUROBIOL, V35, P331, DOI 10.1016/0301-0082(90)90036-G; KUWAKI T, 1991, NEUROCHEM INT, V18, P519, DOI 10.1016/0197-0186(91)90150-C; KUWAKI T, 1991, J AUTONOM NERV SYST, V36, P149, DOI 10.1016/0165-1838(91)90111-F; KUWAKI T, 1990, JPN J PHYSIOL, V40, P827, DOI 10.2170/jjphysiol.40.827; KUWAKI T, 1991, J CARDIOVASC PHARM, V17, pS343, DOI 10.1097/00005344-199100177-00098; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; LUSCHER TF, 1992, HYPERTENSION, V19, P117, DOI 10.1161/01.HYP.19.2.117; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUMOTO H, 1989, BIOCHEM BIOPH RES CO, V164, P74, DOI 10.1016/0006-291X(89)91684-7; MCKENZIE J, 1958, ARCH DIS CHILD, V33, P477, DOI 10.1136/adc.33.171.477; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MORISHITA R, 1989, BIOCHEM BIOPH RES CO, V160, P628, DOI 10.1016/0006-291X(89)92479-0; MORTENSEN LH, 1990, HYPERTENSION, V15, P729, DOI 10.1161/01.HYP.15.6.729; MOSQUEDAGARCIA R, 1993, CIRC RES, V72, P20, DOI 10.1161/01.RES.72.1.20; NODEN DM, 1991, BRAIN BEHAV EVOLUT, V38, P190, DOI 10.1159/000114388; NODEN DM, 1986, J CRAN GENET DEV BIO, P15; OUCHI Y, 1989, AM J PHYSIOL, V256, pH1747, DOI 10.1152/ajpheart.1989.256.6.H1747; RAKUGI H, 1988, BIOCHEM BIOPH RES CO, V155, P1244, DOI 10.1016/S0006-291X(88)81273-7; SAIDA K, 1989, J BIOL CHEM, V264, P14613; SPYER KM, 1991, J CARDIOVASC PHARM, V17, pS385, DOI 10.1097/00005344-199100177-00108; SUZUKI N, 1989, J IMMUNOL METHODS, V118, P245, DOI 10.1016/0022-1759(89)90012-4; TAKAGI Y, 1991, AM J HYPERTENS, V4, P389, DOI 10.1093/ajh/4.4.389; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/0092-8674(93)90678-J; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YASUJIMA M, 1990, AM J HYPERTENS, V3, P635, DOI 10.1093/ajh/3.8.635; YOKOKAWA K, 1991, ANN INTERN MED, V114, P213, DOI 10.7326/0003-4819-114-3-213	47	863	873	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 21	1994	368	6473					703	710		10.1038/368703a0	http://dx.doi.org/10.1038/368703a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152482				2022-12-01	WOS:A1994NG55300048
J	SHALLICE, T; FLETCHER, P; FRITH, CD; GRASBY, P; FRACKOWIAK, RSJ; DOLAN, RJ				SHALLICE, T; FLETCHER, P; FRITH, CD; GRASBY, P; FRACKOWIAK, RSJ; DOLAN, RJ			BRAIN-REGIONS ASSOCIATED WITH ACQUISITION AND RETRIEVAL OF VERBAL EPISODIC MEMORY	NATURE			English	Article							PREFRONTAL CORTEX; HIPPOCAMPUS; ATTENTION; NETWORKS; AMNESIA; HUMANS; PET	IT is widely held that conscious recall of past experiences involves a specific system-episodic memory1. Patients with amnesia have gross impairments of episodic memory while other kinds of memory remain intact2,3, suggesting that a separable brain system underlies episodic memory. We have used positron emission tomography (PET) to identify components of this system in normal volunteers. A dual-task interference paradigm4 was used to isolate brain areas associated with acquisition, and a cueing paradigm5 to isolate the areas concerned with retrieval from verbal episodic memory. Acquisition was associated with activity in the left prefrontal cortex and the retrosplenial area, whereas retrieval was associated with activity in right prefrontal cortex and the precuneus. Our results provide clear evidence that episodic memory involves a network of specific prefrontal and posterior structures6,7 which can be fractionated into different component processes.	UCL, DEPT PSYCHOL, GOWER ST, LONDON WC1E 6TB, ENGLAND; HAMMERSMITH HOSP, MRC, CYCLOTRON UNIT, LONDON W12 0HS, ENGLAND; ROYAL FREE HOSP, SCH MED, LONDON NW3 2QG, ENGLAND; NATL HOSP NEUROL & NEUROSURG, LONDON WC1 3BG, ENGLAND; INST NEUROL, LONDON WC1N 3BG, ENGLAND	University of London; University College London; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London			Frackowiak, Richard/H-4383-2011; Frith, Chris D/A-2171-2009; Frackowiak, Richard S/I-1809-2013; Fletcher, Paul/F-5380-2011	Frackowiak, Richard/0000-0002-3151-822X; Frith, Chris D/0000-0002-8665-0690; Dolan, Ray/0000-0001-9356-761X; Fletcher, Paul/0000-0001-8257-1517				[Anonymous], 1983, CANADIAN PSYCHOL; BADDELEY A, 1984, J EXP PSYCHOL GEN, V113, P518, DOI 10.1037/0096-3445.113.4.518; Baddeley A. D., 1990, HUMAN MEMORY; Baddeley A.D., 1986, WORKING MEMORY; BADDELEY AD, 1986, AUTOBIOGRAPHICAL MEM; BURGESS PW, 1992, THESIS U LONDON; FARAH MJ, 1984, COGNITION, V18, P245, DOI 10.1016/0010-0277(84)90026-X; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1991, J COMPUT ASSIST TOMO, V15, P634, DOI 10.1097/00004728-199107000-00020; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.ne.11.030188.001033; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; Jacoby L.L., 1993, ATTENTION SELECTION; Mayes A. R., 1988, HUMAN ORGANIC MEMORY; PARKIN AJ, 1990, MEM COGNITION, V18, P507, DOI 10.3758/BF03198483; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; ROBB R A, 1991, Australasian Physical and Engineering Sciences in Medicine, V14, P9; ROLAND PE, 1989, WENNER-GR C, V53, P141; Rolls ET, 1990, NETWORK-COMP NEURAL, V1, P407, DOI 10.1088/0954-898X/1/4/002; RUDGE P, 1991, BRAIN, V114, P349, DOI 10.1093/brain/114.1.349; Shallice T, 1988, NEUROPSYCHOLOGY MENT, DOI DOI 10.1017/IPM.2020.45; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; STUSS DT, 1978, NEUROLOGY, V28, P1166, DOI 10.1212/WNL.28.11.1166; Tournoux P., 1988, COPLANAR STEREOTACTI; VALENSTEIN E, 1987, BRAIN, V110, P1631, DOI 10.1093/brain/110.6.1631; WARRINGTON EK, 1982, NEUROPSYCHOLOGIA, V20, P233, DOI 10.1016/0028-3932(82)90099-9; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803	30	722	730	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 14	1994	368	6472					633	635		10.1038/368633a0	http://dx.doi.org/10.1038/368633a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	8145849	Green Published			2022-12-01	WOS:A1994NF39200060
J	CZAJA, R; MCFALL, SL; WARNECKE, RB; FORD, L; KALUZNY, AD				CZAJA, R; MCFALL, SL; WARNECKE, RB; FORD, L; KALUZNY, AD			PREFERENCES OF COMMUNITY PHYSICIANS FOR CANCER SCREENING GUIDELINES	ANNALS OF INTERNAL MEDICINE			English	Article							FAMILY PHYSICIANS; PRIMARY CARE; PATTERNS; MAMMOGRAPHY; PREVENTION; MEDICINE	Objective: To assess factors related to consensus among community physicians regarding appropriate screening intervals for eight cancer screening procedures for which guidelines have been published. Design: Interviews were conducted with a national random sample of 3436 physicians in family practice, internal medicine, general surgery, and gynecology by mail or telephone or both. The overall response rate was 67%. Measurements: Consensus by specialization and by physician and practice characteristics on the appropriate screening intervals for early detection of cancers of the breast, cervix, colon and rectum, and lung for asymptomatic adults at normal risk. ii Results: More than 60% of the physicians surveyed agreed on the length of the screening intervals for six of eight procedures. Consensus most closely followed American Cancer Society- and National Cancer Institute-recommended screening intervals for all procedures except chest roentgenogram Acceptance of screening intervals was not related to the extent of agreement among published guidelines. Surgeons tended to favor more aggressive screening than family physicians and internists; gynecologists most consistently favored aggressive screening for cancers occurring in women. Older physicians and those in solo practice tended to favor outmoded procedures such as routine chest roentgenograms and to be more conservative about screening intervals. Conclusions: Physicians stated that they follow the American Cancer Society and National Cancer Institute guidelines for cancer screening more than the guidelines published by their own specialty societies, but they also reported procedures not recommended in any guidelines. These findings suggest that changing physician screening practices will be difficult.	UNIV ILLINOIS, SURVEY RES LAB, CHICAGO, IL USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT HLTH PROMOT SCI, OKLAHOMA CITY, OK 73190 USA; NCI, BETHESDA, MD 20892 USA; UNIV N CAROLINA, CECIL G SHEPS HLTH SERV RES CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH PUBL HLTH, CHAPEL HILL, NC 27599 USA; N CAROLINA STATE UNIV, RALEIGH, NC USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; North Carolina State University					DIVISION OF CANCER PREVENTION AND CONTROL [N01CN075435] Funding Source: NIH RePORTER; NCI NIH HHS [N01CN75435] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANES D, 1988, PREV MED, V17, P643, DOI 10.1016/0091-7435(88)90057-6; [Anonymous], COMMON SCREENING TES; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BASSETT LW, 1986, AM J ROENTGENOL, V147, P689, DOI 10.2214/ajr.147.4.689; BATTISTA RN, 1988, ANNU REV PUBL HEALTH, V9, P21; BATTISTA RN, 1985, CAN MED ASSOC J, V132, P1013; BATTISTA RN, 1983, AM J PUBLIC HEALTH, V73, P1036, DOI 10.2105/AJPH.73.9.1036; BERGNER M, 1990, ARCH INTERN MED, V150, P431, DOI 10.1001/archinte.150.2.431; Canadian Task Force on the Periodic Health Examination, 1979, CAN MED ASSOC J, V121, P1193; COLEMAN JS, 1986, MED INNOVATION DIFFU; DIETRICH AJ, 1984, AM J PUBLIC HEALTH, V74, P223, DOI 10.2105/AJPH.74.3.223; EISENBERG JM, 1985, MED CARE, V23, P461, DOI 10.1097/00005650-198505000-00010; FOX SA, 1988, RADIOLOGY, V166, P431, DOI 10.1148/radiology.166.2.3336718; GEMSON DH, 1987, NEW YORK STATE J MED, V87, P643; GREENWALD P, 1986, NCI MONOGRAPH, V2; Havlicek P L, 1984, IMJ Ill Med J, V166, P285; HAYWARD RSA, 1991, ANN INTERN MED, V114, P758, DOI 10.7326/0003-4819-114-9-758; KALUZNY AD, 1989, J NATL CANCER I, V81, P1717, DOI 10.1093/jnci/81.22.1717; Kanouse DE, 1989, CHANGING MED PRACTIC; KANOUSE DE, 1991, DISSEMINATION PRACTI; LEMESHOW S, 1984, AM J EPIDEMIOL, V119, P147, DOI 10.1093/oxfordjournals.aje.a113732; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; MILLER AB, 1986, J CHRON DIS, V39, P1067, DOI 10.1016/0021-9681(86)90140-2; Nash D B, 1991, Front Health Serv Manage, V8, P3; WARNER SL, 1989, J FAM PRACTICE, V29, P281; WEISMAN CS, 1986, PREV MED, V15, P342, DOI 10.1016/0091-7435(86)90002-2; WOOLF SH, 1990, ARCH INTERN MED, V150, P1811, DOI 10.1001/archinte.150.9.1811; 1990, OM900086 AG HLTH CAR; 1985, CA-CANCER J CLIN, V35, P197; 1987, JAMA-J AM MED ASSOC, V257, P2196; 1978, I MED PREVENTION PRO, P1; 1987, WORKING GUIDELINES E; 1980, PROMOTING HLTH PREVE; 1990, CONSENSUS DEV NIH IM; 1989, JAMA-J AM MED ASSOC, V261, P2535	36	73	73	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1994	120	7					602	608		10.7326/0003-4819-120-7-199404010-00012	http://dx.doi.org/10.7326/0003-4819-120-7-199404010-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC764	8117000				2022-12-01	WOS:A1994NC76400012
J	PLEIMAN, CM; HERTZ, WM; CAMBIER, JC				PLEIMAN, CM; HERTZ, WM; CAMBIER, JC			ACTIVATION OF PHOSPHATIDYLINOSITOL-3' KINASE BY SRC-FAMILY KINASE SH3 BINDING TO THE P85 SUBUNIT	SCIENCE			English	Article							RECEPTOR TYROSINE KINASES; CELL ANTIGEN RECEPTOR; FACTOR-I RECEPTOR; LYMPHOCYTES-B; GROWTH-FACTOR; PDGF RECEPTOR; MIDDLE-T; C-SRC; PROTEIN; 3-KINASE	Engagement of antigen receptor complexes induces rapid activation of Src-family kinases and association with phosphatidylinositol-3' kinase (Pl-3 kinase). Here it was found that the Src homology 3 (SH3) domain of Lyn and Fyn bound to a proline-rich region (residues 84 to 99) within the 85-kilodalton subunit (p85) of Pl-3 kinase. The binding of SH3 to the purified kinase led to a five- to sevenfold increase in the specific activity of Pl-3 kinase. Ligand-induced receptor stimulation activated Pl-3 kinase, and this activation was blocked by a peptide containing residues 84 to 99 of p85. These data demonstrate a mechanism for Pl-3 kinase activation and show that binding of SH3 domains to proline-rich target sequences can regulate enzymatic activity.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL, DENVER, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Cambier, John/0000-0002-7803-242X	PHS HHS [A121768, A129903, A120519] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DEFRANCO AL, 1989, NATURE, V342, P340, DOI 10.1038/342340a0; DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOLD MR, 1992, J IMMUNOL, V148, P2012; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PLEIMAN CM, UNPUB; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WARD SG, 1992, J BIOL CHEM, V267, P23862; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAMOTO T, 1992, SCIENCE, V89, P1118; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	57	424	433	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 18	1994	263	5153					1609	1612		10.1126/science.8128248	http://dx.doi.org/10.1126/science.8128248			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128248				2022-12-01	WOS:A1994NB67300031
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW REGULATION REQUIRES IMPRINTING ON SOLID ORAL DOSAGE FORM-DRUG PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					812	812						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114223				2022-12-01	WOS:A1994MZ49800004
J	COGGON, D; INSKIP, H				COGGON, D; INSKIP, H			IS THERE AN EPIDEMIC OF CANCER .1.	BRITISH MEDICAL JOURNAL			English	Article							HELICOBACTER-PYLORI; TESTICULAR CANCER; GASTRIC-CANCER; STOMACH-CANCER; MORTALITY; ENGLAND; WALES; INFECTION; CHILDHOOD; TRENDS	Trends in cancer mortality in England and Wales are dominated by a slowly evolving epidemic of lung cancer attributable to smoking. When the substantial effects of tobacco are discounted there is no evidence that the overall incidence of cancer is rising, but striking trends are apparent for several specific tumours. These may offer important clues to aetiology.			COGGON, D (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.		Inskip, Hazel/L-5467-2018	Inskip, Hazel/0000-0001-8897-1749				ARMSTRONG BK, 1988, J DERMATOL SURG ONC, V14, P835, DOI 10.1111/j.1524-4725.1988.tb03588.x; BARKER DJP, 1990, BRIT J CANCER, V61, P575, DOI 10.1038/bjc.1990.129; COGGON D, 1983, THORAX, V38, P721, DOI 10.1136/thx.38.10.721; COGGON D, 1989, J NATL CANCER I, V81, P1178, DOI 10.1093/jnci/81.15.1178; DAVIES JM, 1981, LANCET, V1, P928; DAVIS DL, 1990, LANCET, V336, P474, DOI 10.1016/0140-6736(90)92020-I; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; GILLIS CR, 1992, BRIT MED J, V302, P1331; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; Lee JAH, 1982, CANC EPIDEMIOLOGY PR, P984; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MODAN B, 1974, LANCET, V1, P277; NOMURA A, 1991, NEW ENGL J MED, V325, P1170; OSMOND C, 1983, OPCS SERIES DH1, V11; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; POWELL J, 1990, BRIT J CANCER, V62, P440, DOI 10.1038/bjc.1990.314; SHORE RE, 1976, ARCH ENVIRON HEALTH, V31, P21, DOI 10.1080/00039896.1976.10667184; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P97, DOI 10.1038/bjc.1987.20; 1992, DOCUMENTS NRPB, V31, P1; 1983, SERIES DH2; [No title captured]	21	16	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					705	708		10.1136/bmj.308.6930.705	http://dx.doi.org/10.1136/bmj.308.6930.705			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142798	Green Published			2022-12-01	WOS:A1994NA86900026
J	BARFORD, D; FLINT, AJ; TONKS, NK				BARFORD, D; FLINT, AJ; TONKS, NK			CRYSTAL-STRUCTURE OF HUMAN PROTEIN-TYROSINE-PHOSPHATASE 1B	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; HUMAN-PLACENTA; MACROMOLECULAR CRYSTALLOGRAPHY; SEQUENCE HOMOLOGY; CATALYTIC SUBUNIT; SH2 DOMAIN; EXPRESSION; CLONING; KINASE; LAR	Protein tyrosine phosphatases (PTPs) constitute a family of receptor-like and cytoplasmic signal transducing enzymes that catalyze the dephosphorylation of phosphotyrosine residues and are characterized by homologous catalytic domains. The crystal structure of a representative member of this family, the 37-kilodalton form (residues 1 to 321) of PTP1 B, has been determined at 2.8 Angstrom resolution. The enzyme consists of a single domain with the catalytic site located at the base of a shallow cleft. The phosphate recognition site is created from a loop that is located at the amino-terminus of an or helix. This site is formed from an 11-residue sequence motif that is diagnostic of PTPs and the dual specificity phosphatases, and that contains the catalytically essential cysteine and arginine residues. The position of the invariant cysteine residue within the phosphate binding site is consistent with its role as a nucleophile in the catalytic reaction. The structure of PTP1B should serve as a model for other members of the PTP family and as a framework for understanding the mechanism of tyrosine dephosphorylation.			BARFORD, D (corresponding author), COLD SPRING HARBOR LAB, WM KECK STRUCT BIOL LAB, COLD SPRING HARBOR, NY 11724 USA.				NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABADZAPATERO C, 1987, J MOL BIOL, V198, P445, DOI 10.1016/0022-2836(87)90293-2; ALESSI DR, 1993, ONCOGENE, V8, P2015; BARFORD D, UNPUB DESCRIPTION CO; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BROWNSHIMER S, 1992, CANCER RES, V52, P478; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHHO H, 1993, PROTEIN SCI, V2, P977; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KENNER KA, 1993, J BIOL CHEM, V268, P25455; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LIVINGSTON CD, IN PRESS INT J PEPTI; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; POT DA, 1991, J BIOL CHEM, V266, P19688; POTTS M, 1993, J BIOL CHEM, V268, P7632; RAMALINGAM R, 1993, J BIOL CHEM, V268; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; Schultz Leonard D., 1993, Cell, V73, P1445; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STRAUSS MG, 1991, P SOC PHOTO I ENG, V1447, P12; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tonks N K, 1993, Semin Cell Biol, V4, P373, DOI 10.1006/scel.1993.1044; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WARY KK, 1993, CANCER RES, V53, P1498; WEISSMAN L, 1982, COMPUTATIONAL CRYSTA, P56; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; [No title captured]	76	673	690	3	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 11	1994	263	5152					1397	1404		10.1126/science.8128219	http://dx.doi.org/10.1126/science.8128219			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128219				2022-12-01	WOS:A1994MZ92700020
J	PASCUALLEONE, A; GRAFMAN, J; HALLETT, M				PASCUALLEONE, A; GRAFMAN, J; HALLETT, M			MODULATION OF CORTICAL MOTOR OUTPUT MAPS DURING DEVELOPMENT OF IMPLICIT AND EXPLICIT KNOWLEDGE	SCIENCE			English	Article							FREQUENCY-DISCRIMINATION TASK; FOCAL MAGNETIC STIMULATION; ADULT OWL MONKEYS; FUNCTIONAL REORGANIZATION; MEMORY; CORTEX; BRAIN; SYSTEM; DEAFFERENTATION; REPRESENTATION	The excitability of the human motor cortex during the development of implicit and declarative knowledge of a motor task was examined. During a serial reaction time test, subjects developed implicit knowledge of the test sequence, which was reflected by diminishing response times. Motor cortical mapping with transcranial magnetic stimulation revealed that the cortical output maps to the muscles involved in the task became progressively larger until explicit knowledge was achieved, after which they returned to their baseline topography. These results illustrate the rapid functional plasticity of cortical outputs associated with learning and with the transfer of knowledge from an implicit to explicit state.	NINCDS, MED NEUROL BRANCH, COGNIT NEUROSCI SECT, BETHESDA, MD 20892 USA; NINCDS, MED NEUROL BRANCH, HUMAN MOTOR CONTROL SECT, BETHESDA, MD 20892 USA; UNIV VALENCIA, DEPT FISIOL, UNIDAD NEUROBIOL, VALENCIA, SPAIN	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Valencia			Pascual-Leone, Alvaro/G-6566-2011; Pascual-Leone, Alvaro/AAC-5101-2019	Pascual-Leone, Alvaro/0000-0001-8975-0382; Grafman, Jordan H./0000-0001-8645-4457				ASANUMA H, 1991, NEUROREPORT, V2, P217, DOI 10.1097/00001756-199105000-00001; BRASILNETO JP, 1993, BRAIN, V116, P511, DOI 10.1093/brain/116.3.511; BRASILNETO JP, 1992, NEUROLOGY, V42, P1302, DOI 10.1212/WNL.42.7.1302; CAREW TJ, 1986, ANNU REV NEUROSCI, V9, P435, DOI 10.1146/annurev.ne.09.030186.002251; COHEN LG, 1990, ELECTROEN CLIN NEURO, V75, P350, DOI 10.1016/0013-4694(90)90113-X; COHEN LG, 1991, BRAIN, V114, P615, DOI 10.1093/brain/114.1.615; FABRETHORPE M, 1991, BEHAV NEUROSCI, V105, P176, DOI 10.1037/0735-7044.105.1.176; GLUCK MA, 1993, ANNU REV NEUROSCI, V16, P667, DOI 10.1146/annurev.ne.16.030193.003315; GRAFTON ST, 1992, J NEUROSCI, V12, P2542; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; JENKINS WM, 1990, NEUROPSYCHOLOGIA, V28, P573, DOI 10.1016/0028-3932(90)90035-M; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; LEVY WJ, 1990, BRAIN RES, V510, P130, DOI 10.1016/0006-8993(90)90738-W; LEVY WJ, 1991, ELECTROEN CLIN NEURO, P51; MACCABEE PJ, 1990, ELECTROEN CLIN NEURO, V76, P131, DOI 10.1016/0013-4694(90)90211-2; MERZENICH MM, 1990, COLD SPRING HARB SYM, V55, P873; NUDO RJ, 1992, J NEUROSCI, V12, P2918, DOI 10.1523/JNEUROSCI.12-08-02918.1992; PASCUALLEONE A, 1993, ANN NEUROL, V34, P33, DOI 10.1002/ana.410340108; PASCUALLEONE A, 1993, NEUROLOGY, V43, pA157; PASCUALLEONE A, 1993, BRAIN, V116, P39, DOI 10.1093/brain/116.1.39; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RAMACHANDRAN VS, 1992, SCIENCE, V258, P1159, DOI 10.1126/science.1439826; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1015, DOI 10.1152/jn.1992.67.5.1015; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1057, DOI 10.1152/jn.1992.67.5.1057; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031, DOI 10.1152/jn.1992.67.5.1031; ROTH BJ, 1991, ELECTROEN CLIN NEURO, V81, P47, DOI 10.1016/0168-5597(91)90103-5; SANES JN, 1992, CEREB CORTEX, V2, P141, DOI 10.1093/cercor/2.2.141; SAYPOL JM, 1991, ANN BIOMED ENG, V19, P317, DOI 10.1007/BF02584306; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; Schieber M. H., 1992, Society for Neuroscience Abstracts, V18, P504; Seitz R J, 1990, Neuroreport, V1, P57, DOI 10.1097/00001756-199009000-00016; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SQUIRE LR, 1988, TRENDS NEUROSCI, V11, P170, DOI 10.1016/0166-2236(88)90144-0; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; TOFTS PS, 1990, PHYS MED BIOL, V35, P1119, DOI 10.1088/0031-9155/35/8/008; Wassermann E. M., 1992, Society for Neuroscience Abstracts, V18, P939; WASSERMANN EM, 1992, ELECTROEN CLIN NEURO, V85, P1, DOI 10.1016/0168-5597(92)90094-R; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WILLINGHAM DB, 1989, J EXP PSYCHOL LEARN, V15, P1047, DOI 10.1037/0278-7393.15.6.1047; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	42	518	524	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 4	1994	263	5151					1287	1289		10.1126/science.8122113	http://dx.doi.org/10.1126/science.8122113			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122113				2022-12-01	WOS:A1994MY57000039
J	MARTIN, JR; RAIBAUD, A; OLLO, R				MARTIN, JR; RAIBAUD, A; OLLO, R			TERMINAL PATTERN ELEMENTS IN DROSOPHILA EMBRYO INDUCED BY THE TORSO-LIKE PROTEIN	NATURE			English	Article							RECEPTOR TYROSINE KINASE; GENE; MELANOGASTER; SEQUENCE; POLARITY; SITES	THE genes torso (tor)1 and torso-like (tsl)2 are two of the Drosophila maternal group genes implicated in a receptor tyrosine kinase signalling pathway that specifies terminal cell fate (reviewed in ref. 3). Loss-of function mutations in these loci cause an identical phenotype in which pattern elements from the anterior (acron) and posterior (telson) ends have been deleted. We have cloned the tsl gene and demonstrate here that, in agreement with previous genetic data, it encodes a protein that is secreted and whose transcription is restricted to specialized categories of follicle cells localized at the poles of the egg chamber. At early blastoderm, stage, tsl protein forms a symmetrical concentration gradient at the poles on the surface of the devitellinized embryo. Unrestricted expression of the tsl protein in tsl female mutants induces terminal pattern elements and suppresses the formation of abdomen in embryos. These results suggest that the tsl protein is the ligand that binds to the torso receptor.			MARTIN, JR (corresponding author), INST PASTEUR, BIOL MOLEC DROSOPHILE LAB, 25 RUE DOCTEUR ROUX, F-75724 PARIS 15, FRANCE.							ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1993, NATURE, V362, P152, DOI 10.1038/362152a0; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DEGELMANN A, 1986, DEV BIOL, V115, P479, DOI 10.1016/0012-1606(86)90268-X; King RC., 1970, OVARIAN DEV DROSOPHI; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T., 1982, MOL CLONING; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; PERRIMON N, 1986, GENETICS, V113, P695; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Roberts D. B, 1986, DROSOPHILA PRACTICAL; ROBERTSON HM, 1988, GENETICS, V118, P461; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STEINHAUER WR, 1989, MOL CELL BIOL, V9, P5726, DOI 10.1128/MCB.9.12.5726; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	25	84	86	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 24	1994	367	6465					741	745		10.1038/367741a0	http://dx.doi.org/10.1038/367741a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107870				2022-12-01	WOS:A1994MX63100060
J	CANESSA, CM; SCHILD, L; BUELL, G; THORENS, B; GAUTSCHI, I; HORISBERGER, JD; ROSSIER, BC				CANESSA, CM; SCHILD, L; BUELL, G; THORENS, B; GAUTSCHI, I; HORISBERGER, JD; ROSSIER, BC			AMILORIDE-SENSITIVE EPITHELIAL NA+ CHANNEL IS MADE OF 3 HOMOLOGOUS SUBUNITS	NATURE			English	Article							ION CHANNEL; SODIUM-CHANNEL; HAIR CELL; MEMBRANE; PROTEIN; STRETCH; CHICK; EXPRESSION; CURRENTS; OOCYTES	THE amiloride-sensitive epithelial sodium channel constitutes the rate-limiting step for sodium reabsorption in epithelial cells that line the distal part of the renal tubule, the distal colon, the duct of several exocrine glands, and the lung. The activity of this channel is upregulated by vasopressin and aldosterone, hormones involved in the maintenance of sodium balance, blood volume and blood pressure1,2. We have identified the primary structure of the alpha-subunit of the rat epithelial sodium channel by expression cloning in Xenopus laevis oocytes3. An identical subunit has recently been reported4. Here we identify two other subunits (beta and gamma) by functional complementation of the alpha-subunit of the rat epithelial Na+ channel. The ion-selective permeability, the gating properties and the pharmacological profile of the channel formed by coexpressing the three subunits in oocytes are similar to that of the native channel.	UNIV LAUSANNE,INST PHARMACOL & TOXIKOL,BUGNON 27,CH-1005 LAUSANNE,SWITZERLAND; GLAXO INST MOLEC BIOL,CH-1228 PLAN LES OUATES,SWITZERLAND	University of Lausanne; GlaxoSmithKline			Horisberger, Jean-Daniel/A-2538-2009					AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BEAR CE, 1990, AM J PHYSIOL, V258, pC421, DOI 10.1152/ajpcell.1990.258.3.C421; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; Canessa C. M., 1993, Journal of the American Society of Nephrology, V4, P864; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CHALFIE M, 1993, NATURE, V361, P504, DOI 10.1038/361504a0; CUTHBERT AW, 1992, J ROY SOC MED, V85, P2; DRISCOLL M, 1992, TRENDS NEUROSCI, V15, P15, DOI 10.1016/0166-2236(92)90343-7; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; HUDSPETH AJ, 1986, HEARING RES, V22, P21, DOI 10.1016/0378-5955(86)90070-5; JORGENSEN F, 1988, J PHYSIOL-LONDON, V403, P577, DOI 10.1113/jphysiol.1988.sp017265; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; OHMORI H, 1984, J PHYSIOL-LONDON, V350, P561, DOI 10.1113/jphysiol.1984.sp015218; PALMER LG, 1990, J GEN PHYSIOL, V96, P23, DOI 10.1085/jgp.96.1.23; PALMER LG, 1986, P NATL ACAD SCI USA, V83, P2767, DOI 10.1073/pnas.83.8.2767; PALMER LGA, 1992, REV PHYSL, V54, P51; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; Rossier BC, 1992, KIDNEY PHYSL PATHOPH, P1373; SARIBANSOHRABY S, 1992, AM J PHYSIOL, V263, pC1111, DOI 10.1152/ajpcell.1992.263.5.C1111; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497; TAGLIETTI V, 1988, J PHYSIOL-LONDON, V407, P311, DOI 10.1113/jphysiol.1988.sp017417; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; VANRENTERGHEM C, 1991, PFLUG ARCH EUR J PHY, V419, P401, DOI 10.1007/BF00371123; VIGNE P, 1989, J BIOL CHEM, V264, P7663	33	1699	1737	2	48	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					463	467		10.1038/367463a0	http://dx.doi.org/10.1038/367463a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	8107805				2022-12-01	WOS:A1994MU67900055
J	YIP, J; MATTOCK, MB; MOROCUTTI, A; SETHI, M; TREVISAN, R; VIBERTI, GC				YIP, J; MATTOCK, MB; MOROCUTTI, A; SETHI, M; TREVISAN, R; VIBERTI, GC			INSULIN-RESISTANCE IN INSULIN-DEPENDENT DIABETIC-PATIENTS WITH MICROALBUMINURIA	LANCET			English	Article							SODIUM-LITHIUM COUNTERTRANSPORT; AMBULATORY BLOOD-PRESSURE; ESCAPE RATE; MELLITUS; DISEASE; HYPERINSULINEMIA; HYPERTENSION; SENSITIVITY; MORTALITY; ALBUMIN	In insulin-dependent diabetes, microalbuminuria increases the risk of cardiovascular and renal disease. By means of a euglycaemic hyperinsulinaemic clamp method, we measured total-body glucose utilisation rate and studied the interaction of this measure of insulin sensitivity with known risk factors for cardiovascular disease in 14 diabetic patients with microalbuminuria and 14 with normal albumin excretion (median albumin excretion rate [AER] 56.2 [range 39.2-80.6] vs 8.8 [7.4-10.7] mug per min). The two groups were of similar age, duration of diabetes, and body-mass index. Total-body glucose disposal rate was significantly lower in the patients with microalbuminuria than in those without (mean 7.86 [SD 1.40] vs 9.04 [0.90] mg/kg per min; p<0.05). There were also significant differences between the groups in the daily insulin dose needed for equivalent glucose control (0.76 [0.20] vs 0.65 [0.10] U/kg, p<0.05), mean systolic blood pressure over 24 h ambulatory monitoring (134 [7] vs 127 [7] mm Hg; p<0.05), and various plasma lipid concentrations, contributing to a more atherogenic profile in the microalbuminuric group. Total-body glucose disposal rate was inversely correlated with body-mass index and log10 AER. The insulin sensitivity of the microalbuminuric group remained impaired after adjustment for blood pressure and body-mass index. Impaired insulin sensitivity is a feature of insulin-dependent diabetic patients with microalbuminuria, which adds, with other factors, to the increased risks of renal and cardiovascular disease in these patients.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,METAB MED UNIT,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			TREVISAN, ROBERTO/Q-8706-2016	TREVISAN, ROBERTO/0000-0003-0420-4468				COLLINS ACG, 1985, DIABETIC MED, V2, P456, DOI 10.1111/j.1464-5491.1985.tb00682.x; DEFARIA JBL, 1992, DIABETES, V41, P610, DOI 10.2337/diab.41.5.610; DEFRONZO RA, 1982, DIABETES, V31, P795, DOI 10.2337/diab.31.9.795; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FELDTRASMUSSEN B, 1986, DIABETOLOGIA, V29, P282, DOI 10.1007/BF00452063; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FERRARI P, 1991, AM J MED, V91, P589, DOI 10.1016/0002-9343(91)90211-F; HAFFNER SM, 1993, J CLIN ENDOCR METAB, V76, P541, DOI 10.1210/jc.76.3.541; HANSEN KW, 1992, KIDNEY INT, V41, P847, DOI 10.1038/ki.1992.130; JONES SL, 1989, BRIT MED J, V298, P487, DOI 10.1136/bmj.298.6672.487; LAGER I, 1983, BRIT MED J, V287, P1661, DOI 10.1136/bmj.287.6406.1661; MARTIN FIR, 1987, DIABETOLOGIA, V30, P149, DOI 10.1007/BF00274219; MESSENT JWC, 1992, KIDNEY INT, V41, P836, DOI 10.1038/ki.1992.128; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; MONTINI G, 1989, PAEDIATR NEPHROL, V3, pA2010; MOORE WV, 1992, DIABETES, V41, P1035, DOI 10.2337/diabetes.41.9.1035; NESTLER JE, 1990, DIABETES, V39, P1212, DOI 10.2337/diabetes.39.10.1212; PYORALA K, 1985, ACTA MED SCAND S, V701, P38; REAVEN GM, 1967, J CLIN INVEST, V46, P1756, DOI 10.1172/JCI105666; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; TREVISAN R, 1992, KIDNEY INT, V41, P855, DOI 10.1038/ki.1992.131; VIBERTI GC, 1982, LANCET, V1, P32; Welborn T A, 1979, Diabetes Care, V2, P154, DOI 10.2337/diacare.2.2.154; WHITE WB, 1989, AM HEART J, V118, P782, DOI 10.1016/0002-8703(89)90593-0; WHITE WB, 1992, J HYPERTENS, V10, pS35, DOI 10.1097/00004872-199204001-00008; WISEMAN MJ, 1984, DIABETOLOGIA, V2, P401; YIP J, 1993, LANCET, V341, P369, DOI 10.1016/0140-6736(93)90167-F; 1993, BMJ, V306, P1235	30	226	228	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 9	1993	342	8876					883	887		10.1016/0140-6736(93)91943-G	http://dx.doi.org/10.1016/0140-6736(93)91943-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA963	8105164				2022-12-01	WOS:A1993MA96300007
J	MCGUIRE, PK; SHAH, GMS; MURRAY, RM				MCGUIRE, PK; SHAH, GMS; MURRAY, RM			INCREASED BLOOD-FLOW IN BROCA AREA DURING AUDITORY HALLUCINATIONS IN SCHIZOPHRENIA	LANCET			English	Article							TEMPORAL-LOBE EPILEPSY; PSYCHOSIS	Verbal auditory hallucinations are common in schizophrenia but little is known about how they arise. We have used single photon emission tomography (SPET) to measure regional cerebral blood flow with the aim of identifying brain areas that are especially active during auditory hallucinations. We scanned twelve men with schizophrenia while they were experiencing hallucinations. The subjects were rescanned under identical conditions when their hallucinations had resolved (mean 19 weeks later). Blood flow was significantly greater during hallucinations than in the non-hallucinating state in Broca's area (mean count density on SPET 1.18 [SD 0.04] vs 1.13 [0.06]; p<0.001); flow was also higher during hallucinations in the left anterior cingulate cortex and regions in the left temporal lobe, but these differences did not achieve significance. The increased flow in Broca's area was not accounted for by changes in other clinical variables nor by changes in the dose of neuroleptic drugs. These findings suggest that the production of auditory hallucinations in schizophrenia is associated with increased activity in a network of cortical areas specialised for language.	INST PSYCHIAT, DEPT PSYCHOL MED, GENET SECT, LONDON SE5 8AF, ENGLAND	University of London; King's College London	MCGUIRE, PK (corresponding author), KINGS COLL HOSP, DEPT NUCL MED, DE CRESPIGNY PK, LONDON SE5 8AF, ENGLAND.		Murray, Robin M/F-8658-2012	Murray, Robin M/0000-0003-0829-0519; McGuire, Philip/0000-0003-4381-0532	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANNETT M, 1970, BRIT J PSYCHOL, V61, P303, DOI 10.1111/j.2044-8295.1970.tb01248.x; BARTA PE, 1990, AM J PSYCHIAT, V39, P784; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BOGERTS B, 1985, ARCH GEN PSYCHIAT, V43, P36; CLEGHORN JM, 1992, AM J PSYCHIAT, V149, P1062; COSTA DC, 1986, NUCL MED COMMUN, V7, P647; DAVID AS, 1993, NEUROPSYCHOLOGY SCHI, P269; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; FALKAI P, 1986, EUR ARCH PSY CLIN N, V236, P154, DOI 10.1007/BF00380943; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; FRITH CD, 1988, BRIT J PSYCHIAT, V153, P437, DOI 10.1192/bjp.153.4.437; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; GROSSMAN M, 1993, J CEREB BLOOD FLO S1, V13, pS525; HOWARD D, 1992, BRAIN, V115, P1769, DOI 10.1093/brain/115.6.1769; LAGER AC, 1985, PSYCHIAT RES, V16, P27, DOI 10.1016/0165-1781(85)90025-3; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; MUSALEK M, 1989, COMPR PSYCHIAT, V30, P99, DOI 10.1016/0010-440X(89)90123-5; NIE NH, 1975, STATISTICAL PACKAGE; PANDYA DN, CEREBRAL CORTEX, V4; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; PENFIELD W, 1963, BRAIN, V86, P595, DOI 10.1093/brain/86.4.595; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PRICE C, 1993, J CEREB BLOOD FLO S1, V13, pS501; ROBERTS GW, 1990, BIOL PSYCHIAT, V28, P127, DOI 10.1016/0006-3223(90)90630-K; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; TALAIRACH J, 1988, COPLANOR STEREOTAXIC; TAYLOR DC, 1975, PSYCHOL MED, V5, P249, DOI 10.1017/S0033291700056609; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; [No title captured]	29	330	336	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1993	342	8873					703	706		10.1016/0140-6736(93)91707-S	http://dx.doi.org/10.1016/0140-6736(93)91707-S			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103821				2022-12-01	WOS:A1993LX46900008
J	JAMES, A				JAMES, A			PAINLESS HUMAN RIGHT	LANCET			English	Editorial Material																		BONICA JJ, 1985, ADV PAIN RES THER, V9, P589; STJERNSWARD J, 1993, J PAIN SYMPTOM MANAG, V8, P340, DOI 10.1016/0885-3924(93)90050-6; ZENZ M, 1993, LANCET, V341, P1075, DOI 10.1016/0140-6736(93)92425-S; 1990, CANCER PAIN RELIEF P; 1986, CANCER PAIN RELIEF	5	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					567	568		10.1016/0140-6736(93)91403-9	http://dx.doi.org/10.1016/0140-6736(93)91403-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102713				2022-12-01	WOS:A1993LV96300003
J	PELTOLA, H				PELTOLA, H			EARLY MENINGOCOCCAL DISEASE - ADVISING THE PUBLIC AND THE PROFESSION	LANCET			English	Editorial Material							TUMOR NECROSIS FACTOR; MENINGITIS				PELTOLA, H (corresponding author), UNIV HELSINKI,CHILDRENS HOSP,SF-00100 HELSINKI 10,FINLAND.							BEGG N, 1992, BRIT MED J, V305, P133, DOI 10.1136/bmj.305.6846.133; CARTWRIGHT K, 1992, BRIT MED J, V305, P774, DOI 10.1136/bmj.305.6856.774; FRIEDLAND J, 1990, LANCET, V335, P300, DOI 10.1016/0140-6736(90)90128-R; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; MCGOWAN JE, 1992, J INFECT DIS, V165, P1, DOI 10.1093/infdis/165.1.1; PELTOLA H, 1983, REV INFECT DIS, V5, P71; SORENSEN HT, 1992, BRIT MED J, V305, P774, DOI 10.1136/bmj.305.6856.774-a; TARLOW MJ, 1992, LANCET, V340, P1481, DOI 10.1016/0140-6736(92)92678-9; THOMSON AP, 1993, ARCH DIS CHILD, V69, P166, DOI 10.1136/adc.69.1.166; WAAGE A, 1987, LANCET, V1, P355; 1985, LANCET, V2, P594	11	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					509	510		10.1016/0140-6736(93)91642-Y	http://dx.doi.org/10.1016/0140-6736(93)91642-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102663				2022-12-01	WOS:A1993LU58200005
J	WALSH, D				WALSH, D			DYSPNEA IN ADVANCED CANCER	LANCET			English	Editorial Material											WALSH, D (corresponding author), CLEVELAND CLIN EDUC FDN,PALLAT CARE PROGRAM,CLEVELAND,OH 44106, USA.			Walsh, (Thomas) Declan/0000-0002-9310-1729				Bruera E, 1990, J Pain Symptom Manage, V5, P341, DOI 10.1016/0885-3924(90)90027-H; BRUERA E, 1993, LANCET, V342, P13, DOI 10.1016/0140-6736(93)91880-U; COOKE N, 1988, SYMPTOM CONTROL, P157; Curtis E B, 1991, J Palliat Care, V7, P25; KRECH RL, 1991, J PAIN SYMPTOM MANAG, V6, P360, DOI 10.1016/0885-3924(91)90027-2; NELSON K, 1991, CANCER B, V4, P423; RESTRICK LJ, 1992, LANCET, V339, P850; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; VENTAFRIDDA V, 1990, CHEST, V6, P1544; WALSH TD, 1984, RECENT RESULTS CANC, V89, P115	10	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 21	1993	342	8869					450	451		10.1016/0140-6736(93)91588-D	http://dx.doi.org/10.1016/0140-6736(93)91588-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU075	8102424				2022-12-01	WOS:A1993LU07500005
J	GOLDACRE, M; SEAGROATT, V; HAWTON, K				GOLDACRE, M; SEAGROATT, V; HAWTON, K			SUICIDE AFTER-DISCHARGE FROM PSYCHIATRIC INPATIENT CARE	LANCET			English	Article							IOWA RECORD-LINKAGE; MORTALITY	People with a history of psychiatric disorder are at higher risk of suicide than people without such a history. The policy of reducing inpatient care in psychiatry has probably meant that some of the risk of suicide has shifted from the hospital to the community setting. We have quantified the risk of suicide within a year of psychiatric discharge in a population-based study in the Oxford health region, UK. We calculated suicide rates per 1000 person-years at risk (time from discharge to death, subsequent readmission, or the end of the study) and the standardised mortality ratio (SMR) for suicide, taking the value among the general population as 1. Among male patients the SMR for suicide (defined by coroner's verdict of suicide) in the first 28 days after discharge from inpatient care was 213 (95% CI 137-317); the equivalent SMR for female patients was 134 (67-240). The result was similar when we defined suicide more broadly as a suicide, open, or misadventure verdict. The suicide rate in the first 28 days after discharge was 7.1 (4.1-12) times higher for male patients and 3.0 (1.5-6.0) times higher for female patients than the rate during the remaining 48 weeks of the first year after discharge. Most of the patients studied (both those who committed suicide and those who did not) had been psychiatric inpatients for only a short time. The findings confirm that there is significant clustering of suicide soon after discharge from psychiatric care. Skilled support after discharge for high-risk patients in the community is essential. Audit of suicides that occur soon after discharge may help identify the patients at highest risk and thereby reduce the number of avoidable deaths.	UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7J,ENGLAND	University of Oxford	GOLDACRE, M (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OLD RD,OXFORD OX3 7LF,ENGLAND.							Acheson E.D., 1967, MED RECORD LINKAGE; BAKER RJ, 1978, GLIM SYSTEM; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BLACK DW, 1985, JAMA-J AM MED ASSOC, V253, P58, DOI 10.1001/jama.253.1.58; BLACK DW, 1989, SUICIDE LIFE-THREAT, V19, P78; Charlton J., 1992, Population Trends, P10; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; GILL LE, 1987, TXB MED RECORD LINKA, P39; HAWTON K, 1992, BMJ-BRIT MED J, V304, P1000, DOI 10.1136/bmj.304.6833.1000; HAWTON K, 1987, BRIT J PSYCHIAT, V150, P145, DOI 10.1192/bjp.150.2.145; HENDERSON J, 1992, J EPIDEMIOL COMMUN H, V46, P297, DOI 10.1136/jech.46.3.297; HOFFMANN H, 1987, SOC PSYCH PSYCH EPID, V22, P93, DOI 10.1007/BF00584011; MILES CP, 1977, J NERV MENT DIS, V164, P231, DOI 10.1097/00005053-197704000-00002; MONK M, 1987, EPIDEMIOL REV, V9, P51, DOI 10.1093/oxfordjournals.epirev.a036308; ODEGARD O, 1952, ACTA PSYCH NEUROL, V27, P353, DOI 10.1111/j.1600-0447.1952.tb04667.x; PIERCE J, 1964, ARCH GEN PSYCHIAT, V10, P43; POUNDER DJ, 1992, BRIT MED J, V305, P472, DOI 10.1136/bmj.305.6851.472; ROY A, 1983, COMPR PSYCHIAT, V24, P487, DOI 10.1016/0010-440X(83)90040-8; ROY A, 1984, CAN J PSYCHIAT, V29, P319, DOI 10.1177/070674378402900408; SCHNEIDMAN ES, 1981, SUICIDE LIFE-THREAT, V11, P325; SEAGROATT V, 1991, BRIT MED J, V303, P1431, DOI 10.1136/bmj.303.6815.1431; SURTEES J, 1992, BRIT MED J, V305, P716, DOI 10.1136/bmj.305.6855.716-a; 1992, LANCET, V340, P700; 1992, HLTH NATION STRATEGY; 1982, STEERING GROUP HLTH	25	297	300	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 31	1993	342	8866					283	286		10.1016/0140-6736(93)91822-4	http://dx.doi.org/10.1016/0140-6736(93)91822-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101307				2022-12-01	WOS:A1993LQ16300015
J	FISHBEIN, DB; DAWSON, JE; ROBINSON, LE				FISHBEIN, DB; DAWSON, JE; ROBINSON, LE			HUMAN EHRLICHIOSIS IN THE UNITED-STATES, 1985 TO 1990	ANNALS OF INTERNAL MEDICINE			English	Article						EHRLICHIOSIS; EHRLICHIA; CHLORAMPHENICOL; TETRACYCLINE; AGE FACTORS	TROPICAL CANINE PANCYTOPENIA; MOUNTAIN SPOTTED-FEVER; HUMAN INFECTION; RICKETTSIA; FEATURES; TICKS; TEXAS	Objective: To describe the epidemiology, clinical features, laboratory manifestations, response to therapy, and factors related to morbidity and mortality in a large group of patients with ehrlichiosis. Design: Case-series. Setting: Laboratory-based surveillance in the United States. Patients: 237 patients whose serum had a fourfold increase or decrease in antibodies to Ehrlichia canis or E. chaffeensis. Measurements: Epidemiologic, clinical, laboratory data, hospitalization, duration of illness, complications, and treatment response. Results: From 1985 through 1990, 237 case-patients were identified in 21 states; rates exceeded 1 per 100 000 per year in only 5 counties. Incidence rates increased with age and were higher among men. Most case-patients had nonspecific illness and were not suspected of having a rickettsial infection. Many patients (60.8%) were hospitalized. Leukocyte and platelet counts typically decreased and liver function tests typically increased through day 7. Three (6.1%) of 49 outpatients treated only with tetracycline were hospitalized compared with 35 (92%) of 38 outpatients treated only with antibiotics other than tetracycline or chloramphenicol (P < 0.001). Among hospitalized patients, recovery was faster for those initially treated with tetracycline (median, 16 days) or chloramphenicol (median, 12 days) than for those initially treated with other antibiotics (median, 27 days; P = 0.03 for both comparisons). In a logistic regression analysis, severe illness or death was more probable among case-patients 60 years or older (odds ratio [OR], 4.60; 95% Cl, 1.87 to 11.2) and among those who did not receive tetracycline or chloramphenicol until 8 or more days after symptom onset (OR, 4.38; Cl, 1.36 to 14.0). Conclusions: The findings of this!study are primarily representative of more seriously ill patients with human ehrlichiosis. Although rates are low, ehrlichiosis is found in many areas of the United States. Patients with a history of tick exposure, acute febrile illness, decreasing leukocyte counts, and decreasing platelet counts may have ehrlichiosis. Prompt treatment with tetracycline or chloramphenicol markedly decreases the morbidity.	NATL CTR INFECT DIS, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA	FISHBEIN, DB (corresponding author), CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA.							ABBOTT KC, 1991, AM J HEMATOL, V38, P230, DOI 10.1002/ajh.2830380315; ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; [Anonymous], 1989, SAS STAT USERS GUIDE, V2; BROUQUI P, 1992, 32ND INT C ANT AG CH, P394; BUHLES WC, 1974, J INFECT DIS, V130, P357, DOI 10.1093/infdis/130.4.357; DAWSON JE, 1991, J CLIN MICROBIOL, V29, P2741, DOI 10.1128/JCM.29.12.2741-2745.1991; DORAN TI, 1989, J PEDIATR-US, V114, P809, DOI 10.1016/S0022-3476(89)80143-X; DUMLER JS, 1991, JAMA-J AM MED ASSOC, V266, P1365, DOI 10.1001/jama.266.10.1365; ELLISON RT, 1987, JAMA-J AM MED ASSOC, V258, P1731, DOI 10.1001/jama.258.13.1731; ENG TR, 1990, JAMA-J AM MED ASSOC, V264, P2251, DOI 10.1001/jama.264.17.2251; FISHBEIN DB, 1989, J INFECT DIS, V160, P803, DOI 10.1093/infdis/160.5.803; FISHBEIN DB, 1987, JAMA-J AM MED ASSOC, V257, P3100, DOI 10.1001/jama.257.22.3100; FISHBEIN DB, 1991, MANUAL CLIN MICROBIO, P1054; GOODPASTURE HC, 1978, ANN INTERN MED, V88, P303, DOI 10.7326/0003-4819-88-3-303; HARKESS JR, 1989, J INFECT DIS, V159, P576, DOI 10.1093/infdis/159.3.576; HATTWICK MAW, 1978, JAMA-J AM MED ASSOC, V240, P1499; HELMICK CG, 1984, J INFECT DIS, V150, P480, DOI 10.1093/infdis/150.4.480; HUXSOLL DL, 1976, VET PARASITOL, V2, P49, DOI 10.1016/0304-4017(76)90052-2; Kaplowitz LG., 1981, CURR CLIN TOP INFECT, V2, P108; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; MCDADE JE, 1986, ANNU REV MICROBIOL, V40, P287, DOI 10.1146/annurev.mi.40.100186.001443; PEARCE CJ, 1988, AM J HEMATOL, V28, P53, DOI 10.1002/ajh.2830280111; PETERSEN LR, 1989, J INFECT DIS, V159, P562, DOI 10.1093/infdis/159.3.562; ROHRBACH BW, 1990, AM J PUBLIC HEALTH, V80, P442, DOI 10.2105/AJPH.80.4.442; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; Strausbaugh L J, 1987, Hematol Oncol Clin North Am, V1, P185; TAYLOR JP, 1988, J INFECT DIS, V158, P217, DOI 10.1093/infdis/158.1.217; WOODWARD TE, 1984, J INFECT DIS, V150, P465, DOI 10.1093/infdis/150.4.465; YEVICH SJ, 1991, 25TH P INT C ANT AG, P999; 1988, MMWR MORB MORTAL WKL, V37, P270; 1988, MMWR MORB MORTAL WKL, V37, P275; 1990, MMWR MORB MORTAL WKL, V39, P281	32	250	256	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					736	743		10.7326/0003-4819-120-9-199405010-00003	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147546				2022-12-01	WOS:A1994NH25100003
J	AFAR, DEH; GOGA, A; MCLAUGHLIN, J; WITTE, ON; SAWYERS, CL				AFAR, DEH; GOGA, A; MCLAUGHLIN, J; WITTE, ON; SAWYERS, CL			DIFFERENTIAL COMPLEMENTATION OF BCR-ABL POINT MUTANTS WITH C-MYC	SCIENCE			English	Article							V-SRC; TYROSINE KINASES; SH2; TRANSFORMATION; DOMAIN; ONCOGENE; RAS; LEUKEMIA; PROTEINS; MUTATION	A complementation strategy was developed to define the signaling pathways activated by the Bcr-Abl tyrosine kinase. Transformation inactive point mutants of Bcr-Abl were tested for complementation with c-Myc. Single point mutations in the Src-homology 2 (SH2) domain, the major tyrosine autophosphorylation site of the kinase domain, and the Grb-2 binding site in the Bcr region impaired the transformation of fibroblasts by Bcr-Abl. Hyperexpression of c-Myc efficiently restored transformation activity only to the Bcr-Abl SH2 mutant. These data support a model in which Bcr-Abl activates at least two independent pathways for transformation. This strategy may be useful for discerning signaling pathways activated by other oncogenes.	UNIV CALIF LOS ANGELES,INST MICROBIOL,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Sawyers, Charles/G-5327-2016		NATIONAL CANCER INSTITUTE [R35CA053867, K11CA001551] Funding Source: NIH RePORTER; NCI NIH HHS [CA 01551, CA 53867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, IN PRESS; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAWYERS C, UNPUB; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	34	185	188	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 15	1994	264	5157					424	426		10.1126/science.8153630	http://dx.doi.org/10.1126/science.8153630			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG194	8153630				2022-12-01	WOS:A1994NG19400040
J	SOONPAA, MH; KOH, GY; KLUG, MG; FIELD, LJ				SOONPAA, MH; KOH, GY; KLUG, MG; FIELD, LJ			FORMATION OF NASCENT INTERCALATED DISKS BETWEEN GRAFTED FETAL CARDIOMYOCYTES AND HOST MYOCARDIUM	SCIENCE			English	Article							TRANSGENIC MICE; T-ANTIGEN; EXPRESSION; HYPERTROPHY; MYOCYTES; NEURONS; INVIVO; CELLS; GENES	Fetal cardiomyocytes isolated from transgenic mice carrying a fusion gene of the alpha-cardiac myosin heavy chain promoter with a beta-galactosidase reporter were examined for their ability to form stable intracardiac grafts. Embryonic day 15 transgenic cardiomyocytes delivered directly into the myocardium of syngeneic hosts formed stable graft, as identified by nuclear beta-galactosidase activity. Grafted cardiomyocytes were observed as long as 2 months after implantation, the latest date assayed. Intracardiac graft formation did not induce overtly negative effects on the host myocardium and was not associated with chronic immune rejection. Electron microscopy revealed the presence of nascent intercalated disks connecting the engrafted fetal cardiomyocytes and the host myocardium. These results suggest that intracardiac grafting might provide a useful approach for myocardial repair, provided that the grafted cells can contribute to myocardial function.	INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,1111 W 10TH ST,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis			Koh, Gou Young/C-1615-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045453] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45453] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRODSKY WY, 1980, CELL TISSUE RES, V210, P133; BULLOCK GR, 1983, TECHNIQUES IMMUNOCYT, V1, P188; CLUBB FJ, 1984, LAB INVEST, V50, P571; DAUD AI, 1993, AM J PHYSIOL, V264, pH1693, DOI 10.1152/ajpheart.1993.264.5.H1693; DELCARPIO JB, 1991, CIRC RES, V69, P1591, DOI 10.1161/01.RES.69.6.1591; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GULICK J, 1991, J BIOL CHEM, V266, P9180; Hogan B., 1986, MANIPULATING MOUSE E; KOH GY, 1993, AM J PHYSIOL, V264, pH1727, DOI 10.1152/ajpheart.1993.264.5.H1727; KOH GY, 1993, J CLIN INVEST, V92, P1548, DOI 10.1172/JCI116734; LANSON NA, 1992, CIRCULATION, V85, P1835, DOI 10.1161/01.CIR.85.5.1835; LOEWY AD, 1991, BRAIN RES, V555, P346, DOI 10.1016/0006-8993(91)90364-2; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MIKAWA T, 1992, DEV DYNAM, V195, P133, DOI 10.1002/aja.1001950208; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; RUMYANTSEV PP, 1991, GROWTH HYPERPLASIA C, P3; SOONPAA MH, UNPUB; STEINHELPER ME, 1990, AM J PHYSIOL, V259, pH1826, DOI 10.1152/ajpheart.1990.259.6.H1826; STEINHELPER ME, 1990, HYPERTENSION, V16, P301, DOI 10.1161/01.HYP.16.3.301; UBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613	23	460	552	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					98	101		10.1126/science.8140423	http://dx.doi.org/10.1126/science.8140423			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	8140423				2022-12-01	WOS:A1994ND53600039
J	TENDIJKE, P; YAMASHITA, H; ICHIJO, H; FRANZEN, P; LAIHO, M; MIYAZONO, K; HELDIN, CH				TENDIJKE, P; YAMASHITA, H; ICHIJO, H; FRANZEN, P; LAIHO, M; MIYAZONO, K; HELDIN, CH			CHARACTERIZATION OF TYPE-I RECEPTORS FOR TRANSFORMING GROWTH-FACTOR-BETA AND ACTIVIN	SCIENCE			English	Article							SERINE THREONINE KINASE; EXPRESSION CLONING; PROTEIN; SEQUENCE; COMPLEX; SITES	Transforming growth factor-beta (TGF-beta) and activin exert their effects by binding to heteromeric complexes of type I and type II receptors. The type II receptors for TGF-beta and activin are transmembrane serine-threonine kinases; a series of related receptors, denoted activin receptor-like kinase (ALK) 1 to 5, have recently been identified, and ALK-6 is described here. ALK-5 has been shown to be a functional TGF-beta type I receptor. A systematic analysis revealed that most ALKs formed heteromeric complexes with the type II receptors for TGF-beta and activin after overexpression in COS cells; however, among the six ALKs, only ALK-5 was a functional TGF-beta type I receptor for activation of plasminogen activator inhibitor-1, and only ALK-2 and ALK-4 bound activin with high affinity.	LUDWIG INST CANC RES,BOX 595 BIOMED CTR,S-75124 UPPSALA,SWEDEN; UNIV HELSINKI,DEPT VIROL,SF-00014 HELSINKI,FINLAND	Ludwig Institute for Cancer Research; University of Helsinki			Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Ichijo, Hidenori/0000-0002-5005-6438				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; ICHIJO H, 1993, BIOCHEM BIOPH RES CO, V194, P1508, DOI 10.1006/bbrc.1993.1995; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; RANZEN P, 1993, CELL, V75, P681; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TENDIJKE P, UNPUB; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	29	519	596	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					101	104		10.1126/science.8140412	http://dx.doi.org/10.1126/science.8140412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	8140412				2022-12-01	WOS:A1994ND53600040
J	VANLEEUWEN, F; SAMOS, CH; NUSSE, R				VANLEEUWEN, F; SAMOS, CH; NUSSE, R			BIOLOGICAL-ACTIVITY OF SOLUBLE WINGLESS PROTEIN IN CULTURED DROSOPHILA IMAGINAL DISC CELLS	NATURE			English	Article							SEGMENT-POLARITY GENE; ENCODES; EXPRESSION; ARMADILLO; PRODUCT; HOMOLOG; INT-1; PLAKOGLOBIN; EPIDERMIS; EMBRYOS	THE phenotypes caused by mutations in Wnt genes suggest that their gene products are involved in cell-to-cell communication(1-6) Wnt genes indeed encode secreted molecules(7-10), but soluble active Wnt protein has not been found. We have developed a novel cell culture assay for the Drosophila Wnt gene wingless(11,12), using a Drosophila imaginal disc cell line (cl-8; ref. 13), and measured effects on the adherens junction protein armadillo(14,15), a known genetic target of wingless(16). Transfection of a temperature-sensitive wingless complementary DNA into cl-8 cells increases the levels of the armadillo protein. The wingless protein does not affect the rate of synthesis of armadillo, but leads to increased stability of an otherwise rapidly decaying armadillo protein. The wingless protein in the extracellular matrix and soluble medium from donor cells also increases the levels of armadillo protein. The protein in the medium acts fast and is inhibited by an antibody to wingless protein, demonstrating that Wnt products can act as soluble extracellular signalling molecules.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,BECKMAN CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University			van Leeuwen, Frank/AAQ-6799-2020	van Leeuwen, Frank/0000-0003-1107-6513				BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; CMBERLEDGE S, 1993, NATURE, V363, P549; CURRIE DA, 1988, DEVELOPMENT, V102, P804; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PEEL DJ, 1992, ROUX ARCH DEV BIOL, V201, P120, DOI 10.1007/BF00420423; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2	27	181	193	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					342	344		10.1038/368342a0	http://dx.doi.org/10.1038/368342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	8127369				2022-12-01	WOS:A1994NB98500048
J	BASLER, K; STRUHL, G				BASLER, K; STRUHL, G			COMPARTMENT BOUNDARIES AND THE CONTROL OF DROSOPHILA LIMB PATTERN BY HEDGEHOG PROTEIN	NATURE			English	Article							SEGMENT-POLARITY GENE; CELL-CELL COMMUNICATION; FACTOR-BETA FAMILY; ENGRAILED EXPRESSION; IMAGINAL DISKS; POSTERIOR COMPARTMENTS; DECAPENTAPLEGIC GENE; GERM LAYERS; MELANOGASTER; WINGLESS	Drosophila limbs are subdivided into anterior and posterior compartments which derive from adjacent cell populations founded early in development. Evidence is now provided that posterior cells organize growth and cell patterning in both compartments by secreting hedgehog protein and that hedgehog protein acts indirectly by inducing neighbouring anterior cells to secrete decapentaplegic or wingless protein.	COLUMBIA UNIV, COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	BASLER, K (corresponding author), UNIV ZURICH, INST ZOOL, WINTERTHURERSTR 190, CH-8057 ZURICH, SWITZERLAND.			Basler, Konrad/0000-0003-3534-1529				ANDERSON R, 1993, DEVELOPMENT, V117, P1421; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BROACH JR, 1980, CELL, V21, P501, DOI 10.1016/0092-8674(80)90487-0; CABRERA CV, 1987, CELL, V50, P569; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; CRICK FHC, 1975, SCIENCE, V189, P340, DOI 10.1126/science.806966; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GARCIABELLIDO A, 1975, GENETIC CONTROL WING; GOLIC K, 1981, SCIENCE, V252, P958; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MOAZED D, 1992, DEVELOPMENT, V116, P805; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, MOL CELL BIOL, V10, P2669, DOI 10.1128/MCB.10.6.2669; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PLACZEK M, 1993, DEVELOPMENT, V117, P205; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STRUHL G, 1981, DEV BIOL, V84, P372, DOI 10.1016/0012-1606(81)90406-1; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; VOGEL A, 1993, DEVELOPMENT, V119, P199; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1993, DEVELOPMENT, V117, P1223	72	761	783	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 17	1994	368	6468					208	214		10.1038/368208a0	http://dx.doi.org/10.1038/368208a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145818				2022-12-01	WOS:A1994NA87000045
J	LEE, KF; BACHMAN, K; LANDIS, S; JAENISCH, R				LEE, KF; BACHMAN, K; LANDIS, S; JAENISCH, R			DEPENDENCE ON P75 FOR INNERVATION OF SOME SYMPATHETIC TARGETS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; FACTOR FAMILY; SWEAT GLANDS; NEUROTRANSMITTER PLASTICITY; RECEPTORS; MEMBER; MATURATION; NEURONS; BRAIN	The low-affinity neurotrophin receptor p75 binds all neurotrophins with similar affinity. For elucidation of its function, mice bearing a null mutation in the p75 locus were generated. Examination of sympathetic innervation of target tissues revealed that pineal glands lacked innervation and sweat gland innervation was absent or reduced in particular footpads. The absence of adult innervation reflects the failure of axons to reach these targets during development rather than a target deficit. These results indicate that p75 facilitates development of specific populations of sympathetic neurons, for which it may support axon growth.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT NEUROSCI, CLEVELAND, OH 44106 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Case Western Reserve University					NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023678] Funding Source: NIH RePORTER; NCI NIH HHS [5 R35 CA44339] Funding Source: Medline; NINDS NIH HHS [NS 023678] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBACID M, 1993, ONCOGENE, V8, P2033; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; de Champlain J, 1970, ACTA PHYSIOL SCAND, V80, P276, DOI 10.1111/j.1748-1716.1970.tb04791.x; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GRANT ME, UNPUB; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KENNEDY WR, 1984, NEUROSCIENCE, V11, P741, DOI 10.1016/0306-4522(84)90057-5; LANDIS SC, 1988, DEV BIOL, V126, P129, DOI 10.1016/0012-1606(88)90246-1; LANDIS SC, 1983, DEV BIOL, V98, P349, DOI 10.1016/0012-1606(83)90365-2; LEBLANC G, 1986, J NEUROSCI, V6, P260; Lee K. T., UNPUB; LEE KF, IN PRESS DEVELOPMENT; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI K, 1991, CELL TISSUE RES, V264, P515, DOI 10.1007/BF00319041; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; RUBIN E, 1985, J NEUROSCI, V5, P673; SACHS C, 1970, European Journal of Pharmacology, V9, P67, DOI 10.1016/0014-2999(70)90322-5; SLOTKIN TA, 1987, J PHARMACOL EXP THER, V243, P101; STEVENS LM, 1988, DEV BIOL, V130, P703, DOI 10.1016/0012-1606(88)90362-4; TUCKER DC, 1990, ANN NY ACAD SCI, V588, P120, DOI 10.1111/j.1749-6632.1990.tb13202.x; YAN Q, 1988, J NEUROSCI, V8, P3481; ZHANG ET, 1991, CELL TISSUE RES, V265, P63, DOI 10.1007/BF00318140	33	173	173	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 11	1994	263	5152					1447	1449		10.1126/science.8128229	http://dx.doi.org/10.1126/science.8128229			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128229				2022-12-01	WOS:A1994MZ92700035
J	ESCOBAR, AL; MONCK, JR; FERNANDEZ, JM; VERGARA, JL				ESCOBAR, AL; MONCK, JR; FERNANDEZ, JM; VERGARA, JL			LOCALIZATION OF THE SITE OF CA2+ RELEASE AT THE LEVEL OF A SINGLE SARCOMERE IN SKELETAL-MUSCLE FIBERS	NATURE			English	Article							CALCIUM TRANSIENTS; ARSENAZO-III; SARCOPLASMIC-RETICULUM; CONTRACTION; FIBERS; RESOLUTION	THE development of mechanical force in skeletal muscle fibres is brought about by rapid increases in the intracellular calcium concentration (Ca2+ transients) which can be detected by optical methods1-7. Local stimulation experiments8 and ultrastructural evidence9,10 suggest that, at a microscopic level, these Ca2+ transients are generated by the release of Ca2+ ions from the terminal cisternae of the sarcoplasmic reticulum in response to the depolarization of the transverse tubules (t-tubules)11-14 . Nevertheless, to date, there is no functional information on the exact location at which Ca2+ release takes place. The present experiments were designed to obtain direct evidence about dynamic changes in localization and microscopic distribution of Ca2+ in a single sarcomere using two independent novel methodologies: confocal spot detection of Ca2+ transients15,16 and Ca2+ imaging with pulsed laser excitation17,18.	UNIV CALIF LOS ANGELES,DEPT PHYSIOL,LOS ANGELES,CA 90024; MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,ROCHESTER,MN 55905	University of California System; University of California Los Angeles; Mayo Clinic								BAYLOR SM, 1982, J PHYSIOL-LONDON, V331, P179, DOI 10.1113/jphysiol.1982.sp014369; DULHUNTY AF, 1992, P ROY SOC B-BIOL SCI, V247, P69, DOI 10.1098/rspb.1992.0010; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; ESCOBAR A, 1993, BIOPHYS J, V64, pA241; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; GRINVALD A, 1988, PHYSIOL REV, V68, P1285, DOI 10.1152/physrev.1988.68.4.1285; HIBINO M, 1991, BIOPHYS J, V59, P209, DOI 10.1016/S0006-3495(91)82212-3; HUXLEY AF, 1958, J PHYSIOL-LONDON, V144, P426, DOI 10.1113/jphysiol.1958.sp006111; MILEDI R, 1977, PROC R SOC SER B-BIO, V198, P201, DOI 10.1098/rspb.1977.0094; MINTA A, 1989, J BIOL CHEM, V264, P8171; MONCK J, 1994, BIOPHYS J, V66, pA351; MONCK JR, 1992, J CELL BIOL, V116, P745, DOI 10.1083/jcb.116.3.745; NIGGLI E, 1990, CELL CALCIUM, V11, P121, DOI 10.1016/0143-4160(90)90065-3; PALADE P, 1982, J GEN PHYSIOL, V79, P679, DOI 10.1085/jgp.79.4.679; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PARKER I, 1993, J PHYSIOL-LONDON, V461, P133, DOI 10.1113/jphysiol.1993.sp019506; PEACHEY LD, 1965, J CELL BIOL, V25, P209, DOI 10.1083/jcb.25.3.209; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Sandow A, 1970, Annu Rev Physiol, V32, P87, DOI 10.1146/annurev.ph.32.030170.000511; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SHEPPARD JR, J MICROSC, V149, P73; SOMLYO AV, 1981, J CELL BIOL, V90, P577, DOI 10.1083/jcb.90.3.577; TAKAMATSU T, 1990, CELL CALCIUM, V11, P111, DOI 10.1016/0143-4160(90)90064-2; VERGARA J, 1992, ADV EXP MED BIOL, V311, P227; VERGARA J, 1991, BIOPHYS J, V59, P12, DOI 10.1016/S0006-3495(91)82193-2; VERGARA J, 1993, BIOPHYS J, V64, pA37; WILSON T, 1987, OPT LETT, V12, P227, DOI 10.1364/OL.12.000227; WINEGRAD S, 1970, J GEN PHYSIOL, V55, P77, DOI 10.1085/jgp.55.1.77	30	98	99	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					739	741		10.1038/367739a0	http://dx.doi.org/10.1038/367739a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107869				2022-12-01	WOS:A1994MX63100059
J	MOMBURG, F; ROELSE, J; HOWARD, JC; BUTCHER, GW; HAMMERLING, GJ; NEEFJES, JJ				MOMBURG, F; ROELSE, J; HOWARD, JC; BUTCHER, GW; HAMMERLING, GJ; NEEFJES, JJ			SELECTIVITY OF MHC-ENCODED PEPTIDE TRANSPORTERS FROM HUMAN, MOUSE AND RAT	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; ANTIGEN PRESENTATION; LINKED TRANSPORTER; RMA-S; EXPRESSION; INVITRO; HLA-B27; CELLS; GENES	MAJOR histocompatibility complex (MHC) class I molecules present peptides from degraded intracellular antigens to CD8(+) T cells(1). These peptides are translocated in an ATP-dependent fashion(2-4) into the lumen of the endoplasmic reticulum (ER) for binding to class I molecules(5,6) by means of the MHC-encoded transporters associated with antigen processing, TAP1 and TAP2. These are members of a family of proteins containing an ATP-binding cassette and form heterodimers in the ER membrane(7-10). Defects in the genes encoding TAP1 or TAP2 account for impaired class I assembly and antigen presentation in several human and rodent cell lines(7,11-13). Whereas MHC class I molecules select peptides according to binding motifs(14-17), it is not clear to what extent the TAP1-TAP2 transporters have peptide sequence and length specificity. Previous studies of the rat MHC class I molecule, RT1A(a), suggested a specific conveyance of peptides by rat TAP1-TAP2 (ref. 18). Here we substitute the amino- and carboxy-terminal and the penultimate amino-acid residues of model peptides to show that these residues influence the efficiency of transport. Human TAP and rat TAP(a) translocated peptides with hydrophobic and basic C termini, whereas mouse TAP and rat TAP(u) preferred peptides with hydrophobic C termini. This pattern correlates with the predominant peptide binding profiles of mouse and human class I molecules.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS; BABRAHAM INST,AGR & FOOD RES COUNCIL,DEPT IMMUNOL,CAMBRIDGE CB2 4AT,ENGLAND	Netherlands Cancer Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	MOMBURG, F (corresponding author), GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAM,NEUENHEIMER FELD 280,D-69120 HEIDELBERG,GERMANY.		Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211; Howard, Jonathan/0000-0003-2756-5143				ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; POWIS SJ, 1991, J EXP MED, V173, P913, DOI 10.1084/jem.173.4.913; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RADA C, 1990, P NATL ACAD SCI USA, V87, P2167, DOI 10.1073/pnas.87.6.2167; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; YOUNG Y, 1992, J BIOL CHEM, V267, P11669; ZHANG QJ, 1993, P NATL ACAD SCI USA, V90, P2217, DOI 10.1073/pnas.90.6.2217	28	335	337	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 17	1994	367	6464					648	651		10.1038/367648a0	http://dx.doi.org/10.1038/367648a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107849				2022-12-01	WOS:A1994MW68800055
J	YEO, JP; ALDERUCCIO, F; TOH, BH				YEO, JP; ALDERUCCIO, F; TOH, BH			A NEW CHROMOSOMAL PROTEIN ESSENTIAL FOR MITOTIC SPINDLE ASSEMBLY	NATURE			English	Article							CELL-FREE-EXTRACTS; LARGE T-ANTIGEN; XENOPUS EGGS; MICROTUBULES; CENTROSOMES; COMPONENTS; LINES	ASSEMBLY of the mitotic spindle, the machinery responsible for chromosomal segregation, is regulated by Cdc2 kinase1-5, and requires mitotic chromatin5-8. However, the molecular identity of the kinase substrate and chromatin factor is unknown. Here we have cloned a human complementary DNA encoding an evolutionarily conserved chromosomal protein of relative molecular mass 47,000 (M(r) 47K) which has three consensus motifs for Cdc2 kinase-mediated phosphorylation9. The protein is phosphorylated only during mitosis and is associated with polypeptides having M(r)s of 31K, 67K and 200K. Mitotic arrest is induced by antisense messenger RNA or by affinity-purified autoantibody. In the arrested cells, the chromosomes remain unsegregated and the mitotic spindle is absent. We propose that the chromosomal protein is activated by phosphorylation at the interphase/mitosis transition by Cdc2 kinase, and that the protein, alone or as a complex, is a previously unidentified Cdc2 kinase substrate and chromatin factor necessary for spindle assembly.	MONASH UNIV,SCH MED,DEPT PATHOL & IMMUNOL,PRAHRAN,VIC 3181,AUSTRALIA	Monash University			Alderuccio, Frank/D-5808-2011	Alderuccio, Frank/0000-0003-4853-3394				ALDERUCCIO F, 1991, J EXP MED, V173, P941, DOI 10.1084/jem.173.4.941; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BOOTSMA D, 1964, EXP CELL RES, V33, P301, DOI 10.1016/S0014-4827(64)81035-1; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICUTTINI FM, 1992, BLOOD, V80, P102; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; Karsenti E, 1991, Semin Cell Biol, V2, P251; KARSENTI E, 1986, TRENDS BIOCHEM SCI, V11, P460, DOI 10.1016/0968-0004(86)90247-1; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KOOY J, 1992, J BIOL CHEM, V267, P20255; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MU FT, 1988, CLIN EXP IMMUNOL, V71, P100; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICKLAS RB, 1985, J CELL BIOL, V100, P1, DOI 10.1083/jcb.100.1.1; Nigg E A, 1991, Semin Cell Biol, V2, P261; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PEDEN KWC, 1989, EXP CELL RES, V185, P60, DOI 10.1016/0014-4827(89)90037-2; PICARD A, 1988, DEV BIOL, V128, P121, DOI 10.1016/0012-1606(88)90273-4; SANDERS WS, 1992, CELL, V70, P451; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SCHICKEDANZ J, 1986, VIROLOGY, V148, P47, DOI 10.1016/0042-6822(86)90402-2; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	30	24	25	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					288	291		10.1038/367288a0	http://dx.doi.org/10.1038/367288a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	8121495				2022-12-01	WOS:A1994MR49400061
J	SIEGFRIED, E; WILDER, EL; PERRIMON, N				SIEGFRIED, E; WILDER, EL; PERRIMON, N			COMPONENTS OF WINGLESS SIGNALING IN DROSOPHILA	NATURE			English	Article							SEGMENT-POLARITY GENE; MOLECULAR-CLONING; HUMAN PLAKOGLOBIN; PROTEIN; ARMADILLO; EXPRESSION; PRODUCT; HOMOLOG; ENCODES; MELANOGASTER	THE determination of specific cell fates and polarity within each segmental unit of the Drosophila embryo involves the products of the segment polarity genes1. One of these, wingless (wg), encodes a secreted protein 2,3 that is homologous to the mammalian protooncogene Wnt-1 (refs 4, 5). In the embryonic epidermis, wg is expressed in a single row of cells within each segmental unit, although its activity is required for the correct patterning of most of the epidermis4,6. Initially Wg signals to adjacent posterior cells, maintaining engrailed (en) expression7,8. Later during embryogenesis, wg specifies the differentiation of naked cuticle9. Wg signalling functions by inactivating or antagonizing the activity of zeste-white 3 (zw3)10. We have investigated the requirement in the Wg signal transduction pathway for the three genes armadillo (arm)11,12, dishevelled (dsh) and porcupine (porc)13, all of which have embryonic mutant phenotypes similar to wg. Our results indicate that dsh and porc act upstream of zw3, and arm acts down-stream of zw3.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	SIEGFRIED, E (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,200 LONGWOOD AVE,BOSTON,MA 02115, USA.			Perrimon, Norbert/0000-0001-7542-472X				BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CHOU TB, 1992, GENETICS, V131, P643; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; KLINGENSMITH J, IN PRESS GENES DEV; MARTINEZARIAS A, 1988, DEVELOPMENT, V103, P153; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; PEIFER M, IN PRESS DEVELOPMENT; PERRIMON N, 1984, GENETICS, V108, P927; PERRIMON N, 1989, DEV BIOL, V135, P287, DOI 10.1016/0012-1606(89)90180-2; PERRIMON N, 1989, GENETICS, V121, P333; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANDENHEUVEL M, IN PRESS EMBO J; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	33	295	297	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					76	80		10.1038/367076a0	http://dx.doi.org/10.1038/367076a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	8107779				2022-12-01	WOS:A1994MP86500063
J	NIGHTINGALE, SL				NIGHTINGALE, SL			MEDWATCH CONFERENCE COSPONSORED BY THE FDA AND THE AMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1993	270	22					2669	2669						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ821	8133573				2022-12-01	WOS:A1993MJ82100006
J	FANG, FC; MCCLELLAND, M; GUINEY, DG; JACKSON, MM; HARTSTEIN, AI; MORTHLAND, VH; DAVIS, CE; MCPHERSON, DC; WELSH, J				FANG, FC; MCCLELLAND, M; GUINEY, DG; JACKSON, MM; HARTSTEIN, AI; MORTHLAND, VH; DAVIS, CE; MCPHERSON, DC; WELSH, J			VALUE OF MOLECULAR EPIDEMIOLOGIC ANALYSIS IN A NOSOCOMIAL METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS OUTBREAK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMID ANALYSIS; ARBITRARY PRIMERS; STRAINS; INFECTIONS; DNA; EPIDERMIDIS; EVOLUTION; MARKERS	Objective.-To evaluate two molecular epidemiologic methods used in the analysis of a nosocomial methicillin-resistant Staphylococcus aureus (MRSA) outbreak. Design.-Restriction endonuclease analysis of plasmid DNA (REAP) was used in the analysis of 45 MRSA isolates. After termination of the outbreak, isolates were retrospectively analyzed in a blind fashion using the newly described technique of arbitrarily primed polymerase chain reaction (AP-PCR). Molecular analyses were compared with epidemiologic and antimicrobial susceptibility data. Setting.-Tertiary care university hospital. Subjects.-Twenty-eight patients and 12 employees infected or colonized with MRSA during a 6-week period. Results.-A clonal relationship demonstrated among isolates from burn unit patients and staff was clearly distinguishable from MRSA isolates arising from other hospital wards. The combination of REAP and AP-PCR provided complementary information in several instances. Aggressive measures to isolate infected patients and eradicate colonization from patients and staff terminated the outbreak. Conclusions.-Although traditional epidemiologic methods retain their central role in modem hospital infection control, molecular epidemiologic analysis can significantly enhance the ability of infection control officers to analyze and terminate hospital epidemics. The combination of AP-PCR and REAP may prove to be a particularly informative means of tracking the nosocomial spread of microbial strains and their mobile genetic elements.	CALIF INST BIOL RES, LA JOLLA, CA USA; OREGON HLTH SCI UNIV, DEPT PATHOL, PORTLAND, OR 97201 USA; UNIV CALIF SAN DIEGO, MED CTR, DIV INFECT DIS, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, MED CTR, EPIDEMIOL UNIT, LA JOLLA, CA 92093 USA	Oregon Health & Science University; University of California System; University of California San Diego; University of California System; University of California San Diego			McClelland, Michael/A-8583-2011	Fang, Ferric/0000-0002-3243-110X; McClelland, Michael/0000-0003-1788-9347				[Anonymous], 1961, BMJ-BRIT MED J, V1, P113; ARCHER GL, 1983, J CLIN MICROBIOL, V18, P395, DOI 10.1128/JCM.18.2.395-399.1983; BENNER EJ, 1968, LANCET, V2, P741; BOYCE JM, 1991, INFECT CONT HOSP EP, V12, P46, DOI 10.2307/30147088; BOYCE JM, 1983, JAMA-J AM MED ASSOC, V249, P2803, DOI 10.1001/jama.249.20.2803; BRANGER C, 1987, J MED MICROBIOL, V24, P275, DOI 10.1099/00222615-24-3-275; BRANGER C, 1990, J CLIN MICROBIOL, V28, P150, DOI 10.1128/JCM.28.1.150-151.1990; BRAUDE AI, 1955, ANTIBIOT ANNU, P1133; BRUMFITT W, 1989, NEW ENGL J MED, V320, P1188, DOI 10.1056/NEJM198905043201806; Chambers H.F., 1988, CLIN MICROBIOL REV, V1, P173, DOI DOI 10.1128/CMR.1.2.173; COHEN ML, 1982, ANTIMICROB AGENTS CH, V21, P210, DOI 10.1128/AAC.21.2.210; CRISTINO JAGM, 1989, J HOSP INFECT, V13, P133, DOI 10.1016/0195-6701(89)90019-4; EISENSTEIN BI, 1990, J INFECT DIS, V161, P595, DOI 10.1093/infdis/161.4.595; FRENCH GL, 1990, J HOSP INFECT, V15, P117, DOI 10.1016/0195-6701(90)90120-D; HALL LMC, 1989, EPIDEMIOL INFECT, V103, P183, DOI 10.1017/S095026880003048X; HARTSTEIN AI, 1989, J CLIN MICROBIOL, V27, P1874, DOI 10.1128/JCM.27.8.1874-1879.1989; KOZARSKY PE, 1986, INFECT CONT HOSP EP, V7, P577, DOI 10.1017/S0195941700065413; KREISWIRTH B, 1993, SCIENCE, V259, P227, DOI 10.1126/science.8093647; LACEY RW, 1973, J MED MICROBIOL, V6, P511, DOI 10.1099/00222615-6-4-511; LOCKSLEY RM, 1982, ANN INTERN MED, V97, P317, DOI 10.7326/0003-4819-97-3-317; LUPSKI JR, 1987, REV INFECT DIS, V9, P357; LYON BR, 1987, MICROBIOL REV, V51, P88, DOI 10.1128/MMBR.51.1.88-134.1987; MCDONNELL RW, 1983, ANTIMICROB AGENTS CH, V23, P151, DOI 10.1128/AAC.23.1.151; MCMANUS AT, 1989, ARCH SURG-CHICAGO, V124, P1456; MUDER RR, 1991, ANN INTERN MED, V114, P107, DOI 10.7326/0003-4819-114-2-1-107; MULLIGAN ME, 1991, INFECT CONT HOSP EP, V12, P20, DOI 10.2307/30147085; PEACOCK JE, 1980, ANN INTERN MED, V93, P526, DOI 10.7326/0003-4819-93-4-526; PFALLER MA, 1991, DIAGN MICR INFEC DIS, V14, P209, DOI 10.1016/0732-8893(91)90034-D; PFALLER MA, 1991, MANUAL CLIN MICROBIO, P171; RALPH D, 1993, J BACTERIOL, V175, P973, DOI 10.1128/JB.175.4.973-981.1993; REBOLI AC, 1990, INFECT CONT HOSP EP, V11, P291, DOI 10.1086/646174; RHINEHART E, 1987, ARCH INTERN MED, V147, P521, DOI 10.1001/archinte.147.3.521; RUTALA WA, 1983, J CLIN MICROBIOL, V18, P683, DOI 10.1128/JCM.18.3.683-688.1983; Sambrook J., 1989, MOL CLONING LAB MANU; SCHABERG DR, 1986, REV INFECT DIS, V8, P705; STEWART G T, 1963, Br Med J, V1, P308; WACHSMUTH K, 1986, REV INFECT DIS, V8, P682; WAKEFIELD DS, 1988, AM J INFECT CONTROL, V16, P185, DOI 10.1016/0196-6553(88)90058-2; WELSH J, 1992, INT J SYST BACTERIOL, V42, P370, DOI 10.1099/00207713-42-3-370; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; Welsh John, 1993, P595; WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531	42	32	33	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1323	1328		10.1001/jama.270.11.1323	http://dx.doi.org/10.1001/jama.270.11.1323			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8103118				2022-12-01	WOS:A1993LW34500029
J	JAMIL, S; KEER, JT; LUCAS, SB; DOCKRELL, HM; CHIANG, TJ; HUSSAIN, R; STOKER, NG				JAMIL, S; KEER, JT; LUCAS, SB; DOCKRELL, HM; CHIANG, TJ; HUSSAIN, R; STOKER, NG			USE OF POLYMERASE CHAIN-REACTION TO ASSESS EFFICACY OF LEPROSY CHEMOTHERAPY	LANCET			English	Article							MYCOBACTERIUM-LEPRAE; BIOPSIES; THERAPY; PCR	The assessment of chemotherapy efficacy in leprosy is difficult, since the only reliable method for determining whether the causative organism, Mycobacterium leprae, is viable depends on its growth in mouse foot pads. In an attempt to replace this expensive, time-consuming test, methods based on the polymerase chain reaction (PCR) have been developed. These methods depend on detection of DNA, which is more susceptible to degradation on cell death than are other cell components, so should be a more accurate indicator of viability. We have used a specific PCR assay to detect M leprae DNA in skin biopsy samples from leprosy patients. By use of limiting dilution PCR (LD-PCR), the concentration of M leprae DNA in the original sample could be measured. The DNA concentration was more closely correlated with the morphological index (derived from a staining technique that distinguishes morphologically intact and damaged bacteria) than with the number of bacteria visible (bacterial index, BI, which counts both alive and dead bacteria). In a longitudinal study of multibacillary patients on multi-drug therapy, skin biopsy samples were collected before treatment and 3, 6, 12, and 24 months after the start of therapy. While the BI showed little or no change during treatment, the number of genomes detected by PCR fell sharply, in parallel with the MI. We propose that PCR can be used as a rapid measure of M leprae viability and that this approach can be used for monitoring individual leprosy patients and for assessment of existing and new regimens. The method may be applicable to other infectious diseases in which culture of the causative organism is slow or impossible.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT CLIN SCI, KEPPEL ST, LONDON WC1E 7HT, ENGLAND; AGA KHAN UNIV, DEPT MICROBIOL, KARACHI, PAKISTAN; MARIE ADELAIDE LEPROSY CTR, KARACHL, PAKISTAN; UNIV LONDON UNIV COLL, SCH MED, DEPT HISTOPATHOL, LONDON WC1E 6BT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine; Aga Khan University; University of London; University College London; UCL Medical School			Stoker, Neil G/L-8812-2016; Hussain, Rabia/E-9982-2015	Stoker, Neil G/0000-0001-7055-6184; Dockrell, Hazel/0000-0003-1869-9107				BANCROFT JD, 1984, MAUAL HISTOLOGICAL T, P207; BAOHONG J, 1987, International Journal of Leprosy and Other Mycobacterial Diseases, V55, P830; BECXBLEUMINCK M, 1989, INT J LEPROSY, V57, P540; COLSTON M J, 1987, International Journal of Leprosy and Other Mycobacterial Diseases, V55, P859; DEWIT MYL, 1991, J CLIN MICROBIOL, V29, P906, DOI 10.1128/JCM.29.5.906-910.1991; Grosset J H, 1986, Lepr Rev, V57 Suppl 3, P223; GROSSET JH, 1988, INT J LEPROSY, V56, P259; Haas M, 1993, Int J Antimicrob Agents, V2, P117, DOI 10.1016/0924-8579(93)90050-F; HARTSKEERL RA, 1989, J GEN MICROBIOL, V135, P2357; HONORE N, 1993, ANTIMICROB AGENTS CH, V37, P414, DOI 10.1128/AAC.37.3.414; Leiker D L, 1971, Lepr Rev, V42, P121; MCCULLAGH P, 1984, GENERALIZED LINEAR M, P1; MCRAE DH, 1971, INFECT IMMUN, V3, P116, DOI 10.1128/IAI.3.1.116-120.1971; REES RJW, 1985, LEPROSY, P31; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; RIDLEY D. S., 1958, LEPROSY REV, V29, P45; RIDLEY D. S., 1955, TRANS ROY SOC TROP MED AND HYG, V49, P449, DOI 10.1016/0035-9203(55)90010-9; Ridley D S, 1967, Int J Lepr Other Mycobact Dis, V35, P184; Ridley M J, 1971, Lepr Rev, V42, P88; SHEPARD CC, 1974, AM J TROP MED HYG, V23, P1120, DOI 10.4269/ajtmh.1974.23.1120; Sheppard CC, 1985, LEPROSY, P269; VEGALOPEZ F, 1993, INFECT IMMUN, V61, P2145; Waters M F, 1974, Lepr Rev, V45, P288; WATERS M F, 1962, Int J Lepr, V30, P266; WILLIAMS DL, 1990, J INFECT DIS, V162, P193, DOI 10.1093/infdis/162.1.193; WILLIAMS DL, 1992, MOL CELL PROBE, V6, P401, DOI 10.1016/0890-8508(92)90034-U; WOODS SA, 1989, FEMS MICROBIOL LETT, V65, P305; WHO82 TECH REP, P675; 1987, INT J LEPROSY, V55, P864	29	37	40	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 31	1993	342	8866					264	268		10.1016/0140-6736(93)91816-5	http://dx.doi.org/10.1016/0140-6736(93)91816-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ163	8101301				2022-12-01	WOS:A1993LQ16300009
J	EVERETT, ED; EVANS, KA; HENRY, RB; MCDONALD, G				EVERETT, ED; EVANS, KA; HENRY, RB; MCDONALD, G			HUMAN EHRLICHIOSIS IN ADULTS AFTER TICK EXPOSURE - DIAGNOSIS USING POLYMERASE CHAIN-REACTION	ANNALS OF INTERNAL MEDICINE			English	Article						EHRLICHIOSIS; DIAGNOSIS, DIFFERENTIAL; TICK-BORNE DISEASES; DOXYCYCLINE; POLYMERASE CHAIN REACTION	HUMAN INFECTION; CHAFFEENSIS; CANIS; PATIENT; AGENT	Objective: To identify and prospectively follow patients with suspected human ehrlichiosis regarding clinical manifestations, laboratory variables, methods for confirming the diagnosis, and complications. Design: Prospective case study. Setting: University and Veterans Affairs hospital and clinics. Patients: Observations in 30 adult patients with acute febrile illness or with unexplained fevers and cytopenias or abnormal liver profiles or both. Measurements:Serial clinical examinations, hematologic profiles, liver profiles, electrolyte determinations, chest radiographs, and response to therapy; other studies appropriate for patient care. Intervention: Therapy with doxycycline. Results: Thirty cases of ehrlichiosis were identified between 1989 and 1992. Tick exposure was strongly associated with the illness (P = 0.0001). Symptoms were nonspecific; fever, chills, and headache predominated but many other symptoms also occurred. Fever and skin rashes with various morphologic characteristics were the most common physical findings. Laboratory investigations indicate that the hematologic, hepatic, and central nervous systems are commonly involved in human ehrlichiosis. Twenty of 23 patients (87%) tested by the polymerase chain reaction using Ehrlichia chaffeensis sequences and whole blood samples were positive for E. chaffeensis. Conclusions: The syndrome of human ehrlichiosis is not commonly recognized by physicians. Ehrlichiosis should be considered in the differential diagnosis of patients with febrile illness after known or possible tick exposure, particularly if accompanying cytopenias or abnormal liver profiles or both are present. The therapeutic response to doxycycline is prompt, and complications are uncommon in promptly treated patients. The polymerase chain reaction applied to whole blood samples is a promising test for rapid confirmation of the diagnosis within 24 to 48 hours.	UNIV MISSOURI, HLTH SCI CTR, COLUMBIA, MO USA; HARRY S TRUMAN MEM VET HOSP, COLUMBIA, MO USA	University of Missouri System; University of Missouri Columbia; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital								ANDERSON BE, 1992, J CLIN MICROBIOL, V30, P775, DOI 10.1128/JCM.30.4.775-780.1992; ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; BARTON LL, 1989, PEDIATRICS, V84, P580; BROUQUI P, 1992, ANTIMICROB AGENTS CH, V36, P2799, DOI 10.1128/AAC.36.12.2799; DAWSON JE, 1991, J INFECT DIS, V163, P564, DOI 10.1093/infdis/163.3.564; DAWSON JE, 1991, J CLIN MICROBIOL, V29, P2741, DOI 10.1128/JCM.29.12.2741-2745.1991; DIMMITT DC, 1989, AM J MED, V87, P677, DOI 10.1016/S0002-9343(89)80404-8; DUNN BE, 1992, J CLIN MICROBIOL, V30, P2207, DOI 10.1128/JCM.30.8.2207-2210.1992; EDWARDS MS, 1988, PEDIATR INFECT DIS J, V7, P651, DOI 10.1097/00006454-198809000-00010; ENG TR, 1990, JAMA-J AM MED ASSOC, V264, P2251, DOI 10.1001/jama.264.17.2251; FISHBEIN DB, 1989, J INFECT DIS, V160, P803, DOI 10.1093/infdis/160.5.803; FISHBEIN DB, 1987, JAMA-J AM MED ASSOC, V257, P3100, DOI 10.1001/jama.257.22.3100; HARKESS JR, 1990, SOUTHERN MED J, V83, P1341, DOI 10.1097/00007611-199011000-00031; HARKESS JR, 1989, J INFECT DIS, V159, P576, DOI 10.1093/infdis/159.3.576; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; MOSKOVITZ M, 1991, J CLIN GASTROENTEROL, V13, P86, DOI 10.1097/00004836-199102000-00019; PEARCE CJ, 1988, AM J HEMATOL, V28, P53, DOI 10.1002/ajh.2830280111; PETERSEN LR, 1989, J INFECT DIS, V159, P562, DOI 10.1093/infdis/159.3.562; Sambrook J., 1989, MOL CLONING LAB MANU, P931; TAYLOR JP, 1988, J INFECT DIS, V158, P217, DOI 10.1093/infdis/158.1.217; WALLACE RB, 1987, GUIDE MOL CLONING TE, P432	21	100	105	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					730	735		10.7326/0003-4819-120-9-199405010-00002	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	8147545				2022-12-01	WOS:A1994NH25100002
J	HANEIN, D; GEIGER, B; ADDADI, L				HANEIN, D; GEIGER, B; ADDADI, L			DIFFERENTIAL ADHESION OF CELLS TO ENANTIOMORPHOUS CRYSTAL-SURFACES	SCIENCE			English	Article								Interactions during cell adhesion to external surfaces may reach the level of discrimination of molecular chirality. Cultured epithelial cells interact differently with the {011} faces of the (R,R) and (S,S) calcium tartrate tetrahydrate crystals. In a modified version of the classical Pasteur experiment, the enantiomorphous crystals were sorted out from a 1:1 mixture by the selective adhesion of cells to the (R,R) crystals. This stereospecificity results from molecular recognition between chiral components on the cell surface and the structured crystal surface. Crystals may allow experimental differentiation between distinct stages in cell substrate contacts, providing mechanistic information not readily attainable on conventional heterogeneous surfaces.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	HANEIN, D (corresponding author), WEIZMANN INST SCI,DEPT STRUCT BIOL,IL-76100 REHOVOT,ISRAEL.							AMBADY GK, 1968, ACTA CRYSTALL B-STRU, VB 24, P1548, DOI 10.1107/S0567740868004619; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CURTIS ASG, 1990, CRIT REV BIOCOMPAT, V5, P343; GEIGER B, 1992, J CELL SCI, V103, P943; GEIGER B, 1987, J CELL SCI S, V8, P251; GRINNELL F, 1978, EXP CELL RES, V116, P275, DOI 10.1016/0014-4827(78)90449-4; HANEIN D, 1993, LANGMUIR, V9, P1058, DOI 10.1021/la00028a030; HANEIN D, 1993, J CELL SCI, V104, P257; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; PASTEUR L., 1848, ANN CHIM PHYS, V24, P442; VASILIEV JM, 1981, DEV CELL BIOL SERIES, V8, P19	11	109	111	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1413	1416		10.1126/science.8128221	http://dx.doi.org/10.1126/science.8128221			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128221				2022-12-01	WOS:A1994MZ92700023
J	STARK, WM; PARKER, CN; BOOCOCK, MR; HALFORD, SE				STARK, WM; PARKER, CN; BOOCOCK, MR; HALFORD, SE			STEREOSELECTIVITY OF DNA CATENANE FUSION BY RESOLVASE	NATURE			English	Article							SITE-SPECIFIC RECOMBINATION; TN3 RESOLVASE; BACTERIOPHAGE-LAMBDA; SEGMENTS; PRODUCTS; RES	COMMUNICATIONS between distant sites on DNA often depend on the way in which the sites are connected(1,2). For example, site-specific recombination catalysed by Tn3 resolvase is most efficient when the 114-base-pair res recombination sites are directly repeated in the same DNA molecule(3). In vitro a supercoiled plasmid substrate containing two directly repeated res sites gives a resolution product in which the two recombinant circles are topologically linked as a simple (two-noded) catenane (Fig. 1a). Resolvase is highly selective in forming this product rather than unlinked circles or more complex catenanes. It does not catalyse recombination between sites on separate supercoiled molecules, or between inverted sites in the same supercoiled molecule(3-5). Tn3 resolution removes four negative supercoils from the substrate, an energetically favourable change which may drive the reaction(6): in relaxed or nicked circular substrates, resolution is incomplete and slower. Resolvase can catalyse fusion of the circles of a nicked or relaxed catenane, giving a single unknotted circular product(6,7). The fusion is the precise topological reversal of resolution, introducing four negative supercoils into a related catenane substrate(6), and should therefore not proceed if the catenane is already negatively supercoiled. Here we study recombination between res sites in non-supercoiled DNA circles linked into simple catenanes. We used (+2) and (-2) catenanes, which differ only in the direction in which one circle is threaded through the other (Fig. 2a). Although stereoselectivity is a feature of enzyme catalysis, it is not obvious how resolvase can distinguish between these subtly different catenane diastereomers. A model for the intertwining of the res site DNA in the catalytically active complex(4,7) predicts that only the (-2) catenane will recombine, giving unknotted and 4-noded knot circular products. We have confirmed this prediction for the Tn3 and Tn21 resolvases.	UNIV BRISTOL,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol	STARK, WM (corresponding author), UNIV GLASGOW,INST GENET,CHURCH ST,GLASGOW G11 5JS,SCOTLAND.		Boocock, Martin/K-5825-2012		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABREMSKI K, 1985, J MOL BIOL, V184, P211, DOI 10.1016/0022-2836(85)90374-2; BEATTY LG, 1986, J MOL BIOL, V188, P529, DOI 10.1016/S0022-2836(86)80003-1; BENJAMIN HW, 1990, J BIOL CHEM, V165, P6441; BOOCOCK MR, 1986, BIOCHEM SOC T, V14, P214; BOOCOCK MR, 1987, UCLA S MOL CELLULAR, V47, P703; CASTELL SE, 1986, NUCLEIC ACIDS RES, V14, P7213, DOI 10.1093/nar/14.18.7213; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; GELLERT M, 1987, NATURE, V325, P401, DOI 10.1038/325401a0; Hatfull GF, 1988, GENETIC RECOMBINATIO, P357; MIZUUCHI K, 1980, J MOL BIOL, V141, P485, DOI 10.1016/0022-2836(80)90256-9; PARKER CN, 1991, CELL, V66, P781, DOI 10.1016/0092-8674(91)90121-E; POLLOCK TJ, 1983, J MOL BIOL, V170, P1, DOI 10.1016/S0022-2836(83)80224-1; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; STARK WM, 1989, TRENDS GENET, V5, P304, DOI 10.1016/0168-9525(89)90113-3; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STARK WM, 1991, EMBO J, V10, P3541, DOI 10.1002/j.1460-2075.1991.tb04918.x; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WASSERMAN SA, 1985, SCIENCE, V229, P171, DOI 10.1126/science.2990045; WASSERMAN SA, 1988, NATURE, V334, P448, DOI 10.1038/334448a0; WASSERMAN SA, 1985, P NATL ACAD SCI USA, V82, P1079, DOI 10.1073/pnas.82.4.1079	20	21	21	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					76	78		10.1038/368076a0	http://dx.doi.org/10.1038/368076a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	8107889				2022-12-01	WOS:A1994MY56900058
J	MITSUHASHI, M; COOPER, A; OGURA, M; SHINAGAWA, T; YANO, K; HOSOKAWA, T				MITSUHASHI, M; COOPER, A; OGURA, M; SHINAGAWA, T; YANO, K; HOSOKAWA, T			OLIGONUCLEOTIDE PROBE DESIGN - A NEW APPROACH	NATURE			English	Article							SEQUENCE		HITACHI CHEM RES CTR INC,IRVINE,CA 92715; DIGITALWORD,BELLEVUE,WA 98008; NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 3,NAGASAKI 852,JAPAN; HITACHI CHEM CO LTD,TOKYO,JAPAN	Hitachi Limited; Nagasaki University; Hitachi Limited	MITSUHASHI, M (corresponding author), ADV GENE COMP TECHNOL INC,2102 BUSINESS CTR DR,SUITE 170,IRVINE,CA 92715, USA.							BERNSTAM VA, 1992, HDB GENE LEVEL DIAGN, P161; IIZUKA N, 1987, VIROLOGY, V156, P64, DOI 10.1016/0042-6822(87)90436-3; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MITSUHASHI M, 1992, NATURE, V357, P519, DOI 10.1038/357519a0; Mitsuhashi M, 1994, Nihon Rinsho, V52, P530; Reynolds T, 1992, J Natl Cancer Inst, V84, P288, DOI 10.1093/jnci/84.5.288; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; WU DY, 1989, GENE, V76, P245, DOI 10.1016/0378-1119(89)90165-0	8	46	52	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					759	761		10.1038/367759a0	http://dx.doi.org/10.1038/367759a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107873				2022-12-01	WOS:A1994MX63100064
J	SUNDAR, S; THAKUR, BB; TANDON, AK; AGRAWAL, NR; MISHRA, CP; MAHAPATRA, TM; SINGH, VP				SUNDAR, S; THAKUR, BB; TANDON, AK; AGRAWAL, NR; MISHRA, CP; MAHAPATRA, TM; SINGH, VP			CLINICOEPIDEMIOLOGIC STUDY OF DRUG-RESISTANCE IN INDIAN KALAAZAR	BRITISH MEDICAL JOURNAL			English	Article							SODIUM STIBOGLUCONATE		BANARAS HINDU UNIV,INST MED SCI,VARANASI 221005,UTTAR PRADESH,INDIA; SK MED COLL,MUZAFFARPUR,INDIA	Banaras Hindu University (BHU)								HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296; Jha S N, 1991, J Assoc Physicians India, V39, P314; JHA TK, 1992, J ASSOC PHYSICIAN I, V42, P868; THAKUR CP, 1991, INDIAN J MED RES-A, V93, P103; 1984, WHO TECH REP SER, V701, P99	5	51	52	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 29	1994	308	6924					307	307		10.1136/bmj.308.6924.307	http://dx.doi.org/10.1136/bmj.308.6924.307			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU492	8124119	Green Published			2022-12-01	WOS:A1994MU49200021
J	HABUCHI, T; TAKAHASHI, R; YAMADA, H; KAKEHI, Y; SUGIYAMA, T; YOSHIDA, O				HABUCHI, T; TAKAHASHI, R; YAMADA, H; KAKEHI, Y; SUGIYAMA, T; YOSHIDA, O			METACHRONOUS MULTIFOCAL DEVELOPMENT OF UROTHELIAL CANCERS BY INTRALUMINAL SEEDING	LANCET			English	Note							BLADDER-CANCER; CLONAL ORIGIN; P53 MUTATIONS	To investigate the clonal origin of multifocal urothelial tumours, we analysed the p53 tumour-suppressor gene in 3 cases with bladder tumours developing after treatment for a renal pelvic or ureteral tumour and in 1 case with a ureteral tumour after treatment for a bladder tumour. For each case, identical p53 gene mutations were detected in all primary and recurrent tumours. The results suggest that heterotopic recurrence by intraluminal seeding from the original tumour is common in urothelial cancer. The data also support the view that multifocal urothelial tumours are derived from a single progenitor cell.	KYOTO UNIV,FAC MED,DEPT UROL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PATHOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University								HABUCHI T, 1993, CANCER RES, V53, P3795; HARRIS AL, 1992, NEW ENGL J MED, V326, P759, DOI 10.1056/NEJM199203123261108; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LUNEC J, 1992, LANCET, V339, P439, DOI 10.1016/0140-6736(92)90135-P; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; SPRUCK CH, 1993, CANCER RES, V53, P1162	8	169	170	2	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1087	1088		10.1016/0140-6736(93)92066-3	http://dx.doi.org/10.1016/0140-6736(93)92066-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105314				2022-12-01	WOS:A1993ME82200012
J	GOODWIN, CS				GOODWIN, CS			GASTRIC-CANCER AND HELICOBACTER-PYLORI - THE WHISPERING KILLER	LANCET			English	Editorial Material							INFECTION; STOMACH				GOODWIN, CS (corresponding author), UNITED ARAB EMIRATES UNIV, FAC MED, DEPT MED MICROBIOL, AL AIN, U ARAB EMIRATES.							BARKER DJP, 1990, BRIT J CANCER, V61, P575, DOI 10.1038/bjc.1990.129; FORMAN D, 1993, LANCET, V341, P1359; GOODWIN CS, 1992, CURR OPIN GASTROEN, V8, P122; GRAHAM DY, 1993, NEW ENGL J MED, V328, P349, DOI 10.1056/NEJM199302043280512; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; Logan Robert P. H., 1993, P307; Mitchell Hazel M., 1993, P95; NEWELL DG, 1991, J CLIN PATHOL, V44, P385, DOI 10.1136/jcp.44.5.385; PARSONNET J, 1993, GASTROENTEROL CLIN N, V22, P89; QIN DX, 1993, CANCER, V71, P216, DOI 10.1002/1097-0142(19930101)71:1<216::AID-CNCR2820710133>3.0.CO;2-#; RECAVARRENARCE S, 1991, SCAND J GASTROENTERO, V26, P51, DOI 10.3109/00365529109093208; SEDGWICK DM, 1991, BRIT MED J, V302, P1305, DOI 10.1136/bmj.302.6788.1305; Sipponen Pentti, 1993, P37; SOBALA GM, 1991, CARCINOGENESIS, V12, P193, DOI 10.1093/carcin/12.2.193	15	18	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1993	342	8870					507	508		10.1016/0140-6736(93)91640-8	http://dx.doi.org/10.1016/0140-6736(93)91640-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102661				2022-12-01	WOS:A1993LU58200003
J	MATUSCHKA, FR; SPIELMAN, A				MATUSCHKA, FR; SPIELMAN, A			RISK OF INFECTION FROM AND TREATMENT OF TICK BITE	LANCET			English	Article							LYME-DISEASE SPIROCHETE; BORRELIA-BURGDORFERI; IXODES-DAMMINI; BABESIA-MICROTI; TRANSMISSION; ATTACHMENT; DURATION		HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	MATUSCHKA, FR (corresponding author), FREE UNIV BERLIN,UNIV KLINIKUM RUDOLF VIRCHOW,INST PATHOL,D-12249 BERLIN,GERMANY.							MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; MATUSCHKA FR, 1992, PARASITOL RES, V78, P695, DOI 10.1007/BF00931523; MATUSCHKA FR, 1992, NEW ENGL J MED, V327, P542, DOI 10.1056/NEJM199208203270807; MATUSCHKA FR, 1992, WOOD TICKS LYME DISE; PIESMAN J, 1991, J INFECT DIS, V163, P895, DOI 10.1093/infdis/163.4.895; PIESMAN J, 1986, INT J PARASITOL, V16, P381, DOI 10.1016/0020-7519(86)90118-9; PIESMAN J, 1987, J CLIN MICROBIOL, V25, P557, DOI 10.1128/JCM.25.3.557-558.1987; PIESMAN J, 1986, ACTA TROP, V43, P263; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; SHIH CM, 1992, J INFECT DIS, V166, P827, DOI 10.1093/infdis/166.4.827	10	17	18	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 28	1993	342	8870					529	530		10.1016/0140-6736(93)91650-B	http://dx.doi.org/10.1016/0140-6736(93)91650-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU582	8102671				2022-12-01	WOS:A1993LU58200013
J	DARIANSMITH, C; GILBERT, CD				DARIANSMITH, C; GILBERT, CD			AXONAL SPROUTING ACCOMPANIES FUNCTIONAL REORGANIZATION IN ADULT CAT STRIATE CORTEX	NATURE			English	Article							MASSIVE CORTICAL REORGANIZATION; VISUAL-CORTEX; SOMATOSENSORY CORTEX; DIGIT AMPUTATION; MOTOR CORTEX; OWL MONKEYS; SPINAL-CORD; CONNECTIONS; NEURONS; LESIONS	REMOVAL Of sensory input from a focal region of adult neocortex can lead to a large reorganization of cortical topography within the deprived area during subsequent months(1-9). Although this form of functional recovery is now well documented across several sensory systems, the underlying cellular mechanisms remain elusive. Weeks after binocular retinal lesions silence a corresponding portion of striate cortex in the adult cat, this cortex again becomes responsive, this time to retinal loci immediately outside the scotoma. Earlier findings showed a lack of reorganization in the lateral geniculate nucleus and an inadequate spread of geniculocortical afferents to account for the cortical reorganization, suggesting the involvement of intrinsic cortical connections(4,10). We investigated the possibility that intracortical axonal sprouting mediates long-term reorganization of cortical functional architecture. The anterograde label biocytin was used to compare the density of lateral projections into reorganized and non-deprived cortex. We report here that structural changes in the form of axonal sprouting of long-range laterally projecting neurons accompany topographic remodelling of the visual cortex.	ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University				Darian-Smith, Corinna/0000-0002-4753-4574				ALLARD T, 1991, J NEUROPHYSIOL, V66, P1048, DOI 10.1152/jn.1991.66.3.1048; BAILEY CH, 1983, NEUROSCIENCE, V8, P2452; CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CHINO YM, 1992, VISION RES, V32, P789, DOI 10.1016/0042-6989(92)90021-A; Darian-Smith C., 1992, Society for Neuroscience Abstracts, V18, P11; FITZGERALD M, 1990, J COMP NEUROL, V300, P370, DOI 10.1002/cne.903000308; FLORENCE SL, 1993, BRAIN RES, V601, P343, DOI 10.1016/0006-8993(93)91734-A; GANCHROW D, 1981, EXP NEUROL, V71, P437, DOI 10.1016/0014-4886(81)90022-4; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; GILBERT CD, 1983, J NEUROSCI, V3, P1116; HEINEN SJ, 1991, EXP BRAIN RES, V83, P670; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; KELLER A, 1990, EXP BRAIN RES, V80, P23; KELLER A, 1992, J NEUROPHYSIOL, V68, P295, DOI 10.1152/jn.1992.68.1.295; LAMOTTE CC, 1993, J COMP NEUROL, V330, P83, DOI 10.1002/cne.903300107; LUND JS, 1993, CEREB CORTEX, V3, P148, DOI 10.1093/cercor/3.2.148; MCMAHON SB, 1991, J COMP NEUROL, V304, P307, DOI 10.1002/cne.903040211; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; MOLANDER C, 1988, J COMP NEUROL, V276, P436, DOI 10.1002/cne.902760308; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RAJAN R, 1993, J COMP NEUROL, V338, P17, DOI 10.1002/cne.903380104; RAMACHANDRAN VS, 1992, NEUROREPORT, V3, P583, DOI 10.1097/00001756-199207000-00009; RASMUSSON DD, 1982, J COMP NEUROL, V205, P313, DOI 10.1002/cne.902050402; RECANZONE GH, 1993, J NEUROSCI, V13, P87; ROCKLAND KS, 1983, J COMP NEUROL, V216, P303, DOI 10.1002/cne.902160307; Steward O., 1991, CEREB CORTEX, V9, P81; WALL JT, 1984, J NEUROSCI, V4, P1499; WELLS J, 1987, J COMP NEUROL, V255, P466, DOI 10.1002/cne.902550312	32	493	501	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					737	740		10.1038/368737a0	http://dx.doi.org/10.1038/368737a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	8152484				2022-12-01	WOS:A1994NG55300057
J	MOHER, M; JOHNSON, N				MOHER, M; JOHNSON, N			USE OF ASPIRIN BY GENERAL-PRACTITIONERS IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article									RADCLIFFE INFIRM, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX2 6HE, OXON, ENGLAND	Radcliffe Infirmary	MOHER, M (corresponding author), SOUTHMEAD SURG, FARNHAM SL2 3ER, BUCKS, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; JULIAN DG, 1989, BMJ-BRIT MED J, V299, P555	3	16	16	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	1994	308	6931					760	760		10.1136/bmj.308.6931.760	http://dx.doi.org/10.1136/bmj.308.6931.760			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	8142831	Green Published			2022-12-01	WOS:A1994NC34800020
J	VOSSHALL, LB; PRICE, JL; SEHGAL, A; SAEZ, L; YOUNG, MW				VOSSHALL, LB; PRICE, JL; SEHGAL, A; SAEZ, L; YOUNG, MW			BLOCK IN NUCLEAR-LOCALIZATION OF PERIOD PROTEIN BY A 2ND CLOCK MUTATION, TIMELESS	SCIENCE			English	Article							MESSENGER-RNA LEVELS; MINDED GENE ENCODES; AH DIOXIN RECEPTOR; DROSOPHILA-MELANOGASTER; CIRCADIAN-RHYTHMS; DNA INTERACTIONS; VISUAL-SYSTEM; PRODUCT; TRANSLOCATION; EXPRESSION	In wild-type Drosophila, the period protein (PER) is found in nuclei of the eyes and brain, and PER immunoreactivity oscillates with a circadian rhythm. The studies described here indicate that the nuclear localization of PER is blocked by timeless (tim), a second chromosome mutation that, like per null mutations, abolishes circadian rhythms. PER fusion proteins without a conserved domain (PAS) and some flanking sequences are nuclear in tim mutants. This suggests that a segment of PER inhibits nuclear localization in firn mutants. The tim gene may have a role in establishing rhythms of PER abundance and nuclear localization in wild-type flies.	ROCKEFELLER UNIV,NATL SCI FDN SCI & TECHNOL CTR BIOL TIMING,HOWARD HUGHES MED INST,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; National Science Foundation (NSF); Rockefeller University; Rockefeller University			, 机智的马小跳和机智的羊不愁/ABC-5169-2020	Vosshall, Leslie/0000-0002-6060-8099	NIGMS NIH HHS [GM07982-09] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAYLIES MK, 1992, NEURON, V9, P575, DOI 10.1016/0896-6273(92)90194-I; BAYLIES MK, 1993, MOL GENETICS BIOL RH, P123; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; COLOT HV, 1988, EMBO J, V7, P3929, DOI 10.1002/j.1460-2075.1988.tb03279.x; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EWER J, 1992, J NEUROSCI, V12, P3321; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KARENLAMPI SO, 1988, J BIOL CHEM, V263, P10111; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU X, 1992, J NEUROSCI, V12, P2735; LIU X, 1991, NEURON, V6, P753, DOI 10.1016/0896-6273(91)90172-V; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; OKEY AB, 1980, J BIOL CHEM, V255, P1415; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; SAEZ L, 1988, MOL CELL BIOL, V8, P5378, DOI 10.1128/MCB.8.12.5378; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VOSSHALL LB, 1993, THESIS ROCKEFELLER U; VOSSHALL LB, UNPUB; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZWIEBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882, DOI 10.1073/pnas.88.9.3882	32	288	304	4	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 18	1994	263	5153					1606	1609		10.1126/science.8128247	http://dx.doi.org/10.1126/science.8128247			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	8128247				2022-12-01	WOS:A1994NB67300030
J	GODFREYFAUSSETT, P; BAGGALEY, R; SCOTT, G; SICHONE, M				GODFREYFAUSSETT, P; BAGGALEY, R; SCOTT, G; SICHONE, M			HIV IN ZAMBIA - MYTH OR MONSTER	NATURE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS-INFECTION; KAPOSIS SARCOMA; TUBERCULOSIS; MORTALITY; NAIROBI		LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND; KARA COUNSELLING & TRAINING TRUST,LUSAKA,ZAMBIA	University of London; London School of Hygiene & Tropical Medicine	GODFREYFAUSSETT, P (corresponding author), UNIV ZAMBIA,TEACHING HOSP,DEPT MED,ZAMBART PROJECT,POB 50110,LUSAKA,ZAMBIA.							BAYLEY AC, 1985, LANCET, V1, P359; BAYLEY AC, 1984, LANCET, V1, P1318; BIGGAR RJ, 1985, LANCET, V2, P520; BUVE A, IN PRESS AIDS; ELLIOTT AM, 1993, J TROP MED HYG, V96, P1; ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; GILKS CF, 1992, Q J MED, V82, P25; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; HODGKINSON N, 1993, SUNDAY TIMES    1003, P10; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MELBYE M, 1986, LANCET, V2, P1113; NKOWANE BM, 1991, AIDS, V5, pS7; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; NUNN P, 1991, LANCET, V337, P627; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; 7TH MAR INT C AIDS A; 1992, WHO WKLY EPIDEM REC, V67, P145	17	3	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					183	184		10.1038/368183a0	http://dx.doi.org/10.1038/368183a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	8145813				2022-12-01	WOS:A1994NA87000023
J	TAN, KL; GOH, KT; OON, CJ; CHAN, SH				TAN, KL; GOH, KT; OON, CJ; CHAN, SH			IMMUNOGENICITY OF RECOMBINANT YEAST-DERIVED HEPATITIS-B VACCINE IN NONRESPONDERS TO PERINATAL IMMUNIZATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ENDEMIC AREA SENEGAL; ANTIBODY-RESPONSE; EFFICACY; ANTIGEN; TRANSMISSION; SINGAPORE; INFANTS; TRIAL	Objective.-Nonresponse to hepatitis B vaccine in the perinatal period occasionally occurs. This report documents the results of reimmunization of nonrespenders to perinatal immunization. Design.-From a cohort of 1154 infants immunized with plasma-based vaccine in the perinatal period and followed up for more than 8 years, 45 nonresponders were identified. These children were reimmunized at 4 years of age. Each child received a yeast-derived recombinant hepatitis B vaccine on a 0-, 1-, and 5-month schedule, 33 children with 10-mu g and 12 with 5-mu g doses. Blood was sampled 1 month after the third vaccination and thereafter at 1, 2, and 4 years. Setting.-The follow-up clinic where the cohort of children was regularly seen. Patients.-Forty-five 4-year-old children who had no antibody to hepatitis B despite perinatal immunization. Main Outcome Measure.-Antibody levels to hepatitis B surface antigen. Results.-Seroconversion with titers higher than 10 mlU/mL occurred in all children. More than 70% still had titers higher than 10 mlU/mL 4 years after vaccination. Conclusion.-Nonresponders to perinatal hepatitis B vaccination respond well to subsequent vaccination.	MINIST ENVIRONM,DEPT QUARANTINE & EPIDEMIOL,SINGAPORE,SINGAPORE; SINGAPORE GEN HOSP,DEPT CLIN RES,SINGAPORE,SINGAPORE; NATL UNIV SINGAPORE,DEPT MICROBIOL,SINGAPORE,SINGAPORE	Singapore General Hospital; National University of Singapore	TAN, KL (corresponding author), NATL UNIV SINGAPORE HOSP,DEPT NEONATOL,5 LOWER KENT RIDGE RD,SINGAPORE 0511,SINGAPORE.		Chan, Soh Ha/B-6709-2009					ALPER CA, 1989, NEW ENGL J MED, V321, P708, DOI 10.1056/NEJM198909143211103; CHAN SH, 1985, INT J EPIDEMIOL, V14, P173, DOI 10.1093/ije/14.1.173; COURSAGET P, 1986, LANCET, V2, P1143; EGEA E, 1991, J EXP MED, V173, P531, DOI 10.1084/jem.173.3.531; FLEWETT TH, 1986, BRIT MED J, V293, P404, DOI 10.1136/bmj.293.6544.404; INSKIP HM, 1991, INT J EPIDEMIOL, V20, P764, DOI 10.1093/ije/20.3.764; MAUPAS P, 1981, LANCET, V1, P289; OON CJ, 1986, J INFECTION, V13, P155; PROZESKY OW, 1983, J INFECTION, V7, P53, DOI 10.1016/S0163-4453(83)96649-5; SHIRAKI K, 1977, AM J DIS CHILD, V131, P644, DOI 10.1001/archpedi.1977.02120190038007; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; Stevens CE, 1988, VIRAL HEPATITIS LIVE, P982; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; TAN KL, 1990, ACTA PAEDIATR SCAND, V79, P593, DOI 10.1111/j.1651-2227.1990.tb11522.x; YAP EH, 1972, VOX SANG, V22, P371, DOI 10.1111/j.1423-0410.1972.tb03982.x; 1991, MMWR MORB MORTAL WKL, V40, P1; 1991, EPIDEMIOL NEWS B SIN, V17, P37; 1992, PEDIATRICS, V89, P795; 1992, EPIDEMIOL NEWS B SIN, V18, P39	19	25	28	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 16	1994	271	11					859	861		10.1001/jama.271.11.859	http://dx.doi.org/10.1001/jama.271.11.859			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MZ498	8114241				2022-12-01	WOS:A1994MZ49800033
J	LINDBLAD, U; RASTAM, L; RYDEN, L; RANSTAM, J; ISACSSON, SO; BERGLUND, G				LINDBLAD, U; RASTAM, L; RYDEN, L; RANSTAM, J; ISACSSON, SO; BERGLUND, G			CONTROL OF BLOOD-PRESSURE AND RISK OF FIRST ACUTE MYOCARDIAL-INFARCTION - SKARABORG HYPERTENSION PROJECT	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; PRIMARY PREVENTION TRIAL; MEDICAL-CARE PROGRAM; ANTIHYPERTENSIVE THERAPY; TREATED HYPERTENSION; SERUM-CHOLESTEROL; FOLLOW-UP; REDUCTION; CURVE	Objective-To analyse the relation between treated blood pressure and concomitant risk factor and morbidity from acute myocardial infarction. Design-Prospective longitudinal study. Treated blood pressures and other variables were used to predict acute myocardial infarction. Setting-Primary health care in Skaraborg, Sweden. Subjects-1121 men and 1453 women aged 40-69 years at registration at outpatient clinics, 1977-81, with no evidence of previous myocardial infarction were followed up for an average of 7.4 years. Subjects were undergoing treatment with drugs to lower blood pressure or had blood pressure that exceeded the systolic or diastolic limits, or both, for diagnosis (>170/>105 mm Hg (patients aged 40-60 years) and >180/>110 mm Hg (older than 60 years)) on three different occasions, or both. Main outcome measures-First validated event of fatal or non-fatal acute myocardial infarction. Results-In men but not in women there was a negative relation between treated diastolic blood pressure and risk of acute myocardial infarction. Left ventricular hypertrophy and smoking were contributory risk factors in both sexes, as was serum cholesterol concentration in men. In men with normal electrocardiograms (n=345) risk increased with increasing diastolic blood pressure (P=0.047), whereas the opposite was found in men with electrocardiograms suggesting ischaemia or hypertrophy, or both (n=499, P=0.009). In those with a reading of 95-99 mm Hg the relative risk was 0.30 (P=0.034); at greater than or equal to 100 mm Hg it was 0.37 (P=0.027). No similar relations were seen in women or for systolic blood pressure. Conclusion-It may be hazardous to lower diastolic blood pressure below 95 mm Hg in hypertensive men with possible ischaemia or hypertrophy, or both. Electrocardiographic findings should be considered when treatment goals are decided for men with hypertension.	LUND UNIV,DEPT COMMUNITY HLTH SCI,S-21401 MALMO,SWEDEN; LUND UNIV,MALMO GEN HOSP,DEPT MED,S-21401 MALMO,SWEDEN; KAROLINSKA HOSP,DEPT CARDIOL,S-10401 STOCKHOLM,SWEDEN	Lund University; Lund University; Karolinska Institutet; Karolinska University Hospital			Ranstam, Jonas/A-4386-2009	Ranstam, Jonas/0000-0002-8287-7273				ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSON TW, 1978, LANCET, V2, P1139; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; BERGLUND G, 1987, LANCET, V1, P1154; BERGLUND G, 1989, AM J HYPERTENS, V2, P586, DOI 10.1093/ajh/2.7.586; BERGLUND G, 1977, PROGRAM MANAGEMENT H; BERGLUND G, 1979, ACTA MED SCAND S626, V205, P64; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOPER SP, 1988, AM J EPIDEMIOL, V127, P387, DOI 10.1093/oxfordjournals.aje.a114812; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DUNN FG, 1990, J HYPERTENS, V8, P775, DOI 10.1097/00004872-199008000-00012; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; FLETCHER AE, 1988, J HUM HYPERTENS, V2, P11; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; FROHLICH ED, 1992, NEW ENGL J MED, V327, P998, DOI 10.1056/NEJM199210013271406; HELGELAND A, 1980, AM J MED, V69, P725, DOI 10.1016/0002-9343(80)90438-6; KALBFLEISCH JD, 1979, STATISTICAL ANAL FAI; KANNEL WB, 1987, AM J CARDIOL, V59, pA80, DOI 10.1016/0002-9149(87)90182-2; KANNEL WB, 1987, AM J CARDIOL, V60, P851; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; LINDBLAD U, 1993, J INTERN MED, V233, P155, DOI 10.1111/j.1365-2796.1993.tb00668.x; LINDBLAD U, 1993, EUR HEART J, V14, P291, DOI 10.1093/eurheartj/14.3.291; LINDBLAD U, 1993, SCAND J SOC MED, V21, P3, DOI 10.1177/140349489302100102; RASTAM L, 1986, ACTA MED SCAND, V219, P249; RASTAM L, 1986, ACTA MED SCAND, V219, P261; ROSE GA, 1968, MONOGRAPH SERIES, V56, P98; SAMUELSSON O, 1987, JAMA-J AM MED ASSOC, V258, P1768; SAMUELSSON O, 1985, ACTA MED SCAND S, V702, P1; SAMUELSSON OG, 1990, J HYPERTENS, V8, P547, DOI 10.1097/00004872-199006000-00008; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; STEWART IMG, 1979, LANCET, V1, P861; STRANDEGAARD S, 1987, LANCET, V1, P658; WALLER PC, 1988, J HUM HYPERTENS, V2, P7; WILHELMSEN L, 1987, J HYPERTENS, V5, P561, DOI 10.1097/00004872-198710000-00009; ZACHETTI A, 1989, J HYPERTENS, V7, pS338; 1979, JAMA-J AM MED ASSOC, V242, P2572; 1982, JAMA-J AM MED ASSOC, V248, P1465; 1980, LANCET, V1, P1261; 1984, CIRCULATION, V70, P996; 1985, BRIT MED J, V291, P97; 1987, LANCET, V2, P251; 1979, JAMA-J AM MED ASSOC, V242, P2562; 1990, CIRCULATION, V82, P1616; 1989, J HYPERTENS, V7, P689	50	43	44	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					681	686		10.1136/bmj.308.6930.681	http://dx.doi.org/10.1136/bmj.308.6930.681			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8142790	Green Published			2022-12-01	WOS:A1994NA86900017
J	SCHNABEL, R				SCHNABEL, R			AUTONOMY AND NONAUTONOMY IN CELL FATE SPECIFICATION OF MUSCLE IN THE CAENORHABDITIS-ELEGANS EMBRYO - A RECIPROCAL INDUCTION	SCIENCE			English	Article							C-ELEGANS; GLP-1; GENE	EMS, a blastomere of the Caenorhabditis elegans embryo, produces body wall muscle cell-autonomously in isolation. Within the embryonic context, however, the specification of body wall muscle derived from EMS depends on inductive interactions between its daughter MS and ABa descendants that are required to overcome inhibitory interactions with other cells. The inductive events between the MS and ABa descendants are reciprocal, specifying subsequent fates in both lineages. Both induction events are blocked by mutations in the gene glp-1, known to encode a Notch-like transmembrane receptor protein.			SCHNABEL, R (corresponding author), MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY.							AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; COWAN AE, 1985, CELL, V41, P923, DOI 10.1016/S0092-8674(85)80073-8; GOH PY, 1991, DEVELOPMENT, V111, P667; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; HUTTER H, UNPUB; KIMBLE J, 1992, COLD SPRING HARB SYM, V57, P401, DOI 10.1101/SQB.1992.057.01.045; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; SCHNABEL R, 1991, MECH DEVELOP, V34, P85, DOI 10.1016/0925-4773(91)90046-9; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4	15	41	42	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1449	1452		10.1126/science.8128230	http://dx.doi.org/10.1126/science.8128230			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	8128230				2022-12-01	WOS:A1994MZ92700036
J	ERNFORS, P; LEE, KF; JAENISCH, R				ERNFORS, P; LEE, KF; JAENISCH, R			MICE LACKING BRAIN-DERIVED NEUROTROPHIC FACTOR DEVELOP WITH SENSORY DEFICITS	NATURE			English	Article							FACTOR PREVENTS; CELL-DEATH; NEURONS; SURVIVAL; MOTONEURONS; INVIVO	DURING vertebrate development, neuronal survival depends on target-derived neurotrophic factors(1,2). Brain-derived neurotrophic factor(3) (BDNF), a member of the neurotrophin family, can prevent the death of particular peripheral sensory neurons in vitro(4-6), and of central motor neurons as well as dopaminergic and cholinergic neurons of the basal forebrain during development(7-9). It also prevents the death of motor neurons and midbrain dopaminergic neurons induced by lesions(8,10-12). Here we show that mutant mice lacking BDNF have severe deficiencies in coordination and balance, associated with excessive degeneration in several sensory ganglia including the vestibular ganglion. The few remaining vestibular axons fail to contact the vestibular sensory epithelia, and terminate in the adjacent connective tissue. Survival of sympathetic, midbrain dopaminergic and motor neurons is not affected. These results indicate that BDNF is required for the survival and target innervation of particular neuronal populations.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	ERNFORS, P (corresponding author), MIT,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; AVILA MA, 1993, DEV BIOL, V159, P266, DOI 10.1006/dbio.1993.1239; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; DAVIES AM, 1986, J NEUROSCI, V6, P1897; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1993, J NEUROSCI, V13, P3394; KALCHEIM C, 1987, EMBO J, V6, P2871, DOI 10.1002/j.1460-2075.1987.tb02589.x; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; LE E, 1992, CELL, V69, P915; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LYON MF, 1989, GENETIC VARIANT STRA; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; PIRVOLA U, 1992, P NATL ACAD SCI USA, V89, P9915, DOI 10.1073/pnas.89.20.9915; SEGAL RA, 1992, NEURON, V9, P1041, DOI 10.1016/0896-6273(92)90064-K; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; WOOD JN, 1981, BIOSCIENCE REP, V1, P263, DOI 10.1007/BF01114913; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	23	824	840	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					147	150		10.1038/368147a0	http://dx.doi.org/10.1038/368147a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139657				2022-12-01	WOS:A1994NA03000066
J	SHENG, M; CUMMINGS, J; ROLDAN, LA; JAN, YN; JAN, LY				SHENG, M; CUMMINGS, J; ROLDAN, LA; JAN, YN; JAN, LY			CHANGING SUBUNIT COMPOSITION OF HETEROMERIC NMDA RECEPTORS DURING DEVELOPMENT OF RAT CORTEX	NATURE			English	Article							VISUAL-CORTEX; CHANNEL; CURRENTS; CLONING; NEURONS; BRAIN	ACTIVATION Of the N-methyl-D-aspartate (NMDA) receptor is important for certain forms of activity-dependent synaptic plasticity, such as long-term potentiation (reviewed in ref. 1), and the patterning of connections during development of the visual system (reviewed in refs 2, 3). Several subunits of the NMDA receptor have been cloned: these are NMDAR1 (NR1), and NMDAR2A, 2B, 2C and 2D (NR2A-D)(4-8). Based on heterologous co-expression studies, it is inferred that NR1 encodes an essential subunit of NMDA receptors and that functional diversity of NMDA receptors in vivo is effected by differential incorporation of subunits NR2A-NR2D(5-8). Little is known, however, about the actual subunit composition or heterogeneity of NMDA receptors in the brain. By co-immunoprecipitation with subunit-specific antibodies, we present here direct evidence that NMDA receptors exist in rat neocortex as heteromeric complexes of considerable heterogeneity, some containing both NR2A and NR2B subunits. A progressive alteration in subunit composition seen postnatally could contribute to NMDA-receptor variation and changing synaptic plasticity during cortical development.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	SHENG, M (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.			Jan, Lily/0000-0003-3938-8498; Sheng, Morgan/0000-0002-8703-5366; Jan, Yuh Nung/0000-0003-1367-6299				ANANTHARAM V, 1992, FEBS LETT, V305, P27, DOI 10.1016/0014-5793(92)80648-Z; BENARI Y, 1988, NEUROSCI LETT, V94, P88, DOI 10.1016/0304-3940(88)90275-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CHAZOT PL, 1992, J NEUROCHEM, V59, P1176, DOI 10.1111/j.1471-4159.1992.tb08364.x; CONSTANTINEPATO.M, 1990, REV NEUROSCI, V13, P129; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; ISHII T, 1993, J BIOL CHEM, V268, P2836; KATO N, 1993, P NATL ACAD SCI USA, V90, P7114, DOI 10.1073/pnas.90.15.7114; KATO N, 1991, DEV BRAIN RES, V60, P43, DOI 10.1016/0165-3806(91)90153-A; KLECKNER NW, 1991, MOL BRAIN RES, V11, P151; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; SCHATZ CJ, 1990, NEURON, V5, P745; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K	28	1100	1120	0	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 10	1994	368	6467					144	147		10.1038/368144a0	http://dx.doi.org/10.1038/368144a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA030	8139656				2022-12-01	WOS:A1994NA03000065
J	YUAN, Y; ALTMAN, S				YUAN, Y; ALTMAN, S			SELECTION OF GUIDE SEQUENCES THAT DIRECT EFFICIENT CLEAVAGE OF MESSENGER-RNA BY HUMAN RIBONUCLEASE-P	SCIENCE			English	Article							RNASE-P; TARGETED CLEAVAGE; MESSENGER-RNA; INVITRO; ENZYME; TETRAHYMENA; EVOLUTION; RIBOZYMES	Any RNA, when in a complex with another oligoribonucleotide known as an external guide sequence (EGS), can become a substrate for ribonuclease P. Simulation of evolution in vitro was used to select EGSs that bind tightly to a target substrate messenger RNA and that increase the efficiency of cleavage of the target by human ribonuclease P to a level equal to that achieved with natural substrates. The most efficient EGSs form transfer RNA precursor-like structures with the target RNA, in which the analog of the anticodon stem has been disrupted, an indication that selection for the optimal substrate for ribonuclease P yields an RNA structure different from that of present-day transfer RNA precursors.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	Yale University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031876] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019422, R37GM019422] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31876] Funding Source: Medline; NIGMS NIH HHS [GM19422] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1990, J BIOL CHEM, V265, P20053; ALTMAN S, 1974, BROOKHAVEN S BIOL, V26, P12; ALTMAN S, 1988, STRUCTURE FUNCTION M, P183; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; DOERSEN CJ, 1985, J BIOL CHEM, V260, P5942; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; INOKUCHI H, COMMUNICATION; LI Y, 1992, P NATL ACAD SCI USA, V89, P3185, DOI 10.1073/pnas.89.8.3185; LI Y, UNPUB; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; SMITH JD, 1974, BROOKHAVEN SYM BIOL, V26, P1; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; YUAN Y, 1992, P NATL ACAD SCI USA, V89, P8006, DOI 10.1073/pnas.89.17.8006; YUAN YC, UNPUB	22	84	118	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1269	1273		10.1126/science.8122108	http://dx.doi.org/10.1126/science.8122108			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	8122108				2022-12-01	WOS:A1994MY57000033
J	GINOCCHIO, CC; OLMSTED, SB; WELLS, CL; GALAN, JE				GINOCCHIO, CC; OLMSTED, SB; WELLS, CL; GALAN, JE			CONTACT WITH EPITHELIAL-CELLS INDUCES THE FORMATION OF SURFACE APPENDAGES ON SALMONELLA-TYPHIMURIUM	CELL			English	Article							MAMMALIAN-CELLS; MOLECULAR CHARACTERIZATION; ESCHERICHIA-COLI; GROWTH-FACTORS; A431 CELLS; INVASION; IDENTIFICATION; REORGANIZATION; FIBROBLASTS; PENETRATION	The enteric bacteria Salmonella typhimurium has the ability to invade (enter) nonphagocytic cells. The internalization process occurs as a result of an intimate interaction between the bacteria and the host cell, in which S. typhimurium triggers a cascade of host cell-signaling events leading to the formation of host cell membrane ruffles and bacterial uptake. Using high resolution scanning electron microscopy, we have observed that contact with cultured epithelial cells results in the formation of appendages on the surface of S. typhimurium. The formation of such appendages did not require de novo protein synthesis, and it was transient, since these surface structures were no longer present on bacteria that had initiated the internalization event. Salmonella mutants defective in the transient formation of these surface organelles were unable to enter into cultured epithelial cells, indicating that such structures are required for bacterial internalization.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; University of Minnesota System; University of Minnesota Twin Cities					NIAID NIH HHS [AI30492, AI23484] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030492, R23AI023484, R37AI030492, R01AI023484, R29AI030492, R29AI023484] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAOUI A, 1993, MOL MICROBIOL, V7, P759; Allen Terence D., 1993, Trends in Cell Biology, V3, P205, DOI 10.1016/0962-8924(93)90215-M; ALTMEYER RM, 1993, MOL MICROBIOL, V7, P89, DOI 10.1111/j.1365-2958.1993.tb01100.x; ANDERSON TF, 1951, T NEW YORK ACAD SCI, V13, P130, DOI 10.1111/j.2164-0947.1951.tb01007.x; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; EISENSTEIN BI, 1987, CELLULAR MOL BIOL, P84; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; ERNST RK, 1990, INFECT IMMUN, V58, P2014, DOI 10.1128/IAI.58.6.2014-2016.1990; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cellbio.8.1.333; FENSELAU S, 1992, MOL PLANT MICROBE IN, V5, P390, DOI 10.1094/MPMI-5-390; FINLAY BB, 1990, J INFECT DIS, V162, P1096, DOI 10.1093/infdis/162.5.1096; FINLAY BB, 1989, SCIENCE, V243, P940, DOI 10.1126/science.2919285; FINLAY BB, 1988, J CELL BIOL, V107, P221, DOI 10.1083/jcb.107.1.221; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; GALAN JE, 1990, INFECT IMMUN, V58, P1879; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GALAN JE, 1992, J BACTERIOL, V174, P4338; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; GOUGH CL, 1993, MOL GEN GENET, V239, P378, DOI 10.1007/BF00276936; HE SY, 1993, CELL, V73, P1255, DOI 10.1016/0092-8674(93)90354-S; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KIHLSTROM E, 1976, INFECT IMMUN, V14, P851; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; MACBETH KJ, 1993, INFECT IMMUN, V61, P1544, DOI 10.1128/IAI.61.4.1544-1546.1993; MACNAB RM, 1987, CELLULAR MOL BIOL, P70; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; MIYATA Y, 1989, EXP CELL RES, V175, P286; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RIJKEN PJ, 1991, J CELL SCI, V100, P491; SANSONETTI PJ, 1992, CURR TOP MICROBIOL, V180, P1; SCHNEIDER HA, 1956, J EXP MED, V103, P207, DOI 10.1084/jem.103.2.207; STONE BJ, 1992, J BACTERIOL, V174, P3945, DOI 10.1128/jb.174.12.3945-3952.1992; STRALEY SC, 1993, INFECT IMMUN, V61, P3105, DOI 10.1128/IAI.61.8.3105-3110.1993; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; VENKATESAN MM, 1992, J BACTERIOL, V174, P1990, DOI 10.1128/jb.174.6.1990-2001.1992; VITANEN AM, 1990, J BACTERIOL, V172, P3152; VOGLER AP, 1991, J BACTERIOL, V173, P3564, DOI 10.1128/jb.173.11.3564-3572.1991	48	231	237	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 25	1994	76	4					717	724		10.1016/0092-8674(94)90510-X	http://dx.doi.org/10.1016/0092-8674(94)90510-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	8124710				2022-12-01	WOS:A1994MZ28500013
J	RAUMANN, BE; ROULD, MA; PABO, CO; SAUER, RT				RAUMANN, BE; ROULD, MA; PABO, CO; SAUER, RT			DNA RECOGNITION BY BETA-SHEETS IN THE ARC REPRESSOR-OPERATOR CRYSTAL-STRUCTURE	NATURE			English	Article							MOLECULAR-DYNAMICS; BINDING; REFINEMENT	TRANSCRIPTION of the ant gene during lytic growth of bacteriophage P22 (ref. 1) is regulated by the cooperative binding of two Arc repressor dimers to a 21-base-pair operator site2,3. Here we report the co-crystal structure of this Arc tetramer-operator complex at 2.6 angstrom resolution. As expected from genetic4-6 and structural studies7 and from the co-crystal structure of the homologous Escherichia coli MetJ repressor8, each Arc dimer uses an antiparallel beta-sheet to recognize bases in the major groove. However, the Arc and MetJ complexes differ in several important ways: the beta-sheet-DNA interactions of Arc are far less symmetrical; DNA binding by Arc is accompanied by important conformational changes in the beta-sheet; and Arc uses a different part of its protein surface for dimer-dimer interactions.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	RAUMANN, BE (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.			Sauer, Robert/0000-0002-1719-5399				BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; BROWN BM, 1993, BIOCHEMISTRY-US, V32, P1354, DOI 10.1021/bi00056a022; BROWN BM, 1990, BIOCHEMISTRY-US, V29, P11189, DOI 10.1021/bi00503a006; BROWN BM, IN PRESS NATURE STRU; BRUNGER A, 1992, X PLOR V3 1 MANUAL; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KNIGHT KL, 1989, P NATL ACAD SCI USA, V86, P797, DOI 10.1073/pnas.86.3.797; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SUSSKIND MM, 1983, LAMBDA, V2, P347; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VERSHON A K, 1986, Proteins Structure Function and Genetics, V1, P302, DOI 10.1002/prot.340010404; VERSHON AK, 1987, J MOL BIOL, V195, P323, DOI 10.1016/0022-2836(87)90653-X; VERSHON AK, 1989, J BIOL CHEM, V264, P3267; 1979, SERC4 DAR LAB COLL C	20	258	263	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					754	757		10.1038/367754a0	http://dx.doi.org/10.1038/367754a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	8107872				2022-12-01	WOS:A1994MX63100063
J	MINOR, DL; KIM, PS				MINOR, DL; KIM, PS			MEASUREMENT OF THE BETA-SHEET-FORMING PROPENSITIES OF AMINO-ACIDS	NATURE			English	Article							COIL STABILITY-CONSTANTS; STREPTOCOCCAL PROTEIN-G; N-15 NMR; HELIX; TENDENCIES; WATER	SEVERAL model systems have been used to evaluate the alpha-helical propensities of different amino acids(1-7). In contrast, experimental quantitation of beta-sheet preferences has been addressed in only one model system, a zinc-finger peptide(8). Here we measure the relative propensity for beta-sheet formation of the twenty naturally occurring amino acids in a variant of the small, monomeric, beta-sheet-rich, IgG-binding domain from protein G. Amino-acid substitutions were made at a guest site on the solvent-exposed surface of the beta-sheet. Several criteria were used to establish that the mutations did not cause significant structural changes: binding to the Fc domain of IgG, calorimetric unfolding and NMR spectroscopy. Characterization of the thermal stabilities of these proteins leads to a thermodynamic scale for beta-sheet propensities that spans a range of similar to 2 kcal mol(-1) for the naturally occurring amino acids, excluding proline. The magnitude of the differences suggests that beta-sheet preferences can be important determinants of protein stability.	MIT,HOWARD HUGHES MED INST,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	MINOR, DL (corresponding author), MIT,HOWARD HUGHES MED INST,WHITEHEAD INST BIOMED RES,DEPT CHEM,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; DEMARCO A, 1977, J MAGN RESON, V26, P527, DOI 10.1016/0022-2364(77)90104-4; DOERING D, 1992, FUNCTIONAL STRUCTURA; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FAHNESTOCK SR, 1986, J BACTERIOL, V167, P870, DOI 10.1128/jb.167.3.870-880.1986; FAHNESTOCK SR, 1990, BACTERIAL IMMUNOGLOB; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; HARLOW E, 1988, ANTIBODIES LABORATOR; HOROVITZ A, 1992, J MOL BIOL, V227, P560, DOI 10.1016/0022-2836(92)90907-2; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MCINTOSH LP, 1990, BIOCHEMISTRY-US, V29, P6341, DOI 10.1021/bi00479a003; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; Sambrook J., 1989, MOL CLONING LAB MANU; SCHERAGA HA, 1978, PURE APPL CHEM, V50, P315, DOI 10.1351/pac197850040315; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VILLEUMIER S, 1993, BIOCHEMISTRY-US, V32, P10303; WOJCIK J, 1990, BIOPOLYMERS, V30, P121, DOI 10.1002/bip.360300113; Wuthrich K., 1986, NMR PROTEINS NUCL AC	29	542	563	2	85	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 17	1994	367	6464					660	663		10.1038/367660a0	http://dx.doi.org/10.1038/367660a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	8107853				2022-12-01	WOS:A1994MW68800059
J	MILNER, SM; HODGETTS, TJ; RYLAH, LTA				MILNER, SM; HODGETTS, TJ; RYLAH, LTA			THE BURNS-CALCULATOR - A SIMPLE PROPOSED GUIDE FOR FLUID RESUSCITATION	LANCET			English	Article							CHILDREN	Most burn casualties will receive their primary care in an emergency department. These departments are staffed by doctors with a varying degree of supervision, and their experience of the treatment of burns is often very modest. Evidently there is a need for a simple method to calculate the fluid requirements of these patients. The Burns Calculator is designed for use during the first eight hours post-injury and is based upon the Parkland resuscitation formula, using only Hartmann's solution BP. It is expected that the patient will have received expert aid by the end of this time. Values for children have been predetermined using body surface area nomograms. The calculator will assist the non-specialist to determine the correct amount of fluid needed to resuscitate a burned patient, and perhaps decrease morbidity and mortality associated with this injury.	ST ANDREWS HOSP,REG BURNS UNIT,BILLERICAY,ESSEX,ENGLAND; ROYAL ARMY MED COLL,LONDON SW1P 4RJ,ENGLAND		MILNER, SM (corresponding author), CHEM & BIOL DEF ESTAB,SALISBURY,WILTS,ENGLAND.							Baxter C R, 1974, Clin Plast Surg, V1, P693; BAXTER CR, 1981, J TRAUMA, V21, P687, DOI 10.1097/00005373-198108001-00016; GRAVES TA, 1988, J TRAUMA, V28, P1656, DOI 10.1097/00005373-198812000-00007; HAMMOND JS, 1987, J TRAUMA, V27, P1161, DOI 10.1097/00005373-198710000-00011; HERNDON DN, 1985, PEDIATR CLIN N AM, V32, P1311; HERNDON DN, 1987, CURR PROB SURG, P347; Lund CC., 1944, SURG GYNECOL OBSTET, V79, P352; MILNER SM, 1993, BRIT J HOSP MED, V50, P163; MONAFO WW, 1993, CRITICAL CARE BURNED; Muir IFK, 1987, BURNS THEIR TREATMEN; OAKLEY P, 1993, BRIT MED J, V306, P1613, DOI 10.1136/bmj.306.6892.1613; PRUITT BA, 1987, CLIN SURG, P2823; RYLAH LTA, 1991, ANESTHESIOLOGY, V5, P35; 1988, ADV TRAUMA LIFE SUPP, P206; 1993, ADV PAEDIATRIC LIFE	15	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 30	1993	342	8879					1089	1091		10.1016/0140-6736(93)92067-4	http://dx.doi.org/10.1016/0140-6736(93)92067-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME822	8105315				2022-12-01	WOS:A1993ME82200013
J	SCHEPERHUGHES, N				SCHEPERHUGHES, N			AIDS, PUBLIC-HEALTH, AND HUMAN-RIGHTS IN CUBA	LANCET			English	Article									UNIV CALIF BERKELEY,DEPT ANTHROPOL,BERKELEY,CA 94720	University of California System; University of California Berkeley									0	36	38	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 16	1993	342	8877					965	967		10.1016/0140-6736(93)92006-F	http://dx.doi.org/10.1016/0140-6736(93)92006-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MC005	8105218				2022-12-01	WOS:A1993MC00500013
J	STEEL, M				STEEL, M			CANCER GENES - COMPLEXES AND COMPLEXITIES	LANCET			English	Editorial Material							NM23 GENE				STEEL, M (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.							BASERGA R, 1993, CANCER SURV, V16, P201; BLACK DM, 1993, AM J HUM GENET, V52, P702; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; LEONE A, 1993, ONCOGENE, V8, P2325; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEL CM, 1989, J R COLL PHYSICIANS, V19, P413; ZHOU M, 1993, BRIT J CANCER, V68, P385, DOI 10.1038/bjc.1993.345	11	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1993	342	8874					754	755		10.1016/0140-6736(93)91533-R	http://dx.doi.org/10.1016/0140-6736(93)91533-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	8103869				2022-12-01	WOS:A1993LY86800002
J	SAUNDERS, AM; SCHMADER, K; BREITNER, JCS; BENSON, MD; BROWN, WT; GOLDFARB, L; GOLDGABER, D; MANWARING, MG; SZYMANSKI, MH; MCCOWN, N; DOLE, KC; SCHMECHEL, DE; STRITTMATTER, WJ; PERICAKVANCE, MA; ROSES, AD				SAUNDERS, AM; SCHMADER, K; BREITNER, JCS; BENSON, MD; BROWN, WT; GOLDFARB, L; GOLDGABER, D; MANWARING, MG; SZYMANSKI, MH; MCCOWN, N; DOLE, KC; SCHMECHEL, DE; STRITTMATTER, WJ; PERICAKVANCE, MA; ROSES, AD			APOLIPOPROTEIN-E-EPSILON-4 ALLELE DISTRIBUTIONS IN LATE-ONSET ALZHEIMERS-DISEASE AND IN OTHER AMYLOID-FORMING DISEASES	LANCET			English	Note								The frequency of the allele for apolipoprotein E type 4 (epsilon4) is increased in late-onset familial and sporadic Alzheimer's disease (AD). We have examined epsilon4 frequencies in. four distinct, normal, elderly control groups and, most importantly, in patients with amyloid-forming diseases whose epsilon4 distributions were not previously known (Creutzfeldt-Jakob disease, familial amyloidotic polyneuropathy, Down's syndrome). There were no differences between any of these controls and published control series, cementing the relevance of epsilon4 for late-onset AD. The increase in late-onset AD was confirmed in two new series.	DUKE UNIV,MED CTR,BRYAN ALZHEIMERS DIS RES CTR,DIV NEUROL,DURHAM,NC 27710; SUNY,DEPT PSYCHIAT,STONY BROOK,NY 11794; INDIANA UNIV,SCH MED,INDIANAPOLIS,IN 46202; NIH,BETHESDA,MD 20892; NEW YORK STATE INST BASIC RES DEV DISABIL,STATEN ISL,NY 10314	Duke University; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; SUNY Maritime College; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; Institute for Basic Research in Developmental Disabilities			Brown, William/GXN-2777-2022		NATIONAL INSTITUTE ON AGING [U24AG021886, R35AG007922] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-30] Funding Source: Medline; NIA NIH HHS [U24 AG021886, AGO7922, AG05128] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		LIDDELL M, IN PRESS J MED GENET; MAYEAX R, IN PRESS ANN NEUROL; Robinette C. D., 1990, Dementia and Geriatric Cognitive Disorders,, V1, P297, DOI [10.1159/000107157, DOI 10.1159/000107157]; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C	6	481	492	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 18	1993	342	8873					710	711		10.1016/0140-6736(93)91709-U	http://dx.doi.org/10.1016/0140-6736(93)91709-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX469	8103823				2022-12-01	WOS:A1993LX46900010
J	HORNER, PJ; GILROY, CB; THOMAS, BJ; NAIDOO, ROM; TAYLORROBINSON, D				HORNER, PJ; GILROY, CB; THOMAS, BJ; NAIDOO, ROM; TAYLORROBINSON, D			ASSOCIATION OF MYCOPLASMA-GENITALIUM WITH ACUTE NONGONOCOCCAL URETHRITIS	LANCET			English	Article							POLYMERASE CHAIN-REACTION; HUMAN UROGENITAL TRACT; DISCOVERED MYCOPLASMA; CHLAMYDIA-TRACHOMATIS; DNA PROBES; PNEUMONIAE; SPECIMENS; INFECTION	Chlamydia trachomatis is known to be a cause of acute non-gonococcal urethritis (NGU), though the aetiology of this disorder is not fully understood. Mycoplasma genitalium has been isolated from a few men with NGU, but culture has remained difficult and reliable detection became possible only with a specific polymerase chain reaction (PCR). We have used the PCR to examine the role of M genitalium in NGU. M genitalium was detected in urethral samples from 24 (23%) of 103 men with symptoms, signs, or both, of acute NGU, but from only 3 (6%) of 53 men without NGU (p < 0.006). This association was independent of the presence of C trachomatis and could not be explained by differences in age, ethnic origin, lifetime number of sexual partners or a change in sexual partner during the previous 3 months. The clinical response of the mycoplasma-positive men to doxycycline treatment was at least as satisfactory as that of the chlamydia-positive men. These findings suggest that the association of M genitalium with NGU is likely to be causal, a notion consistent with the known virulence characteristics of this microorganism and its ability to cause urethritis in male sub-human primates.	CLIN RES CTR,DIV SEXUALLY TRANSMITTED DIS,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND; ST MARYS HOSP,LONDON,ENGLAND	Imperial College London				Horner, Paddy/0000-0003-0411-8332				BOWIE WR, 1981, ANN INTERN MED, V95, P306, DOI 10.7326/0003-4819-95-3-306; DALLO SF, 1989, INFECT IMMUN, V57, P1059, DOI 10.1128/IAI.57.4.1059-1065.1989; HAWKINS DA, 1986, MICROBIAL DISEASES N, P47; HAY PE, 1992, INT J STD AIDS, V3, P191, DOI 10.1177/095646249200300307; HOOTON TM, 1988, LANCET, V1, P266; HYMAN HC, 1987, J CLIN MICROBIOL, V25, P726, DOI 10.1128/JCM.25.4.726-728.1987; JENSEN JS, 1991, J CLIN MICROBIOL, V29, P46, DOI 10.1128/JCM.29.1.46-50.1991; KIRCHHOFF H, 1984, ISRAEL J MED SCI, V20, P848; MUNDAY PE, 1985, CLIN PROBLEMS SEXUAL, P15; Palmer H M, 1991, Int J STD AIDS, V2, P261; PALMER HM, 1991, FEMS MICROBIOL LETT, V77, P199, DOI 10.1016/0378-1097(91)90551-K; ROBERTS MC, 1987, ISRAEL J MED SCI, V23, P618; SAMRA Z, 1988, EUR J CLIN MICROBIOL, V7, P49, DOI 10.1007/BF01962172; TAYLORROBINSON D, 1987, ISRAEL J MED SCI, V23, P561; TAYLORROBINSON D, 1980, J CLIN PATHOL, V33, P205, DOI 10.1136/jcp.33.3.205; TAYLORROBINSON D, 1981, ISRAEL J MED SCI, V17, P524; TAYLORROBINSON D, 1985, GENITOURIN MED, V61, P319; TAYLORROBINSON D, 1993, CLIN INFECT DIS   S1, V17, P66; THOMAS BJ, 1984, J CLIN PATHOL, V37, P812, DOI 10.1136/jcp.37.7.812; TULLY JG, 1981, LANCET, V1, P1288; TULLY JG, 1983, INT J SYST BACTERIOL, V33, P387, DOI 10.1099/00207713-33-2-387; TULLY JG, 1986, J INFECT DIS, V153, P1046, DOI 10.1093/infdis/153.6.1046; WILSON K, 1987, CUURRENT PROTOCOLS M, V1	23	173	182	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 4	1993	342	8871					582	585		10.1016/0140-6736(93)91411-E	http://dx.doi.org/10.1016/0140-6736(93)91411-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV963	8102721				2022-12-01	WOS:A1993LV96300011
J	NEWMAN, AB; SUTTONTYRRELL, K; VOGT, MT; KULLER, LH				NEWMAN, AB; SUTTONTYRRELL, K; VOGT, MT; KULLER, LH			MORBIDITY AND MORTALITY IN HYPERTENSIVE ADULTS WITH A LOW ANKLE ARM BLOOD-PRESSURE INDEX	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To evaluate the relationship between the ankle/arm blood pressure index (AAI, the ratio of ankle to arm systolic blood pressure, a measure of peripheral arterial disease) and short-term cardiovascular morbidity and mortality in older adults with systolic hypertension. Design.-Prospective cohort study, 1- to 2-year follow-up (mean, 16 months). Setting.-Eleven of 16 field centers from the Systolic Hypertension in the Elderly Program. Participants.-1537 older men and women with systolic hypertension. Main Outcome Measures.- All-cause mortality, coronary heart disease (CHD) mortality, cardiovascular disease (CVD) mortality, and CHD and CVD morbidity and mortality. Results.-The AAI was measured at the 1989-1990 clinic examination and was 0.9 or less in 25.5% of 1537 participants. A low AAI was associated with most major CHD and CVD risk factors. In those with a low AAI (less-than-or-equal-to 0.9) compared with those with an AAI of more than 0.9, age- and sex-adjusted relative risks for mortality end points at follow-up were as follows: total mortality, 3.8 (95% confidence interval [CI], 2.1 to 6.9); CHD mortality, 3.24 (95% CI, 1.4 to 7.5); and CVD mortality, 3.7 (95% CI, 1.8 to 7.7). For CVD morbidity and mortality, the age- and sex-adjusted relative risk was 2.5 (95% CI, 1.5 to 4.3). After adjustment for baseline CVD and other cardiovascular risk factors, the relative risk for total mortality was 4.1 (95% CI, 2.0 to 8.3) and for CVD morbidity and mortality, 2.4 (95% CI, 1.3 to 4.4). Results were similar when participants with clinical CVD at baseline were excluded. Conclusion.-A low AAI appears to be an important predictor of morbidity and mortality among older adults with systolic hypertension.	UNIV PITTSBURGH, DEPT EPIDEMIOL, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Newman, Anne B./C-6408-2013	Newman, Anne B./0000-0002-0106-1150	NATIONAL INSTITUTE ON AGING [R29AG008047] Funding Source: NIH RePORTER; NIA NIH HHS [R29-AG08047-03] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1991, JAMA, V265, P3255; CRIQUI MH, 1985, CIRCULATION, V71, P516, DOI 10.1161/01.CIR.71.3.516; CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; HIATT WR, 1990, J CLIN EPIDEMIOL, V43, P597, DOI 10.1016/0895-4356(90)90164-K; MCKENNA M, 1991, ATHEROSCLEROSIS, V87, P119, DOI 10.1016/0021-9150(91)90014-T; NEWMAN AB, 1991, J CLIN EPIDEMIOL, V44, P15, DOI 10.1016/0895-4356(91)90196-G; REUNANEN A, 1982, ACTA MED SCAND, V211, P249; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; SCHROLL M, 1981, J CHRON DIS, V34, P261, DOI 10.1016/0021-9681(81)90031-X	11	267	282	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					487	489		10.1001/jama.270.4.487	http://dx.doi.org/10.1001/jama.270.4.487			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8147959				2022-12-01	WOS:A1993LN42600029
